File Nos. 002-98772
811-04347
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 29, 2016
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-1A
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 | x | |
Pre-Effective Amendment No. | ¨ | |
Post-Effective Amendment No. 188 | x |
REGISTRATION STATEMENT
UNDER
THE INVESTMENT COMPANY ACT OF 1940 | x | |
Amendment No. 234 | x |
GMO TRUST
(Exact Name of Registrant as Specified in Charter)
40 Rowes Wharf, Boston, Massachusetts 02110
(Address of principal executive offices)
617-330-7500
(Registrants telephone number, including area code)
J.B. Kittredge, Esq.
GMO Trust
40 Rowes Wharf
Boston, Massachusetts 02110
(Name and address of agent for service)
with a copy to:
Thomas R. Hiller, Esq.
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, Massachusetts 02199
It is proposed that this filing will become effective:
¨ | Immediately upon filing pursuant to paragraph (b) |
¨ | On , pursuant to paragraph (b) |
¨ | 60 days after filing pursuant to paragraph (a)(1) |
x | On June 30, 2016, pursuant to paragraph (a)(1) |
¨ | 75 days after filing pursuant to paragraph (a)(2) |
¨ | On , pursuant to paragraph (a)(2) of Rule 485. |
This filing relates solely to the 34 series of the Registrant listed on the front cover of the GMO Trust Prospectus, dated June 30, 2016 and filed herewith. No information contained herein is intended to amend or supersede any prior filing relating to any other series of the Registrant.
GMO Trust
Prospectus
June 30, 2016
Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf ● Boston, Massachusetts 02110
The Securities and Exchange Commission and the Commodity Futures Trading Commission have not approved or disapproved these securities or passed upon the adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Grantham, Mayo, Van Otterloo & Co. LLC (GMO) is not offering or placing interests in the series of GMO Trust set forth above (each, a Fund, and collectively, the Funds), to or with or otherwise promoting the Funds to any natural or legal persons domiciled or with a registered office in any European Economic Area (EEA) Member State where the Alternative Investment Fund Managers Directive (Directive 2011/61/EU) is in force and effect. GMO, in its discretion, may accept any such investor into a Fund, but only if it is satisfied that, by accepting such investor, it would not be in breach of any law, rule, regulation or other legislative or administrative measure in or otherwise applicable to the relevant EEA Member State and such investor is otherwise eligible under the laws of such EEA Member State to invest in the Fund. None of the Funds, GMO, their respective affiliates or any natural or legal person acting on their behalf have been registered with, have been approved by or have made a notification to any EEA Member State, European Union or other regulatory, governmental or similar body with respect to the Funds, and no such body has approved, endorsed, reviewed, acquiesced or taken any similar action with respect to any offering, marketing or other promotional materials relating to the Funds.
Page | ||
FUND SUMMARIES |
||
Multi-Asset Class Funds |
1 | |
1 | ||
6 | ||
Absolute Return Fund |
11 | |
11 | ||
Equity Funds |
16 | |
Global Equity Funds |
16 | |
16 | ||
20 | ||
24 | ||
28 | ||
32 | ||
International Equity Funds |
36 | |
36 | ||
40 | ||
44 | ||
48 | ||
52 | ||
56 | ||
60 | ||
64 | ||
U.S. Equity Fund |
68 | |
68 | ||
Emerging Markets Equity Funds |
72 | |
72 | ||
76 | ||
80 | ||
Fixed Income Funds |
84 | |
84 | ||
89 | ||
94 | ||
99 | ||
103 | ||
Implementation Funds |
107 | |
107 | ||
111 | ||
116 | ||
121 | ||
126 | ||
130 | ||
135 | ||
139 | ||
143 |
i
Page |
||
146 | ||
ADDITIONAL INFORMATION ABOUT THE FUNDS INVESTMENT STRATEGIES, RISKS, AND EXPENSES |
148 | |
151 | ||
167 | ||
173 | ||
175 | ||
176 | ||
176 | ||
179 | ||
181 | ||
182 | ||
185 | ||
191 | ||
195 | ||
196 | ||
198 | ||
200 | ||
back cover | ||
back cover | ||
back cover |
ii
GMO BENCHMARK-FREE ALLOCATION FUND
Investment objective
Positive total return not relative return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | Class MF | ||||||||||
Purchase premium (as a percentage of amount invested) |
[0.18 | ]% | [0.18 | ]% | [0.18 | ]% | ||||||
Redemption fee (as a percentage of amount redeemed) |
[0.18 | ]% | [0.18 | ]% | [0.18 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class MF | ||||||||||
Management fee |
0.65 | % 1 | 0.65 | % 1 | 0.65 | % 1 | ||||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | N/A | |||||||
Supplemental support fee |
N/A | N/A | 0.10 | % 1,2 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 3 | [ | ]% 3 | [ | ]% 3 | ||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1,2 | ||||||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees. GMO also has contractually agreed to waive or reduce the Funds management, shareholder service, and supplemental support fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds).] |
2 | [GMO has contractually agreed to reduce the rate of the supplemental support fees charged each month to the Funds Class MF shares based on the net assets attributable to Class MF shares as of the last business day of the preceding month based on the following schedule: 0.10% on the first $6 billion of net assets, 0.05% on the next $2 billion, 0.03% on the next $2 billion, and 0.01% thereafter; provided, however, that the effective rate charged at any time will not be reduced to less than 0.06% of Class MFs average daily net assets. This rate will be calculated before giving effect to any other reduction or waiver. This reduction will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
3 | [These indirect expenses include interest expense and dividend expenses on short sales that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense, dividend expenses on short sales and transaction fees), indirect interest expense, indirect dividend expenses on short sales and indirect transaction fees were approximately [ ]%, less than [ ]%, [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The amounts shown reflect applicable expense reimbursements and waivers noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class MF |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended
1
February 29, 2016, the Funds portfolio turnover rate (including the accounts of Implementation Fund, and excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of Implementation Fund and excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund seeks annualized excess returns of 5% (net of fees) above the Consumer Price Index, and GMO expects annualized volatility of 5-10%, each over a complete market cycle. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
GMO seeks to achieve the Funds investment objective by investing in asset classes GMO believes offer the most attractive return and risk opportunities. GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds allocations to various asset classes. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. The factors GMO considers and investment methods GMO uses can change over time.
The Fund is structured as a fund of funds and gains its investment exposures primarily by investing in Implementation Fund. In addition, the Fund may invest in any other GMO Fund (together with Implementation Fund, the underlying GMO Funds), whether now existing or created in the future, including GMO Funds not offered by or described in this Prospectus. These underlying GMO Funds may include, among others, Alpha Only Fund, Debt Opportunities Fund, Emerging Country Debt Fund, Special Opportunities Fund, and SGM Major Markets Fund (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds). Implementation Fund is permitted to invest in any asset class. The Fund also may invest directly in securities (including other underlying funds) and derivatives.
The Fund is permitted to invest (directly or through Implementation Fund or other underlying GMO Funds) in any asset class (including, for example, U.S. and non-U.S. equities (including emerging country equities), U.S. and non-U.S. fixed income securities (including emerging country debt securities), real estate, and commodities), sector, country, or region, and at times may have substantial exposure to a single asset class, sector, country, or region. In addition, the Fund is not restricted in its exposure to any particular market and may invest in securities of companies of any market capitalization, credit quality, maturity or duration. The Fund may have indirect exposure to derivatives and short sales through its investment in Implementation Fund and the other underlying GMO Funds. GMOs ability to shift investments within Implementation Fund and between it and the other underlying GMO Funds is not subject to any limits.
Prior to January 1, 2012, the Fund served as a principal component of a broader GMO real return strategy that also included a pooled investment vehicle with a cash-like benchmark. Since January 1, 2012, the Fund has been managed as a standalone investment.
In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results (including expected annualized volatility and the annualized excess returns the Fund seeks above the Consumer Price Index). Additionally, the Fund could produce results consistent with expected annualized volatility over a complete market cycle yet experience shorter periods of significantly higher volatility. GMO often uses quantitative analyses and models as part of its investment process. GMOs analyses and models may not accurately predict future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
2
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Futures Contracts Risk The risk of loss relating to some uses of futures contracts is potentially unlimited. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract or at any particular time. In the event no such market exists for a particular derivative, it might not be possible to effect closing transactions, and the Fund will be unable to terminate its exposure to the futures contract. If the Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the futures contract and movements in the securities or index underlying the futures contract or movements in the prices of the Funds investments that are the subject of such hedge. Foreign futures contracts may be less liquid and more volatile than U.S. contracts. [The Fund may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse.] |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
|
Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the |
3
market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance and Volatility [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Barclays U.S. Treasury Inflation Notes: 1-10 Year Index and the Consumer Price Index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance. [For additional information regarding the Funds historical performance and volatility, please see Supplemental Performance and Volatility Information beginning on page [ ] of this Prospectus.]
Annual Total Returns /Class III Shares a
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
4
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III a |
7/23/03 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
12/11/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class MF |
3/1/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% |
a | The returns shown for periods prior to January 1, 2012 are for Class III shares of the Fund under the Funds prior fee arrangement. Under the Funds current fee arrangement, the returns for periods prior to January 1, 2012 would have been lower. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
5
GMO GLOBAL ASSET ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the GMO Global Asset Allocation Index, an internally maintained index computed by GMO, consisting of 65% MSCI ACWI and 35% Barclays U.S. Aggregate Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.14 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.14 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, less than [ ]%, and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in shares of other series of GMO Trust (collectively, the underlying GMO Funds), which may include the Equity Funds, the Fixed Income Funds, the Implementation Funds, and SGM Major Markets Fund, as well as GMO High Quality Short-Duration Bond Fund and GMO World Opportunity Overlay Fund, each a series of GMO Trust not offered by this Prospectus (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
6
The Fund is permitted to invest in any asset class, including, for example, U.S. and non-U.S. equities (including emerging country equities), U.S. and non-U.S. fixed income securities (including emerging country debt securities) and commodities. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to select the underlying GMO Funds in which the Fund invests and to decide how much to invest in each. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. Under normal circumstances, GMO intends to invest not more than 85% of the Funds assets in the Equity Funds. The factors GMO considers and investment methods GMO uses can change over time.
The Fund also may invest in money market funds unaffiliated with GMO or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
|
Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in |
7
the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| [ Futures Contracts Risk The risk of loss relating to some uses of futures contracts is potentially unlimited. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract or at any particular time. In the event no such market exists for a particular derivative, it might not be possible to effect closing transactions, and the Fund will be unable to terminate its exposure to the futures contract. If the Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the futures contract and movements in the securities or index underlying the futures contract or movements in the prices of the Funds investments that are the subject of such hedge. Foreign futures contracts may be less liquid and more volatile than U.S. contracts. The Fund may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse.] |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
8
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of broad-based indices and the Funds benchmark (which is a composite index computed by GMO). Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns*
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
6/28/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI ACWI (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Barclays U.S. Aggregate Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
GMO Global Asset Allocation Index (Fund benchmark) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
* | The Fund commenced operations on June 28, 1996 with two classes of shares Class I shares and Class II shares. No Class II shares were outstanding as of October 16, 1996. Class III shares were first issued on October 22, 1996. Class I shares converted to Class III shares on January 9, 1998. Class III performance information presented in the table represents Class II performance from June 28, 1996 to October 16, 1996, Class I performance from October 16, 1996 to October 21, 1996, and Class III performance thereafter. The performance information (before and after taxes) for all periods prior to June 30, 2002 was achieved prior to the change in the Funds principal investment strategies, effective June 30, 2002. |
9
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
10
(formerly known as GMO Systematic Global Macro Opportunity Fund)
Investment objective
Long-term total return.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class VI | ||||||||||
Management fee |
[0.85 | ]% 1,2 | [0.85 | %] 1,2 | [0.85 | %] 1,2 | ||||||
Shareholder service fee |
[0.15 | ]% 1 | [0.10 | ]% 1 | [0.055 | ]% 1 | ||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% | ||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Expense reimbursement/waiver |
[ | ]% 1 | [ | ]% 1 | [ | ]% 1 | ||||||
Total annual fund operating expenses after expense reimbursement/waiver |
||||||||||||
(Fund and underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero as a result of this waiver. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [The amount has been restated to reflect current management fees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Alternative Asset SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Alternative Asset SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio.]
11
Principal investment strategies
The Funds benchmark is the Citigroup 3-Month Treasury Bill Index. The Fund seeks annualized excess returns of 5% (gross of fees) above the Citigroup 3-Month Treasury Bill Index, and GMO expects annualized volatility of approximately 6-10%, each over a complete market cycle. The Fund does not maintain a specified interest rate duration for its portfolio.
The Fund typically takes long and short positions in a range of global equity, bond, currency, and commodity markets using exchange-traded futures and forward non-U.S. exchange contracts, as well as making other investments. The Fund seeks to take advantage of GMOs proprietary investment models for global tactical asset allocation and equity, bond, currency, and commodity market selection.
The Fund normally invests assets not held as margin for futures or forward transactions in cash directly (e.g., Treasury bills, Treasury floating rate notes, Treasury Separately Traded Registered Interest and Principal Securities (STRIPS), and Federal Home Loan Bank discount notes), money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds. The Fund also may invest in U.S. and non-U.S. fixed income securities of any credit quality, maturity or duration and in shares of U.S. Treasury Fund.
GMOs models for this systematic process are based on the following strategies:
| Value-Based Strategies . Value factors compare the price of an asset class or market to an economic fundamental value. Generally, value strategies include yield analysis and mean reversion analysis. |
| Sentiment-Based Strategies . Generally, sentiment-based strategies assess factors such as risk aversion, analyst behavior, and momentum. |
In implementing the Funds investment strategy, GMO seeks to take risk positions that, in GMOs view, are proportionate to the return opportunities. As a result, during time periods when GMO believes the return opportunities are high relative to the risks involved, the Fund may take more risk relative to the Funds benchmark. Conversely, during time periods when GMO believes the return opportunities are low relative to the risks involved, the Fund may take less risk (or no risk) relative to the Funds benchmark.
GMO may eliminate strategies or add new strategies in response to additional research, changing market conditions, or other factors. The factors GMO considers and investment methods GMO uses can change over time.
The Fund gains exposure to commodities and some other asset classes by investing through a wholly-owned subsidiary advised by GMO, which does not receive any additional management or other fees for its services. The subsidiary invests primarily in commodity-related derivatives and fixed income securities but also may invest in any other investment in which the Fund is permitted to invest directly. References in this Prospectus to the Fund may refer to actions undertaken by the subsidiary as well as the Fund. The Fund does not invest directly in commodities and commodity-related derivatives, but may do so indirectly through its subsidiary (or otherwise).
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. An investment in the Fund is subject to different risks, and greater overall risk, than an investment in the components of the Funds benchmark. References to investments include those held directly by the Fund and indirectly through the Funds investments in its wholly-owned subsidiary and in underlying funds. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in its wholly-owned subsidiary and in underlying funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results (including expected annualized volatility and the annualized excess returns the Fund seeks above the Citigroup 3-Month Treasury Bill Index). Additionally, the Fund could produce results consistent with expected annualized volatility over a complete market cycle yet experience shorter periods of significantly higher volatility. GMO often uses quantitative analyses and models as part of its investment process, and quantitative models are one of the key components of investment decisions for the Fund. GMOs analyses and models may not accurately predict future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
12
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| [ Futures Contracts Risk The risk of loss relating to some uses of futures contracts is potentially unlimited. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract or at any particular time. In the event no such market exists for a particular derivative, it might not be possible to effect closing transactions, and the Fund will be unable to terminate its exposure to the futures contract. If the Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the futures contract and movements in the securities or index underlying the futures contract or movements in the prices of the Funds investments that are the subject of such hedge. Foreign futures contracts may be less liquid and more volatile than U.S. contracts. The Fund may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse.] |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
13
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of its investment in its wholly-owned subsidiary and the underlying funds in which it invests, including the risk that its wholly-owned subsidiary and those underlying funds will not perform as expected. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance and Volatility [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index and a composite index computed by GMO. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance. [Prior to October 3, 2011, the Fund was managed pursuant to a materially different investment strategy and would have achieved materially different performance [and volatility] results under its current investment strategy from that shown for periods prior to October 3, 2011. [For additional information regarding the Funds historical volatility, please see Supplemental Performance and Volatility Information beginning on page [ ] of this Prospectus.]
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: -[ ]% ([ ])
Year-to-Date (as of 03/31/16): [ ]%
14
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
8/1/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Citigroup 3-Month Treasury Bill Index (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Citigroup 3-Month Treasury Bill Index+++ (Composite Index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
12/1/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Citigroup 3-Month Treasury Bill Index (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Citigroup 3-Month Treasury Bill Index+++ (Composite Index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Member of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Systematic Global Macro | Jason Halliwell (since 2011) | Head, Systematic Global Macro Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
15
GMO GLOBAL EQUITY ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the MSCI ACWI.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.19 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.19 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in equities traded in U.S. and non-U.S. markets (including emerging markets) through shares of the Equity Funds, Alpha Only Fund and Risk Premium Fund (collectively, the underlying GMO Funds) (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds allocations to particular underlying GMO Funds. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings
16
of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. The factors GMO considers and investment methods GMO uses can change over time.
Under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities (see Name Policies). The term equities refers to direct and indirect (e.g., through the underlying GMO Funds) investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
17
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Funds benchmark (which is a broad-based index) and a composite index computed by GMO. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
18
Annual Total Returns/ Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
11/26/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI ACWI (Fund benchmark ) (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI ACWI + (Composite index ) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
19
GMO GLOBAL DEVELOPED EQUITY ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the MSCI World Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.08 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.08 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in equities traded in U.S. and non-U.S. markets (including emerging markets) through shares of the Equity Funds, Alpha Only Fund and Risk Premium Fund (collectively, the underlying GMO Funds) (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds allocations to particular underlying GMO Funds. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings
20
of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. The factors GMO considers and investment methods GMO uses can change over time.
Under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities (see Name Policies). In addition, under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities tied economically to developed markets (see Name Policies). The Fund also may invest in equities in emerging markets, but those investments typically will represent 10% or less of the Funds net assets measured at the time of purchase. The term equities refers to direct and indirect (e.g., through the underlying GMO Funds) investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. The term developed markets means those countries included in the MSCI World Index, a global developed markets equity index, and countries with similar characteristics (e.g., countries that have sustained economic development, sufficient liquidity for listed companies and accessible markets).
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
|
Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the |
21
relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
22
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
6/16/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
23
GMO DEVELOPED WORLD STOCK FUND
Investment objective
High total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | |||||||
Purchase premium (as a percentage of amount invested) |
[0.25 | ]% 1 | [0.25 | ]% 1 | ||||
Redemption fee (as a percentage of amount redeemed) |
[0.25 | ]% 1 | [0.25 | ]% 1 |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | |||||||
Management fee |
0.45 | % 2 | 0.45 | % 2 | ||||
Shareholder service fee |
0.15 | % 2 | 0.10 | % 2 | ||||
Other expenses |
[ | ]% | [ | ]% | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 2 | ([ | ]%) 2 | ||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% |
1 | [An additional purchase premium and redemption fee of 0.005% is charged for any purchases/redemptions (or any portion of a purchase/redemption) effected in a currency other than the U.S. dollar.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of stocks in global developed equity markets.
GMO selects the stocks the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, equity and bond markets, the overall global economy, and governmental policies.
24
In selecting stocks for the Fund, GMO uses a combination of investment methods to identify stocks that GMO believes have positive return potential relative to other stocks in global developed equity markets. Some of these methods evaluate individual stocks or groups of stocks based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a stock or groups of stocks relative to global developed equity markets. GMO also uses its multi-year return forecasts for asset classes and other groups of securities in its investment process and may adjust the Funds portfolio based on factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. At times, the Fund may have substantial exposure to a single asset class, industry, sector, country, region, or currency. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
As an alternative to investing directly in stocks, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, forward currency contracts, and swap contracts. In addition, the Fund may lend its portfolio securities.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in stocks tied economically to developed markets (see Name Policies). The Fund also may invest in stocks in emerging markets, but those investments typically will represent 10% or less of the Funds net assets measured at the time of purchase. For this purpose, the term stocks refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts, and the term developed markets refers to those countries included in the MSCI World Index, a global developed markets equity index, and countries with similar characteristics (e.g., countries that have sustained economic development, sufficient liquidity for listed companies and accessible markets).
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
|
Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, |
25
expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
26
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
8/1/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Teams and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
27
Investment objective
Total return.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Management fee |
0.33 | % 1 | 0.33 | % 1 | 0.33 | % 1 | 0.33 | % 1 | ||||||||
Shareholder service fee |
0.15 | % 1 | 0.105 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of equities of companies that GMO believes to be of high quality. A high quality company is generally one that GMO believes has an established business that will deliver a high level of return on equity and that will utilize cash flows in the future by making investments with potential for high levels of return or returning cash to shareholders through dividends, share buybacks or other mechanisms.
In selecting securities for the Fund, GMO uses a combination of investment methods and may consider both quantitative factors, based on profitability, profit stability, leverage, and other publicly available financial information, and fundamental factors, based on an assessment of future profitability, capital allocation, sustainability against competitive forces, and growth opportunities. GMO may also rely on valuation methodologies, such as discounted cash flow analysis, use of forecasted financial information, and analysis of patterns of information, such as price movement or volatility of a security or groups of securities.
28
The Fund is permitted to invest directly and indirectly (e.g., through underlying funds or derivatives) in equities of companies tied economically to any country in the world, including emerging countries. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
At times, the Fund may have substantial exposure to a single industry, sector, country, region, or currency. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, forward currency contracts, and swap contracts. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. The Fund invests in the securities of a limited number of issuers, and a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund invested in the securities of a larger number of issuers. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
29
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
30
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
2/6/04 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
2/6/04 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class V |
12/8/06 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Class VI |
12/8/06 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Focused Equity | Thomas Hancock (since 2009) | Head, Focused Equity Team, GMO. | ||
Focused Equity | Anthony Hene (since 2015) | Portfolio Manager, Focused Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
31
Investment objective
Total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Purchase premium (as a percentage of amount invested) |
[0.30 | ]% | [0.30 | ]% | [0.30 | ]% | [0.30 | ]% | ||||||||
Redemption fee (as a percentage of amount redeemed) |
[0.30 | ]% | [0.30 | ]% | [0.30 | ]% | [0.30 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Management fee |
0.50 | % 1 | 0.50 | % 1 | 0.50 | % 1 | 0.50 | % 1 | ||||||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the portion of its Specified Operating Expenses (as defined below) that exceeds 0.10% of the Funds average daily net assets. Specified Operating Expenses means only the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in securities of companies in the natural resources sector (as defined below). Given the limited supply of many natural resources and the expected growth and industrialization of
32
countries that are not members of the Organisation for Economic Co-operation and Development (OECD), GMO believes global demand for many natural resources, and therefore prices of these natural resources generally, will increase over a longer-term period. In managing the Fund, GMO seeks to invest in the securities of companies that it believes will benefit from this expected longer-term rise in natural resource prices.
GMO selects the securities the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, commodities prices, equity and bond markets, the overall global economy, and government policies.
In selecting securities for the Fund, GMO uses a combination of investment methods to identify securities that GMO believes have positive return potential relative to other securities of companies in the natural resources sector. Some of these methods evaluate individual securities or groups of securities based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a security or groups of securities relative to other stocks in the natural resources sector. At times, the Fund may have substantial exposure to a single asset class, industry, sector, country, or region. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark. The Fund may invest in companies of any market capitalization.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, and swap contracts. In addition, the Fund may lend its portfolio securities.
The Fund has a fundamental policy to concentrate its investments in the natural resources sector, and, under normal market conditions, the Fund invests at least 80% of its assets in the securities of companies in that sector. The Fund considers the natural resources sector to include companies that own, produce, refine, process, transport, and market natural resources and companies that provide related equipment, infrastructure, and services. The sector includes, for example, the following industries: integrated oil, oil and gas exploration and production, gold and other precious metals, steel and iron ore production, energy services and technology, base metal production, forest products, farming products, paper products, chemicals, building materials, coal, water, alternative energy sources, and environmental services. The Fund is permitted to invest directly and indirectly (e.g., through underlying funds or derivatives) in securities of companies tied economically to any country in the world, including emerging countries. In addition to its investments in companies in the natural resources sector, the Fund also may invest up to 20% of its net assets in securities of any type of company.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Focused Investment Risk By concentrating its investments in the natural resources sector, the Fund is particularly exposed to adverse developments, including adverse price movements, affecting issuers in that sector and is subject to greater risks than a fund that invests in a wider range of industries. In addition, the market prices of securities of companies in the natural resources sector are often more volatile than securities of companies in other industries. Some of the commodities used as raw materials or produced by these companies are subject to broad price fluctuations as a result of industry-wide supply and demand factors. Companies in the natural resources sector often have limited pricing power over supplies or for the products they sell and that can affect their profitability, and are often capital-intensive and use significant amounts of leverage. Projects in the natural resources sector may have long setup times and companies cannot ensure that the market will be favorable at the time the project begins production. Companies in the natural resources sector also may be subject to special risks associated with natural or man-made disasters. In addition, the natural resources sector can be especially affected by events relating to international political and economic developments, government regulations, energy conservation, and the success of exploration projects. Because the Fund invests primarily in the natural resources sector, it runs the risk of performing poorly during an economic downturn or a decline in demand for natural resources. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate more than if the Fund had a broader range of investments. |
|
Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by |
33
GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
34
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the MSCI ACWI and the MSCI ACWI Commodity Producers Index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
12/28/11 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI ACWI Commodity Producers Index (Fund benchmark) (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI ACWI (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class IV |
3/20/13 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI ACWI Commodity Producers Index (Fund benchmark) (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI ACWI (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Focused Equity | Thomas Hancock (since the Funds inception) | Head, Focused Equity Team, GMO. | ||
Focused Equity | Lucas White (since 2015) | Portfolio Manager, Focused Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
35
GMO INTERNATIONAL EQUITY ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the MSCI ACWI ex USA.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.27 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.27 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ] % and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in equities traded in non-U.S. markets (including emerging markets) through shares of the Equity Funds, Alpha Only Fund and Risk Premium Fund (collectively, the underlying GMO Funds) (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds allocations to particular underlying GMO Funds. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings
36
of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. The factors GMO considers and investment methods GMO uses can change over time.
Under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities (see Name Policies). The term equities refers to direct and indirect (e.g., through the underlying GMO Funds) investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
37
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
38
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
10/11/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI ACWI ex USA (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
39
GMO INTERNATIONAL DEVELOPED EQUITY ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the MSCI EAFE Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.08 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.08 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in equities traded in non-U.S. markets (including emerging markets) through shares of the Equity Funds, Alpha Only Fund and Risk Premium Fund (collectively, the underlying GMO Funds) (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds allocations to particular underlying GMO Funds. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings
40
of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. The factors GMO considers and investment methods GMO uses can change over time.
Under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities (see Name Policies). In addition, under normal circumstances, the Fund invests (including through investment in the underlying GMO Funds) at least 80% of its assets in equities tied economically to developed markets (see Name Policies). The Fund also may invest in equities in emerging markets, but those investments typically will represent 10% or less of the Funds net assets measured at the time of purchase. The term equities refers to direct and indirect (e.g., through the underlying GMO Funds) investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. The term developed markets means those countries included in the MSCI World Index, a global developed markets equity index, and countries with similar characteristics (e.g., countries that have sustained economic development, sufficient liquidity for listed companies and accessible markets).
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
|
Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in |
41
the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
42
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
6/5/06 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
43
GMO TAX-MANAGED INTERNATIONAL EQUITIES FUND
Investment objective
High after-tax total return.
Fees and expenses
The table below describes the fees and expenses that you may bear if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.50 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amount shown reflects the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of equities in international equity markets.
GMO selects the securities the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, equity and bond markets, the overall global economy, and governmental policies.
In selecting securities for the Fund, GMO uses a combination of investment methods to identify securities that GMO believes have positive return potential relative to other securities in international equity markets. Some of these methods evaluate individual securities or groups of securities based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a security or groups of securities relative to international equity markets. GMO also uses its multi-year return forecasts for asset classes and other groups of securities in its investment process and may adjust the Funds portfolio based on factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. At times, the Fund may have substantial exposure to a single asset class, industry, sector, country, region, or currency. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
44
GMO may consider the tax effects of a proposed trade in conjunction with the return forecast of the identified equities, and their potential contribution to the overall portfolio. GMO also may consider the Funds realized and unrealized gains and losses, and current market conditions, because these factors also influence the decision to buy or sell securities.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, forward currency contracts, and swap contracts. In addition, the Fund may lend its portfolio securities.
The Fund typically invests directly and indirectly (e.g., through underlying funds or derivatives) in equities of companies tied economically to countries other than the United States, including both developed and emerging countries. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in equities (see Name Policies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. There can be no assurance that the Funds tax management strategies will be effective, and you may incur tax liabilities that exceed your economic return. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
45
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Funds benchmark (which is computed by GMO) and a broad-based international stock index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
46
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
7/29/98 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (after tax) (Fund benchmark) (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Teams and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
47
Investment objective
High total return.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class II | Class III | Class IV | ||||||||||
Management fee |
0.50 | % 1 | 0.50 | % 1 | 0.50 | % 1 | ||||||
Shareholder service fee |
0.22 | % 1 | 0.15 | % 1 | 0.09 | % 1 | ||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class II |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of non-U.S. developed market equities.
GMO selects the securities the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, equity and bond markets, the overall global economy, and governmental policies.
In selecting securities for the Fund, GMO uses a combination of investment methods to identify securities that GMO believes have positive return potential relative to other securities in the international equity markets. Some of these methods evaluate individual securities or groups of securities based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a security or groups of securities relative to international equity markets. GMO also uses its multi-year return forecasts for asset classes and other groups of securities in
48
its investment process and may adjust the Funds portfolio based on factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. At times, the Fund may have substantial exposure to a single asset class, industry, sector, country, region, or currency. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, forward currency contracts, and swap contracts. In addition, the Fund may lend its portfolio securities.
Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in equities (see Name Policies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
|
Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity |
49
risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
50
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class II |
9/26/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class III |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Teams and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
51
GMO INTERNATIONAL LARGE/MID CAP EQUITY FUND
Investment objective
High total return.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class VI | ||||||||||
Management fee |
0.38 | % 1 | 0.38 | % 1 | 0.38 | % 1 | ||||||
Shareholder service fee |
0.15 | % 1 | 0.09 | % 1 | 0.055 | % 1 | ||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of non-U.S. developed market equities.
GMO selects the securities the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, equity and bond markets, the overall global economy, and governmental policies.
In selecting securities for the Fund, GMO uses a combination of investment methods to identify securities that GMO believes have positive return potential relative to other securities in the international equity markets. Some of these methods evaluate individual securities or groups of securities based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a security or groups of securities relative to international equity markets. GMO also uses its multi-year return forecasts for asset classes and other groups of securities in
52
its investment process and may adjust the Funds portfolio based on factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. At times, the Fund may have substantial exposure to a single asset class, industry, sector, country, region, or currency. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, forward currency contracts, and swap contracts. In addition, the Fund may lend its portfolio securities.
Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in equities (see Name Policies). In addition, under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in equities of large- and mid-cap companies (see Name Policies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. The term large- and mid-cap companies means non-U.S. companies that issue stocks included in the MSCI Standard Indices and international stock indices that target approximately 85% of each markets free-float adjusted market capitalization, and companies with similar market capitalizations.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
53
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares*
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
54
Average Annual Total Returns *
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
1/29/02 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
6/30/03 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class VI |
3/28/06 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | N/A | [ | ]% |
* | The Fund is the successor to GMO International Disciplined Equity Fund, a former series of GMO Trust that had an investment objective and investment policies and restrictions substantially identical to those of the Fund. Performance of the Fund through September 16, 2005 is that of GMO International Disciplined Equity Fund and reflects GMO International Disciplined Equity Funds annual operating expenses (0.02% higher than those of the Fund). |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Teams and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
55
Investment objective
Total return in excess of that of its benchmark, the MSCI EAFE Index.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class II | Class III | Class IV | ||||||||||
Management fee |
0.60 | % 1 | 0.60 | % 1 | 0.60 | % 1 | ||||||
Shareholder service fee |
0.22 | % 1 | 0.15 | % 1 | 0.09 | % 1 | ||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | ||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class II |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly in equities of companies tied economically to countries other than the United States. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in investments tied economically to countries other than the United States, including both developed and emerging countries (see Name Policies).
GMO selects investments using value-based fundamental analysis that is informed by a disciplined quantitative screening process. GMO analyzes companies for financial, operational, and managerial strength and compares them to their global, regional, and industry peers. GMO also considers a companys accounting and governance practices. As part of the investment process, GMO frequently meets with management and visits companies.
56
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment objective, the Fund may (but is not obligated to) invest in a wide variety of exchange-traded and over-the-counter (OTC) derivatives, including, without limitation, forward currency contracts, futures and options, as well as exchange-traded funds (ETFs). The Funds foreign currency exposure may differ from the currency exposure of its equity investments. The Fund may invest in securities of issuers of any market capitalization and may have significant exposure to securities of issuers with smaller market capitalizations. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
57
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Information on the Funds return after taxes is unavailable prior to June 28, 1996, the date the Fund commenced operations as a registered investment company. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
58
Average Annual Total Returns a
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class II |
9/30/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class III b |
8/31/84 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | N/A | a | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | N/A | a | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
1/9/98 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
a | Information on the Funds return after taxes is unavailable prior to June 28, 1996, the date the Fund commenced operations as a registered investment company. Prior to that date, the Fund operated as a private investment pool with investment objectives, policies, and guidelines that were substantially the same as those of the Fund. |
b | Performance of Class III shares prior to June 28, 1996 is that of the private investment pool and reflects the pools higher annual operating expenses. The pool was not registered as an investment company and therefore was not subject to restrictions imposed on the Fund by the Investment Company Act of 1940, as amended, and the Internal Revenue Code of 1986, as amended. Had the pool been subject to these restrictions, its performance may have been adversely affected. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Member of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
International Active | Drew Spangler (since 2011) | Head, International Active Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
59
GMO FOREIGN SMALL COMPANIES FUND
Investment objective
Total return in excess of that of its benchmark, the S&P Developed ex-U.S. Small Cap Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | |||||||
Purchase premium (as a percentage of amount invested) |
[0.50 | ]% | [0.50 | ]% | ||||
Redemption fee (as a percentage of amount redeemed) |
[0.50 | ]% | [0.50 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | |||||||
Management fee |
0.70 | % 1 | 0.70 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | ||||
Other expenses |
[ | ]% | [ | ]% | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly in equities of companies tied economically to countries other than the United States whose outstanding publicly traded equities are in the lowest 25% of publicly traded market capitalization (float) in a particular country at the time of investment (small companies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. The market capitalization range of companies whose equities are held by the Fund is generally within the market capitalization range of companies in the Funds benchmark, which represents the lowest 15% of publicly traded
60
market capitalization (float) of the S&P Broad Market Index in each country. Depending on the country, as of May 31, 2016, the market capitalization of the outstanding common stock and other stock-related securities of the largest company in a particular country included in the S&P Developed ex-U.S. Small Cap Index ranged from approximately $[ ] ([ ]) to $[ ] ([ ]) (based on exchange rates as of May 31, 2016). As of May 31, 2016, the publicly traded market capitalization of the largest small company (as defined by the Fund) ranged from approximately $[ ] ([ ]) to $[ ] ([ ]) (based on exchange rates as of May 31, 2016). Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in securities of small companies that are tied economically to countries other than the United States, including both developed and emerging countries (see Name Policies).
GMO selects investments using value-based fundamental analysis that is informed by a disciplined quantitative screening process. GMO analyzes companies for financial, operational, and managerial strength and compares them to their global, regional, and industry peers. GMO also considers a companys accounting and governance practices. As part of the investment process, GMO frequently meets with management and visits companies.
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment objective, the Fund may (but is not obligated to) invest in a wide variety of exchange-traded and over-the-counter (OTC) derivatives, including, without limitation, forward currency contracts, futures and options, as well as exchange-traded funds (ETFs). The Funds foreign currency exposure may differ from the currency exposure of its equity investments. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
|
Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying |
61
assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
62
Average Annual Total Returns a
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III b |
1/4/95 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | N/A | a | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | N/A | a | ||||||||
S&P Developed ex-U.S. Small Cap Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV c |
6/14/02 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P Developed ex-U.S. Small Cap Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
a | Information on the Funds return after taxes is unavailable prior to June 30, 2000, the date the Fund commenced operations as a registered investment company. Prior to that date, the Fund operated as a private investment pool with investment objectives, policies, and guidelines that were substantially the same as those of the Fund. |
b | Performance of Class III shares prior to June 30, 2000 is that of the private investment pool, restated to reflect the Funds higher annual operating expenses. The pool was not registered as an investment company and therefore was not subject to certain restrictions imposed on the Fund by the Investment Company Act of 1940, as amended, and the Internal Revenue Code of 1986, as amended. Had the pool been subject to these restrictions, its performance may have been adversely affected. |
c | For the period from March 16, 2009 to August 12, 2009, no Class IV shares were outstanding. The returns shown in the table for that period are those of Class III shares, which have higher expenses. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Member of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
International Active | Drew Spangler (since 2011) | Head, International Active Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
63
GMO INTERNATIONAL SMALL COMPANIES FUND
Investment objective
Total return in excess of that of its benchmark, the S&P Developed ex-U.S. Small Cap Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.50 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.50 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.60 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly in equities of companies tied economically to countries other than the United States whose outstanding publicly traded equities are in the lowest 25% of publicly traded market capitalization (float) in a particular country at the time of investment (small companies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. The market capitalization range of companies whose equities are held by the Fund is generally within the market capitalization range of companies in the Funds benchmark, which represents the lowest 15% of publicly traded market capitalization (float) of the S&P Broad Market Index in each country. Depending on the country, as of May 31, 2016, the market capitalization of the outstanding common stock and other stock-related securities of the largest company in a particular country
64
included in the S&P Developed ex-U.S. Small Cap Index ranged from approximately $[ ] ([ ]) to $[ ] ([ ]) (based on exchange rates as of May 31, 2016). As of May 31, 2016, the publicly traded market capitalization of the largest small company (as defined by the Fund) ranged from approximately $[ ] ([ ]) to $[ ] ([ ]) (based on exchange rates as of May 31, 2016). Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in securities of small companies that are tied economically to countries other than the United States, including both developed and emerging countries (see Name Policies).
GMO selects investments using value-based fundamental analysis that is informed by a disciplined quantitative screening process. GMO analyzes companies for financial, operational, and managerial strength and compares them to their global, regional, and industry peers. GMO also considers a companys accounting and governance practices. As part of the investment process, GMO frequently meets with management and visits companies.
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment objective, the Fund may (but is not obligated to) invest in a wide variety of exchange-traded and over-the-counter (OTC) derivatives, including, without limitation, forward currency contracts, futures and options, as well as exchange-traded funds (ETFs). The Funds foreign currency exposure may differ from the currency exposure of its equity investments. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
65
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
[The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of two broad-based indices (including the Funds benchmark) and a composite index computed by GMO.] Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance. [The Fund was managed by a different investment team pursuant to a different investment objective and strategy during the periods covered by the bar chart and table below, which materially reduces the relevance of those performance results.]
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
66
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
10/14/91 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P Developed ex-U.S. Small Cap Index a (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P Developed ex-U.S. Small Cap + Index (Composite index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI EAFE Small Cap Index a (Prior Fund benchmark) (returns reflect no deductions for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | N/A |
a | [Effective May 1, 2016, the Fund changed its benchmark from the MSCI EAFE Small Cap Index to the S&P Developed ex-U.S. Small Cap Index because GMO believes the S&P Developed ex-U.S. Small Cap Index is a more appropriate comparative, broad-based market index for the Fund in light of changes to the Funds investment objective and principal investment strategies.] |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Member of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
International Active | Drew Spangler (since May 2016) | Head, International Active Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
67
GMO U.S. EQUITY ALLOCATION FUND
Investment objective
High total return.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Management fee |
0.31 | % 1 | 0.31 | % 1 | 0.31 | % 1 | 0.31 | % 1 | ||||||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO seeks to achieve the Funds investment objective by investing primarily in a portfolio of equities in U.S. equity markets.
GMO selects the securities the Fund should buy or sell based on its evaluation of companies published financial information and corporate behavior, securities prices, equity and bond markets, the overall global economy, and governmental policies.
In selecting securities for the Fund, GMO uses a combination of investment methods to identify securities that GMO believes have positive return potential relative to other securities in U.S. equity markets. Some of these methods evaluate individual securities or groups of securities based on the ratio of their price to historical financial information and forecasted financial information, such as book value, cash flow and earnings, and a comparison of these ratios to industry or market averages or to their own history. Other methods focus on patterns of information, such as price movement or volatility of a security or groups of securities relative to U.S. equity markets. GMO also uses its multi-year return forecasts for asset classes and other groups of securities in its investment process
68
and may adjust the Funds portfolio based on factors such as position size, industry and sector exposure, and market capitalization. At times, the Fund may have substantial exposure to a single industry, sector or market capitalization. The factors GMO considers and investment methods GMO uses can change over time. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark. The Fund may invest in companies of any market capitalization.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include futures, options, and swap contracts. In addition, the Fund may lend its portfolio securities.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through underlying funds or derivatives) at least 80% of its assets in equities tied economically to the United States (see Name Policies). The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Focused Investment Risk Investments focused in sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
69
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares*
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns *
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
9/18/85 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
1/9/98 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class VI |
6/30/03 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P 500 Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
* | The Fund is the successor to GMO U.S. Core Fund, a former series of GMO Trust that had an investment objective and investment policies and restrictions substantially identical to those of the Fund. Performance of the Fund through September 16, 2005 is that of GMO U.S. Core Fund and reflects GMO U.S. Core Funds annual operating expenses (0.02% higher than those of the Fund). As of the date of this Prospectus, no Class V shares of the Fund or its predecessor have been outstanding since February 11, 2005. Class V shares would be invested in the same portfolio of securities as Class III shares. Annual returns would principally differ to the extent Class V shares do not have the same expenses as Class III shares. |
70
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Teams and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2013) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
71
Investment objective
Total return in excess of that of its benchmark, the S&P/IFCI Composite Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class II | Class III | Class IV | Class V | Class VI | ||||||||||||||||
Purchase premium (as a percentage of amount invested) |
[0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% | ||||||||||
Redemption fee (as a percentage of amount redeemed) |
[0.80 | ]% 1 | [0.80 | ]% 1 | [0.80 | ]% 1 | [0.80 | ]% 1 | [0.80 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class II | Class III | Class IV | Class V | Class VI | ||||||||||||||||
Management fee |
0.75 | % 2 | 0.75 | % 2 | 0.75 | % 2 | 0.75 | % 2 | 0.75 | % 2 | ||||||||||
Shareholder service fee |
0.22 | % 2 | 0.15 | % 2 | 0.105 | % 2 | 0.085 | % 2 | 0.055 | % 2 | ||||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 3 | [ | ]% 3 | [ | ]% 3 | [ | ]% 3 | [ | ]% 3 | ||||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||||
Expense reimbursement/waiver |
([ | ]%) 2 | ([ | ]%) 2 | ([ | ]%) 2 | ([ | ]%) 2 | ([ | ]%) 2 | ||||||||||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Applies only to shares acquired on or after June 1, 1995 (including shares acquired by reinvestment of dividends or other distribution). With respect to Class III shares purchased through third-party intermediaries and any shares acquired prior to March 27, 2002, the level of redemption fee charged by the Fund is 0.40%.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses and state and federal registration fees. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. In addition, GMO has contractually agreed to waive the shareholder service fees charged to each class of shares of the Fund to the extent necessary to prevent the shareholder service fees paid by the class from exceeding the following amounts of the classs average daily net assets: 0.20% for Class II shares, 0.15% for Class III shares, 0.10% for Class IV shares, 0.05% for Class V shares, and 0.02% for Class VI shares. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
3 | [These indirect expenses include commissions paid to brokers by the Fund for executing transactions in unaffiliated underlying funds (transaction fees). Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class II |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
72
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly (e.g., through underlying funds or derivatives) in equities of companies tied economically to emerging markets. Emerging markets include all markets that are not treated as developed markets in the MSCI World Index or MSCI EAFE Index. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in investments tied economically to emerging markets (see Name Policies). In addition to investing in companies tied economically to emerging markets, the Fund may invest in companies that GMO believes are likely to benefit from growth in the emerging markets. GMO expects that the Fund will have a value bias relative to its benchmark.
GMO uses proprietary quantitative techniques and fundamental analysis to evaluate and select countries, sectors, and equity investments based on factors including, but not limited to, valuation and macroeconomic factors. In constructing the Funds portfolio, GMO weighs a number of factors, including the trade-off among forecasted returns, risk relative to the benchmark, transaction costs, and liquidity. GMO also adjusts the Funds portfolio for factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. The factors GMO considers and investment methods GMO uses can change over time.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include options, futures, warrants, swap contracts, and reverse repurchase agreements. The Funds foreign currency exposure may differ from the currency exposure represented by its equity investments. In addition, the Fund may overweight and underweight its positions in particular currencies relative to its benchmark. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
|
Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or |
73
exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Focused Investment Risk Investments focused in a limited number of countries and regions (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests (including ETFs), including the risk that those underlying funds will not perform as expected. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations.. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
74
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class II a |
11/29/96 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class III |
12/9/93 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
1/9/98 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class V b |
8/4/03 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class VI |
6/30/03 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
a | For the period from January 9, 1998 to August 12, 2009, no Class II shares were outstanding. The returns shown in the table for that period are those of Class III shares, which have been adjusted downward to reflect Class IIs higher total annual fund operating expenses (Class IIs expenses during these periods were calculated by adjusting Class IIIs actual total annual fund operating expenses during such periods upward by the current differential between Total annual fund operating expenses for Class II and Class III shares shown in the Funds Annual Fund operating expenses table). |
b | For the period from October 26, 2004 to February 11, 2005, no Class V shares were outstanding. The returns shown in the table for that period are those of Class IV shares, which have higher expenses. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Emerging Markets Equity | Arjun Divecha (since the Funds inception) | Head, Emerging Markets Equity Team, GMO. | ||
Emerging Markets Equity | Amit Bhartia (since September 2015) | [Portfolio Manager, Emerging Markets Equity Team, GMO.] | ||
Emerging Markets Equity | Warren Chiang (since June 2015) | Portfolio Manager, Emerging Markets Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
75
Investment objective
Total return in excess of that of its benchmark, the S&P/IFCI Composite Index.
Fees and expenses
The table below describes the fees and expenses that you may bear if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.65 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 2 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the portion of its Specified Operating Expenses (as defined below) that exceeds 0.35% of the Funds average daily net assets. Specified Operating Expenses means only the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [These indirect expenses include commissions paid to brokers by the Fund for executing transactions in unaffiliated underlying funds (transaction fees). Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were [ ]% and less than [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amount shown reflects the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly (e.g., through underlying funds or derivatives) in equities of companies tied economically to emerging countries. Emerging countries include all countries that are not treated as developed market countries in the MSCI World Index or MSCI EAFE Index. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in investments tied economically to emerging countries (see Name Policies). In addition to investing in companies tied economically to emerging countries, the Fund may invest in companies that GMO believes are likely to benefit from growth in the emerging markets. GMO expects that the Fund will have a value bias relative to its benchmark. In general, the Fund typically invests in companies with larger market capitalizations than does Emerging Markets Fund.
GMO uses proprietary quantitative techniques and fundamental analysis to evaluate and select countries, sectors, and equity investments based on factors including, but not limited to, valuation and macroeconomic factors. In constructing the Funds portfolio,
76
GMO weighs a number of factors, including the trade-off among forecasted returns, risk relative to the benchmark, transaction costs, and liquidity. GMO also adjusts the Funds portfolio for factors such as position size, market capitalization, and exposure to particular industries, sectors, countries, regions, or currencies. The factors GMO considers and investment methods GMO uses can change over time.
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include options, futures, warrants, swap contracts, and reverse repurchase agreements. The Funds foreign currency exposure may differ from the currency exposure represented by its equity investments. In addition, the Fund may overweight and underweight its positions in particular currencies relative to its benchmark. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
77
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Focused Investment Risk Investments focused in a limited number of countries and regions (or in sectors within a country or region) that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests (including ETFs), including the risk that those underlying funds will not perform as expected. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
8/29/97 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
S&P/IFCI Composite Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
78
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Emerging Markets Equity | Arjun Divecha (since the Funds inception) | Head, Emerging Markets Equity Team, GMO. | ||
Emerging Markets Equity | Amit Bhartia (since September 2015) | [Portfolio Manager, Emerging Markets Equity Team, GMO.] | ||
Emerging Markets Equity | Warren Chiang (since June 2015) | Portfolio Manager, Emerging Markets Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
79
GMO EMERGING DOMESTIC OPPORTUNITIES FUND
Investment objective
Total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class II | Class III | Class IV | Class V | Class VI | ||||||||||||||||
Purchase premium (as a percentage of amount invested) |
[0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% | ||||||||||
Redemption fee (as a percentage of amount redeemed) |
[0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% | [0.80 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class II | Class III | Class IV | Class V | Class VI | ||||||||||||||||
Management fee |
0.75 | % 1 | 0.75 | % 1 | 0.75 | % 1 | 0.75 | % 1 | 0.75 | % 1 | ||||||||||
Shareholder service fee |
0.22 | % 1 | 0.15 | % 1 | 0.105 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 2 | [ | ]% 2 | [ | ]% 2 | [ | ]% 2 | [ | ]% 2 | ||||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and any portion of custody expenses that exceeds 0.10% of the Funds average daily net assets. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [These indirect expenses include commissions paid to brokers by the Fund for executing transactions in unaffiliated underlying funds (transaction fees). Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class II |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
80
Principal investment strategies
The Fund typically invests directly and indirectly (e.g., through underlying funds or derivatives) in equities, and, to a lesser extent, fixed income securities, of companies whose prospects are linked to the internal (domestic) development and growth of the worlds non-developed markets (emerging markets), including companies that provide goods and services to emerging market consumers. Emerging markets include all markets that are not treated as developed markets in the MSCI World Index or MSCI EAFE Index.
The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in investments related to emerging markets (see Name Policies). The Funds investments are not limited to investments in companies located in any particular country or geographic region, and often include investments in companies located in developed markets (e.g., the United States) that are related to, or whose prospects are linked to, emerging markets. GMO does not manage the Fund to, or control the Funds risk relative to, any index or benchmark.
GMO primarily uses fundamental analysis to evaluate and select countries, sectors, and companies that it believes are likely to benefit from domestic growth in emerging markets. The process begins with country and sector allocation and then focuses on the selection of individual companies. In evaluating and selecting investments, GMO may consider many factors, including, among others, GMOs assessment of a countrys and/or sectors fundamentals or growth prospects as well as a companys positioning relative to its competitors. In constructing the Funds portfolio, GMO weighs a number of factors, including the trade-off among forecasted returns, risk, transaction costs, and liquidity. The factors GMO considers and investment methods GMO uses can change over time.
As an alternative to investing directly in equities and fixed income securities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include options, futures, warrants, swap contracts, and reverse repurchase agreements. The Funds foreign currency exposure may differ from the currency exposure represented by its equity investments. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
81
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Focused Investment Risk The Funds investments in companies whose prospects are linked to the internal development and growth of a particular emerging markets country create additional risk because the performance of those companies is likely to be highly correlated. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests (including ETFs), including the risk that those underlying funds will not perform as expected. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
82
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class II shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class II Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class II |
3/24/11 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI Emerging Markets Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class III |
6/29/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI Emerging Markets Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class IV |
5/2/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI Emerging Markets Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class V |
11/29/13 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI Emerging Markets Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class VI |
9/19/11 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI Emerging Markets Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Sub-Adviser: GMO Singapore Pte. Limited (GMO Singapore)
Investment Team and Senior Members of GMO and/or GMO Singapore primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Emerging Markets Equity | Arjun Divecha (since the Funds inception) | Head, Emerging Markets Equity Team, GMO. | ||
Emerging Markets Equity | Amit Bhartia (since the Funds inception) | [Portfolio Manager, Emerging Markets Equity Team, GMO Singapore.] |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
83
Investment objective
Total return in excess of that of its benchmark, the J.P. Morgan GBI Global.
Fees and expenses
The table below describes the fees and expenses that you may bear if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.19 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% 2 | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 3 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the portion of its Specified Operating Expenses (as defined below) that exceeds 0.06% of the Funds average daily net assets. Specified Operating Expenses means only the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [The amount includes interest expense incurred by the Fund as a result of entering into reverse repurchase agreements and/or margin on cleared swap contracts, if any. Other expenses (before addition of interest expense) and interest expense were approximately [ ]% and less than [ ]%, respectively.] |
3 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, [ ]%, and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amount shown reflects the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Funds investment program has two principal components. One component seeks to replicate the Funds benchmark. The second component seeks to add value relative to the Funds benchmark by making investments that will often not track its benchmark. These investments principally include global interest rate and currency derivatives and indirect (through other GMO Funds) and direct credit investments in asset-backed, government and emerging country debt securities, and can cause the Funds performance to differ significantly from that of its benchmark. The Fund typically has substantial direct and indirect investment exposure to the countries (e.g., Japan) and regions (e.g., Eurozone) that represent a significant portion of the Funds benchmark.
84
In deciding what investments to make in global interest rate and currency markets and the size of those investments, GMO considers fundamental factors (e.g., inflation and current account positions) as well as price-based factors (e.g., interest and exchange rates). GMO evaluates the relative attractiveness of particular markets and instruments using various fixed income risk premium measures, which typically include exposure to term structure, foreign exchange, volatility, credit, liquidity and other risks. GMO also may consider the relative attractiveness of yield curve and duration positions in these markets.
In making decisions regarding credit investments, GMO uses fundamental investment techniques to assess the expected performance of each investment relative to the Funds benchmark.
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment program, the Fund may make investments in:
| derivatives, including without limitation, futures contracts, currency options, interest rate options, currency forwards, reverse repurchase agreements, and swap contracts, such as credit default swaps, swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, correlation swaps, and other types of swaps (to generate a return comparable to the Funds benchmark and to generate return in global interest rate, currency, and credit markets); |
| non-U.S. bonds and other bonds denominated in various currencies, including non-U.S. and U.S. government bonds, asset-backed securities issued by non-U.S. governments and U.S. government agencies (whether or not guaranteed or insured by those governments), corporate bonds, and mortgage-backed and other asset-backed securities issued by private issuers; |
| shares of Debt Opportunities Fund (to provide exposure to credit (particularly, asset-backed) markets); |
| shares of GMO World Opportunity Overlay Fund, a GMO Fund not offered by this Prospectus (Overlay Fund) (to provide exposure to the global interest rate, currency, and credit markets); |
| shares of Emerging Country Debt Fund (ECDF) (to provide exposure to emerging country debt securities); and |
| shares of U.S. Treasury Fund, money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds. |
As a result primarily of its investment in shares of Debt Opportunities Fund, Overlay Fund, and ECDF, the Fund has and expects to continue to have material exposure to U.S. asset-backed and emerging country debt securities that are below investment grade (below investment grade debt investments are sometimes referred to as junk bonds, although this term is not generally used to refer to emerging country debt securities).
GMO normally seeks to maintain the Funds estimated interest rate duration within 2 years of the benchmarks duration (approximately [ ] years as of 5/31/16). For an additional discussion of duration, see Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds Duration.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in bonds (see Name Policies). The term bond includes (i) obligations of an issuer to make payments on future dates of principal, interest (whether fixed or variable) or both and (ii) synthetic debt instruments created by GMO by using derivatives (e.g., a futures contract, swap contract, currency forward, or option).
From time to time, the Fund may have some direct or indirect exposure to equities.
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
|
Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to |
85
honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated, such as the Funds investments in non-U.S. government bonds and asset-backed securities secured by different types of consumer debt (e.g., credit-card receivables, automobile loans, and home equity loans), are subject to greater overall risk than investments that are more diversified. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
86
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
12/28/95 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan GBI Global (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
87
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Michael Emanuel (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Greg Jones (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
88
GMO CURRENCY HEDGED INTERNATIONAL BOND FUND
Investment objective
Total return in excess of that of its benchmark, the J.P. Morgan GBI Global ex Japan ex U.S. (Hedged).
Fees and expenses
The table below describes the fees and expenses that you may bear if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.25 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% 2 | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 3 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [The amount includes interest expense incurred by the Fund as a result of entering into reverse repurchase agreements and/or margin on cleared swap contracts, if any. Other expenses (before addition of interest expense) and interest expense were approximately [ ]% and less than [ ]%, respectively.] |
3 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amount shown reflects the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Funds investment program has two principal components. One component seeks to replicate the Funds benchmark. The second component seeks to add value relative to the Funds benchmark by making investments that will often not track its benchmark. These investments principally include global interest rate and currency derivatives and indirect (through other GMO Funds) and direct credit investments in asset-backed, government and emerging country debt securities, and can cause the Funds performance to differ significantly from that of its benchmark. The Fund typically has substantial direct and indirect investment exposure to the countries (e.g., United Kingdom) and regions (e.g., Eurozone) that represent a significant portion of the Funds benchmark.
In deciding what investments to make in global interest rate and currency markets and the size of those investments, GMO considers fundamental factors (e.g., inflation and current account positions) as well as price-based factors (e.g., interest and exchange
89
rates). GMO evaluates the relative attractiveness of particular markets and instruments using various fixed income risk premium measures, which typically include exposure to term structure, foreign exchange, volatility, credit, liquidity and other risks. GMO also may consider the relative attractiveness of yield curve and duration positions in these markets.
In making decisions regarding credit investments, GMO uses fundamental investment techniques to assess the expected performance of each investment relative to the Funds benchmark.
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment program, the Fund may make investments in:
| derivatives, including without limitation, futures contracts, currency options, interest rate options, currency forwards, reverse repurchase agreements, and swap contracts, such as credit default swaps, swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, correlation swaps, and other types of swaps (to generate a return comparable to the Funds benchmark and to generate return in global interest rate, currency, and credit markets); |
| bonds denominated in various currencies, including non-U.S. and U.S. government bonds, asset-backed securities issued by non-U.S. governments and U.S. government agencies (whether or not guaranteed or insured by those governments), corporate bonds, and mortgage-backed and other asset-backed securities issued by private issuers; |
| shares of Debt Opportunities Fund (to provide exposure to credit (particularly, asset-backed) markets); |
| shares of GMO World Opportunity Overlay Fund, a GMO Fund not offered by this Prospectus (Overlay Fund) (to provide exposure to the global interest rate, currency, and credit markets); |
| shares of Emerging Country Debt Fund (ECDF) (to provide exposure to emerging country debt securities); and |
| shares of U.S. Treasury Fund, money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds. |
The Fund generally attempts to hedge at least 75% of its net foreign currency exposure into U.S. dollars.
As a result primarily of its investment in shares of Debt Opportunities Fund, Overlay Fund, and ECDF, the Fund has and expects to continue to have material exposure to U.S. asset-backed and emerging country debt securities that are below investment grade (below investment grade debt investments are sometimes referred to as junk bonds, although this term is not generally used to refer to emerging country debt securities).
GMO normally seeks to maintain the Funds estimated interest rate duration within 2 years of the benchmarks duration (approximately [ ] years as of 5/31/16). For an additional discussion of duration, see Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds Duration.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in bonds (see Name Policies). The term bond includes (i) obligations of an issuer to make payments on future dates of principal, interest (whether fixed or variable) or both and (ii) synthetic debt instruments created by GMO by using derivatives (e.g., a futures contract, swap contract, currency forward, or option).
From time to time, the Fund may have some direct or indirect exposure to equities.
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
90
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated, such as the Funds investments in non-U.S. government bonds and asset-backed securities secured by different types of consumer debt (e.g., credit-card receivables, automobile loans, and home equity loans), are subject to greater overall risk than investments that are more diversified. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
91
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Funds benchmark (which is a broad-based index) and a composite index computed by GMO. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
9/30/94 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan GBI Global ex Japan ex U.S. (Hedged) (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan GBI Global ex Japan ex U.S. (Hedged) + (Composite index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
92
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Michael Emanuel (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Greg Jones (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
93
Investment objective
Total return in excess of that of its benchmark, the Barclays U.S. Aggregate Index.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | |||||||
Management fee |
0.25 | % 1 | 0.25 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | ||||
Other expenses |
[ | ]% 2 | [ | ]% 2 | ||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 3 | [ | ]% 3 | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [The amount includes interest expense incurred by the Fund as a result of entering into reverse repurchase agreements and/or margin on cleared swap contracts, if any. Other expenses (before addition of interest expense) and interest expense were approximately [ ]% and less than [ ]%, respectively.] |
3 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Funds investment program has two principal components. One component seeks to replicate the Funds benchmark. The second component seeks to add value relative to the Funds benchmark by making investments that will often not track its benchmark. These investments principally include global interest rate and currency derivatives and indirect (through other GMO Funds) and direct credit investments in asset-backed, government and emerging country debt securities, and can cause the Funds performance to differ significantly from that of its benchmark.
94
In deciding what investments to make in global interest rate and currency markets and the size of those investments, GMO considers fundamental factors (e.g., inflation and current account positions) as well as price-based factors (e.g., interest and exchange rates). GMO evaluates the relative attractiveness of particular markets and instruments using various fixed income risk premium measures, which typically include exposure to term structure, foreign exchange, volatility, credit, liquidity and other risks. GMO also may consider the relative attractiveness of yield curve and duration positions in these markets.
In making decisions regarding credit investments, GMO uses fundamental investment techniques to assess the expected performance of each investment relative to the Funds benchmark.
The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment program, the Fund may make investments in:
| derivatives, including without limitation, futures contracts, currency options, interest rate options, currency forwards, reverse repurchase agreements, short sales, and swap contracts, such as credit default swaps, swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, correlation swaps, and other types of swaps (to generate a return comparable to the Funds benchmark and to generate return in global interest rate, currency, and credit markets); |
| bonds denominated in various currencies, including non-U.S. and U.S. government bonds, asset-backed securities issued by non-U.S. governments and U.S. government agencies (whether or not guaranteed or insured by those governments), corporate bonds, and mortgage-backed and other asset-backed securities issued by private issuers; |
| shares of Debt Opportunities Fund (to provide exposure to credit (particularly, asset-backed) markets); |
| shares of GMO World Opportunity Overlay Fund, a GMO Fund not offered by this Prospectus (Overlay Fund) (to provide exposure to the global interest rate, currency, and credit markets); |
| shares of Emerging Country Debt Fund (ECDF) (to provide exposure to emerging country debt securities); and |
| shares of U.S. Treasury Fund, money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds. |
As a result primarily of its investment in shares of Debt Opportunities Fund, Overlay Fund, and ECDF, the Fund has and expects to continue to have material exposure to U.S. asset-backed and emerging country debt securities that are below investment grade (below investment grade debt investments are sometimes referred to as junk bonds, although this term is not generally used to refer to emerging country debt securities).
GMO normally seeks to maintain the Funds estimated interest rate duration within 2 years of the benchmarks duration (approximately [ ] years as of 5/31/16). For an additional discussion of duration, see Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds Duration.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in bonds (see Name Policies). The term bond includes (i) obligations of an issuer to make payments on future dates of principal, interest (whether fixed or variable) or both and (ii) synthetic debt instruments created by GMO by using derivatives (e.g., a futures contract, swap contract, currency forward, or option).
From time to time, the Fund may have some direct or indirect exposure to equities.
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
|
Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade |
95
securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated, such as the Funds investments in non-U.S. government bonds and asset-backed securities secured by different types of consumer debt (e.g., credit-card receivables, automobile loans, and home equity loans), are subject to greater overall risk than investments that are more diversified. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
96
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
4/30/97 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Barclays U.S. Aggregate Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
7/26/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Barclays U.S. Aggregate Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
97
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Michael Emanuel (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Greg Jones (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
98
GMO EMERGING COUNTRY DEBT FUND
Investment objective
Total return in excess of that of its benchmark, the J.P. Morgan EMBI Global.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | |||||||
Purchase premium (as a percentage of amount invested) |
[0.75 | ]% | [0.75 | ]% | ||||
Redemption fee (as a percentage of amount redeemed) |
[0.75 | ]% | [0.75 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | |||||||
Management fee |
0.35 | % 1 | 0.35 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | ||||
Other expenses |
[ | ]% | [ | ]% | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense waiver |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees. During the Funds most recent fiscal year, the impact of this waiver was less than [ ]%.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund invests primarily in debt of emerging market sovereign or quasi-sovereign issuers that usually is denominated in U.S. dollars, Euros, Japanese yen, Swiss francs or British pounds sterling. Sovereign refers to a government and quasi-sovereign refers to a governmental agency, political subdivision or other instrumentality or issuer that is majority owned, directly or indirectly, or whose obligations are guaranteed, by a government. Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in debt investments tied economically to emerging countries (see Name Policies). The term emerging countries means the worlds less developed countries. In general, the Fund considers emerging countries to be the countries included in the Funds benchmark, as well as other countries with similar national domestic products or default histories.
99
The Fund typically gains its investment exposure by [purchasing debt investments or by using derivatives, typically credit default swaps.] The Fund may invest in debt instruments of all credit qualities, including securities that are in default. (These debt instruments may include below investment grade debt investments, which are sometimes referred to as junk bonds, although this term is not generally used to refer to emerging country debt securities.) Generally, at least 75% of the Funds assets are denominated in, or hedged into, U.S. dollars. The Funds performance is likely to be more volatile than that of its benchmark.
When constructing the portfolio, GMO considers risk at both the portfolio and individual security level and generally takes into account, among other factors, interest rate duration, credit spread duration, and default duration as well as the idiosyncratic risk of each instrument. GMO relies principally on a bottom-up approach using fundamental analytical techniques in selecting investments. GMO also considers its outlook for a country in making investment decisions. The factors GMO considers and investment methods GMO uses can change over time.
In pursuing its investment objective, the Fund typically invests in exchange-traded and over-the-counter (OTC) derivatives, including options, swap contracts (in addition to credit default swaps), currency forwards (including currency forwards on currencies of the developed markets), reverse repurchase agreements and futures. The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
GMO normally seeks to maintain an interest rate duration for the Fund that is similar to that of its benchmark (approximately [ ] years as of 5/31/16). For an additional discussion of duration, see Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds Duration.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. In addition, investments in emerging country sovereign or quasi-sovereign debt involve a heightened risk that the issuer responsible for repayment of the debt may be unable or unwilling to pay interest and repay principal when due, and the Fund may lack recourse against the issuer in the event of default. Investments in quasi-sovereign debt are also subject to the risk that the issuer will default independently of its sovereign. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). In addition, the market prices of emerging country sovereign and quasi-sovereign debt instruments can decline due to uncertainty about their credit quality and the reliability of their payment streams. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
100
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Funds benchmark (which is a broad-based index) and a composite index computed by GMO. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax
101
returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
4/19/94 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan EMBI Global (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan EMBI Global + (Composite index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
1/9/98 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan EMBI Global (Fund benchmark) (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
J.P. Morgan EMBI Global + (Composite index) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Emerging Country Debt | Thomas Cooper* (since the Funds inception) | Co-Head, Emerging Country Debt Team, GMO. | ||
Emerging Country Debt | Tina Vandersteel (since 2015) | Co-Head, Emerging Country Debt Team, GMO. |
* | As part of a transition plan, Mr. Cooper will be reducing his involvement in the day-to-day management of the Fund until his retirement on September 30, 2016, after which Ms. Vandersteel will be the sole Senior Member and Head of the Emerging Country Debt Team. |
Additional information
Please see the table in Management of the Trust for important information on the above investment team members. For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
102
Investment objective
Positive total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class VI | |||||||
Purchase premium (as a percentage of amount invested) |
[0.40 | ]% | [0.40 | ]% | ||||
Redemption fee (as a percentage of amount redeemed) |
[0.40 | ]% | [0.40 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class VI | |||||||
Management fee |
0.25 | % 1 | 0.25 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.055 | % 1 | ||||
Other expenses |
[ | ]% | [ | ]% | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees, and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund invests primarily in debt investments (including both direct and indirect investments) and is not restricted in its exposure to any type of debt investment. The Fund may invest in securities of any credit quality and has no limit on how much it may invest in below investment grade securities (commonly referred to as junk bonds). The Funds debt investments may include all types of interest rate, payment, and reset terms, including fixed rate, adjustable rate, zero coupon, contingent, deferred, payment-in-kind, and auction rate features.
103
The Fund may invest in debt investments issued by a wide range of U.S. and, typically to a lesser extent, non-U.S. private issuers and by federal, state, local, and non-U.S. governments (whether or not guaranteed or insured by those governments). The Fund may invest in asset-backed securities (including, but not limited to, securities backed by pools of residential and commercial mortgages (including sub-prime mortgages), credit-card receivables, home equity loans, automobile loans, educational loans, corporate, sovereign and quasi-sovereign bonds, and bank loans made to corporations), corporate debt securities, money market instruments, and commercial paper. [As of the date of this Prospectus, the Fund has invested a substantial portion of its assets in asset-backed securities, many of which are below investment grade.]
In selecting debt investments for the Funds portfolio, GMO uses analytical techniques to evaluate the relative attractiveness of particular sectors and securities. The factors GMO considers and investment methods GMO uses can change over time.
The Fund does not maintain a specified interest rate duration for its portfolio.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in debt investments (see Name Policies).
From time to time, the Fund may have some direct or indirect exposure to equities.
The Fund also may invest in exchange-traded and over-the-counter (OTC) derivatives, including swap contracts (such as credit default swaps, swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, correlation swaps, and other types of swaps), reverse repurchase agreements, and repurchase agreements. The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund may have gross investment exposures in excess of its net assets (i.e., the Fund may be leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
The Fund may, but is not required to, hedge part or all of its net foreign currency exposure into U.S. dollars.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
|
Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in |
104
the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin, or otherwise honor its obligations. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests, including the risk that those underlying funds will not perform as expected. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
105
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class VI Shares* ,
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns * ,
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class VI |
10/3/11 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
J.P. Morgan U.S. 3 Month Cash Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% |
* | The Fund is the accounting and performance successor to GMO Debt Opportunities Fund, a former series of GMO Trust offered pursuant to a private placement memorandum (the Predecessor Fund) that had an investment objective and investment policies and restrictions substantially identical to those of the Fund. Effective February 12, 2014, the Predecessor Fund merged into the Fund (which was formerly known as GMO Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund. Performance of the Fund through February 12, 2014 is that of the Predecessor Fund and reflects the Predecessor Funds annual operating expenses (0.01% lower than those of the Fund). For information regarding GMO Short-Duration Collateral Funds performance history, please see page [ ] of this Prospectus. |
| On December 21, 2015 GMO changed the primary pricing source for certain fixed income asset-backed securities held by the Fund, which resulted in an increase of $0.04 to the December 21, 2015 net asset value of Class VI shares of the Fund. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Joe Auth (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
106
Investment objective
Total return greater than that of its benchmark, the Citigroup 3-Month Treasury Bill Index.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | |||||||
Management fee |
0.50 | % 1 | 0.50 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | ||||
Other expenses |
[ | ]% | [ | ]% | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other funds or accounts managed by GMO. Accordingly, the Fund is not a standalone investment.
The Funds investment program involves having both long and short investment exposures. GMO seeks to construct a portfolio in which the Fund has long investment exposure to asset classes and sub-asset classes that GMO expects will outperform relative to the asset classes and sub-asset classes to which the Fund has short investment exposure.
To gain long investment exposure, the Fund invests directly in securities and may invest in other GMO Funds (collectively, the underlying GMO Funds). To gain short investment exposure, the Fund typically invests in over-the-counter (OTC) and exchange-traded derivatives (including futures, swaps and currency forwards) and sell securities short, including short sales of securities the Fund does not own. The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
107
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds long and short positions. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. If the Funds long and short positions are effective, the Funds performance should have a low correlation to the performance of U.S. and non-U.S. equity markets. The factors GMO considers and investment methods GMO uses can change over time.
[In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.]
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. An investment in the Fund is subject to different risks, and greater overall risk, than an investment in the components of the Funds benchmark. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. The Fund and some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund or those underlying GMO Funds may affect the Funds or an underlying GMO Funds performance more than if the Fund or the underlying GMO Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
|
Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund or an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund or an underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these |
108
equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. In addition, the value of the Funds shares will be adversely affected if the equities that are the subject of the Funds short positions appreciate in value. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives creates leverage. The Fund and some underlying GMO Funds are not limited in their use of derivatives or in the total notional value of their derivative positions. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected or that the Fund will invest in underlying GMO Funds with higher fees or expenses. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
109
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
7/29/94 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Citigroup 3-Month Treasury Bill Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Class IV |
3/2/06 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Citigroup 3-Month Treasury Bill Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since 1996) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
110
GMO ASSET ALLOCATION BOND FUND
Investment objective
Total return in excess of that of its benchmark, the Citigroup 3-Month Treasury Bill Index.
Fees and expenses
The table below describes the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class VI | |||||||
Management fee |
0.25 | % 1 | 0.25 | % 1 | ||||
Shareholder service fee |
0.15 | % 1 | 0.055 | % 1 | ||||
Other expenses |
[ | ]% 2 | [ | ]% 2 | ||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | ||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [The amount includes interest expense incurred by the Fund as a result of entering into reverse repurchase agreements and/or margin on cleared swap contracts, if any. Other expenses (before addition of interest expense) and interest expense were approximately [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other funds or accounts managed by GMO. Accordingly, the Fund is not a standalone investment.
The Fund invests in a portfolio of fixed income instruments of varying maturities, which may be represented by bonds, forwards or derivatives such as options, futures contracts, or swap agreements. GMO uses a variety of fundamental and quantitative processes to manage the Fund. GMO evaluates the relative attractiveness of particular markets and instruments using various fixed income risk premium measures, which typically include exposure to term structure, foreign exchange, volatility, credit, liquidity and other risks.
Under normal circumstances, the Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in bonds (see Name Policies). The term bond includes (i) obligations of an issuer to make payments on future dates of principal, interest (whether fixed or variable) or both and (ii) synthetic debt instruments created by GMO by using derivatives (e.g., a futures contract, swap contract, currency forward, or option). The Fund is permitted to invest in bonds of any kind (e.g., bonds of any maturity, duration, or credit quality).
111
The Fund may invest in any sector of the bond market and is not required to maintain a minimum or maximum allocation of investments in any one sector. The sectors and types of bonds in which the Fund may invest include, but are not limited to:
| investment grade bonds denominated in various currencies, including bonds issued by the U.S. and non-U.S. governments and their respective agencies or instrumentalities (whether or not guaranteed or insured by those governments), corporations and municipalities (taxable and tax-exempt); |
| below investment grade bonds (commonly referred to as junk bonds); |
| inflation-indexed bonds issued by the U.S. government (including Inflation-Protected Securities issued by the U.S. Treasury (TIPS)) and non-U.S. governments and their respective agencies or instrumentalities (whether or not guaranteed or insured by those governments) and inflation-indexed bonds issued by corporations; |
| bonds issued in emerging countries (including sovereign and quasi-sovereign debt and below investment grade bonds); |
| asset-backed securities, including mortgage related and mortgage-backed securities; |
| pooled investment vehicles, including both vehicles managed by GMO and vehicles unaffiliated with GMO; and |
| commodities. |
From time to time, the Fund may have some direct or indirect exposure to equities.
The Fund also may invest in exchange-traded and over-the-counter (OTC) derivatives, including futures contracts, currency options, currency forwards, reverse repurchase agreements, swap contracts (such as credit default swaps, swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, correlation swaps, and other types of swaps), interest rate options, and other types of derivatives. The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund typically has gross investment exposures in excess of its net assets (i.e., the Fund typically is leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund may gain exposure to the investments described above by investing in shares of other GMO Funds, including Debt Opportunities Fund (to provide exposure to credit (particularly, asset-backed) markets), Emerging Country Debt Fund (to provide exposure to emerging country debt securities), GMO High Quality Short-Duration Bond Fund (High Quality Fund) (to seek a return in excess of that of the J.P. Morgan U.S. 3 Month Cash Index by investing in a wide variety of high quality U.S. and non-U.S. debt investments), and GMO World Opportunity Overlay Fund (Overlay Fund) (to gain exposure to global interest rate, currency, and credit markets). Each of High Quality Fund and Overlay Fund is a GMO Fund not offered by this Prospectus. The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
The Fund may invest up to 100% of its assets in below investment grade bonds.
GMO does not seek to maintain a specified interest rate duration for the Fund, and the Funds interest rate duration will change depending on the Funds investments and GMOs assessment of different sectors of the bond market. The Funds interest rate duration may be positive or negative. The Funds performance may differ significantly from that of its benchmark.
In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. An investment in the Fund is subject to different risks, and greater overall risk, than an investment in the components of the Funds benchmark. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
112
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
113
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests, including the risk that those underlying funds will not perform as expected. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
3/27/09 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Citigroup 3-Month Treasury Bill Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Class VI |
3/18/09 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Citigroup 3-Month Treasury Bill Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% |
114
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Michael Emanuel (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Greg Jones (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
115
Investment objective
Positive total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.18 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.18 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ])% 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, less than [ ]%, and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees, and the Funds direct non-emerging market custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund is a fund of funds and invests primarily in shares of other series of GMO Trust (each, a GMO Fund). The Fund may invest in any GMO Fund (collectively, the underlying GMO Funds), whether now existing or created in the future, including GMO Funds not offered by this Prospectus. These underlying GMO Funds may include, among others, the Equity Funds, the Fixed Income
116
Funds, the Implementation Funds, and SGM Major Markets Fund, as well as GMO High Quality Short-Duration Bond Fund and GMO World Opportunity Overlay Fund, each a series of the Trust not offered by this Prospectus (see Additional Information About the Funds Investment Strategies, Risks and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (particularly asset-backed securities, and including other underlying funds).
GMO implements the Funds strategy by allocating its assets among asset classes represented by the underlying GMO Funds (e.g., non-U.S. equity, U.S. equity, emerging country equity, emerging country debt, non-U.S. fixed income, U.S. fixed income and commodities). The Fund is not restricted in its exposure to any particular asset class, and at times may be substantially invested in underlying GMO Funds that primarily invest in a single asset class (e.g., Fixed Income Funds). In addition, the Fund is not restricted in its exposure to any particular market, capitalization range, quality or maturity. At times, the Fund may have substantial exposure to a particular country or type of country (including non-U.S. countries). GMO does not manage the Fund to, or control the Funds risk relative to, any index or benchmark.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to select the underlying GMO Funds in which the Fund invests and to decide how much to invest in each. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. GMOs ability to shift investments among the underlying GMO Funds is not subject to any limits. The Fund may invest substantially all of its assets in a few underlying GMO Funds that primarily invest in the same asset class and may, at times, also invest a substantial portion of its assets in a single underlying GMO Fund. The Fund may have indirect exposure to derivatives and short sales through its investment in other underlying GMO Funds. The Fund also reserves the right to invest directly in asset classes, or to adjust its exposure to asset classes, through direct investments. The factors GMO considers and investment methods GMO uses can change over time.
To the extent the Fund seeks exposure to commodities and some other asset classes, it will obtain such exposures by investing through a wholly-owned subsidiary advised by GMO, which does not receive management or other fees for its services. The subsidiary invests primarily in commodity-related derivatives and fixed income securities but also may invest in any other investment in which the Fund is permitted to invest directly. References in this Prospectus to the Fund may refer to actions undertaken by the subsidiary as well as the Fund. The Fund does not invest directly in commodities and commodity-related derivatives, but may do so indirectly through its subsidiary company (or otherwise).
In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.
The Fund also may invest in in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
|
Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in |
117
those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| [ Futures Contracts Risk The risk of loss relating to some uses of futures contracts is potentially unlimited. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract or at any particular time. In the event no such market exists for a particular derivative, it might not be possible to effect closing transactions, and the Fund will be unable to terminate its exposure to the futures contract. If the Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the futures contract and movements in the securities or index underlying the futures contract or movements in the prices of the Funds investments that are the subject of such hedge. Foreign futures contracts may be less liquid and more volatile than U.S. contracts. The Fund may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse.] |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
118
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin, or otherwise honor its obligations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Barclays U.S. Treasury Inflation Notes: 1-10 Year Index and the Consumer Price Index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
6/15/11 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% |
119
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
120
Investment objective
Positive total return, not relative return.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Purchase premium (as a percentage of amount invested) |
[0.20 | %] | ||
Redemption fee (as a percentage of amount redeemed) |
[0.20 | %] |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Management fee |
0.00 | % | ||
Other expenses |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ])% 2 | ||
Total annual fund operating expenses after expense reimbursement |
[ | ]% |
1 | [The amount includes interest expense and dividend expenses incurred by the Fund as a result of short sales. Other expenses (before addition of interest expense and dividend expenses on short sales), interest expense and dividend expenses on short sales were approximately [ ]%, less than [ ]% and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees, and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
GMO Implementation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Implementation SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Implementation SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other funds or accounts managed by GMO. Accordingly, the Fund is not a standalone investment. GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to determine the Funds strategic direction. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. The factors GMO considers and investment methods GMO uses can change over time.
GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark. Depending on GMOs outlook, the Fund may have exposure to any asset class (e.g., non-U.S. equity, U.S. equity, emerging country equity, emerging country debt, non-U.S. fixed income, U.S. fixed income, real estate, and commodities) and at times may be
121
substantially invested in a single asset class. The Fund may invest in companies of any market capitalization. In addition, the Fund is not limited in how much it may invest in any market, and it may invest all of its assets in the securities of a limited number of companies in a single country and/or capitalization range. The Fund may invest a significant portion of its assets in the securities of issuers in industries that are subject to the same or similar risk factors. To the extent the Fund invests in fixed income securities, it may have significant exposure to fixed income instruments of any credit quality, including those that are below investment grade (commonly referred to as junk bonds) and having any maturity or duration. The Fund also may have exposure to short sales. GMOs ability to shift investments among asset classes is not subject to any limits.
The Fund may engage in transactions in which it purchases securities at prices below the value of the consideration GMO expects to be paid for them upon consummation of a proposed merger, exchange offer, tender offer, or other similar transaction (merger arbitrage transactions). The purchase price may substantially exceed the market price of the securities before the announcement of the transaction.
In conjunction with merger arbitrage transactions, the Fund may invest in derivatives or sell securities short in an effort to protect against market fluctuations or other risks or to adjust long or short investment exposure to one or more asset classes or issuers.
As an alternative to investing directly in securities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives (e.g., selling put options on securities) and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include options, futures, warrants, swap contracts, and reverse repurchase agreements. The Funds foreign currency exposure may differ from the currency exposure of its securities. In addition, the Fund may lend its portfolio securities.
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund may have gross investment exposures in excess of its net assets (i.e., the Fund may be leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund gains exposure to commodities and some other asset classes by investing through a wholly-owned subsidiary advised by GMO, which does not receive management or other fees for its services. The subsidiary invests primarily in commodity-related derivatives and fixed income securities but also may invest in any other investment in which the Fund is permitted to invest directly. References in this Prospectus to the Fund may refer to actions undertaken by the subsidiary as well as the Fund. The Fund does not invest directly in commodities and commodity-related derivatives, but may do so indirectly through its subsidiary company (or otherwise).
In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in its wholly-owned subsidiary and in any underlying funds in which it invests. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in its wholly-owned subsidiary and in any underlying funds, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
|
Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher |
122
commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin, or otherwise honor its obligations. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
123
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. A merger arbitrage transaction can fail for many reasons, including regulatory and antitrust restrictions, political motivations, industry weakness, stock specific events, failed financings, and general market declines. When merger activity is low, GMO may be unable to identify enough opportunities to provide sufficient diversification. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. The Funds investments in derivatives or short sales of securities to hedge or otherwise adjust investment exposure in connection with a merger arbitrage transaction may not perform as expected or may otherwise reduce the Funds gains or increase its losses. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will disrupt the Funds operations. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in its wholly-owned subsidiary and in any underlying funds in which it invests (including ETFs), including the risk that its wholly-owned subsidiary and those underlying funds will not perform as expected. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Barclays U.S. Treasury Inflation Notes: 1-10 Year Index and the Consumer Price Index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
3/1/12 | ||||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% |
124
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
125
Investment objective
Total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Purchase premium (as a percentage of amount invested) |
[0.15 | ]% | [0.15 | ]% | [0.15 | ]% | [0.15 | ]% | ||||||||
Redemption fee (as a percentage of amount redeemed) |
[0.15 | ]% | [0.15 | ]% | [0.15 | ]% | [0.15 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Management fee |
0.45 | % 1 | 0.45 | % 1 | 0.45 | % 1 | 0.45 | % 1 | ||||||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
126
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other funds or accounts managed by GMO. Accordingly, the Fund is not a standalone investment.
The Fund seeks to capture returns commensurate with the equity risk premium over a full market cycle with less sensitivity to equity valuations by writing put options on stock indices and by engaging in merger arbitrage strategies. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark.
The Fund primarily uses options by selling (writing) put options on U.S. and non-U.S. (e.g., Europe, United Kingdom, Japan, Hong Kong, Canada, and Australia) stock indices. While the Fund may write put options with any strike price or duration, the Fund generally writes put options with a strike price at or near the market price of the underlying asset and with a duration of one to three months. Other methods focus on patterns of information, such as price movement or volatility of a stock or groups of stocks relative to the Funds investment universe. The Funds portfolio allocations are based on the relative attractiveness of each index in conjunction with other factors such as the liquidity available in each indexs options markets. The Fund may have substantial exposures to relatively few U.S. and international stock indices. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund may purchase and sell put and call options of any type, including options on global, regional and country stock indices and options on exchange-traded funds (ETFs). The Fund may purchase and sell exchange-traded and over-the-counter (OTC) options, including options that are cash-settled as well as physically settled. The Fund may purchase and sell options and other securities tied economically to any country in the world, including emerging countries. The Fund may invest in forward currency contracts to manage its currency exposure.
GMO expects that the Funds sold option positions typically will be fully collateralized at the time the Fund sells them. GMO, therefore, expects that the Fund will hold sufficient assets to cover the maximum possible loss the Fund might sustain upon the exercise of an option sold by the Fund.
The Fund typically engages in transactions in which it purchases securities at prices below the value of the consideration GMO expects to be paid for them upon consummation of a proposed merger, exchange offer, tender offer, or other similar transaction (merger arbitrage transactions). Purchase prices may substantially exceed the market price of the securities before the announcement of the transaction.
In conjunction with merger arbitrage transactions, the Fund may invest in derivatives or sell securities short in an effort to protect against market fluctuations or other risks or to adjust long or short investment exposure to one or more asset classes or issuers.
The factors GMO considers and investment methods GMO uses can change over time.
For collateral and cash management purposes, the Fund invests a substantial portion of its assets in shares of U.S. Treasury Fund, in U.S. Treasury bills and other highly rated securities, in money market funds unaffiliated with GMO[, or directly in the types of investments typically held by money market funds.]
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities Because of the Funds emphasis on selling put options on stock indices, GMO generally expects the Funds net asset value to decline when those indices decline in value. The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. Also, the Funds investment strategies of writing put options on stock indices and engaging in merger arbitrage transactions can be expected to cause the Fund to underperform relative to those indices when those markets rise sharply. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from closing its option positions at desirable prices. The Funds ability to use options as part of its investment program depends on the liquidity of the options market. That market may not be liquid when the Fund seeks to close out an option position. If the Fund receives a redemption request and is unable to close out an option it has sold, the Fund may temporarily be leveraged in relation to its assets. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
127
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Focused Investment Risk Because the Fund can have substantial exposure through a limited number of options contracts and/or merger arbitrage transactions and because the Funds exposures may relate to relatively few stock indices and/or merger arbitrage transactions, the Fund is subject to more risk than if the Funds investments were more diversified. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. A merger arbitrage transaction can fail for many reasons, including regulatory and antitrust restrictions, political motivations, industry weakness, stock specific events, failed financings, and general market declines. When merger activity is low, GMO may be unable to identify enough opportunities to provide sufficient diversification. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. The Funds investments in derivatives or short sales of securities to hedge or otherwise adjust investment exposure in connection with a merger arbitrage transaction may not perform as expected or may otherwise reduce the Funds gains or increase its losses. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Market Risk Fixed Income Investments The market price of a fixed income investment (e.g., U.S. Treasury bills) can decline due to market-related factors, primarily rising interest rates. |
| Credit Risk Securities issued by the U.S. Treasury historically have presented minimal credit risk. However, events in 2011 led to a downgrade in the long-term credit rating of U.S. bonds by several major rating agencies and introduced greater uncertainty about the repayment by the United States of its obligations. A further credit rating downgrade could decrease, and a U.S. credit default would decrease, the value of the Funds investments and increase the volatility of the Funds portfolio. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. To the extent the Fund focuses its investments in the stock index of a particular region, adverse geopolitical and other events in that region could have a disproportionate impact on the Fund. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
128
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing the Funds annual total returns for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). After-tax returns are shown for Class III shares only; after-tax returns for other classes will vary. Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
12/14/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class IV |
12/17/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Class VI |
11/15/12 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | N/A | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Global Equity | David Cowan (since 2012) | Head, Global Equity Team, GMO. | ||
Global Equity | Neil Constable (since 2015) | Portfolio Manager, Global Equity Team, GMO. | ||
Global Equity | Chris Fortson (since 2015) | Portfolio Manager, Global Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
129
GMO SPECIAL OPPORTUNITIES FUND
Investment objective
Positive total return.
Fees and expenses
The tables below describe the fees and expenses that you may bear for each class of shares if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Purchase premium (as a percentage of amount invested) |
[0.50 | ]% | [0.50 | ]% | [0.50 | ]% | [0.50 | ]% | ||||||||
Redemption fee (as a percentage of amount redeemed) |
[0.50 | ]% | [0.50 | ]% | [0.50 | ]% | [0.50 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | Class IV | Class V | Class VI | |||||||||||||
Management fee |
1.10 | % 1 | 1.10 | % 1 | 1.10 | % 1 | 1.10 | % 1 | ||||||||
Shareholder service fee |
0.15 | % 1 | 0.10 | % 1 | 0.085 | % 1 | 0.055 | % 1 | ||||||||
Other expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 2 | [ | ]% 2 | [ | ]% 2 | [ | ]% 2 | ||||||||
Total annual fund operating expenses |
[ | ]% | [ | ]% | [ | ]% | [ | ]% 2 | ||||||||
Expense reimbursement/waiver |
([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ([ | ]%) 1 | ||||||||
Total annual fund operating expenses after expense reimbursement/waiver (Fund and underlying fund expenses) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the portion of its Specified Operating Expenses (as defined below) that exceeds 0.10% of the Funds average daily net assets. Specified Operating Expenses means only the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund or a class of shares of the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [These indirect expenses include commissions paid to brokers by the Fund for executing transactions in unaffiliated underlying funds (transaction fees). Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class IV |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class V |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | ||||||||
Class VI |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Special
130
Opportunities SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (including the accounts of the Funds wholly-owned subsidiary, GMO Special Opportunities SPC Ltd., and excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO generally uses a fundamental approach to identify investments that are, in GMOs judgment, trading below their fundamental fair (or intrinsic) value. GMO expects that the Funds portfolio will consist of a limited number of investments. GMO does not manage the Fund to, or control the Funds risk relative to, any securities index or securities benchmark. The factors GMO considers and investment methods GMO uses can change over time.
The Fund may have long or short exposure to non-U.S. and U.S. equities (which may include emerging country equities and equities of any market capitalization), non-U.S. and U.S. fixed income instruments (which may include asset-backed securities and other fixed income instruments of any credit quality, including those that are below investment grade (commonly referred to as junk bonds), including distressed and defaulted debt securities, and having any maturity or duration), currencies, and, from time to time, other alternative instruments (e.g., instruments that seek exposure to, or reduce risks of, market volatility).
The Fund is not restricted in its exposure to any particular asset class and at times may be substantially exposed (long or short) to a single asset class (e.g., equities or fixed income securities). In addition, the Fund is not restricted in its exposure (long or short) to any particular market. The Fund may have substantial exposure (long or short) to securities of companies in a particular country or type of country (e.g., emerging countries). The Fund could be subject to material losses from a single investment.
In pursuing its investment objective, the Fund may (but is not obligated to) invest in a wide variety of exchange-traded and over-the-counter (OTC) derivatives, including, without limitation, reverse repurchase agreements, options, futures, swap contracts (such as swaps on securities and securities indices, total return swaps, interest rate swaps, currency swaps, cross currency basis swaps, credit default swaps, variance swaps, commodity swaps, inflation swaps, and other types of swaps), swaptions, and foreign currency derivative transactions. In addition, the Fund may lend its portfolio securities. The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund may have gross investment exposures in excess of its net assets (i.e., the Fund may be leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
The Fund gains exposure to commodities and some other assets by investing through a wholly-owned subsidiary advised by GMO, which does not receive management or other fees for its services. The subsidiary invests primarily in commodity-related derivatives and fixed income securities but also may invest in any other investment in which the Fund is permitted to invest directly. References in this Prospectus to the Fund may refer to actions undertaken by the subsidiary as well as the Fund. The Fund does not invest directly in commodities and commodity-related derivatives, but may do so indirectly through its subsidiary company (or otherwise).
In seeking to achieve the Funds investment objective, GMO may invest a significant portion of the Funds net assets in cash and cash equivalents. GMO would not consider such investments to be temporary defensive positions.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in its wholly-owned subsidiary and in any underlying funds in which it invests. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in its wholly-owned subsidiary and in any underlying funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. Because the Fund normally does not take temporary defensive positions, declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
131
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. Investments in distressed or defaulted or other low quality debt securities generally are considered speculative and may involve substantial risks not normally associated with investments in higher quality securities, including adverse business, financial or economic conditions that lead to payment defaults and insolvency proceedings on the part of their issuers. In particular, distressed or defaulted obligations might be repaid, if at all, only after lengthy workout or bankruptcy proceedings, during which the issuer might not make any interest or other payments, and the Fund may incur additional expenses to seek recovery. If GMOs assessment of the eventual recovery value of a distressed or defaulted debt security proves incorrect, the Fund may lose a substantial portion or all of its investment or may be required to accept cash or instruments worth less than its original investment. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could reduce the value of the Funds investments. |
| Focused Investment Risk Investments focused in a limited number of countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
132
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin, or otherwise honor its obligations. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in its wholly-owned subsidiary and in any underlying funds in which it invests, including the risk that its wholly-owned subsidiary or those underlying funds will not perform as expected. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of the Barclays U.S. Treasury Inflation Notes: 1-10 Years Index and the Consumer Price Index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class VI Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
133
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class VI |
7/28/14 | |||||||||||||||
Return Before Taxes |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% | ||||||||||
Consumer Price Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | N/A | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Chris Hudson (since the Funds inception) | Portfolio Manager, Asset Allocation Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
134
GMO STRATEGIC OPPORTUNITIES ALLOCATION FUND
Investment objective
Total return greater than that of its benchmark, the GMO Strategic Opportunities Allocation Index, an internally maintained composite index computed by GMO, consisting of 75% MSCI World Index (MSCI Standard Index Series) and 25% Barclays U.S. Aggregate Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.14 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.14 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.00 | % | ||
Shareholder service fee |
0.00 | % | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 1 | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement |
([ | ]%) 2 | ||
Total annual fund operating expenses after expense reimbursement (Fund and underlying fund expenses) |
[ | ]% |
1 | [These indirect expenses include interest expense that may be incurred by certain underlying funds and also include, to the extent applicable, purchase premiums and redemption fees (transaction fees) charged by certain underlying funds. Net fees and expenses of underlying funds (before addition of interest expense and transaction fees), indirect interest expense, and indirect transaction fees were approximately [ ]%, less than [ ]%, and [ ]%, respectively.] |
2 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. This reimbursement will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amounts shown reflect the expense reimbursement noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other accounts managed by GMO. Accordingly, the Fund is not a standalone investment.
The Fund is a fund of funds and invests primarily in shares of other series of GMO Trust (collectively, the underlying GMO Funds), which may include the Equity Funds, the Fixed Income Funds, the Implementation Funds, and SGM Major Markets Fund, as
135
well as GMO High Quality Short-Duration Bond Fund, a series of GMO Trust not offered by this Prospectus (see Additional Information About the Funds Investment Strategies, Risks, and Expenses Asset Allocation Funds and Investment in Other GMO Funds). The Fund also may invest directly in securities (including other underlying funds) and derivatives.
The Fund is permitted to invest in any asset class, including, for example, U.S. and non-U.S. equities (including emerging country equities), U.S. and non-U.S. fixed income securities (including emerging country debt securities) and commodities. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts.
GMO uses its multi-year forecasts of returns among asset classes, together with its assessment of the relative risks of such asset classes, to select the underlying GMO Funds in which the Fund invests and to decide how much to invest in each. An important component of those forecasts is GMOs expectation that valuations ultimately revert to their fundamental fair (or intrinsic) value. GMO changes the Funds holdings of the underlying GMO Funds in response to changes in GMOs investment outlook and market valuations and may use redemptions or purchases of Fund shares to rebalance the Funds investments. The factors GMO considers and investment methods GMO uses can change over time.
The Fund also may invest in money market funds unaffiliated with GMO or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. References to investments include those held directly by the Fund and indirectly through the Funds investments in the underlying GMO Funds. Some of the underlying GMO Funds are non-diversified investment companies under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by those underlying GMO Funds may affect the performance of those underlying GMO Funds more than if they were diversified investment companies. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, including those risks to which the Fund is exposed as a result of its investments in the underlying GMO Funds, see Description of Principal Risks.
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If an underlying GMO Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. An underlying GMO Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. |
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). |
136
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| [ Futures Contracts Risk The risk of loss relating to some uses of futures contracts is potentially unlimited. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract or at any particular time. In the event no such market exists for a particular derivative, it might not be possible to effect closing transactions, and the Fund will be unable to terminate its exposure to the futures contract. If the Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the futures contract and movements in the securities or index underlying the futures contract or movements in the prices of the Funds investments that are the subject of such hedge. Foreign futures contracts may be less liquid and more volatile than U.S. contracts. The Fund may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse.] |
| Credit Risk The Fund runs the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure. Below investment grade securities (commonly referred to as junk bonds) have speculative characteristics, and changes in economic conditions or other circumstances are more likely to impair the ability of issuers of those securities to make principal and interest payments than is the case with issuers of investment grade securities. |
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of foreign currency holdings and investments denominated in foreign currencies. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying GMO Funds in which it invests, including the risk that those underlying GMO Funds will not perform as expected. Because the Fund bears the fees and expenses of the underlying GMO Funds in which it invests, a reallocation of the Funds investments to underlying GMO Funds with higher fees or expenses will increase the Funds total expenses. The fees and expenses associated with an investment in the Fund are less predictable than those associated with an investment in funds that charge a fixed management fee. |
| Commodities Risk Commodity prices can be extremely volatile, and exposure to commodities can cause the net asset value of the Funds shares to decline or fluctuate in a rapid and unpredictable manner. |
| Merger Arbitrage Risk If the Fund purchases securities in anticipation of a proposed merger, exchange offer, tender offer, or other similar transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund or an underlying GMO Fund from selling particular securities or closing derivative positions at desirable prices. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
|
Market Risk Asset-Backed Securities The market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of |
137
their payment streams. Payment streams associated with asset-backed securities held by the Fund depend on many factors (e.g., the cash flow generated by the assets backing the securities, the deal structure, the creditworthiness of any credit-support provider, and the reliability of various other service providers with access to the payment stream), and a problem in any one of these factors can lead to a reduction in the payment stream GMO expected the Fund to receive at the time the Fund purchased the asset-backed security. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor), the Fund is subject to the risk that a redemption by that shareholder of all or a large portion of its Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of broad-based indices and the Funds benchmark (which is a composite index computed by GMO). Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
5/31/05 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI World Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Barclays U.S. Aggregate Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
GMO Strategic Opportunities Allocation Index (Fund benchmark) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Asset Allocation | Ben Inker (since the Funds inception) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Asset Allocation | Sam Wilderman (since 2012) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
138
Investment objective
Total return in excess of that of its benchmark, the MSCI Taiwan Index.
Fees and expenses
The tables below describe the fees and expenses that you may bear if you buy and hold shares of the Fund.
Shareholder fees
(fees paid directly from your investment)
Class III | ||||
Purchase premium (as a percentage of amount invested) |
[0.15 | ]% | ||
Redemption fee (as a percentage of amount redeemed) |
[0.45 | ]% |
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Class III | ||||
Management fee |
0.81 | % 1 | ||
Shareholder service fee |
0.15 | % 1 | ||
Other expenses |
[ | ]% | ||
Acquired fund fees and expenses (underlying fund expenses) |
[ | ]% 2 | ||
Total annual fund operating expenses (Fund and underlying fund expenses) |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to waive or reduce the Funds management fees and shareholder service fees to the extent necessary to offset the management fees and shareholder service fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees and shareholder service fees will not be waived below zero. This waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
2 | [These indirect expenses include commissions paid to brokers by the Fund for executing transactions in unaffiliated underlying funds (transaction fees). Net fees and expenses of underlying funds (before addition of transaction fees) and indirect transaction fees were approximately less than [ ]% and [ ]%, respectively.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
If you sell your shares | If you do not sell your shares | |||||||||||||||||||||||||||||||
1 Year | 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||||||||||||||
Class III |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio. [That portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Fund uses as a short-term cash management vehicle. Excluding transactions in U.S. Treasury Fund, during its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.]
Principal investment strategies
The Fund typically invests directly and indirectly (e.g., through underlying funds or derivatives) in equities of companies doing business in or otherwise tied economically to Taiwan. The term equities refers to direct and indirect investments in common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts. Under normal circumstances, the Fund invests directly and indirectly at least 80% of its assets in investments tied economically to Taiwan (see Name Policies).
GMO uses proprietary quantitative techniques and fundamental analysis to evaluate and select sectors and equity investments based on factors including, but not limited to, valuation and macroeconomic factors, GMOs assessment of a sectors fundamentals as well as a companys positioning relative to its competitors. In constructing the Funds portfolio, GMO weighs a number of factors, including the trade-off among forecasted returns, risk relative to the benchmark, transaction costs, and liquidity. GMO also adjusts the Funds portfolio for factors such as position size, market capitalization, and exposure to particular industries or sectors. The factors GMO considers and investment methods GMO uses can change over time.
139
The Fund may invest a significant portion of its assets in securities of issuers in industries that are subject to the same or similar risk factors or whose security prices have strong correlations (e.g., issuers in different industries within broad sectors, such as technology or financial services).
As an alternative to investing directly in equities, the Fund may invest in exchange-traded and over-the-counter (OTC) derivatives and exchange-traded funds (ETFs). The Fund also may invest in derivatives and ETFs: (i) in an attempt to obtain long or short investment exposure; (ii) in an attempt to adjust elements of the Funds investment exposure; and (iii) as a substitute for securities lending. Derivatives used may include options, futures, warrants, swap contracts, and reverse repurchase agreements. The Funds foreign currency exposure may differ from the currency exposure represented by its equity investments.
In addition, the Fund may overweight and underweight its positions in particular currencies relative to its benchmark. In addition, the Fund may lend its portfolio securities.
The Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by the Fund may affect the Funds performance more than if the Fund were a diversified investment company. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Equities The market price of an equity may decline due to factors affecting the issuer, its industry or the economy and equity markets generally. If the Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The Fund also may purchase equities that typically trade at higher multiples of current earnings than other securities, and the market prices of these equities often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples. Declines in stock market prices generally are likely to reduce the net asset value of the Funds shares. |
| Non-U.S. Investment Risk The market prices of many non-U.S. securities fluctuate more than those of U.S. securities. Many non-U.S. securities markets are less stable, smaller, less liquid, and less regulated than U.S. securities markets, and the cost of trading in those markets often is higher than in U.S. securities markets. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs than similar transactions in U.S. securities. In addition, the Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Also, the Fund needs a license to invest directly in many non-U.S. securities markets, and the Fund is subject to the risk that it could not invest if its license were terminated or suspended. In some non-U.S. securities markets, prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose the Fund to credit and other risks. Further, adverse changes in investment regulations, capital requirements or exchange controls could adversely affect the value of the Funds investments. These and other risks (e.g., nationalization, expropriation or other confiscation of assets of non-U.S. issuers) tend to be greater for investments in companies tied economically to emerging countries, the economies of which may be predominantly based on only a few industries or dependent on revenues from particular commodities and which often are more volatile than the economies of developed countries. Certain characteristics of Taiwans economy and geographic location also subject the Fund to non-U.S. investment risks. For example, Taiwan is a small island with few raw material resources and limited land area and thus relies heavily on imports for its commodity needs. Any fluctuations or shortages in the commodity markets could have a negative impact on the Taiwanese economy. Also, rising labor costs and increasing environmental consciousness have led some labor-intensive industries to relocate to countries with cheaper work forces, and continued labor outsourcing may adversely affect the Taiwanese economy. Taiwans economy also is intricately linked with economies of Asian countries that have experienced over-extensions of credit, frequent and pronounced currency fluctuations, currency devaluations, currency repatriation, rising unemployment, and fluctuations in inflation. Currency devaluations in one country in the region can have a significant effect on all countries in the region. Political and social unrest in Asian countries could cause further economic and market uncertainty in Taiwan. In particular, the Taiwanese economy is dependent on the economies of Japan and China, as well as the United States, and a reduction in purchases by any of them of Taiwanese products and services or negative changes in their economies would likely have an adverse effect on the Taiwanese economy. Taiwans geographic proximity to China and Taiwans history of political contention with China have resulted in ongoing tensions with China, including the risk of war with China. These tensions may materially affect the Taiwanese economy and securities markets. Any of these risks, should they occur, could materially reduce the value of an investment in Taiwan Fund. |
140
| Currency Risk Fluctuations in exchange rates can adversely affect the market value of the Funds foreign currency holdings and investments denominated in foreign currencies. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. GMO often uses quantitative analyses and models as part of its investment process. Analyses and models are not necessarily predictive of future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness) that could adversely affect the Funds performance. The Fund also runs the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong or that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Illiquidity Risk Low trading volume, lack of a market maker, large position size, or legal restrictions may limit or prevent the Fund from selling particular securities or closing derivative positions at desirable prices. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
| Focused Investment Risk Investments focused in countries, regions, sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are strongly correlated, such as the Funds investments tied economically to Taiwan, are subject to greater overall risk than investments that are more diversified. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Small Company Risk Smaller companies may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a few key employees. The securities of companies with smaller market capitalizations often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. |
| Counterparty Risk The Fund runs the risk that the counterparty to a derivatives contract, a clearing member used by the Fund to hold a cleared derivatives contract, or a borrower of the Funds securities will be unable or unwilling to make timely settlement payments, return the Funds margin or otherwise honor its obligations. |
| Derivatives and Short Sales Risk The use of derivatives involves the risk that their value may not change as expected relative to changes in the value of the underlying assets, rates, or indices. Derivatives also present other risks, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The Fund may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. The risks of loss associated with derivatives that provide short investment exposure and short sales of securities are theoretically unlimited. |
| Fund of Funds Risk The Fund is indirectly exposed to all of the risks of an investment in the underlying funds in which it invests (including ETFs), including the risk that those underlying funds will not perform as expected. |
| Leveraging Risk The use of reverse repurchase agreements and other derivatives and securities lending creates leverage. Leverage increases the Funds losses when the value of its investments (including derivatives) declines. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. Purchase premiums and redemption fees are not reflected in the bar chart, but are reflected in the table; as a result, the returns in the table are lower than the returns in the bar chart. Returns in the table reflect current purchase premiums and redemption fees. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns /Class III Shares
Years Ending December 31
141
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
Class III |
10/4/02 | |||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions a |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
Return After Taxes on Distributions and Sale of Fund Shares a |
[ | ]% | [ | ]% | [ | ]% | [ | ]% | ||||||||
MSCI Taiwan Index (returns reflect no deduction for fees or expenses, but are net of withholding tax on dividend reinvestments) |
[ | ]% | [ | ]% | [ | ]% | [ | ]% |
a | For periods prior to the public offering of the Funds shares, which began on October 29, 2009, the Funds after-tax returns reflect dividends that included certain non-deductible investment expenses. |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Emerging Markets Equity | Arjun Divecha (since the Funds inception) | Head, Emerging Markets Equity Team, GMO. | ||
Emerging Markets Equity | Amit Bhartia (since September 2015) | [Portfolio Manager, Emerging Markets Equity Team, GMO.] | ||
Emerging Markets Equity | Warren Chiang (since June 2015) | Portfolio Manager, Emerging Markets Equity Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
142
Investment objective
Liquidity and safety of principal with current income as a secondary objective.
Fees and expenses
The table below describes the fees and expenses that you may bear if you buy and hold shares of the Fund.
Annual Fund operating expenses
(expenses that you bear each year as a percentage of the value of your investment)
Management fee |
0.08 | % 1 | ||
Other expenses |
[ | ]% | ||
Total annual fund operating expenses |
[ | ]% | ||
Expense reimbursement/waiver |
([ | ]%) 1 | ||
Total annual fund operating expenses after expense reimbursement/waiver |
[ | ]% |
1 | [Grantham, Mayo, Van Otterloo & Co. LLC (GMO) has contractually agreed to reimburse the Fund for the following expenses: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Fund by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees and custody expenses. GMO also has contractually agreed to waive or reduce the Funds management fees to the extent necessary to offset the management fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other series of GMO Trust (GMO Funds). Management fees will not be waived below zero. This reimbursement and waiver will continue through at least June 30, 2017, and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.] |
Example
This example is intended to help you compare the cost of investing in the Fund with the cost of investing in other mutual funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated, regardless of whether or not you redeem your shares at the end of such periods. The example also assumes that your investment has a 5% return each year and that the Funds operating expenses remain the same as those shown in the table. The one year amount shown reflects the expense reimbursement and waiver noted in the expense table. Although your actual costs may be higher or lower, based on these assumptions your costs would be:
1 Year | 3 Years | 5 Years | 10 Years | |||||||||||||
GMO U.S. Treasury Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | $ | [ | ] |
Portfolio turnover
The Fund pays transaction costs, such as commissions, when it buys and sells securities. A higher portfolio turnover rate may result in higher transaction costs and, when Fund shares are held in a taxable account, higher taxes. These transaction costs, which are not reflected in Annual Fund operating expenses or in the Example, affect the Funds performance. During its fiscal year ended February 29, 2016, the Funds portfolio turnover rate (excluding short-term investments) was [ ]% of the average value of its portfolio.
Principal investment strategies
GMO pursues investment strategies for the Fund that are intended to complement the strategies it is pursuing in other funds or accounts managed by GMO. Accordingly, the Fund is not a standalone investment.
Under normal circumstances, the Fund invests at least 80% of its assets in Direct U.S. Treasury Obligations and repurchase agreements collateralized by these Obligations (see Name Policies). Direct U.S. Treasury Obligations include U.S. Treasury bills, bonds and notes and other securities issued by the U.S. Treasury, as well as Separately Traded Registered Interest and Principal Securities (STRIPS) and other zero-coupon securities. GMO normally seeks to maintain an interest rate duration of one year or less for the Funds portfolio. For an additional discussion of duration, see Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds Duration.
The Fund also may enter into repurchase agreements, under which the Fund purchases a security backed by the full faith and credit of the U.S. government from a seller who simultaneously commits to repurchase, on an agreed upon date in the future, the security from the Fund at the original purchase price plus an agreed upon amount representing the original purchase price plus interest. The counterparties in repurchase agreements are typically brokers and banks, and the safety of the arrangement depends on, among other things, the Funds having an interest in the security that it can realize in the event of the insolvency of the counterparty.
In addition to Direct U.S. Treasury Obligations, the Fund may invest in other fixed income securities that are backed by the full faith and credit of the U.S. government, such as fixed income securities issued by the Government National Mortgage Association (GNMA) and the Federal Deposit Insurance Corporation (FDIC) that are guaranteed by the U.S. government. The Fund also may invest in money market funds unaffiliated with GMO.
143
Although the fixed income securities purchased by the Fund normally will have a stated or remaining maturity of one year or less, Direct U.S. Treasury Obligations purchased pursuant to repurchase agreements may not, and, therefore, if the counterparty to the repurchase agreement defaults, the Fund may end up owning a security with a stated or remaining maturity of more than one year.
The Fund is not a money market fund and is not subject to the duration, quality, diversification and other requirements applicable to money market funds.
In selecting U.S. Treasury securities for the Funds portfolio, GMO focuses primarily on the relative attractiveness of different obligations (such as bonds, notes or bills), which can vary depending on the general level of interest rates as well as supply and demand imbalances and other market conditions. The factors GMO considers and investment methods GMO uses can change over time.
Principal risks of investing in the Fund
The value of the Funds shares changes with the value of the Funds investments. Many factors can affect this value, and you may lose money by investing in the Fund. The principal risks of investing in the Fund are summarized below. For a more complete discussion of these risks, see Description of Principal Risks.
| Market Risk Fixed Income Investments The market price of a fixed income investment can decline due to market-related factors, primarily rising interest rates. |
| Credit Risk Securities issued by the U.S. Treasury historically have presented minimal credit risk. However, events in 2011 led to a downgrade in the long-term credit rating of U.S. bonds by several major rating agencies and introduced greater uncertainty about the repayment by the United States of its obligations. A further credit rating downgrade could decrease, and a U.S. credit default would decrease, the value of the Funds investments and increase the volatility of the Funds portfolio. |
| Focused Investment Risk Because the Funds investments are focused in investments in securities issued by the U.S. Treasury and other fixed income securities that are backed by the full faith and credit of the U.S. government, the Fund is subject to greater U.S. Treasury credit risk than a more diversified Fund. |
| Large Shareholder Risk To the extent that a large number of shares of the Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will require the Fund to sell securities at disadvantageous prices or otherwise disrupt the Funds operations. |
| Management and Operational Risk The Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results. The Fund also runs the risk that deficiencies in GMOs or another service providers internal systems or controls will cause losses for the Fund or impair Fund operations. |
| Market Disruption and Geopolitical Risk Geopolitical and other events may disrupt securities markets and adversely affect global economies and markets. Those events, as well as other changes in non-U.S. and U.S. economic and political conditions, could adversely affect the value of the Funds investments. |
Performance [TO BE UPDATED BY AMENDMENT]
The bar chart and table below provide some indication of the risks of investing in the Fund by showing changes in the Funds annual total returns from year to year for the periods indicated and by comparing the Funds average annual total returns for different calendar periods with those of a broad-based index. After-tax returns are calculated using the historical highest individual federal marginal income tax rates and do not reflect the impact of state and local taxes. Actual after-tax returns depend on your tax situation and may differ from those shown. After-tax returns shown are not relevant if you are tax-exempt or if you hold your Fund shares through tax-advantaged arrangements (such as a 401(k) plan or individual retirement account). Updated performance information for the Fund is available at www.gmo.com. Past performance (before and after taxes) is not an indication of future performance.
Annual Total Returns
Years Ending December 31
Highest Quarter: [ ]% ([ ])
Lowest Quarter: [ ]% ([ ])
Year-to-Date (as of 3/31/16): [ ]%
144
Average Annual Total Returns
Periods Ending December 31, 2015
1 Year | 5 Years | 10 Years | Incept. | |||||||||||||
3/17/09 | ||||||||||||||||
Return Before Taxes |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Return After Taxes on Distributions and Sale of Fund Shares |
[ | ]% | [ | ]% | N/A | [ | ]% | |||||||||
Citigroup 3-Month Treasury Bill Index (reflects no deduction for fees, expenses, or taxes) |
[ | ]% | [ | ]% | N/A | [ | ]% |
Management of the Fund
Investment Adviser: Grantham, Mayo, Van Otterloo & Co. LLC
Investment Team and Senior Members of GMO primarily responsible for portfolio management of the Fund:
Investment Team | Senior Member (Length of Service with Fund) | Title | ||
Developed Fixed Income | Ben Inker (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Sam Wilderman (since November 2014) | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Michael Emanuel (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. | ||
Developed Fixed Income | Greg Jones (since February 2015) | Portfolio Manager, Developed Fixed Income Team, GMO. |
Additional information
For important information about purchase and sale of Fund shares, taxes, and financial intermediary compensation, please see Additional Summary Information About the Funds on page [ ] of this Prospectus.
145
ADDITIONAL SUMMARY INFORMATION ABOUT THE FUNDS
Purchase and sale of Fund shares
Under ordinary circumstances, you may purchase a Funds shares directly from GMO Trust (the Trust) on days when the New York Stock Exchange (NYSE) is open for business (and, in the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, on days when the U.S. bond markets also are open for business and, in the case of Taiwan Fund, on days when the Taiwan Stock Exchange (TSE) [also is open for business]). In addition, some brokers and agents are authorized to accept purchase and redemption orders on the Funds behalf.
Except for Class MF shares of Benchmark-Free Allocation Fund, an investors eligibility to purchase Fund shares or different classes of Fund shares depends on its meeting either (i) the Minimum Total Fund Investment, which includes only an investors total investment in a particular Fund, or (ii) the Minimum Total GMO Investment, both of which are set forth in the table below. Mutual funds that wish to invest in shares of Benchmark-Free Allocation Fund and wish to receive supplemental support services are eligible to purchase its Class MF shares. No minimum initial investment is required to purchase Class MF shares. For investors owning shares of a Fund, no minimum additional investment is required to purchase additional shares of that Fund.
Minimum Investment Criteria for Class Eligibility
Minimum Total
Fund Investment |
Minimum Total
GMO Investment |
|||||
Class II Shares |
All Funds Offering Class II Shares |
N/A | $10 million | |||
Class III Shares |
Tax-Managed International Equities Fund |
N/A |
$10 million
(or $5 million in
|
|||
International Equity Fund Foreign Fund |
N/A | $35 million | ||||
Emerging Markets Fund Emerging Domestic Opportunities Fund |
$50 million | N/A | ||||
All Other Funds Offering Class III Shares |
N/A | $10 million | ||||
Class IV Shares |
All Funds Offering Class IV Shares |
$125 million | $250 million | |||
Class V Shares |
All Funds Offering Class V Shares |
$250 million | $500 million | |||
Class VI Shares |
All Funds Offering Class VI Shares |
$300 million | $750 million |
Minimum Investment Criteria and Eligibility for Implementation Fund and U.S. Treasury Fund
Minimum Total
Fund Investment |
Minimum Total
GMO Investment |
|||||
Implementation Fund U.S. Treasury Fund |
N/A | $10 million |
Fund shares are redeemable. Under ordinary circumstances, you may redeem a Funds shares on days when the NYSE is open for business (and, in the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, on days when the U.S. bond markets also are open for business and, in the case of Taiwan Fund, on days when the TSE also is open for business). Redemption orders should be submitted directly to the Trust unless the Fund shares to be redeemed were purchased through a broker or agent, in which case the redemption order should be submitted to that broker or agent. For instructions on redeeming shares directly, call the Trust at 1-617-346-7646 or send an e-mail to SHS@GMO.com.
Purchase order forms and redemption orders can be submitted by mail, facsimile, or e-mail (or by other form of communication pre-approved by GMO Shareholder Services) to the Trust at:
GMO Trust
c/o Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf
Boston, Massachusetts 02110
Facsimile: 1-617-439-4192
Attention: Shareholder Services
E-mail: clientorder@gmo.com
146
U.S. tax information
Each of the Funds has elected to be treated or intends to elect to be treated, and intends to qualify and be treated each year, as a regulated investment company (each, a RIC) under Subchapter M of the Internal Revenue Code of 1986, as amended (the Code) for U.S. federal income tax purposes and to distribute net investment income and net realized capital gains, if any, to shareholders. These distributions generally are taxable to U.S. shareholders as ordinary income or capital gains, unless they are exempt from income tax or are investing through a tax-advantaged account. U.S. shareholders who are investing through a tax-advantaged account may be taxed upon withdrawals from that account.
Financial intermediary compensation
GMO may pay brokers, agents or other financial intermediaries for the sale of Fund shares and related services. These payments would create a conflict of interest by influencing the broker or other financial intermediary and your salesperson to recommend the Fund over another investment. Ask your salesperson or consult your financial intermediarys website for more information.
147
ADDITIONAL INFORMATION ABOUT THE FUNDS INVESTMENT STRATEGIES, RISKS, AND EXPENSES
Fund Summaries. The preceding sections contain a summary of the investment objective, fees and expenses, principal investment strategies, principal risks, performance, management, and other important information for each series of the Trust listed on the cover page of this Prospectus (each a Fund and collectively, the Funds, and together with other series of the Trust not offered by this Prospectus, each a GMO Fund and collectively, the GMO Funds). The summaries are not all-inclusive, and a Fund may make investments, employ strategies, and be exposed to risks that are not described in its summary. More information about the Funds investments and strategies is contained in the Statement of Additional Information (SAI). See the back cover of this Prospectus for information about how to receive the SAI. Additional information about the Funds benchmarks and other comparative indices may be found under Fund Benchmarks and Comparative Indices.
Fundamental Investment Objectives/Policies. The Board of Trustees (Trustees) of the Trust may change a Funds investment objective or policies without shareholder approval or prior notice unless an objective or policy is identified in this Prospectus or in the SAI as fundamental. Only International Equity Fund and U.S. Equity Allocation Fund have fundamental investment objectives. Neither the Funds nor GMO guarantees that the Funds will be able to achieve their investment objectives.
Definitions. When used in this Prospectus, the term invest includes both direct and indirect investing as well as both long and short investing and the term investments includes both direct and indirect investments as well as both long and short investments. For example, a Fund may invest indirectly in a given asset or asset class by investing in another GMO Fund or a wholly-owned subsidiary or by investing in derivatives and synthetic instruments, and the resulting exposure to the asset or asset class may be long or short. When used in this Prospectus, (i) the terms bonds, fixed income investments, and fixed income securities include (a) obligations of an issuer to make payments on future dates of principal, interest (whether fixed or variable) or both and (b) synthetic debt instruments created by GMO by using derivatives (e.g., a futures contract, swap contract, currency forward or option); (ii) the term emerging countries (except in the case of Emerging Countries Fund, which has a separate definition in its Fund summary) means the worlds less developed countries; (iii) the term equities refers to common and preferred stocks and other stock-related securities, such as convertible securities, depositary receipts, and equity real estate investment trusts (REITs) and income trusts; (iv) the term sovereign debt refers to a fixed income security issued by a government, or exposure to sovereign debt through derivatives contracts; (v) the term quasi-sovereign debt refers to debt issued by a governmental agency, political subdivision or other instrumentality or issuer that is majority owned, directly or indirectly, or whose obligations are guaranteed, by a government, or exposure to quasi-sovereign debt through derivatives contracts; (vi) the term total return includes capital appreciation and income; (vii) the term underlying GMO Funds refers to other series of GMO Trust; and (viii) the term underlying funds refers to underlying GMO Funds and investment companies not advised by GMO, including, among others, closed-end funds, money market funds, and ETFs.
Tax Consequences. Unless otherwise specified in this Prospectus or in the SAI, GMO is not obligated to, and generally will not consider, tax consequences when seeking to achieve a Funds investment objective (e.g., a Fund may engage in transactions or make investments in a manner that is not tax efficient for U.S. federal income or other federal, state, local, or non-U.S. tax purposes).
In particular, a Funds investment through a wholly-owned subsidiary could affect the amount, timing and character of its distributions and could cause the Fund to recognize taxable income in excess of the cash generated by such investment, requiring the Fund in turn to liquidate investments at disadvantageous times to generate cash needed to make required distributions. See Distributions and Taxes below and Taxes in the SAI for more information about the tax consequences of a Funds investments through a wholly-owned subsidiary.
Portfolio Turnover. Because portfolio turnover is not a principal consideration when GMO makes investment decisions for the Funds, GMO causes a Fund to trade based on its assessment of market conditions and purchase or redemption requests. The Funds are not subject to any limit on the frequency with which portfolio securities may be purchased or sold. High turnover rates may create additional taxable income and gains for shareholders. If portfolio turnover results in the recognition of short-term capital gains, those gains, when distributed, typically are taxed to shareholders at ordinary income tax rates. See Distributions and Taxes below for more information.
Benchmarks. Fund benchmarks (if any) and other comparative indices listed in the Average Annual Total Returns table in the Fund summaries are described under Fund Benchmarks and Comparative Indices. In some cases, a Funds summary states that a Fund seeks total return greater than that of its benchmark. Neither the Funds nor GMO can provide any assurance that this goal will be achieved. A Funds benchmark is stated as of the date of this Prospectus and may be changed without notice to shareholders.
Fee and Expense Information. The following paragraphs contain additional information about the fee and expense information included in the Fund summaries.
Annual Fund Operating Expenses Other Expenses and Acquired Fund Fees and Expenses. The amounts listed under Other expenses in the Annual Fund operating expenses table included in each Funds summary generally reflect direct expenses associated with an investment in a Fund for the fiscal year (or initial fiscal period, as applicable) ended February 29, 2016. A Fund may invest in other GMO Funds as well as exchange-traded funds (ETFs) and other pooled investment vehicles (collectively, the acquired funds), and the indirect net expenses associated with a Funds investment (if any) in acquired funds are reflected in Other
148
expenses if those expenses are less than 0.01% of the average net assets of the Fund. If the indirect net expenses associated with a Funds investment in acquired funds (acquired fund fees and expenses) are 0.01% or more of the Funds average net assets, these expenses are reflected in the Annual Fund operating expenses table under Acquired fund fees and expenses. Acquired fund fees and expenses do not include expenses associated with investments in the securities of unaffiliated companies unless those companies hold themselves out to be investment companies. Acquired fund fees and expenses generally are based on expenses incurred by the Fund for the fiscal year ended February 29, 2016, and actual indirect expenses will vary depending on the particular acquired funds in which the Fund invests.
Fee and Expense Examples. The expense example under Example included in each Funds summary assumes that a shareholder reinvests all dividends and distributions, if any.
Bond Funds. The following Funds (collectively, the Bond Funds) invest substantially all of their assets in fixed income securities: the Fixed Income Funds, Asset Allocation Bond Fund, and U.S. Treasury Fund. Many of the Bond Funds invest in other GMO Funds. In particular, pursuant to an exemptive order granted by the Securities and Exchange Commission (SEC), many of the Bond Funds invest in Emerging Country Debt Fund, Debt Opportunities Fund, U.S. Treasury Fund, GMO High Quality Short-Duration Bond Fund (High Quality Fund, which has not commenced operations as of the date of this Prospectus), and GMO World Opportunity Overlay Fund (Overlay Fund). For information regarding High Quality Fund and Overlay Fund, which are not offered by this Prospectus, see Investment in Other GMO Funds beginning on page [ ] of this Prospectus.
[Credit Quality. For purposes of this Prospectus, the term investment grade refers to a rating of Baa3/P-2 or better by Moodys Investors Service, Inc. (Moodys) or BBB-/A-2 or better by Standard & Poors Ratings Services (S&P) and the term below investment grade refers to any rating by Moodys or by S&P below those ratings. Fixed income securities rated below investment grade are commonly referred to as high yield or junk bonds. In addition, in this Prospectus, securities and commercial paper that are rated Aa/P-1 or better by Moodys or AA/A-1 or better by S&P are sometimes referred to as high quality. Securities referred to in this Prospectus as investment grade, below investment grade, or high quality, include securities rated by Moodys, S&P or both, and unrated securities that GMO determines have comparable credit qualities.]
Duration. For purposes of this Prospectus, the term duration refers to the weighted measure of interest rate sensitivity of a fixed income security. GMO employs a variety of techniques to adjust the sensitivity of a Bond Funds net asset value to changes in interest rates. This sensitivity is often measured by, and correlates with, the estimated interest rate duration of a Funds portfolio. For example, the value of an investment with a duration of five years decreases by approximately 5% for every 1% increase in interest rates, while the value of an investment with a duration of six years increases by approximately 6% with every 1% decrease in interest rates. In many cases, the Principal investment strategies section of a Bond Funds summary section provides the Funds dollar-weighted average interest rate duration. GMO estimates that duration by aggregating the durations of the Funds direct and indirect individual holdings and weighting each holding based on its market value. Duration needs to be estimated when the obligor is required to prepay principal or interest on a fixed income security and the payments are not denominated in U.S. dollars. GMO may significantly alter the duration of a Fund by using derivatives.
Asset Allocation Funds. The following Funds (collectively, the Asset Allocation Funds) invest primarily in other GMO Funds: Benchmark-Free Allocation Fund, Global Asset Allocation Fund, Global Equity Allocation Fund, Global Developed Equity Allocation Fund, International Equity Allocation Fund, International Developed Equity Allocation Fund, Benchmark-Free Fund, and Strategic Opportunities Allocation Fund. Several GMO Funds in which the Asset Allocation Funds invest themselves invest a substantial portion of their assets in other GMO Funds. As a result, the Asset Allocation Funds are exposed to all of the risks of not only the GMO Funds in which they invest but also the GMO Funds in which those Funds invest. In some cases, the Asset Allocation Funds may invest in GMO Funds not offered by this Prospectus, as indicated in the Asset Allocation Fund Summaries. For more information regarding these GMO Funds, see Investment in Other GMO Funds beginning on page [ ] of this Prospectus.
149
When used in the Asset Allocation Fund summaries, references to the Equity Funds, the Fixed Income Funds and the Implementation Funds include the GMO Funds listed under those headings below:
Equity Funds
| Developed World Stock Fund |
| Quality Fund |
| Resources Fund |
| Tax-Managed International Equities Fund |
| International Equity Fund |
| International Large/Mid Cap Equity Fund |
| Foreign Fund |
| Foreign Small Companies Fund |
| International Small Companies Fund |
| U.S. Equity Allocation Fund |
| Emerging Markets Fund |
| Emerging Countries Fund |
| Emerging Domestic Opportunities Fund |
Fixed Income Funds
| Global Bond Fund |
| Currency Hedged International Bond Fund |
| Core Plus Bond Fund |
| Emerging Country Debt Fund |
| Debt Opportunities Fund |
Implementation Funds
| Alpha Only Fund |
| Asset Allocation Bond Fund |
| Implementation Fund |
| Risk Premium Fund |
| Special Opportunities Fund |
| Taiwan Fund |
| U.S. Treasury Fund |
When used elsewhere in this Prospectus, references to the Multi-Asset Class Funds, the Equity Funds, the Fixed Income Funds, and the Implementation Funds include the GMO Funds listed under those headings on the front cover of this Prospectus.
Investments in U.S. Treasury Fund and Unaffiliated Money Market Funds. Each of the Funds may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
Temporary Defensive Positions. Temporary defensive positions are positions that are inconsistent with a Funds principal investment strategies and are taken in response to adverse market, economic, political, or other conditions.
Benchmark-Free Allocation Fund, Benchmark-Free Fund, Implementation Fund, and the Bond Funds (other than Emerging Country Debt Fund and U.S. Treasury Fund) may take temporary defensive positions if deemed prudent by GMO. Many of the Bond Funds have previously taken temporary defensive positions.
To the extent a Fund takes a temporary defensive position, or otherwise holds cash, cash equivalents, or high quality debt investments on a temporary basis, the Fund may not achieve its investment objective.
Fund Codes. See Fund Codes on page 200 of this Prospectus for information regarding each Funds ticker, news-media symbol, and CUSIP number.
This Prospectus does not offer shares of the Trust in any state where they may not lawfully be offered.
150
DESCRIPTION OF PRINCIPAL RISKS
The following chart identifies the Principal Risks associated with each Fund. Risks not marked for a particular Fund may, however, still apply to some extent to that Fund at various times.
Multi-
Asset Class Funds |
Absolute
|
Equity Funds | ||||||||||||||||||||||||||||||||||||||
Global Equity
Funds |
International Equity Funds |
|
Emerging
Equity Funds |
|||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Commodities Risk |
| | | | ||||||||||||||||||||||||||||||||||||
Counterparty Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Credit Risk |
| | | | | | | | ||||||||||||||||||||||||||||||||
Currency Risk |
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||
Derivatives and Short Sales Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Focused Investment Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Fund of Funds Risk |
| | | | | | | | | | ||||||||||||||||||||||||||||||
Futures Contracts Risk |
| | | |||||||||||||||||||||||||||||||||||||
Illiquidity Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Large Shareholder Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Leveraging Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Management and Operational Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Market Disruption and Geopolitical Risk |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Market Risk Asset-Backed Securities |
| | | |||||||||||||||||||||||||||||||||||||
Market Risk Equities |
| | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Market Risk Fixed Income Investments |
| | | | | | | | ||||||||||||||||||||||||||||||||
Merger Arbitrage Risk |
| | | | ||||||||||||||||||||||||||||||||||||
Non-Diversified Funds |
| | | | | | | | | | | | | | | |||||||||||||||||||||||||
Non-U.S. Investment Risk |
| | | | | | | | | | | | | | | | | | | |||||||||||||||||||||
Small Company Risk |
| | | | | | | | | | | | | | | | | |
151
Fixed Income Funds | Implementation Funds | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
Commodities Risk |
| | | | | |||||||||||||||||||||||
Counterparty Risk |
| | | | | | | | | | | | | |||||||||||||||
Credit Risk |
| | | | | | | | | | | | | |||||||||||||||
Currency Risk |
| | | | | | | | | | | | | |||||||||||||||
Derivatives and Short Sales Risk |
| | | | | | | | | | | | | |||||||||||||||
Focused Investment Risk |
| | | | | | | | | | | | | | ||||||||||||||
Fund of Funds Risk |
| | | | | | | | | | | | ||||||||||||||||
Futures Contracts Risk |
| | ||||||||||||||||||||||||||
Illiquidity Risk |
| | | | | | | | | | | | | |||||||||||||||
Large Shareholder Risk |
| | | | | | | | | | | | | | ||||||||||||||
Leveraging Risk |
| | | | | | | | | | | | ||||||||||||||||
Management and Operational Risk |
| | | | | | | | | | | | | | ||||||||||||||
Market Disruption and Geopolitical Risk |
| | | | | | | | | | | | | | ||||||||||||||
Market Risk Asset-Backed Securities |
| | | | | | | | | | ||||||||||||||||||
Market Risk Equities |
| | | | | | | | | | | | ||||||||||||||||
Market Risk Fixed Income Investments |
| | | | | | | | | | | | | |||||||||||||||
Merger Arbitrage Risk |
| | | | | | ||||||||||||||||||||||
Non-Diversified Funds |
| | | | | | | | | | | | | |||||||||||||||
Non-U.S. Investment Risk |
| | | | | | | | | | | | | |||||||||||||||
Small Company Risk |
| | | | | | | | | | | |
152
Investing in mutual funds involves many risks. Factors that may affect a particular Funds portfolio as a whole, called principal risks, are discussed briefly in each Funds summary and in additional detail in this section. The risks of investing in a particular Fund depend on the types of investments in its portfolio and the investment strategies GMO employs on its behalf. This section describes the principal risks and some related risks but does not describe every potential risk of investing in the Funds. Funds could be subject to additional risks because of the types of investments they make and market conditions, which may change over time. The SAI includes more information about the Funds and their investments.
Each Fund that invests in underlying funds or in a wholly-owned subsidiary (as indicated under Principal investment strategies in those Funds summaries and further described in Additional Information About the Funds Investment Strategies, Risks, and Expenses) is exposed to the risks to which the underlying funds or wholly-owned subsidiary are exposed, as well as the risk that the underlying funds or wholly-owned subsidiary will not perform as expected. Therefore, unless otherwise noted, the principal risks summarized below include both direct and indirect risks, and, as indicated in the Additional Information About the Funds Investment Strategies, Risks, and Expenses section of this Prospectus, references in this section to investments made by a Fund include those made both directly by the Fund and indirectly by the Fund through underlying funds or a wholly-owned subsidiary.
An investment in a Fund, by itself, generally does not provide a complete investment program but rather is intended to serve as part of an investors overall investment program. An investment in a Fund is not a bank deposit and, therefore, is not insured or guaranteed by the Federal Deposit Insurance Corporation or any other government agency.
COMMODITIES RISK. Commodity prices can be extremely volatile and are affected by many factors. Exposure to commodities can cause the net asset value of a Funds shares to decline or fluctuate in a rapid and unpredictable manner. The value of commodity-related derivatives or indirect investments in commodities may fluctuate more than the commodity, commodities or commodity index to which they relate. See Derivatives and Short Sales Risk for a discussion of specific risks of a Funds derivatives investments, including commodity-related derivatives.
COUNTERPARTY RISK. Funds that enter into contracts with counterparties, such as repurchase or reverse repurchase agreements or OTC derivatives contracts, or that lend their securities run the risk that the counterparty will be unable or unwilling to make timely settlement payments or otherwise honor its obligations. If a counterparty fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or otherwise hold investments it would prefer to sell, resulting in losses for the Fund. In addition, a Fund may suffer losses if a counterparty fails to comply with applicable laws or other requirements. The Funds are not subject to any limits on their exposure to any one counterparty nor to a requirement that counterparties with whom they enter into contracts maintain a specific rating by a nationally recognized rating organization. Counterparty risk is pronounced during unusually adverse market conditions and is particularly acute in environments (like those of 2008) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions.
Participants in OTC derivatives markets typically are not subject to the same level of credit evaluation and regulatory oversight as are members of exchange-based markets, and, therefore, OTC derivatives generally expose a Fund to greater counterparty risk than exchange-traded derivatives. A Fund is subject to the risk that a counterparty will not settle a derivative in accordance with its terms because of a dispute over the terms of the contract (whether or not bona fide) or because of a credit or liquidity problem. If a counterpartys obligation to a Fund is not collateralized, then the Fund is essentially an unsecured creditor of the counterparty. If a counterparty defaults, the Fund will have contractual remedies (whether or not the obligation is collateralized), but the Fund may be unable to enforce them, thus causing the Fund to suffer a loss. Counterparty risk is greater for derivatives with longer maturities because of the longer time during which events may occur that prevent settlement. Counterparty risk also is greater when a Fund has entered into derivatives contracts with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. Funds that use swap contracts are subject, in particular, to the creditworthiness of the counterparties because some types of swap contracts have terms longer than six months (and, in some cases, decades). The creditworthiness of a counterparty may be adversely affected by greater than average volatility in the markets, even if the counterpartys net market exposure is small relative to its capital. Counterparty risk still exists even if a counterpartys obligations are secured by collateral because the Funds interest in the collateral may not be perfected or additional collateral may not be promptly posted as required. GMOs view with respect to a particular counterparty is subject to change. The fact, however, that it changes adversely (whether due to external events or otherwise) does not mean a Funds existing transactions with that counterparty will necessarily be terminated or modified. In addition, a Fund may enter into new transactions with a counterparty that GMO no longer considers a desirable counterparty if the transaction is primarily designed to reduce the Funds overall risk of potential exposure to that counterparty (for example, re-establishing the transaction with a lower notional amount or entering into a countervailing trade with the same counterparty).
153
The Funds also are subject to counterparty risk because they execute their securities transactions through brokers and dealers. If a broker or dealer fails to meet its contractual obligations, goes bankrupt, or otherwise experiences a business interruption, the Funds could miss investment opportunities or be unable to dispose of investments they would prefer to sell, resulting in losses for the Funds.
Counterparty risk with respect to derivatives has been and will continue to be affected by new rules and regulations relating to the derivatives market. As described under Derivatives and Short Sales Risk, some derivatives transactions are required to be centrally cleared, and a party to a cleared derivatives transaction is subject to the credit risk of the clearing house and the clearing member through which it holds its cleared position. Credit risk of market participants with respect to derivatives that are centrally cleared is concentrated in a few clearing houses, and it is not clear how an insolvency proceeding of a clearing house would be conducted and what impact an insolvency of a clearing house would have on the financial system. Also, in the event of a counterpartys (or its affiliates) insolvency, the Funds ability to exercise remedies, such as the termination of transactions, netting of obligations and realization on collateral, could be stayed or eliminated under new special resolution regimes adopted in the United States, the European Union and various other jurisdictions. Such regimes provide government authorities with broad authority to intervene when a financial institution is experiencing financial difficulty.
CREDIT RISK. [This is the risk that the issuer or guarantor of a fixed income investment or the obligor of an obligation underlying an asset-backed security will be unable or unwilling to satisfy its obligation to pay principal and interest or otherwise to honor its obligations in a timely manner. The market price of a fixed income investment will normally decline as a result of the issuers, guarantors, or obligors failure to meet its payment obligations, or in anticipation of such failure, or the downgrade of the relevant credit rating. This risk is particularly acute in environments (like those of 2008) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions.]
All fixed income securities are subject to credit risk. Financial strength and solvency of an issuer are the primary factors influencing credit risk. The risk varies depending upon whether the issuer is a corporation, a government or government entity, whether the particular security has a priority over other obligations of the issuer in payment of principal and interest and whether it has any collateral backing or credit enhancement. Credit risk may change over the term of a fixed income security. U.S. government securities are subject to varying degrees of credit risk depending upon whether the securities are supported by the full faith and credit of the United States, supported by the ability to borrow from the U.S. Treasury, supported only by the credit of the issuing U.S. government agency, instrumentality, or corporation, or otherwise supported by the United States. For example, issuers of many types of U.S. government securities (e.g., the Federal Home Loan Mortgage Corporation (Freddie Mac), Federal National Mortgage Association (Fannie Mae), and Federal Home Loan Banks), although chartered or sponsored by Congress, are not funded by Congressional appropriations and their fixed income securities, including mortgage-backed and other asset-backed securities, are neither guaranteed nor insured by the U.S. government. These securities are subject to more credit risk than U.S. government securities that are supported by the full faith and credit of the United States (e.g., U.S. Treasury bonds). Investments in sovereign or quasi-sovereign debt involve the risk that the governmental entities responsible for repayment may be unable or unwilling to pay interest and repay principal when due. A governmental entitys ability and willingness to pay interest and repay principal in a timely manner may be affected by a variety of factors, including its cash flow, the size of its reserves, its access to foreign exchange, the relative size of its debt service burden to its economy as a whole, and political constraints. Investments in quasi-sovereign issuers are subject to the additional risk that the issuer may default independently of its sovereign. Sovereign debt risk is greater for fixed income securities issued or guaranteed by emerging countries.
In many cases, the credit risk of a fixed income security is reflected in its credit ratings, and a Fund holding a rated security is subject to the risk that the investments rating will be downgraded.
Securities issued by the U.S. government historically have presented minimal credit risk. However, events in 2011 led to a downgrade in the long-term credit rating of U.S. bonds by several major rating agencies and introduced greater uncertainty about the repayment by the United States of its obligations. A further credit rating downgrade could decrease, and a default in the payment of principal or interest on U.S. government securities would decrease, the value of a Funds investments and increase the volatility of a Funds portfolio.
As described under Market Risk Asset-Backed Securities, asset-backed securities may be backed by many types of assets and their payment of interest and repayment of principal largely depend on the cash flows generated by the assets backing them. The credit risk of a particular asset-backed security depends on many factors, as described under Market Risk Asset-Backed Securities. The obligations of issuers also may be subject to bankruptcy, insolvency and other laws affecting the rights and remedies of creditors.
A Fund also is exposed to credit risk on a reference security to the extent it writes protection under credit default swaps. See Derivatives and Short Sales Risk for more information regarding risks associated with the use of credit default swaps.
154
The extent to which the market price of a fixed income security changes in response to a credit event depends on many factors and can be difficult to predict. For example, even though the effective duration of a long-term floating rate security is very short, an adverse credit event or change in the perceived creditworthiness of its issuer could cause its market price to decline much more than its effective duration would suggest.
Credit risk is particularly pronounced for below investment grade securities (commonly referred to as junk bonds), which are defined in this Prospectus under Additional Information About the Funds Investment Strategies, Risks, and Expenses Bond Funds. The sovereign debt of many non-U.S. governments, including their sub-divisions and instrumentalities, is below investment grade. Many asset-backed securities also are below investment grade. Below investment grade securities have speculative characteristics, often are less liquid than higher quality securities, present a greater risk of default and are more susceptible to real or perceived adverse industry conditions. Investments in distressed or defaulted or other low quality debt securities generally are considered speculative and may involve substantial risks not normally associated with investments in higher quality securities, including adverse business, financial or economic conditions that lead to payment defaults and insolvency proceedings on the part of their issuers. In particular, distressed or defaulted obligations might be repaid, if at all, only after lengthy workout or bankruptcy proceedings, during which the issuer might not make any interest or other payments, and a Fund may incur additional expenses to seek recovery. If GMOs assessment of the eventual recovery value of a distressed or defaulted debt security proves incorrect, a Fund may lose a substantial portion or all of its investment or may be required to accept cash or instruments worth less than its original investment. In the event of default of sovereign debt, the Funds may be unable to pursue legal action against the issuer.
CURRENCY RISK. Currency risk is the risk that fluctuations in exchange rates will adversely affect the market value of a Funds investments. Currency risk includes the risk that the currencies in which a Funds investments are traded, in which a Fund receives income, or in which a Fund has taken a position, will decline in value relative to the currency in which the Fund is denominated. Currency risk also includes the risk that the currency to which the Fund has obtained exposure through hedging declines in value relative to the currency being hedged, in which event the Fund may realize a loss on both the hedging instrument and the currency being hedged. Currency exchange rates can fluctuate significantly for many reasons. See Market Disruption and Geopolitical Risk.
Many of the Funds use derivatives to take currency positions that are under- or over-weighted (in some cases significantly) relative to the currency exposure of their portfolios and their benchmarks. If the exchange rates of the currencies involved do not move as expected, a Fund could lose money on both its holdings of a particular currency and the derivative. See also Non-U.S. Investment Risk.
Some currencies are illiquid (e.g., some emerging country currencies), and a Fund may not be able to convert them into U.S. dollars, in which case GMO may decide to purchase U.S. dollars in a parallel market with an unfavorable exchange rate. Exchange rates for many currencies (e.g., some emerging country currencies) are particularly affected by exchange control regulations.
Derivative transactions in foreign currencies (such as futures, forwards, options, and swaps) may involve leveraging risk in addition to currency risk, as described under Leveraging Risk. In addition, the obligations of counterparties in currency derivative transactions are often not secured by collateral, which increases counterparty risk (see Counterparty Risk).
DERIVATIVES AND SHORT SALES RISK. All of the Funds may invest in derivatives, which are financial contracts whose value depends on, or is derived from, the value of underlying assets, reference rates, or indices. Derivatives involve the risk that their value may not change as expected relative to changes in the value of the assets, rates, or indices they are designed to track. Derivatives include futures contracts, forward contracts, foreign currency contracts, swap contracts, contracts for differences, options on securities and indices, options on futures contracts, options on swap contracts, interest rate caps, floors and collars, reverse repurchase agreements, and other over-the-counter (OTC) contracts. Derivatives may relate to securities, commodities, currencies, currency exchange rates, interest rates, inflation rates, and indices. The SAI describes the various types of derivatives in which the Funds invest and how they are used in the Funds investment strategies.
The use of derivatives involves risks that are in addition to, and potentially greater than, the risks of investing directly in securities and other more traditional assets. In particular, a Funds use of OTC derivatives exposes it to the risk that the counterparties will be unable or unwilling to make timely settlement payments or otherwise honor their obligations. An OTC derivatives contract typically can be closed only with the consent of the other party to the contract. If the counterparty defaults, the Fund will still have contractual remedies but may not be able to enforce them. Because the contract for each OTC derivative is individually negotiated, the counterparty may interpret contractual terms (e.g., the definition of default) differently than the Fund, and if it does, the Fund may decide not to pursue its claims against the counterparty to avoid the cost and unpredictability of legal proceedings. The Fund, therefore, may be unable to obtain payments GMO believes are owed to it under OTC derivatives contracts, or those payments may be delayed or made only after the Fund has incurred the cost of litigation.
155
A Fund may invest in derivatives that (i) do not require the counterparty to post collateral (e.g., foreign currency forwards), (ii) require collateral but that do not provide for the Funds security interest in it to be perfected, (iii) require a significant upfront deposit by the Fund unrelated to the derivatives fundamental fair (or intrinsic) value, or (iv) do not require that collateral be regularly marked-to-market. When a counterpartys obligations are not fully secured by collateral, a Fund runs a greater risk of not being able to recover what it is owed if the counterparty defaults. Even when derivatives are required by contract to be collateralized, a Fund typically will not receive the collateral for one or more days after the collateral is required to be posted.
The Funds may invest in derivatives with a limited number of counterparties, and events affecting the creditworthiness of any of those counterparties may have a pronounced effect on the Funds. Derivatives risk is particularly acute in environments (like those of 2008) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions. In addition, during those periods, a Fund may have a greater need for cash to provide collateral for large swings in its mark-to-market obligations under the derivatives in which it has invested.
Derivatives also present other risks described in this section, including market risk, illiquidity risk, currency risk, credit risk, and counterparty risk. Many derivatives, in particular OTC derivatives, are complex and their valuation often requires modeling and judgment, which increases the risk of mispricing or improper valuation. The pricing models used may not produce valuations that are consistent with the values a Fund realizes when it closes or sells an OTC derivative. Valuation risk is more pronounced when a Fund enters into OTC derivatives with specialized terms because the value of those derivatives in some cases is determined only by reference to similar derivatives with more standardized terms. As a result, incorrect valuations may result in increased cash payments to counterparties, undercollateralization and/or errors in the calculation of a Funds net asset value.
A Funds use of derivatives may not be effective or have the desired results. Moreover, suitable derivatives will not be available in all circumstances. For example, the economic costs of taking some derivative positions may be prohibitive, and if a counterparty or its affiliate is deemed to be an affiliate of a Fund, the Funds will not be permitted to trade with that counterparty. In addition, GMO may decide not to use derivatives to hedge or otherwise reduce a Funds risk exposures, potentially resulting in losses for the Fund.
Swap contracts and other OTC derivatives are highly susceptible to illiquidity risk (see Illiquidity Risk) and counterparty risk (see Counterparty Risk). These derivatives are also subject to documentation risk, which is the risk that ambiguities, inconsistencies or errors in the documentation relating to a derivative transaction may lead to a dispute with the counterparty or unintended investment results. In addition, see Commodities Risk for a discussion of risks specific to commodity-related derivatives. Because many derivatives have a leverage component (i.e., a notional value in excess of the assets needed to establish and/or maintain the derivative position), adverse changes in the value or level of the underlying asset, rate or index may result in a loss substantially greater than the amount invested in the derivative itself. See Leveraging Risk.
A Funds use of derivatives may be subject to special tax rules and could generate additional taxable income for shareholders. In addition, the tax treatment of a Funds use of derivatives may be unclear because there is little case or other law interpreting the terms of most derivatives or determining their tax treatment. See Distributions and Taxes. In addition, the SEC recently proposed a rule under the Investment Company Act of 1940, as amended, regulating the use by registered investment companies of derivatives and many related instruments. That rule, if adopted as proposed, could, among other things, restrict a Funds ability to engage in derivatives transactions or so increase the cost of derivatives transactions such that a Fund would be unable to implement its investment strategy.
Derivatives Regulation . The U.S. government has enacted legislation that provides for new regulation of the derivatives market, including clearing, margin, reporting, and registration requirements. The European Union (and some other countries) are implementing similar requirements, which will affect a Fund when it enters into a derivatives transaction with a counterparty organized in that country or otherwise subject to that countrys derivatives regulations. Because these requirements are new and evolving (and some of the rules are not yet final), their ultimate impact remains unclear.
Transactions in some types of swaps (including interest rate swaps and credit default swaps on North American and European indices) are required to be centrally cleared. In a transaction involving those swaps (cleared derivatives), a Funds counterparty is a clearing house rather than a bank or broker. Since the Funds are not members of clearing houses and only members of a clearing house (clearing members) can participate directly in the clearing house, the Funds hold cleared derivatives through accounts at clearing members. In cleared derivatives positions, the Funds make payments (including margin payments) to and receive payments from a clearing house through their accounts at clearing members. Clearing members guarantee performance of their clients obligations to the clearing house.
In some ways, cleared derivative arrangements are less favorable to mutual funds than bilateral arrangements, for example, by requiring that funds provide more margin for their cleared derivatives positions. Also, as a general matter, in contrast to a bilateral derivatives position, following a period of notice to a Fund, a clearing member at any time can require termination of an existing
156
cleared derivatives position or an increase in margin requirements above those required at the outset of a transaction. Clearing houses also have broad rights to increase margin requirements for existing positions or to terminate those positions at any time. Any increase in margin requirements or termination of existing cleared derivatives positions by the clearing member or the clearing house could interfere with the ability of a Fund to pursue its investment strategy. Further, any increase in margin requirements by a clearing member could expose a Fund to greater credit risk to its clearing member because margin for cleared derivatives positions in excess of a clearing houses margin requirements typically is held by the clearing member (see Counterparty Risk). Also, a Fund is subject to risk if it enters into a derivatives transaction that is required to be cleared (or that GMO expects to be cleared), and no clearing member is willing or able to clear the transaction on the Funds behalf. While the documentation in place between the Funds and their clearing members generally provides that the clearing members will accept for clearing all cleared derivatives transactions that are within credit limits (specified in advance) for each Fund, the Funds are still subject to the risk that no clearing member will be willing or able to clear a transaction. In those cases, the position might have to be terminated, and the Fund could lose some or all of the benefit of the position, including loss of an increase in the value of the position and loss of hedging protection. In addition, the documentation governing the relationship between the Funds and clearing members is drafted by the clearing members and generally is less favorable to the Funds than typical bilateral derivatives documentation. For example, documentation relating to cleared derivatives generally includes a one-way indemnity by the Funds in favor of the clearing member for losses the clearing member incurs as the Funds clearing member. Also, such documentation typically does not provide the Funds any remedies if the clearing member defaults or becomes insolvent. While futures contracts entail similar risks, the risks may be more pronounced for cleared derivatives due to their more limited liquidity and market history.
Some types of cleared derivatives are required to be executed on an exchange or on a swap execution facility. A swap execution facility is a trading platform where multiple market participants can execute derivatives by accepting bids and offers made by multiple other participants in the platform. While this execution requirement is designed to increase transparency and liquidity in the cleared derivatives market, trading on a swap execution facility can create additional costs and risks for the Funds. For example, swap execution facilities typically charge fees, and if a Fund executes derivatives on a swap execution facility through a broker intermediary, the intermediary may impose fees as well. Also, a Fund may indemnify a swap execution facility, or a broker intermediary who executes cleared derivatives on a swap execution facility on the Funds behalf, against any losses or costs that may be incurred as a result of the Funds transactions on the swap execution facility. [If a Fund wishes to execute a package of transactions that include a swap that is required to be executed on a swap execution facility as well as other transactions (for example, a transaction that includes both a security and an interest rate swap that hedges interest rate exposure with respect to such security), the Fund may be unable to execute all components of the package on the swap execution facility. In that case, the Fund would need to trade some components of the package on the swap execution facility and other components in another manner, which could subject the Fund to the risk that some components would be executed successfully and others would not, or that the components would be executed at different times, leaving the Fund with an unhedged position for a period of time.]
The U.S. government and the European Union have adopted mandatory minimum margin requirements for bilateral derivatives. GMO expects that the Funds transactions will become subject to variation margin requirements under such rules in 2017 and initial margin requirements under such rules in 2020. Similar requirements are expected to be adopted by the European Union. Such requirements could increase the amount of margin a Fund needs to provide in connection with its derivatives transactions and, therefore, make derivatives transactions more expensive.
These and other new rules and regulations could, among other things, further restrict a Funds ability to engage in, or increase the cost to the Fund of, derivatives transactions, for example, by making some types of derivatives no longer available to the Fund or otherwise limiting liquidity. The implementation of the clearing requirement has increased the costs of derivatives transactions for the Funds, since the Funds have to pay fees to their clearing members and are typically required to post more margin for cleared derivatives than they have historically posted for bilateral derivatives. The costs of derivatives transactions are expected to increase further as clearing members raise their fees to cover the costs of additional capital requirements and other regulatory changes applicable to the clearing members, which will take effect when rules imposing mandatory minimum margin requirements on bilateral swaps become effective. These rules and regulations are new and evolving, so their potential impact on the Funds and the financial system are not yet known. While the new rules and regulations and central clearing of some derivatives transactions are designed to reduce systemic risk (i.e., the risk that the interdependence of large derivatives dealers could cause them to suffer liquidity, solvency or other challenges simultaneously), there is no assurance that they will achieve that result, and in the meantime, as noted above, central clearing and related requirements expose the Funds to new kinds of costs and risks.
Options . Some Funds, particularly Risk Premium Fund, are permitted to write options. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The market price of an option also may be adversely affected if the market for the option becomes less liquid. In addition, since an American-style option allows the holder to exercise its rights any time before the options expiration, the writer of an American-style option has no control over when it will be required to fulfill its obligations as a writer of the option. (The writer of a European-style option is not subject to this risk because the holder may only exercise the option on its expiration date.) If a Fund writes a call option and does not hold the underlying security or instrument, the Funds potential loss is theoretically unlimited.
157
National securities exchanges generally have established limits on the maximum number of options an investor or group of investors acting in concert may write. A Fund, GMO, and other funds advised by GMO will likely constitute such a group. When applicable, these limits restrict a Funds ability to purchase or write options on a particular security.
Unlike exchange-traded options, which are standardized with respect to the underlying instrument, expiration date, contract size, and strike price, the terms of OTC options (i.e., options not traded on exchanges) generally are established through negotiation with the other party to the option contract. While a Fund has greater flexibility to tailor an OTC option, OTC options generally expose a Fund to greater credit risk than exchange-traded options, which are guaranteed by the clearing organization of the exchanges where they are traded. Purchasing and writing put and call options are highly specialized activities and entail greater than ordinary market risks.
Special tax rules apply to a Funds transactions in options, which could increase the taxes payable by shareholders. In particular, a Funds options transactions potentially could cause a substantial portion of the Funds income to consist of net short-term capital gain, which, when distributed, is taxable to shareholders subject to U.S. income tax at ordinary income tax rates. Due to Risk Premium Funds primary investment strategy of selling put options on various stock indices, a substantial portion of that Funds income could consist of short-term capital gains. See Distributions and Taxes for more information.
Short Investment Exposure . Some Funds may sell securities or currencies short as part of their investment programs in an attempt to increase their returns or for hedging purposes. Short sales expose a Fund to the risk that it will be required to acquire, convert, or exchange a security or currency to replace the borrowed security or currency when the security or currency sold short has appreciated in value, thus resulting in a loss to the Fund. Purchasing a security or currency to close out a short position can itself cause the price of the security or currency to rise further, thereby exacerbating any losses. A Fund that sells short a security or currency it does not own also may have to pay borrowing fees to a broker and may be required to pay the broker any dividends or interest it receives on a borrowed security.
A Fund also may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. See Derivatives and Short Sales Risk for a discussion of the specific risks of a Funds investments in derivatives.
Short sales of securities or currencies a Fund does not own and short derivative positions involve forms of investment leverage, and the amount of the Funds potential loss is theoretically unlimited. A Fund is subject to increased leveraging risk and other investment risks described in this Description of Principal Risks section to the extent it sells short securities or currencies it does not own or takes short derivative positions.
FOCUSED INVESTMENT RISK. Funds with investments that are focused in particular countries, regions, sectors, industries or issuers that are subject to the same or similar risk factors and funds with investments whose prices are strongly correlated are subject to greater overall risk than funds with investments that are more diversified and/or whose prices are more loosely correlated.
A Fund that invests in the securities of a small number of issuers has greater exposure to adverse developments affecting those issuers and to a decline in the market price of particular securities than Funds investing in the securities of a larger number of issuers. Securities, sectors, or companies that share common characteristics are often subject to similar business risks and regulatory burdens, and often react similarly to specific economic, market, political or other developments.
Similarly, Funds having a significant portion of their assets in investments tied economically (or related) to a particular geographic region, country (e.g., Taiwan or Japan) or market (e.g., emerging markets), or to sectors within a region, country or market (e.g., Russian oil), have more exposure to regional and country economic risks than funds making investments throughout the world. The political and economic prospects of one country or group of countries within the same geographic region may affect other countries in that region, and a recession, debt crisis or decline in the value of the currency of one country can spread to other countries. Furthermore, companies in a particular geographic region or country are vulnerable to events affecting other companies in that region or country because they often share common characteristics, are exposed to similar business risks and regulatory burdens, and react similarly to specific economic, market, political or other developments. See also Non-U.S. Investment Risk.
Because Resources Fund concentrates its investments in the natural resources sector, it is particularly exposed to adverse developments, including adverse price movements, affecting issuers in the natural resources sector and is subject to greater risks than a fund that invests in a wider range of industries. In addition, the market prices of securities of companies in the natural resources sector are often more volatile than those of securities of companies in other industries. Some of the commodities used as raw materials or produced by these companies are subject to broad price fluctuations as a result of industry-wide supply and demand factors. Companies in the natural resources sector often have limited pricing power over the supplies they purchase and the products they sell, which can affect their profitability[, and are often capital-intensive and use significant amounts of leverage. Projects in the natural
158
resources sector may have long setup times and companies cannot ensure that the market will be favorable at the time the project begins production. Companies in the natural resources sector also may be subject to special risks associated with natural or man-made disasters. In addition, the natural resources sector can be especially affected by political and economic developments, government regulations including changes in tax law or interpretations of law, energy conservation, and the success of exploration projects. Specifically, the natural resource sector can be significantly affected by import controls, worldwide competition and cartels, changes in consumer sentiment and spending, and can be subject to liability for, among other things, environmental damage, depletion of resources, and mandated expenditures for safety and pollution control. Resources Funds concentration in the securities of natural resource companies exposes it to the price movements of natural resources to a greater extent than if it were more broadly diversified. Because Resources Fund invests primarily in the natural resources sector, it runs the risk of performing poorly during an economic downturn or a decline in demand for natural resources.
Because Risk Premium Fund can have substantial exposure through a limited number of options contracts and because the Funds exposures may relate to relatively few stock indices, the Fund is subject to focused investment risk.
FUND OF FUNDS RISK. Funds that invest in underlying funds or in a wholly-owned subsidiary are exposed to the risk that the underlying funds or wholly-owned subsidiary will not perform as expected. The Funds also are indirectly exposed to all of the risks to which the underlying funds or a wholly-owned subsidiary are exposed.
Because a Fund bears the fees and expenses of an underlying fund and the expenses of a wholly-owned subsidiary in which it invests, absent reimbursement, the Fund will incur additional expenses when investing in an underlying fund or wholly owned subsidiary. In addition, total Fund expenses will increase if a Fund makes a new or further investment in underlying funds with higher fees or expenses than the average fees and expenses of the underlying funds then in the Funds portfolio.
Because some underlying GMO Funds (e.g., many of the Bond Funds) invest a substantial portion of their assets in other GMO Funds (pursuant to an exemptive order obtained from the SEC), the Asset Allocation Funds have more tiers of investments than funds in many other groups of investment companies and therefore may be subject to greater fund of funds risk. In addition, to the extent a Fund invests in shares of underlying GMO Funds, it is indirectly subject to Large Shareholder Risk because those underlying GMO Funds are more likely to have large shareholders (e.g., other GMO Funds). See Large Shareholder Risk.
Investments in ETFs involve the risk that an ETFs performance may not track the performance of the index the ETF is designed to track. In addition, ETFs often use derivatives to track the performance of the relevant index, and, therefore, investments in those ETFs are subject to the same derivatives risks discussed in Derivatives and Short Sales Risk.
A Funds investments in one or more underlying funds or a wholly-owned subsidiary could affect the amount, timing and character of its distributions and could cause the Fund to recognize taxable income in excess of the cash generated by such investments, requiring the Fund in turn to liquidate investments at disadvantageous times to generate cash needed to make required distributions. See Distributions and Taxes for more information about the tax consequences of a Funds investments in a wholly-owned subsidiary and Taxes in the SAI for more information about the tax consequences of a Funds investments in underlying funds.
[ FUTURES CONTRACTS RISK. The risk of loss relating to some uses of futures contracts is potentially unlimited. The ability to establish and close out positions in futures contracts will be subject to the development and maintenance of a liquid secondary market. There is no assurance that a liquid secondary market on an exchange will exist for any particular futures contract at any particular time. In the event no such market exists for a particular contract, it might not be possible to effect closing transactions, and a Fund will be unable to terminate its exposure to the contract. In using futures contracts, a Fund will be reliant on GMOs ability to predict market and price movements correctly; the skills needed to use such futures contracts successfully are different from those needed for traditional portfolio management. If a Fund uses futures contracts for hedging purposes, there is a risk of imperfect correlation between movements in the prices of the contracts and movements in the securities or index underlying the contracts or movements in the prices of the Funds investments that are the subject of such hedge. The prices of futures, for a number of reasons, may not correlate perfectly with movements in the securities or index underlying them. For example, participants in the futures markets are subject to margin deposit requirements. Such requirements may cause investors to take actions with respect to their futures positions that they would not otherwise take. The margin requirements in the futures markets may be less onerous than margin requirements in the securities markets in general, and as a result those markets may attract more speculators than the securities markets do. Increased participation by speculators in those markets may cause temporary price distortions. Due to the possibility of price distortion, even a correct forecast of general market trends by GMO still may not result in a successful futures investment or investments. The risk of a position in a futures contract may be very large compared to the relatively low level of margin a Fund is required to deposit. In many cases, a relatively small price movement in a futures contract may result in immediate and substantial loss or gain to the Fund relative to the size of a required margin deposit. A Fund will incur brokerage fees in connection with its exchange-traded derivatives transactions.
159
A Fund will typically be required to post margin with its futures commission merchant in connection with its transactions in futures contracts. In the event of an insolvency of the futures commission merchant, a Fund may not be able to recover all (or any) of the margin it has posted with the futures commission merchant, or to realize the value of any increase in the price of its positions. A Fund also may be delayed or prevented from recovering margin or other amounts deposited with a futures commission merchant or futures clearinghouse. The Commodity Futures Trading Commission (the CFTC) and the various exchanges have established limits referred to as speculative position limits on the maximum net long or net short positions that any person and certain affiliated entities may hold or control in a particular futures contract. Trading limits are imposed on the number of contracts that any person may trade on a particular trading day. An exchange may order the liquidation of positions found to be in violation of these limits and it may impose sanctions or restrictions. In addition, the Dodd-Frank Wall Street Reform and Consumer Protection Act requires the CFTC to establish speculative position limits on listed futures and economically equivalent over-the-counter (OTC) derivatives. Regulatory action taken by the CFTC to establish these additional position limits may adversely affect the market liquidity of the futures, options and economically equivalent derivatives in which a Fund may invest. It is possible that, as a result of such limits, GMO will be precluded from taking positions in certain futures contracts or OTC derivatives as a result of positions held by other GMO clients or by GMO or its affiliates themselves.
Futures contracts traded on markets outside the United States are not generally subject to regulation by the CFTC or other U.S. regulatory entities, including without limitation as to the execution, delivery, and clearing of transactions. U.S. regulators neither regulate the activities of a foreign exchange, nor have the power to compel enforcement of the rules of the foreign exchange or the laws of the foreign country in question. Margin and other payments made by a Fund may not be afforded the same protections as are afforded those payments in the United States, including in connection with the insolvency of an executing or clearing broker or a clearinghouse or exchange. Foreign futures contracts may be less liquid and more volatile than U.S. contracts.]
ILLIQUIDITY RISK. Illiquidity risk is the risk that low trading volume, lack of a market maker, large position size, or legal restrictions (including daily price fluctuation limits or circuit breakers) limits or prevents a Fund from selling particular securities or closing derivative positions at desirable prices. In addition to these risks, a Fund is exposed to illiquidity risk when it has an obligation to purchase particular securities (e.g., as a result of entering into reverse repurchase agreements, writing a put, or closing a short position). To the extent a Funds investments include asset-backed securities, distressed, defaulted or other low quality debt securities, emerging country debt securities, securities of companies with smaller market capitalizations or smaller total float-adjusted market capitalizations, or emerging market securities, it is subject to increased illiquidity risk. These types of investments can be difficult to value (see Determination of Net Asset Value), exposing a Fund to the risk that the price at which it sells them will be less than the price at which they were valued when held by the Fund. Illiquidity risk also may be greater in times of financial stress. For example, TIPS have experienced periods of greatly reduced liquidity during disruptions in fixed income markets, such as the events surrounding the bankruptcy of Lehman Brothers in 2008. Less liquid securities are more susceptible than other securities to price declines when market prices decline generally.
A Fund may buy securities that are less liquid than those in its benchmark.
A Funds, and particularly Risk Premium Funds, ability to use options as part of its investment program depends on the liquidity of the options market. In addition, that market may not be liquid when a Fund seeks to close out an option position. Also, the hours of trading for options on an exchange may not conform to the hours during which the securities held by a Fund are traded. To the extent that the options markets close before the markets for the underlying securities, significant price and rate movements can take place in the markets for underlying securities that are not immediately reflected in the options markets. If a Fund receives a redemption request and is unable to close out an option it has sold, the Fund may temporarily be leveraged in relation to its assets.
LARGE SHAREHOLDER RISK. To the extent a large number of shares of a Fund is held by a single shareholder (e.g., an institutional investor or another GMO Fund) or a group of shareholders with a common investment strategy (e.g., GMO asset allocation accounts), the Fund is subject to the risk that a redemption by those shareholders of all or a large portion of their Fund shares will adversely affect the Funds performance by forcing the Fund to sell portfolio securities to raise the cash needed to satisfy the redemption request. In addition, the Funds and other accounts over which GMO has investment discretion that invest in the Funds are not limited in how often they may purchase or sell Fund shares. The Asset Allocation Funds and separate accounts managed by GMO for its clients hold substantial percentages of the shares of many Funds, and asset allocation decisions by GMO may result in substantial redemptions from (or investments in) those Funds. These transactions may adversely affect the Funds performance to the extent that the Fund is required to sell investments (or invest cash) when it would not otherwise do so. Redemptions of a large number of shares also may increase transaction costs or, by necessitating a sale of portfolio securities, have adverse tax consequences for Fund
160
shareholders. Additionally, redemptions by a large shareholder also potentially limit the use of any capital loss carryforwards and other losses to offset future realized capital gains (if any) and may limit or prevent a Funds use of tax equalization. In addition, to the extent a Fund invests in other GMO Funds subject to large shareholder risk, the Fund is indirectly subject to this risk.
LEVERAGING RISK. The use of reverse repurchase agreements and other derivatives and securities lending creates leverage (i.e., a Funds investment exposures exceed its net asset value). Leverage increases a Funds losses when the value of its investments (including derivatives) declines. Because many derivatives have a leverage component (i.e., a notional value in excess of the assets needed to establish or maintain the derivative position), adverse changes in the value or level of the underlying asset, rate, or index may result in a loss substantially greater than the amount invested in the derivative itself. In the case of swaps, the risk of loss generally is related to a notional principal amount, even if the parties have not made any initial investment. Some derivatives have the potential for unlimited loss, regardless of the size of the initial investment. A Funds portfolio also will be leveraged if it borrows money to meet redemption requests or settle investment transactions or if it exercises its right to delay payment on a redemption.
A Fund may manage some of its derivative positions by offsetting derivative positions against one another or against other assets. To the extent offsetting positions do not behave in relation to one another as expected, a Fund may perform as if it were leveraged.
MANAGEMENT AND OPERATIONAL RISK . Each Fund is subject to management risk because it relies on GMO to achieve its investment objective. Each Fund runs the risk that GMOs investment techniques (which may be fundamental, quantitative, or a combination of the two) will fail to produce desired results and cause the Fund to incur significant losses. GMO also may fail to use derivatives effectively, choosing to hedge or not to hedge positions at disadvantageous times. In the case of Tax-Managed International Equities Fund, GMOs tax-management strategies may be ineffective or limited by market conditions, the timing of cash flows into and out of the Fund, and current or future developments in tax legislation and regulation.
As described in the Fund summaries, for some Funds, GMO uses quantitative analyses and models as part of its investment process and, in the case of SGM Major Markets Fund, those models are one of the key components of investment decisions. Analyses and models may not accurately predict future market events and make simplifying assumptions that can limit their effectiveness. In addition, the data on which the analyses and models are based is subject to limitations (e.g., inaccuracies, staleness)that could adversely affect a Funds performance. The Funds also run the risk that GMOs assessment of an investment (including a companys fundamental fair (or intrinsic) value) may be wrong.
GMO relies heavily on quantitative models in making investment decisions for SGM Major Markets Fund. The usefulness of those models may be diminished by the faulty incorporation of mathematical models into computer code, by reliance on proprietary and third-party technology that may include bugs or viruses, and by the retrieval of imperfect data for processing by the model. These risks are present in the ordinary course of business and are more likely to occur at times during which GMO is making changes to its models. Any of these risks could adversely affect SGM Major Markets Funds performance.
There can be no assurance that key GMO personnel will continue to be employed by GMO. The loss of their services could have an adverse impact on GMOs ability to achieve the Funds investment objectives.
The Funds also are subject to the risk of loss as a result of other services provided by GMO and other service providers, including pricing, administrative, accounting, tax, legal, custody, transfer agency, and other services. Operational risk includes the possibility of loss caused by inadequate procedures and controls, human error, and system failures by a service provider. For example, trading delays or errors could prevent a Fund from benefiting from potential investment gains or avoiding losses. GMO is not contractually liable to the Funds for losses associated with operational risk absent its willful misfeasance, bad faith, gross negligence, or reckless disregard of its contractual obligations to provide services to the Funds. Other Fund service providers also have contractual limitations on their liability to the Funds for losses resulting from their errors.
The Funds and their service providers (including GMO) are susceptible to cyber-attacks and technological malfunctions that may have effects that are similar to those of a cyber-attack. Cyber-attacks include, among others, stealing or corrupting data maintained online or digitally, preventing legitimate users from accessing information or services on a website, releasing confidential information without authorization, and causing operational disruption. Successful cyber-attacks against, or security breakdowns of, a Fund, GMO, a sub-adviser, or a custodian, transfer agent, or other service provider may adversely affect the Fund or its shareholders. For instance, cyber-attacks may interfere with the processing of shareholder transactions, affect a Funds ability to calculate its net asset value, cause the release or misappropriation of private shareholder information or confidential Fund information, impede trading, cause reputational damage, and subject the Fund to regulatory fines, penalties or financial losses, reimbursement or other compensation costs, and additional compliance costs. While GMO has established business continuity plans and systems designed to prevent cyber-attacks, such plans and systems are subject to inherent limitations. Similar types of cyber security risks also are present for issuers of securities in which the Funds invest, which could result in material adverse consequences for such issuers, and may cause a Funds investment in such securities to lose value.
161
MARKET DISRUPTION AND GEOPOLITICAL RISK. The Funds are subject to the risk that geopolitical and other events (e.g., wars and terrorism) will disrupt securities markets and adversely affect global economies and markets, thereby decreasing the value of the Funds investments. Sudden or significant changes in the supply or prices of commodities or other economic inputs (e.g., the marked decline in oil prices that began in late 2014) may have material and unexpected effects on both global securities markets and individual countries, regions, sectors, companies, or industries, which could significantly reduce the value of a Funds investments. Terrorism in the United States and around the world has increased geopolitical risk. The terrorist attacks on September 11, 2001 resulted in the closure of some U.S. securities markets for four days, and similar attacks are possible in the future. Securities markets may be susceptible to market manipulation (e.g., the manipulation of the London Interbank Offered Rate (LIBOR)) or other fraudulent trading practices, which could disrupt the orderly functioning of markets or reduce the value of investments traded in them, including investments of the Funds. While the U.S. government has always honored its credit obligations, a default by the U.S. government (as has been threatened in recent years) would be highly disruptive to the U.S. and global securities markets and could significantly reduce the value of the Funds investments. Similarly, political events within the United States at times have resulted, and may in the future result, in a shutdown of government services, which could adversely affect the U.S. economy, decrease the value of many Fund investments, and increase uncertainty in or impair the operation of the U.S. or other securities markets. Uncertainty surrounding the sovereign debt of several European Union countries, as well as the continued existence of the European Union itself, has disrupted and may continue to disrupt markets in the United States and around the world. If a country changes its currency or leaves the European Union or if the European Union dissolves, the worlds securities markets likely will be significantly disrupted. Substantial government interventions (e.g., currency controls) also could adversely affect the Funds. War, terrorism, economic uncertainty, and related geopolitical events have led, and in the future may lead, to increased short-term market volatility and may have adverse long-term effects on U.S. and world economies and markets generally. Likewise, natural and environmental disasters, such as the earthquake and tsunami in Japan in early 2011, and systemic market dislocations of the kind surrounding the insolvency of Lehman Brothers in 2008, if repeated, would be highly disruptive to economies and markets, adversely affecting individual companies and industries, securities markets, interest rates, credit ratings, inflation, investor sentiment, and other factors affecting the value of the Funds investments. During such market disruptions, the Funds exposure to the risks described elsewhere in this Description of Principal Risks section will likely increase. Market disruptions, including sudden government interventions, can also prevent the Funds from implementing their investment programs and achieving their investment objectives. For example, a market disruption may adversely affect the orderly functioning of the securities markets and may cause the Funds derivatives counterparties to discontinue offering derivatives on some underlying commodities, securities, reference rates, or indices, or to offer them on a more limited basis. To the extent a Fund has focused its investments in the stock index of a particular region, adverse geopolitical and other events in that region could have a disproportionate impact on the Fund.
MARKET RISK. All of the Funds are subject to market risk, which is the risk that the market value of their holdings will decline. Market risks include:
Asset-Backed Securities. Investments in asset-backed securities not only are subject to all of the market risks described under Market Risk Fixed Income Investments, but to other market risks as well.
[A Funds investments in asset-backed securities are exposed to greater risk of severe credit downgrades, illiquidity, and defaults than many other types of fixed income investments.] These risks are particularly acute during periods of adverse market conditions, such as those that occurred in 2008. Asset-backed securities may be backed by many types of assets, including pools of residential and commercial mortgages, automobile loans, educational loans, home equity loans, and credit-card receivables. They also may be backed by pools of corporate, sovereign or quasi-sovereign bonds, bank loans to corporations, or a combination of bonds and loans (commonly referred to as collateralized debt obligations or collateralized loan obligations) and by the fees payable to service providers.
As described under Market Risk Fixed Income Investments, the market price of fixed income investments with complex structures, such as asset-backed securities, can decline due to a variety of factors, including market uncertainty about their credit quality and the reliability of their payment streams. Payment of interest on asset-backed securities and repayment of principal largely depend on the cash flow generated by the assets backing the securities, as well as the deal structure (e.g., the amount of underlying assets or other support available to produce the cash flows necessary to service interest and make principal payments), the quality of the underlying assets, the level of credit support and the credit quality of the credit-support provider, if any, and the reliability of various other service providers with access to the payment stream. A problem in any one of these factors can lead to a reduction in the payment stream GMO expected a Fund to receive at the time the Fund purchased the asset-backed security. Asset-backed securities involve risk of loss of principal if obligors of the underlying obligations default and the value of the defaulted obligations exceeds whatever credit support the securities may have. Asset-backed securities backed by sub-prime mortgage loans, in particular, may expose a Fund to significantly greater declines in value due to defaults because sub-prime mortgage loans are typically made to less
162
creditworthy borrowers and thus have a higher risk of default than conventional mortgage loans. The obligations of issuers (and obligors of asset-backed securities) also are subject to bankruptcy, insolvency and other laws affecting the rights and remedies of creditors. As of the date of this Prospectus, many asset-backed securities owned by the Funds that were once rated investment grade are now rated below investment grade. See Credit Risk for more information about credit risk.
With the deterioration of worldwide economic and liquidity conditions that occurred and became acute in 2008, the markets for asset-backed securities became fractured, and uncertainty about the creditworthiness of those securities (and underlying assets) caused credit spreads (the difference between yields on asset-backed securities and U.S. Government securities) to widen dramatically. Concurrently, systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions reduced the ability of financial institutions to make markets in many fixed income securities. These events reduced liquidity and contributed to substantial declines in the market prices of asset-backed and other fixed income securities. For an illustration, see GMO Short-Duration Collateral Funds 2008 performance on page [ ] of this Prospectus. These conditions may occur again. Also, government actions and proposals affecting the terms of underlying home and consumer loans, changes in demand for products (e.g., automobiles) financed by those loans, and the inability of borrowers to refinance existing loans (e.g., sub-prime mortgages) have had, and may continue to have, adverse valuation and liquidity effects on asset-backed securities.
The market price of an asset-backed security may depend on the servicing of its underlying assets and is, therefore, subject to risks associated with the negligence or defalcation of its servicer. In some circumstances, the mishandling of documentation for underlying assets also may affect the rights of holders of those underlying assets. The insolvency of an entity that generated the assets underlying an asset-backed security is likely to result in a decline in the market price of that security, as well as costs and delays. The obligations underlying asset-backed securities, in particular securities backed by pools of residential and commercial mortgages, also are subject to unscheduled prepayment, and a Fund may be unable to invest prepayments at as high a yield as was provided by the asset-backed security. When interest rates rise, these obligations also may be repaid more slowly than anticipated, and the market price of the Funds investment may decrease.
In addition, the existence of insurance on an asset-backed security does not guarantee that the principal and interest will be paid because the insurer could default on its obligations.
The risk of investing in asset-backed securities has increased since the deterioration in worldwide economic and liquidity conditions referred to above because performance of the various sectors in which the assets underlying asset-backed securities are concentrated (e.g., auto loans, student loans, sub-prime mortgages, and credit card receivables) has become more highly correlated. See Focused Investment Risk for more information about risks of investing in correlated sectors. A single financial institution may serve as trustee for many asset-backed securities. As a result, a disruption in that institutions business may have a material impact on many investments. [The risks associated with asset-backed securities are particularly pronounced for Debt Opportunities Fund, which has invested a substantial portion of its assets in asset-backed securities, and for each Fund that has invested a substantial portion of its assets in Debt Opportunities Fund.]
Equities. Funds that invest in equities run the risk that the market price of an equity will decline. That decline may be attributable to factors affecting the issuer, such as poor performance by the companys management or reduced demand for its goods or services, or to factors affecting a particular industry, such as a decline in demand, labor or raw material shortages, or increased production costs. A decline also may result from general market conditions not specifically related to a company or industry, such as real or perceived adverse economic conditions, changes in the general outlook for corporate earnings, changes in interest or currency rates, or adverse investor sentiment generally. Equities generally have significant price volatility, and their market prices can decline in a rapid or unpredictable manner. If a Fund purchases an equity for less than its fundamental fair (or intrinsic) value as determined by GMO, the Fund runs the risk that the market price of the equity will not appreciate or will decline due to GMOs incorrect assessment of the equitys fundamental fair (or intrinsic) value. The market prices of equities trading at high multiples of current earnings often are more sensitive to changes in future earnings expectations than the market prices of equities trading at lower multiples.
Because of Risk Premium Funds emphasis on selling put options on stock indices, GMO expects its net asset value to decline when those indices decline in value. Also, Risk Premium Funds investment strategy of writing put options on stock indices can be expected to cause the Fund to underperform relative to those indices when those markets rise sharply because of the Funds lack of exposure to the upside of those markets.
Fixed Income Investments. Funds that invest in fixed income securities (including bonds, notes, bills, synthetic debt instruments, and asset-backed securities) are subject to various market risks. The market price of a fixed income investment can decline due to market-related factors, including rising interest rates and widening credit spreads, or decreased liquidity stemming from the markets uncertainty about the value of a fixed income investment (or class of fixed income investments). In addition, the market
163
price of fixed income investments with complex structures, such as asset-backed securities, and sovereign and quasi-sovereign debt instruments can decline due to uncertainty about their credit quality and the reliability of their payment streams. Some fixed income securities also are subject to unscheduled prepayment, and a Fund may be unable to invest prepayments at as high a yield as was provided by the fixed income security. When interest rates rise, these securities also may be repaid more slowly than anticipated, and the market price of the Funds investment may decrease. During periods of economic uncertainty and change, the market price of a Funds investments in below investment grade securities (commonly referred to as junk bonds) may be particularly volatile. Often below investment grade securities are subject to greater sensitivity to interest rate and economic changes than higher rated bonds and can be more difficult to value (see Determination of Net Asset Value), exposing a Fund to the risk that the price at which it sells them will be less than the price at which they were valued when held by the Fund. See Credit Risk and Illiquidity Risk for more information about these risks.
A principal risk run by each Fund with a significant investment in fixed income securities is that an increase in prevailing interest rates will cause the market price of those securities to decline. The risk associated with increases in interest rates (also called interest rate risk) is generally greater for Funds investing in fixed income securities with longer durations. In addition, in managing some Funds, GMO may seek to evaluate potential investments in part by considering the volatility of interest rates. The value of a Funds investments may be significantly reduced if GMOs assessment proves incorrect.
The extent to which a fixed income securitys price changes with changes in interest rates is referred to as interest rate duration, which can be measured mathematically or empirically. A longer-maturity investment generally has longer interest rate duration because the investments fixed rate is locked in for a longer period of time. Floating-rate or adjustable-rate securities, however, generally have shorter interest rate durations because their interest rates are not fixed but rather float up and down as interest rates change. Conversely, inverse floating-rate securities have durations that move in the opposite direction from short-term interest rates and thus tend to underperform fixed rate securities when interest rates rise but outperform them when interest rates decline. Fixed income securities paying no interest, such as zero coupon and principal-only securities, are subject to additional interest rate risk.
The market price of inflation-indexed bonds (including Inflation-Protected Securities issued by the U.S. Treasury (TIPS)) typically declines during periods of rising real interest rates (i.e., nominal interest rate minus inflation) and increases during periods of declining real interest rates. In some interest rate environments, such as when real interest rates are rising faster than nominal interest rates, the market price of inflation-indexed bonds may decline more than the price of non-inflation-indexed (or nominal) fixed income bonds with similar maturities.
Generally, when interest rates on short term U.S. Treasury obligations equal or approach zero, a Fund that invests a substantial portion of its assets in U.S. Treasury obligations, such as U.S. Treasury Fund, will have a negative return unless GMO waives or reduces its management fees.
Fixed income securities denominated in foreign currencies also are subject to currency risk. See Currency Risk.
In response to government intervention, economic or market developments, or other factors, fixed income markets may experience periods of high volatility, reduced liquidity or both. During those periods, a Fund could have unusually high shareholder redemptions, requiring it to generate cash by selling securities when it would otherwise not do so, including at unfavorable prices. Fixed income investments may be difficult to value during such periods. In recent periods, central banks and governmental financial regulators, including the U.S. Federal Reserve, have maintained historically low interest rates by purchasing bonds. Steps to curtail or taper such activities and other actions by central banks or regulators (such as intervention in foreign currency markets or currency controls) could have a material adverse effect on the Funds.
MERGER ARBITRAGE RISK. Some Funds may engage in transactions in which a Fund purchases securities at prices below the value of the consideration GMO expects to be paid for them upon consummation of a proposed merger, exchange offer, tender offer, or other similar transaction (merger arbitrage transactions). The purchase price paid by the Fund may substantially exceed the market price of the securities before the announcement of the transaction.
If a Fund engages in a merger arbitrage transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric, as the losses in failed transactions often far exceed the gains in successful transactions. A merger arbitrage transaction can fail for many reasons, including regulatory and antitrust restrictions, political motivations, industry weakness, stock specific events, failed financings, and general market declines.
Merger arbitrage strategies depend for success on the overall volume of merger activity, which has historically been cyclical. When merger activity is low, GMO may be unable to identify enough opportunities to provide sufficient diversification.
Merger arbitrage strategies are subject to the risk of overall market movements, and a Fund may experience losses even if a transaction is consummated. A Funds investments in derivatives or short sales of securities to hedge or otherwise adjust long or short
164
investment exposure in connection with a merger arbitrage transaction may not perform as GMO expected or may otherwise reduce the Funds gains or increase its losses. Also, a Fund may be unable to hedge against market fluctuations or other risks. In addition, a Fund that sells securities short that GMO expects it to receive upon consummation of a transaction but it does not actually receive (and thus has an unintended naked short position) may be required to cover its short position at a time when the securities sold short have appreciated in value, thus resulting in a loss.
NON-DIVERSIFIED FUNDS. Some of the Funds are not diversified investment companies within the meaning of the Investment Company Act of 1940, as amended. This means they are allowed to invest in the securities of relatively few issuers. As a result, they may be subject to greater credit, market and other risks, and poor performance by a single issuer may have a greater impact on their performance, than if they were diversified.
The following Funds are not diversified investment companies within the meaning of the Investment Company Act of 1940, as amended:
| SGM Major Markets Fund |
| Developed World Stock Fund |
| Quality Fund |
| Resources Fund |
| Tax-Managed International Equities Fund |
| Foreign Fund |
| Emerging Markets Fund |
| Emerging Countries Fund |
| Emerging Domestic Opportunities Fund |
| Alpha Only Fund |
| Implementation Fund |
| Risk Premium Fund |
| Special Opportunities Fund |
| Taiwan Fund |
| all of the Bond Funds (except U.S. Treasury Fund) |
In addition, each Asset Allocation Fund and each Bond Fund (other than U.S. Treasury Fund) invests, and Alpha Only Fund may invest, a portion of its assets in shares of one or more other GMO Funds that are not diversified investment companies under the Investment Company Act of 1940, as amended. Except as otherwise noted in the Fund summaries of this Prospectus under Principal investment strategies, each of the Asset Allocation Funds may invest without limitation in other GMO Funds that are not diversified.
NON-U.S. INVESTMENT RISK. Funds that invest in non-U.S. securities are subject to more risks than Funds that invest only in U.S. securities. Non-U.S. securities markets often include securities of only a small number of companies in a small number of industries. As a result, the market prices of many of the securities traded on those markets fluctuate more than those of U.S. securities. In addition, issuers of non-U.S. securities often are not subject to as much regulation as U.S. issuers, and the reporting, accounting, custody, and auditing standards to which those issuers are subject differ, in some cases significantly, from U.S. standards. Transactions in non-U.S. securities generally involve higher commission rates, transfer taxes, and custodial costs. In addition, some jurisdictions may limit a Funds ability to profit from short-term trading (as defined in the relevant jurisdiction).
A Fund may be subject to non-U.S. taxation, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest, or other amounts it realizes or accrues in respect of non-U.S. investments, (ii) transactions in those investments, and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. A Fund may seek a refund of taxes paid, but its efforts may not be successful, in which case the Fund will have incurred additional expenses for no economic benefit. A Funds decision to seek a refund is in its sole discretion, and, particularly in light of the cost involved, it may decide not to seek a refund, even if eligible. The outcome of a Funds efforts to obtain a refund is not predictable, and the potential to receive some refunds in the future is not typically reflected in a Funds net asset value.
165
Also, investing in non-U.S. securities exposes a Fund to the risk of nationalization, expropriation, or confiscatory taxation of assets of their issuers, other government involvement in the economy or in the affairs of specific companies or industries (including in the case of wholly or partially state-owned enterprises), adverse changes in investment regulations, capital requirements or exchange controls (which may include suspension of the ability to transfer currency from a country), and adverse political and diplomatic developments, including the imposition of economic sanctions.
In some non-U.S. securities markets, custody arrangements for securities provide significantly less protection than custody arrangements in U.S. securities markets, and prevailing custody and trade settlement practices (e.g., the requirement to pay for securities prior to receipt) expose a Fund to credit and other risks it does not have in the United States with respect to brokers, custodians, clearing banks or other clearing agents, escrow agents, and issuers. Fluctuations in foreign currency exchange rates also affect the market value of a Funds non-U.S. investments (see Currency Risk).
The Funds need a license to invest directly in many non-U.S. securities markets. These licenses are often subject to limitations, including maximum investment amounts. Once a license is obtained, a Funds ability to continue to invest directly is subject to the risk that the license will be terminated or suspended. If a license to invest in a particular market is terminated or suspended, to obtain exposure to that market the Fund will be required to purchase American Depositary Receipts, Global Depositary Receipts, shares of other funds that are licensed to invest directly, or derivative instruments. The receipt of a non-U.S. license by one of GMOs clients may preclude other clients, including a Fund, from obtaining a similar license, and this could limit the Funds investment opportunities. In addition, the activities of a GMO client could cause the suspension or revocation of a license and thereby limit the Funds investment opportunities.
Funds that invest a significant portion of their assets in securities of issuers tied economically to emerging countries (or investments related to emerging markets) are subject to greater non-U.S. investment risk than Funds investing primarily in more developed non-U.S. countries (or markets). The risks of investing in those securities include: greater fluctuations in currency exchange rates; increased risk of default (by both government and private issuers); greater social, economic, and political uncertainty and instability (including the risk of war or natural disaster); increased risk of nationalization, expropriation, or other confiscation of assets of issuers of securities in a Funds portfolio; greater governmental involvement in the economy or in the affairs of specific companies or industries (including in the case of wholly or partially state-owned enterprises); less governmental supervision and regulation of the securities markets and participants in those markets; controls on non-U.S. investment, capital controls and limitations on repatriation of invested capital, dividends, interest and other income and on a Funds ability to exchange local currencies for U.S. dollars; inability to purchase and sell investments or otherwise settle security or derivative transactions (i.e., a market freeze); unavailability of currency hedging techniques; differences in, or lack of, auditing and financial reporting standards and resulting unavailability of material information about issuers; slower clearance and settlement; difficulties in obtaining and enforcing legal judgments; and significantly smaller market capitalizations of issuers. In addition, the economies of emerging countries may be predominantly based on only a few industries or dependent on revenues from particular commodities.
SMALL COMPANY RISK. Companies with smaller market capitalizations may have limited product lines, markets, or financial resources, may lack the competitive strength of larger companies, may have inexperienced managers or may depend on a smaller group of key employees as compared to larger companies. In addition, their securities often are less widely held and trade less frequently and in lesser quantities, and their market prices often fluctuate more, than the securities of companies with larger market capitalizations. Market risk and illiquidity risk are particularly pronounced for securities of these companies.
166
GMO, 40 Rowes Wharf, Boston, Massachusetts 02110, provides investment management and shareholder servicing and supplemental support to the Funds (and to their respective wholly-owned subsidiary or subsidiaries, if any) and other GMO Funds. GMO is a private company, founded in 1977. As of May 31, 2016, GMO managed on a worldwide basis more than $[ ] billion.
Subject to the oversight of the Trustees, GMO establishes and modifies when it deems appropriate the investment strategies of the Funds. In addition to its management of the Funds investment portfolios and the shareholder services and supplemental support it provides to the Funds, GMO administers the Funds business affairs.
Except for Implementation Fund, U.S. Treasury Fund and Class MF shares of Benchmark-Free Allocation Fund, each class of shares of a Fund offered by this Prospectus pays GMO directly or indirectly a shareholder service fee for providing client services and reporting, such as performance information, client account information, personal and electronic access to Fund information, access to analysis and explanations of Fund reports, and assistance in maintaining and correcting client-related information. Class MF shares of Benchmark-Free Allocation Fund are subject to a supplemental support fee payable to GMO for providing supplemental support services to Class MF shareholders and their investment advisers. Those supplemental support services include, without limitation, (1) provision and presentation of educational and explanatory information about the Fund and its asset allocation strategy as requested or directed by an investor or its investment adviser, (2) provision and presentation of similar educational and explanatory information about the strategies of the GMO Funds in which the Fund invests, (3) provision and presentation of information for inclusion in the quarterly or other periodic reports of the investor, (4) provision of responses to information requests relating to oversight functions of the investors board of directors in areas including pricing, compliance, and taxation, (5) access to and meetings with GMOs Chief Investment Strategist and Heads of GMOs Asset Allocation Team and other investment professionals of GMO, (6) assistance with services provided by an investors investment adviser, and (7) such other assistance as may be requested from time to time by an investor or its agent, provided that such assistance is not primarily intended to result in the sale of Fund shares.
167
For the fiscal year ended February 29, 2016, GMO received a management fee (after any applicable waivers or reimbursements) equal to the percentage of each Funds average daily net assets set forth in the table below.
Fund |
% of Average Net Assets |
|||
Benchmark-Free Allocation Fund |
[ | ]% | ||
Global Asset Allocation Fund |
[ | ]%* | ||
SGM Major Markets Fund |
[ | ]% | ||
Global Equity Allocation Fund |
[ | ]%* | ||
Global Developed Equity Allocation Fund |
[ | ]%* | ||
Developed World Stock Fund |
[ | ]% | ||
Quality Fund |
[ | ]% | ||
Resources Fund |
[ | ]% | ||
International Equity Allocation Fund |
[ | ]%* | ||
International Developed Equity Allocation Fund |
[ | ]%* | ||
Tax-Managed International Equities Fund |
[ | ]% | ||
International Equity Fund |
[ | ]% | ||
International Large/Mid Cap Equity Fund |
[ | ]% | ||
Foreign Fund |
[ | ]% | ||
Foreign Small Companies Fund |
[ | ]% | ||
International Small Companies Fund |
[ | ]% | ||
U.S. Equity Allocation Fund |
[ | ]% | ||
Emerging Markets Fund |
[ | ]% | ||
Emerging Countries Fund |
[ | ]% | ||
Emerging Domestic Opportunities Fund |
[ | ]% | ||
Global Bond Fund |
[ | ]% | ||
Currency Hedged International Bond Fund |
[ | ]% | ||
Core Plus Bond Fund |
[ | ]% | ||
Emerging Country Debt Fund |
[ | ]% | ||
Debt Opportunities Fund |
[ | ]% | ||
Alpha Only Fund |
[ | ]% | ||
Asset Allocation Bond Fund |
[ | ]% | ||
Benchmark-Free Fund |
[ | ]%* | ||
Risk Premium Fund |
[ | ]% | ||
Special Opportunities Fund |
[ | ]% | ||
Strategic Opportunities Allocation Fund |
[ | ]%* | ||
Taiwan Fund |
[ | ]% | ||
U.S. Treasury Fund |
[ | ]% |
* | These Funds do not charge management fees directly but pay the management fees charged by the underlying GMO Fund(s) in which they invest. |
GMO does not charge Implementation Fund a management fee for the management and administrative services provided to the Fund.
A discussion of the basis for the Trustees approval of each Funds investment management contract is included in the Funds shareholder report for the period during which the Trustees approved that contract, except that, in the case of a new Fund, a discussion of the basis for the Trustees approval of the Funds initial investment management contract is included in the Funds initial shareholder report.
With respect to SGM Major Markets Fund (SGM), GMO has entered into a personnel sharing arrangement with GMOs wholly-owned subsidiary, GMO Australia Limited and the GMO Australia Partnership (together, GMO Australia). Pursuant to this arrangement, some employees of GMO Australia may serve as dual officers and associated persons of GMO and in this capacity may provide investment management and other services to SGM. These individuals are identified in GMOs Form ADV, a copy of which is on file with the SEC. See Distributions and Taxes for information regarding tax matters relating to the personnel sharing arrangement.
168
GMO is registered as an investment adviser with the SEC. GMO Australia is not registered as an investment adviser with the SEC.
[GMO has retained its affiliate, GMO Singapore Pte. Limited, 1 Raffles Place, #53-00, Singapore 048616 (GMO Singapore), to assist GMO in furnishing an investment program for Emerging Domestic Opportunities Fund (EDOF). GMO Singapore commenced operations in February 2003 and furnishes discretionary investment advisory services, predominantly to institutional clients. Pursuant to a sub-advisory agreement with GMO and EDOF, GMO Singapore makes investment decisions for and places orders for the purchase and sale of securities for all or part of EDOFs portfolio, as determined by GMO. GMO (and not EDOF) will pay a sub-advisory fee to GMO Singapore for its services at a rate equal to 60% of the management fees received by GMO under EDOFs investment management contract, net of any fee waiver or expense reimbursement obligations of GMO as may be in effect. A discussion of the basis for the Trustees approval of the sub-advisory agreement with GMO Singapore is included in EDOFs shareholder report for the period during which the Trustees approved that agreement. See Distributions and Taxes below for information regarding tax matters relating to the discretionary investment advisory services GMO Singapore provides to EDOF.]
Different GMO Investment Teams have primary responsibility for managing the investments of different Funds. Investment Teams may include personnel of both GMO and its affiliates, including GMO Singapore. Each Investment Teams investment professionals work collaboratively and often share investment insights with, and benefit from the insights of, other Investment Teams. For example, the Global Equity Team and the Asset Allocation Team collaborate on performance forecasts for groups of equities. The table below identifies the Investment Teams and the Funds for which they are primarily responsible.
Investment Team | Primary Responsibilities | |
Asset Allocation |
Asset Allocation Funds, Alpha Only Fund, Implementation Fund, and Special Opportunities Fund
High-level investment oversight : Developed World Stock Fund, Tax-Managed International Equities Fund, International Equity Fund, International Large/Mid Cap Equity Fund, and U.S. Equity Allocation Fund |
|
Developed Fixed Income | Bond Funds (except Emerging Country Debt Fund) | |
Emerging Country Debt | Emerging Country Debt Fund | |
Emerging Markets Equity | Emerging Markets Fund, Emerging Countries Fund, Emerging Domestic Opportunities Fund, and Taiwan Fund | |
Focused Equity | Quality Fund and Resources Fund | |
Global Equity | Developed World Stock Fund, Tax-Managed International Equities Fund, International Equity Fund, International Large/Mid Cap Equity Fund, U.S. Equity Allocation Fund, and Risk Premium Fund | |
International Active | Foreign Fund, Foreign Small Companies Fund, and International Small Companies Fund | |
Systematic Global Macro | SGM Major Markets Fund |
The following table identifies the senior member(s) of the Investment Team(s) with primary responsibility for managing the investments of different Funds and their title and business experience during the past five years. The senior members directly manage, or allocate to members of their Team responsibility for portions of the portfolios of, Funds for which they have responsibility, oversee the implementation of trades, review the overall composition of the Funds portfolios, including compliance with stated investment objectives and strategies, and monitor cash.
Funds | Senior Member | Title; Business Experience During Past 5 Years | ||
Asset Allocation Funds,* Alpha Only Fund, and Implementation Fund*
High-level investment oversight : Developed World Stock Fund, Tax-Managed International Equities Fund, International Equity Fund, International Large/Mid Cap Equity Fund, and U.S. Equity Allocation Fund |
Ben Inker | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. Mr. Inker has been responsible for overseeing the portfolio management of GMOs asset allocation portfolios since 1996 and of GMOs developed fixed income portfolios since November 2014. | ||
Sam Wilderman | Co-Head, Asset Allocation Team and Co-Head, Developed Fixed Income Team, GMO. Mr. Wilderman has been responsible for overseeing the portfolio management of GMOs asset allocation portfolios since September 2012 and of GMOs developed fixed income portfolios since November 2014. Previously, Mr. Wilderman was Co-Head of GMOs Global Equity Team from 2009 to September 2012. | |||
Bond Funds (except Debt Opportunities Fund and Emerging Country Debt Fund) | Ben Inker | See above. | ||
Sam Wilderman | See above. | |||
Michael Emanuel | Portfolio Manager, Developed Fixed Income Team, GMO. Mr. Emanuel has been responsible for providing portfolio management services to GMOs developed fixed income portfolios since 2014. Previously, Mr. Emanuel was a portfolio manager at Convexity Capital Management. | |||
Greg Jones | Portfolio Manager, Developed Fixed Income Team, GMO. Dr. Jones has been responsible for providing portfolio management and research services to GMOs developed fixed income portfolios since 2008. |
169
Funds | Senior Member | Title; Business Experience During Past 5 Years | ||
Debt Opportunities Fund | Ben Inker | See above. | ||
Sam Wilderman | See above. | |||
Joe Auth | Portfolio Manager, Developed Fixed Income Team, GMO. Mr. Auth has been responsible for providing portfolio management services to GMOs structured credit portfolios since 2014. Previously, Mr. Auth was a portfolio manager at Harvard Management Company. | |||
Developed World Stock Fund, Tax-Managed International Equities Fund, International Equity Fund, International Large/Mid Cap Equity Fund, U.S. Equity Allocation Fund, and Risk Premium Fund | David Cowan | Head, Global Equity Team, GMO. Dr. Cowan has provided research and portfolio management services to GMOs global equity portfolios since 2006 and was Co-Head of the Global Equity Team from 2012 to September 2015. | ||
Neil Constable | Portfolio Manager, Global Equity Team, GMO. Dr. Constable has been responsible for providing portfolio management and research services to GMOs global equity portfolios since 2006. | |||
Chris Fortson | Portfolio Manager, Global Equity Team, GMO. Mr. Fortson has been responsible for providing portfolio management and research services to GMOs global equity portfolios since 2009. | |||
Emerging Country Debt Fund** | Thomas Cooper | Co-Head, Emerging Country Debt Team, GMO. Mr. Cooper has been responsible for overseeing the portfolio management of GMOs emerging country debt portfolios since 1994. | ||
Tina Vandersteel | Co-Head, Emerging Country Debt Team, GMO. Ms. Vandersteel has been in this role since October 2015. Ms. Vandersteel has been responsible for providing research and portfolio management services for this and other emerging debt portfolios at GMO since 2004. | |||
Emerging Domestic Opportunities Fund | Arjun Divecha | Head, Emerging Markets Equity Team, GMO. Mr. Divecha has been responsible for overseeing the portfolio management of GMOs emerging markets equity portfolios since 1993. | ||
Amit Bhartia | [Portfolio Manager, Emerging Markets Equity Team, GMO Singapore. Mr. Bhartia has been responsible for providing portfolio management and research services to this and GMOs other emerging markets equity portfolios since 1995 and has overseen the portfolio management of GMOs emerging domestic opportunity equity portfolios since 2011.] |
170
Funds | Senior Member | Title; Business Experience During Past 5 Years | ||
Emerging Markets Fund, | Arjun Divecha | See above. | ||
Emerging Countries Fund, and Taiwan Fund | Amit Bhartia | See above. | ||
Warren Chiang | Portfolio Manager, Emerging Markets Equity Team, GMO. Mr. Chiang has been responsible for overseeing the portfolio management of these emerging markets equity portfolios since June 2015. Previously, Mr. Chiang was Managing Director, Head of Active Equity Strategies at Mellon Capital Management. | |||
Foreign Fund, Foreign Small Companies Fund, and International Small Companies Fund | Drew Spangler | Head, International Active Team, GMO. Mr. Spangler has been responsible for overseeing the portfolio management of GMOs international active equity portfolios since May 2011. Previously, Mr. Spangler provided portfolio and research services to GMOs international active equity portfolios since 1994. | ||
Quality Fund | Thomas Hancock | Head, Focused Equity Team, GMO. Dr. Hancock was responsible for overseeing the portfolio management of GMOs international developed market and global equity portfolios beginning in 1998 and was Co-Head of the Global Equity Team from 2009 to September 2015. | ||
Anthony Hene | Portfolio Manager, Focused Equity Team, GMO. Mr. Hene has been in this role since September 2015. Mr. Hene has been responsible for providing portfolio management and research services for this and other global equity portfolios at GMO since 1995. | |||
Resources Fund | Thomas Hancock | See above. | ||
Lucas White | Portfolio Manager, Focused Equity Team, GMO. Mr. White has been responsible for providing portfolio management and research services for this and GMOs other Focused Equity portfolios since September 2015. Mr. White previously served in other capacities at GMO, including providing portfolio management for the GMO Quality Strategy, since joining GMO in 2006. | |||
SGM Major Markets Fund | Jason Halliwell | Head, Systematic Global Macro Team, GMO. Mr. Halliwell has been responsible for overseeing the portfolio management of GMOs systematic global macro portfolios since 1999. | ||
Special Opportunities Fund | Ben Inker | See above. | ||
Sam Wilderman | See above. | |||
Chris Hudson | Portfolio Manager, Asset Allocation Team, GMO. Mr. Hudson has been responsible for overseeing the portfolio management of some of GMOs asset allocation portfolios since 2009. |
* | For Benchmark-Free Fund and Implementation Fund, allocations among asset classes are made by the Asset Allocation Team and specific security selections are made primarily by other Investment Teams in collaboration with the Asset Allocation Team. For example, the Global Equity Team selects equity securities within Implementation Fund. |
** | As part of a transition plan, Mr. Cooper will be reducing his involvement in the day-to-day management of Emerging Country Debt Fund until his retirement on September 30, 2016, after which Ms. Vandersteel will be the sole Senior Member and Head of the Emerging Country Debt Team. |
The SAI contains information about how GMO determines the compensation of the senior members, other accounts they manage and related conflicts, and their ownership of Funds for which they have responsibility.
171
Custodians and Fund Accounting Agents
State Street Bank and Trust Company (State Street Bank), 1 Heritage Drive, North Quincy, MA 02171, serves as the Trusts custodian and fund accounting agent on behalf of the Asset Allocation Funds, the Bond Funds, SGM Major Markets Fund, Quality Fund, U.S. Equity Allocation Fund, Implementation Fund, Risk Premium Fund, and Special Opportunities Fund. Brown Brothers Harriman & Co., 50 Post Office Square, Boston, Massachusetts 02110, serves as the Trusts custodian and fund accounting agent on behalf of the Equity Funds (other than Global Equity Allocation Fund, Global Developed Equity Allocation Fund, International Equity Allocation Fund, International Developed Equity Allocation Fund, U.S. Equity Allocation Fund, and Quality Fund), Alpha Only Fund, and Taiwan Fund. State Street Bank provides similar services with respect to each of Implementation Funds, Benchmark-Free Funds, SGM Major Markets Funds and Special Opportunities Funds wholly-owned subsidiary.
Transfer Agent
State Street Bank serves as the Trusts transfer agent on behalf of the Funds.
Expense Reimbursement [TO BE UPDATED BY AMENDMENT]
[Except for Emerging Countries Fund, Resources Fund, Global Bond Fund, Emerging Country Debt Fund, Special Opportunities Fund, and Taiwan Fund, GMO has contractually agreed to reimburse each GMO Fund for its Specified Operating Expenses (as defined below). GMO has contractually agreed to reimburse each of Emerging Countries Fund, Resources Fund, Global Bond Fund, and Special Opportunities Fund for the portion of its Specified Operating Expenses (as defined below) that exceeds the following percentages of the Funds average daily net assets:
Emerging Countries Fund |
0.35 | % | ||
Resources Fund |
0.10 | % | ||
Global Bond Fund |
0.06 | % | ||
Special Opportunities Fund |
0.10 | % |
As used in this Prospectus, subject to the exclusions noted below, Specified Operating Expenses means: audit expenses, fund accounting expenses, pricing service expenses, expenses of non-investment related tax services, transfer agency expenses, expenses of non-investment related legal services provided to the Funds by or at the direction of GMO, federal securities law filing expenses, printing expenses, state and federal registration fees, and custody expenses. In the case of Emerging Markets Fund, Specified Operating Expenses does not include custody expenses, and in the case of Emerging Domestic Opportunities Fund, Specified Operating Expenses only includes custody expenses to the extent that they exceed 0.10% of the Funds average daily net assets. In the case of Benchmark-Free Fund, Specified Operating Expenses does not include the Funds direct custody expenses attributable to its holdings of emerging market securities.
For each Fund (other than Benchmark-Free Allocation Fund) that pays GMO a management fee, GMO has contractually agreed to waive or reduce that fee, but not below zero, to the extent necessary to offset the management fees paid to GMO that are directly or indirectly borne by the Fund as a result of the Funds direct or indirect investments in other GMO Funds.
For each Fund (other than Benchmark-Free Allocation Fund) that charges a shareholder service fee, GMO has contractually agreed to waive or reduce the shareholder service fee charged to holders of each class of shares of the Fund, but not below zero, to the extent necessary to offset the shareholder service fees directly or indirectly borne by the class of shares of the Fund as a result of the Funds direct or indirect investments in other GMO Funds.
In addition, for Emerging Markets Fund only, GMO has contractually agreed to waive the shareholder service fee charged to holders of each class of shares of the Fund offered by this Prospectus to the extent necessary to prevent the shareholder service fees borne by each class of shares of the Fund from exceeding the percentage of the classs average daily net assets specified in the Funds Annual Fund operating expenses table.
These contractual waivers and reimbursements will continue through at least [June 30, 2017] for each Fund unless the Funds Board of Trustees authorizes their modification or termination or reduces the fee rates paid to GMO under the Funds management contract or servicing and supplement support agreement.
In addition to the contractual waivers and reimbursements described above, GMO has voluntarily waived U.S. Treasury Funds entire management fee. GMO may change or terminate this waiver at any time. While this waiver is in effect, the Fund will incur management fees at a lower annual rate than the rate shown in the Annual Fund operating expenses table in the Funds summary, and, as a result, total annual fund operating expenses after expense reimbursement for the Fund will be lower than the amount(s) shown in the table.
172
For Benchmark-Free Allocation Fund only, the fees payable to GMO under its management contract and servicing and supplemental support agreement are reduced by amounts equal to the management fees and shareholder service fees, respectively, that GMO receives as a result of the Funds investment in underlying GMO Funds. In addition, effective March 1, 2014, GMO has contractually agreed to reduce the rate of the supplemental support fees charged to the Funds Class MF shares to a rate to be charged in any month (starting on the first business day of the month) based on the net assets attributable to Class MF shares as of the last business day of the preceding month based on the following schedule: 0.10% on the first $6 billion of net assets, 0.05% on the next $2 billion, 0.03% on the next $2 billion, and 0.01% thereafter; provided, however, that the effective rate charged at any time will not be reduced to less than 0.06% of Class MFs average daily net assets. The rate will be calculated before giving effect to any reduction or waiver described above, and any applicable reduction or waiver will serve to further reduce the supplemental support fees paid to GMO. This reduction will continue through at least [June 30, 2017], and may not be terminated prior to this date without the action or consent of the Funds Board of Trustees.]
Additional Information
The Trust has contractual arrangements with various parties, including, among others, the Funds investment manager, shareholder service provider, sub-adviser, custodians and fund accounting agents, transfer agent, distributor and placement agent, who provide services to the Funds. Shareholders are not parties to, or intended (or third-party) beneficiaries of, any of those contractual arrangements, and those contractual arrangements are not intended to create in any individual shareholder or group of shareholders any right to enforce them against the service providers or to seek any remedy under them against the service providers, either directly or on behalf of the Trust.
This Prospectus provides information concerning the Trust and the Funds that you should consider in determining whether to purchase shares of a Fund. Neither this Prospectus, the SAI nor any contract that is an exhibit to the Trusts registration statement is intended to, and does not, give rise to an agreement or contract between the Trust or the Funds and any investor, or give rise to any contract or other rights in any individual shareholder, group of shareholders or other person other than any rights conferred explicitly by federal or state securities laws that those laws do not permit to be waived.
The Trusts Amended and Restated Agreement and Declaration of Trust, as amended (the Declaration), provides that shareholders shall not have the right to bring or enforce certain types of claims except as provided in the Trusts by-laws or expressly provided by law and not permitted to be waived. The Trusts Amended and Restated By-Laws (the By-Laws) provide that no shareholder shall have the right to bring or maintain any court action or other proceeding asserting a derivative claim (as defined in the By-Laws) without first making a written demand on the Trustees, and that any decision by the Trustees in such matters is binding on all shareholders. The By-Laws further provide that the laws of Massachusetts shall govern the operations of the Trust and that, absent the consent of all parties, the sole and exclusive forum for many types of claims involving the Trust shall be the federal courts sitting within the City of Boston or the Business Litigation Session of the Massachusetts Superior Court. Please see the SAI for additional information regarding the provisions of the Declaration and By-Laws. Copies of the Trusts Declaration and By-Laws, as amended from time to time, have been filed with the SEC as exhibits to the Trusts registration statement, and are available on the EDGAR database on the SECs website at www.sec.gov .
DETERMINATION OF NET ASSET VALUE
The net asset value or NAV of a Fund or each class of shares of a Fund, as applicable, is determined as of the close of regular trading on the NYSE, generally at 4:00 p.m. Eastern time. Current net asset values per share for each series of GMO Trust are available at www.gmo.com.
The NAV per share of a class of shares of a Fund is determined by dividing the total value of the Funds portfolio investments and other assets, less any liabilities, allocated to that share class by the total number of outstanding shares of that class. NAV is not determined on any days when the NYSE is closed for business. In addition, NAV for the Bond Funds, SGM Major Markets Fund, and Special Opportunities Fund is not determined (and accordingly transactions in shares of the Bond Funds, SGM Major Markets Fund or Special Opportunities Fund are not processed) on days when either the NYSE or the U.S. bond markets are closed. Taiwan Fund does not determine NAV on days when either the NYSE or the Taiwan Stock Exchange (TSE) is scheduled to be closed for trading. As a result, from time to time, Taiwan Fund may not determine NAV for several consecutive weekdays (e.g., during the Chinese Lunar New Year), during which time investors will be unable to redeem their shares in Taiwan Fund. In addition, because some Funds hold portfolio securities listed on non-U.S. exchanges that trade on days on which the NYSE or the U.S. bond markets are closed, the net value of those Funds assets may change significantly on days when shares cannot be redeemed.
173
A Fund may elect not to determine NAV on days when none of its shares are tendered for redemption and it accepts no orders to purchase its shares.
The value of the Funds investments is generally determined as follows:
Exchange-traded securities (other than exchange-traded options) for which market quotations are readily available:
| Last sale price or |
| Official closing price or |
| Most recent quoted price published by the exchange (if no reported last sale or official closing price) or |
| Quoted price provided by a pricing source (in the event GMO deems the private market to be a more reliable indicator of market value than the exchange) |
(Also, see discussion in Fair Value pricing below.)
Exchange-traded options:
| Exchange-traded options are valued at the last sale price, provided that price is between the closing bid and ask prices. If the last sale price is not within this range, then they will be valued at the closing bid price for long positions and the closing ask price for short positions |
Cleared derivatives:
| Price quoted (which may be based on a model) by the relevant clearing house (if an updated quote for a cleared derivative is not available by the time that a Fund calculates its NAV on any business day, then that derivative will generally be valued using an industry standard model, which may differ from the model used by the relevant clearing house) |
OTC derivatives:
| Price generally determined by an industry standard model |
Unlisted non-fixed income securities for which market quotations are readily available:
| Most recent quoted price |
Fixed income securities (includes bonds, loans, loan participations, asset-backed securities, and other structured notes):
| Most recent price supplied by a specific relevant pricing source determined by GMO (if a reliable updated price for a fixed income security is not available by the time that a Fund calculates its NAV on any business day, the Fund will generally use the most recent reliable price to value that security) |
Note: Reliable prices, including reliable quoted prices, may not always be available. When they are not available, the Funds may use alternative valuation methodologies (e.g., valuing the relevant assets at fair value as described below).
Shares of other GMO Funds and other open-end registered investment companies:
| Most recent NAV |
Quoted price typically means the bid price for securities held long and the ask price for securities sold short. If a market quotation for a security does not involve a bid or an ask, the quoted price may be the price provided by a market participant or other third-party pricing source in accordance with the market practice for that security. [If an updated quoted price for a security is not available by the time a Fund calculates its NAV on any business day, the Fund will generally use the last quoted price so long as the Fund believes that the quoted price continues to represent that securitys fair value.]
In the case of derivatives, prices determined by a model may reflect an estimate of the average of bid and ask prices, regardless of whether a Fund has a long position or a short position.
The prices of non-U.S. securities quoted in foreign currencies, foreign currency balances, and the value of non-U.S. forward currency contracts are typically translated into U.S. dollars at the close of regular trading on the NYSE, generally at 4:00 p.m. Eastern time, at then current exchange rates or at such other rates as the Trustees or persons acting at their direction may determine in computing NAV.
Although GMO normally does not evaluate pricing sources on a day-to-day basis, it does evaluate pricing sources on an ongoing basis and may change a pricing source at any time. GMO monitors erratic or unusual movements (including unusual inactivity) in the prices supplied for a security and has discretion to override a price supplied by a source (e.g., by taking a price supplied by another) when it believes that the price supplied is not reliable. Alternative pricing sources are often but not always available for securities held by a Fund.
174
Fair Value pricing:
For all other assets and securities, including derivatives, and in cases where quotations are not readily available or circumstances make an existing valuation methodology or procedure unreliable, the Funds investments are valued at fair value, as determined in good faith by the Trustees or persons acting at their direction pursuant to procedures approved by the Trustees.
With respect to the Funds use of fair value pricing, you should note the following:
u | In some cases, a significant percentage of a Funds assets may be fair valued. Factors that may be considered in determining fair value include, among others, the value of other financial instruments traded on other markets, trading volumes, changes in interest rates, observations from financial institutions, significant events (which may be considered to include changes in the value of U.S. securities or securities indices) that occur after the close of the relevant market and before a Funds NAV is calculated, other news events, and significant unobservable inputs (including the Funds own assumptions in determining the fair value of investments). Because of the uncertainty inherent in fair value pricing, the price determined for a particular security may be materially different from the value realized upon its sale. |
u | The valuation methodologies described above are modified for equities that trade in non-U.S. securities markets that close prior to the close of the NYSE due to time zone differences, including the value of equities that underlie futures, options and other derivatives (to the extent the market for those derivatives closes prior to the close of the NYSE). In those cases, the price will generally be adjusted, to the extent practicable and available, based on inputs from an independent pricing service approved by the Trustees that are intended to reflect valuation changes through the NYSE close. |
u | A Funds use of fair value pricing may cause the Funds returns to differ from those of its benchmark or other comparative index or indices more than would otherwise be the case. For example, a Fund may fair value its international equity holdings as a result of significant events that occur after the close of the relevant market and before the time the Funds NAV is calculated. In these cases, the benchmark or index may use the local market closing price, while the Fund uses an adjusted fair value price. |
To comply with SEC rules regarding the use of descriptive words in a funds name, some Funds have adopted policies (which apply at the time of investment, unless stated otherwise) of investing at least 80% of the value of their net assets plus the amount of any borrowings made for investment purposes in specific types of investments, industries, countries, or geographic regions (each policy, a Name Policy). Those Name Policies are described in the Principal investment strategies section of their summaries.
A Fund will not change its Name Policy without providing its shareholders at least 60 days prior written notice. When used in connection with a Funds Name Policy, assets include the Funds net assets plus any borrowings made for investment purposes. In addition, a Name Policy calling for a Fund to invest in a particular country or geographic region requires that the Funds investments be tied economically (or related in the case of Emerging Domestic Opportunities Fund) to that country or region. For purposes of this Prospectus, an investment is tied economically (or related) to a particular country or region if, at the time of purchase, it is (i) in an issuer that is organized under the laws of that country or of a country within that region or in an issuer that maintains its principal place of business in that country or region; (ii) traded principally in that country or region; or (iii) in an issuer that derived at least 50% of its revenues or profits from goods produced or sold, investments made, or services performed in that country or region, or has at least 50% of its assets in that country or region. A Fund may invest directly in securities of companies in a particular industry, country, or geographic region or indirectly, for example, by purchasing securities of another Fund or investing in derivatives or synthetic instruments with underlying assets that have economic characteristics similar to investments tied economically (or related) to a particular industry, country, or geographic region. Funds with the term international, global, or world included in their names have not adopted formal Name Policies with respect to those terms but typically invest in investments that are tied economically to, or seek exposure to, a number of countries throughout the world. GMO relies on publicly available information and third-party data to monitor compliance with Name Policies. If that information is inaccurate or incomplete, GMOs ability to monitor compliance with a Funds Name Policy would be impaired.
175
DISCLOSURE OF PORTFOLIO HOLDINGS
[The Funds have established a policy with respect to disclosure of their portfolio holdings. That policy is described in the SAI. The Funds portfolio holdings are available quarterly on the SECs website when the Funds file a Form N-CSR (annual/semiannual report) or Form N-Q (quarterly schedule of portfolio holdings).
Up to the largest fifteen portfolio holdings of some Funds (on a look through basis in the case of the Asset Allocation Funds) and all of the direct holdings of the Asset Allocation Funds (which includes GMO Funds in which the Fund invests) may be posted monthly on GMOs website (www.gmo.com). In addition, attribution information regarding the positions of some Funds may be posted monthly on GMOs website (e.g., best/worst performing positions in the Fund over a specified time period). For Asset Allocation Funds, position attribution information may be provided on a look through basis. Such information is available without a confidentiality agreement to registered users on GMOs website.
Additional information regarding the portfolio holdings of some Funds as of each months end is made available to shareholders of the Trust (including shareholders of record who have indirect investments in a Fund through another GMO Fund) (permitted shareholders), qualified potential shareholders as determined by GMO (including qualified potential shareholders of record who are considering an indirect investment in a Fund through another fund managed by GMO) (potential shareholders), and their consultants and agents, as set forth below:
Funds |
Approximate date of release of
holdings
information |
|
All Funds except Asset Allocation Funds | 5 days after month end (final) | |
Asset Allocation Funds |
2 days after month end (preliminary) 5 days after month end (final) |
Permitted shareholders and qualified potential shareholders of Funds that invest in other GMO Funds, as well as their consultants and agents (collectively, permitted recipients), are able to access the portfolio holdings of the GMO Funds in which those Funds invest when that information is posted each month on GMOs website. Periodically, in response to heightened market interest in specific issuers, a Funds holdings in one or more issuers may be made available on a more frequent basis to permitted recipients through a secured link on GMOs website. This information may be posted as soon as the business day following the date to which the information relates.
To access this information on GMOs website (www.gmo.com/america/strategies), permitted recipients must contact GMO to obtain a user name and password (to the extent they do not already have them) and generally must enter into a confidentiality and non-use agreement with GMO. Any exception must be approved in advance as described in the SAI. GMO also may make portfolio holdings information (including information regarding underlying GMO Fund holdings) available in alternate formats and under additional circumstances under the conditions described in the SAI. Beneficial owners of shares of a Fund who have invested in the Fund through a broker or agent should contact that broker or agent for information on how to obtain access to information on the website regarding the Funds portfolio holdings.
The Funds or GMO may suspend the posting of portfolio holdings of one or more Funds, and the Funds may modify the disclosure policy, without notice to shareholders. Once posted, a Funds portfolio holdings typically will remain available on the website at least until the Fund files a Form N-CSR (annual/semiannual report) or Form N-Q (quarterly schedule of portfolio holdings) for the period that includes the date of those holdings.]
Under ordinary circumstances, you may purchase a Funds shares directly from the Trust on days when the NYSE is open for business (and, in the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, on days when the U.S. bond markets also are open for business, and, in the case of Taiwan Fund, on days when the TSE also is open for business). In addition, some brokers and agents are authorized to accept purchase and redemption orders on the Funds behalf. These brokers and agents may charge transaction fees and impose restrictions on purchases of Fund shares through them. For instructions on purchasing shares, call the Trust at 1-617-346-7646, send an e-mail to SHS@GMO.com, or contact your broker or agent. The Trust will not accept a purchase order until it has received a GMO Trust Application deemed to be in good order by the Trust or its agent. In addition, the Trust will typically not accept a purchase order unless an Internal Revenue Service (IRS) Form W-9 (for U.S. shareholders) or the appropriate IRS Form W-8 (for non-U.S. shareholders) with a correct taxpayer identification number (if required) is on file with, and that W-9 or W-8 is deemed to be in good order by, the Trusts withholding agent, State Street Bank and Trust Company. The Trust, its agent or a
176
financial intermediary may require additional tax-related certifications, information or other documentation from you in order to comply with applicable U.S. federal reporting and withholding tax provisions, including the Foreign Account Tax Compliance Act. If you do not provide such IRS forms and other certifications, information or documentation, you may be subject to withholding taxes on distributions or proceeds received upon the sale, exchange or redemption of your Fund shares. For more information on these rules, see Taxes in the SAI. Please consult your tax adviser to ensure all tax forms provided to the Trust or its agent are completed properly and maintained, as required, in good order. GMO and/or its agents have the right to decide when a completed form is in good order.
Purchase Policies. You must submit a purchase order in good order to avoid its being rejected. In general, a purchase order is in good order if it includes:
| The name of the Fund being purchased; |
| The U.S. dollar amount of the shares to be purchased; |
| The date on which the purchase is to be made (subject to receipt prior to the close of regular trading on the NYSE (generally 4:00 p.m. Eastern time) (the Cut-off Time) on that date); |
| The name and/or the account number (if any) set forth with sufficient clarity to avoid ambiguity; and |
| The signature of an authorized signatory as identified in the GMO Trust Application or subsequent authorized signers list. |
For retirement accounts, additional information regarding contributions typically is required.
If payment in full (in U.S. funds paid by check or wire or, when approved, by securities) is not received prior to the Cut-off Time on the intended purchase date, the order may be rejected or deferred until payment in full is received unless prior arrangements for later payment have been approved by GMO.
If a purchase order is received in good order by the Trust or its agent, together with payment in full, prior to the Cut-off Time, the purchase price for the Fund shares to be purchased is the net asset value per share of the class of Fund shares being purchased determined on that day (plus any applicable purchase premium). If that order is received after the Cut-off Time, the purchase price for the Fund shares to be purchased is the net asset value per share of the class of Fund shares to be purchased determined on the next business day that the NYSE is open (plus any applicable purchase premium). In the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, purchase orders that are received on days when either the NYSE or the U.S. bond markets are closed will not be accepted until the next day on which both the NYSE and the U.S. bond markets are open, and the purchase price will be the net asset value per share of the class of Fund shares to be purchased determined on that day (plus any applicable purchase premium). In the case of Taiwan Fund, purchase orders that are received on days when either the NYSE or the TSE is scheduled to be closed will not typically be accepted until the next day on which both the NYSE and the TSE are open, and the purchase price will be the net asset value per share determined that day (plus any applicable purchase premium). See Purchase Premiums and Redemption Fees on page [ ] of this Prospectus for a discussion of purchase premiums charged by some Funds, including circumstances under which all or a portion of the purchase premiums may be waived. Purchase premiums are not charged on reinvestments of dividends or other distributions.
To help the U.S. government fight the funding of terrorism and money laundering activities, federal law requires the Trust to verify identifying information provided by each investor in its GMO Trust Application, and the Trust may require further identifying documentation. If the Trust is unable to verify the information shortly after your account is opened, the account may be closed and your shares redeemed at their net asset value at the time of the redemption.
The Trust and its agents reserve the right to reject any purchase order. In addition, without notice, a Fund in its sole discretion may temporarily or permanently suspend sales of its shares to new investors and/or existing shareholders.
Minimum initial investment amounts (by class, if applicable) are set forth in the tables on page [ ] of this Prospectus. No minimum initial investment is required to purchase Class MF shares of Benchmark-Free Allocation Fund. The Trust may increase minimum initial investment amounts at any time and may waive initial minimums for some investors.
Funds advised or sub-advised by GMO (Top Funds) may purchase shares of other GMO Funds after the Cut-off Time and receive the current days price if the following conditions are met: (i) the Top Fund received a purchase order in good order prior to the Cut-off Time on that day; and (ii) the purchase(s) by the Top Fund of shares of the other GMO Funds are executed pursuant to an allocation predetermined by GMO prior to that days Cut-off Time.
177
Submitting Your Purchase Order Form. Completed purchase order forms can be submitted by mail, facsimile, or e-mail (provided that a PDF copy of the completed purchase order form is attached to the e-mail) or other form of communication pre-approved by Shareholder Services to the Trust at:
GMO Trust
c/o Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf
Boston, Massachusetts 02110
Facsimile: 1-617-439-4192
Attention: Shareholder Services
E-mail: clientorder@gmo.com
Call the Trust at 1-617-346-7646 or send an e-mail to SHS@GMO.com to confirm that GMO received, made a good order determination regarding, and accepted your purchase order form. Do not send cash, checks, or securities directly to the Trust. A purchase order submitted by mail, facsimile or e-mail is received by the Trust when it is actually received by the Trust or its agent. The Trust is not responsible for purchase orders submitted but not actually received by the Trust or its agent for any reason, including purchase orders not received on account of a computer virus or other third-party interference.
Funding Your Investment. You may purchase shares:
| with cash (by means of wire transfer or check or other form of payment preapproved by GMO Shareholder Services) |
u | By wire. Instruct your bank to wire your investment to: |
State Street Bank and Trust Company, [North Quincy], Massachusetts
ABA#: 011000028
Attn: Transfer Agent
Credit: GMO Trust Deposit Account 00330902
Further credit: GMO Fund/Account name and number
u | By check. All checks must be made payable to the appropriate Fund or to GMO Trust. The Trust will not accept checks payable to a third party that have been endorsed by the payee to the Trust. Mail checks to: |
By U.S. Postal Service: | By Overnight Courier: | |
State Street Bank and Trust Company | State Street Bank and Trust Company | |
Attn: GMO Transfer Agent | Attn: GMO Transfer Agent | |
Mail Stop OHD0100 | 1 Heritage Drive | |
Box 5493 | Mail Stop OHD0100 | |
Boston, Massachusetts 02206 | North Quincy, Massachusetts 02171 |
| in exchange for securities acceptable to GMO |
u | securities must be approved by GMO prior to transfer to the Fund |
u | securities will be valued as set forth under Determination of Net Asset Value |
u | you may bear any stamp or other transaction-based taxes or other costs arising in connection with the transfer of securities to the Fund. |
| by a combination of cash and securities |
The Trust is not responsible for cash (including wire transfers and checks) or securities delivered in connection with a purchase of Fund shares until they are actually received by the Fund. A purchaser will not earn interest on any funds prior to their investment in a Fund. A purchase may be made in U.S. dollars or, in GMOs sole discretion, in another currency deemed acceptable by GMO. Non-U.S. dollar currencies used to purchase Fund shares will be valued in accordance with the Trusts valuation procedures.
Frequent Trading Activity. As a matter of policy, the Trust will not honor requests for purchases or exchanges by shareholders identified as engaging in frequent trading strategies, including market timing, that GMO determines could be harmful to a Fund and its shareholders. Frequent trading strategies generally are strategies that involve repeated exchanges or purchases and redemptions (or redemptions and purchases) within a short period of time. Frequent trading strategies can be disruptive to the efficient management of a Fund, materially increase portfolio transaction costs and taxes, dilute the value of shares held by long-term investors, or otherwise be harmful to a Fund and its shareholders.
178
The Trustees have adopted procedures designed to detect and prevent frequent trading activity that could be harmful to a Fund and its shareholders (the Procedures). The Procedures include the fair valuation of non-U.S. securities, periodic surveillance of trading in shareholder accounts and inquiry as to the nature of trading activity. If GMO determines that an account is engaging in frequent trading that has the potential to be harmful to a Fund or its shareholders, the Procedures permit GMO to adopt various preventative measures, including suspension of the accounts exchange and purchase privileges. There is no assurance that the Procedures will be effective in all instances. The Funds reserve the right to reject any order or terminate the sale of Fund shares at any time.
Each of the Procedures does not apply to all Funds or all Fund trading activity. Application of the Procedures is dependent upon: (1) whether a Fund imposes purchase premiums or redemption fees or both, (2) the nature of a Funds investment program, including its typical cash positions and whether it invests in non-U.S. securities, and (3) whether GMO has investment discretion over the purchase, exchange, or redemption activity. The Asset Allocation Funds and other funds and accounts over which GMO has investment discretion invest in other GMO Funds and are not subject to restrictions on how often they may purchase those Funds shares. Although GMO may not take affirmative steps to detect frequent trading for some Funds, GMO will not honor requests for purchases or exchanges by shareholders identified as engaging in frequent trading strategies that GMO determines could be harmful to the Funds involved and their shareholders.
Shares of some Funds are distributed through financial intermediaries that submit aggregate or net purchase and redemption orders through omnibus accounts. These omnibus accounts often by nature engage in frequent transactions due to the daily trading activity of their investors. Because transactions by omnibus accounts often take place on a net basis, GMOs ability to detect and prevent the implementation of frequent trading strategies within those accounts is limited. GMO ordinarily seeks the agreement of a financial intermediary to monitor and restrict frequent trading in accordance with the Procedures. In addition, the Funds may rely on a financial intermediary to monitor and restrict frequent trading in accordance with the intermediarys policies and procedures in lieu of the Procedures if GMO believes that the financial intermediarys policies and procedures are reasonably designed to detect and prevent frequent trading activity that could be harmful to a Fund and its shareholders. Shareholders who own Fund shares through an intermediary should consult with that intermediary regarding its frequent trading policies.
Under ordinary circumstances, you may redeem a Funds shares on days when the NYSE is open for business (and, in the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, on days when the U.S. bond markets also are open for business, and, in the case of Taiwan Fund, on days when the TSE also is open for business). Redemption orders should be submitted directly to the Trust unless the Fund shares to be redeemed were purchased through a broker or agent, in which case the redemption order should be submitted to that broker or agent. The broker or agent may charge transaction fees and impose restrictions on redemptions of Fund shares through it. For instructions on redeeming shares directly, call the Trust at 1-617-346-7646 or send an e-mail to SHS@GMO.com. A Fund may remit the redemption proceeds for redemption orders received on the same day at different times for different shareholders and may take up to seven days to remit proceeds.
Redemption Policies. You must submit a redemption order in good order to avoid having it rejected by the Trust or its agent. In general, a redemption order is in good order if it includes:
| The name of the Fund being redeemed; |
| The number of shares or the dollar amount of the shares to be redeemed or, in the case of a Fund with a redemption fee, the dollar amount that the investor wants to receive; |
| The date on which the redemption is to be made (subject to receipt prior to the Cut-off Time on that date); |
| The name or the account number set forth with sufficient clarity to avoid ambiguity; |
| The signature of an authorized signatory as identified in the GMO Trust Application or subsequent authorized signers list; and |
| Wire instructions or registration address that match the wire instructions or registration address (as applicable) on file at GMO or confirmation from an authorized signatory that the wire instructions are valid. |
For retirement accounts, additional information regarding distributions typically is required.
If a redemption order is received in good order by the Trust or its agent prior to the Cut-off Time, the redemption price for the Fund shares being redeemed is the net asset value per share of the class of Fund shares being redeemed determined on that day (less any applicable redemption fee). In the case of a Bond Fund, SGM Major Markets Fund, and Special Opportunities Fund, redemption orders in good order that are received on days when either the NYSE or the U.S. bond markets are closed will not be accepted until the next day on which both the NYSE and the U.S. bond markets are open, and the redemption price will be the net asset value per share
179
of the class of Fund shares being redeemed determined that day (less any applicable redemption fee). In the case of Taiwan Fund, redemption orders in good order that are received on days when either the NYSE or the TSE is scheduled to be closed will not typically be accepted until the next day on which both the NYSE and the TSE are open, and the redemption price will be the net asset value per share determined that day (less any applicable redemption fee). If a redemption order is received after the Cut-off Time, the redemption price for the Fund shares to be redeemed will be the net asset value per share determined on the next business day that the NYSE is open (less any applicable redemption fee), and, in the case of the Bond Funds, SGM Major Markets Fund, and Special Opportunities Fund, the next business day that the U.S. bond markets also are open (less any applicable redemption fee), and, in the case of Taiwan Fund, the next business day that the TSE also is open (less any applicable redemption fee), unless you or another authorized person on your account has instructed GMO Shareholder Services in writing to defer the redemption to another day. You or another authorized person on your account may revoke your redemption order in writing at any time prior to the Cut-off Time on the redemption date. Redemption fees, if any, apply to all shares of a Fund regardless of how the shares were acquired (e.g., by direct purchase or by reinvestment of dividends or other distributions). See Purchase Premiums and Redemption Fees on page [ ] for a discussion of redemption fees charged by some Funds, including circumstances under which all or a portion of the fees may be waived. In the event of a disaster affecting Boston, Massachusetts, you should contact GMO to confirm that your redemption order was received and is in good order.
Failure to provide the Trust or its agent with a properly authorized redemption order or otherwise satisfy the Trust as to the validity of any change to the wire instructions or registration address may result in a delay in processing a redemption order, delay in remittance of redemption proceeds, or a rejection of the redemption order.
In GMOs sole discretion, a Fund may pay redemption proceeds wholly or partly in securities (selected by GMO) instead of cash. In particular, if market conditions deteriorate and GMO believes a Funds redemption fee (if any) will not fairly compensate a Fund for transaction costs, the Fund may limit cash redemptions and use portfolio securities to pay the redemption price to protect the interests of all Fund shareholders. Redemptions paid with portfolio securities may require shareholders to enter into new custodial arrangements if they do not have accounts available for holding securities directly.
If a redemption is paid in cash:
| payment will generally be made by means of a federal funds transfer to the bank account designated in the relevant GMO Trust Application |
u | designation of one or more additional bank accounts or any change in the bank accounts originally designated in the GMO Trust Application must be made in a recordable format by an authorized signatory according to the procedures in the GMO Trust Redemption Order Form |
u | if an ambiguity in wire instructions cannot be resolved in a timely manner, GMO may elect to remit redemption proceeds by check |
| upon request, payment will be made by check mailed to the registered address (unless another address is specified according to the procedures in the GMO Trust Redemption Order Form) |
| In GMOs sole discretion, a redemption may be paid in whole or in part in a currency other than U.S. dollars when the redeeming shareholder has indicated a willingness to receive the redemption proceeds in that currency. Non-U.S. dollar currencies used to pay redemption proceeds will be valued in accordance with the Trusts valuation procedures. |
The Trust will not process what it reasonably believes are duplicate redemption requests.
The Trust will not pay redemption proceeds to third parties and does not offer check-writing privileges.
The Trust typically will not pay redemption proceeds to multiple bank accounts.
Redemption requests may be revoked prior to the Cut-off Time on the redemption date.
If a redemption is paid with securities, you should note that:
| the securities will be valued as set forth under Determination of Net Asset Value; |
| the securities will be selected by GMO in light of the Funds objective and other practical considerations and may not represent a pro rata distribution of each security held in the Funds portfolio; |
| you will likely incur brokerage charges on the sale of the securities; |
| redemptions paid in securities generally are treated by shareholders for tax purposes the same as redemptions paid in cash; |
| you may bear any stamp or other transaction-based taxes or other costs arising in connection with the Funds transfer of securities to you; and |
| the securities will be transferred and delivered by the Trust as directed in writing by an authorized person on your account. |
180
Each Fund may suspend the right of redemption and may postpone payment for more than seven days:
| during periods when the NYSE is closed other than customary weekend or holiday closings; |
| during periods when trading on the NYSE is restricted; |
| during an emergency that makes it impracticable for a Fund to dispose of its securities or to fairly determine its net asset value; or |
| during any other period permitted by the SEC. |
Pursuant to the Trusts Amended and Restated Agreement and Declaration of Trust, the Trust has the unilateral right to redeem Fund shares held by a shareholder at any time (i) if at that time the shareholder owns shares of a Fund or a class of shares of a Fund having an aggregate net asset value of less than an amount determined from time to time by the Trustees; (ii) to the extent the shareholder owns shares of a Fund or a class of shares of a Fund equal to or in excess of a percentage of the outstanding shares of the Fund or the class of shares of the Fund determined from time to time by the Trustees; or (iii) as a means of satisfying legal obligations of the Trust in respect of a withholding tax and related interest, penalty and similar charges, including but not limited to obligations occasioned by the failure of a shareholder to provide any documentation requested by the Trust or its agent. The Trustees have authorized GMO in its sole discretion to redeem shares to prevent a shareholder from becoming an affiliated person of a Fund.
Top Funds may redeem shares of other GMO Funds after the Cut-off Time and receive the current days price if the following conditions are met: (i) the Top Fund received a redemption order prior to the Cut-off Time on that day; and (ii) the redemption of the shares of the other GMO Funds is executed pursuant to an allocation predetermined by GMO prior to that days Cut-off Time.
Cost Basis Reporting. If your account is subject to U.S. federal tax reporting or you otherwise have informed a Fund that you would like to receive informational only U.S. federal tax reporting, upon your redemption or exchange of Fund shares that you hold in that account, the Fund will provide you with cost basis and other related tax information about those shares. This cost basis reporting requirement is effective for shares purchased, including through dividend reinvestment, on or after January 1, 2012. Shares of a Fund acquired prior to January 1, 2012 generally are not subject to these rules, and shareholders are responsible for keeping their own records for determining their tax basis in these shares. Please consult the Trust for more information regarding methods for cost basis reporting, including the Funds default method, and how to select or change a method. You should consult your tax adviser to determine which cost basis method made available by the Fund is most appropriate for you.
If you purchased shares of a Fund through an intermediary, the intermediary and not the Fund ordinarily is responsible for providing the cost basis and related reporting described above. Shareholders purchasing Fund shares through an intermediary should contact the intermediary for more information about how to select a cost basis accounting method for those shares, as well as for information about the intermediarys default method.
Submitting Your Redemption Order. Redemption orders can be submitted by mail, facsimile, or e-mail or other form of communication pre-approved by Shareholder Services to the Trust at the address/facsimile number/e-mail address set forth under How to Purchase Shares Submitting Your Purchase Order Form. Redemption orders are received by the Trust when they are actually received by the Trust or its agent. Call the Trust at 1-617-346-7646 or send an e-mail to SHS@GMO.com to confirm that GMO received, made a good order determination regarding, and accepted your redemption order.
PURCHASE PREMIUMS AND REDEMPTION FEES
Purchase premiums and redemption fees are paid to and retained by a Fund to help offset estimated portfolio transaction costs and other related costs (e.g., bid to ask spreads, stamp duties, and transfer fees) incurred by the Fund (directly or indirectly through investments in underlying GMO Funds or a wholly-owned subsidiary) as a result of the purchase or redemption by allocating estimated transaction costs to the purchasing or redeeming shareholder.
Each of the Asset Allocation Funds may charge purchase premiums and redemption fees. Purchase premiums and redemption fees for the Asset Allocation Funds are typically reassessed annually by GMO based on the weighted average of (i) the estimated transaction costs for directly held assets (including assets held by a wholly-owned subsidiary) and (ii) the purchase premiums and redemption fees, if any, imposed by the underlying GMO Funds in which the Asset Allocation Funds invest. If that weighted average is less than 0.05%, the Asset Allocation Funds usually will not charge a purchase premium or redemption fee.
181
A Fund may impose a new purchase premium and redemption fee or modify an existing fee at any time. Please refer to the Shareholder fees table under the caption Fees and expenses in each Funds summary for details regarding the purchase premium and redemption fee, if any, charged by a Fund.
Purchase premiums are not charged on reinvestments of dividends or other distributions. Redemption fees apply to all shares of a Fund regardless of how the shares were acquired (e.g., by direct purchase or by reinvestment of dividends or other distributions).
Waiver of Purchase Premiums/Redemption Fees
If GMO determines that any portion of a cash purchase or redemption, as applicable, is offset by a corresponding cash redemption or purchase occurring on the same day, it ordinarily will waive or reduce the purchase premium or redemption fee with respect to that portion.
GMO also may waive or reduce the purchase premium or redemption fee for a cash purchase or redemption of a Funds shares if the Fund will not incur transaction costs or will incur reduced transaction costs. For example, GMO may waive all or a portion of the purchase premiums and redemption fees for the Asset Allocation Funds when they are de minimis or GMO deems it equitable to do so, including without limitation when the weighted average of (i) the estimated transaction costs for directly held assets and (ii) the purchase premiums and redemption fees, if any, imposed by the underlying GMO Funds in which an Asset Allocation Fund invests are less than the purchase premium and redemption fee imposed by the Asset Allocation Fund.
GMO will waive or reduce the purchase premium when securities are used to purchase a Funds shares except to the extent that the Fund incurs transaction costs (e.g., stamp duties or transfer fees) in connection with its acquisition of those securities. GMO may waive or reduce redemption fees when a Fund uses portfolio securities to redeem its shares. However, when a substantial portion of a Fund is being redeemed in-kind, the Fund may nonetheless charge a redemption fee equal to known or estimated costs.
Purchase premiums or redemption fees generally will not be waived for purchases and redemptions of Fund shares executed through brokers or agents, including, without limitation, intermediary platforms that are allowed pursuant to agreements with the Trust to transmit orders for purchases and redemptions the day after those orders are received.
GMO may consider known cash flows out of or into Funds when placing orders for the cash purchase or redemption of Fund shares by accounts over which it has investment discretion, including the Asset Allocation Funds and other pooled investment vehicles. Consequently, participants in those accounts will tend to benefit more from waivers of the Funds purchase premiums and redemption fees than other Fund shareholders.
MULTIPLE CLASSES AND ELIGIBILITY
Most Funds offer multiple classes of shares. The sole economic difference among the various classes of shares is in their shareholder service fee (and supplemental support fee in the case of Benchmark-Free Allocation Fund). Differences in the shareholder service fee reflect the fact that, as the size of an investor relationship increases, the cost to service that investor decreases as a percentage of the investors assets managed by GMO and its affiliates. Thus, the shareholder service fee generally is lower for classes requiring greater minimum investments.
Except for Class MF shares of Benchmark-Free Allocation Fund, an investors eligibility to purchase Fund shares or different classes of Fund shares depends on the investors meeting either (i) the Minimum Total Fund Investment, which involves only an investors total investment in a particular Fund, or (ii) the Minimum Total GMO Investment, both of which are set forth in the table below. Mutual funds that wish to invest in shares of Benchmark-Free Allocation Fund and to receive supplemental support services are eligible to purchase its Class MF shares. No minimum initial investment is required to purchase Class MF shares. For investors owning shares of a Fund, no minimum additional investment is required to purchase additional shares of that Fund.
182
Minimum Investment Criteria for Class Eligibility
Minimum Total Fund Investment |
Minimum Total GMO Investment 1 |
Shareholder Service Fee (as a % of average daily net assets) |
||||||||
Class II Shares |
All Funds Offering Class II Shares | N/A | $10 million | 0.22 | % | |||||
Class III Shares |
Global Asset Allocation Fund Global Equity Allocation Fund Global Developed Equity Allocation Fund International Equity Allocation Fund International Developed Equity Allocation Fund Benchmark-Free Fund Strategic Opportunities Allocation Fund |
N/A | $10 million | 0.00 | % 2 | |||||
Tax-Managed International Equities Fund | N/A | $10 million (or $5 million in tax-managed GMO products) | 0.15 | % | ||||||
International Equity Fund Foreign Fund |
N/A | $35 million | 0.15 | % | ||||||
Emerging Markets Fund Emerging Domestic Opportunities Fund |
$50 million | N/A | 0.15 | % | ||||||
All Other Funds Offering Class III Shares | N/A | $10 million | 0.15 | % | ||||||
Class IV Shares |
Benchmark-Free Allocation Fund SGM Major Markets Fund Developed World Stock Fund Resources Fund Foreign Small Companies Fund U.S. Equity Allocation Fund Core Plus Bond Fund Emerging Country Debt Fund Alpha Only Fund Risk Premium Fund Special Opportunities Fund |
$125 million | $250 million | 0.10 | % | |||||
International Equity Fund International Large/Mid Cap Equity Fund Foreign Fund |
$125 million | $250 million | 0.09 | % | ||||||
Quality Fund Emerging Markets Fund Emerging Domestic Opportunities Fund |
$125 million | $250 million | 0.105 | % | ||||||
Class V Shares |
All Funds Offering Class V Shares | $250 million | $500 million | 0.085 | % | |||||
Class VI Shares |
All Funds Offering Class VI Shares | $300 million | $750 million | 0.055 | % |
Minimum Investment Criteria and Eligibility for Implementation Fund and U.S. Treasury Fund
Minimum Total Fund Investment |
Minimum Total GMO Investment 1 |
Shareholder Service Fee (as a % of average daily net assets) |
||||||||
Implementation Fund U.S. Treasury Fund |
N/A | $10 million | N/A |
1 | The eligibility requirements in the table above are subject to exceptions and special rules for plan investors investing through financial intermediaries and for investors with continuous investments in Foreign Fund or International Equity Fund since May 31, 1996. See discussion immediately following these tables for more information about these exceptions and special rules. |
2 | These Funds indirectly bear shareholder service fees by virtue of their investments in other GMO Funds. |
An investors Minimum Total GMO Investment equals GMOs estimate of the market value of all the investors assets managed by GMO and its affiliates (i) at the time of the investors initial investment, (ii) at the close of business on the last business day of each calendar quarter, or (iii) at other times as determined by GMO (including those described below under Conversions between Classes) (each, a Determination Date). However, an investors Minimum Total GMO Investment required to purchase Class III shares of Tax-Managed International Equities Fund also may equal the market value of all of the investors assets invested in tax-managed GMO products in the aggregate on a Determination Date. When purchasing shares of a Fund, investors should consult with GMO to determine the applicable Determination Date and the share class for which they are eligible.
183
For shareholders of Foreign Fund or International Equity Fund since May 31, 1996: Any investor that has been a continuous shareholder of Foreign Fund or International Equity Fund since May 31, 1996 is eligible indefinitely to remain invested in Class III shares of that Fund.
Upon request GMO may permit an investor to undertake in writing to meet the applicable Minimum Total Fund Investment or Minimum Total GMO Investment over a specified period (a Commitment Letter).
You should note:
| No minimum additional investment is required to purchase additional shares of a Fund or any class of shares of a Fund that you currently hold. |
| GMO makes all determinations as to which investor accounts should be aggregated for purposes of determining eligibility for a Fund or the various classes of shares offered by a Fund, as the case may be. When making decisions regarding whether accounts should be aggregated because they are part of a larger client relationship, GMO considers several factors including, but not limited to, whether: the accounts are for one or more subsidiaries of the same parent company; the accounts have the same beneficial owner regardless of the legal form of ownership; the registered owner has full discretion over all underlying assets; the investment mandate is the same or substantially similar across the relationship; the asset allocation strategies are substantially similar across the relationship; GMO reports to the same investment board; GMO services the relationship through a single GMO relationship manager; the relationships have substantially similar reporting requirements; and the relationship can be serviced from a single geographic location. |
| Eligibility requirements for a Fund or each class of shares of a Fund, as the case may be, are subject to change. |
| GMO may waive eligibility requirements for some persons, accounts, or special situations. These waivers include the waiver of eligibility requirements for (i) GMO Funds and other accounts over which GMO has investment discretion that invest in other GMO Funds, (ii) GMO directors, partners, employees, agents, and their family members, (iii) the Trustees of the Trust, (iv) Trustees of other mutual funds sponsored by GMO, and (v) clients of an investment consultant or similar investment professional with a substantial ongoing business relationship with GMO. GMO may discontinue such waivers at any time without notice. |
| Investors investing through a financial intermediary may be permitted to invest in Class III Shares and investments through a financial intermediary may not be subject to conversions between classes. |
Conversions between Classes
As described in Additional Summary Information About the Funds, in determining whether an investor is eligible to purchase Fund shares, GMO considers each investors Minimum Total Fund Investment and Minimum Total GMO Investment on each Determination Date. Based on this determination, and subject to the following, each investors shares of a Fund eligible for conversion will be converted to the class of shares of that Fund with the lowest shareholder service fee for which the investor satisfies all minimum investment requirements (or, to the extent the investor already holds shares of that class, the investor will remain in that class). Class MF shareholders are not currently eligible to convert their Class MF shares into, or exchange Class MF shares for, other classes of shares. Except as noted below, with respect to any Fund:
| If an investor satisfies all minimum investment requirements for a class of shares then being offered that bears a lower shareholder service fee than the class held by the investor on the Determination Date (generally at the close of business on the last business day of each calendar quarter), the investors shares eligible for conversion generally will be automatically converted to that class within approximately 45 calendar days following the Determination Date on a date selected by GMO. |
|
If an investor no longer satisfies all minimum investment requirements for the class of shares of a Fund held by the investor on the last Determination Date of a calendar year (generally at the close of business on the last business day of the calendar year), the Fund generally will convert the investors shares to the class it is then offering bearing the lowest shareholder service fee for which the investor satisfies all minimum investment requirements (which class typically will bear a higher shareholder service fee than the class then held by the investor). If an investor no longer satisfies all minimum investment requirements for any class of a Fund as of the last Determination Date of a calendar year, the Fund will convert the investors shares to the class of that Fund then being offered bearing the highest shareholder service fee. Notwithstanding the foregoing, an investors shares will not be converted to a class of shares bearing a higher shareholder service fee without at least 15 calendar days prior notice, and if the investor makes an additional investment or the value of the investors shares otherwise increases prior to the end of the notice period so as to satisfy all minimum investment requirements for the investors current class of shares, |
184
the investor will remain in the class of shares then held by the investor. Solely for the purpose of determining whether an investor has satisfied the minimum investment requirements for an investors current class of shares, the value of the investors shares is considered to be the greater of (i) the value of the investors shares on the relevant Determination Date, (ii) the value of the investors shares on the date that GMO reassesses the value of the investors account for the purpose of sending notice of a proposed conversion, or (iii) the value of the investors shares immediately prior to the date when the conversion would take place. If the investor is not able to make an additional investment in a Fund solely because the Fund is closed to new investment or is capacity constrained, the class of shares then held by the investor will not be converted unless GMO approves reopening the Fund to permit the investor to make an additional investment. The conversion of an investors shares to a class of shares bearing a higher shareholder service fee generally will occur within approximately 60 calendar days following the last Determination Date of a calendar year or, in the case of conversion due to an abusive pattern of investments or redemptions (see next paragraph), on any other date GMO determines. |
A Fund may at any time without notice convert an investors shares to the class it is then offering bearing the lowest shareholder service fee for which the investor satisfied all minimum investment requirements (or, if the Fund has no such class, the class of that Fund bearing the highest shareholder service fee) if the investor no longer satisfies all minimum investment requirements for the class of shares held by the investor and: (i) GMO believes the investor has engaged in an abusive pattern of investments or redemptions (e.g., a large investment just before a Determination Date and a redemption immediately after the Determination Date), (ii) the investor fails to meet the applicable Minimum Total Fund Investment or Minimum Total GMO Investment by the time specified in the investors Commitment Letter, or (iii) the total expense ratio borne by the investor immediately following the conversion is equal to or less than the total expense ratio borne by the investor immediately before the conversion (after giving effect to any applicable fee and expense waivers or reimbursements).
For U.S. federal income tax purposes, the conversion of an investors investment from one class of shares of a Fund to another class of shares of the same Fund generally should not result in the recognition of gain or loss in the shares that are converted. Thus, in general, the investors tax basis in the new class of shares immediately after the conversion should equal the investors basis in the converted shares immediately before the conversion, and the holding period of the new class of shares should include the holding period of the converted shares.
[TO BE UPDATED BY AMENDMENT]
Except as specifically noted below, this section provides a general summary of the principal U.S. federal income tax consequences of investing in a Fund for shareholders who are U.S. citizens, residents, or corporations. You should consult your own tax advisers about the precise tax consequences of an investment in a Fund in light of your particular tax situation, including possible non-U.S., state, local, or other applicable taxes (including the federal alternative minimum tax). A Funds shareholders may include GMO Funds, including GMO Funds not offered in this Prospectus, some of which are regulated investment companies (each, a RIC) as defined by Subchapter M of the Internal Revenue Code of 1986, as amended (the Code). The summary below does not address tax consequences to shareholders of those other GMO Funds. Shareholders of those other GMO Funds should refer to the prospectuses or private placement memoranda, as applicable, and statements of additional information for those GMO Funds for a summary of the tax consequences applicable to them.
Except for U.S. Treasury Fund, the policy of each Fund is to declare and pay dividends of its net investment income, if any, at least annually, although the Funds are permitted to, and will from time to time, declare and pay dividends of net investment income, if any, more frequently. Each Fund also intends to distribute net realized capital gains, whether from the sale of investments held by the Fund for not more than one year (net short-term capital gains) or from the sale of investments held by the Fund for more than one year (net long-term capital gains), if any, at least annually. In addition, the Funds may, from time to time and at their discretion, make unscheduled distributions in advance of large redemptions by shareholders or as otherwise deemed appropriate by a Fund. Net investment income of a Fund includes (i) distributions received from an underlying fund taxed as a RIC attributable to the underlying funds own net investment income and net short-term capital gains and (ii) the Funds allocable share of net investment income of an underlying fund taxed as a partnership. Net realized capital gains includes (x) distributions received from an underlying fund taxed as a RIC attributable to the underlying funds net long-term capital gains and (y) the Funds allocable share of net short-term or net long-term capital gains of an underlying fund taxed as a partnership. From time to time, distributions by a Fund could constitute a return of capital to shareholders for U.S. federal income tax purposes. Shareholders should read the description below for information regarding the tax character of distributions from a Fund to shareholders.
185
The policy of U.S. Treasury Fund is to declare dividends daily, to the extent net investment income is available, and U.S. Treasury Fund generally will pay dividends on the first business day following the end of each month in which dividends were declared. Shareholders of U.S. Treasury Fund will generally begin earning dividends on their shares of the Fund on the business day following the effective date of their purchase of those shares. U.S. Treasury Fund shareholders, however, can begin earning dividends on the same business day as the effective date of their purchase if each of the following criteria are met: (i) their order is received by the Fund prior to 11:00 a.m. Eastern time on the effective date, (ii) they have requested same-day settlement, (iii) the Fund receives the purchase proceeds on the effective date and (iv) the Fund is able to invest such purchase amounts in a timely manner. Shareholders of U.S. Treasury Fund will generally continue to earn dividends on the effective date of their redemption from the Fund unless they request receipt of their redemption proceeds on the effective date.
All dividends of net investment income and capital gain distributions paid to shareholders will be reinvested in additional shares of the Fund making them automatically, at net asset value, unless GMO or its agents receive and process a shareholder election to receive cash. Shareholders may elect to receive cash by marking the appropriate boxes on the GMO Trust Application, by writing to the Trust, or by notifying their broker or agent. The Funds do not charge a purchase premium on reinvested dividends or distributions.
It is important for you to note:
| Each Fund is treated as a separate taxable entity for U.S. federal income tax purposes. Each of the Funds has elected to be treated or intends to elect to be treated, and intends to qualify and be treated each year, as a RIC under Subchapter M of the Code. A RIC generally is not subject to tax at the fund level on income and gains from investments that are timely distributed to shareholders. However, a Funds failure to qualify as a RIC would result in, among other things, Fund-level taxation, and consequently, a reduction in the value of the Fund. See Taxes in the SAI for more information about the tax consequences of not qualifying as a RIC. |
| For U.S. federal income tax purposes, distributions of net investment income generally are taxable to shareholders as ordinary income. |
| For U.S. federal income tax purposes, taxes on distributions of net realized capital gains generally are determined by how long a Fund owned the investments generating the gains, rather than by how long a shareholder has owned shares in the Fund. Distributions of net realized capital gains from the sale of investments that a Fund owned for more than one year and that are reported by a Fund as capital gain dividends generally are taxable to shareholders as long-term capital gains. Distributions of net realized capital gains from the sale of investments that a Fund owned for one year or less generally are taxable to shareholders as ordinary income. Tax rules can alter a Funds holding period in investments and thereby affect the tax treatment of gain or loss on such investments. |
| A Fund may make total distributions during a taxable year in an amount that exceeds the Funds net investment income and net realized capital gains for that year, in which case the excess generally would be treated as a return of capital, which would reduce a shareholders tax basis in its shares, with any amounts exceeding such basis treated as capital gain. A return of capital is not taxable to shareholders to the extent such amount does not exceed a shareholders tax basis, but it reduces a shareholders tax basis in its shares, thus reducing any loss or increasing any gain on a subsequent taxable disposition by the shareholder of its shares. |
| A Fund will carry any net realized capital losses (i.e., realized capital losses in excess of realized capital gains) from any taxable year forward to one or more subsequent taxable years to offset capital gains, if any, realized during such subsequent years. If a Fund incurs or has incurred net capital losses in a taxable year beginning after December 22, 2010, those losses will be carried forward to one or more subsequent taxable years without expiration. A Fund must apply such carryforwards first against gains of the same character. If a Fund has incurred net capital losses in a taxable year beginning on or before December 22, 2010, the Fund is permitted to carry those losses forward for up to eight taxable years. Any such losses remaining at the end of the eight-year period will expire unused. A Funds available capital loss carryforwards, if any, will be set forth in its annual shareholder report for each fiscal year. A Funds ability to utilize these and certain other losses to reduce distributable net realized capital gains in succeeding taxable years may be limited by reason of direct or indirect changes in the actual or constructive ownership of the Fund. See Taxes in the SAI for more information. |
| Distributions of net investment income properly reported by a Fund as derived from qualified dividend income will be taxable to shareholders taxed as individuals at the rates applicable to net capital gain, provided holding period and other requirements are met at both the shareholder and Fund levels. |
| Distributions of net investment income derived from dividends eligible for the dividends-received deduction may allow a corporate shareholder (other than an S corporation) to deduct a percentage of such distribution, as a dividends-received deduction, in computing its taxable income, provided holding period and other requirements are met at both the shareholder and Fund levels. |
186
| The Code generally imposes a 3.8% Medicare contribution tax on the net investment income of individuals and of certain trusts and estates to the extent their income exceeds certain threshold amounts. Net investment income generally includes for this purpose dividends, including any capital gain dividends, paid by a Fund, and net gains recognized on the sale, redemption or exchange of shares in a Fund, and may be reduced by certain allowable deductions. Shareholders are advised to consult their tax advisers regarding the possible implications of this additional tax on their investment in a Fund in light of their particular circumstances. |
| Distributions by a Fund generally are taxable to a shareholder even if they are paid from income or gains earned by the Fund before that shareholder invested in the Fund (and accordingly the income or gains were included in the price the shareholder paid for the Funds shares). Distributions are taxable whether shareholders receive them in cash or reinvest them in additional shares. |
| Distributions by a Fund to retirement plans that qualify for tax-exempt treatment under U.S. federal income tax laws generally will not be taxable. Special tax rules apply to investments through such plans. You should consult your tax adviser to determine the suitability of a Fund as an investment through such a plan and the tax treatment of distributions from such a plan. |
| Any gain resulting from a shareholders sale, exchange, or redemption of Fund shares generally will be taxable to the shareholder as short- or long-term capital gain, depending on how long the Fund shares were held by the shareholder for U.S. federal income tax purposes. Redemptions paid in securities generally are treated by shareholders for U.S. federal income tax purposes the same as redemptions paid in cash. |
| To the extent a Fund invests, directly or indirectly, in other GMO Funds, subsidiaries of GMO Funds, or other investment companies treated as RICs, partnerships, trusts or other pass-through structures for U.S. federal income tax purposes, including certain ETFs, the Funds distributions could vary in terms of their timing, character, and/or amount, in some cases significantly, from what the Funds distributions would have been had the Fund invested directly in the portfolio investments held by the underlying investment companies. See Taxes in the SAI for more information. |
| A Funds income from or the proceeds of dispositions of its non-U.S. investments may be subject to non-U.S. withholding or other taxes. A Fund may otherwise be subject to non-U.S. taxation on repatriation proceeds generated from those investments or to other transaction-based non-U.S. taxes on those investments. Those withholding and other taxes will reduce the Funds return on and taxable distributions in respect of its non-U.S. investments. In some cases, a Fund may seek a refund in respect of taxes paid to a non-U.S. country (see Description of Principal RisksNon-U.S. Investment Risk for more information). The non-U.S. withholding and other tax rates applicable to a Funds investments in certain non-U.S. jurisdictions may be higher in certain circumstances, for instance, if a Fund has a significant number of non-U.S. shareholders, if a Fund owns a significant holding of a non-U.S. issuer or if a Fund or an underlying GMO Fund invests through a subsidiary. In certain instances, shareholders may be entitled to claim a credit or deduction (but not both) for non-U.S. taxes paid directly or indirectly. In addition, a Funds investments in certain non-U.S. investments, foreign currencies or foreign currency derivatives may accelerate Fund distributions to shareholders and increase the distributions taxed to shareholders as ordinary income. See Taxes in the SAI for more information. |
| Any U.S. withholding or other taxes applicable to a Funds investments, including in respect of investments in its wholly-owned subsidiary, if any, will reduce the Funds return on its investments. |
| Under the Funds securities lending arrangements, if a Fund lends a portfolio security and a dividend is paid in respect of the security out on loan, the borrower will be required to pay to that Fund a substitute payment at least equal, on an after-tax basis, to the dividend that the Fund would have received if it had received the dividend directly. Because some borrowers of non-U.S. securities may be subject to levels of taxation that are lower than the rates applicable to that Fund, some borrowers are likely to be motivated by the ability to earn a profit on those differential tax rates and to pay that Fund for the opportunity to earn that profit. In the United States, Congress has enacted legislation limiting the ability of certain swaps and similar derivative instruments and securities lending transactions to reduce otherwise applicable U.S. withholding taxes on U.S. stock dividends paid to a non-U.S. person. There can be no assurance that similar legislation will not be adopted in other jurisdictions with respect to non-U.S. investments or that non-U.S. taxing authorities will not otherwise challenge beneficial tax results arising from swaps or other derivative instruments or securities lending arrangements. |
|
Some of a Funds investment practices, including derivative transactions, short sales, hedging activities generally, and securities lending activities, as well as some of a Funds investments, including debt obligations issued or purchased at a |
187
discount, asset-backed securities, assets marked to the market for U.S. federal income tax purposes, REITs, equity in certain non-U.S. corporations, master limited partnerships and, potentially, so-called indexed securities (such as TIPS or other inflation-indexed bonds), are subject to special and complex U.S. federal income tax provisions. These special rules may affect the timing, character, and amount of a Funds distributions and, in some cases, may cause a Fund to liquidate investments at disadvantageous times. |
| A Funds investment through a wholly-owned subsidiary could affect the amount, timing and character of its distributions and could cause the Fund to recognize taxable income in excess of the cash generated by such investment, requiring the Fund in turn to liquidate investments at disadvantageous times to generate cash needed to make required distributions. See Taxes in the SAI for more information about the tax consequences of specific Fund investment practices and investments, including a Funds investments in a wholly-owned subsidiary. |
| The Funds do not expect to pass through to shareholders the tax-exempt character of interest from investments in tax-exempt municipal bonds, if any. Therefore, any interest on municipal bonds will be taxable to shareholders of a Fund when received as a distribution from the Fund. |
| In general, in order to qualify as a RIC, a Fund must, among other things, derive at least 90% of its gross income from certain specified sources (qualifying income). Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund generally should be entitled to treat income that it recognizes from its investment in a wholly-owned foreign subsidiary as qualifying income. There is a risk, however, that the IRS could determine that some or all of the gross income derived from investments in one or more of these foreign subsidiaries is not qualifying income, which might adversely affect a Funds ability to qualify as a RIC under the Code. |
| A Funds pursuit of its investment strategy, including a strategy involving the ability to engage in certain derivative transactions, will potentially be limited by the Funds intention to qualify as a RIC, and could adversely affect the Funds ability to so qualify. |
| It is possible that withholding taxes will apply to certain categories of the U.S.-source income of the wholly-owned foreign subsidiaries of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund (each, a parent fund). The Funds expect that: (i) all the net income and gain from the investments of each such foreign subsidiary will be includible in its parent funds net investment income at the end of such subsidiarys taxable year as so-called subpart F income; and (ii) all such subpart F income will be treated as ordinary income in the hands of the subsidiarys parent fund. A subsidiarys distributions to its parent fund, including in redemption of subsidiary shares, are generally tax-free to the extent of the subsidiarys subpart F income previously included in its parent funds income. Each such subsidiary may be required to liquidate investments at disadvantageous times to generate cash needed to make such distributions to its parent fund. Net losses a subsidiary recognizes during a taxable year will not flow through to its parent fund to offset income or gain generated by the parent funds other investments, or carry forward to subsequent taxable years; this will limit the benefit from those losses. |
| Dividends paid to non-U.S. shareholders that a Fund properly reports as capital gain dividends, short-term capital gain dividends or interest-related dividends, each as further defined in the SAI, are not subject to withholding of U.S. federal income tax, provided that certain other requirements are met. A Fund is permitted, but is not required, to report the part, if any, of its dividends that is eligible for such treatment. A Funds dividends other than those the Fund properly reports as capital gain dividends, short-term capital gain dividends or interest-related dividends generally will be subject to withholding of U.S. federal income tax at a rate of 30% (or lower applicable treaty rate). For more information on the tax consequences of investing in a Fund for non-U.S. shareholders, see Taxes in the SAI. Non-U.S. shareholders described in section 892 of the Code should consult their tax advisers with respect to their investment in a Fund. |
| The Code generally requires a Fund to obtain information sufficient to identify the status of each of its shareholders under Sections 1471-1474 of the Code (including the U.S. Treasury Regulations and IRS guidance issued thereunder, FATCA) or under an applicable intergovernmental agreement (an IGA). If a shareholder fails to provide this information or otherwise fails to comply with FATCA or an IGA, a Fund or its agent may be required under FATCA to withhold 30% of the distributions, other than those properly reported as capital gain dividends, the Fund pays to that shareholder. On or after January 1, 2017 (which date, under Treasury guidance, is expected to be delayed until at least January 1, 2019), the Fund or its agent may also be required under FATCA to withhold 30% of the gross proceeds of the sale, redemption or exchange of Fund shares and certain capital gain dividends the Fund pays to that shareholder. If a payment by a Fund is subject to FATCA withholding, the Fund or its agent is required to withhold even if the payment would otherwise be exempt from withholding under rules applicable to non-U.S. shareholders (e.g., capital gain dividends). Each prospective shareholder is urged to consult its tax adviser regarding the applicability of FATCA and any other reporting requirements. In addition, foreign countries are considering, and may implement, laws similar in purpose and scope to FATCA, as more fully described above. See Taxes in the SAI for more information. |
| Most states permit mutual funds, such as the Funds, to pass through to their shareholders the state tax exemption on income earned from investments in some direct U.S. Treasury obligations, as well as some limited types of U.S. government agency securities, so long as a fund meets all applicable state requirements. Therefore, you may be allowed to exclude from your state taxable income distributions made to you by a Fund that are attributable to interest the Fund directly or indirectly earned on such investments. The availability of these exemptions varies by state. You should consult your tax adviser regarding the applicability of any such exemption to your situation. |
188
See Taxes in the SAI for more information, including a summary of some of the tax consequences of investing in a Fund for non-U.S. shareholders.
Certain Non-U.S. Tax Issues Relating to Singapore
As described under Management of the Trust, GMO Singapore furnishes discretionary investment advisory services and makes investment decisions for all or part of EDOFs portfolio, as determined by GMO.
GMO believes that an exemption from Singapore taxation should apply to income and gains derived from the provision of such discretionary investment advisory services and from such investment decisions made by GMO Singapore for a qualifying fund, so long as, among other requirements, such income and gains constitute specified income from designated investments as those terms are defined under current Singapore tax law. In this regard, the sources of specified income from designated investments earned solely by EDOF (and not by any other GMO Fund), are considered. GMO expects that substantially all such income and gains earned by EDOF will constitute specified income from designated investments. This tax position takes into account advice received from Singapore legal counsel and relevant Singapore tax law. All income and gains that are considered to be Singapore-sourced (including amounts attributable to fund-level permanent establishment in Singapore) and that do not otherwise qualify for the exemption would generally be subject to Singapore taxation at the current corporate rate of 17%. Shareholders bear the risk of all Fund income tax consequences in the event that income or gains are subject to Singapore taxation.
In addition to the foregoing, a non-qualifying shareholder (described below) may be required to pay a financial amount to the Inland Revenue Authority of Singapore and fulfill certain Singapore tax reporting requirements. Very generally, non-qualifying shareholders may include, but are not limited to, Singapore-domiciled shareholders that maintain a permanent establishment in Singapore and who, either alone or with their associates, beneficially own applicable qualifying fund shares representing in excess of 50% of a qualifying funds net assets as of the final day of that qualifying funds financial year-end (or in excess of 30% of the qualifying funds net assets, to the extent the qualifying fund has less than 10 shareholders). The financial amount is generally computed by applying the prevailing corporate rate of tax to a non-qualifying shareholders share of qualifying fund profits.
Shareholders are responsible for evaluating their percentage interest of net assets in a qualifying fund for the purpose of their own particular situations. Relevant information may be derived from account statements and other information provided to shareholders in respect of the qualifying fund. Upon the reasonable request of a shareholder, GMO will provide information necessary to allow the shareholder to assess its percentage ownership in the qualifying fund.
A Fund or an investor that invests in EDOF will be indirectly exposed to the Singapore taxation issues described above.
Certain Non-U.S. Tax Issues Relating to Australia
[As described under Management of the Fund, GMO has entered into a personnel sharing agreement with GMO Australia. GMO believes that SGMs (including its subsidiarys) (for purposes of this and the next two paragraphs only, the Fund) income or gains should not be treated as Australian sourced and thus should not be subject to Australian income tax merely by virtue of such personnel sharing arrangement and the provision of certain investment management and other services in Australia, as described in Management of the Fund. The Australian Government has recently enacted legislation relating to the taxation of foreign-managed funds in Australia that may mitigate the Australian tax risks for the Fund. To the extent the Fund or its shareholders are not qualified to claim tax treaty benefits with Australia, the income or gains of the Fund, as a non-resident of Australia, will be subject to Australian income tax, if that income or those gains constitute ordinary income, only if they are Australian sourced. In light of the way in which the Fund undertakes its trading activities, GMO believes the risk is low that the Fund will have any Australian sourced income or gains.]
GMOs position (described in the prior paragraph) takes into account advice of Australian counsel and the published views of the Australian Commissioner of Taxation (Commissioner) on similar arrangements. Any income or gains of the Fund that the Commissioner considers to be Australian sourced and which do not otherwise qualify for tax treaty benefits with Australia (or with the Investment Manager Regime (IMR) described below) would generally be subject to Australian tax at the corporate rate of 30%. Shareholders of the Fund bear the risk of any such Australian income tax consequences should the Funds income or gains be subject to Australian tax.
189
The Australian Government has undertaken a review of Australian laws relating to the taxation of foreign-managed funds in Australia. In particular, it has enacted tax exemptions/concessions as part of IMR that may mitigate the Australian tax risks for the Fund and its shareholders. The effect of IMR may be to exempt the Fund and its shareholders from Australian taxes even if the income or gains of the Fund were held to have an Australian source.
Shareholders should consult their own tax advisers regarding the tax consequences of an investment in a Fund, including the implications described herein.
See Taxes in the SAI for more information, including a summary of some of the tax consequences of investing in the Fund for non-U.S. shareholders.
190
FUND BENCHMARKS AND COMPARATIVE INDICES
[TO BE UPDATED BY AMENDMENT]
The following section provides additional information about the Funds benchmarks (if any) and other comparative indices listed under Investment objective and the Average Annual Total Returns table or referenced under Principal investment strategies in the Fund summaries:
Benchmark/Comparative Index | Description | |
Barclays U.S. Aggregate Index | The Barclays U.S. Aggregate Index is an independently maintained and widely published index comprised of U.S. fixed rate debt issues having a maturity of at least one year and rated investment grade or higher. | |
Barclays U.S. Treasury Inflation Notes: 1-10 Year Index | The Barclays U.S. Treasury Inflation Notes: 1-10 Year Index is an independently maintained and widely published index comprised of inflation-protected securities issued by the U.S. Treasury (TIPS) having a maturity of at least one year and less than ten years. | |
Citigroup 3-Month Treasury Bill Index | The Citigroup 3-Month Treasury Bill Index is an independently maintained and widely published index comprised of short-term U.S. Treasury bills. | |
Consumer Price Index | The Consumer Price Index for All Urban Consumers U.S. All Items is published monthly by the U.S. government as an indicator of changes in price levels (or inflation) paid by urban consumers for a representative basket of goods and services. | |
GMO Global Asset Allocation Index | The GMO Global Asset Allocation Index is an internally maintained composite benchmark computed by GMO, comprised of (i) the MSCI ACWI (All Country World Index) (MSCI Standard Index Series, net of withholding tax) through 6/30/2002, (ii) 48.75% S&P 500 Index, 16.25% MSCI ACWI ex USA (MSCI Standard Index Series, net of withholding tax), and 35% Barclays U.S. Aggregate Index from 6/30/2002 through 3/31/2007, and (iii) 65% MSCI ACWI (All Country World Index) (MSCI Standard Index Series, net of withholding tax) and 35% Barclays U.S. Aggregate Index thereafter. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. | |
GMO Strategic Opportunities Allocation Index | The GMO Strategic Opportunities Allocation Index is an internally maintained composite benchmark computed by GMO, comprised of 75% MSCI World Index (MSCI Standard Index Series, net of withholding tax) and 25% Barclays U.S. Aggregate Index. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
J.P. Morgan EMBI Global | The J.P. Morgan EMBI (Emerging Markets Bond Index) Global is an independently maintained and widely published index comprised of U.S. dollar-denominated Eurobonds, traded loans, and legacy Brady bonds issued by sovereign and quasi-sovereign entities. | |
J.P. Morgan EMBI Global + | The J.P. Morgan EMBI (Emerging Markets Bond Index) Global + is an internally maintained composite benchmark computed by GMO, comprised of (i) the J.P. Morgan EMBI through 8/31/1995, (ii) the J.P. Morgan EMBI + through 12/31/1999, and (iii) the J.P. Morgan EMBI Global thereafter. |
191
Benchmark/Comparative Index | Description | |
J.P. Morgan GBI Global | The J.P. Morgan GBI (Government Bond Index) Global is an independently maintained and widely published index comprised of government bonds of developed countries with maturities of one year or more. | |
J.P. Morgan GBI Global ex Japan ex U.S. (Hedged) | The J.P. Morgan GBI (Government Bond Index) Global ex Japan ex U.S. (Hedged) is an independently maintained and widely published index comprised of non-U.S. government bonds (excluding Japanese government bonds) with maturities of one year or more that are hedged into U.S. dollars. | |
J.P. Morgan GBI Global ex Japan ex U.S. (Hedged) + | The J.P. Morgan GBI (Government Bond Index) Global ex Japan ex U.S. (Hedged) + is an internally maintained composite benchmark computed by GMO, comprised of (i) the J.P. Morgan GBI Global ex U.S. (Hedged) through 12/31/2003 and (ii) the J.P. Morgan GBI Global ex Japan ex U.S. (Hedged) thereafter. | |
J.P. Morgan GBI Global ex U.S. (Hedged) | The J.P. Morgan GBI (Government Bond Index) Global ex U.S. (Hedged) is an independently maintained and widely published index comprised of non-U.S. government bonds with maturities of one year or more. | |
J.P. Morgan U.S. 3 Month Cash Index | The J.P. Morgan U.S. 3 Month Cash Index is an independently maintained and widely published index comprised of three month U.S. dollar Euro-deposits. | |
MSCI ACWI | The MSCI ACWI (All Country World Index) (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed and emerging markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI ACWI + | The MSCI ACWI (All Country World Index) + is an internally maintained composite benchmark computed by GMO, comprised of (i) the GMO Global Equity Index, an internally maintained composite benchmark computed by GMO, comprised of 75% S&P 500 Index and 25% MSCI ACWI ex USA (MSCI Standard Index Series, net of withholding tax) through 5/31/2008 and (ii) the MSCI ACWI (MSCI Standard Index Series, net of withholding tax) thereafter. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. | |
MSCI ACWI Commodity Producers Index | The MSCI ACWI (All Country World Index) Commodity Producers Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of listed large and mid capitalization commodity producers within the global developed and emerging markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. |
192
Benchmark/Comparative Index | Description | |
MSCI ACWI ex USA | The MSCI ACWI (All Country World Index) ex USA (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international (excluding U.S. and including emerging) large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI EAFE Index | The MSCI EAFE (Europe, Australasia, and Far East) Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI EAFE Index (after tax) | The MSCI EAFE (Europe, Australasia, and Far East) Index (after tax) is an internally maintained benchmark computed by GMO by adjusting the return of the MSCI EAFE Index (MSCI Standard Index Series, net of withholding tax) by its tax cost. GMO estimates the MSCI EAFE Indexs tax cost by applying the maximum historical individual U.S. federal tax rate to the MSCI EAFE Indexs dividend yield and to its estimated short-term and long-term realized capital gains (losses) (arising from changes in the constituents of the MSCI EAFE Index). MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI EAFE Small Cap Index | The MSCI EAFE (Europe, Australasia, and Far East) Small Cap Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international small capitalization stocks. Depending upon the country, as of May 31, 2016, the market capitalization of the largest company in a particular country included in the MSCI EAFE Small Cap Index ranged from approximately $[ ] billion ([ ]) to $[ ] billion ([ ]). MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI Emerging Markets Index | The MSCI Emerging Markets Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global emerging markets large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI Taiwan Index | The MSCI Taiwan Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of equity securities issued by Taiwanese companies. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. | |
MSCI World Index | The MSCI World Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. |
193
Benchmark/Comparative Index | Description | |
S&P 500 Index | The S&P 500 Index is an independently maintained and widely published index comprised of U.S. large capitalization stocks. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. | |
S&P Developed ex-U.S. Small Cap Index | The S&P Developed ex-U.S. Small Cap Index is an independently maintained and widely published index comprised of the small capitalization stock component of the S&P Broad Market Index (BMI). The BMI includes listed shares of companies from developed and emerging countries with a total available market capitalization (float) of at least the local equivalent of $100 million USD. The S&P Developed ex-U.S. Small Cap Index represents the bottom 15% of available market capitalization (float) of the BMI in each country. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. | |
S&P Developed ex-U.S. Small Cap + Index | The S&P Developed ex-U.S. Small Cap + Index is an internally maintained composite benchmark computed by GMO, comprised of (i) the S&P Developed ex-U.S. Small Cap Index through 5/30/2008; (ii) the MSCI EAFE Small Cap Index (MSCI Standard Index Series, net of withholding tax) from 5/31/2008 to 4/30/2016 and (iii) the S&P Developed ex-U.S. Small Cap Index thereafter. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. | |
S&P/IFCI Composite Index | The S&P/IFCI Composite Index is an independently maintained and widely published index comprised of emerging markets stocks. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third-party licensors. |
194
(For a share outstanding throughout each period)
The financial highlights tables are intended to help you understand each Funds financial performance for the past five years (or, if shorter, the period of the Funds operations). Some information reflects financial results for a single Fund share. The total returns in the tables represent the rate that an investor would have earned (or lost) on an investment in the Fund (assuming reinvestment of all dividends and distributions). This information has been audited by [ ], an independent registered public accounting firm, whose report, along with each Funds financial statements, is incorporated by reference in the SAI and included in the Trusts annual reports, which are available upon request. Information is presented for each Fund, and class of Fund shares, that had investment operations during the reporting periods and is currently being offered through this Prospectus.
[**TO BE UPDATED BY AMENDMENT**]
195
[TO BE UPDATED BY AMENDMENT]
GMO High Quality Short-Duration Bond Fund. GMO High Quality Short-Duration Bond Fund (High Quality Fund), a series of the Trust, is not offered by this Prospectus and its shares are available only to other GMO Funds and other accredited investors. High Quality Fund is managed by GMO and has not commenced operations as of the date of this Prospectus.
High Quality Fund pays an investment management fee to GMO at the annual rate of 0.05% of High Quality Funds average daily net assets for each class of shares. High Quality Fund offers Class III and Class VI shares, which pay shareholder service fees to GMO at the annual rate, respectively, of 0.15% and 0.055% of the classs average daily net assets.
High Quality Funds investment objective is total return in excess of that of its benchmark, the J.P. Morgan U.S. 3 Month Cash Index, which is an independently maintained and widely published index comprised of three month U.S. dollar Euro-deposits.
High Quality Fund seeks to add value relative to its benchmark to the extent consistent with the preservation of capital and liquidity.
High Quality Fund will invest primarily in high quality U.S. and non-U.S. fixed income securities. High Quality Fund may invest in fixed income securities of any type, including asset-backed securities, corporate debt securities, money market instruments, and commercial paper, and enter into credit default swaps, reverse repurchase agreements, and repurchase agreements. High Quality Fund also may invest in other exchange-traded and over-the-counter (OTC) derivatives. High Quality Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, High Quality Fund typically will have gross investment exposures in excess of its net assets (i.e., High Quality Fund typically will be leveraged) and therefore is subject to heightened risk of loss. High Quality Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
High Quality Funds fixed income securities may include all types of interest rate, payment, and reset terms, including fixed rate, adjustable rate, zero coupon, contingent, deferred, payment-in-kind, and auction rate features. While High Quality Fund primarily invests in high quality bonds, it may invest in securities that are not high quality and may hold bonds and other fixed income securities whose ratings after they were acquired were reduced below high quality.
High Quality Fund also may invest in U.S. Treasury Fund, in money market funds unaffiliated with GMO, or directly in the types of investments typically held by money market funds.
In selecting fixed income securities for High Quality Funds portfolio, GMO focuses primarily on the securities credit quality. GMO uses fundamental investment techniques to identify the credit risk associated with investments in fixed income securities and bases its investment decisions on that assessment. The factors GMO considers and investment methods GMO uses can change over time.
GMO will normally seek to maintain an estimated interest rate duration of 365 days or less for High Quality Funds portfolio (which may be substantially shorter than High Quality Funds dollar-weighted average portfolio maturity). GMO estimates High Quality Funds dollar-weighted average interest rate duration by aggregating the durations of High Quality Funds direct and indirect individual holdings and weighting each holding based on its market value.
Under normal circumstances, High Quality Fund invests directly and indirectly (e.g., through other GMO Funds or derivatives) at least 80% of its assets in high quality bonds.
If deemed prudent by GMO, High Quality Fund may take temporary defensive positions.
A GMO Fund that invests in High Quality Fund is subject to all of the risks to which High Quality Fund is exposed. The principal risks of an investment in High Quality Fund include Credit Risk, Market Risk Asset-Backed Securities, Illiquidity Risk, Market Risk Fixed Income Investments, Focused Investment Risk, Management and Operational Risk, Derivatives and Short Sales Risk, Leveraging Risk, Counterparty Risk, Fund of Funds Risk, Market Disruption and Geopolitical Risk, Large Shareholder Risk, and Non-U.S. Investment Risk. High Quality Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by High Quality Fund may affect High Quality Funds performance more than if High Quality Fund were a diversified investment company. Shareholders of each GMO Fund investing in High Quality Fund are indirectly exposed to these risks.
196
GMO World Opportunity Overlay Fund. GMO World Opportunity Overlay Fund (Overlay Fund), a series of the Trust, is not offered by this Prospectus and its shares are available only to other GMO Funds and other accredited investors. Overlay Fund is managed by GMO.
Overlay Fund does not pay an investment management or shareholder service fee to GMO. Overlay Fund offers a single class of shares.
Overlay Funds investment objective is total return greater than that of its benchmark, the J.P. Morgan U.S. 3 Month Cash Index, which is an independently maintained and widely published index comprised of three month U.S. dollar Euro-deposits.
GMO seeks to achieve Overlay Funds investment objective by attempting to identify and estimate relative misvaluation of global interest rate, credit, and currency markets. Based on those estimates, GMO establishes Overlay Funds positions across those markets. Those positions may include direct investments and derivatives. Overlay Funds direct investments in fixed income securities include U.S. and non-U.S. asset-backed securities and other fixed income securities (including Treasury Separately Traded Registered Interest and Principal Securities (STRIPS), Inflation-Protected Securities issued by the U.S. Treasury (TIPS), Treasury Securities and global bonds). The factors GMO considers and investment methods GMO uses can change over time.
Derivatives used by Overlay Fund are primarily interest rate swaps and futures contracts, currency forwards and options, and credit default swaps on single issuers or indices. As a result of its derivative positions, Overlay Fund typically will have higher volatility than its benchmark. Overlay Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, Overlay Fund typically has gross investment exposures in excess of its net assets (i.e., Overlay Fund typically is leveraged) and therefore is subject to heightened risk of loss. Overlay Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Overlay Fund typically holds asset-backed securities. Overlay Fund also may invest in government securities, corporate debt securities, money market instruments and commercial paper, and enter into credit default swaps, reverse repurchase agreements, and repurchase agreements. Overlay Funds fixed income securities may include all types of interest rate, payment and reset terms, including fixed rate, zero coupon, contingent, deferred, payment-in-kind and auction rate features.
Because of the deterioration in credit markets that became acute in 2008, Overlay Fund has and is expected to continue to have material exposure to below investment grade securities (commonly referred to as junk bonds).
If deemed prudent by GMO, Overlay Fund may take temporary defensive positions.
A GMO Fund that invests in Overlay Fund is subject to all of the risks to which Overlay Fund is exposed. The principal risks of an investment in Overlay Fund include Market Risk Fixed Income Investments, Currency Risk, Credit Risk, Market Risk Asset-Backed Securities, Illiquidity Risk, Derivatives and Short Sales Risk, Leveraging Risk, Counterparty Risk, Focused Investment Risk, Non-U.S. Investment Risk, Management and Operational Risk, Market Disruption and Geopolitical Risk, and Large Shareholder Risk. Overlay Fund is a non-diversified investment company under the Investment Company Act of 1940, as amended, and therefore a decline in the market price of a particular security held by Overlay Fund may affect Overlay Funds performance more than if Overlay Fund were a diversified investment company. Shareholders of each GMO Fund investing in Overlay Fund are indirectly exposed to these risks.
197
SUPPLEMENTAL PERFORMANCE AND VOLATILITY INFORMATION
[TO BE UPDATED BY AMENDMENT]
ILLUSTRATION OF VOLATILITY OF INVESTMENTS IN ASSET-BACKED SECURITIES
Effective February 12, 2014 (the Merger Date), GMO Debt Opportunities Fund merged into GMO Short-Duration Collateral Fund (Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund (Debt Opportunities Fund).
THE PERFORMANCE INFORMATION PRESENTED BELOW IS THAT OF SHORT-DURATION COLLATERAL FUND FOR THE TEN FULL CALENDAR YEARS PRECEDING THE MERGER DATE. IT IS NOT THE PERFORMANCE OF DEBT OPPORTUNITIES FUND OR ANY OTHER FUND OFFERED IN THIS PROSPECTUS. PAST PERFORMANCE IS NOT AN INDICATION OF FUTURE PERFORMANCE.
This performance information is provided to illustrate the historical volatility of asset-backed securities, which represented the primary component of Short-Duration Collateral Funds portfolio and which also represents a material portion of Debt Opportunities Funds portfolio.
The bar chart below shows changes in Short-Duration Collateral Funds annual total returns from year to year for the periods indicated. Performance information reflects Short-Duration Collateral Funds annual operating expenses (which were approximately 0.00% in most periods), which were substantially lower than those of Debt Opportunities Fund. Purchase premiums and redemption fees are not reflected in the bar chart.
Annual Total Returns
Years Ending December 31
Highest Quarter: 9.78% (2Q2009)
Lowest Quarter: 15.22% (4Q2008)
198
[SUPPLEMENTAL PERFORMANCE AND VOLATILITY INFORMATION FOR BENCHMARK-FREE ALLOCATION FUND AND SGM MAJOR MARKETS FUND TO BE UPDATED BY AMENDMENT]
199
The following chart identifies the ticker, news-media symbol, and CUSIP number for each share class of each Fund currently being offered (if any).
Fund Name (and page # in Prospectus) |
Share Class | Ticker | Symbol | CUSIP | ||||
Multi-Asset Class Funds |
||||||||
Benchmark-Free Allocation Fund (p. [ ]) |
Class III | GBMFX | N/A | 362008 31 0 | ||||
Class IV | GBMBX | N/A | 362014 60 7 | |||||
Class MF | | | 362014 80 5 | |||||
Global Asset Allocation Fund (p. [ ]) |
Class III | GMWAX | N/A | 362007 17 1 | ||||
Absolute Return Fund |
||||||||
SGM Major Markets Fund (p. [ ]) |
Class III | | | | ||||
Class IV | | | | |||||
Class V | | | | |||||
Class VI | | | | |||||
Equity Funds |
||||||||
Global Equity Funds |
||||||||
Global Equity Allocation Fund (p. [ ]) |
Class III | GMGEX | N/A | 362007 14 8 | ||||
Global Developed Equity Allocation Fund (p. [ ]) |
Class III | GWOAX | N/A | 362008 15 3 | ||||
Developed World Stock Fund (p. [ ]) |
Class III | GDWTX | DevWldStk | 362013 20 3 | ||||
Class IV | GDWFX | DevWldStk | 362013 30 2 | |||||
Quality Fund (p. [ ]) |
Class III | GQETX | Quality | 362008 26 0 | ||||
Class IV | GQEFX | Quality | 362008 24 5 | |||||
Class V | GQLFX | Quality | 362008 23 7 | |||||
Class VI | GQLOX | Quality | 362008 22 9 | |||||
Resources Fund (p. [ ]) |
Class III | GOFIX | N/A | 362014 10 2 | ||||
Class IV | GOVIX | N/A | 362014 20 1 | |||||
Class V | | | 362014 30 0 | |||||
Class VI | | | 362014 40 9 | |||||
International Equity Funds |
||||||||
International Equity Allocation Fund (p. [ ]) |
Class III | GIEAX | N/A | 362007 21 3 | ||||
International Developed Equity Allocation Fund (p. [ ]) |
Class III | GIOTX | N/A | 362013 45 0 | ||||
Tax-Managed International Equities Fund (p. [ ]) |
Class III | GTMIX | TxMngIntEq | 362008 66 6 | ||||
International Equity Fund (p. [ ]) |
Class II | GMICX | IntlIntrVal | 362007 20 5 | ||||
Class III | GMOIX | IntlIntrVal | 362007 30 4 | |||||
Class IV | GMCFX | IntlIntrVal | 362008 83 1 | |||||
International Large/Mid Cap Equity Fund (p. [ ]) |
Class III | GMIEX | IntlCoreEq | 362013 69 0 | ||||
Class IV | GMIRX | IntlCoreEq | 362013 68 2 | |||||
Class VI | GCEFX | IntlCoreEq | 362013 66 6 | |||||
Foreign Fund (p. [ ]) |
Class II | GMFRX | Foreign | 362007 56 9 | ||||
Class III | GMOFX | Foreign | 362007 55 1 | |||||
Class IV | GMFFX | Foreign | 362008 82 3 | |||||
Foreign Small Companies Fund (p. [ ]) |
Class III | GMFSX | ForSmCos | 362008 61 7 | ||||
Class IV | GFSFX | ForSmCos | 362008 34 4 | |||||
International Small Companies Fund (p. [ ]) |
Class III | GMISX | IntSmCos | 362007 52 8 | ||||
U.S. Equity Fund |
||||||||
U.S. Equity Allocation Fund (p. [ ]) |
Class III | GMUEX | USCoreEq | 362013 65 8 | ||||
Class IV | GMRTX | USCoreEq | 362013 64 1 | |||||
Class V | GMEQX | USCoreEq | 362013 63 3 | |||||
Class VI | GMCQX | USCoreEq | 362013 62 5 | |||||
Emerging Markets Equity Funds |
||||||||
Emerging Markets Fund (p. [ ]) |
Class II | GMEMX | EmergMkt | 362007 50 2 | ||||
Class III | GMOEX | EmergMkt | 362007 60 1 | |||||
Class IV | GMEFX | EmergMkt | 362008 79 9 | |||||
Class V | GEMVX | GMOEmgMktsV | 362008 28 6 | |||||
Class VI | GEMMX | EmergMkt | 362008 27 8 | |||||
Emerging Countries Fund (p. [ ]) |
Class III | GMCEX | EmergCntr | 362008 85 6 | ||||
Emerging Domestic Opportunities Fund (p. [ ]) |
Class II | GEDTX | N/A | 362013 22 9 | ||||
Class III | GEDSX | N/A | 362013 21 1 | |||||
Class IV | GEDIX | N/A | 362013 19 5 | |||||
Class V | GEDOX | N/A | 362013 18 7 | |||||
Class VI | GEDFX | N/A | 362013 17 9 | |||||
Fixed Income Funds |
||||||||
Global Bond Fund (p. [ ]) |
Class III | GMGBX | GlobalBd | 362007 31 2 | ||||
Currency Hedged International Bond Fund (p. [ ]) |
Class III | GMHBX | CurHgIntBd | 362007 34 6 | ||||
Core Plus Bond Fund (p. [ ]) |
Class III | GUGAX | CorePlusBd | 362008 60 9 | ||||
Class IV | GPBFX | CorePlusBd | 362008 12 0 | |||||
Emerging Country Debt Fund (p. [ ]) |
Class III | GMCDX | EmgCntrDt | 362007 27 0 | ||||
Class IV | GMDFX | EmgCntrDt | 362008 78 1 |
200
Fund Name (and page # in Prospectus) |
Share Class | Ticker | Symbol | CUSIP | ||||
Debt Opportunities Fund (p. [ ]) |
Class III | | | 362013 12 0 | ||||
Class VI | GMODX | N/A | 362013 11 2 | |||||
Implementation Funds |
||||||||
Alpha Only Fund (p. [ ]) |
Class III | GGHEX | N/A | 362007 44 5 | ||||
Class IV | GAPOX | N/A | 362013 48 4 | |||||
Asset Allocation Bond Fund (p. [ ]) |
Class III | GMOBX | AssetAllBd | 362013 38 5 | ||||
Class VI | GABFX | AssetAllBd | 362013 37 7 | |||||
Benchmark-Free Fund (p. [ ]) |
Class III | | N/A | 362013 16 1 | ||||
Implementation Fund (p. [ ]) |
N/A | | N/A | 362014 50 8 | ||||
Risk Premium Fund (p. [ ]) |
Class III | GMRPX | N/A | 362014 83 9 | ||||
Class IV | GMRVX | N/A | 362014 82 1 | |||||
Class V | | | 362014 81 3 | |||||
Class VI | GMOKX | N/A | 362014 79 7 | |||||
Special Opportunities Fund (p. [ ]) |
Class III | | | 362014 75 5 | ||||
Class IV | | N/A | 362014 74 8 | |||||
Class V | | | 362014 73 0 | |||||
Class VI | GSOFX | | 362014 72 2 | |||||
Strategic Opportunities Allocation Fund (p. [ ]) |
Class III | GBATX | N/A | 362008 16 1 | ||||
Taiwan Fund (p. [ ]) |
Class III | GMOTX | Taiwan | 362013 26 0 | ||||
U.S. Treasury Fund (p. [ ]) |
N/A | GUSTX | USTreas | 362013 36 9 |
201
GMO TRUST
Each Funds annual and semiannual reports to shareholders contain additional information about the Funds investments. Each Funds annual report contains a discussion of the market conditions and investment strategies that significantly affected the Funds performance during its last fiscal year. The Funds annual and semiannual reports, and the Funds SAI, are available free of charge at http://www.gmo.com or by writing to Shareholder Services at GMO, 40 Rowes Wharf, Boston, Massachusetts 02110 or by calling collect at 1-617-346-7646. The SAI contains more detailed information about each Fund and is incorporated by reference into this Prospectus, which means that it is legally considered to be part of this Prospectus.
You can review and copy the Prospectus, SAI, and reports at the SECs Public Reference Room in Washington, D.C. Information regarding the operation of the Public Reference Room may be obtained by calling the SEC at 1-202-551-8090. Reports and other information about the Funds are available on the EDGAR database on the SECs Internet site at http://www.sec.gov. Copies of this information may be obtained, upon payment of a duplicating fee, by electronic request at the following e-mail address: publicinfo@sec.gov, or by writing the Public Reference Section of the SEC, Washington, D.C. 20549-1520.
Shareholders who wish to communicate with the Trustees must do so by mailing a written communication, addressed as follows: To the Attention of the Board of Trustees, c/o GMO Trust Chief Compliance Officer, 40 Rowes Wharf, Boston, Massachusetts 02110. The shareholder communication must (i) be in writing and be signed by the shareholder, (ii) identify the Fund to which it relates, and (iii) identify the class and number of shares held beneficially or of record by the shareholder.
Shareholders may request additional
information from and direct inquiries to:
Shareholder Services at
Grantham, Mayo, Van Otterloo & Co. LLC
40 Rowes Wharf, Boston, Massachusetts 02110
1-617-346-7646 (call collect)
1-617-439-4192 (fax)
SHS@GMO.com
website: http://www.gmo.com
Funds Distributor, LLC
3 Canal Plaza
Suite 100
Portland, Maine 04101
Investment Company Act File No. 811-04347
GMO TRUST
STATEMENT OF ADDITIONAL INFORMATION
June 30, 2016
Multi-Asset Class Funds
Benchmark-Free Allocation Fund Class III: GBMFX Class IV: GBMBX Class MF:
Global Asset Allocation Fund Class III: GMWAX
Absolute Return Fund
SGM Major Markets Fund Class III: Class IV: Class V: Class VI:
Equity Funds
Global Equity Funds
Global Equity Allocation Fund Class III: GMGEX
Global Developed Equity Allocation Fund Class III: GWOAX
Developed World Stock Fund Class III: GDWTX Class IV: GDWFX
Quality Fund Class III: GQETX Class IV: GQEFX Class V: GQLFX Class VI: GQLOX
Resources Fund Class III: GOFIX Class IV: GOVIX Class V: Class VI: |
Equity Funds (continued)
International Equity Funds
International Equity Allocation Fund Class III: GIEAX
International Developed Equity Allocation Fund Class III: GIOTX
Tax-Managed International Equities Fund Class III: GTMIX
International Equity Fund Class II: GMICX Class III: GMOIX Class IV: GMCFX
International Large/Mid Cap Equity Fund Class III: GMIEX Class IV: GMIRX Class VI: GCEFX
Foreign Fund Class II: GMFRX Class III: GMOFX Class IV: GMFFX
Foreign Small Companies Fund Class III: GMFSX Class IV: GFSFX
International Small Companies Fund Class III: GMISX
U.S. Equity Fund
U.S. Equity Allocation Fund Class III: GMUEX Class IV: GMRTX Class V: GMEQX Class VI: GMCQX |
Equity Funds (continued)
Emerging Market Equity Funds
Emerging Markets Fund Class II: GMEMX Class III: GMOEX Class IV: GMEFX Class V: GEMVX Class VI: GEMMX
Emerging Countries Fund Class III: GMCEX
Emerging Domestic Opportunities Fund Class II: GEDTX Class III: GEDSX Class IV: GEDIX Class V: GEDOX Class VI: GEDFX
Fixed Income Funds
Global Bond Fund Class III: GMGBX
Currency Hedged International Bond Fund Class III: GMHBX
Core Plus Bond Fund Class III: GUGAX Class IV: GPBFX
Emerging Country Debt Fund Class III: GMCDX Class IV: GMDFX
Debt Opportunities Fund Class III: Class VI: GMODX |
Implementation Funds
Alpha Only Fund Class III: GGHEX Class IV: GAPOX
Asset Allocation Bond Fund Class III: GMOBX Class VI: GABFX
Benchmark-Free Fund Class III:
Implementation Fund Ticker:
Risk Premium Fund Class III: GMRPX Class IV: GMRVX Class V: Class VI: GMOKX
Special Opportunities Fund Class III: Class IV: Class V: Class VI: GSOFX
Strategic Opportunities Allocation Fund Class III: GBATX
Taiwan Fund Class III: GMOTX
U.S. Treasury Fund Ticker: GUSTX |
This Statement of Additional Information (SAI) is not a prospectus. It relates to the GMO Trust Prospectus for each series of GMO Trust (the Trust) set forth above, dated June 30, 2016, as amended and revised from time to time (the Prospectus), and should be read in conjunction therewith. Information from the Prospectus relating to the series of GMO Trust set forth above (each a Fund, and collectively, the Funds, and together with other series of the Trust not offered in the Prospectus, each a GMO Fund, and collectively, the GMO Funds) and the Trusts audited financial statements, financial highlights, and report of the independent registered public accounting firm of the Funds, which are included in the annual report to shareholders of each Fund, are incorporated by reference into this SAI. The Prospectus and the annual report to shareholders of each Fund may be obtained free of charge from GMO Trust, 40 Rowes Wharf, Boston, Massachusetts 02110, or by calling the Trust collect at 1-617-346-7646.
Grantham, Mayo, Van Otterloo & Co. LLC (GMO) is not offering or placing interests in the Funds to or with or otherwise promoting the Funds to any natural or legal persons domiciled or with a registered office in any European Economic Area (EEA) Member State where the Alternative Investment Fund Managers Directive (Directive 2011/61/EU) is in force and effect. GMO, in its discretion, may accept any such investor into a Fund, but only if it is satisfied that, by accepting such investor, it would not be in breach of any law, rule, regulation or other legislative or administrative measure in or otherwise applicable to the relevant EEA Member State and such investor is otherwise eligible under the laws of such EEA Member State to invest in the Fund. None of the Funds, GMO, their respective affiliates, or any natural or legal person acting on their behalf have been registered with, have been approved by, or have made a notification to any EEA Member State, European Union, or other regulatory, governmental, or similar body with respect to the Funds, and no such body has approved, endorsed, reviewed, acquiesced, or taken any similar action with respect to any offering, marketing, or other promotional materials relating to the Funds.
Table of Contents
Page | ||||
1 | ||||
1 | ||||
10 | ||||
69 | ||||
71 | ||||
77 | ||||
82 | ||||
84 | ||||
85 | ||||
85 | ||||
116 | ||||
128 | ||||
147 | ||||
152 | ||||
152 | ||||
156 | ||||
160 | ||||
161 | ||||
161 | ||||
162 | ||||
163 | ||||
A-1 | ||||
B-1 | ||||
C-1 |
-i-
INVESTMENT OBJECTIVES AND POLICIES
The investment objectives and principal strategies of, and risks of investing in, each Fund are described in each Funds Prospectus. Unless otherwise indicated in the Prospectus or this SAI, the investment objectives and policies of the Funds may be changed without shareholder approval.
The charts on the following pages indicate the types of investments that each Fund is generally permitted (but not required) to make. A Fund may, however, make other types of investments, provided the investments are consistent with the Funds investment objective and policies and the Funds investment restrictions do not expressly prohibit it from so doing.
Investors should note that, when used in this SAI, (i) the term invest includes both direct and indirect investing as well as both long and short investing and (ii) the term investments includes both direct and indirect investments as well as both long and short investments. For example, a Fund may invest indirectly in a given asset or asset class by investing in another GMO Fund or a wholly-owned subsidiary or by investing in derivatives and synthetic instruments, and the resulting exposure to the asset or asset class may be long or short. Accordingly, the following charts indicate the types of investments that a Fund is directly or indirectly permitted to make.
1
Multi-Asset Class Funds |
Benchmark-Free
Allocation Fund |
Global Asset
Allocation Fund |
||
U.S. Equity Securities 1 |
X | X | ||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | ||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | ||
Non-U.S. Investments Emerging Countries 2 |
X | X | ||
Securities Lending |
X | X | ||
Depositary Receipts |
X | X | ||
Convertible Securities |
X | X | ||
Preferred Stocks |
X | X | ||
Master Limited Partnerships |
X | X | ||
Income Trusts |
X | X | ||
Warrants and Rights |
X | X | ||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | X | ||
Options, Futures, and Forward Contracts |
X | X | ||
Swap Contracts and Other Two-Party Contracts |
X | X | ||
Foreign Currency Transactions |
X | X | ||
Repurchase Agreements |
X | X | ||
Debt and Other Fixed Income Securities |
X | X | ||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | ||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | ||
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | X | ||
Cash and Other High Quality Investments |
X | X | ||
U.S. Government Securities and Foreign Government Securities |
X | X | ||
Auction Rate Securities |
X | X | ||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | X | ||
Asset-Backed and Related Securities |
X | X | ||
Adjustable Rate Securities |
X | X | ||
Below Investment Grade Securities |
X | X | ||
Distressed or Defaulted Debt Securities |
X | X | ||
Brady Bonds |
X | X | ||
Euro Bonds |
X | X | ||
Zero Coupon Securities |
X | X | ||
Indexed Investments |
X | X | ||
Structured Notes |
X | X | ||
Firm Commitments, When-Issued Securities and TBAs |
X | X | ||
Loans, Loan Participations, and Assignments |
X | X | ||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | ||
Commodity-Related Investments |
X | X | ||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | ||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | ||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | ||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
2
Absolute Return Fund |
SGM Major
Markets Fund |
|
U.S. Equity Securities 1 |
X | |
Non-U.S. Investments Non-U.S. Issuers 2 |
X | |
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | |
Non-U.S. Investments Emerging Countries 2 |
X | |
Securities Lending |
X | |
Depositary Receipts |
X | |
Convertible Securities |
X | |
Preferred Stocks |
X | |
Master Limited Partnerships |
||
Income Trusts |
||
Warrants and Rights |
X | |
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | |
Options, Futures, and Forward Contracts |
X | |
Swap Contracts and Other Two-Party Contracts |
X | |
Foreign Currency Transactions |
X | |
Repurchase Agreements |
X | |
Debt and Other Fixed Income Securities |
X | |
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | |
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | |
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | |
Cash and Other High Quality Investments |
X | |
U.S. Government Securities and Foreign Government Securities |
X | |
Auction Rate Securities |
X | |
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | |
Asset-Backed and Related Securities |
X | |
Adjustable Rate Securities |
X | |
Below Investment Grade Securities |
X | |
Distressed or Defaulted Debt Securities |
X | |
Brady Bonds |
X | |
Euro Bonds |
X | |
Zero Coupon Securities |
X | |
Indexed Investments |
X | |
Structured Notes |
X | |
Firm Commitments, When-Issued Securities and TBAs |
X | |
Loans, Loan Participations, and Assignments |
X | |
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | |
Commodity-Related Investments |
X | |
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | |
Investments in Other Investment Companies or Other Pooled Investments |
X | |
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | |
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
X |
3
Equity Funds
Global Equity Funds |
Global Equity
Allocation Fund |
Global Developed
Equity Allocation Fund |
Developed World
Stock Fund |
Quality
Fund |
Resources
Fund |
|||||
U.S. Equity Securities 1 |
X | X | X | X | X | |||||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | X | X | X | |||||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | X | X | X | |||||
Non-U.S. Investments Emerging Countries 2 |
X | X | X | X | X | |||||
Securities Lending |
X | X | X | X | X | |||||
Depositary Receipts |
X | X | X | X | X | |||||
Convertible Securities |
X | X | X | X | X | |||||
Preferred Stocks |
X | X | X | X | X | |||||
Master Limited Partnerships |
X | X | X | X | ||||||
Income Trusts |
X | X | X | X | X | |||||
Warrants and Rights |
X | X | X | X | X | |||||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | X | X | X | ||||||
Options, Futures, and Forward Contracts |
X | X | X | X | X | |||||
Swap Contracts and Other Two-Party Contracts |
X | X | X | X | X | |||||
Foreign Currency Transactions |
X | X | X | X | X | |||||
Repurchase Agreements |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | X | X | |||||||
Cash and Other High Quality Investments |
X | X | X | X | X | |||||
U.S. Government Securities and Foreign Government Securities |
X | X | X | X | X | |||||
Auction Rate Securities |
X | X | X | |||||||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | X | X | X | X | |||||
Asset-Backed and Related Securities |
X | X | X | |||||||
Adjustable Rate Securities |
X | X | X | |||||||
Below Investment Grade Securities |
X | X | X | [X] | ||||||
Distressed or Defaulted Debt Securities |
X | X | X | |||||||
Brady Bonds |
X | X | X | |||||||
Euro Bonds |
X | X | X | |||||||
Zero Coupon Securities |
X | X | X | |||||||
Indexed Investments |
X | X | X | |||||||
Structured Notes |
X | X | X | X | ||||||
Firm Commitments, When-Issued Securities and TBAs |
X | X | X | |||||||
Loans, Loan Participations, and Assignments |
X | X | X | |||||||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | X | X | X | |||||
Commodity-Related Investments |
X | X | X | X | ||||||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | X | X | X | |||||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | X | X | X | |||||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | X | X | X | |||||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
4
Equity Funds (continued)
International Equity Funds |
International
Equity Allocation Fund |
International
Developed Equity Allocation Fund |
Tax-Managed
International Equities Fund |
International
Equity Fund |
International
Large/Mid Cap Equity Fund |
Foreign
Fund |
Foreign
Small Companies Fund |
International
Small Companies Fund |
||||||||
U.S. Equity Securities 1 |
X | X | X | X | X | X | X | X | ||||||||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | X | X | X | X | X | X | ||||||||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | X | X | X | X | X | X | ||||||||
Non-U.S. Investments Emerging Countries 2 |
X | X | X | X | X | X | X | X | ||||||||
Securities Lending |
X | X | X | X | X | X | X | X | ||||||||
Depositary Receipts |
X | X | X | X | X | X | X | X | ||||||||
Convertible Securities |
X | X | X | X | X | X | X | X | ||||||||
Preferred Stocks |
X | X | X | X | X | X | X | X | ||||||||
Master Limited Partnerships |
X | X | X | X | X | |||||||||||
Income Trusts |
X | X | X | X | X | X | X | X | ||||||||
Warrants and Rights |
X | X | X | X | X | X | X | X | ||||||||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | X | X | X | X | X | X | X | ||||||||
Options, Futures, and Forward Contracts |
X | X | X | X | X | X | X | X | ||||||||
Swap Contracts and Other Two-Party Contracts |
X | X | X | X | X | X | X | X | ||||||||
Foreign Currency Transactions |
X | X | X | X | X | X | X | X | ||||||||
Repurchase Agreements |
X | X | X | X | X | X | ||||||||||
Debt and Other Fixed Income Securities |
X | X | X | X | X | X | ||||||||||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | X | X | X | X | ||||||||||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | X | X | X | X | ||||||||||
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | X | X | X | X | |||||||||||
Cash and Other High Quality Investments |
X | X | X | X | X | X | X | X | ||||||||
U.S. Government Securities and Foreign Government Securities |
X | X | X | X | X | X | X | X | ||||||||
Auction Rate Securities |
X | X | X | X | X | |||||||||||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | X | X | X | X | X | X | X | ||||||||
Asset-Backed and Related Securities |
X | X | X | X | X | |||||||||||
Adjustable Rate Securities |
X | X | X | X | X | |||||||||||
Below Investment Grade Securities |
X | X | X | X | X | |||||||||||
Distressed or Defaulted Debt Securities |
X | X | X | X | X | |||||||||||
Brady Bonds |
X | X | X | X | X | |||||||||||
Euro Bonds |
X | X | X | X | X | |||||||||||
Zero Coupon Securities |
X | X | X | X | X | |||||||||||
Indexed Investments |
X | X | X | X | X | X | X | |||||||||
Structured Notes |
X | X | X | X | X | X | X | X | ||||||||
Firm Commitments, When-Issued Securities and TBAs |
X | X | X | X | X | X | X | |||||||||
Loans, Loan Participations, and Assignments |
X | X | X | X | X | |||||||||||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | X | X | X | X | X | X | ||||||||
Commodity-Related Investments |
X | X | X | X | X | |||||||||||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | X | X | X | X | X | X | ||||||||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | X | X | X | X | X | X | ||||||||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | X | X | X | X | X | X | ||||||||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
5
Equity Funds (continued)
U.S. Equity Fund |
U.S. Equity
Allocation Fund |
|
U.S. Equity Securities 1 |
X | |
Non-U.S. Investments Non-U.S. Issuers 2 |
X | |
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | |
Non-U.S. Investments Emerging Countries 2 |
X | |
Securities Lending |
X | |
Depositary Receipts |
X | |
Convertible Securities |
X | |
Preferred Stocks |
X | |
Master Limited Partnerships |
X | |
Income Trusts |
X | |
Warrants and Rights |
X | |
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | |
Options, Futures, and Forward Contracts |
X | |
Swap Contracts and Other Two-Party Contracts |
X | |
Foreign Currency Transactions |
X | |
Repurchase Agreements |
X | |
Debt and Other Fixed Income Securities |
X | |
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | |
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | |
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | |
Cash and Other High Quality Investments |
X | |
U.S. Government Securities and Foreign Government Securities |
X | |
Auction Rate Securities |
X | |
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | |
Asset-Backed and Related Securities |
X | |
Adjustable Rate Securities |
X | |
Below Investment Grade Securities |
X | |
Distressed or Defaulted Debt Securities |
X | |
Brady Bonds |
X | |
Euro Bonds |
X | |
Zero Coupon Securities |
X | |
Indexed Investments |
X | |
Structured Notes |
X | |
Firm Commitments, When-Issued Securities and TBAs |
X | |
Loans, Loan Participations, and Assignments |
X | |
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | |
Commodity-Related Investments |
X | |
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | |
Investments in Other Investment Companies or Other Pooled Investments |
X | |
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | |
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
6
Equity Funds (continued)
Emerging Markets Equity Funds |
Emerging Markets
Fund |
Emerging Countries
Fund |
Emerging Domestic
Opportunities Fund |
|||
U.S. Equity Securities 1 |
X | X | X | |||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | X | |||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | X | |||
Non-U.S. Investments Emerging Countries 2 |
X | X | X | |||
Securities Lending |
X | X | X | |||
Depositary Receipts |
X | X | X | |||
Convertible Securities |
X | X | X | |||
Preferred Stocks |
X | X | X | |||
Master Limited Partnerships |
||||||
Income Trusts |
X | X | X | |||
Warrants and Rights |
X | X | X | |||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | X | X | |||
Options, Futures, and Forward Contracts |
X | X | X | |||
Swap Contracts and Other Two-Party Contracts |
X | X | X | |||
Foreign Currency Transactions |
X | X | X | |||
Repurchase Agreements |
X | X | X | |||
Debt and Other Fixed Income Securities |
X | X | X | |||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | X | |||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | X | |||
Debt and Other Fixed Income Securities Municipal Securities 4 |
||||||
Cash and Other High Quality Investments |
X | X | X | |||
U.S. Government Securities and Foreign Government Securities |
X | X | X | |||
Auction Rate Securities |
||||||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | X | X | |||
Asset-Backed and Related Securities |
||||||
Adjustable Rate Securities |
||||||
Below Investment Grade Securities |
X | X | X | |||
Distressed or Defaulted Debt Securities |
||||||
Brady Bonds |
||||||
Euro Bonds |
||||||
Zero Coupon Securities |
||||||
Indexed Investments |
X | X | X | |||
Structured Notes |
X | X | X | |||
Firm Commitments, When-Issued Securities and TBAs |
X | X | X | |||
Loans, Loan Participations, and Assignments |
||||||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | X | |||
Commodity-Related Investments |
||||||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | X | |||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | X | |||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | X | |||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
7
Fixed Income Funds |
Global Bond
Fund |
Currency
Hedged International Bond Fund |
Core Plus
Bond Fund |
Emerging
Country Debt Fund |
Debt
Opportunities Fund |
|||||
U.S. Equity Securities 1 |
X | X | X | X | X | |||||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | X | X | X | |||||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | X | X | X | |||||
Non-U.S. Investments Emerging Countries 2 |
X | X | X | X | X | |||||
Securities Lending |
X | X | X | X | X | |||||
Depositary Receipts |
X | X | X | X | X | |||||
Convertible Securities |
X | X | X | X | X | |||||
Preferred Stocks |
X | X | X | X | X | |||||
Master Limited Partnerships |
||||||||||
Income Trusts |
||||||||||
Warrants and Rights |
X | X | X | X | X | |||||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | |||||||||
Options, Futures, and Forward Contracts |
X | X | X | X | X | |||||
Swap Contracts and Other Two-Party Contracts |
X | X | X | X | X | |||||
Foreign Currency Transactions |
X | X | X | X | X | |||||
Repurchase Agreements |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | X | X | X | |||||
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | X | X | X | X | |||||
Cash and Other High Quality Investments |
X | X | X | X | X | |||||
U.S. Government Securities and Foreign Government Securities |
X | X | X | X | X | |||||
Auction Rate Securities |
X | X | X | X | X | |||||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
||||||||||
Asset-Backed and Related Securities |
X | X | X | X | X | |||||
Adjustable Rate Securities |
X | X | X | X | X | |||||
Below Investment Grade Securities |
X | X | X | X | X | |||||
Distressed or Defaulted Debt Securities |
X | X | X | X | X | |||||
Brady Bonds |
X | X | X | X | X | |||||
Euro Bonds |
X | X | X | X | X | |||||
Zero Coupon Securities |
X | X | X | X | X | |||||
Indexed Investments |
X | X | X | X | X | |||||
Structured Notes |
X | X | X | X | X | |||||
Firm Commitments, When-Issued Securities and TBAs |
X | X | X | X | X | |||||
Loans, Loan Participations, and Assignments |
X | X | X | X | X | |||||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | X | X | X | |||||
Commodity-Related Investments |
X | |||||||||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | X | X | X | |||||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | X | X | X | |||||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | X | X | X | |||||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
8
Implementation Funds |
Alpha
Only Fund |
Asset
Allocation Bond Fund |
Benchmark-
Free Fund |
Implementation
Fund |
Risk
Premium Fund |
Special
Opportunities Fund |
Strategic
Opportunities Allocation Fund |
Taiwan
Fund |
U.S.
Treasury Fund |
|||||||||
U.S. Equity Securities 1 |
X | X | X | X | X | X | X | X | ||||||||||
Non-U.S. Investments Non-U.S. Issuers 2 |
X | X | X | X | X | X | X | X | ||||||||||
Non-U.S. Investments Non-U.S. Issuers (Traded on U.S. Exchanges) 2 |
X | X | X | X | X | X | X | X | ||||||||||
Non-U.S. Investments Emerging Countries 2 |
X | X | X | X | X | X | X | X | ||||||||||
Securities Lending |
X | X | X | X | X | X | X | X | ||||||||||
Depositary Receipts |
X | X | X | X | X | X | X | X | ||||||||||
Convertible Securities |
X | X | X | X | X | X | X | X | ||||||||||
Preferred Stocks |
X | X | X | X | X | X | X | X | ||||||||||
Master Limited Partnerships |
X | X | X | X | X | X | ||||||||||||
Income Trusts |
X | X | X | X | X | X | X | |||||||||||
Warrants and Rights |
X | X | X | X | X | X | X | X | X | |||||||||
Non-Standard Warrants (GDP Warrants, LEPOs, and P-Notes) |
X | X | X | X | X | X | X | |||||||||||
Options, Futures, and Forward Contracts |
X | X | X | X | X | X | X | X | X | |||||||||
Swap Contracts and Other Two-Party Contracts |
X | X | X | X | X | X | X | X | X | |||||||||
Foreign Currency Transactions |
X | X | X | X | X | X | X | X | ||||||||||
Repurchase Agreements |
X | X | X | X | X | X | X | X | X | |||||||||
Debt and Other Fixed Income Securities |
X | X | X | X | X | X | X | X | X | |||||||||
Debt and Other Fixed Income Securities Long- and Medium-Term Corporate & Government Bonds 3 |
X | X | X | X | X | X | X | X | ||||||||||
Debt and Other Fixed Income Securities Short-Term Corporate & Government Bonds 3 |
X | X | X | X | X | X | X | X | X | |||||||||
Debt and Other Fixed Income Securities Municipal Securities 4 |
X | X | X | X | X | X | X | |||||||||||
Cash and Other High Quality Investments |
X | X | X | X | X | X | X | X | X | |||||||||
U.S. Government Securities and Foreign Government Securities |
X | X | X | X | X | X | X | X | X 6 | |||||||||
Auction Rate Securities |
X | X | X | X | X | X | X | |||||||||||
Real Estate Investment Trusts and Other Real Estate-Related Investments |
X | X | X | X | X | X | X | X | ||||||||||
Asset-Backed and Related Securities |
X | X | X | X | X | X | X | |||||||||||
Adjustable Rate Securities |
X | X | X | X | X | X | X | |||||||||||
Below Investment Grade Securities |
X | X | X | X | X | X | X | X | ||||||||||
Distressed or Defaulted Debt Securities |
X | X | X | X | X | X | X | |||||||||||
Brady Bonds |
X | X | X | X | X | X | X | |||||||||||
Euro Bonds |
X | X | X | X | X | X | X | |||||||||||
Zero Coupon Securities |
X | X | X | X | X | X | X | |||||||||||
Indexed Investments |
X | X | X | X | X | X | X | X | ||||||||||
Structured Notes |
X | X | X | X | X | X | X | X | X | |||||||||
Firm Commitments, When-Issued Securities and TBAs |
X | X | X | X | X | X | X | X | ||||||||||
Loans, Loan Participations, and Assignments |
X | X | X | X | X | X | X | |||||||||||
Reverse Repurchase Agreements and Dollar Roll Agreements |
X | X | X | X | X | X | X | X | X | |||||||||
Commodity-Related Investments |
X | X | X | X | X | X | ||||||||||||
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities |
X | X | X | X | X | X | X | X | X 7 | |||||||||
Investments in Other Investment Companies or Other Pooled Investments |
X | X | X | X | X | X | X | X | X | |||||||||
Investments in Other Investment Companies Shares of Other GMO Trust Funds |
X | X | X | X | X | X | X | X | ||||||||||
Investments in Subsidiary Companies Shares of Wholly-Owned Subsidiary 5 |
X | X | X |
9
Footnotes to Fund Investments Charts
1 | For more information, see, among other sections, Description of Principal Risks Market Risk Equities in the Prospectus. |
2 | For more information, see, among other sections, Description of Principal Risks Non-U.S. Investment Risk in the Prospectus and Descriptions and Risks of Fund Investments Risks of Non-U.S. Investments herein. |
3 | For more information, see, among other sections, Descriptions and Risks of Fund Investments U.S. Government Securities and Foreign Government Securities herein. |
4 | For more information, see, among other sections, Descriptions and Risks of Fund Investments Municipal Securities herein. |
5 | For more information, see, among other sections, Descriptions and Risks of Fund Investments Investments in Wholly-Owned Subsidiaries herein. |
6 | U.S. Treasury Fund is not generally permitted to invest in Foreign Government Securities. |
7 | U.S. Treasury Fund is not generally permitted to invest in Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities. |
( Note : Some of the footnotes to the above charts refer investors to various risks described in the Description of Principal Risks section of the Prospectus for more information relating to a particular type of investment listed in the charts. The presence of such a risk cross-reference for a particular Fund investment is not intended to indicate that such risk is a principal risk of that Fund, and instead is intended to provide more information regarding the risks associated with the particular investment. Please refer to the Fund Summaries and Description of Principal Risks sections of the Prospectus for a description of each Funds principal risks.)
DESCRIPTIONS AND RISKS OF FUND INVESTMENTS
The following is a description of investment practices in which the Funds may engage and the risks associated with their use. Benchmark-Free Allocation Fund, Benchmark-Free Fund, Global Asset Allocation Fund, Global Developed Equity Allocation Fund, Global Equity Allocation Fund, International Developed Equity Allocation Fund, International Equity Allocation Fund, and Strategic Opportunities Allocation Fund (collectively, the Asset Allocation Funds), as well as Implementation Fund, SGM Major Markets Fund, Special Opportunities Fund and other Funds that may invest in wholly-owned subsidiaries, other GMO Funds, or other investment companies (such other GMO Funds and other investment companies, Underlying Funds), as noted in the Prospectus or in Fund Investments above, are indirectly exposed to the investment practices of the subsidiaries and Underlying Funds in which they invest, and are therefore subject to all risks associated with the practices of the subsidiaries and Underlying Funds. UNLESS OTHERWISE NOTED HEREIN, THE INVESTMENT PRACTICES AND ASSOCIATED RISKS DETAILED BELOW ALSO INCLUDE THOSE TO WHICH A FUND INDIRECTLY MAY BE EXPOSED THROUGH ITS INVESTMENT IN SUBSIDIARIES AND THE UNDERLYING FUNDS. ANY REFERENCES TO INVESTMENTS MADE BY A FUND INCLUDE THOSE THAT MAY BE MADE BOTH DIRECTLY BY THE FUND AND INDIRECTLY BY THE FUND (E.G., THROUGH ITS INVESTMENTS IN SUBSIDIARIES AND THE UNDERLYING FUNDS OR THROUGH ITS INVESTMENTS IN DERIVATIVES OR SYNTHETIC INSTRUMENTS). Not all Funds may engage in all practices described below. Please refer to Fund Summaries in the Prospectus and Fund Investments above for additional information regarding the practices in which a particular Fund may engage.
10
Portfolio Turnover
Based on GMOs assessment of market conditions, GMO may trade a Funds investments more frequently at some times than at others, resulting in a higher portfolio turnover rate. Increased portfolio turnover involves correspondingly greater brokerage commissions and other transaction costs, which will be borne directly by a Fund and which may adversely affect the Funds performance. It also may give rise to additional taxable income for shareholders, including through the realization of capital gains or other types of income that are taxable to Fund shareholders when distributed by a Fund to them, unless those shareholders are themselves exempt from taxation or otherwise investing in the Fund through a tax-advantaged account. If portfolio turnover results in the recognition of short-term capital gains, those gains typically are taxed to shareholders at ordinary income tax rates when distributed to shareholders. The after-tax impact of portfolio turnover is not considered when making investment decisions for a Fund, except for Tax-Managed International Equities Fund. See Distributions and Taxes in the Prospectus and Distributions and Taxes below for more information.
The historical portfolio turnover rate for each Fund is shown under the heading Financial Highlights in the Funds Prospectus. The portfolio turnover rate includes transactions in U.S. Treasury Fund, which the Funds use as a short-term cash management vehicle, and, for each of Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund, accounts of each Funds respective wholly-owned subsidiary. Excluding transactions in U.S. Treasury Fund, each Funds portfolio turnover rate (excluding short-term investments) would be lower. [Changes in portfolio turnover rates were generally the result of active trading strategies employed by such Funds portfolio manager(s) in response to market conditions, and not reflective of a material change in investment strategy.] [To be updated by amendment.]
Diversified and Non-Diversified Portfolios
As set forth in Investment Restrictions below, Funds that are diversified funds are required to satisfy the diversified fund requirements under the Investment Company Act of 1940, as amended (the 1940 Act). At least 75% of the value of a diversified funds total assets must be represented by cash and cash items (including receivables), government securities, securities of other investment companies, and other securities that for the purposes of this calculation are limited in respect of any one issuer to not greater than 5% of the value of the funds total assets and not more than 10% of the outstanding voting securities of any single issuer.
As stated in the Prospectus, Funds that are non-diversified funds under the 1940 Act are not required to satisfy the requirements for diversified funds. A non-diversified Fund is permitted (but is not required) to invest a higher percentage of its assets in the securities of fewer issuers. That concentration could increase the risk of loss to a Fund resulting from a decline in the market value of particular portfolio securities. Investment in a non-diversified fund may entail greater risks than investment in a diversified fund.
All Funds, whether diversified or non-diversified, must meet diversification standards to qualify as a regulated investment company under the Internal Revenue Code of 1986, as amended (the Code). See the Taxes section for a description of these diversification standards.
11
Accelerated Transactions
For a Fund to take advantage of certain available investment opportunities, GMO may need to make investment decisions on an expedited basis. In such cases, the information available to GMO at the time of an investment decision may be limited. GMO may not, therefore, have access to the detailed information necessary for a full analysis and evaluation of the investment opportunity.
Risks of Non-U.S. Investments
General . Investment in non-U.S. issuers or securities principally traded outside the United States may involve special risks due to non-U.S. economic, political, and legal developments, including favorable or unfavorable changes in currency exchange rates, exchange control regulations (including currency blockage), expropriation, nationalization or confiscatory taxation of assets, other government involvement in the economy or in the affairs of specific companies or industries (including in the case of wholly or partially state-owned enterprises) and possible difficulty in obtaining and enforcing judgments against non-U.S. entities. A Fund may be subject to non-U.S. taxes, including potentially on a retroactive basis, on (i) capital gains it realizes or dividends, interest or other amounts it realizes or accrues in respect of non-U.S. investments; (ii) transactions in those investments; and (iii) repatriation of proceeds generated from the sale or other disposition of those investments. Any taxes or other charges paid or incurred by a Fund in respect of its non-U.S. investments will reduce its return thereon. A Fund may seek a refund in respect of taxes paid to a foreign country. In those cases, all or a portion of those taxes could ultimately be recovered by a Fund. However, the recovery process could take several years and the Fund will incur expenses in its efforts to collect the refund, which will reduce the benefit of any recovery. A Funds efforts to collect a refund may not be successful, in which case the Fund will have incurred additional expenses for no economic benefit. A Funds decision to seek a refund is in its sole discretion, and it may decide not to seek a refund, even if eligible. The outcome of a Funds efforts to obtain a refund is not predictable, and some refunds may not be reflected in a Funds net asset value. See the Taxes section for more information about other special tax considerations applicable to non-U.S. investments. In addition, for information on possible Australian or Singapore tax consequences of an investment in SGM Major Markets Fund or Emerging Domestic Opportunities Fund, respectively, see Distributions and Taxes in the Funds Prospectus.
In addition, the tax laws of some non-U.S. jurisdictions in which a Fund may invest are unclear and interpretations of such laws can change over time, including on a retroactive basis in which case a Fund could potentially incur non-U.S. taxes on a retroactive basis. Moreover, in order to comply with guidance related to the accounting and disclosure of uncertain tax positions under U.S. generally accepted accounting principles (GAAP), a Fund may be required to accrue for book purposes certain non-U.S. taxes in respect of its non-U.S. securities or other non-U.S. investments that it may or may not ultimately pay. Such tax accruals will reduce a Funds net asset value at the time accrued, even though, in some cases, the Fund ultimately will not pay the related tax liabilities. Conversely, a Funds net asset value will be increased by any tax accruals that are ultimately reversed.
12
Issuers of non-U.S. securities are subject to different, often less comprehensive, accounting, custody, reporting, and disclosure requirements than U.S. issuers. The securities of some foreign governments, companies, and securities markets are less liquid, and at times more volatile, than comparable U.S. securities and securities markets. Non-U.S. brokerage commissions and related fees also are generally higher than in the United States. Funds that invest in non-U.S. securities also may be affected by different custody and/or settlement practices or delayed settlements in some non-U.S. markets. The laws of some foreign countries may limit a Funds ability to invest in securities of certain issuers located in those countries. Foreign countries may have reporting requirements with respect to the ownership of securities, and those reporting requirements may be subject to interpretation or change without prior notice to investors. While the Funds make reasonable efforts to stay informed of foreign reporting requirements relating to the Funds non-U.S. portfolio securities (e.g., through the Funds brokerage contacts, publications of the Investment Company Institute, which is the national association of U.S. investment companies, the Funds custodial network, and, to the extent deemed appropriate by the Funds under the circumstances, local counsel in the relevant foreign country), no assurance can be given that the Funds will satisfy applicable foreign reporting requirements at all times.
Emerging Countries. The risks described above apply to an even greater extent to investments in emerging countries. Taiwan is considered by GMO to be an emerging country. The securities markets of emerging countries are generally smaller, less developed, less liquid, and more volatile than the securities markets of the United States and other developed countries, and disclosure and regulatory standards in many respects are less stringent. In addition, the securities markets of emerging countries are typically subject to a lower level of monitoring and regulation. Government enforcement of existing securities regulations is limited, and any such enforcement may be arbitrary and the results may be difficult to predict. In addition, reporting requirements of emerging countries with respect to the ownership of securities are more likely to be subject to interpretation or changes without prior notice to investors than more developed countries.
Many emerging countries have experienced substantial, and in some periods extremely high, rates of inflation for many years. Inflation and rapid fluctuations in inflation rates have had and may continue to have negative effects on such countries economies and securities markets.
Economies of emerging countries generally are heavily dependent on international trade and, accordingly, have been and may continue to be affected adversely by trade barriers, exchange controls, managed adjustments in relative currency values, and other protectionist measures imposed or negotiated by the countries with which they trade. Economies of emerging countries also have been and may continue to be adversely affected by economic conditions in the countries with which they trade. The economies of emerging countries may be predominantly based on only a few industries or dependent on revenues from particular commodities. In many cases, governments of emerging countries continue to exercise significant control over their economies, and government actions relative to the economy, as well as economic developments generally, may affect the capacity of creditors in those countries to make payments on their debt obligations, regardless of their financial condition.
13
Custodial services are often more expensive and other investment-related costs higher in emerging countries than in developed countries, which could reduce a Funds income from investments in securities or debt instruments of emerging country issuers.
Emerging countries are more likely than developed countries to experience political uncertainty and instability, including the risk of war, terrorism, nationalization, limitations on the removal of funds or other assets, or diplomatic developments that affect U.S. investments in these countries. No assurance can be given that adverse political changes will not cause a Fund to suffer a loss of any or all of its investments (or, in the case of fixed income securities, interest) in emerging countries.
Special Risks of Investing in Asian Securities. In addition to the risks of non-U.S. investments and emerging countries investments described above, investments in Asia are subject to other risks. The economies of Asian countries are at varying levels of development. Markets of countries whose economies are in the early stages of development typically exhibit a high concentration of market capitalization and have less trading volume, lower liquidity, and more volatility than more developed markets. Some Asian countries depend heavily on foreign trade and can be adversely affected by trade barriers, exchange controls, and other measures imposed or negotiated by the countries with which they trade. The economies of some Asian countries are not diversified and are based on only a few commodities or industries. Financial imbalances among various economic sectors, fueled by rising asset prices, strong credit growth, and relatively easy financing conditions in certain economies in Asia may also negatively impact those economies.
Investments in Asia also are susceptible to social, political, legal, and operational risks. Some countries have authoritarian or relatively unstable governments. Certain Asian countries have experienced violence, terrorism, armed conflict, and social instability, which has negatively impacted their economies. Some governments in the region provide less supervision and regulation of their financial markets and in some countries less financial information is available than is typical of more developed markets. Some governments in the region exercise considerable influence on their respective economies and, as a result, companies in the region may be subject to government interference and nationalization. Some Asian countries restrict direct foreign investment in securities markets, and investments in securities traded on those markets may be made, if at all, only indirectly (e.g., through Depositary Receipts, as defined below under Depositary Receipts, derivatives, etc.). For example, Taiwan permits foreign investment only through authorized qualified foreign institutional investors (FINI). For Taiwan Fund, GMO is registered with the Securities and Futures Commission of Taiwan as a FINI and is therefore authorized to invest directly in the Taiwanese securities market, subject to certain limitations including a maximum investment amount. Taiwan Fund is listed as a sub-account under GMOs FINI license and is authorized to invest directly in the Taiwanese securities market. Taiwan Funds ability to continue to invest directly in Taiwan is subject to the risk that GMOs FINI license or the Funds sub-account under GMOs FINI license may be terminated or suspended by the Securities and Futures Commission. In addition, the maximum investment amount permitted under GMOs FINI license applies to investments by GMO and any other entities listed as sub-accounts under GMOs license, including Taiwan Fund. Investments by GMO and any other sub-accounts may limit the amount which Taiwan Fund can invest, and the activities of the other entities listed as sub-accounts could cause the termination or suspension of GMOs FINI license.
14
Some Asian countries require foreign investors to be registered with local authorities prior to investing in the securities markets and impose limitations on the amount of investments that may be made by foreign investors and the repatriation of the proceeds from investments.
Asian countries periodically experience increases in market volatility and declines in foreign currency exchange rates. Currency fluctuations affect the value of securities because the prices of these securities are generally denominated or quoted in currencies other than the U.S. dollar. Fluctuations in currency exchange rates can also affect a countrys or companys ability to service its debt. The governments of certain Asian countries also maintain their currencies at artificial levels in relation to the U.S. dollar rather than at levels determined by the market, which may have an adverse impact on foreign investors.
Investment in particular Asian countries is subject to unique risks, yet the political and economic prospects of one country or group of countries can affect other countries in the region. For example, the economies of some Asian countries are directly affected by Japanese capital investment in the region and by Japanese consumer demands. In addition, a recession, debt crisis, or decline in currency valuation in one Asian country may spread to other Asian countries. The economies of Asian countries are also vulnerable to effects of natural disasters occurring within the region, including droughts, floods, tsunamis, and earthquakes. Disaster recovery in Asia can be poorly coordinated, and the economic impact of natural disasters is significant at both the country and company levels.
Special Risks of Investing in Russian Securities . Certain of the Funds may invest directly in the securities of Russian issuers. Certain other Funds may have indirect exposure to Russian securities through their investment in one or more of the GMO Funds with direct investments in Russia. Investment in those securities presents many of the same risks as investing in the securities of emerging country issuers, as described in the preceding sections.
The social, political, legal, and operational risks of investing in Russian issuers, and of having assets held in custody within Russia, however, may be particularly pronounced relative to investments in more developed countries.
Russias system of share registration and custody creates certain risks of loss (including the risk of total loss) that are not normally associated with investments in other securities markets. The recent formation of the Russian securities markets and the underdeveloped state of Russias banking system subjects settlement, clearing, and registration of securities transactions to significant risks. Prior to 2013, there was no central registration system for equity share registration in Russia and registration was carried out by either the issuers themselves or by registrars located throughout Russia. Such registrars were not necessarily subject to effective state supervision, nor were they licensed with any governmental entity, thereby increasing the risk that a Fund could lose ownership of its securities through fraud, negligence, or even mere oversight. With the implementation of the National Settlement Depository (NSD) in Russia as a recognized central securities depository, title to Russian equities is now based on the records of the NSD and not the registrars. Although the implementation of the NSD is generally expected
15
to decrease the risk of loss in connection with recording and transferring title to securities, issues resulting in loss still may occur. In addition, issuers and registrars are still prominent in the validation and approval of documentation requirements for corporate action processing in Russia. Because the documentation requirements and approval criteria vary between registrars and/or issuers, there remain unclear and inconsistent market standards in the Russian market with respect to the completion and submission of corporate action elections. To the extent that a Fund suffers a loss relating to title or corporate actions relating to its portfolio securities, it may be difficult for the Fund to enforce its rights or otherwise remedy the loss.
In addition, as a result of political and military actions undertaken by Russia, the United States and the European Union have instituted sanctions against certain Russian officials and institutions. These sanctions and any additional sanctions or other intergovernmental actions that may be undertaken against Russia in the future may result in the devaluation of Russian currency, a downgrade in the countrys credit rating, and a decline in the value and liquidity of Russian securities. Such actions could result in a freeze of Russian securities, impairing the ability of a Fund to buy, sell, receive, or deliver those securities. Retaliatory action by the Russian government could involve the seizure of U.S. and/or European residents assets, and any such actions are likely to impair the value and liquidity of such assets. Any or all of these potential results could have an adverse/recessionary effect on Russias economy. All of these factors could have a negative effect on the performance of Funds that have significant exposure to Russia.
Securities Lending
A Fund may make secured loans of its portfolio securities amounting to not more than one-third of its total assets (one-quarter in the case of International Equity Fund). For these purposes, total assets include the proceeds of such loans. The risks in lending portfolio securities, as with other extensions of credit, consist of possible delay in recovery of the securities or possible loss of rights in the collateral should the borrower fail financially, including possible impairment of the Funds ability to vote the securities. However, securities loans will be made to brokers that GMO believes to be of relatively high credit standing pursuant to agreements requiring that the loans be collateralized by cash, liquid securities, or shares of other investment companies with a value at least equal to the market value of the loaned securities (marked to market daily). If a loan is collateralized by U.S. government or other securities, the Fund receives a fee from the borrower. If a loan is collateralized by cash, the Fund typically invests the cash collateral for its own account in one or more money market funds (in which case the Fund will bear its pro rata share of such money market funds fees and expenses), or directly in interest-bearing, short-term securities, and typically pays a fee to the borrower that normally represents a portion of the Funds earnings on the collateral. As with other extensions of credit, the Fund bears the risk of delay in the recovery of loaned securities and of loss of rights in the collateral should the borrower fail financially. The Fund also bears the risk that the value of investments made with collateral may decline. The Fund bears the risk of total loss with respect to the investment of collateral.
Voting rights or rights to consent with respect to the loaned securities pass to the borrower. The Fund has the right to call loans at any time on reasonable notice and will do so if both (i) GMO receives adequate notice of a proposal upon which shareholders are being asked to vote, and (ii)
16
GMO believes that the benefits to the Fund of voting on such proposal outweigh the benefits to the Fund of having the security remain out on loan. However, the Fund bears the risk of delay in the return of the security, impairing the Funds ability to vote on such matters. GMO may retain lending agents on behalf of several of the Funds that would be compensated based on a percentage of the Funds return on its securities lending. The Funds also may pay various fees in connection with securities loans, including shipping fees and custodian fees.
Depositary Receipts
Many of the Funds invest in American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs), and European Depositary Receipts (EDRs) or other similar securities representing ownership of non-U.S. securities (collectively, Depositary Receipts) if issues of such Depositary Receipts are available that are consistent with the Funds investment objective. Depositary Receipts generally evidence an ownership interest in a corresponding non-U.S. security on deposit with a financial institution. Transactions in Depositary Receipts usually do not settle in the same currency as the underlying non-U.S. securities are denominated or traded. Generally, ADRs are designed for use in the U.S. securities markets and EDRs are designed for use in European securities markets. GDRs may be traded in any public or private securities market and may represent securities held by institutions located anywhere in the world. GDRs and other types of Depositary Receipts are typically issued by foreign banks or trust companies, although they may be issued by U.S. financial institutions, and evidence ownership interests in a security or pool of securities issued by either a U.S. or foreign corporation.
Because the value of a Depositary Receipt is dependent upon the market price of an underlying non-U.S. security, Depositary Receipts are subject to most of the risks associated with investing in non-U.S. securities directly. Depositary Receipts may be issued as sponsored or unsponsored programs. See Risks of Non-U.S. Investments. Depositary Receipts also may be subject to illiquidity risk.
Convertible Securities
A convertible security is a security (a bond or preferred stock) that may be converted at a stated price within a specified period into a specified number of shares of common stock of the same or a different issuer. Convertible securities are senior to common stock in a corporations capital structure, but are usually subordinated to senior debt obligations of the issuer. Convertible securities provide holders, through their conversion feature, an opportunity to participate in increases in the market prices of their underlying securities. The price of a convertible security is influenced by the market price of the underlying security, and tends to increase as the market price rises and decrease as the market price declines. GMO regards convertible securities as a form of equity security.
The value of a convertible security is a function of its investment value (determined by its yield in comparison with the yields of other securities of comparable maturity and quality that do not have a conversion privilege) and its conversion value (the securitys worth, at market value, if converted into the underlying common stock). The investment value of a convertible security is influenced by changes in interest rates, with investment value declining as interest rates increase and increasing as interest rates decline. The credit standing of the issuer and other
17
factors also may have an effect on the convertible securitys investment value. The conversion value of a convertible security is determined by the market price of the underlying common stock. If the conversion value is low relative to the investment value, as in the case of broken or busted convertibles, the price of the convertible security is governed principally by its investment value. To the extent the market price of the underlying common stock approaches or exceeds the conversion price, the price of the convertible security will be increasingly influenced by its conversion value. A convertible security generally will sell at a premium over its conversion value by the extent to which investors place value on the right to acquire the underlying common stock while holding a fixed income security. Generally, the amount of the premium decreases as the convertible security approaches maturity.
A convertible security may be subject to redemption at the option of the issuer at a price established in the convertible securitys governing instrument. If a convertible security held by a Fund is called for redemption, the Fund will be required to permit the issuer to redeem the security, convert it into the underlying common stock or sell it to a third party.
Preferred Stocks
Preferred stocks include convertible and non-convertible preferred and preference stocks that are senior to common stock. Preferred stocks are equity securities that are senior to common stock with respect to the right to receive dividends and a fixed share of the proceeds resulting from the issuers liquidation. Some preferred stocks also entitle their holders to receive additional liquidation proceeds on the same basis as holders of the issuers common stock, and thus represent an ownership interest in the issuer. Depending on the features of the particular security, holders of preferred stock may bear the risks disclosed in the Prospectus or this SAI regarding equity or fixed income securities.
Investment in preferred stocks involves certain risks. Certain preferred stocks contain provisions that allow an issuer under certain conditions to skip or defer distributions. If a Fund owns a preferred stock that is deferring its distribution, it may be required to report income for tax purposes despite the fact that it is not receiving current income on this position. Preferred stocks often are subject to legal provisions that allow for redemption in the event of certain tax or legal changes or at the issuers call. In the event of redemption, a Fund may not be able to reinvest the proceeds at comparable rates of return. Preferred stocks are subordinated to bonds and other debt securities in an issuers capital structure in terms of priority for corporate income and liquidation payments, and therefore will be subject to greater credit risk than those debt securities. Preferred stocks may trade less frequently and in a more limited volume and may be subject to more abrupt or erratic price movements than many other securities, such as common stocks, corporate debt securities, and U.S. government securities.
Master Limited Partnerships
A master limited partnership (MLP) generally is a publicly traded company organized as a limited partnership or limited liability company and treated as a partnership for U.S. federal income tax purposes. MLPs may derive income and gains from, among other things, the exploration, development, mining or production, processing, refining, transportation (including pipelines transporting gas, oil, or products thereof), or the marketing of any mineral or natural
18
resources. MLPs generally have two classes of owners, the general partner and limited partners. The general partner of an MLP is typically owned by one or more of the following: a major energy company, an investment fund, or the direct management of the MLP. The general partner may be structured as a private or publicly traded corporation or other entity. The general partner typically controls the operations and management of the MLP through an up to 2% equity interest in the MLP plus, in many cases, ownership of common units and subordinated units. Limited partners own the remainder of the partnership through ownership of common units and have a limited role in the partnerships operations and management. For purposes of qualifying as a regulated investment company under the Code, the extent to which a Fund can invest in MLPs is limited. See the Taxes section for more information about these and other special tax considerations that can arise in respect of a Funds investments in MLPs.
MLP securities in which a Fund may invest can include, but are not limited to: (i) equity securities of MLPs, including common units, preferred units or convertible subordinated units; (ii) debt securities of MLPs, including debt securities rated below investment grade; (iii) securities of MLP affiliates; (iv) securities of open-end funds, closed-end funds or exchange-traded funds (ETFs) that invest primarily in MLP securities; or (v) exchange-traded notes whose returns are linked to the returns of MLPs or MLP indices.
The risks of investing in an MLP are generally those inherent in investing in a partnership as opposed to a corporation. For example, state law governing partnerships is often less restrictive than state law governing corporations. Accordingly, there may be fewer protections afforded investors in an MLP than investors in a corporation. Additional risks involved with investing in an MLP are risks associated with the specific industry or industries in which the partnership invests.
Income Trusts
Income trusts are investment trusts that hold income-producing assets and distribute income generated by such assets to the unitholders of the trust, which are entitled to participate in the trusts income and capital as its beneficiaries.
Income trusts generally invest in assets that provide a return to the trust and its unitholders based on the cash flows of an underlying business. Such assets may include equity and debt instruments, royalty interests or real properties. The income trust can receive interest, royalty or lease payments from an operating entity carrying on a business, as well as dividends and a return of capital.
Income trusts also may include royalty trusts, a particular type of income trust whose securities are listed on a stock exchange and which controls an underlying company whose business relates to, without limitation, the acquisition, exploitation, production and sale of oil and natural gas.
Investments in income trusts (including royalty trusts) are subject to operating risk based on the income trusts underlying assets and their respective businesses. Such risks may include lack of or limited operating histories. Income trusts are particularly subject to interest rate risk and increases in interest rates offered by competing investments may diminish the value of trust units. Changes in the interest rate also may affect the value of future distributions from the
19
income trusts underlying assets or the value of the underlying assets themselves. Interest rate risk is also present within the income trusts themselves because they often hold very long-term capital assets, and much of the excess distributable income is derived from a maturity (or duration) mismatch between the life of the asset and the life of the financing associated with it. In an increasing interest rate environment, the income trusts distributions to its unitholders may decrease. Income trusts also may be subject to additional risk, including, without limitation, limited access to debt markets.
Income trusts do not guarantee minimum distributions or returns of capital to unitholders. The amount of distributions paid on a trusts units will vary from time to time based on production levels, commodity prices, royalty rates and certain expenses, deductions and costs, as well as on the distribution payout ratio policy adopted. The reduction or elimination of distributions to unitholders may decrease the value of trust units. Income trusts generally pay out to unitholders the majority of the cash flow that they receive from the production and sale of underlying assets. As a result of distributing the bulk of their cash flow to unitholders, the ability of a trust to finance internal growth is limited. Therefore, income trusts typically grow through acquisition of additional assets, funded through the issuance of additional equity or, where the trust is able, additional debt. Because an income trust may make distributions to unitholders in excess of its net income, unitholder equity may decline over time.
Finally, for purposes of qualifying as a regulated investment company under the Code, the extent to which the Funds can invest in a particular income trust may be limited, depending, for instance, on the trusts treatment for U.S. federal income tax purposes and its underlying assets. See the Taxes section for more information about these and other special tax considerations that can arise in respect of the Funds investments in income trusts, including royalty trusts.
Warrants and Rights
Warrants and rights generally give the holder the right to receive, upon exercise, a security of the issuer at a stated price. Funds typically use warrants and rights in a manner similar to their use of options on securities, as described in Options, Futures, and Forward Contracts below. Risks associated with the use of warrants and rights are generally similar to risks associated with the use of options. Unlike most options, however, warrants and rights are issued in specific amounts, and warrants generally have longer terms than options. Warrants and rights are not likely to be as liquid as exchange-traded options backed by a recognized clearing agency. In addition, the terms of warrants or rights may limit a Funds ability to exercise the warrants or rights at such time, or in such quantities, as the Fund would otherwise wish.
Non-Standard Warrants. From time to time, certain Funds may use non-standard warrants, including GDP warrants, low exercise price warrants or low exercise price options (LEPOs), and participatory notes (P-Notes), to gain exposure to issuers in certain countries. GDP warrants require the issuer (a country) to make payments to the holder that vary based on the issuers gross domestic product or economic growth. LEPOs are different from standard warrants in that they do not give their holders the right to receive a security of the issuer upon exercise. Rather, LEPOs pay the holder the difference in price of the underlying security between the date the LEPO was purchased and the date it is sold. P-Notes are a type of equity-linked derivative that generally are traded over-the-counter and constitute general unsecured
20
contractual obligations of the banks or brokers that issue them. Generally, banks and brokers associated with non-U.S.-based brokerage firms buy securities listed on certain non-U.S. exchanges and then issue P-Notes that are designed to replicate the performance of certain issuers and markets. The performance results of P-Notes will not replicate exactly the performance of the issuers or markets that the notes seek to replicate due to transaction costs and other expenses. The return on a P-Note that is linked to a particular underlying security generally is increased to the extent of any dividends paid in connection with the underlying security. However, the holder of a P-Note typically does not receive voting or other rights as it would if it directly owned the underlying security, and P-Notes present similar risks to investing directly in the underlying security. Additionally, LEPOs and P-Notes entail the same risks as other over-the-counter (OTC) derivatives. These include the risk that the counterparty or issuer of the LEPO or P-Note may not be able to fulfill its obligations, that the holder and counterparty or issuer may disagree as to the meaning or application of contractual terms, or that the instrument may not perform as expected. See Description of Principal Risks Derivatives and Short Sales Risk and Counterparty Risk in the Prospectus and Uses of Derivatives, below. Additionally, while LEPOs or P-Notes may be listed on an exchange, there is no guarantee that a liquid market will exist or that the counterparty or issuer of a LEPO or P-Note will be willing to repurchase such instrument when a Fund wishes to sell it.
Options, Futures, and Forward Contracts
Many of the Funds use options, futures, and forward contracts for various purposes, including for investment purposes and as a means to hedge other investments. See Uses of Derivatives for more information regarding the various derivatives strategies those Funds may employ using options, futures, and forward contracts. The use of options contracts, futures contracts, forward contracts, and options on futures contracts involves risk. Thus, while a Fund may benefit from the use of options, futures, forward contracts, and options on futures, unanticipated changes in interest rates, securities prices, currency exchange rates, or other underlying assets or reference rates may adversely affect a Funds performance.
Options on Securities and Indices. Many of the Funds may purchase and sell put and call options on equity, fixed income, or other securities or indices in standardized exchange-traded contracts. An option on a security or index is a contract that gives the holder of the option, in return for a premium, the right (but not the obligation) to buy from (in the case of a call) or sell to (in the case of a put) the writer of the option the security underlying the option (or the cash value of the index underlying the option) at a specified price. Upon exercise, the writer of an option on a security has the obligation to deliver the underlying security upon payment of the exercise price or to pay the exercise price upon delivery of the underlying security. Upon exercise, the writer of an option on an index is required to pay the difference between the cash value of the index and the exercise price multiplied by the specified multiplier for the index option.
Purchasing Options on Securities and Indices. Among other reasons, a Fund may purchase a put option to hedge against a decline in the value of a portfolio security. If such a decline occurs, the put option will permit the Fund to sell the security at the higher exercise price or to close out the option at a profit. By using put options in this manner, the Fund will reduce any profit it might otherwise have realized in the underlying security by the amount of the premium paid for the put
21
option and by its transaction costs. In order for a put option purchased by a Fund to be profitable, the market price of the underlying security must decline sufficiently below the exercise price to cover the premium paid by the Fund and transaction costs.
Among other reasons, a Fund may purchase call options to hedge against an increase in the price of securities the Fund anticipates purchasing in the future. If such a price increase occurs, a call option will permit the Fund to purchase the securities at the exercise price or to close out the option at a profit. The premium paid for the call option, plus any transaction costs, will reduce the benefit, if any, that the Fund realizes upon exercise of the option and, unless the price of the underlying security rises sufficiently, the option may expire worthless to the Fund. Thus, for a call option purchased by a Fund to be profitable, the market price of the underlying security must rise sufficiently above the exercise price to cover the premium paid by the Fund to the writer and transaction costs.
In the case of both call and put options, the purchaser of an option risks losing the premium paid for the option plus related transaction costs if the option expires worthless.
Writing Options on Securities and Indices. Because a Fund receives a premium for writing a put or call option, a Fund may seek to increase its return by writing call or put options on securities or indices. The premium a Fund receives for writing an option will increase the Funds return in the event the option expires unexercised or is closed out at a profit. The size of the premium a Fund receives reflects, among other things, the relationship of the market price and volatility of the underlying security or index to the exercise price of the option, the remaining term of the option, supply and demand, and interest rates.
A Fund may write a call option on a security or other instrument held by the Fund (commonly known as writing a covered call option). In such case, the Fund limits its opportunity to profit from an increase in the market price of the underlying security above the exercise price of the option. Alternatively, a Fund may write a call option on securities in which it may invest but that are not currently held by the Fund (commonly known as writing a naked call option). During periods of declining securities prices or when prices are stable, writing these types of call options can be a profitable strategy to increase a Funds income with minimal capital risk. However, when securities prices increase, the Fund is exposed to an increased risk of loss, because if the price of the underlying security or instrument exceeds the options exercise price, the Fund will suffer a loss equal to the amount by which the market price exceeds the exercise price at the time the call option is exercised, minus the premium received. Calls written on securities that the Fund does not own are riskier than calls written on securities owned by the Fund because there is no underlying security held by the Fund that can act as a partial hedge. When such a call is exercised, the Fund must purchase the underlying security to meet its call obligation or make a payment equal to the value of its obligation in order to close out the option. Calls written on securities that the Fund does not own have speculative characteristics and the potential for loss is theoretically unlimited. There is also a risk, especially with less liquid preferred and debt securities, that the securities may not be available for purchase.
A Fund also may write a put option on a security. In so doing, the Fund assumes the risk that it may be required to purchase the underlying security for an exercise price higher than its then-current market price, resulting in a loss on exercise equal to the amount by which the market price of the security is below the exercise price minus the premium received.
22
OTC Options . A Fund also may invest in OTC options. OTC options differ from exchange-traded options in that they are two-party contracts, with price and other terms negotiated between the buyer and seller, and generally do not have as much market liquidity as exchange-traded options.
Closing Options Transactions . The holder of an option may terminate its position in a put or call option it has purchased by allowing it to expire or by exercising the option. If an option is American-style, it may be exercised on any day up to its expiration date. In contrast, a European-style option may be exercised only on its expiration date.
In addition, a holder of an option may terminate its obligation prior to the options expiration by effecting an offsetting closing transaction. In the case of exchange-traded options, a Fund, as a holder of an option, may effect an offsetting closing sale transaction by selling an option of the same series as the option previously purchased. A Fund realizes a loss from a closing sale transaction if the premium received from the sale of the option is less than the premium paid to purchase the option (plus transaction costs). Similarly, a Fund that has written an option may effect an offsetting closing purchase transaction by buying an option of the same series as the option previously written. A Fund realizes a loss from a closing purchase transaction if the cost of the closing purchase transaction (option premium plus transaction costs) is greater than the premium received from writing the option. If a Fund desires to sell a security on which it has written a call option, it will effect a closing purchase prior to or concurrently with the sale of the security. There can be no assurance, however, that a closing purchase or sale can be effected when a Fund desires to do so.
Risk Factors in Options Transactions. The market price of an option is affected by many factors, including changes in the market prices or dividend rates of underlying securities (or in the case of indices, the securities in such indices); the time remaining before expiration; changes in interest rates or exchange rates; and changes in the actual or perceived volatility of the relevant stock market and underlying securities. The market price of an option also may be adversely affected if the market for the option becomes less liquid. In addition, since an American-style option allows the holder to exercise its rights any time before the options expiration, the writer of an American-style option has no control over when it will be required to fulfill its obligations as a writer of the option. (The writer of a European-style option is not subject to this risk because the holder may only exercise the option on its expiration date.)
The Funds ability to use options as part of their investment programs depends on the liquidity of the options market. In addition, that market may not exist when a Fund seeks to close out an option position. If a Fund were unable to close out an option that it had purchased on a security, it would have to exercise the option in order to realize any profit or the option may expire worthless. As the writer of a call option on a portfolio security, during the options life, the Fund foregoes the opportunity to profit from increases in the market value of the security underlying the call option above the sum of the premium and the strike price of the call, but retains the risk of loss (net of premiums received) should the price of the underlying security decline. Similarly,
23
as the writer of a call option on a securities index, a Fund foregoes the opportunity to profit from increases in the index over the strike price of the option, though it retains the risk of loss (net of premiums received) should the price of the Funds portfolio securities decline. If a Fund writes a call option and does not hold the underlying security or instrument, the amount of the Funds potential loss is theoretically unlimited.
An exchange-traded option may be closed out by means of an offsetting transaction only on a national securities exchange (Exchange), which provides a secondary market for an option of the same series. If a liquid secondary market for an exchange-traded option does not exist, a Fund might not be able to effect an offsetting closing transaction for a particular option. Reasons for the absence of a liquid secondary market on an Exchange include the following: (i) insufficient trading interest in some options; (ii) restrictions by an Exchange on opening or closing transactions, or both; (iii) trading halts, suspensions, or other restrictions on particular classes or series of options or underlying securities; (iv) unusual or unforeseen interruptions in normal operations on an Exchange; (v) inability to handle current trading volume; or (vi) discontinuance of options trading (or trading in a particular class or series of options) (although outstanding options on an Exchange that were issued by the Options Clearing Corporation should continue to be exercisable in accordance with their terms). In addition, the hours of trading for options on an Exchange may not conform to the hours during which the securities held by a Fund are traded. To the extent that the options markets close before the markets for the underlying securities, significant price and rate movements can take place in the markets for underlying securities that are not immediately reflected in the options markets.
The Exchanges generally have established limits on the maximum number of options an investor or group of investors acting in concert may write. The Funds, GMO, and other funds advised by GMO may constitute such a group. These limits could restrict a Funds ability to purchase or write options on a particular security.
An OTC option may be closed only with the consent of the counterparty, although either party may engage in an offsetting transaction that puts that party in the same economic position as if it had closed out the option with the counterparty; however, the exposure to counterparty risk may differ. No guarantee exists that a Fund will be able to effect a closing purchase or a closing sale with respect to a specific option at any particular time. See Swap Contracts and Other Two-Party Contracts Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts for a discussion of counterparty risk and other risks associated with investing in OTC options.
Currency Options and Quantity-Adjusting ( Quanto ) Options. Certain Funds may purchase and sell options on currencies. Options on currencies possess many of the same characteristics as options on securities and generally operate in a similar manner. Funds that are permitted to invest in securities denominated in foreign currencies may purchase or sell options on currencies. In addition, a Fund may purchase and sell quanto options, which are cash-settled options in which the underlying asset (often an index) is denominated in a currency other than the currency in which the option is settled. See Foreign Currency Transactions for more information on those Funds use of currency options.
24
Futures. To the extent consistent with applicable law and its investment restrictions, a Fund permitted to invest in futures contracts may invest in futures contracts on, among other things, financial instruments (such as a U.S. government security or other fixed income security), individual equity securities (single stock futures), securities indices, interest rates, currencies, inflation indices, and (to the extent a Fund is permitted to invest in commodities and commodity-related derivatives (as defined in Commodity-Related Investments below)) commodities or commodities indices. Futures contracts on securities indices are referred to herein as Index Futures. The purchase of futures contracts can serve as a long hedge, and the sale of futures contracts can serve as a limited short hedge. The purchase and sale of futures contracts also may be used for speculative purposes.
Certain futures contracts are physically settled (i.e., involve the making and taking of delivery of a specified amount of an underlying security or other asset). For instance, the sale of futures contracts on foreign currencies or financial instruments creates an obligation of the seller to deliver a specified quantity of an underlying foreign currency or financial instrument called for in the contract for a stated price at a specified time. Conversely, the purchase of such futures contracts creates an obligation of the purchaser to pay for and take delivery of the underlying foreign currency or financial instrument called for in the contract for a stated price at a specified time. In some cases, the specific instruments delivered or taken, respectively, on the settlement date are not determined until on or near that date. That determination is made in accordance with the rules of the exchange on which the sale or purchase was made.
Some futures contracts are cash settled (rather than physically settled), which means that the purchase price is subtracted from the current market value of the instrument and the net amount, if positive, is paid to the purchaser by the seller of the futures contract and, if negative, is paid by the purchaser to the seller of the futures contract. In particular, Index Futures are agreements pursuant to which two parties agree to take or make delivery of an amount of cash equal to the difference between the value of a securities index at the close of the last trading day of the contract and the price at which the index contract was originally written. Although the value of a securities index might be a function of the value of certain specified securities, no physical delivery of these securities is made.
The purchase or sale of a futures contract differs from the purchase or sale of a security or option in that no price or premium is paid or received. Instead, an amount of cash, U.S. government securities, or other liquid assets equal in value to a percentage of the face amount of the futures contract must be deposited with the broker. This amount is known as initial margin. The amount of the initial margin is generally set by the market on which the contract is traded (margin requirements on non-U.S. exchanges may be different than those on U.S. exchanges). Subsequent payments to and from the broker, known as variation margin, are made on a daily basis as the price of the underlying futures contract fluctuates, making the long and short positions in the futures contract more or less valuable, a process known as marking to the market. Prior to the settlement date of the futures contract, the position may be closed by taking an opposite position. A final determination of variation margin is then made, additional cash is required to be paid to or released by the broker, and the purchaser realizes a loss or gain. In addition, a commission is paid to the broker on each completed purchase and sale.
25
Although some futures contracts call for making or taking delivery of the underlying securities, currencies, commodities, or other underlying instrument, in most cases futures contracts are closed before the settlement date without the making or taking of delivery by offsetting purchases or sales of matching futures contracts (i.e., with the same exchange, underlying financial instrument, currency, commodity, or index, and delivery month). If the price of the initial sale exceeds the price of the offsetting purchase, the seller is paid the difference and realizes a gain. Conversely, if the price of the offsetting purchase exceeds the price of the initial sale, the seller realizes a loss. Similarly, a purchase of a futures contract is closed out by selling a corresponding futures contract. If the offsetting sale price exceeds the original purchase price, the purchaser realizes a gain, and, if the original purchase price exceeds the offsetting sale price, the purchaser realizes a loss. Any transaction costs must also be included in these calculations.
In the United States, futures contracts are traded only on commodity exchanges or boards of trade known as contract markets approved by the Commodity Futures Trading Commission (CFTC), and must be executed through a futures commission merchant or brokerage firm that is a member of the relevant market. Certain Funds also may purchase futures contracts on non-U.S. exchanges or similar entities, which are not regulated by the CFTC and may not be subject to the same degree of regulation as the U.S. contract markets. See Additional Risks of Options on Securities, Futures Contracts, and Options on Futures Contracts Traded on Non-U.S. Exchanges.
Index Futures. To the extent consistent with applicable law and investment restrictions, a Fund may purchase or sell Index Futures. A Fund may close open positions on a contract market on which Index Futures are traded at any time up to and including the expiration day. In general, all positions that remain open at the close of business on that day must be settled on the next business day (based on the value of the relevant index on the expiration day). Additional or different margin requirements as well as settlement procedures may apply to non-U.S. stock Index Futures.
Interest Rate Futures. Some Funds may engage in transactions involving the use of futures on interest rates. These transactions may be in connection with investments in U.S. government securities and other fixed income securities.
Inflation-Linked Futures. The Fixed Income Funds, Asset Allocation Bond Fund, U.S. Treasury Fund (collectively, the Bond Funds), Implementation Fund and SGM Major Markets Fund may engage in transactions involving inflation-linked futures, including Consumer Price Index (CPI) futures, which are exchange-traded futures contracts that represent the inflation on a notional value of $1,000,000 for a period of three months, as implied by the CPI. Inflation-linked futures may be used by the Fund to hedge the inflation risk in nominal bonds (i.e., non-inflation-indexed bonds) thereby creating synthetic inflation-indexed bonds. A Fund also may combine inflation-linked futures with U.S. Treasury futures contracts to create synthetic inflation-indexed bonds issued by the U.S. Treasury. See Indexed Investments Inflation-Indexed Bonds for a discussion of inflation-indexed bonds.
Currency Futures. Funds that are permitted to invest in securities denominated in foreign currencies may buy and sell futures contracts on currencies. See Foreign Currency Transactions for a description of those Funds use of currency futures.
26
Options on Futures Contracts. Options on futures contracts give the purchaser the right in return for the premium paid to assume a long position (in the case of a call option) or a short position (in the case of a put option) in a futures contract at the option exercise price at any time during the period of the option (in the case of an American-style option) or on the expiration date (in the case of European-style option). Upon exercise of a call option, the holder acquires a long position in the futures contract and the writer is assigned the opposite short position. In the case of a put option, the holder acquires a short position and the writer is assigned the opposite long position in the futures contract. Accordingly, in the event that an option is exercised, the parties will be subject to all the risks associated with the trading of futures contracts, such as payment of initial and variation margin deposits.
Funds may use options on futures contracts in lieu of writing or buying options directly on the underlying securities or purchasing and selling the underlying futures contracts. For example, to hedge against a possible decrease in the value of its portfolio securities, a Fund may purchase put options or write call options on futures contracts rather than selling futures contracts. Similarly, a Fund may hedge against a possible increase in the price of securities the Fund expects to purchase by purchasing call options or writing put options on futures contracts rather than purchasing futures contracts. In addition, a Fund may purchase and sell interest rate options on U.S. Treasury or Eurodollar futures to take a long or short position on interest rate fluctuations. Options on futures contracts generally operate in the same manner as options purchased or written directly on the underlying investments. See Foreign Currency Transactions for a description of some Funds use of options on currency futures.
A Fund is also required to deposit and maintain margin with respect to put and call options on futures contracts written by it. Such margin deposits may vary depending on the nature of the underlying futures contract (and the related initial margin requirements), the current market value of the option, and other futures positions held by the Fund.
A position in an option on a futures contract may be terminated by the purchaser or seller prior to expiration by effecting a closing purchase or sale transaction, subject to the availability of a liquid secondary market, which is the purchase or sale of an option of the same type (i.e., the same exercise price and expiration date) as the option previously purchased or sold. The difference between the premiums paid and received represents the Funds profit or loss on the transaction.
Commodity Futures and Options on Commodity Futures. Some Funds may have direct or indirect exposure to futures contracts on various commodities or commodities indices (commodity futures) and options on commodity futures, including through their investments in Implementation Fund, SGM Major Markets Fund, or Special Opportunities Fund. A futures contract on a commodity is an agreement between two parties in which one party agrees to purchase a commodity, such as an energy, agricultural, or metal commodity, from the other party at a later date at a price and quantity agreed upon when the contract is made. Futures contracts on commodities indices operate in a manner similar to Index Futures. While commodity futures on individual commodities are physically settled, GMO intends to close out those futures contracts before the settlement date without the making or taking of delivery. See also Commodity-Related Investments.
27
Forward Contracts. A forward contract is a contract to buy or sell an underlying security or currency at a pre-determined price on a specific future date. The initial terms of the contract are set so that the contract has no value at the outset. Forward prices are obtained by taking the spot price of a security or currency and adding to it the cost of carry. No money is transferred upon entering into a forward contract and the trade is delayed until the specified date when the underlying security or currency is exchanged for cash. Subsequently, as the price of the underlying security or currency moves, the value of the contract also changes, generally in the same direction.
Forward contracts involve a number of the same characteristics and risks as futures contracts but there also are several differences. Forward contracts are not market traded, and are not necessarily marked to market on a daily basis. They settle only at the pre-determined settlement date. This can result in deviations between forward prices and futures prices, especially in circumstances where interest rates and futures prices are positively correlated. Second, in the absence of exchange trading and involvement of clearing houses, there are no standardized terms for forward contracts. Accordingly, the parties are free to establish such settlement times and underlying amounts of a security or currency as desirable, which may vary from the standardized provisions available through any futures contract. Finally, forward contracts, as two party obligations for which there is no secondary market, involve counterparty credit risk not present with futures.
Forward currency contracts are contracts between two parties to purchase and sell a specific quantity of a particular currency at a specified price, with delivery and settlement to take place on a specified future date. Currency transactions involve significant risk. Currency exchange rates may fluctuate significantly over short periods of time. They generally are determined by the forces of supply and demand in the foreign exchange markets, the relative merits of investments in different countries, actual or perceived changes in interest rates and other complex factors. Currency exchange rates also can be affected unpredictably as a result of intervention (or the failure to intervene) by U.S. governments or foreign governments or central banks, or by currency controls or political developments in the United States or abroad, including repatriation limitations. A Funds exposure to foreign dollar currencies means that a change in the value of any such currency against the U.S. dollar will result in a change in the U.S. dollar value of a Funds assets.
Risk Factors in Futures and Futures Options Transactions . Investment in futures contracts involves risk. A purchase or sale of futures contracts may result in losses in excess of the amount invested in the futures contract. If a futures contract is used for hedging, an imperfect correlation between movements in the price of the futures contract and the price of the security, currency, or other investment being hedged creates risk. Correlation is higher when the investment being hedged underlies the futures contract. Correlation is lower when the investment being hedged is different than the security, currency, or other investment underlying the futures contract, such as when a futures contract on an index of securities or commodities is used to hedge a single security or commodity, a futures contract on one security (e.g., U.S. Treasury bonds) or commodity (e.g., gold) is used to hedge a different security (e.g., a mortgage-backed security) or commodity (e.g., copper), or when a futures contract in one currency is used
28
to hedge a security denominated in another currency. In the case of Index Futures and futures on commodity indices, changes in the price of those futures contracts may not correlate perfectly with price movements in the relevant index due to market distortions. In the event of an imperfect correlation between a futures position and the portfolio position (or anticipated position) intended to be hedged, the Fund may realize a loss on the futures contract at the same time the Fund is realizing a loss on the portfolio position intended to be hedged. To compensate for imperfect correlations, a Fund may purchase or sell futures contracts in a greater amount than the hedged investments if the volatility of the price of the hedged investments is historically greater than the volatility of the futures contracts. Conversely, a Fund may purchase or sell fewer futures contracts if the volatility of the price of the hedged investments is historically less than that of the futures contract. The successful use of transactions in futures and related options for hedging also depends on the direction and extent of exchange rate, interest rate and asset price movements within a given time frame. For example, to the extent equity prices remain stable during the period in which a futures contract or option is held by a Fund investing in equity securities (or such prices move in a direction opposite to that anticipated), the Fund may realize a loss on the futures transaction, which is not fully or partially offset by an increase in the value of its portfolio securities. As a result, the Funds total return for such period may be less than if it had not engaged in the hedging transaction.
All participants in the futures market are subject to margin deposit and maintenance requirements. Instead of meeting margin calls, investors may close futures contracts through offsetting transactions, which could distort normal correlations. The margin deposit requirements in the futures market are less onerous than margin requirements in the securities market, allowing for more speculators who may cause temporary price distortions. Furthermore, the low margin deposits normally required in futures trading permit a high degree of leverage. Accordingly, a relatively small price movement in a futures contract can result in immediate and substantial losses. Trading hours for non-U.S. stock Index Futures may not correspond perfectly to the trading hours of the non-U.S. exchange to which a particular non-U.S. stock Index Future relates. As a result, the lack of continuous arbitrage may cause a disparity between the price of non-U.S. stock Index Futures and the value of the relevant index.
A Fund may purchase futures contracts (or options on them) as an anticipatory hedge against a possible increase in the price of a currency in which securities the Fund anticipates purchasing is denominated. In such instances, the currency may instead decline. If the Fund does not then invest in those securities, the Fund may realize a loss on the futures contract that is not offset by a reduction in the price of the securities purchased.
The Funds ability to engage in the futures and options on futures strategies described above depends on the liquidity of those instruments. Trading interest in various types of futures and options on futures cannot be predicted. Therefore, no assurance can be given that a Fund will be able to utilize these instruments at all or that their use will be effective. In addition, a liquid market may not exist at a time when a Fund seeks to close out a futures or option on a futures contract position, and that Fund would remain obligated to meet margin requirements until the position is closed. The liquidity of a secondary market in a futures contract may be adversely affected by daily price fluctuation limits established by commodity exchanges to limit the amount of fluctuation in a futures contract price during a single trading day. Once the daily limit
29
has been reached, no trades of the contract may be entered at a price beyond the limit, thus preventing the liquidation of open futures positions. In the past, prices have exceeded the daily limit on several consecutive trading days. Short (and long) positions in Index Futures or futures on commodities indices may be closed only by purchasing (or selling) a futures contract on the exchange on which the Index Futures or commodity futures, as applicable, are traded.
As discussed above, if a Fund purchases or sells a futures contract, it is only required to deposit initial and variation margin as required by relevant CFTC regulations and the rules of the contract market. The Funds net asset value will generally fluctuate with the value of the security or other instrument underlying a futures contract as if it were already in the Funds portfolio. Futures transactions can have the effect of investment leverage. Furthermore, if a Fund combines short and long positions, in addition to possible declines in the values of its investment securities, the Fund will incur losses if the index underlying the long futures position underperforms the index underlying the short futures position.
In addition, if a futures broker of a Fund becomes bankrupt or insolvent, or otherwise defaults on its obligations to the Fund, the Fund may not receive all amounts owing to it in respect of its trading, despite the futures clearing house fully discharging all of its obligations. In the event of the bankruptcy of a futures broker, a Fund could be limited to recovering only a pro rata share of all available funds segregated on behalf of the futures brokers combined customer accounts. Also, in contrast to the treatment of margin provided for cleared derivatives, the futures broker does not typically notify the futures clearing house of the amount of margin provided by the futures broker to the futures clearing house that is attributable to each customer. Therefore, a Fund is subject to the risk that its margin will be used by the futures clearing house to satisfy the obligations of another customer of its futures broker. In addition, in the event of the bankruptcy or insolvency of a clearing house, a Fund might experience a loss of funds deposited through its futures broker as margin with the clearing house, a loss of unrealized profits on its open positions, and the loss of funds owed to it as realized profits on closed positions. Such a bankruptcy or insolvency might also cause a substantial delay before a Fund could obtain the return of funds owed to it by a futures broker who was a member of such clearing house. Furthermore, if a futures broker does not comply with the applicable regulations or its agreement with a Fund, or in the event of fraud or misappropriation of customer assets by a futures broker, a Fund could have only an unsecured creditor claim in an insolvency of the futures broker with respect to the margin held by the futures broker.
Additional Risk Associated with Commodity Futures Transactions. Several additional risks are associated with transactions in commodity futures contracts.
Physical Delivery Risk. A Fund may trade in physical commodities and/or invest in certain futures contracts on commodities that are not required to be cash settled. In such cases, a Fund may take physical delivery of commodities. Such commodities may be subject to the risk of theft, spoilage, destruction and similar risks. In addition, storage, insurance, and other costs associated with holding commodities will affect the value of such contracts. In the event that a Fund holds physical commodities and one or more of the foregoing risks materialize, and in light of the costs associated with holding commodities, the Funds may suffer losses.
30
Reinvestment Risk. In the commodity futures markets, producers of an underlying commodity may sell futures contracts to lock in the price of the commodity at delivery. To induce speculators to purchase the other side (the long side) of the contract, the commodity producer generally must sell the contract at a lower price than the expected futures spot price. Conversely, if most purchasers of the underlying commodity purchase futures contracts to hedge against a rise in commodity prices, then speculators will only sell the contract at a higher price than the expected future spot price of the commodity. The changing nature of the hedgers and speculators in the commodity markets will influence whether futures prices are above or below the expected futures spot price. As a result, when GMO reinvests the proceeds from a maturing contract, it may purchase a new futures contract at a higher or lower price than the expected futures spot prices of the maturing contract or choose to pursue other investments.
Additional Economic Factors. The value of the commodities underlying commodity futures contracts may be subject to additional economic and non-economic factors, such as drought, floods or other weather conditions, livestock disease, trade embargoes, competition from substitute products, transportation bottlenecks or shortages, fluctuations in supply and demand, tariffs, and international economic, political, and regulatory developments.
See also Commodity-Related Investments for more discussion of the special risks of investing in commodity futures, options on commodity futures, and related types of derivatives, including certain tax-related risks.
Additional Risks of Options on Securities, Futures Contracts, and Options on Futures Contracts Traded on Non-U.S. Exchanges. Options on securities, futures contracts, options on futures contracts, and options on currencies may be traded on non-U.S. exchanges. Such transactions may not be regulated as effectively as similar transactions in the United States (which are regulated by the CFTC) and may be subject to greater risks than trading on U.S. exchanges. For example, some non-U.S. exchanges may be principal markets so that no common clearing facility exists and a trader may look only to the broker for performance of the contract. The lack of a common clearing facility creates counterparty risk. If a counterparty defaults, a Fund will have contractual remedies against that counterparty, but may be unsuccessful in enforcing those remedies. When seeking to enforce a contractual remedy, a Fund also is subject to the risk that the parties may interpret contractual terms (e.g., the definition of default) differently. Counterparty risk is greater for derivatives with longer maturities where events may intervene to prevent settlement. Counterparty risk is also greater when a Fund has entered into derivatives contracts with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. If a dispute occurs, the cost and unpredictability of the legal proceedings required for the Fund to enforce its contractual rights may lead the Fund to decide not to pursue its claims against the counterparty. A Fund thus assumes the risk that it may be unable to obtain payments owed under foreign futures contracts or that those payments may be delayed or made only after the Fund has incurred the costs of litigation. To the extent that GMOs view with respect to a particular counterparty changes adversely (whether due to external events or otherwise), a Funds existing transactions with that counterparty will not necessarily be required to be terminated or modified. In addition, a Fund may enter into new transactions with a counterparty that GMO no longer considers a desirable counterparty if the transaction is primarily designed to reduce the Funds overall risk of potential exposure to that counterparty (for example, re-establishing the transaction with a lower notional
31
amount). In addition, unless a Fund hedges against fluctuations in the exchange rate between the currencies in which trading is done on non-U.S. exchanges and other currencies, any profits that a Fund might realize in trading could be offset (or worse) by adverse changes in the exchange rate. The value of non-U.S. options and futures also may be adversely affected by other factors unique to non-U.S. investing. See Risks of Non-U.S. Investments.
Swap Contracts and Other Two-Party Contracts
Many of the Funds use swap contracts (or swaps) and other two-party contracts for the same or similar purposes as options, futures, and forward contracts. See Uses of Derivatives for more information regarding the various derivatives strategies those Funds may employ using swap contracts and other two-party contracts.
Swap Contracts. The Funds may directly or indirectly use various different swaps, such as swaps on securities and securities indices, total return swaps, interest rate swaps, basis swaps, currency swaps, credit default swaps, variance swaps, commodity swaps, inflation swaps, municipal swaps, dividend swaps, volatility swaps, correlation swaps, and other types of available swap agreements, depending on a Funds investment objective and policies. Swap contracts are two-party contracts entered into primarily by institutional investors for periods ranging from a few weeks to a number of years. Under a typical swap, one party may agree to pay a fixed rate or a floating rate determined by reference to a specified instrument, rate, or index, multiplied in each case by a specified amount (notional amount), while the other party agrees to pay an amount equal to a different floating rate multiplied by the same notional amount. On each payment date, the parties obligations are netted, with only the net amount paid by one party to the other.
Swap contracts are typically individually negotiated and structured to provide exposure to a variety of different types of investments or market factors. Swap contracts may be entered into for hedging or non-hedging purposes and therefore may increase or decrease a Funds exposure to the underlying instrument, rate, asset or index. Swaps can take many different forms and are known by a variety of names. A Fund is not limited to any particular form or variety of swap agreement if GMO determines it is consistent with the Funds investment objective and policies.
A Fund may enter into swaps on securities, baskets of securities or securities indices. For example, the parties to a swap contract may agree to exchange returns calculated on a notional amount of a security, basket of securities, or securities index (e.g., S&P 500 Index). Additionally, a Fund may use total return swaps, which typically involve commitments to pay amounts computed in the same manner as interest in exchange for a market-linked return, both based on notional amounts. A Fund may use such swaps to gain investment exposure to the underlying security or securities where direct ownership is either not legally possible or is economically unattractive. To the extent the total return of the security, basket of securities, or index underlying the transaction exceeds or falls short of the offsetting interest rate obligation, a Fund will receive a payment from or make a payment to the counterparty, respectively.
In addition, a Fund may enter into interest rate swaps (including municipal swaps) in order to protect against declines in the value of fixed income securities held by the Fund. In such an instance, the Fund may agree with a counterparty to pay a fixed rate (multiplied by a notional
32
amount) and the counterparty pay a floating rate multiplied by the same notional amount. If interest rates rise, resulting in a diminution in the value of the Funds portfolio, the Fund would receive payments under the swap that would offset, in whole or in part, such diminution in value. A Fund also may enter into swaps to modify its exposure to particular currencies using cross-currency swaps. For instance, a Fund may enter into a cross-currency swap between the U.S. dollar and the Japanese yen in order to increase or decrease its exposure to each such currency. Cross-currency swaps are contracts between two counterparties to exchange interest and principal payments in different currencies. A Fund entering into a cross-currency swap is exposed to both interest rate risk and foreign currency exchange risk. A Fund may also enter into basis swaps in order to limit interest-rate risk as a result of the difference between borrowing and lending rates. Basis swaps are interest rate swaps that involve the exchange of two floating interest rate payments and may involve the exchange of two different currencies.
A Fund may use inflation swaps (including inflation swaps tied to the CPI), which involve commitments to pay a regular stream of inflation-indexed cash payments in exchange for receiving a stream of nominal interest payments (or vice versa), where both payment streams are based on a notional amount. The nominal interest payments may be based on either a fixed interest rate or variable interest rate, such as LIBOR. Inflation swaps may be used to hedge the inflation risk in nominal bonds (i.e., non-inflation-indexed bonds), thereby creating synthetic inflation-indexed bonds, or combined with U.S. Treasury futures contracts to create synthetic inflation-indexed bonds issued by the U.S. Treasury. See Indexed Investments Inflation-Indexed Bonds.
In addition, a Fund may directly or indirectly use credit default swaps to take an active long or short position with respect to the likelihood of default by a corporate or sovereign issuer of fixed income securities (including asset-backed securities). In a credit default swap, one party pays, in effect, an insurance premium through a stream of payments to another party in exchange for the right to receive a specified return in the event of default (or similar events) by one or more third parties on their obligations. For example, in purchasing a credit default swap, a Fund may pay a premium in return for the right to put specified bonds or loans to the counterparty, such as a U.S. or non-U.S. issuer or basket of such issuers, upon issuer default (or similar events) at their par (or other agreed-upon) value. A Fund, as the purchaser in a credit default swap, bears the risk that the investment might expire worthless. It also would be subject to counterparty risk the risk that the counterparty may fail to satisfy its payment obligations to the Fund in the event of a default (or similar event) (see Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts). In addition, as a purchaser in a credit default swap, the Funds investment would only generate income in the event of an actual default (or similar event) by the issuer of the underlying obligation. A Fund also may invest in credit default indices, which are indices that reflect the performance of a basket of credit default swaps.
A Fund also may use credit default swaps for investment purposes by selling a credit default swap, in which case the Fund will receive a premium from its counterparty in return for the Funds taking on the obligation to pay the par (or other agreed-upon) value to the counterparty upon issuer default (or similar events). As the seller in a credit default swap, a Fund effectively adds economic leverage to its portfolio because, in addition to its total net assets, the Fund is subject to investment exposure on the notional amount of the swap. If no event of default (or
33
similar event) occurs, the Fund would keep the premium received from the counterparty and generally would have no payment obligations, with the exception of an initial payment made on the credit default swap or any margin requirements with the credit default swap counterparty. For credit default swap agreements, trigger events for payment under the agreement vary by the type of underlying investment (e.g., corporate and sovereign debt, asset-backed securities, and credit default swap indices) and by jurisdiction (e.g., United States, Europe and Asia).
A Fund may use dividend swaps. Under a dividend swap, one party pays to the other party the dividends paid with respect to a notional amount of a security (or a basket or index of securities) during the term of the swap, in exchange for interest rate or other payments. To the extent the dividends paid on the security, basket of securities, or index underlying the transaction exceeds or falls short of the offsetting obligation, a Fund will receive a payment from or make a payment to the counterparty, respectively.
In addition, a Fund may use volatility swaps. Volatility swaps involve the exchange of forward contracts on the future realized volatility of a given underlying asset, and allow the Fund to take positions on the volatility of that underlying asset. A Fund also may use a particular type of volatility swap, known as a variance swap agreement, which involves an agreement by two parties to exchange cash flows based on the measured variance (volatility squared) of a specified underlying asset. One party agrees to exchange a fixed rate or strike price payment for the floating rate or realized price variance on the underlying asset with respect to the notional amount. At inception, the strike price chosen is generally fixed at a level such that the fair value of the swap is zero. As a result, no money changes hands at the initiation of the contract. At the expiration date, the amount paid by one party to the other is the difference between the realized price variance of the underlying asset and the strike price multiplied by the notional amount. A receiver of the realized price variance would receive a payment when the realized price variance of the underlying asset is greater than the strike price and would make a payment when that variance is less than the strike price. A payer of the realized price variance would make a payment when the realized price variance of the underlying asset is greater than the strike price and would receive a payment when that variance is less than the strike price. This type of agreement is essentially a forward contract on the future realized price variance of the underlying asset.
A Fund may use correlation swaps, which provide exposure to increases or decreases in the correlation between the prices of different assets or market rates. Correlation swaps involve receiving a stream of payments based on the actual average correlation between or among the price movements of two or more underlying variables over a period of time, in exchange for making a regular stream of payments based on a fixed strike correlation level (or vice versa), where both payment streams are based on a notional amount. The underlying variables may include, without limitation, commodity prices, exchange rates, interest rates and stock indices.
Some Funds may have direct or indirect exposure to commodity swaps on one or more broad-based commodities indices (e.g., the Dow Jones-UBS Commodity Index) or to commodity swaps on individual commodities or baskets of commodities, including through their investments in Implementation Fund, SGM Major Markets Fund, or Special Opportunities Fund. See Commodity-Related Investments for more discussion of the Funds use of commodity swap contracts and other related types of derivatives.
34
Contracts for Differences. Contracts for differences are swap arrangements in which the parties agree that their return (or loss) will be based on the relative performance of two different groups or baskets of securities. Often, one or both baskets will be an established securities index. The Funds return will be based on changes in value of theoretical long futures positions in the securities comprising one basket (with an aggregate face value equal to the notional amount of the contract for differences) and theoretical short futures positions in the securities comprising the other basket. A Fund also may use actual long and short futures positions and achieve similar market exposure by netting the payment obligations of the two contracts. A Fund will only enter into contracts for differences (and analogous futures positions) when GMO believes that the basket of securities constituting the long position will outperform the basket constituting the short position. If the short basket outperforms the long basket, the Fund will realize a loss even in circumstances when the securities in both the long and short baskets appreciate in value. In addition, some Funds may use contracts for differences that are based on the relative performance of two different groups or baskets of commodities. Often, one or both baskets is a commodities index. Contracts for differences on commodities operate in a similar manner to contracts for differences on securities described above.
Interest Rate Caps, Floors, and Collars. The Funds may use interest rate caps, floors, and collars for the same or similar purposes as they use interest rate futures contracts and related options and, as a result, will be subject to similar risks. See Options, Futures, and Forward Contracts Risk Factors in Options Transactions and Risk Factors in Futures and Futures Options Transactions. Like interest rate swap contracts, interest rate caps, floors, and collars are two-party agreements in which the parties agree to pay or receive interest on a notional principal amount and are generally individually negotiated with a specific counterparty. The purchaser of an interest rate cap receives interest payments from the seller to the extent that the return on a specified index exceeds a specified interest rate. The purchaser of an interest rate floor receives interest payments from the seller to the extent that the return on a specified index falls below a specified interest rate. The purchaser of an interest rate collar receives interest payments from the seller to the extent that the return on a specified index falls outside the range of two specified interest rates.
Swaptions. An option on a swap agreement, also called a swaption, is an OTC option that gives the buyer the right, but not the obligation, to enter into a swap on a specified future date in exchange for paying a market-based premium. A receiver swaption gives the owner the right to receive the total return of a specified asset, reference rate, or index (such as a call option on a bond). A payer swaption gives the owner the right to pay the total return of a specified asset, reference rate, or index (such as a put option on a bond). Swaptions also include options that allow one of the counterparties to terminate or extend an existing swap.
Risk Factors in Swap Contracts, OTC Options, and Other Two-Party Contracts. A Fund may only close out a swap, contract for differences, cap, floor, collar, or OTC option (including swaption) with its particular counterparty, and may only transfer a position with the consent of that counterparty. If a counterparty fails to meet or disputes its contractual obligations, goes
35
bankrupt, or otherwise experiences a business interruption, the Fund could miss investment opportunities or otherwise hold investments it would prefer to sell, resulting in losses for the Fund. If the counterparty defaults, a Fund will have contractual remedies, but there can be no assurance that the counterparty will be able to meet its contractual obligations or that the Fund will be able to enforce its rights. For example, because the contract for each OTC derivatives transaction is individually negotiated with a specific counterparty, a Fund is subject to the risk that a counterparty may interpret contractual terms (e.g., the definition of default) differently than the Fund. The cost and unpredictability of the legal proceedings required for the Fund to enforce its contractual rights may lead it to decide not to pursue its claims against the counterparty. Counterparty risk is greater for derivatives with longer maturities where events may intervene to prevent settlement. Counterparty risk is also greater when a Fund has concentrated its derivatives with a single or small group of counterparties as it sometimes does as a result of its use of swaps and other OTC derivatives. To the extent a Fund has significant exposure to a single counterparty, this risk will be particularly pronounced for the Fund. The Fund, therefore, assumes the risk that it may be unable to obtain payments GMO believes are owed under an OTC derivatives contract or that those payments may be delayed or made only after the Fund has incurred the costs of litigation. In addition, counterparty risk is pronounced during unusually adverse market conditions and is particularly acute in environments (like those of 2008) in which financial services firms are exposed to systemic risks of the type evidenced by the insolvency of Lehman Brothers and subsequent market disruptions.
The credit rating of a counterparty may be adversely affected by greater-than-average volatility in the markets, even if the counterpartys net market exposure is small relative to its capital.
Counterparty risk with respect to derivatives has been and will continue to be affected by new rules and regulations relating to the derivatives market. Some derivatives transactions are required to be centrally cleared, and a party to a cleared derivatives transaction is subject to the credit risk of the clearing house and the clearing member through which it holds its cleared position. Credit risk of market participants with respect to derivatives that are centrally cleared is concentrated in a few clearing houses, and it is not clear how an insolvency proceeding of a clearing house would be conducted and what impact an insolvency of a clearing house would have on the financial system. A clearing member is obligated by contract and regulation to segregate all funds received from customers with respect to cleared derivatives positions from the clearing members proprietary assets. However, all funds and other property received by a clearing member from its customers with respect to cleared derivatives are generally held by the clearing member on a commingled basis in an omnibus account (which can be invested in instruments permitted under the regulations). Therefore, a Fund might not be fully protected in the event of the bankruptcy of a Funds clearing member because the Fund would be limited to recovering only a pro rata share of the funds held by the clearing member on behalf of customers, with a claim against the clearing member for any deficiency. Also, the clearing member is required to transfer to the clearing house the amount of margin required by the clearing house for cleared derivatives, which amount is generally held in an omnibus account at the clearing house for all customers of the clearing member. Regulations promulgated by the CFTC require that the clearing member notify the clearing house of the initial margin provided by the clearing member to the clearing house that is attributable to each customer. However, if the clearing member does not accurately report a Funds initial margin, the Fund is subject to the risk that a clearing house
36
will use the assets attributable to it in the clearing houses omnibus account to satisfy payment obligations a defaulting customer of the clearing member has to the clearing house. In addition, clearing members generally provide the clearing house the net amount of variation margin required for cleared swaps for all of its customers, rather than individually for each customer. The Funds are therefore subject to the risk that a clearing house will not make variation margin payments owed to a Fund if another customer of the clearing member has suffered a loss and is in default, and the risk that a Fund will be required to provide additional variation margin to the clearing house before the clearing house will move the Funds cleared derivatives positions to another clearing member. In addition, if a clearing member does not comply with the applicable regulations or its agreement with the Funds, or in the event of fraud or misappropriation of customer assets by a clearing member, a Fund could have only an unsecured creditor claim in an insolvency of the clearing member with respect to the margin held by the clearing member.
Additional Risk Factors in OTC Derivatives Transactions. OTC derivatives are also subject to documentation risk, which is the risk that ambiguities, inconsistencies, or errors in the documentation relating to a derivative transaction lead to a dispute with the counterparty or unintended investment results.
Additionally, participants in OTC derivatives markets typically are not subject to the same level of credit evaluation and regulatory oversight as are members of exchange-based markets and, therefore, OTC derivatives generally expose a Fund to greater counterparty risk than exchange-traded derivatives.
Among other trading agreements, certain Funds are party to International Swaps and Derivatives Association, Inc. Master Agreements (ISDA Agreements) or other similar types of agreements with select counterparties that generally govern OTC derivative transactions entered into by such Funds. The ISDA Agreements typically include representations and warranties as well as contractual terms related to collateral, events of default, termination events, and other provisions. Termination events may include the decline in the net assets of a Fund below a certain level over a specified period of time and entitle a counterparty to elect to terminate early with respect to some or all the transactions under the ISDA Agreement with that counterparty. Such an election by one or more of the counterparties could have a material adverse impact on a Funds operations.
Additional Risk Factors in Cleared Derivatives Transactions. Under recently adopted rules and regulations, transactions in some types of swaps (including interest rate swaps and credit default swaps on North American and European indices) are required to be centrally cleared. In a transaction involving those swaps (cleared derivatives), a Funds counterparty is a clearing house, rather than a bank or broker. Since the Funds are not members of clearing houses and only members of a clearing house (clearing members) can participate directly in the clearing house, the Funds hold cleared derivatives through accounts at clearing members. In cleared derivatives positions, the Funds make payments (including margin payments) to and receive payments from a clearing house through their accounts at clearing members. Clearing members guarantee performance of their clients obligations to the clearing house.
In some ways, cleared derivative arrangements are less favorable to mutual funds than bilateral arrangements, for example, by requiring that funds provide more margin for their cleared
37
derivatives positions. Also, as a general matter, in contrast to a bilateral derivatives position, following a period of notice to a Fund, a clearing member at any time can require termination of an existing cleared derivatives position or an increase in margin requirements above those required at the outset of a transaction. Clearing houses also have broad rights to increase margin requirements for existing positions or to terminate those positions at any time. Any increase in margin requirements or termination of existing cleared derivatives positions by the clearing member or the clearing house could interfere with the ability of a Fund to pursue its investment strategy. Further, any increase in margin requirements by a clearing member could expose a Fund to greater credit risk to its clearing member because margin for cleared derivatives positions in excess of a clearing houses margin requirements typically is held by the clearing member. Also, a Fund is subject to risk if it enters into a derivatives transaction that is required to be cleared (or that GMO expects to be cleared), and no clearing member is willing or able to clear the transaction on the Funds behalf. While the documentation in place between the Funds and their clearing members generally provides that the clearing members will accept for clearing all cleared derivatives transactions that are within credit limits (specified in advance) for each Fund, the Funds are still subject to the risk that no clearing member will be willing or able to clear a transaction. In those cases, the position might have to be terminated, and the Fund could lose some or all of the benefit of the position, including loss of an increase in the value of the position and/or loss of hedging protection. In addition, the documentation governing the relationship between the Funds and clearing members is drafted by the clearing members and generally is less favorable to the Funds than typical bilateral derivatives documentation. For example, documentation relating to cleared derivatives generally includes a one-way indemnity by the Funds in favor of the clearing member for losses the clearing member incurs as the Funds clearing member. Also, such documentation typically does not provide the Funds any remedies if the clearing member defaults or becomes insolvent. While futures contracts entail similar risks, the risks likely are more pronounced for cleared swaps due to their more limited liquidity and market history.
Some types of cleared derivatives are required to be executed on an exchange or on a swap execution facility. A swap execution facility is a trading platform where multiple market participants can execute derivatives by accepting bids and offers made by multiple other participants in the platform. While this execution requirement is designed to increase transparency and liquidity in the cleared derivatives market, trading on a swap execution facility can create additional costs and risks for the Funds. For example, swap execution facilities typically charge fees, and if a Fund executes derivatives on a swap execution facility through a broker intermediary, the intermediary may impose fees as well. Also, a Fund may indemnify a swap execution facility, or a broker intermediary who executes cleared derivatives on a swap execution facility on the Funds behalf, against any losses or costs that may be incurred as a result of the Funds transactions on the swap execution facility. [If a Fund wishes to execute a package of transactions that include a swap that is required to be executed on a swap execution facility as well as other transactions (for example, a transaction that includes both a security and an interest rate swap that hedges interest rate exposure with respect to such security), the Fund may be unable to execute all components of the package on the swap execution facility. In that case, the Fund would need to trade some components of the package on the swap execution facility and other components in another manner, which could subject the Fund to the risk that some components would be executed successfully and others would not, or that the components would be executed at different times, leaving the Fund with an unhedged position for a period of time.]
These and other new rules and regulations could, among other things, further restrict a Funds ability to engage in, or increase the cost to the Fund of, derivatives transactions, for example, by making some types of derivatives no longer available to the Fund or otherwise limiting liquidity. The implementation of the clearing requirement has increased the costs of derivatives transactions for the Funds since the Funds have to pay fees to their clearing members and are typically required to post more margin for cleared derivatives than they have historically posted
38
for bilateral derivatives. The costs of derivatives transactions are expected to increase further as clearing members raise their fees to cover the costs of additional capital requirements and other regulatory changes applicable to the clearing members, and when rules imposing mandatory minimum margin requirements on bilateral swaps become effective. These rules and regulations are new and evolving, so their potential impact on the Funds and the financial system are not yet known. While the new rules and regulations and central clearing of some derivatives transactions are designed to reduce systemic risk (i.e., the risk that the interdependence of large derivatives dealers could cause them to suffer liquidity, solvency or other challenges simultaneously), there is no assurance that they will achieve that result, and in the meantime, as noted above, central clearing and related requirements expose the Funds to new kinds of costs and risks.
Use of Futures and Related Options, Interest Rate Floors, Caps and Collars, Certain Types of Swap Contracts and Related Instruments Commodity Pool Operator Status. Each of Alpha Only Fund, Asset Allocation Bond Fund, Benchmark-Free Allocation Fund, Benchmark-Free Fund, Core Plus Bond Fund, Currency Hedged International Bond Fund, Emerging Country Debt Fund, Global Asset Allocation Fund, Global Bond Fund, Implementation Fund, SGM Major Markets Fund, Special Opportunities Fund, and Strategic Opportunities Allocation Fund, together with GMO GAAR Implementation Fund and GMO World Opportunity Overlay Fund (each a series of the Trust offered through a separate private placement memorandum), is a commodity pool under the Commodity Exchange Act (the CEA) and GMO is registered as a commodity pool operator under the CEA with respect to these Funds. As a result, additional CFTC-mandated disclosure, reporting and recordkeeping obligations apply to these Funds and compliance with the CFTCs regulatory requirements could increase Fund expenses, adversely affecting a Funds total return.
The Trust, with respect to each GMO Fund not listed in the previous paragraph (the Excluded Funds), has claimed an exclusion from the definition of commodity pool operator under the CEA pursuant to CFTC Rule 4.5 (the exclusion). Accordingly, neither the Excluded Funds nor the Trust (with respect to the Excluded Funds) are subject to registration or regulation as a commodity pool operator under the CEA. To remain eligible for the exclusion, each Excluded Fund will be limited in its ability to use certain financial instruments regulated under the CEA (commodity interests), including futures and options on futures and certain swaps transactions. In the event that an Excluded Funds investments in commodity interests are not within the thresholds set forth in the exclusion, GMO may be required to register as a commodity pool operator with the CFTC with respect to that Excluded Fund. The eligibility of the Trust to claim the exclusion with respect to an Excluded Fund will be based upon, among other things, the level and scope of the funds investment in commodity interests, the purposes of such investments, and the manner in which the Excluded Fund holds out its use of commodity interests. An Excluded Funds ability to invest in commodity interests (including, but not limited to, futures and swaps on broad-based securities indexes and interest rates) is limited by the requirements of Rule 4.5, which may adversely affect the Excluded Funds total return. In the event the Trust becomes unable to rely on the exclusion in Rule 4.5 with respect to an Excluded Fund and GMO is required to register with the CFTC as a commodity pool operator with respect to an Excluded Fund, the Excluded Funds expenses may increase, adversely affecting that Funds total return.
39
Foreign Currency Transactions
Currency exchange rates may fluctuate significantly over short periods of time. They generally are determined by the forces of supply and demand in the currency exchange markets, trade balances, the relative merits of investments in different countries, actual or perceived changes in interest rates, differences in relative values of similar assets in different currencies, long-term opportunities for investment and capital appreciation, and other complex factors. Currency exchange rates also can be affected unpredictably as a result of intervention (or the failure to intervene) by the U.S. or foreign governments, central banks, or supranational agencies such as the International Monetary Fund, or by currency or exchange controls or political and economic developments in the United States or abroad. Currencies in which a Funds assets are denominated, or in which a Fund has taken a long position, may be devalued against other currencies, resulting in a loss to the Fund. Similarly, currencies in which a Fund has taken a short position may increase in value relative to other currencies, resulting in a loss to the Fund.
In addition, some currencies are illiquid (e.g., emerging country currencies), and a Fund may not be able to convert these currencies into U.S. dollars, in which case GMO may decide to purchase U.S. dollars in a parallel market with an unfavorable exchange rate. Exchange rates for many currencies (e.g., emerging country currencies) are particularly affected by exchange control regulations.
Funds that are permitted to invest in securities denominated in foreign currencies may buy or sell foreign currencies or deal in forward foreign currency contracts, currency futures contracts and related options, and options on currencies. Those Funds may use such currency instruments for hedging, investment, and/or currency risk management. Currency risk management may include taking overweighted or underweighted currency positions relative to both the securities portfolio of a Fund and the Funds performance benchmark or index. Those Funds also may purchase forward foreign currency contracts in conjunction with U.S. dollar-denominated securities in order to create a synthetic foreign currency-denominated security that approximates desired risk and return characteristics when the non-synthetic securities either are not available in non-U.S. markets or possess undesirable characteristics.
Forward foreign currency contracts are contracts between two parties to purchase and sell a specified quantity of a particular currency at a specified price, with delivery and settlement to take place on a specified future date. A forward foreign currency contract can reduce a Funds exposure to changes in the value of the currency it will deliver and can increase its exposure to changes in the value of the currency it will receive for the duration of the contract. The effect on the value of a Fund is similar to the effect of selling securities denominated in one currency and purchasing securities denominated in another currency. Contracts to sell a particular foreign currency would limit any potential gain that might be realized by a Fund if the value of the hedged currency increases. In addition, it is not always possible to hedge fully or perfectly against currency fluctuations affecting the value of the securities denominated in foreign currencies because the value of such securities also is likely to fluctuate because of independent factors not related to currency fluctuations. If a forward foreign currency contract is used for hedging, an imperfect correlation between movements in the price of the forward foreign currency contract and the price of the currency or other investment being hedged creates risk.
40
Forward foreign currency contracts involve a number of the same characteristics and risks as currency futures contracts (discussed below) but there also are several differences. Forward foreign currency contracts settle only at the pre-determined settlement date. This can result in deviations between forward foreign currency prices and currency futures prices, especially in circumstances where interest rates and currency futures prices are positively correlated. Second, in the absence of exchange trading and involvement of clearing houses, there are no standardized terms for forward currency contracts. Accordingly, the parties are free to establish such settlement times and underlying amounts of a currency as desirable, which may vary from the standardized provisions available through any currency futures contract.
A Fund also may purchase or sell currency futures contracts and related options. Currency futures contracts are contracts to buy or sell a standard quantity of a particular currency at a specified future date and price. However, currency futures can be and often are closed out prior to delivery and settlement. In addition, a Fund may use options on currency futures contracts, which give their holders the right, but not the obligation, to buy (in the case of a call option) or sell (in the case of a put option) a specified currency futures contract at a fixed price during a specified period. See Options, Futures, and Forward Contracts Futures for more information on futures contracts and options on futures contracts.
A Fund also may purchase or sell options on currencies. Options on currencies possess many of the same characteristics as options on securities and generally operate in a similar manner. They may be traded on an exchange or in the OTC markets. Options on currencies traded on U.S. or other exchanges may be subject to position limits, which may limit the ability of a Fund to reduce foreign currency risk using options. See Options, Futures, and Forward Contracts Currency Options for more information on currency options.
Repurchase Agreements
A Fund may (in the case of U.S. Treasury Fund, as a principal investment strategy) enter into repurchase agreements with banks and brokers. A repurchase agreement is a contract under which the Fund acquires a security (usually an obligation of the government in the jurisdiction where the transaction is initiated or in whose currency the agreement is denominated or, in the case of U.S. Treasury Fund, usually a security backed by the full faith and credit of the U.S. government, such as a U.S. Treasury bill, bond or note) for a relatively short period (usually less than a week) for cash and subject to the commitment of the seller to repurchase the security for an agreed-upon price on a specified date. The repurchase price exceeds the acquisition price and reflects an agreed-upon market rate unrelated to the coupon rate on the purchased security. Repurchase agreements afford a Fund the opportunity to earn a return on temporarily available cash without market risk, although the Fund bears the risk of a sellers failure to meet its obligation to pay the repurchase price when it is required to do so. Such a default may subject the Fund to expenses, delays, and risks of loss including: (i) possible declines in the value of the underlying security while the Fund seeks to enforce its rights thereto; (ii) possible reduced levels of income and lack of access to income during this period; and (iii) the inability to enforce its rights and the expenses involved in attempted enforcement. Entering into repurchase agreements entails certain risks, which include the risk that the counterparty to the repurchase agreement may not be able to fulfill its obligations, as discussed above, that the parties may disagree as to the meaning or application of contractual terms, or that the instrument may not perform as expected. See Description of Principal Risks Counterparty Risk in the Prospectus.
41
Debt and Other Fixed Income Securities Generally
Debt and other fixed income securities include fixed and floating rate securities of any maturity. Fixed rate securities pay a specified rate of interest or dividends. Floating rate securities pay a rate that is adjusted periodically by reference to a specified index or market rate. Fixed and floating rate securities include securities issued by federal, state, local, and foreign governments and related agencies, and by a wide range of private issuers, and generally are referred to in this SAI as fixed income securities. Indexed bonds are a type of fixed income security whose principal value and/or interest rate is adjusted periodically according to a specified instrument, index, or other statistic (e.g., another security, inflation index, currency, or commodity). See Adjustable Rate Securities and Indexed Investments. In addition, the Funds may create synthetic bonds which approximate desired risk and return profiles. This may be done where a non-synthetic security having the desired risk/return profile either is unavailable (e.g., short-term securities of certain foreign governments) or possesses undesirable characteristics (e.g., interest payments on the security would be subject to non-U.S. withholding taxes). See, for example, Options, Futures, and Forward Contracts Inflation-Linked Futures above.
Holders of fixed income securities are exposed to both market and credit risk. Market risk (or interest rate risk) relates to changes in a securitys value as a result of changes in interest rates. In general, the values of fixed income securities increase when interest rates fall and decrease when interest rates rise. Credit risk relates to the ability of an issuer to make payments of principal and interest. Obligations of issuers are subject to bankruptcy, insolvency and other laws that affect the rights and remedies of creditors. Fixed income securities denominated in foreign currencies also are subject to the risk of a decline in the value of the denominating currency.
Because interest rates vary, the future income of a Fund that invests in floating rate fixed income securities cannot be predicted with certainty. To the extent a Fund invests in indexed securities, the future income of the Fund also will be affected by changes in those securities indices over time (e.g., changes in inflation rates, currency rates, or commodity prices).
The Funds may invest in a wide range of debt and fixed income instruments, including, but not limited to, Asset-Backed and Mortgage-Backed Securities, Brady Bonds, Euro Bonds, U.S. Government and Foreign Government Securities and Zero Coupon Securities, each of which is described below.
Cash and Other High Quality Investments
Many of the Funds may temporarily invest a portion of their assets in cash or cash items pending other investments or to maintain liquid assets required in connection with some of the Funds investments. These cash items and other high quality debt securities may include money market instruments, such as securities issued by the U.S. government and its agencies, bankers acceptances, commercial paper, and bank certificates of deposit. If a custodian holds cash on behalf of a Fund, the Fund may be an unsecured creditor in the event of the insolvency of the custodian. In addition, the Fund will be subject to credit risk with respect to such a custodian, which may be heightened to the extent the Fund takes a temporary defensive position.
42
U.S. Government Securities and Foreign Government Securities
U.S. government securities include securities issued or guaranteed by the U.S. government or its authorities, agencies, or instrumentalities. Foreign government securities include securities issued or guaranteed by foreign governments (including political subdivisions) or their authorities, agencies, or instrumentalities or by supra-national agencies. Different kinds of U.S. and foreign government securities have different kinds of government support. For example, some U.S. government securities (e.g., U.S. Treasury bonds) are supported by the full faith and credit of the United States. Other U.S. government securities are issued or guaranteed by federal agencies or government-chartered or -sponsored enterprises but are neither guaranteed nor insured by the U.S. government (e.g., debt securities issued by the Federal Home Loan Mortgage Corporation (Freddie Mac), Federal National Mortgage Association (Fannie Mae), and Federal Home Loan Banks (FHLBs)). Similarly, some foreign government securities are supported by the full faith and credit of a foreign national government or political subdivision and some are not. Foreign government securities of some countries may involve varying degrees of credit risk as a result of financial or political instability in those countries or the possible inability of a Fund to enforce its rights against the foreign government. As with issuers of other fixed income securities, sovereign issuers may be unable or unwilling to satisfy their obligations to pay principal or interest payments.
Supra-national agencies are agencies whose member nations make capital contributions to support the agencies activities. Examples include the International Bank for Reconstruction and Development (the World Bank), the Asian Development Bank, and the Inter-American Development Bank.
As with other fixed income securities, U.S. and foreign government securities expose their holders to market risk because their values typically change as interest rates fluctuate. For example, the value of U.S. or foreign government securities may fall during times of rising interest rates. Yields on U.S. and foreign government securities tend to be lower than those of corporate securities of comparable maturities. Generally, when interest rates on short-term U.S. Treasury obligations equal or approach zero, a Fund that invests a substantial portion of its assets in U.S. Treasury obligations, such as U.S. Treasury Fund, will have a negative return unless GMO waives or reduces its management fees.
In addition to investing directly in U.S. and foreign government securities, a Fund may purchase certificates of accrual or similar instruments evidencing undivided ownership interests in interest payments and/or principal payments of U.S. government securities and foreign government securities. A Fund also may invest in Separately Traded Registered Interest and Principal Securities (STRIPS), which are interests in separately traded interest and principal component parts of U.S. Treasury obligations that represent future interest payments, principal payments, or both, are direct obligations of the U.S. government, and are transferable through the federal reserve book-entry system. Certificates of accrual and similar instruments may be more volatile than other government securities.
43
Municipal Securities
Municipal obligations are issued by or on behalf of states, territories and possessions of the United States, including Puerto Rico, and their political subdivisions, agencies and instrumentalities and the District of Columbia to obtain funds for various public purposes. Municipal obligations are subject to more credit risk than U.S. government securities that are supported by the full faith and credit of the United States. The ability of municipalities to meet their obligations will depend on the availability of tax and other revenues, economic, political, and other conditions within the state and municipality, and the underlying fiscal condition of the state and municipality. As with other fixed income securities, municipal securities also expose their holders to market risk because their values typically change as interest rates fluctuate. The two principal classifications of municipal obligations are notes and bonds.
Municipal notes are generally used to provide for short-term capital needs, such as to finance working capital needs of municipalities or to provide various interim or construction financing, and generally have maturities of one year or less. They are generally payable from specific revenues expected to be received at a future date or are issued in anticipation of long-term financing to be obtained in the market to provide for the repayment of the note.
Municipal bonds, which meet longer-term capital needs and generally have maturities of more than one year when issued, have two principal classifications: general obligation bonds and revenue bonds. Issuers of general obligation bonds, the proceeds of which are used to fund a wide range of public projects including the construction or improvement of schools, highways and roads, water and sewer systems and a variety of other public purposes, include states, counties, cities, towns and regional districts. The basic security behind general obligation bonds is the issuers pledge of its full faith, credit, and taxing power for the payment of principal and interest.
Revenue bonds have been issued to fund a wide variety of capital projects including: electric, gas, water and sewer systems; highways, bridges and tunnels; port and airport facilities; colleges and universities; and hospitals. The principal security for a revenue bond is generally the net revenues derived from a particular facility or group of facilities or, in some cases, from the proceeds of a special excise or other specific revenue source. Although the principal security behind these bonds varies widely, many provide additional security in the form of a debt service reserve fund whose monies also may be used to make principal and interest payments on the issuers obligations. In addition to a debt service reserve fund, some authorities provide further security in the form of a states ability (without obligation) to make up deficiencies in the debt reserve fund.
Puerto Rico Municipal Securities. Municipal obligations issued by the Commonwealth of Puerto Rico or its political subdivisions, agencies, instrumentalities, or public corporations may be affected by economic, market, political, and social conditions in Puerto Rico. Puerto Rico currently is experiencing significant fiscal and economic challenges, including substantial debt service obligations, high levels of unemployment, underfunded public retirement systems, and persistent government budget deficits. These challenges may negatively affect the value of a Funds investments in Puerto Rico municipal securities. Major ratings agencies have downgraded the general obligation debt of Puerto Rico to below investment grade and continue to maintain a negative outlook for this debt, which increases the likelihood that the rating will be lowered further. In both August 2015 and January 2016, Puerto Rico defaulted on its debt by failing to make full payment due on its outstanding bonds, and there can be no assurance that Puerto Rico will be able to satisfy its future debt obligations. Further downgrades or defaults may place additional strain on the Puerto Rico economy and may negatively affect the value, liquidity, and volatility of a Funds investments in Puerto Rico municipal securities. Future legislation, including legislation that would allow Puerto Rico to restructure its municipal debt obligations, thus increasing the risk that Puerto Rico may never pay off municipal indebtedness, or may pay only a small fraction of the amount owed, could also impact the value of a Funds investments in Puerto Rico municipal securities.
44
Securities purchased for a Fund may include variable/floating rate instruments, variable mode instruments, put bonds, and other obligations that have a specified maturity date but also are payable before maturity after notice by the holder. There are, in addition, a variety of hybrid and special types of municipal obligations as well as numerous differences in the security of municipal obligations both within and between the two principal classifications (i.e., notes and bonds). A Fund also may invest in credit default swaps on municipal securities. See Swap Contracts and Other Two-Party Contracts Swap Contracts.
See the Taxes section for a discussion of the tax treatment of municipal obligations at the Fund and shareholder level.
Auction Rate Securities
Auction rate securities consist of auction rate municipal securities and auction rate preferred securities sold through an auction process issued by closed-end investment companies, municipalities and governmental agencies. Provided that the auction mechanism is successful, auction rate securities usually permit the holder to sell the securities in an auction at par value at specified intervals. The dividend is reset by Dutch auction in which bids are made by brokers and other institutions for a certain amount of securities at a specified minimum yield. The dividend rate set by the auction is the lowest interest or dividend rate that covers all securities offered for sale. While this process is designed to permit auction rate securities to be traded at par value, there is the risk that an auction will fail due to insufficient demand for the securities.
Real Estate Investment Trusts and Other Real Estate-Related Investments
Certain Funds may invest in pooled real estate investment vehicles (so-called real estate investment trusts or REITs) and other real estate-related investments such as securities of companies principally engaged in the real estate industry. In addition to REITs, companies in the real estate industry and real estate-related investments may include, for example, entities that either own properties or make construction or mortgage loans, real estate developers, and companies with substantial real estate holdings. Each of these types of investments is subject to risks similar to those associated with direct ownership of real estate. Factors affecting real estate values include the supply of real property in particular markets, overbuilding, changes in zoning laws, casualty or condemnation losses, delays in completion of construction, changes in operations costs and property taxes, levels of occupancy, adequacy of rent to cover operating
45
expenses, possible environmental liabilities, regulatory limitations on rent, fluctuations in rental income, increased competition, and other risks related to local and regional market conditions. The value of real estate-related investments also may be affected by changes in interest rates, macroeconomic developments, and social and economic trends. For instance, during periods of declining interest rates, certain mortgage REITs may hold mortgages that the mortgagors elect to prepay, which prepayment may diminish the yield on securities issued by those REITs. Some REITs have relatively small market capitalizations, which can tend to increase the volatility of the market prices of their securities.
REITs are pooled investment vehicles that invest in real estate or real estate-related companies. The Funds may invest in different types of REITs, including equity REITs, mortgage REITs, and hybrid REITs. Equity REITs, which invest in and own real estate directly, generally invest a majority of their assets in income-producing properties to generate cash flow from rental income and gradual asset appreciation. The income-producing properties in which equity REITs invest typically include land, office, retail, industrial, hotel and apartment buildings, self storage, specialty and diversified and healthcare facilities. Equity REITs can realize capital gains (or losses) by selling properties that have appreciated (or depreciated) in value. Mortgage REITs, which make construction, development, or long-term mortgage loans, generally invest the majority of their assets in real estate mortgages or mortgage-backed securities and derive their income primarily from interest payments on the mortgages. Hybrid REITs share characteristics of equity REITs and mortgage REITs.
REITs can be listed and traded on national securities exchanges or can be traded privately between individual owners. An exchange-traded REIT is generally more liquid than a REIT that is not traded on a securities exchange. The Funds may invest in both exchange-traded and privately traded REITs.
In general, the value of a REITs shares changes in light of factors affecting the real estate industry. In addition, equity REITs may be affected by any changes in the value of the underlying property owned by the trusts, while mortgage REITs may be affected by the quality of any credit extended. REITs are also subject to the risk of fluctuations in income from underlying real estate assets, poor performance by the REITs manager and the managers inability to manage cash flows generated by the REITs assets, prepayments and defaults by borrowers, self-liquidation, adverse changes in the tax laws, and, with regard to U.S. REITs (as defined in the Taxes section below), the risk of failing to qualify for tax-free pass-through of income under the Code and/or to maintain exempt status under the 1940 Act. If a REIT were not to be eligible for the favorable tax treatment afforded to REITs under the Code, it would be subject to federal income tax, thus reducing its value. See the Taxes section for a discussion of special tax considerations relating to a Funds investments in U.S. REITs.
By investing in REITs indirectly through a Fund, an investor will bear not only his or her proportionate share of the expenses of the Fund, but also, indirectly, similar expenses of REITs. In addition, REITs depend generally on their ability to generate cash flow to make distributions to investors. Investments in REITs are subject to risks associated with the direct ownership of real estate.
46
Asset-Backed and Related Securities
An asset-backed security is a fixed income security that predominantly derives its creditworthiness from cash flows relating to a pool of assets. There are a number of different types of asset-backed and related securities, including mortgage-backed securities, securities backed by other pools of collateral (such as automobile loans, student loans, sub-prime mortgages, and credit card receivables), collateralized mortgage obligations, and collateralized debt obligations, each of which is described in more detail below. Investments in asset-backed securities are subject to all of the market risks for fixed income securities described in the Prospectus under Description of Principal Risks Market Risk Fixed Income Investments and elsewhere in this SAI.
Mortgage-Backed Securities. Mortgage-backed securities are asset-backed securities backed by pools of residential and commercial mortgages, which may include sub-prime mortgages. Mortgage-backed securities may be issued by agencies or instrumentalities of the U.S. government (including those whose securities are neither guaranteed nor insured by the U.S. government, such as Freddie Mac, Fannie Mae, and FHLBs), foreign governments (or their agencies or instrumentalities), or non-governmental issuers. Interest and principal payments (including prepayments) on the mortgage loans underlying mortgage-backed securities pass through to the holders of the mortgage-backed securities. Prepayments occur when the mortgagor on an individual mortgage loan prepays the remaining principal before the loans scheduled maturity date. Unscheduled prepayments of the underlying mortgage loans may result in early payment of the applicable mortgage-backed securities held by a Fund. The Fund may be unable to invest prepayments in an investment that provides as high a yield as the mortgage-backed securities. Consequently, early payment associated with mortgage-backed securities may cause these securities to experience significantly greater price and yield volatility than traditional fixed income securities. Many factors affect the rate of mortgage loan prepayments, including changes in interest rates, general economic conditions, further deterioration of worldwide economic and liquidity conditions, the location of the property underlying the mortgage, the age of the mortgage loan, governmental action, including legal impairment of underlying home loans, changes in demand for products financed by those loans, the inability of borrowers to refinance existing loans (e.g., sub-prime mortgages), and social and demographic conditions. During periods of falling interest rates, the rate of mortgage loan prepayments usually increases, which tends to decrease the life of mortgage-backed securities. During periods of rising interest rates, the rate of mortgage loan prepayments usually decreases, which tends to increase the life of mortgage-backed securities.
Mortgage-backed securities are subject to varying degrees of credit risk, depending on whether they are issued by agencies or instrumentalities of the U.S. government (including those whose securities are neither guaranteed nor insured by the U.S. government) or by non-governmental issuers. Securities issued by private organizations may not be readily marketable, and since the deterioration of worldwide economic and liquidity conditions that became acute in 2008, mortgage-backed securities have been subject to greater illiquidity risk. These conditions may occur again. Also, government actions and proposals affecting the terms of underlying home loans, changes in demand for products (e.g., automobiles) financed by those loans, and the inability of borrowers to refinance existing loans (e.g., sub-prime mortgages), have had, and may
47
continue to have, adverse valuation and liquidity effects on mortgage-backed securities. Although liquidity of mortgage-backed securities has improved recently, there can be no assurance that in the future the market for mortgage-backed securities will continue to improve and become more liquid. In addition, mortgage-backed securities are subject to the risk of loss of principal if the obligors of the underlying obligations default in their payment obligations, and to certain other risks described in Other Asset-Backed Securities below. The risk of defaults associated with mortgage-backed securities is generally higher in the case of mortgage-backed investments that include sub-prime mortgages. See Description of Principal Risks Market Risk Asset-Backed Securities and Credit Risk in the Prospectus for more information regarding credit and other risks associated with investments in asset-backed securities.
Mortgage-backed securities may include Adjustable Rate Securities as such term is defined in Adjustable Rate Securities below.
Other Asset-Backed Securities. Similar to mortgage-backed securities, other types of asset-backed securities may be issued by agencies or instrumentalities of the U.S. government (including those whose securities are neither guaranteed nor insured by the U.S. government), foreign governments (or their agencies or instrumentalities), or non-governmental issuers. These securities include securities backed by pools of automobile loans, educational loans, home equity loans, and credit card receivables. The underlying pools of assets are securitized through the use of trusts and special purpose entities. These securities may be subject to risks associated with changes in interest rates and prepayment of underlying obligations similar to the risks of investment in mortgage-backed securities described immediately above. Similar to mortgage-backed securities, other asset-backed securities face illiquidity risk from worldwide economic and liquidity conditions as described above in Mortgage-Backed Securities. The risk of investing in asset-backed securities has increased because performance of the various sectors in which the assets underlying asset-backed securities are concentrated (e.g., auto loans, student loans, sub-prime mortgages, and credit card receivables) has become more highly correlated since the deterioration in worldwide economic and liquidity conditions referred to above.
Payment of interest on asset-backed securities and repayment of principal largely depends on the cash flows generated by the underlying assets backing the securities and, in certain cases, may be supported by letters of credit, surety bonds, or other credit enhancements. The amount of market risk associated with asset-backed securities depends on many factors, including the deal structure (e.g., the amount of underlying assets or other support available to produce the cash flows necessary to service interest and make principal payments), the quality of the underlying assets, the level of credit support, if any, provided for the securities, and the credit quality of the credit-support provider, if any. Asset-backed securities involve risk of loss of principal if obligors of the underlying obligations default in payment of the obligations and the defaulted obligations exceed the securities credit support. The obligations of issuers (and obligors of underlying assets) may be subject to bankruptcy, insolvency and other laws affecting the rights and remedies of creditors. In addition, the existence of insurance on an asset-backed security does not guarantee that principal and/or interest will be paid because the insurer could default on its obligations. In recent years, a significant number of asset-backed security insurers have defaulted on their obligations.
48
The market value of an asset-backed security may be affected by the factors described above and other factors, such as the availability of information concerning the pool and its structure, the creditworthiness of the servicing agent for the pool, the originator of the underlying assets, or the entities providing the credit enhancement. The market value of asset-backed securities also can depend on the ability of their servicers to service the underlying collateral and is, therefore, subject to risks associated with servicers performance. In some circumstances, a servicers or originators mishandling of documentation for underlying assets (e.g., failure to properly document a security interest in the underlying collateral) may affect the rights of the holders of those underlying assets. In addition, the insolvency of an entity that generated the assets underlying an asset-backed security is likely to result in a decline in the market price of that security as well as costs and delays.
Certain types of asset-backed securities present additional risks that are not presented by mortgage-backed securities. In particular, certain types of asset-backed securities may not have the benefit of a security interest in the related assets. For example, many securities backed by credit card receivables are unsecured. In addition, a Fund may invest in securities backed by pools of corporate or sovereign bonds, bank loans to corporations, or a combination of bonds and loans, many of which may be unsecured (commonly referred to as collateralized debt obligations or collateralized loan obligations) (see Collateralized Debt Obligations (CDOs)). Even when security interests are present, the ability of an issuer of certain types of asset-backed securities to enforce those interests may be more limited than that of an issuer of mortgage-backed securities. For instance, automobile receivables generally are secured by automobiles rather than by real property. Most issuers of automobile receivables permit loan servicers to retain possession of the underlying assets. In addition, because of the large number of underlying vehicles involved in a typical issue of asset-backed securities and technical requirements under state law, the trustee for the holders of the automobile receivables may not have a proper security interest in all of the automobiles. Therefore, recoveries on repossessed automobiles may not be available to support payments on these securities.
In addition, certain types of asset-backed securities may experience losses on the underlying assets as a result of certain rights provided to consumer debtors under federal and state law. In the case of certain consumer debt, such as credit card debt, debtors are entitled to the protection of a number of state and federal consumer credit laws, many of which give such debtors the right to set off certain amounts owed on their credit cards (or other debt), thereby reducing their balances due. For instance, a debtor may be able to offset certain damages for which a court has determined that the creditor is liable to the debtor against amounts owed to the creditor by the debtor on his or her credit card.
Collateralized Mortgage Obligations ( CMOs ); Residuals and Strips. A CMO is a debt obligation backed by a portfolio of mortgages or mortgage-backed securities held under an indenture. The issuer of a CMO generally pays interest and prepaid principal on a monthly basis. These payments are secured by the underlying portfolio, which typically includes mortgage pass-through securities guaranteed by Freddie Mac, Fannie Mae, or the Government National Mortgage Association (Ginnie Mae) and their income streams, and which also may include whole mortgage loans and private mortgage bonds.
49
CMOs are issued in multiple classes, often referred to as tranches. Each class has a different maturity and is entitled to a different schedule for payments of principal and interest, including pre-payments.
In a typical CMO transaction, the issuer of the CMO bonds uses proceeds from the CMO offering to buy mortgages or mortgage pass-through certificates (the Collateral). The issuer then pledges the Collateral to a third party trustee as security for the CMOs. The issuer uses principal and interest payments from the Collateral to pay principal on the CMOs, paying the tranche with the earliest maturity first. Thus, the issuer pays no principal on a tranche until all other tranches with earlier maturities are paid in full. The early retirement of a particular class or series has the same effect as the prepayment of mortgage loans underlying a mortgage-backed pass-through security.
CMOs may be less liquid and may exhibit greater price volatility than other types of mortgage- or other asset-backed securities.
The Funds also may invest in CMO residuals, which are issued by agencies or instrumentalities of the U.S. government or by private lenders of, or investors in, mortgage loans, including savings and loan associations, homebuilders, mortgage banks, commercial banks, and investment banks. A CMO residual represents excess cash flow generated by the Collateral after the issuer of the CMO makes all required principal and interest payments and after the issuers management fees and administrative expenses have been paid. Thus, CMO residuals have value only to the extent income from the Collateral exceeds the amount necessary to satisfy the issuers debt obligations on all other outstanding CMOs. The amount of residual cash flow resulting from a CMO will depend on, among other things, the characterization of the mortgage assets, the coupon rate of each class of CMO, prevailing interest rates, the amount of administrative expenses, and the pre-payment experience on the mortgage assets.
CMOs also include certificates representing undivided interests in payments of interest-only or principal-only (IO/PO Strips) on the underlying mortgages.
IO/PO Strips and CMO residuals tend to be more volatile than other types of securities. If the underlying securities are prepaid, holders of IO/PO Strips and CMO residuals may lose a substantial portion or the entire value of their investment. In addition, if a CMO pays interest at an adjustable rate, the cash flows on the related CMO residual will be extremely sensitive to rate adjustments.
Collateralized Debt Obligations (CDOs). A Fund may invest in CDOs, which include collateralized bond obligations (CBOs), collateralized loan obligations (CLOs), and other similarly structured securities. CBOs and CLOs are asset-backed securities. A CBO is an obligation of a trust or other special purpose vehicle backed by a pool of fixed income securities. A CLO is an obligation of a trust or other special purpose vehicle typically collateralized by a pool of loans, which may include U.S. and non-U.S. senior secured and unsecured loans, and subordinate corporate loans, including loans that may be rated below investment grade, or equivalent unrated loans.
50
For both CBOs and CLOs, the cash flows from the trust are split into two or more portions, called tranches, which vary in risk and yield. The riskier portions are the residual, equity, and subordinate tranches, which bear some or all of the risk of default by the bonds or loans in the trust, and therefore protect the other, more senior tranches from default in all but the most severe circumstances. Since it is partially protected from defaults, a senior tranche from a CBO trust or CLO trust typically has higher ratings and lower yields than its underlying securities, and can be rated investment grade. Despite the protection from the riskier tranches, senior CBO or CLO tranches can experience substantial losses due to actual defaults (including collateral default), the total loss of the riskier tranches due to losses in the collateral, market anticipation of defaults, fraud by the trust, and the illiquidity of CBO or CLO securities.
The risks of an investment in a CDO largely depend on the type of underlying collateral securities and the tranche in which a Fund invests. The Funds may invest in any tranche of a CBO or CLO. Typically, CBOs, CLOs and other CDOs are privately offered and sold, and thus, are not registered under the securities laws. As a result, a Fund may characterize its investments in CDOs as illiquid, unless an active dealer market for a particular CDO allows the CDO to be purchased and sold in Rule 144A transactions. CDOs are subject to the typical risks associated with debt instruments discussed elsewhere in this SAI and the Prospectus, including interest rate risk (which may be exacerbated if the interest rate payable on a structured financing changes based on multiples of changes in interest rates or inversely to changes in interest rates), default risk, prepayment risk, credit risk, illiquidity risk, market risk, structural risk, and legal risk. Additional risks of CDOs include: (i) the possibility that distributions from collateral securities will be insufficient to make interest or other payments; (ii) the possibility that the quality of the collateral may decline in value or default, due to factors such as the availability of any credit enhancement, the level and timing of payments and recoveries on and the characteristics of the underlying receivables, loans, or other assets that are being securitized, remoteness of those assets from the originator or transferor, the adequacy of and ability to realize upon any related collateral, and the capability of the servicer of the securitized assets; (iii) market and illiquidity risks affecting the price of a structured finance investment, if required to be sold, at the time of sale; and (iv) if the particular structured product is invested in a security in which a Fund is also invested, this would tend to increase the Funds overall exposure to the credit of the issuer of such securities, at least on an absolute, if not on a relative basis. In addition, due to the complex nature of a CDO, an investment in a CDO may not perform as expected. An investment in a CDO also is subject to the risk that the issuer and the investors may interpret the terms of the instrument differently, giving rise to disputes.
The Funds may invest in covered bonds, which are debt securities issued by banks or other credit institutions that are backed by both the issuing institution and underlying pool of assets that compose the bond (a cover pool). The cover pool for a covered bond is typically composed of residential or commercial mortgage loans or loans to public sector institutions. A covered bond may lose value if the credit rating of the issuing bank or credit institution is downgraded or the quality of the assets in the cover pool deteriorates.
Adjustable Rate Securities
Adjustable rate securities are securities that have interest rates that reset at periodic intervals, usually by reference to an interest rate index or market interest rate. Adjustable rate securities
51
include U.S. government securities and securities of other issuers. Some adjustable rate securities are backed by pools of mortgage loans. Although the rate adjustment feature may act as a buffer to reduce sharp changes in the value of adjustable rate securities, changes in market interest rates or changes in the issuers creditworthiness may still affect their value. Because the interest rate is reset only periodically, changes in the interest rates on adjustable rate securities may lag changes in prevailing market interest rates. Also, some adjustable rate securities (or, in the case of securities backed by mortgage loans, the underlying mortgages) are subject to caps or floors that limit the maximum change in interest rate during a specified period or over the life of the security. Because of the rate adjustments, adjustable rate securities are less likely than non-adjustable rate securities of comparable quality and maturity to increase significantly in value when market interest rates fall.
Below Investment Grade Securities
Some Funds may invest some or all of their assets in securities or instruments rated below investment grade (that is, rated below Baa3/P-2 by Moodys Investors Service, Inc. (Moodys) or below BBB-/A-2 by Standard & Poors (S&P) for a particular security/commercial paper, or securities unrated by Moodys or S&P that are determined by GMO to be of comparable quality to securities so rated) at the time of purchase, including securities in the lowest rating categories and comparable unrated securities (Below Investment Grade Securities) (commonly referred to as junk bonds). In addition, some Funds may hold securities that are downgraded to below investment grade status after the time of purchase by the Funds. Many issuers of high yield debt are highly leveraged, and their relatively high debt-to-equity ratios create increased risks that their operations might not generate sufficient cash flow to service their debt obligations. In addition, many issuers of high yield debt may be (i) in poor financial condition; (ii) experiencing poor operating results; (iii) having substantial capital needs or negative net worth; or (iv) facing special competitive or product obsolescence problems, and may include companies involved in bankruptcy or other reorganizations or liquidation proceedings. Compared to higher quality fixed income securities, Below Investment Grade Securities offer the potential for higher investment returns but subject holders to greater credit and market risk. The ability of an issuer of Below Investment Grade Securities to meet principal and interest payments is considered speculative. A Funds investments in Below Investment Grade Securities are more dependent on GMOs own credit analysis than its investments in higher quality bonds. Certain of these securities may not be publicly traded, and therefore it may be difficult to obtain information as to the true condition of the issuers. The market for Below Investment Grade Securities may be more severely affected than other financial markets by economic recession or substantial interest rate increases, changing public perceptions, or legislation that limits the ability of certain categories of financial institutions to invest in Below Investment Grade Securities. In addition, the market may be less liquid for Below Investment Grade Securities than for other types of securities. Reduced liquidity can affect the values of Below Investment Grade Securities, make their valuation and sale more difficult, and result in greater volatility. Because Below Investment Grade Securities are difficult to value and are more likely to be fair valued (see Determination of Net Asset Value in the Prospectus and herein), particularly during erratic markets, the values realized on their sale may differ from the values at which they are carried on the books of a Fund. Some Below Investment Grade Securities in which a Fund invests may be in poor standing or in default.
52
Securities in the lowest investment-grade category (BBB or Baa) also have some speculative characteristics. See Appendix B Commercial Paper and Corporate Debt Ratings for more information concerning commercial paper and corporate debt ratings.
Distressed or Defaulted Debt Securities
Some Funds may invest in securities, claims, and obligations of U.S. and non-U.S. issuers which are experiencing significant financial or business difficulties (including companies involved in bankruptcy or other reorganization and liquidation proceedings). A Fund may purchase distressed securities and instruments of all kinds, including equity and debt instruments and, in particular, loans, loan participations, claims held by trade or other creditors, bonds, notes, non-performing and sub-performing mortgage loans, beneficial interests in liquidating trusts or other similar types of trusts, fee interests and financial interests in real estate, partnership interests and similar financial instruments, executory contracts and participations therein, many of which are not publicly traded and which may involve a substantial degree of risk.
Investments in distressed or defaulted debt securities generally are considered speculative and may involve substantial risks not normally associated with investments in higher quality securities, including adverse business, financial or economic conditions that can lead to payment defaults and insolvency proceedings on the part of their issuers.
In particular, defaulted obligations might be repaid, if at all, only after lengthy workout or bankruptcy proceedings, during which the issuer might not make any interest or other payments. The amount of any recovery may be adversely affected by the relative priority of the Funds investment in the issuers capital structure. The ability to enforce obligations may be adversely affected by actions or omissions of predecessors in interest that give rise to counterclaims or defenses, including causes of action for equitable subordination or debt recharacterization. In addition, such investments, collateral securing such investments, and payments made in respect of such investments may be challenged as fraudulent conveyances or to be subject to avoidance as preferences under certain circumstances.
Investments in distressed securities inherently have more credit risk than do investments in similar securities and instruments of non-distressed companies, and the degree of risk associated with any particular distressed securities may be difficult or impossible for GMO to determine within reasonable standards of predictability. The level of analytical sophistication, both financial and legal, necessary for successful investment in distressed securities is unusually high.
If GMOs assessment of the eventual recovery value of a defaulted debt security proves incorrect, a Fund may lose a substantial portion or all of its investment or may be required to accept cash or instruments worth less than its original investment.
Investments in financially distressed companies domiciled outside the United States involve additional risks. Bankruptcy law and creditor reorganization processes may differ substantially from those in the United States, resulting in greater uncertainty as to the rights of creditors, the enforceability of such rights, reorganization timing and the classification, seniority and treatment of claims. In certain developing countries, although bankruptcy laws have been enacted, the process for reorganization remains highly uncertain.
53
In addition, investments in distressed or defaulted debt securities can present special tax issues for a Fund. See the Taxes section for more information.
Brady Bonds
Brady Bonds are securities created through the restructuring of commercial bank loans to public and private entities under a debt restructuring plan introduced by former U.S. Secretary of the Treasury Nicholas F. Brady (the Brady Plan). Brady Plan debt restructurings have been implemented in Mexico, Uruguay, Venezuela, Costa Rica, Argentina, Nigeria, the Philippines, and other emerging countries.
Brady Bonds may be collateralized, are issued in various currencies (but primarily the U.S. dollar), and are traded in OTC secondary markets. U.S. dollar-denominated, collateralized Brady Bonds, which may be fixed-rate bonds or floating-rate bonds, are generally collateralized in full as to principal by U.S. Treasury zero coupon bonds having the same maturity as the bonds.
The valuation of a Brady Bond typically depends on an evaluation of: (i) any collateralized repayments of principal at final maturity; (ii) any collateralized interest payments; (iii) the uncollateralized interest payments; and (iv) any uncollateralized repayments of principal at maturity (the uncollateralized amounts constitute the residual risk). In light of the history of prior defaults by the issuers of Brady Bonds, investments in Brady Bonds may be viewed as speculative regardless of the current credit rating of the issuer. There are very few remaining Brady Bonds in existence today.
Euro Bonds
Euro bonds are securities denominated in U.S. dollars or another currency and sold to investors outside of the country whose currency is used. Euro bonds may be issued by government or corporate issuers, and are typically underwritten by banks and brokerage firms in numerous countries. While Euro bonds often pay principal and interest in U.S. dollars held in banks outside of the United States (Eurodollars), some Euro bonds may pay principal and interest in other currencies. Euro bonds are subject to the same risks as other fixed income securities. See Debt and Other Fixed Income Securities Generally.
Zero Coupon Securities
A Fund investing in zero coupon fixed income securities accrues interest income at a fixed rate based on initial purchase price and length to maturity, but the securities do not pay interest in cash on a current basis. Each Fund that is a regulated investment company under Subchapter M of the Code is required to distribute the accrued income to its shareholders, even though the Fund is not receiving the income in cash on a current basis. Thus, a Fund may have to sell other investments to obtain cash to make income distributions (including at a time when it may not be advantageous to do so). See the Taxes section. The market value of zero coupon securities is often more volatile than that of non-zero coupon fixed income securities of comparable quality and maturity. Zero coupon securities include IO/PO Strips and STRIPS.
54
Indexed Investments
Each Fund may invest in various transactions and instruments that are designed to track the performance of an index (including, but not limited to, securities indices and credit default indices). Indexed securities are securities the redemption values and/or coupons of which are indexed to a specific instrument, group of instruments, index, or other statistic. Indexed securities typically, but not always, are debt securities or deposits whose value at maturity or coupon rate is determined by reference to other securities, securities or inflation indices, currencies, precious metals or other commodities, or other financial indicators. For example, the maturity value of gold-indexed securities depends on the price of gold and, therefore, their price tends to rise and fall with gold prices.
While investments that track the performance of an index may increase the number, and thus the diversity, of the underlying assets to which the Fund is exposed, such investments are subject to many of the same risks of investing in the underlying assets that comprise the index discussed elsewhere in this section, as well as certain additional risks that are not typically associated with investments in such underlying assets. An investment that is designed to track the performance of an index may not replicate and maintain exactly the same composition and relative weightings of the assets in the index. Additionally, the liquidity of the market for such investments may be subject to the same conditions affecting liquidity in the underlying assets and markets and could be relatively less liquid in certain circumstances. The performance of indexed securities depends on the performance of the security, security index, inflation index, currency, or other instrument to which they are indexed. Interest rate changes in the United States and abroad also may influence performance. Indexed securities also are subject to the credit risks of the issuer, and their values are adversely affected by declines in the issuers creditworthiness.
A Funds investments in certain indexed securities, including inflation-indexed bonds, may generate taxable income in excess of the interest they pay to the Fund, which may cause the Fund to sell investments to obtain cash to make income distributions to shareholders (including at a time when it may not be advantageous to do so). See the Taxes section.
Currency-Indexed Securities. Currency-indexed securities have maturity values or interest rates determined by reference to the values of one or more foreign currencies. Currency-indexed securities also may have maturity values or interest rates that depend on the values of a number of different foreign currencies relative to each other.
Inverse Floating Obligations. Indexed securities in which a Fund may invest include so-called inverse floating obligations or residual interest bonds on which the interest rates typically decline as the index or reference rates, typically short-term interest rates, increase and increase as index or reference rates decline. An inverse floating obligation may have the effect of investment leverage to the extent that its interest rate varies by a magnitude that exceeds the magnitude of the change in the index or reference rate of interest. Generally, leverage will result in greater price volatility.
55
Inflation-Indexed Bonds. Some Funds may invest in inflation-indexed bonds and in futures contracts on inflation-indexed bonds. See Options, Futures, and Forward Contracts Inflation-Linked Futures for a discussion of inflation-linked futures. Inflation-indexed bonds are fixed income securities whose principal value is adjusted periodically according to the rate of inflation. Two structures are common. The U.S. Treasury and some other issuers use a structure that accrues inflation into the principal value of the bond. Most other issuers pay out the CPI accruals as part of a semiannual coupon.
Inflation-indexed securities issued by the U.S. Treasury (or TIPS) have maturities of approximately three, five, ten, or thirty years, although it is possible that securities that have other maturities will be issued in the future. U.S. Treasury securities pay interest on a semi-annual basis equal to a fixed percentage of the inflation-adjusted principal amount. For example, if a Fund purchased an inflation-indexed bond with a par value of $1,000 and a 3% real rate of return coupon (payable 1.5% semi-annually), and the rate of inflation over the first six months was 1%, the mid-year par value of the bond would be $1,010 and the first semi-annual interest payment would be $15.15 ($1,010 times 1.5%). If inflation during the second half of the year resulted in the whole years inflation equaling 3%, the end-of-year par value of the bond would be $1,030 and the second semi-annual interest payment would be $15.45 ($1,030 times 1.5%).
If the periodic adjustment rate measuring inflation falls, the principal value of inflation-indexed bonds will be adjusted downward and, consequently, the interest they pay (calculated with respect to a smaller principal amount) will be reduced. The U.S. government guarantees the repayment of the original bond principal upon maturity (as adjusted for inflation) in the case of a TIPS, even during a period of deflation, although the inflation-adjusted principal received could be less than the inflation-adjusted principal that had accrued to the bond at the time of purchase. However, the current market value of the bonds is not guaranteed and will fluctuate. A Fund also may invest in other inflation-related bonds which may or may not provide a similar guarantee. If a guarantee of principal is not provided, the adjusted principal value of the bond repaid at maturity may be less than the original principal.
The market price of inflation-indexed bonds (including TIPS) normally changes when real interest rates change. Their value typically declines during periods of rising real interest rates (i.e., nominal interest rate minus inflation) and increases during periods of declining real interest rates. Real interest rates, in turn, are tied to the relationship between nominal interest rates (i.e., stated interest rates) and the rate of inflation. Therefore, if the rate of inflation rises at a faster rate than nominal interest rates, real interest rates (i.e., nominal interest rate minus inflation) might decline, leading to an increase in value of inflation-indexed bonds. In contrast, if nominal interest rates increase at a faster rate than inflation, real interest rates might rise, leading to a decrease in value of inflation-indexed bonds. In some interest rate environments, such as when real interest rates are rising faster than nominal interest rates, the market price of inflation-indexed bonds may decline more than the price of non-inflation-indexed (or nominal) fixed income bonds with similar maturities. Moreover, if the index measuring inflation falls, the principal value of inflation-indexed bond investments will be adjusted downward, and, consequently, the interest they pay (calculated with respect to a smaller principal amount) will be reduced.
56
Although inflation-indexed bonds protect their holders from long-term inflationary trends, short-term increases in inflation may result in a decline in value. In addition, inflation-indexed bonds do not protect holders from increases in interest rates due to reasons other than inflation (such as changes in currency exchange rates).
The periodic adjustment of U.S. inflation-indexed bonds is tied to the Consumer Price Index for Urban Consumers (CPI-U), which is calculated monthly by the U.S. Bureau of Labor Statistics. The CPI-U is a measurement of changes in the cost of living, made up of components such as housing, food, transportation, and energy. Inflation-indexed bonds issued by a foreign government are generally adjusted to reflect changes in a comparable inflation index calculated by the foreign government. No assurance can be given that the CPI-U or any foreign inflation index will accurately measure the real rate of inflation in the prices of goods and services. In addition, no assurance can be given that the rate of inflation in a foreign country will correlate to the rate of inflation in the United States.
Coupon payments received by a Fund from inflation-indexed bonds generally are included in the Funds gross income for the period in which they accrue. In addition, any increase in the principal amount of an inflation-indexed bond constitutes taxable ordinary income to investors in the Fund, even though principal is not paid until maturity.
Structured Notes
Similar to indexed securities, structured notes are derivative debt securities, the interest rate or principal of which is determined by reference to changes in the value of a specific asset, reference rate, or index (the reference) or the relative change in two or more references. The interest rate or the principal amount payable upon maturity or redemption may increase or decrease, depending upon changes in the reference. The terms of a structured note may provide that, in certain circumstances, no principal is due at maturity and, therefore, may result in a loss of invested capital. Structured notes may be indexed positively or negatively, so that appreciation of the reference may produce an increase or decrease in the interest rate or value of the principal at maturity. In addition, changes in the interest rate or the value of the principal at maturity may be fixed at a specified multiple of the change in the value of the reference, making the value of the note particularly volatile.
Structured notes may entail a greater degree of market risk than other types of debt securities because the investor bears the risk of the reference. Structured notes also may be more volatile, less liquid, and more difficult to price accurately than less complex securities or more traditional debt securities.
Firm Commitments, When-Issued Securities, and TBAs
Some Funds may enter into firm commitments and similar agreements with banks or brokers for the purchase or sale of securities at an agreed-upon price on a specified future date. For example, a Fund that invests in fixed income securities may enter into a firm commitment agreement if GMO anticipates a decline in interest rates and believes it is able to obtain a more advantageous future yield by committing currently to purchase securities to be issued later. A Fund generally does not earn income on the securities it has committed to purchase until after
57
delivery. A Fund may take delivery of the securities or, if deemed advisable as a matter of investment strategy, may sell the securities before the settlement date. When payment is due on when-issued or delayed-delivery securities, the Fund makes payment from then-available cash flow or the sale of securities, or from the sale of the when-issued or delayed-delivery securities themselves (which may have a value greater or less than what the Fund paid for them).
Certain Funds may purchase or sell securities, including mortgage-backed securities, in the to-be-announced (TBA) market. A TBA purchase commitment is a security that is purchased or sold for a fixed price and the underlying securities are announced at a future date. The seller does not specify the particular securities to be delivered. Instead, a Fund agrees to accept any security that meets specified terms. For example, in a TBA mortgage-backed security transaction, a Fund and the seller would agree upon the issuer, interest rate and terms of the underlying mortgages. The seller would not identify the specific underlying mortgages until it issues the security. The purchaser of TBA securities generally is subject to increased market risk and interest rate risk because the delivered securities may be less favorable than anticipated by the purchaser.
Loans (Including Bank Loans), Loan Participations, and Assignments
Some Funds may invest in direct debt instruments, which are interests in amounts owed to lenders or lending syndicates, to suppliers of goods or services, or to other parties by a corporate, governmental, or other borrower. Such loans may include bank loans, promissory notes, and loan participations, or in the case of suppliers of goods or services, trade claims or other receivables. Investments in direct debt instruments are subject to a Funds policies regarding the quality of debt investments generally. Such instruments may include term loans and revolving loans, may pay interest at a fixed or floating rate, and may be senior or subordinated. The Funds may acquire interests in loans either directly (by way of sale or assignment) or indirectly (by way of participation).
Purchases of loans and other forms of direct indebtedness depend primarily upon the creditworthiness of the borrower for payment of principal and interest, and adverse changes in the creditworthiness of the borrower may affect its ability to pay principal and interest. Direct debt instruments may not be rated by any rating agency. In the event of non-payment of interest or principal, loans that are secured offer a Fund more protection than comparable unsecured loans. However, no assurance can be given that the collateral for a secured loan can be liquidated or that the proceeds will satisfy the borrowers obligation. Investment in the indebtedness of borrowers with low creditworthiness involves substantially greater risks, and may be highly speculative. Borrowers that are in bankruptcy or restructuring may never pay off their indebtedness, or may pay only a small fraction of the amount owed. Investments in sovereign debt similarly involve the risk that the governmental entities responsible for repayment of the debt may be unable or unwilling to pay interest and repay principal when due. The bank loans acquired by a Fund may be below investment grade or unrated.
When investing in a loan participation, a Fund typically purchases participation interests in a portion of a lenders or participants interest in a loan but has no direct contractual relationship with the borrower. Participation interests in a portion of a debt obligation typically result in a contractual relationship only with the institution participating in the interest, not with the
58
borrower. The Fund must rely on the seller of the participation interest not only for the enforcement of the Funds rights against the borrower but also for the receipt and processing of principal, interest, or other payments due under the loan. This may subject the Fund to greater delays, expenses, and risks than if the Fund could enforce its rights directly against the borrower. In addition, the Fund generally will have no rights of set-off against the borrower, and the Fund may not directly benefit from the collateral supporting the debt obligation in which it has purchased the participation. A participation agreement also may limit the rights of the Fund to vote on changes that may be made to the underlying loan agreement, such as waiving a breach of a covenant. In addition, under the terms of a participation agreement, the Fund may be treated as a creditor of the seller of the participation interest (rather than of the borrower), thus exposing the Fund to the credit risk of the seller in addition to the credit risk of the borrower. Additional risks include inadequate perfection of a loans security interest, the possible invalidation or compromise of an investment transaction as a fraudulent conveyance or preference under relevant creditors rights laws, the validity and seniority of bank claims and guarantees, environmental liabilities that may arise with respect to collateral securing the obligations, and adverse consequences resulting from participating in such instruments through other institutions with lower credit quality.
Bank loans and participation interests may not be readily marketable and may be subject to restrictions on resale. There can be no assurance that future levels of supply and demand in loan or loan participation trading will provide an adequate degree of liquidity and no assurance that the market will not experience periods of significant illiquidity in the future.
Investments in loans through direct assignment of a lenders interests may involve additional risks to a Fund. For example, if a secured loan is foreclosed, the Fund could become part owner of any collateral, and would bear the costs and liabilities associated with owning and disposing of the collateral. In addition, under legal theories of lender liability, the Fund potentially might be held liable as a co-lender.
A loan is often administered by a bank or other financial institution that acts as agent for all holders. The agent administers the terms of the loan, as specified in the loan agreement. Unless, under the terms of the loan or other indebtedness a Fund has direct recourse against the borrower, it may have to rely on the agent to enforce its rights against the borrower.
GMO may, with respect to its management of investments in certain loans for a Fund, seek to remain flexible to purchase and sell other securities in the borrowers capital structure, by remaining public. In such cases, GMO will seek to avoid receiving material, non-public information about the borrowers to which the Fund may lend (through assignments, participations or otherwise). GMOs decision not to use material, non-public information about borrowers may place GMO at an information disadvantage relative to other lenders. Also, in instances where lenders are asked to grant amendments, waivers or consents in favor of the borrower, GMOs ability to assess the significance of the amendment, waiver or consent or its desirability from a Funds point of view may be materially and adversely affected.
When GMOs employees, on-site consultants, partners, members, directors, or officers come into possession of material, non-public information about the issuers of loans that may be held by a Fund or other accounts managed by GMO (either intentionally or inadvertently), or material,
59
non-public information is otherwise attributed to GMO, GMOs ability to trade in other securities of the issuers of these loans for the account of GMO may be limited pursuant to applicable securities laws. Such limitations on GMOs ability to trade could have an adverse effect on a Fund. In many instances, these trading restrictions could continue in effect for a substantial period of time.
Direct indebtedness purchased by a Fund may include letters of credit, revolving credit facilities, or other standby financing commitments obligating the Fund to pay additional cash on demand. These commitments may have the effect of requiring the Fund to increase its investment in a borrower at a time when it would not otherwise have done so. A Fund is required to maintain liquid assets to cover the Funds potential obligations under standby financing commitments.
Loans may not be considered securities, and a Fund that purchases a loan may not be entitled to rely on anti-fraud and other protections under the federal securities laws.
Trade Claims. The Funds may purchase trade claims against companies, including companies in bankruptcy or reorganization proceedings. Trade claims generally include claims of suppliers for goods delivered and not paid, claims for unpaid services rendered, claims for contract rejection damages and claims related to litigation. An investment in trade claims is very speculative and carries a high degree of risk. Trade claims are illiquid instruments which generally do not pay interest and there can be no guarantee that the debtor will ever be able to satisfy the obligation on the trade claim. Additionally, there can be restrictions on the purchase, sale, and/or transferability of trade claims during all or part of a bankruptcy proceeding. The markets in trade claims generally are not regulated by U.S. federal securities laws or the Securities and Exchange Commission (SEC).
Trade claims are typically unsecured and may be subordinated to other unsecured obligations of a debtor, and generally are subject to defenses of the debtor with respect to the underlying transaction giving rise to the trade claim. Although GMO endeavors to protect against such risks in connection with the evaluation and purchase of claims, trade claims are subject to risks not generally associated with standardized securities and instruments due to the idiosyncratic nature of the claims purchased. These risks include the risk that the debtor may contest the allowance of the claim due to disputes the debtor has with the original claimant or the inequitable conduct of the original claimant, or due to administrative errors in connection with the transfer of the claim. Recovery on allowed trade claims also may be impaired if the anticipated dividend payable on unsecured claims in the bankruptcy is not realized or if the timing of the bankruptcy distribution is delayed. As a result of the foregoing factors, trade claims are also subject to the risk that if a Fund does receive payment, it may be in an amount less than what the Fund paid for or otherwise expects to receive in respect of the claim.
In addition, because they are not negotiable instruments, trade claims are typically less liquid than negotiable instruments. Given these factors, trade claims often trade at a discount to other pari passu instruments.
60
Reverse Repurchase Agreements and Dollar Roll Agreements
The Funds may enter into reverse repurchase agreements and dollar roll agreements with banks and brokers to enhance return. Reverse repurchase agreements involve sales by a Fund of portfolio securities concurrently with an agreement by the Fund to repurchase the same securities at a later date at a fixed price. During the reverse repurchase agreement period, the Fund continues to receive principal and interest payments on the securities and also has the opportunity to earn a return on the collateral furnished by the counterparty to secure its obligation to redeliver the securities.
Dollar rolls are transactions in which a Fund sells securities for delivery in the current month and simultaneously contracts to repurchase substantially similar (same type and coupon) securities on a specified future date. During the roll period, the Fund foregoes principal and interest paid on the securities. The Fund is compensated by the difference between the current sales price and the forward price for the future purchase (often referred to as the drop) as well as by the interest earned on the cash proceeds of the initial sale.
If the buyer in a reverse repurchase agreement or dollar roll agreement files for bankruptcy or becomes insolvent, a Funds use of proceeds from the sale of its securities may be restricted while the other party or its trustee or receiver determines whether to honor the Funds right to repurchase the securities. Furthermore, in that situation a Fund may be unable to recover the securities it sold in connection with a reverse repurchase agreement and as a result would realize a loss equal to the difference between the value of the securities and the payment it received for them. This loss would be greater to the extent the buyer paid less than the value of the securities the Fund sold to it (e.g., a buyer may only be willing to pay $95 for a bond with a market value of $100). A Funds use of reverse repurchase agreements also subjects the Fund to interest costs based on the difference between the sale and repurchase price of a security involved in such a transaction. Additionally, reverse repurchase agreements entail the same risks as OTC derivatives. These include the risk that the counterparty to the reverse repurchase agreement may not be able to fulfill its obligations, as discussed above, that the parties may disagree as to the meaning or application of contractual terms, or that the instrument may not perform as expected. See Description of Principal Risks Derivatives and Short Sales Risk and Counterparty Risk in the Prospectus and Uses of Derivatives below. Reverse repurchase agreements and dollar rolls are not considered borrowings by a Fund for purposes of a Funds fundamental investment restriction on borrowings.
Commodity-Related Investments
Some Funds may gain exposure to commodity markets by investing in commodities or commodity-related instruments directly or indirectly, including through investments in Implementation Fund, SGM Major Markets Fund, or Special Opportunities Fund. Commodity prices can be extremely volatile and may be directly or indirectly affected by many factors, including changes in overall market movements, real or perceived inflationary trends, commodity index volatility, changes in interest rates or currency exchange rates, population growth and changing demographics, and factors affecting a particular industry or commodity, such as drought, floods, or other weather conditions, livestock disease, trade embargoes, competition from substitute products, transportation bottlenecks or shortages, fluctuations in
61
supply and demand, tariffs, and international regulatory, political, and economic developments (e.g., regime changes and changes in economic activity levels). In addition, some commodities are subject to limited pricing flexibility because of supply and demand factors, and others are subject to broad price fluctuations as a result of the volatility of prices for certain raw materials and the instability of supplies of other materials.
Actions of and changes in governments, and political and economic instability, in commodity-producing and - exporting countries may affect the production and marketing of commodities. In addition, commodity-related industries throughout the world are subject to greater political, environmental, and other governmental regulation than many other industries. Changes in government policies and the need for regulatory approvals may adversely affect the products and services of companies in the commodities industries. For example, the exploration, development, and distribution of coal, oil, and gas in the United States are subject to significant federal and state regulation, which may affect rates of return on coal, oil, and gas and the kinds of services that the federal and state governments may offer to companies in those industries. In addition, compliance with environmental and other safety regulations has caused many companies in commodity-related industries to incur production delays and significant costs. Government regulation also may impede the development of new technologies. The effect of future regulations affecting commodity-related industries cannot be predicted.
The value of commodity-related derivatives fluctuates based on changes in the values of the underlying commodity, commodity index, futures contract, or other economic variable to which they are related. Additionally, economic leverage will increase the volatility of these instruments as they may increase or decrease in value more quickly than the underlying commodity or other relevant economic variable. See Options, Futures, and Forward Contracts, Structured Notes, Swap Contracts and Other Two-Party Contracts, and Uses of Derivatives herein for more information on the Funds investments in derivatives, including commodity-related derivatives such as swap agreements, commodity futures contracts, and options on commodity futures contracts.
Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund should generally be entitled to treat the income it recognizes from its investment in its wholly-owned foreign subsidiary as qualifying income for purposes of qualifying as a regulated investment company under the Code. There is a risk that the Internal Revenue Service (IRS) could determine that some or all of the gross income that one or more of these Funds derive from an investment in such a subsidiary is not qualifying income, which might adversely affect the ability of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund or Special Opportunities Fund, as the case may be, to qualify as a regulated investment company. Each such foreign subsidiary is a controlled foreign corporation (CFC) for U.S. federal tax purposes. See the Investments in Wholly-Owned Subsidiaries and Taxes sections.
A Funds pursuit of an investment strategy that involves exposure to commodity markets will potentially be limited by its intention to qualify as a RIC, and could adversely affect its ability to so qualify. See the Taxes section for more information.
62
Illiquid Securities, Private Placements, Restricted Securities, and IPOs and Other Limited Opportunities
At the time of purchase, each Fund may invest up to 15% of its net assets in illiquid securities. For this purpose, illiquid securities are securities that the Fund may not sell or dispose of within seven days in the ordinary course of business at approximately the amount at which the Fund has valued the securities.
A repurchase agreement maturing in more than seven days is considered illiquid, unless it can be terminated after a notice period of seven days or less.
Private Placements and Restricted Investments. Illiquid securities include securities of private issuers, securities traded in unregulated or shallow markets, securities issued by entities deemed to be affiliates of a Fund, and securities that are purchased in private placements and are subject to legal or contractual restrictions on resale. Because relatively few purchasers of these securities may exist, especially in the event of adverse economic and liquidity conditions or adverse changes in the issuers financial condition, a Fund may not be able to initiate a transaction or liquidate a position in such investments at a desirable price. Disposing of illiquid securities may involve time-consuming negotiation and legal expenses, and selling them promptly at an acceptable price may be difficult or impossible.
While private placements may offer attractive opportunities not otherwise available in the open market, the securities purchased are usually restricted securities or are not readily marketable. Restricted securities cannot be sold without being registered under the Securities Act of 1933, as amended (the 1933 Act), unless they are sold pursuant to an exemption from registration (such as Rules 144 or 144A). Securities that are not readily marketable are subject to other legal or contractual restrictions on resale. A Fund may have to bear the expense of registering restricted securities for resale and the risk of substantial delay in effecting registration. A Fund selling its securities in a registered offering may be deemed to be an underwriter for purposes of Section 11 of the 1933 Act. In such event, the Fund may be liable to purchasers of the securities under Section 11 if the registration statement prepared by the issuer, or the prospectus forming a part of it, is materially inaccurate or misleading, although the Fund may have a due diligence defense.
At times, the inability to sell illiquid securities can make it more difficult to determine their fair value for purposes of computing a Funds net asset value. The judgment of GMO normally plays a greater role in valuing these securities than in valuing publicly traded securities.
IPOs and Other Limited Opportunities . Certain Funds may purchase securities of companies that are offered pursuant to an initial public offering (IPO) or other similar limited opportunities. Although companies can be any age or size at the time of their IPO, they are often smaller and have a limited operating history, which involves a greater potential for the value of their securities to be impaired following the IPO. The price of a companys securities may be highly unstable at the time of its IPO and for a period thereafter due to factors such as market psychology prevailing at the time of the IPO, the absence of a prior public market, the small number of shares available, and limited availability of investor information. Securities purchased in IPOs have a tendency to fluctuate in value significantly shortly after the IPO
63
relative to the price at which they were purchased. These fluctuations could impact the net asset value and return earned on a Funds shares. Investors in IPOs can be adversely affected by substantial dilution in the value of their shares, by sales of additional shares, and by concentration of control in existing management and principal shareholders. In addition, all of the factors that affect the performance of an economy or equity markets may have a greater impact on the shares of IPO companies. IPO securities tend to involve greater risk due, in part, to public perception and the lack of publicly available information and trading history.
Investments in Other Investment Companies or Other Pooled Investments
Subject to applicable regulatory requirements, a Fund may invest in shares of both open- and closed-end investment companies (including other GMO Funds, money market funds, and ETFs). Investing in another investment company exposes a Fund to all the risks of that investment company and, in general, subjects it to a pro rata portion of the other investment companys fees and expenses. Many of the Funds also may invest in private investment funds, vehicles, or structures.
A Funds investment in other investment companies or private investment funds, vehicles or structures could affect the amount, timing and character of distributions to shareholders, and in certain circumstances could cause the Fund to recognize taxable income in excess of the cash generated by such investment, which could, in the case of a Fund treated as a regulated investment company (RIC) for tax purposes, require the Fund in turn to liquidate investments, including when it is not advantageous to do so, in order to make required distributions. See the Taxes section.
ETFs are hybrid investment companies that are registered as open-end investment companies or unit investment trusts (UITs) but possess some of the characteristics of closed-end funds. ETFs in which a Fund may invest typically hold a portfolio of common stocks that is intended to track the price and dividend performance of a particular index. Unlike the index, an ETF incurs administrative expenses and transaction costs in trading securities. In addition, the timing and magnitude of cash inflows and outflows from and to investors buying and redeeming shares in the ETF could create cash balances that cause the ETFs performance to deviate from the index (which remains fully invested at all times). Performance of an ETF and the index it is designed to track also may diverge because the composition of the index and the securities held by the ETF may occasionally differ. The Funds also may invest in actively-managed ETFs. Common examples of ETFs include S&P Depositary Receipts (SPDRs), Vanguard ETFs, and iShares, which may be purchased from the UIT or investment company issuing the securities or in the secondary market (SPDRs, Vanguard ETFs, and iShares are predominantly listed on the NYSE Arca). The market prices for ETF shares may be higher or lower than the ETFs net asset value. The sale and redemption prices of ETF shares purchased from the issuer are based on the issuers net asset value.
Because ETFs are investment companies, investments in ETFs would, absent exemptive relief, be limited under applicable statutory limitations. Those limitations restrict a Funds investment in the shares of an ETF or other investment company to up to 5% of the Funds assets (which may represent no more than 3% of the securities of such ETF or other investment company) and limit aggregate investments in all ETFs and other investment companies to 10% of the Funds
64
assets. Some Funds, including Alpha Only Fund, Asset Allocation Bond Fund, Core Plus Bond Fund, Currency Hedged International Bond Fund, Developed World Stock Fund, Emerging Countries Fund, Emerging Domestic Opportunities Fund, Emerging Markets Fund, Foreign Fund, Foreign Small Companies Fund, Global Bond Fund, Implementation Fund, International Equity Fund, International Large/Mid Cap Equity Fund, International Small Companies Fund, Quality Fund, Resources Fund, Risk Premium Fund, SGM Major Markets Fund, Special Opportunities Fund, Taiwan Fund, Tax-Managed International Equities Fund, and U.S. Equity Allocation Fund, may invest in one or more ETFs beyond the statutory limitations pursuant to an agreement with the ETF, provided that the Fund complies with the terms and conditions of the agreement and the conditions of the ETFs exemptive order.
Alpha Only Fund and many of the Bond Funds may invest without limitation in other GMO Funds. These investments are not made in reliance on the fund of funds exemption provided in Section 12(d)(1)(G) of the 1940 Act, but instead are made in reliance on an SEC exemptive order obtained by GMO and the Trust permitting Funds of the Trust to operate as funds of funds. As described in the Prospectus, shareholders of the investing Funds do not bear directly any of the operating fees and expenses of these Underlying Funds, but bear indirectly a proportionate share of their operating fees and expenses (absent reimbursement of those fees and expenses).
Resources Fund may invest in certain natural resources-related entities that are partnerships, trusts, or other pass-through structures for U.S. federal tax purposes, including, for instance, certain ETFs (e.g., ETFs investing in gold bullion or commodities futures or other derivatives). Resources Funds pursuit of an investment strategy that involves investments in such entities will potentially be limited by its intention to qualify as a RIC, and could adversely affect the Funds ability to so qualify. If Resources Fund were to fail to qualify as a RIC for a particular year, a Funds returns from its investment in Resources Fund could be adversely affected. See the Taxes section.
Tax-Sensitive Strategies
When making investment decisions for Tax-Managed International Equities Fund, GMO considers the after-tax impact of portfolio transactions. In doing so, GMO may employ a variety of tax management techniques, such as seeking to minimize sales of securities that result in capital gains, preferring the sale of securities producing long-term capital gains to those producing short-term capital gains, and selling securities to realize capital losses that can be offset against realized capital gains. Tax-Managed International Equities Funds ability to utilize excess net capital losses from prior taxable years, if any, to reduce distributable net realized capital gains in subsequent taxable years may be limited by reason of direct or indirect changes in actual or constructive ownership of the Fund. Please see the Taxes section for more information, including information about recent changes to the U.S. federal income tax rules concerning capital loss carryforwards. In addition, the tax management techniques employed by GMO may change over time depending upon a variety of factors, including current market conditions, changes in tax law or rates, and the amount of embedded gains and losses in a Funds portfolio. No assurance can be given that GMO will be successful in employing any or all of these strategies.
65
In addition, for redemptions initiated by the shareholder, in lieu of redeeming its shares in cash, a Fund may pay the redemption price in whole or in part with securities. In such cases, the Fund is not required to distribute any capital appreciation in those securities to its remaining shareholders. The effect on the redeeming shareholder is generally the same for U.S. federal income tax purposes as a redemption in cash. Shareholders redeeming their shares from a taxable account in exchange for a portion of a Funds portfolio securities will recognize any capital gains realized on the Fund shares redeemed and may incur additional gains or losses during the period between the date of redemption and the date they sell the securities received. They also may incur brokerage, taxes and/or other charges on the receipt or sale of those securities.
Investments in Wholly-Owned Subsidiaries
Benchmark-Free Fund intends to invest in its wholly-owned foreign subsidiary, GMO Benchmark-Free SPC Ltd. (Benchmark-Free SPC). Implementation Fund invests in its wholly-owned foreign subsidiary, GMO Implementation SPC Ltd. (Implementation SPC). SGM Major Markets Fund invests in its wholly-owned foreign subsidiary, GMO Alternative Asset SPC Ltd. (Alternative Asset SPC). Special Opportunities Fund invests in its wholly-owned foreign subsidiary, GMO Special Opportunities SPC Ltd. (Special Opportunities SPC). These Funds and any other Fund that invests in a foreign subsidiary, including indirectly through these or other GMO Funds, will be indirectly exposed to the risks of any such subsidiarys investments. As described in the Prospectus, the subsidiary of each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund invests primarily in swap contracts on commodities indices, commodities futures contracts, and other commodity-related derivatives, and in fixed income securities, but may also invest in any other investments in which Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund, respectively, may invest directly. Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund is indirectly exposed to the risks of its subsidiarys investments. In particular, see Commodity-Related Investments.
GMO serves as the investment manager to each of Benchmark-Free SPC, Implementation SPC, Alternative Asset SPC, and Special Opportunities SPC, but does not receive any additional management or other fees in respect of such services. In addition, State Street Bank and Trust Company, [One Lincoln Street, Boston, Massachusetts 02111,] serves as Benchmark-Free SPCs, Implementation SPCs, Alternative Asset SPCs, and Special Opportunities SPCs custodian, transfer agent, and fund accounting agent.
Future changes in the securities, corporate, tax or other applicable laws of the United States and/or the jurisdiction in which a foreign subsidiary is organized could result in the inability of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, Special Opportunities Fund, their respective direct or indirect foreign subsidiaries, as the case may be, and other funds investing directly or indirectly through a subsidiary to operate as described in the Prospectus or this SAI and could adversely affect each such Fund and its shareholders. See Commodity-Related Investments and Taxes for more information.
66
Legal and Regulatory Risk
Legal, tax, and regulatory changes could occur during the term of a Fund that may adversely affect the Fund. New (or revised) laws or regulations or interpretations of existing law may be issued by the IRS or Treasury Department, the CFTC, the SEC, the U.S. Federal Reserve or other banking regulators, or other governmental regulatory authorities, or self-regulatory organizations that supervise the financial markets that could adversely affect the Funds. In particular, these agencies are empowered to promulgate a variety of new rules pursuant to recently enacted financial reform legislation in the United States. The Funds also may be adversely affected by changes in the enforcement or interpretation of existing statutes and rules by these governmental regulatory authorities or self-regulatory organizations. For example, there has been an increase in governmental, as well as self-regulatory, scrutiny of the alternative investment industry. It is impossible to predict what, if any, changes in regulations may occur, but any regulation that restricts the ability of a Fund or any Underlying Funds to trade in securities could have a material adverse impact on a Funds performance.
In addition, the securities and futures markets are subject to comprehensive statutes, regulations, and margin requirements. The CFTC, the SEC, the Federal Deposit Insurance Corporation, other regulators, and self-regulatory organizations and exchanges are authorized to take extraordinary actions in the event of market emergencies. The regulation of securitization and derivatives transactions and funds that engage in such transactions is an evolving area of law and is subject to modification by government and judicial action.
The U.S. government has enacted legislation that provides for new regulation of the derivatives market, including clearing, margin, reporting and registration requirements. The CFTC, SEC and other federal regulators have been tasked with developing the rules and regulations enacting the provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act). The European Union (and some other countries) are implementing similar requirements that will affect a Fund when it enters into derivatives transactions with a counterparty organized in that country or otherwise subject to that countrys derivatives regulations.
The U.S. government has adopted mandatory minimum margin requirements for bilateral derivatives. Similar requirements are expected to be adopted by the European Union. Such requirements could increase the amount of margin required to be provided by a Fund in connection with its derivatives transactions and, therefore, make derivatives transactions more expensive.
While certain of the rules are not effective, other rules are not yet final, so their ultimate impact remains unclear. New regulations could, among other things, restrict a Funds ability to engage in derivatives transactions (for example, by making certain types of derivatives transactions no longer available to the Fund) and/or increase the costs of such derivatives transactions, and the Fund may be unable to execute its investment strategy as a result.
The CFTC and certain futures exchanges have established limits, referred to as position limits, on the maximum net long or net short positions which any person may hold or control in particular options and futures contracts. The CFTC has proposed position limits for certain
67
swaps. All positions owned or controlled by the same person or entity, even if in different accounts, may be aggregated for purposes of determining whether the applicable position limits have been exceeded. Thus, even if a Fund does not intend to exceed applicable position limits, it is possible that different clients managed by GMO and its affiliates may be aggregated for this purpose. Although it is possible that the trading decisions of GMO may have to be modified and that positions held by the Funds may have to be liquidated in order to avoid exceeding such limits, GMO believes that this is unlikely. The modification of investment decisions or the elimination of open positions, if it occurs, may adversely affect the profitability of a Fund.
The SEC has in the past adopted interim rules requiring reporting of all short positions above a certain de minimis threshold and may adopt rules requiring monthly public disclosure in the future. In addition, other non-U.S. jurisdictions where a Fund may trade have adopted reporting requirements. If a Funds short positions or its strategy become generally known, it could have a significant effect on GMOs ability to implement its investment strategy. In particular, it would make it more likely that other investors could cause a short squeeze in the securities held short by a Fund forcing the Fund to cover its positions at a loss. Such reporting requirements also may limit GMOs ability to access management and other personnel at certain companies where GMO seeks to take a short position. In addition, if other investors engage in copycat behavior by taking positions in the same issuers as a Fund, the cost of borrowing securities to sell short could increase drastically and the availability of such securities to the Fund could decrease drastically. Such events could make a Fund unable to execute its investment strategy. Short sales are also subject to certain SEC regulations. If the SEC were to adopt additional restrictions regarding short sales, they could restrict a Funds ability to engage in short sales in certain circumstances, and the Fund may be unable to execute its investment strategy as a result.
The SEC and regulatory authorities in other jurisdictions may adopt (and in certain cases, have adopted) bans on short sales of certain securities in response to market events. Bans on short selling may make it impossible for a Fund to execute certain investment strategies and may have a material adverse effect on the Funds ability to generate returns.
Recently adopted rules implementing the credit risk retention requirements of the Dodd-Frank Act for asset-backed securities require the sponsor of certain securitization vehicles to retain, and to refrain from transferring, selling, conveying to a third party, or hedging 5% of the credit risk in assets transferred, sold, or conveyed through the issuance of such vehicle, subject to certain exceptions. These requirements may increase the costs to originators, securitizers, and, in certain cases, collateral managers of securitization vehicles in which a Fund may invest, which costs could be passed along to such Fund as an investor in such transactions.
Investors should also be aware that some EU-regulated institutions (banks, certain investment firms, and authorized managers of alternative investment funds) are currently restricted from investing in securitizations (including U.S.-related securitizations), unless, in summary: (i) the institution is able to demonstrate that it has undertaken certain due diligence in respect of various matters, including its investment position, the underlying assets, and (in the case of authorized managers of alternative investment funds) the sponsor and the originator of the securitization; and (ii) the originator, sponsor, or original lender of the securitization has explicitly disclosed to the institution that it will retain, on an ongoing basis, a net economic interest of not less than five
68
percent of specified credit risk tranches or asset exposures related to the securitization. In the future, EU insurance and reinsurance undertakings and UCITS funds are expected to become subject to similar restrictions. Although the requirements do not apply to any of the Funds directly, the costs of compliance, in the case of any securitization within the EU risk retention rules in which a Fund has invested or is seeking to invest, could be indirectly borne by the Fund and the other investors in the securitization.
ADDITIONAL INVESTMENT STRATEGIES
Merger Arbitrage Transactions
Some Funds may engage in transactions in which a Fund purchases securities at prices below the value of the consideration GMO expects to be paid for them upon consummation of a proposed merger, exchange offer, tender offer, or other similar transaction (merger arbitrage transactions). The purchase price may substantially exceed the market prices of the securities before the announcement of the transaction.
If a Fund engages in a merger arbitrage transaction and that transaction later appears unlikely to be consummated or, in fact, is not consummated or is delayed, the market prices of the securities purchased by the Fund may decline sharply, resulting in losses to the Fund. The risk/reward payout of merger arbitrage strategies typically is asymmetric the losses in failed transactions often far exceeding the gains in successful transactions. A merger arbitrage transaction can fail for many reasons, including regulatory and antitrust restrictions, political motivations, industry weakness, stock specific events, failed financings, and general market declines.
Merger arbitrage strategies depend for success on the overall volume of merger activity, which has historically been cyclical. When merger activity is low, GMO may be unable to identify enough opportunities to provide sufficient diversification.
In conjunction with merger arbitrage transactions, a Fund may sell securities short in an effort to maximize risk-adjusted returns. For example, when the terms of a proposed acquisition call for an exchange of securities, a Fund may sell short the securities of the acquiring company to protect against a decline in the market value of those securities before the acquisitions completion. A Fund also may employ various hedging strategies to protect against market fluctuations or other risks, and also may use derivatives to increase, or reduce, long or short exposure to one or more asset classes or issuers.
Merger arbitrage strategies are subject to the risk of overall market movements, and the Fund may experience losses even if a transaction is consummated. A Funds investments in derivatives or short sales of securities to hedge or otherwise adjust long or short investment exposure in connection with a merger arbitrage transaction may not perform as expected or may otherwise reduce the Funds gains or increase its losses. At any given time, a Fund can become improperly hedged, which can lead to inadvertent market-related losses. Also, in certain transactions, a Fund may be unable to hedge against market fluctuations or other risks, and market movements can result in losses to the Fund even if the proposed transaction is consummated. In addition, a Fund that sells securities short that GMO expects it to receive upon consummation of a
69
transaction but it does not actually receive (and thus has an unintended naked short position) may be required to cover its short position at a time when the securities sold short have appreciated in value, thus resulting in a loss.
A Funds merger arbitrage transactions could result in the realization of short-term capital gains by the Fund, which are generally taxed to shareholders at ordinary income tax rates when distributed.
Short Sales
Some Funds may sell securities or currencies short as part of their investment programs in an attempt to increase their returns or for hedging purposes. Many Funds may make short sales against the box, meaning the Fund may make short sales where the Fund owns, or has the right to acquire at no added cost, securities or currencies identical to those sold short. If a Fund makes a short sale against the box, the Fund will not immediately deliver the securities or currencies sold and will not immediately receive the proceeds from the sale. However, with respect to securities, the Fund is required to hold securities equivalent in kind and amount to the securities sold short (or securities convertible or exchangeable into such securities) while the short sale is outstanding. Once the Fund closes out its short position by delivering the securities or currencies sold short, it will receive the proceeds of the sale. A Fund will incur transaction costs, including interest, in connection with opening, maintaining, and closing short sales against the box. Short sales expose a Fund to the risk that it will be required to acquire, convert, or exchange a security or currency to replace the borrowed security or currency when the security or currency sold short has appreciated in value, thus resulting in a loss to the Fund. To engage in a short sale of a security or currency it does not own, a Fund borrows the security (e.g., shares of an ETF) or currency from a broker and sells it to a third party, pays to borrow the security or currency, and agrees to pay the broker any dividends or interest it receives on the borrowed security or currency. Purchasing securities or currencies to close out a short position can itself cause the price of the securities or currencies to rise further, thereby exacerbating any losses. A Fund that sells short a security or currency it does not own also may have to pay borrowing fees to a broker and may be required to pay the broker any dividends or interest it receives on a borrowed security. To borrow the security or currency, the Fund also may be required to pay a premium, which would increase the cost of the security or currency sold. The net proceeds of the short sale will be retained by the broker, to the extent necessary to meet margin requirements, until the short position is closed out. The Fund also will incur transaction costs in effecting short sales that are not against the box.
A Fund will incur a loss as a result of a short sale if the price of the security or index or currency increases between the date of the short sale and the date on which the Fund replaces the borrowed security or currency. The Fund will realize a gain if the price of the security or currency declines between those dates. The amount of any gain will be decreased, and the amount of any loss increased, by the amount of the premium, dividends or interest the Fund may be required to pay in connection with a short sale. Short sales that are not against the box involve a form of investment leverage, and the amount of the Funds loss on such a short sale is theoretically unlimited. Under adverse market conditions, the Fund may have difficulty purchasing securities or currencies to meet its short sale delivery obligations, and may have to sell portfolio securities or currencies to raise the capital necessary to meet its short sale
70
obligations at a time when it would be unfavorable to do so. If a request for return of borrowed securities and/or currencies occurs at a time when other short sellers of the securities and/or currencies are receiving similar requests, a short squeeze can occur, and the Fund may be compelled to replace borrowed securities and/or currencies previously sold short with purchases on the open market at the most disadvantageous time, possibly at prices significantly in excess of the proceeds received in originally selling the securities and/or currencies short. In addition, the Fund may have difficulty purchasing securities and/or currencies to meet its delivery obligations in the case of less liquid securities and/or currencies sold short by the Fund, such as certain emerging market country securities or securities of companies with smaller market capitalizations. A Fund also may create short investment exposure by taking a derivative position in which the value of the derivative moves in the opposite direction from the price of an underlying investment, pool of investments, index or currency. These derivative positions will typically expose the Fund to economic risks similar to those associated with shorting securities directly. Short sales of securities or currencies a Fund does not own and short derivative positions involve forms of investment leverage, and the amount of the Funds potential loss is theoretically unlimited.
There can be no assurance that the short positions that a Fund holds will act as an effective hedge against its long positions. Any decrease in negative correlation or increase in positive correlation between the positions GMO anticipated would be offsetting (such as short and long positions in securities or currencies held by a Fund) could result in significant losses for the Fund.
To the extent GMO employs a hedging strategy for a Fund, the success of any such hedging strategy will depend, in part, upon GMOs ability to correctly assess the degree of correlation between the performance of the instruments used in the hedging strategy and the performance of the investments being hedged.
A Funds short sale transactions, including in connection with its merger arbitrage activities could result in the realization of short-term capital gains by the Fund, which are generally taxed to shareholders at ordinary income tax rates when distributed.
Introduction and Overview
Derivatives are financial contracts whose value depends on, or is derived from, the value of underlying assets, reference rates, or indices, to increase, decrease, or adjust elements of the investment exposures of a Funds portfolio. Derivatives may relate to securities, interest rates, currencies, currency exchange rates, inflation rates, commodities, and indices, and include foreign currency contracts, swap contracts, reverse repurchase agreements, and other exchange-traded and OTC contracts.
It is the policy of each Fund to comply with Section 18(f) of the 1940 Act and the Funds are permitted to use any practices permitted by or consistent with relevant SEC releases, no-action letters and other pronouncements (Section 18(f)).
71
This overview outlines various ways in which the Funds and any wholly-owned subsidiaries may use different types of exchange-traded and OTC derivatives in implementing their investment programs. It is intended to supplement the information included in each Funds Prospectus, including the risks associated with derivatives described under Description of Principal Risks in the Prospectus, and the information provided in the Fund Investments and Descriptions and Risks of Fund Investments sections above. This overview, however, is not intended to be exhaustive and a Fund may use types of derivatives and/or employ derivatives strategies not otherwise described in this SAI or the Funds Prospectus.
In addition, a Fund may decide not to employ any of the strategies described below, and no assurance can be given that any strategy used will succeed. Also, suitable derivatives transactions may not be available in all circumstances and there can be no assurance that a Fund will be able to identify or employ a desirable derivatives transaction at any time or from time to time, or that any such transactions will be successful.
Each Fund may take advantage of instruments and any security or synthetic or derivative instruments which are not presently contemplated for use by the Fund or which are not currently available, but which may be developed, to the extent such opportunities are both consistent with the Funds investment objective and legally permissible for the Fund. Each Fund may become a party to various other customized derivative instruments entitling the counterparty to certain payments on the gain or loss on the value of an underlying or referenced instrument.
Note : Unless otherwise noted below in this section, the uses of derivatives discussed herein with respect to a particular Fund only refer to the Funds direct use of such derivatives. As indicated in the Prospectus and in the Fund Investments section above, certain Funds may invest in other Funds of the Trust, which, in turn, may use types of derivatives and/or employ derivatives strategies that differ from those described in this SAI or the Prospectus.
Function of Derivatives in the Funds. The types of derivatives used and derivatives strategies employed by a Fund and the extent a Fund uses derivatives varies from Fund to Fund depending on the Funds specific investment objective and strategies. Certain Funds may use exchange-traded and OTC financial derivatives and exchange-traded futures and/or forward contracts as integral parts of their investment programs. In addition, specific market conditions may influence GMOs choice of derivatives and derivatives strategies for a particular Fund, in some cases to a significant extent.
Legal and Regulatory Risk Relating to Derivatives. As described above under Descriptions and Risks of Fund Investments Legal and Regulatory Risk, the U.S. government, the European Union, and some other countries have enacted legislation that includes provisions for new regulation of the derivatives market, including clearing, margin, reporting, and registration requirements. Because the legislation leaves much to rule making (and many of the rules are not yet final), its ultimate impact remains unclear. The SEC recently proposed a rule under the 1940 Act regulating the use by registered investment companies of derivatives and many related instruments. That rule, if adopted as proposed, and other such regulatory changes could, among other things, restrict a Funds ability to engage in derivatives transactions (including because certain types of derivatives transactions may no longer be available to the Fund) and/or increase the costs of such derivatives transactions (including through increased margin or capital requirements), and the Fund may be unable to execute its investment strategy as a result.
72
Use of Derivatives by the Equity Funds (excluding the Asset Allocation Funds), Alpha Only Fund, Risk Premium Fund, Special Opportunities Fund, and Taiwan Fund
The Funds may use derivatives to gain long or short investment exposure to securities or other assets. For example, a Fund may use derivatives instead of investing directly in equity securities, including using equity derivatives to maintain equity exposure when it holds cash by equitizing its cash balances using futures contracts or other types of derivatives. The Funds also may use currency derivatives (including forward currency contracts, futures contracts, swap contracts, cross currency basis swaps, and options) to gain exposure to a given currency. In addition, Special Opportunities Fund may use derivatives to gain investment exposure to commodities, including the use of exchange-traded futures and forward foreign exchange contracts to gain exposure to a range of global equity, bond, currency, and commodity markets.
A Fund also may use currency derivatives in an attempt to reduce some aspect of the currency exposure in its portfolio. For these purposes, the Fund may use an instrument denominated in a different currency that GMO believes is highly correlated with the relevant currency.
The Funds may use derivatives in an attempt to adjust elements of their investment exposures to various securities, sectors, markets, indices, and currencies (and, in the case of Special Opportunities Fund, commodities) without actually having to sell existing investments or make new direct investments. For example, if a Fund holds a large proportion of stocks of companies in a particular sector and GMO believes that stocks of companies in another sector will outperform those stocks, the Fund might use a short futures contract on an appropriate index (to synthetically sell a portion of the Funds portfolio) in combination with a long futures contract on another index (to synthetically buy exposure to that index). In adjusting their investment exposures, the Funds also may use currency derivatives in an attempt to adjust their currency exposure, seeking currency exposure that is different (in some cases, significantly different) from the currencies in which their equities are traded.
The Funds may use derivatives to effect transactions intended as substitutes for securities lending.
The Funds may have investment exposures in excess of their net assets (i.e., they may be leveraged). While GMO expects that Risk Premium Funds option positions typically will be fully collateralized at the time when the Fund is selling them, from time to time the Fund may have investment exposures in excess of its net assets (i.e., it may be leveraged). For example, if Risk Premium Fund receives a redemption request and is unable to close out an option it had sold, the Fund may temporarily have gross investment exposures in excess of its net assets (i.e., the Fund will be leveraged) and therefore is subject to heightened risk of loss. Alpha Only Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, Alpha Only Fund will typically have gross investment exposures in excess of its net assets (i.e., the Fund will be leveraged) and therefore is subject to
73
heightened risk of loss. For each of Alpha Only Fund and Risk Premium Fund, the Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
A Funds foreign currency exposure may differ significantly from the currencies in which its equities are traded.
Use of Derivatives by the Asset Allocation Funds, Benchmark-Free Fund, and Implementation Fund
The Funds may use derivatives to gain long or short investment exposure to securities, commodities or other assets. For example, a Fund may use derivatives instead of investing directly in equity securities, including using equity derivatives to maintain equity exposure when it holds cash by equitizing its cash balances using futures contracts or other types of derivatives. The Funds also may use exchange-traded futures and forward foreign exchange contracts to gain exposure to a range of global equity, bond, currency, and commodity markets and may use currency derivatives (including forward currency contracts, futures contracts, swap contracts, and options) to gain exposure to a given currency.
The Funds may use derivatives, such as futures, related options, and swap contracts, in an attempt to reduce their investment exposures (which may result in a reduction below zero). A Fund also may use currency derivatives in an attempt to reduce (which may result in a reduction below zero) some aspect of the currency exposure in its portfolio. For these purposes, the Fund may use an instrument denominated in a different currency that GMO believes is highly correlated with the relevant currency. Implementation Fund uses exchange-traded futures and forward contracts as an integral part of its investment program.
The Funds may use derivatives in an attempt to adjust elements of their investment exposures to individual commodities, various securities, sectors, markets, indices, and currencies without actually having to sell existing investments or make new direct investments. For example, if a Fund holds a large proportion of a certain type of security or commodity and GMO believes that another security or commodity will outperform such security or commodity, the Fund might use a short futures contract on an appropriate index (to synthetically sell a portion of the Funds portfolio) in combination with a long futures contract on another index (to synthetically buy exposure to that index). Long and short swap contracts and contracts for differences also may be used for these purposes. Derivatives used to effect synthetic sales and purchases will generally be unwound as actual portfolio securities are sold and purchased. In adjusting investment exposures, each Fund also may use currency derivatives, seeking currency exposure that is different (in some cases, significantly different) from the currency exposure represented by its portfolio. Each Funds foreign currency exposure may differ significantly from the currency exposure represented by its investments.
The Funds may use derivatives to effect transactions intended as substitutes for securities lending.
Each of the Funds is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of their derivative positions, the Funds may have gross
74
investment exposures in excess of their net assets (i.e., the Funds may be leveraged) and therefore are subject to heightened risk of loss. Each Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
Use of Derivatives by SGM Major Markets Fund
The Fund may use derivatives to gain long and/or short investment exposure to securities, currencies, commodities, or other assets. In particular, the Fund may use exchange traded futures and forward foreign exchange contracts to gain exposure to a range of global equity, bond, currency, and commodity markets. The Fund also may use currency derivatives (including forward currency contracts, futures contracts, swap contracts and options) to gain exposure to a given currency.
The Fund may use derivatives in an attempt to adjust its investment exposures. For example, the Fund may use credit default swaps to take a short position with respect to the likelihood of default by an issuer. The Fund also may use currency derivatives in an attempt to reduce (which may result in a reduction below zero) some aspect of the currency exposure in its portfolio. For these purposes, the Fund may use an instrument denominated in a different currency that GMO believes is highly correlated with the relevant currency.
The Fund may use derivatives, such as futures, related options, and swap contracts, in an attempt to adjust elements of its investment exposures to individual commodities, various securities, sectors, markets, indices and currencies without actually having to sell existing investments or make new direct investments. For example, if the Fund holds a large proportion of a certain type of security or commodity and GMO believes that another security or commodity will outperform such security or commodity, the Fund might use a short futures contract on an appropriate index (to synthetically sell a portion of the Funds portfolio) in combination with a long futures contract on another index (to synthetically buy exposure to that index). Long and short swap contracts and contracts for differences also may be used for these purposes. Derivatives used to effect synthetic sales and purchases will generally be unwound as actual portfolio securities are sold and purchased. In addition, GMO may alter the interest rate exposure of debt instruments by employing interest rate swaps. Such a strategy is designed to maintain the Funds exposure to the credit of an issuer through the debt instrument but adjust the Funds interest rate exposure through the swap. With these swaps, the Fund and its counterparties exchange interest rate exposure, such as fixed versus variable rates and shorter duration versus longer duration exposure. In adjusting its investment exposure, the Fund also may use currency derivatives in an attempt to adjust its currency exposure, seeking currency exposure that is different (in some cases, significantly different) from the currencies in which their equities are traded.
The Fund is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of its derivative positions, the Fund will typically have gross investment exposures in excess of its net assets (i.e., the Fund will be leveraged) and therefore is subject to heightened risk of loss. The Funds performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
75
Use of Derivatives by the Bond Funds
The Funds may use derivatives to gain long or short investment exposure to securities or other assets. In particular, the Funds may use swaps or other derivatives on an index, a single security, or a basket of securities to gain investment exposures (e.g., by selling protection under a credit default swap). The Funds also may use currency derivatives (including forward currency contracts, futures contracts, swap contracts, cross currency basis swaps, and options) to gain exposure to a given currency.
The Funds may use derivatives in an attempt to reduce their investment exposures (which may result in a reduction below zero). For example, a Fund may use credit default swaps to take a short position with respect to the likelihood of default by an issuer. A Fund also may use currency derivatives in an attempt to reduce (which may result in a reduction below zero) some aspect of the currency exposure in its portfolio. For these purposes, the Fund may use an instrument denominated in a different currency that GMO believes is highly correlated with the relevant currency.
The Funds may use derivatives in an attempt to adjust elements of their investment exposures to various securities, sectors, markets, indices, and currencies without actually having to sell existing investments or make new direct investments. For instance, GMO may alter the interest rate exposure of debt instruments by employing interest rate swaps. Such a strategy is designed to maintain the Funds exposure to the credit of an issuer through the debt instrument but adjust the Funds interest rate exposure through the swap. With these swaps, the Fund and its counterparties exchange interest rate exposure, such as fixed versus variable rates and shorter duration versus longer duration exposure. In adjusting their investment exposures, a Fund also may use currency derivatives in an attempt to adjust its currency exposure, seeking currency exposure that is different (in some cases, significantly different) from the currency exposure represented by its portfolio investments. See Swap Contracts and Other Two-Party Contracts.
Each of the Funds is not limited in its use of derivatives or in the total notional value of its derivative positions. As a result of their derivative positions, the Funds will typically have (or may have, in the case of Debt Opportunities Fund and U.S. Treasury Fund) gross investment exposures in excess of their net assets (i.e., the Funds will be (or may be, in the case of Debt Opportunities Fund and U.S. Treasury Fund) leveraged) and therefore are subject to heightened risk of loss. Each Funds (other than Debt Opportunities Fund and U.S. Treasury Fund) performance can depend substantially, if not primarily, on the performance of assets or indices underlying its derivatives even though it does not own those assets or indices.
76
Fundamental Restrictions:
The following are Fundamental Investment Restrictions of the Funds, which may not be changed without shareholder approval:
(1) Each Fund may not borrow money except under the following circumstances: (i) Each Fund may borrow money from banks so long as after such a transaction, the total assets (including the amount borrowed) less liabilities other than debt obligations, represent at least 300% of outstanding debt obligations; (ii) Each Fund may also borrow amounts equal to an additional 5% of its total assets without regard to the foregoing limitation for temporary purposes, such as for the clearance and settlement of portfolio transactions and to meet shareholder redemption requests; and (iii) Each Fund may enter into transactions that are technically borrowings under the 1940 Act because they involve the sale of a security coupled with an agreement to repurchase that security (e.g . , reverse repurchase agreements, dollar rolls, and other similar investment techniques) without regard to the asset coverage restriction described in (i) above, so long as and to the extent that a Funds custodian earmarks and maintains cash and/or high-grade debt securities equal in value to its obligations in respect of these transactions.
Under current pronouncements of the SEC staff, the above types of transactions are not treated as involving senior securities so long as and to the extent that the Fund maintains liquid assets equal in value to its obligations in respect of these transactions.
(2) With respect to each Fund (except for Asset Allocation Bond Fund, Benchmark-Free Allocation Fund, Benchmark-Free Fund, Developed World Stock Fund, Emerging Domestic Opportunities Fund, Global Developed Equity Allocation Fund, Implementation Fund, International Developed Equity Allocation Fund, Quality Fund, Resources Fund, Risk Premium Fund, SGM Major Markets Fund, Special Opportunities Fund, Strategic Opportunities Allocation Fund, and U.S. Treasury Fund), the Fund may not purchase securities on margin, except such short-term credits as may be necessary for the clearance of purchases and sales of securities. (For this purpose, the deposit or payment of initial or variation margin in connection with futures contracts or related options transactions is not considered the purchase of a security on margin.)
(3) With respect to each Fund (except for Alpha Only Fund, Asset Allocation Bond Fund, Benchmark-Free Allocation Fund, Benchmark-Free Fund, Core Plus Bond Fund, Debt Opportunities Fund, Developed World Stock Fund, Emerging Domestic Opportunities Fund, Global Developed Equity Allocation Fund, Implementation Fund, International Developed Equity Allocation Fund, International Large/Mid Cap Equity Fund, Quality Fund, Resources Fund, Risk Premium Fund, SGM Major Markets Fund, Special Opportunities Fund, Strategic Opportunities Allocation Fund, and U.S. Treasury Fund), the Fund may not make short sales of securities or maintain a short position for the Funds account unless at all times when a short position is open the Fund owns an equal amount of such securities or owns securities which, without payment of any further consideration, are convertible into or exchangeable for securities of the same issue as, and equal in amount to, the securities sold short.
This restriction does not prohibit the payment of an amount to exercise the right to acquire the identical securities, provided that the Fund maintains segregated liquid assets in an amount sufficient to exercise such right.
77
(4) Each Fund may not underwrite securities issued by other persons except to the extent that, in connection with the disposition of its portfolio investments, it may be deemed to be an underwriter under federal securities laws.
(5) Each Fund may not purchase or sell real estate, although it may purchase securities of issuers which deal in real estate, including securities of real estate investment trusts, and may purchase securities which are secured by interests in real estate.
(6) Each Fund may not make loans, except by purchase of debt obligations or by entering into repurchase agreements or through the lending of the Funds portfolio securities. Loans of portfolio securities may be made with respect to up to 33 1/3% of a Funds total assets in the case of each Fund (except International Equity Fund and Taiwan Fund), with respect to not more than 25% of total assets in the case of International Equity Fund, and with respect to 100% of total assets in the case of Taiwan Fund.
(7) Each Fund may not concentrate more than 25% of the value of its total assets in any one industry, except that Resources Fund will invest more than 25% of the value of its assets in the natural resources sector.
For purposes of this Fundamental Restriction (7), the U.S. government and its agencies and instrumentalities are not considered to be an industry.
For purposes of this Fundamental Restriction (7), Resources Fund considers the natural resources sector to include companies in the group of industries that own, produce, refine, process, transport, and market natural resources and companies in the group of industries that provide related equipment, infrastructure and services. The sector includes, for example, the following industries: integrated oil, oil and gas exploration and production, gold and other precious metals, steel and iron ore production, energy services and technology, base metal production, forest products, farming products, paper products, chemicals, building materials, coal, water, alternative energy sources, environmental services, and such other industries as determined by GMO from time to time.
(8)(a) With respect to each Fund (except Asset Allocation Bond Fund, Benchmark-Free Allocation Fund, Benchmark-Free Fund, Developed World Stock Fund, Emerging Domestic Opportunities Fund, Global Asset Allocation Fund, Global Developed Equity Allocation Fund, Global Equity Allocation Fund, Implementation Fund, International Developed Equity Allocation Fund, International Equity Allocation Fund, Resources Fund, Risk Premium Fund, SGM Major Markets Fund, Special Opportunities Fund, and Strategic Opportunities Allocation Fund), the Fund may not purchase or sell commodities or commodity contracts, except that the Funds may purchase and sell financial futures contracts and options thereon.
(b) With respect to each of Asset Allocation Bond Fund, Developed World Stock Fund, Emerging Domestic Opportunities Fund, and Resources Fund, the Fund may not purchase commodities, except that the Fund may purchase and sell commodity contracts or any type of commodity-related derivative instrument (including, without limitation, all types of commodity-related swaps, futures contracts, forward contracts, and options contracts).
78
(c) With respect to each of Benchmark-Free Allocation Fund, Global Asset Allocation Fund, Global Developed Equity Allocation Fund, Global Equity Allocation Fund, International Developed Equity Allocation Fund, International Equity Allocation Fund, and Strategic Opportunities Allocation Fund, the Fund may not purchase commodities or commodities contracts, except that the Fund may purchase and sell financial futures contracts and options thereon and may invest in other registered open-end investment companies that purchase or sell commodities, commodity contracts or any type of commodity-related derivative instrument (including without limitation all types of commodity-related swaps, futures contracts, forward contracts, and option contracts).
(d) With respect to Risk Premium Fund and Special Opportunities Fund, the Fund may not purchase physical commodities, except that the Fund may purchase and sell commodity contracts or any type of commodity-related derivative instrument (including, without limitation, all types of commodity-related swaps, futures contracts, forward contracts, and options contracts).
(e) With respect to Benchmark-Free Fund, Implementation Fund, and SGM Major Markets Fund, the Fund may not purchase commodities, except that the Fund may purchase and sell commodity contracts or any type of commodity-related derivatives (including, without limitation, all types of commodity-related swaps, futures contracts, forward contracts, and options contracts).
For purposes of Fundamental Restrictions (8)(a), (b), (c), and (e) above, at the time of the establishment of the restriction, swap contracts on financial instruments or rates were not within the understanding of the terms commodities or commodity contracts, and notwithstanding any federal legislation or regulatory action by the CFTC that subject such swaps to regulation by the CFTC, the Funds will not consider such instruments to be commodities or commodity contracts for purposes of this restriction.
(9) Each Fund may not issue senior securities, as defined in the 1940 Act and as amplified by rules, regulations and pronouncements of the SEC.
The SEC has concluded that even though reverse repurchase agreements, firm commitment agreements, and standby commitment agreements fall within the functional meaning of the term evidence of indebtedness, the issue of compliance with Section 18 of the 1940 Act will not be raised with the SEC by the Division of Investment Management if a Fund covers such obligations or maintains liquid assets equal in value to its obligations with respect to these transactions. Similarly, so long as such assets are maintained, the issue of compliance with Section 18 will not be raised with respect to any of the following: any swap contract or contract for differences; any pledge or encumbrance of assets permitted by Non-Fundamental Restriction (4) below; any borrowing permitted by Fundamental Restriction (1) above; any collateral arrangements with respect to initial and variation margin permitted by Non-Fundamental Restriction (4) below; and the purchase or sale of options, forward contracts, futures contracts or options on futures contracts.
(10) With respect to each of Benchmark-Free Allocation Fund, Benchmark-Free Fund, Global Asset Allocation Fund, Foreign Small Companies Fund, Global Developed Equity Allocation
79
Fund, Global Equity Allocation Fund, International Developed Equity Allocation Fund, International Equity Allocation Fund, International Equity Fund, International Large/Mid Cap Equity Fund, International Small Companies Fund, Strategic Opportunities Allocation Fund, and U.S. Equity Allocation Fund, the Fund may not cause less than 75% of the value of the Funds total assets to be represented by cash and cash items (including receivables), Government securities, securities of other investment companies, and other securities for the purposes of this calculation limited in respect of any one issuer to an amount not greater than 5% of the value of the Funds total assets and to not more than 10% of the outstanding voting securities of any single issuer.
Non-Fundamental Restrictions:
The following are Non-Fundamental Investment Restrictions of the Funds, which may be changed by the Trustees without shareholder approval:
(1) With respect to each Fund (except Benchmark-Free Fund, Implementation Fund, Resources Fund, SGM Major Markets Fund, and Special Opportunities Fund), the Fund may not buy or sell oil, gas, or other mineral leases, rights or royalty contracts, although it may purchase securities of issuers that deal in oil, gas, or other mineral leases, rights or royalty contracts, including securities of royalty trusts, and may purchase securities which are secured by, or otherwise hold or represent interests in, oil, gas, or other mineral leases, rights or royalty contracts.
(2) Each Fund may not make investments for the purpose of gaining control of a companys management.
With respect to Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund, this restriction shall not apply with respect to the Funds direct or indirect investments in one or more wholly-owned subsidiaries.
(3) Each Fund may not invest more than 15% of its net assets in illiquid securities.
(4) With respect to each Fund (except for Asset Allocation Bond Fund, Benchmark-Free Allocation Fund, Benchmark-Free Fund, Developed World Stock Fund, Emerging Domestic Opportunities Fund, Global Developed Equity Allocation Fund, Implementation Fund, International Developed Equity Allocation Fund, Quality Fund, Resources Fund, Risk Premium Fund, SGM Major Markets Fund, Special Opportunities Fund, Strategic Opportunities Allocation Fund, and U.S. Treasury Fund), the Fund may not pledge, hypothecate, mortgage, or otherwise encumber its assets in excess of 33 1/3% of the Funds total assets (taken at cost). (For the purposes of this restriction, collateral arrangements with respect to swap agreements, the writing of options, stock index, interest rate, currency or other futures, options on futures contracts and collateral arrangements with respect to initial and variation margin are not deemed to be a pledge or other encumbrance of assets. The deposit of securities or cash or cash equivalents in escrow in connection with the writing of covered call or put options, respectively, is not deemed to be a pledge or encumbrance.)
80
(5) With respect to each Fund which has adopted a non-fundamental investment policy pursuant to Rule 35d-1 under the 1940 Act (each, a Name Policy), the Fund may not change its Name Policy as set forth under the Funds Principal investment strategies in the Funds Prospectus without providing the Funds shareholders with a notice meeting the requirement of Rule 35d-1(c) at least 60 days prior to such change.
For purposes of each Name Policy, each Fund considers the term invest to include both direct and indirect investing and the term investments to include both direct and indirect investments (for instance, a Fund may invest indirectly or make indirect investments by investing in another GMO Fund or in derivatives and synthetic instruments with economic characteristics similar to the underlying asset), and a Fund may achieve exposure to a particular investment, industry, country, or geographic region through direct investing or indirect investing and/or direct investments or indirect investments. For Name Policies related to Equity Funds, the term equities refers to direct and indirect investments (described above) in common and preferred stocks and other stock-related securities, such as convertible securities and depositary receipts. These investments also include exchange-traded equity REITs and equity income trusts.
When used in connection with a Funds Name Policy, GMO uses the term assets and tied economically as defined in the Prospectus.
Except as indicated above in Fundamental Restriction (1), all percentage limitations on investments set forth herein and in a Funds Prospectus will apply at the time of the making of an investment and shall not be considered violated unless an excess or deficiency occurs or exists immediately after and as a result of such investment.
With respect to Implementation Fund and SGM Major Markets Fund, for purposes of determining compliance with each Funds policy not to concentrate investments in a particular industry, futures contracts will be valued at current market value (not notional value).
The phrase shareholder approval, as used in the Prospectus and in this SAI, and the phrases vote of a majority of the outstanding voting securities and the approval of shareholders, as used herein with respect to a Fund, mean the affirmative vote of the lesser of (1) more than 50% of the outstanding shares of that Fund, or (2) 67% or more of the shares of that Fund present at a meeting if more than 50% of the outstanding shares are represented at the meeting in person or by proxy. Except for policies and restrictions that are explicitly described as fundamental in the Prospectus or this SAI, the investment policies and restrictions of each Fund may be changed by the Trusts Trustees without the approval of shareholders of that Fund. Policies and restrictions of a Fund that are explicitly described as fundamental in the Funds Prospectus or this SAI cannot be changed without the approval of shareholders of that Fund.
In addition to the Name Policies referenced in Non-Fundamental Restriction (5) above, each of the following Funds has also agreed as follows:
1) | Emerging Country Debt Fund: Under normal circumstances, the Fund will invest at least 80% of its assets in each of (i) investments tied economically to emerging countries and (ii) debt investments. |
2) | Foreign Small Companies Fund: Under normal circumstances, the Fund will invest at least 80% of its assets in each of (i) investments tied economically to countries outside the United States and (ii) investments in small companies. |
81
When used in connection with a Funds Name Policy, GMO uses the terms invest, investments, assets, tied economically and related as defined in the Funds Prospectus.
With respect to each Asset Allocation Fund that has the term international, global, or world included in the Funds name, the Fund typically will invest, through its investments in the Underlying Funds, in investments that are tied economically to a number of countries throughout the world.
With respect to each Bond Fund that has the term international or global included in the Funds name, the Fund typically will have exposure to a number of countries throughout the world, including exposure to the interest rate and currency markets of those countries through the use of futures contracts, swap contracts, currency forwards, and other types of derivatives.
With respect to each Equity Fund (other than Global Developed Equity Allocation Fund, Global Equity Allocation Fund, International Developed Equity Allocation Fund, and International Equity Allocation Fund) that has the term international, global, or world included in the Funds name, the Fund typically will invest in investments that are tied economically to a number of countries throughout the world.
GMO has adopted the following investment guidelines for each of Emerging Domestic Opportunities Fund and SGM Major Markets Fund (for purposes of this section, each a Fund). These guidelines are subject to change at the discretion of GMO and without notice to Fund shareholders. These guidelines are not Fund policies or investment restrictions and investments inconsistent with these guidelines are not violations of any Fund policy or investment restriction. GMO seeks to observe these guidelines only during periods when GMO determines that normal market conditions exist. GMO tests all percentage limitations set forth in these guidelines at the time of the making of an investment and an investment is not considered by GMO to be inconsistent with these guidelines unless an excess or deficiency occurs or exists immediately after and as a result of such investment.
Emerging Domestic Opportunities Fund
(1) The Fund will not purchase securities on margin, except such short-term credits as may be necessary for the clearance of purchases and sales of securities. (For this purpose, the deposit or payment of initial or variation margin in connection with futures contracts or related options transactions is not considered the purchase of a security on margin.)
(2) The Fund will not make short sales of securities or maintain a short position for the Funds account unless at all times when a short position is open the Fund owns an equal amount of such securities or owns securities which are convertible into or exchangeable for securities of the same issue as, and equal in amount to, the securities sold short.
82
This guideline does not prohibit the payment of an amount to exercise the right to acquire the identical securities, provided that the Fund maintains segregated liquid assets in an amount sufficient to exercise such right.
(3) The Fund will not purchase or sell commodities or commodity contracts, except that the Fund may purchase and sell financial futures contracts and options thereon.
For purposes of this guideline, swap contracts on financial instruments or rates are not considered to be commodities or commodity contracts.
(4) The Fund will not invest more than the 30% of its net assets in securities classified as being in any one country. Country classification will be based on generally accepted industry standards including, but not limited to, the issuers country of incorporation, primary listing, domicile and/or other factors GMO believes to be relevant.
(5) The Fund typically will not invest more than 7% of its net assets in the securities of any one company.
(6) Excluding investments made for the purpose of equitizing cash (e.g., exchange-traded funds) or serving as cash substitutes (e.g., money market funds and GMO U.S. Treasury Fund), the Fund will not invest more than 10% of its net assets in pooled investment vehicles.
(7) The Fund will not invest more than the 20% of its net assets in securities classified as being in frontier market countries. Country classification will be based on generally accepted industry standards including, but not limited to, the issuers country of incorporation, primary listing, domicile and/or other factors GMO believes to be relevant.
For purposes of this guideline, frontier market countries are countries that are not included in the MSCI All Country World Index.
(8) Except for limited periods surrounding inflows and outflows, the Fund will not hold more than 10% of its net assets in cash, cash equivalents or cash substitutes (e.g., shares of money market funds or shares of U.S. Treasury Fund).
(9) The Fund will not invest more than 25% of its net assets in any one industry.
(10) The Fund will typically invest in at least fifty (50) different issuers.
SGM Major Markets Fund
Subject to Section 18(f), the Fund generally expects that its typical maximum gross long positions will be not more than one and one half (1.5) times the net asset value of the Fund and its typical maximum gross short positions will be not more than one and one half (1.5) times the net asset value of the Fund.
83
In addition, the Fund generally expects to apply the following ranges in the management of its portfolio:
(1) Exposure (as determined by GMO) to a single asset class ( e.g. , shares, bonds, commodities) will be between -100% and +100% of the Funds net asset value; and
(2) Exposure (as determined by GMO) to a single asset ( e.g. , any single futures contract) will be between -50% and +50% of the Funds net asset value.
The Fund will generally be managed within these ranges, although the Fund may be outside of these ranges for short periods of time. These ranges do not apply to the Funds investments in its wholly-owned subsidiary or cash, cash equivalents or cash substitutes (e.g., shares of money market funds or shares of U.S. Treasury Fund).
DETERMINATION OF NET ASSET VALUE
The net asset value or NAV of a Fund or each class of shares of a Fund, as applicable, is determined as of the close of regular trading on the New York Stock Exchange (NYSE), generally at 4:00 p.m. Eastern time. Current net asset values per share for each series of GMO Trust are available at www.gmo.com.
The NAV per share of a class of shares of a Fund is determined by dividing the total value of the Funds portfolio investments and other assets, less any liabilities, allocated to that share class by the total number of outstanding shares of that class. NAV is not determined on any days when the NYSE is closed for business. In addition, NAV for the Bond Funds, SGM Major Markets Fund and Special Opportunities Fund is not determined (and accordingly transactions in shares of the Bond Funds, SGM Major Market Fund and Special Opportunities Fund are not processed) on days when either the NYSE or the U.S. bond markets are closed. For these purposes, the U.S. bond markets are deemed to be closed on the dates that the Securities Industry and Financial Markets Association recommends a full close for the trading of U.S. dollar-denominated fixed income securities in the United States.
A Fund also may elect not to determine NAV on days during which no share is tendered for redemption and no order to purchase or sell a share is received by that Fund. Taiwan Fund does not determine NAV on days when either the NYSE or the Taiwan Stock Exchange (TSE) is scheduled to be closed for trading. As a result, from time to time, Taiwan Fund may not determine NAV for several consecutive weekdays (e.g., during the Chinese Lunar New Year), during which time investors will be unable to redeem their shares in Taiwan Fund. Please refer to Determination of Net Asset Value in the Prospectus for additional information. In addition, to the extent a Fund holds portfolio securities listed on non-U.S. exchanges that trade on days on which the NYSE or the U.S. bond markets are closed, the net value of those Funds assets may change significantly on days when shares cannot be redeemed.
Although GMO normally does not evaluate pricing sources on a day-to-day basis, it does evaluate pricing sources on an ongoing basis and may change a pricing source at any time. GMO monitors erratic or unusual movements (including unusual inactivity) in the prices supplied for a security and has discretion to override a price supplied by a source (e.g., by taking a price supplied by another) when it believes that the price supplied is not reliable. Alternative
84
pricing sources are often but not always available for securities held by a Fund[, although the prices supplied by those alternative sources do not necessarily align with the prices supplied by primary pricing sources.]
The Prospectus describes the distribution policies of each Fund under the heading Distributions and Taxes. Each Fund generally maintains a policy to pay its shareholders, as dividends, substantially all net investment income, if any, and substantially all net realized capital gains, if any, after offsetting any available capital loss carryforwards. Each Fund generally maintains a policy to make distributions at least annually, sufficient to avoid the imposition of a nondeductible 4% excise tax on certain undistributed amounts of ordinary income and net realized capital gain. Each Fund, from time to time and at the Funds discretion, also may make unscheduled distributions of net investment income, short-term capital gains, and/or long-term capital gains prior to large redemptions by shareholders from the Fund or as otherwise deemed appropriate by the Fund. From time to time or as otherwise provided in the Funds Prospectus, distributions by a Fund could constitute, for U.S. federal income tax purposes, a return of capital to shareholders (see discussion in Taxes).
[To be updated by amendment.]
Except as specifically noted below, the following discussion is a general summary of the principal U.S. federal income tax consequences to shareholders who are U.S. citizens, residents, or corporations. The consequences under other tax laws may differ. This discussion does not address all aspects of taxation that may be relevant to particular shareholders in light of their own investment or tax circumstances, or to particular types of shareholders (including insurance companies, financial institutions or brokers, tax-exempt entities, foreign corporations, and persons who are not citizens or residents of the United States) subject to special treatment under the U.S. federal income tax laws. This summary is based on the Code, the regulations thereunder, published rulings, and court decisions, all as currently in effect. These laws are subject to change, possibly on a retroactive basis. Shareholders should consult their tax advisers about the precise tax consequences of an investment in a Fund in light of their particular tax situation, including possible non-U.S., state, local, or other applicable tax laws (including the federal alternative minimum tax).
Special tax rules apply to investments through defined contribution plans and other tax-qualified plans. Shareholders should consult their tax advisers to determine the suitability of shares of a Fund as an investment through such plans.
85
Tax Status and Taxation of Each Fund
Each Fund is treated as a separate taxable entity for U.S. federal income tax purposes. Each of the Funds has elected to be treated or intends to elect to be treated, as applicable, and intends to qualify and be treated each year, as a RIC under Subchapter M of the Internal Revenue Code of 1986, as amended (previously defined as the Code). In order to qualify for the special tax treatment accorded RICs and their shareholders, each Fund must, among other things:
(a) | derive at least 90% of its gross income for each taxable year from (i) dividends, interest, payments with respect to certain securities loans, and gains from the sale or other disposition of stock, securities, or foreign currencies, or other income (including but not limited to gains from options, futures, or forward contracts) derived with respect to its business of investing in such stock, securities, or currencies and (ii) net income derived from interests in qualified publicly traded partnerships (as defined below); |
(b) | diversify its holdings so that, at the end of each quarter of the Funds taxable year, (i) at least 50% of the market value of the Funds total assets consists of cash and cash items, U.S. government securities, securities of other RICs, and other securities limited in respect of any one issuer to a value not greater than 5% of the value of the Funds total assets and not more than 10% of the outstanding voting securities of such issuer, and (ii) not more than 25% of the value of the Funds total assets is invested, including through corporations in which the Fund owns a 20% or more voting stock interest, in the securities (other than those of the U.S. government or RICs) of any one issuer or of two or more issuers which the Fund controls and which are engaged in the same, similar, or related trades or businesses, or in the securities of one or more qualified publicly traded partnerships (as defined below); and |
(c) | distribute with respect to each taxable year at least 90% of the sum of its investment company taxable income (as that term is defined in the Code without regard to the deduction for dividends paid generally, taxable ordinary income and the excess, if any, of net short-term capital gains over net long-term capital losses) and any net tax-exempt interest income for such year. |
In general, for purposes of the 90% gross income requirement described in paragraph (a) above, income derived from a partnership will be treated as qualifying income only to the extent such income is attributable to items of income of the partnership which would be qualifying income if realized directly by the RIC. However, 100% of the net income derived from an interest in a qualified publicly traded partnership (defined generally as a partnership (i) the interests in which are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof; (ii) that derives at least 90% of its income from passive income sources defined in Section 7704(d) of the Code; and (iii) that derives less than 90% of its income from the qualifying income described in paragraph (a)(i) above) will be treated as qualifying income. In general, such entities will be treated as partnerships for federal income tax purposes because they meet the passive income requirement under Section 7704(c)(2) of the Code. In addition, although in general the passive loss rules of the Code do not apply to RICs, such rules do apply to a RIC with respect to items attributable to an interest in a qualified publicly traded partnership. Further, for the purposes of the diversification test in paragraph (b) above: (i) the term outstanding voting securities of such issuer will include the equity
86
securities of a qualified publicly traded partnership, and (ii) identification of the issuer (or, in some cases, issuers) of a particular Fund investment can depend on the terms and conditions of that investment. In some cases, identification of the issuer (or issuers) is uncertain under current law, and an adverse determination or future guidance by the IRS with respect to issuer identification for a particular type of investment may adversely affect the Funds ability to meet the diversification test in (b) above.
If a Fund qualifies as a RIC that is accorded special tax treatment, the Fund will not be subject to U.S. federal income tax on income distributed in a timely manner to its shareholders in the form of dividends (including Capital Gain Dividends, as defined below).
As described above, each Fund intends generally to distribute at least annually to its shareholders its net investment income (including any net tax-exempt interest income), if any, and its net realized capital gains (including both net short-term and long-term capital gains), if any. Any net taxable investment income or net short-term capital gains (as reduced by any net long-term capital losses) retained by a Fund will be subject to tax at the Fund level at regular corporate rates. Although each Fund intends generally to distribute all of its net capital gain (i.e., the excess of any net long-term capital gains over net short-term capital losses) each year, each Fund reserves the right to retain for investment all or a portion of its net capital gain. If a Fund retains any net capital gain, it will be subject to tax at the Fund level at regular corporate rates on the amount retained. In that case, a Fund is permitted to designate the retained amount as undistributed capital gains in a timely notice to its shareholders, who would then, in turn, be (i) required to include in income for U.S. federal income tax purposes, as long-term capital gain, their shares of such undistributed amount, and (ii) entitled to credit their proportionate shares of the tax paid by the Fund on such undistributed amount against their U.S. federal income tax liabilities, if any, and to claim refunds on a properly filed U.S. tax return to the extent the credit exceeds such liabilities. If a Fund properly makes this designation, for U.S. federal income tax purposes, the tax basis of shares owned by a shareholder of the Fund will be increased by an amount equal under current law to the difference between the amount of undistributed capital gains included in the shareholders gross income under clause (i) of the preceding sentence and the tax deemed paid by the shareholder under clause (ii) of the preceding sentence. A Fund is not required to, and there can be no assurance that a Fund will, make this designation if it retains all or a portion of its net capital gain in a taxable year.
In determining its net capital gain, including in connection with determining the amount available to support a Capital Gain Dividend (as defined below), its taxable income, and its earnings and profits, a Fund generally may elect to treat part or all of any post-October capital loss (defined as any net capital loss attributable to the portion of the taxable year after October 31, or, if there is no such loss, the net long-term capital loss or net short-term capital loss attributable to such portion of the taxable year) or late-year ordinary loss (generally, the sum of its (i) net ordinary loss from the sale, exchange or other taxable disposition of property, attributable to the portion of the taxable year after October 31, and its (ii) other net ordinary loss attributable to the portion of the taxable year after December 31) as if incurred in the succeeding taxable year.
87
If a Fund were to fail to distribute in a calendar year at least an amount generally equal to the sum of 98% of its ordinary income for such calendar year and 98.2% of its capital gain net income for the one-year period ending October 31 within that year, plus any such retained amounts from the prior year, such Fund would be subject to a nondeductible 4% excise tax on the undistributed amounts. Each Fund intends generally to make distributions sufficient to avoid imposition of the 4% excise tax, although each Fund reserves the right to pay an excise tax rather than make an additional distribution when circumstances warrant (e.g., the payment of the excise tax amount is deemed by the Fund to be de minimis).
Realized capital losses in excess of realized capital gains (Net Capital Losses) are not permitted to be deducted against net investment income. Instead, potentially subject to the limitations described below, a Fund will carry Net Capital Losses forward from any taxable year to subsequent taxable years to offset capital gains, if any, realized during such subsequent taxable years. Distributions from capital gains are generally made after applying any available capital loss carryforwards. Capital loss carryforwards are reduced to the extent they offset current-year net realized capital gains, whether a Fund retains or distributes such gains.
If a Fund incurs or has incurred Net Capital Losses in taxable years beginning after December 22, 2010 (post-2010 losses), those losses will be carried forward to one or more subsequent taxable years, and will be treated as realized on the first day of the taxable year in which it is used to reduce capital gain, without expiration; any such carryforward losses will generally retain their character as short-term or long-term and will be applied first against gains of the same character before offsetting gains of a different character (e.g., Net Capital Losses resulting from previously realized net long-term losses will first offset any long-term capital gain, with any remaining amounts available to offset any net short-term capital gain). If a Fund has incurred Net Capital Losses in a taxable year beginning on or before December 22, 2010 (pre-2011 losses), that Fund is permitted to carry such losses forward for eight taxable years; in the year to which they are carried forward, such losses are treated as short-term capital losses that first offset any short-term capital gains, and then offset any long-term capital gains. A Fund must use any post-2010 losses, which will not expire, applying them first against gains of the same character, before it uses any pre-2011 losses. This increases the likelihood that pre-2011 losses will expire unused at the conclusion of the eight-year carryforward period. See each Funds most recent annual shareholder report, as available, for more information concerning the Funds Net Capital Losses available to be carried forward (if any) as of the end of its most recently ended fiscal year.
In addition, a Funds ability to use Net Capital Losses may be limited following the occurrence of certain (i) acquisitive reorganizations and (ii) shifts in the ownership of the Fund by a shareholder owning or treated as owning 5% or more of the shares of the Fund (each, an ownership change). The Code may similarly limit a Funds ability to use any of its other capital losses, or ordinary losses, that have accrued but have not been recognized (i.e., built-in losses) at the time of an ownership change to the extent they are realized within the five-year period following the ownership change.
It is possible that a Fund will make investments through one or more foreign subsidiaries. Any such subsidiary will be a CFC for U.S. federal income tax purposes. See Tax Implications of Certain Investments for more information.
88
Transactions in Fund Shares
The sale, exchange, or redemption of Fund shares generally will give rise to a taxable gain or loss, generally equal to the difference between the amount realized by a shareholder on the disposition of the shares (that is, gross proceeds) and the shareholders adjusted basis in those shares. To the extent a shareholders account is subject to U.S. federal tax reporting (including an account for which a shareholder has informed the Funds that it would like to receive informational only U.S. federal tax reporting), the Funds generally will provide cost-basis information (on an IRS Form 1099-B) to the IRS and to the shareholder with respect to Fund shares acquired on or after January 1, 2012 and held in such accounts (post-2011 shares), when such shares are subsequently redeemed or exchanged. The Funds are required to use the particular cost basis reporting method (e.g., average cost basis, first in-first out, specific share identification) selected by the shareholder in reporting such adjusted basis information, and if a shareholder fails to select a particular method, use the Funds default method. This reporting is generally not required for Fund shares held in a retirement or other tax-advantaged account, unless a shareholder has opted for informational only reporting as described above. Shareholders should contact the Funds for more information about how to select a particular cost basis accounting method in respect of any post-2011 shares, as well as for information about the Funds particular default method.
Shareholders also should consult their tax advisers concerning the application of these rules to their investment in a Fund, and for advice about selecting a cost basis accounting method suitable for them in light of their particular circumstances. Shares of a Fund acquired prior to January 1, 2012 generally are not subject to these rules, and shareholders are responsible for keeping track of their own cost basis in these shares.
If a shareholder has purchased shares of a Fund through an intermediary, in general, the intermediary and not the Fund will be responsible for providing the cost basis and related reporting described above to the shareholder, including pursuant to the intermediarys available cost basis accounting methods. Thus, shareholders purchasing shares through an intermediary should contact the intermediary for more information about how to select a particular cost basis accounting method in respect of any post-2011 shares, as well as for information about the intermediarys particular default method.
In general, any gain or loss realized upon a taxable disposition of shares will be treated as long-term capital gain if the shares have been held, or is treated as having been held, for more than one year and as short-term capital gain if the shares have been held, or is treated as having been held, for not more than one year. However, if a Fund were to be deemed a nonpublicly offered RIC as described under Limitation on Deductibility of Fund Expenses below, depending on a shareholders percentage ownership in that Fund, a shareholders partial redemption of Fund shares could cause the shareholder to be treated as receiving a so-called section 301 distribution, treated, to the extent of such distributions allocable share of the Funds current and accumulated earnings and profits, as a dividend, taxable under the rules applicable to dividends and distributions described below, rather than capital gain income realized in exchange for Fund shares. If a redeeming shareholder were treated as receiving a dividend, there would be a risk that other shareholders of the Fund, whose percentage interests in the Fund increase as a result of such redemption, would be treated as having a taxable distribution from the Fund. In
89
this case, a shareholder would generally not be able to recognize any losses on the redeemed Fund shares. Shareholders should consult their tax advisers regarding the proper tax treatment of their redemptions from a Fund.
Any loss realized upon a taxable disposition of Fund shares held, or is treated as having been held, by a shareholder for six months or less generally will be treated as long-term capital loss to the extent of any Capital Gain Dividends, as defined below, received or deemed received by a shareholder with respect to those shares. Further, all or a portion of any loss realized upon a taxable disposition of Fund shares will be disallowed under the Codes wash-sale rules if other shares of the same Fund are purchased, including by means of dividend reinvestment, within 30 days before or after the disposition. In such a case, the basis of the newly purchased shares will be adjusted to reflect the disallowed loss.
Taxation of Fund Distributions
Fund distributions are taxable to shareholders under the rules described below whether received in cash or reinvested in additional Fund shares.
Dividends and distributions on each Funds shares are generally subject to U.S. federal income tax as described below to the extent they do not exceed the Funds realized income and gains, even though such dividends and distributions may economically represent a return of a particular shareholders investment. Such dividends and distributions are likely to occur in respect of shares purchased at a time when the Funds net asset value reflects unrealized gains, or realized but undistributed income or gains, that were therefore included in the price the shareholder paid for its shares. Such distributions may reduce the net asset value of the Funds shares below the shareholders cost basis in those shares. Such realized income and gains may be required to be distributed even when the Funds net asset value also reflects unrealized losses.
For U.S. federal income tax purposes, distributions of investment income made by a Fund are generally taxable to shareholders as ordinary income. Taxes on distributions of capital gains are determined by how long a Fund owned the investments that generated them, rather than how long a shareholder may have owned shares in the Fund. In general, the Fund will recognize long-term capital gain or loss on investments it has owned for more than one year, and short-term capital gain or loss on investments it has owned for one year or less. Tax rules can alter a Funds holding period in investments and thereby affect the tax treatment of gain or loss on such investments. Distributions of net capital gains (that is, the excess of net long-term capital gain over net short-term capital loss, in each case determined with reference to capital loss carryforwards) that are properly reported by a Fund as capital gain dividends (Capital Gain Dividends) generally are taxable to shareholders as long-term capital gains. Distributions attributable to net short-term capital gain (as reduced by any net long-term capital loss for the taxable year, in each case determined with reference to capital loss carryforwards) generally are taxable to shareholders as ordinary income.
Distributions of investment income properly reported by a Fund as derived from qualified dividend income will be taxable to shareholders taxed as individuals at the rates applicable to long-term capital gain, provided holding period and other requirements are met at both the shareholder and Fund levels.
90
In order for some portion of the dividends received by a Fund shareholder to be qualified dividend income, a Fund must meet holding period and other requirements with respect to some portion of the dividend-paying stocks in its portfolio and the shareholder must meet holding period and other requirements with respect to the Funds shares. In general, a dividend will not be treated as qualified dividend income (at either the Fund or shareholder level) (i) if the dividend is received with respect to any share of stock held, or treated as having been held, for fewer than 61 days during the 121-day period beginning on the date which is 60 days before the date on which such share becomes ex-dividend with respect to such dividend (or, in the case of certain preferred stock, 91 days during the 181-day period beginning 90 days before such date); (ii) to the extent that the recipient is under an obligation (whether pursuant to a short sale or otherwise) to make related payments with respect to positions in substantially similar or related property; (iii) if the recipient elects to have the dividend income treated as investment income for purposes of the limitation on deductibility of investment interest; or (iv) if the dividend is received from a foreign corporation that is (A) not eligible for the benefits of a comprehensive income tax treaty with the United States (with the exception of dividends paid on stock of such a foreign corporation readily tradable on an established securities market in the United States) or (B) treated as a passive foreign investment company (as defined below).
In general, distributions of investment income reported by a Fund as derived from qualified dividend income will be treated as qualified dividend income in the hands of a shareholder taxed as an individual, provided the shareholder meets the holding period and other requirements described above with respect to the Funds shares. If the above described holding period and other requirements are met at both the shareholder and Fund level, qualified dividend income will be taxed in the hands of individuals at the rates applicable to long-term capital gain. If the aggregate qualified dividend income received by a Fund during any taxable year is 95% or more of its gross income, then 100% of the Funds dividends (other than Capital Gain Dividends) will be eligible to be treated as qualified dividend income. For this purpose, the only gain included in the term gross income is the excess of net short-term capital gain over net long-term capital loss.
For information regarding qualified dividend income received by a Fund from certain Underlying Funds, see Special Tax Considerations Pertaining to a Funds Investment in Underlying Funds.
If a Fund receives dividends from an Underlying Fund, including an ETF, that is treated as a RIC for U.S. federal income tax purposes (Underlying RIC), and the Underlying RIC reports such dividends as qualified dividend income, then the Fund is permitted, in turn, to report a portion of its distributions as qualified dividend income, provided that the Fund meets the holding period and other requirements with respect to shares of the Underlying RIC. For corporate shareholders (other than S corporations), the 70% dividends-received deduction will generally apply (subject to holding period and other requirements imposed by the Code) to a Funds dividends paid from investment income to the extent derived from dividends received from U.S. corporations for the taxable year. A dividend received by a Fund from a U.S. corporation will not be treated as a dividend eligible for the dividends-received deduction (1) if it has been received with respect to any share of stock that the Fund has held, or is treated as having been held, for less than 46 days (91 days in the case of certain preferred stock) during the 91-day period beginning on the date which is 45 days before the date on which such share becomes ex-dividend with respect to such
91
dividend (during the 181-day period beginning 90 days before such date in the case of certain preferred stock) or (2) to the extent that the Fund is under an obligation (pursuant to a short sale or otherwise) to make related payments with respect to positions in substantially similar or related property. Moreover, the dividends received deduction may otherwise be disallowed or reduced (1) if the corporate shareholder fails to satisfy the foregoing requirements with respect to its shares of the Fund or (2) by application of various provisions of the Code (for instance, the dividends-received deduction is reduced in the case of a dividend received on debt-financed portfolio stock (generally, stock acquired with borrowed funds)). For information regarding eligibility for the dividends-received deduction of dividends received by a Fund from certain Underlying Funds, see Special Tax Considerations Pertaining to a Funds Investment in Underlying Funds.
Each Fund investing directly or indirectly in a wholly-owned foreign subsidiary treated as a CFC does not expect that income from its investments, including through investments in other GMO Funds, in wholly-owned foreign subsidiaries will be eligible to be treated as qualified dividend income. In addition, each such Fund does not expect that distributions from such subsidiary will be eligible for the corporate dividends-received deduction.
A portion of the original issue discount (OID) accrued on certain high yield discount obligations may not be deductible to the issuer as interest and will instead be treated as a dividend for purposes of the corporate dividends-received deduction. In such cases, if the issuer of the high yield discount obligations is a domestic corporation, dividend payments by the Fund may be eligible for the dividends-received deduction to the extent attributable to the deemed dividend portion of such OID. See Tax Implications of Certain Investments for more discussion of OID.
To the extent that a Fund makes a distribution of income that is attributable to (i) income received by the Fund in lieu of dividends with respect to securities on loan pursuant to a securities lending transaction or (ii) dividend income received by the Fund on securities it temporarily purchased from a counterparty pursuant to a repurchase agreement treated for U.S. federal income tax purposes as a loan, such distribution will not constitute qualified dividend income to individual shareholders and will not be eligible for the dividends-received deduction for corporate shareholders.
The Code generally imposes a 3.8% Medicare contribution tax on the net investment income of certain individuals, trusts, and estates to the extent their income exceeds certain threshold amounts. For these purposes, net investment income generally includes, among other things, (i) distributions paid by a Fund of ordinary dividends and capital gain dividends as described above, and (ii) any net gain from the sale, redemption or exchange of Fund shares. Shareholders are advised to consult their tax advisers regarding the possible implications of this additional tax on their investment in a Fund.
In any taxable year a Fund may make a distribution to its shareholders in excess of its current and accumulated earnings and profits (a Return of Capital Distribution), in which case the excess distribution will be treated as a return of capital to the extent of each shareholders tax basis in its shares, and thereafter as capital gain. A return of capital is not taxable to the extent
92
such an amount does not exceed a shareholders tax basis. Return of Capital Distributions reduce a shareholders tax basis in its shares, thus reducing any loss or increasing any gain on a subsequent taxable disposition by such shareholder of the shares.
A distribution paid to shareholders by a Fund in January of a year generally is deemed to have been received by shareholders on December 31 of the preceding year, if the distribution was declared and payable to shareholders of record on a date in October, November, or December of that preceding year.
A Fund may make distributions in excess of net investment income and net realized capital gain for the taxable year that are nonetheless supported by earnings and profits. In such cases, the distributions will be taxable as ordinary dividends, even though the distributed excess amounts would not have been subject to tax if retained by the Fund.
Early each calendar year, the Trust will provide U.S. federal tax information, including information about the character and amount of dividends and distributions paid during the preceding year, to taxable investors and others requesting such information (generally on an IRS Form 1099). In certain cases, a Fund may be required to amend tax information reported to shareholders in respect of a particular year. In this event, shareholders may be required to file amended U.S. federal income or other tax returns in respect of such amended information and pay additional taxes (including potentially interest and penalties), and may incur other related costs. Shareholders should consult their tax advisers in this regard.
Limitation on Deductibility of Fund Expenses
Each Fund will be considered to be a nonpublicly offered RIC if its shares are not continuously offered pursuant to a public offering within the meaning of the 1933 Act. Very generally, pursuant to Treasury regulations, expenses of nonpublicly offered RICs, except those expenses specific to their status as a RIC or separate entity (e.g., registration fees or transfer agency fees), are subject to special pass-through rules. A RIC is nonpublicly offered if it has fewer than 500 shareholders at any time during a taxable year, and its shares are not continuously offered pursuant to a public offering. In the event that a Fund were deemed to be a nonpublicly offered RIC, the affected expenses (which include Management Fees) would be treated as additional dividends to certain Fund shareholders (generally including individuals and entities that compute their taxable income in the same manner as individuals) and would be deductible by those shareholders, subject to the 2% floor on miscellaneous itemized deductions and other significant limitations on itemized deductions set forth in the Code.
Tax Implications of Certain Investments
A Funds transactions in derivative instruments (e.g., swap agreements, options, futures or forward contracts), as well as any of its other hedging, short sales, or similar transactions, may be subject to one or more special tax rules (e.g., notional principal contract, straddle, constructive sale, wash-sale, and short-sale rules). These rules, the application of which in any given instance may not be clear, may affect whether gains and losses recognized by a Fund are treated as ordinary or capital and/or as short-term or long-term, accelerate the recognition of income or gains to a Fund, defer losses, and cause adjustments in the holding periods of a Funds investments. The rules could therefore affect the amount, timing, and/or character of distributions to shareholders.
93
A Fund may make extensive use of various types of derivative financial instruments to the extent consistent with its investment policies and restrictions. The tax rules applicable to swaps and other derivative financial instruments are in some cases uncertain under current law, including under Subchapter M of the Code. Accordingly, while the Funds intend to account for such transactions in a manner they deem to be appropriate, an adverse determination or future guidance by the IRS with respect to one or more of these rules (which determination or guidance could be retroactive) may adversely affect a Funds ability to meet one or more of the relevant requirements to maintain its qualification as a RIC, as well as to avoid a fund-level tax. See Loss of RIC Status.
To the extent a Fund participates in short sales, including in connection with its merger arbitrage activities, by contracting for the sale of stock it does not own and later purchasing stock necessary to close the sale, the character of the gain or loss realized on such a short sale is determined by reference to the property used to close the short sale and is thus generally short-term. Because net short-term capital gain (after reduction by any long-term capital loss) is generally taxed at ordinary income rates, a Funds short sale transactions will likely increase the percentage of the Funds gains that are taxable to shareholders as ordinary income.
The tax treatment of certain futures contracts, including certain short positions, entered into by a Fund as well as listed non-equity options written or purchased by a Fund on certain U.S. and non-U.S. exchanges (including options on futures contracts, equity indices, and debt securities) will be governed by Section 1256 of the Code (Section 1256 contracts). Gains or losses on Section 1256 contracts generally are considered 60% long-term and 40% short-term capital gains or losses (60/40), although certain foreign currency gains and losses from such contracts may be treated as ordinary in character. Also, Section 1256 contracts held by a Fund at the end of each taxable year (and, for purposes of the 4% excise tax, on certain other dates as prescribed under the Code) are marked to market, with the result that unrealized gains or losses are treated as though they were realized and the resulting gain or loss is treated as ordinary or 60/40 gain or loss, as applicable.
Certain investments made and investment practices engaged in by a Fund can produce a difference between its book income and its taxable income and net tax-exempt income (if any). These can include, but are not limited to, certain hedging activities, as well as investments in foreign currencies, foreign currency-denominated debt instruments, Section 1256 contracts, passive foreign investment companies (as defined below), and debt obligations with discount or purchased at a premium. In addition, certain foreign currency transactions associated with the redemption of Fund shares (in the case of a Fund that permits redemptions of Fund shares in foreign currencies) may produce a difference between a Funds book income and its taxable income. If a Funds book income exceeds the sum of its taxable income and net tax-exempt interest income (if any), the distribution (if any) of such excess generally will be treated as (i) a dividend to the extent of the Funds remaining earnings and profits (including earnings and profits arising from tax-exempt interest income (if any)); (ii) thereafter, as a return of capital to the extent of the recipients basis in its shares; and (iii) thereafter, as gain from the sale or exchange of a capital asset. If a Funds book income is less than the sum of its taxable income and net tax-exempt income (if any), the Fund could be required to make distributions exceeding book income to qualify as a RIC that is accorded special tax treatment.
94
Any transactions by a Fund in foreign currencies, foreign currency-denominated debt obligations, or certain foreign currency options, futures contracts, or forward contracts (or similar instruments) may give rise to ordinary income or loss to the extent such income or loss results from fluctuations in the value of the foreign currency concerned and, as described above, can give rise to differences between the Funds book and taxable income. Such ordinary income treatment may accelerate Fund distributions to shareholders and increase the distributions taxed to shareholders as ordinary income. Any net ordinary losses so created cannot be carried forward by the Fund to offset income or gains earned in subsequent taxable years.
In general, option premiums received by a Fund are not immediately included in the income of the Fund. Instead, the premiums generally are recognized when the option contract expires, the option is exercised by the holder, or the Fund transfers or otherwise terminates the option (e.g., through a closing transaction). The remainder of this paragraph describes the general tax consequences to a Fund of writing a put or call option that is not subject to one or more of the special rules described in the immediately following paragraphs. If securities or other assets are purchased by a Fund pursuant to the exercise of a put option written by it, the Fund generally will subtract the premium received from its cost basis in the securities or other assets purchased. If a call option written by a Fund is exercised and the Fund sells or delivers the underlying securities or other assets, the Fund generally will recognize capital gain or loss equal to (i) the sum of the strike price and the option premium received by the Fund minus (ii) the Funds basis in the underlying securities or other assets. Such gain or loss generally will be short-term or long-term depending upon the holding period of the underlying securities or other assets. The gain or loss with respect to any termination of a Funds obligation under an option other than through the exercise of the option and related purchase, sale, or delivery of the underlying securities or other assets generally will be short-term gain or loss depending on whether the premium income received by the Fund is greater or less than the amount paid by the Fund (if any) in terminating the transaction. Thus, for example, if an option written by a Fund expires unexercised, the Fund generally will recognize short-term gain equal to the premium received.
Certain covered call writing activities and other option strategies of a Fund may trigger the U.S. federal income tax straddle rules of Section 1092 of the Code, requiring the deferral of losses and the termination of holding periods on offsetting positions in options and stocks deemed to constitute substantially similar or related property. Call options on stocks that are not deep in the money may qualify as qualified covered calls, which generally are not subject to the straddle rules; the holding period on stock underlying qualified covered calls that are in the money although not deep in the money will be suspended during the period that such calls are outstanding. Thus, the straddle rules and the rules governing qualified covered calls could cause gains that would otherwise constitute long-term capital gains to be treated as short-term capital gains, and distributions that would otherwise constitute qualified dividend income or qualify for the corporate dividends-received deduction to fail to satisfy the holding period requirements and therefore to be taxed as ordinary income or to fail to qualify for the dividends-received deduction, as the case may be.
95
As a result of the special tax rules described above generally applicable to a Funds options transactions, such transactions could cause a substantial portion of a Funds income to consist of net short-term capital gain, which, when distributed, is treated as taxable to shareholders subject to U.S. income tax as ordinary income. In particular, due to Risk Premium Funds primary investment strategy of selling put options on various stock indices, a substantial portion of that Funds income could consist of short-term capital gains.
Any investment by a Fund in U.S. REIT equity securities may result in the Funds receipt of cash in excess of the U.S. REITs earnings; if the Fund distributes these amounts, these distributions could constitute a return of capital to Fund shareholders for U.S. federal income tax purposes. Investments in U.S. REIT equity securities also may require a Fund to accrue and distribute income not yet received. To generate sufficient cash to make the requisite distributions, a Fund may be required to sell investments (including when it is not advantageous to do so) that it otherwise would have continued to hold. Dividends received by a Fund from a U.S. REIT will not qualify for the corporate dividends-received deduction and generally will not constitute qualified dividend income.
Under a notice issued by the IRS in October 2006 and Treasury regulations that have not yet been issued, but may apply retroactively, a portion of a Funds income (including income allocated to the Fund from a U.S. REIT or other pass-through entity) that is attributable to a residual interest in a real estate mortgage investment conduit (REMIC) (including by investing in residual interests in CMOs with respect to which an election to be treated as a REMIC is in effect) or an equity interest in a taxable mortgage pool (TMP) (referred to in the Code as an excess inclusion) will be subject to U.S. federal income tax in all events. This notice also provides and the regulations are expected to provide that excess inclusion income of RICs, such as the Funds, will be allocated to shareholders of RICs in proportion to the dividends received by such shareholders, with the same consequences as if the shareholders held the related interest directly. As a result, a Fund investing in any such interests may not be a suitable investment for certain tax-exempt investors, as noted below.
In general, excess inclusion income allocated to shareholders (i) cannot be offset by net operating losses (subject to a limited exception for certain thrift institutions); (ii) will constitute unrelated business taxable income (UBTI) to entities (including a qualified pension plan, an individual retirement account, a 401(k) plan, a Keogh plan, or other tax-exempt entity) subject to tax on UBTI, thereby potentially requiring such an entity that is allocated excess inclusion income, and otherwise might not be required to file a tax return, to file a tax return and pay tax on such income; and (iii) in the case of a Non-U.S. Shareholder, will not qualify for any reduction in U.S. federal withholding tax. A shareholder will be subject to U.S. federal income tax on such inclusions notwithstanding any exemption from such income tax otherwise available under the Code.
Under current law, income of a Fund that would be treated as UBTI if earned directly by a tax-exempt entity generally will not be attributed and taxed as UBTI when distributed to tax-exempt shareholders (that is, the Fund blocks this income with respect to such shareholders). Notwithstanding this blocking effect, a tax-exempt shareholder could realize UBTI by virtue of its investment in a Fund if shares in the Fund constitute debt-financed property in the hands of the tax-exempt shareholder within the meaning of Section 514(b) of the Code. A tax-exempt
96
shareholder also may recognize UBTI if a Fund recognizes excess inclusion income derived from direct or indirect investments in residual interests in REMICs or equity interests in TMPs as described above, if the amount of such income recognized by the Fund exceeds the Funds investment company taxable income (after taking into account deductions for dividends paid by the Fund).
In addition, special tax consequences apply to charitable remainder trusts (CRTs) that invest in RICs that invest directly or indirectly in residual interests in REMICs or equity interests in TMPs. Under legislation enacted in December 2006, a CRT (as defined in Section 664 of the Code) that realizes any UBTI for a taxable year must pay an excise tax annually of an amount equal to such UBTI. Under IRS guidance issued in October 2006, a CRT will not recognize UBTI as a result of investing in a Fund that recognizes excess inclusion income. Rather, if at any time during any taxable year a CRT (or one of certain other tax-exempt shareholders, such as the United States, a state or political subdivision, or an agency or instrumentality thereof, and certain energy cooperatives) is a record holder of a share in a Fund that recognizes excess inclusion income, then the Fund will be subject to a tax on that portion of its excess inclusion income for the taxable year that is allocable to such shareholders at the highest U.S. federal corporate income tax rate. The extent to which this IRS guidance remains applicable in light of the December 2006 legislation is unclear. To the extent permitted under the 1940 Act, each Fund may elect to specially allocate any such tax to the applicable CRT, or other shareholder, and thus reduce such shareholders distributions for the year by the amount of the tax that relates to such shareholders interest in the Fund. CRTs and other tax-exempt investors are urged to consult their tax advisers concerning the consequences of investing in the Funds.
Some debt obligations with a fixed maturity date of more than one year from the date of issuance (and zero-coupon debt obligations with a fixed maturity date of more than one year from the date of issuance) will be treated as debt obligations that are issued originally at a discount. Also very generally, the amount of the OID is treated as interest income and is included in a Funds taxable income (and required to be distributed by the Fund) over the term of the debt security, even though payment of that amount is not received until a later time, usually upon partial or full repayment or disposition of the debt security. In addition, payment-in-kind securities will give rise to income which is required to be distributed and is taxable even though the Fund holding the security receives no interest payment in cash on the security during the year.
Some debt obligations with a fixed maturity date of more than one year from the date of issuance that are acquired by a Fund in the secondary market may be treated as having market discount. Very generally, market discount is the excess of the stated redemption price of a debt obligation (or in the case of an obligation issued with OID, its revised issue price) over the purchase price of such obligation. Also very generally, any gain recognized on the disposition of, and any partial payment of principal on, a debt security having market discount is treated as ordinary income to the extent the gain, or principal payment, does not exceed the accrued market discount on such debt security. Alternatively, a Fund may elect to accrue market discount currently, in which case the Fund will be required to include the accrued market discount in the Funds income (as ordinary income) and thus distribute it over the term of the debt security, even though payment of that amount is not received until a later time, upon partial or full repayment or disposition of the debt security. The rate at which the market discount accrues, and thus is included in the Funds income, will depend upon which of the permitted accrual methods the Fund elects.
97
Some debt obligations with a fixed maturity date of one year or less from the date of issuance may be treated as having OID or, in certain cases, acquisition discount (very generally, the excess of the stated redemption price over the purchase price). Also very generally, a Fund will be required to include the OID or acquisition discount in income (as ordinary income) over the term of the debt security, even though payment of that amount is not received until a later time, usually when the debt security matures. The OID or acquisition discount accrues ratably in equal daily installments or, if the Fund so elects, at a constant (compound) interest rate. If the Fund elects the constant interest rate method, the character and timing of recognition of income by the Fund will differ from what they would have been under the default pro rata method.
Increases in the principal amount of an inflation-indexed bond will be treated as OID includible in income (as ordinary income) over the term of the bond, even though payment of that amount is not received until a later time. Decreases in the principal amount of an inflation-indexed bond generally will reduce the amount of interest from the debt instrument that would otherwise be includible in income by a Fund. In addition, if the negative inflation adjustment exceeds the income includible by a Fund with respect to the debt instrument (including any OID) for the taxable year, such excess will be an ordinary loss to the extent a Funds total interest inclusions on the debt instrument in prior taxable years exceed the total amount treated by the Fund as an ordinary loss on the debt instrument in prior taxable years. Any remaining excess may be carried forward to reduce taxable income and/or gain from the instrument in subsequent years.
A Fund may also purchase contingent payment debt instruments. For U.S. federal income tax purposes, holders of contingent payment debt instruments generally have to include taxable income (as interest) on a constant yield basis without regard to whether cash is received with respect thereto. Gain on the disposition of contingent payment debt instruments generally will be treated for U.S. federal income tax purposes as ordinary interest income rather than as capital gain.
If a Fund holds the foregoing kinds of debt instruments, it may be required to pay out as an income distribution each year an amount which is greater than the total amount of cash interest the Fund actually received. Such distributions may be made from the cash assets of the Fund or, if necessary, by liquidation of portfolio investments including at a time when it may not be advantageous to do so. A Fund may realize gains or losses from such liquidations. In the event a Fund realizes net long-term or short-term capital gains from such transactions, its shareholders may receive a larger Capital Gain Dividend or ordinary dividend, respectively, than they would in the absence of such transactions.
Very generally, where a Fund purchases a bond at a price that exceeds the redemption price at maturity, that is, at a premium, the premium is amortizable over the remaining term of the bond. In the case of a taxable bond, if a Fund makes an election applicable to all such bonds it purchases, which election is irrevocable without the consent of the IRS, the Fund reduces the current taxable income from the bond by the amortized premium and reduces its tax basis in the bond by the amount of such offset; upon the disposition or maturity of such bonds acquired on or after January 4, 2013, the Fund is generally permitted to deduct any remaining premium allocable to a prior period. In the case of a tax-exempt bond, tax rules require a Fund to reduce its tax basis by the amount of amortized premium.
98
Investments in debt obligations that are at risk of or in default present special tax issues for a Fund. Tax rules are not entirely clear about issues such as whether and to what extent the Fund should recognize market discount on a debt obligation; when the Fund may cease to accrue interest, OID, or market discount; when and to what extent the Fund may take deductions for bad debts or worthless securities; and how the Fund should allocate payments received on obligations in default between principal and income. These and other related issues will be addressed by a Fund when, as, and if it invests in such securities, in order to seek to ensure that it distributes sufficient income to preserve its status as a RIC and does not become subject to U.S. federal income or excise tax.
A Funds pursuit of an investment strategy that involves investments in certain commodity-linked instruments will potentially be limited by the Funds intention to qualify as a RIC, and could adversely affect the Funds ability to so qualify. Income and gains from certain commodity-linked instruments generally would not constitute qualifying income to a RIC for purposes of the 90% gross income test described above if a RIC were to invest directly in such instruments. The tax treatment of some other commodity-linked instruments in which a Fund might invest is not certain, in particular with respect to whether income or gains from such instruments constitute qualifying income to a RIC. If a Fund were to treat income or gains from a particular instrument as qualifying income and the income or gains were later determined not to constitute qualifying income and, together with any other nonqualifying income, caused the Funds nonqualifying income to exceed 10% of its gross income in any taxable year, the Fund would fail to qualify as a RIC unless it were eligible to and did pay a tax at the Fund level. See Loss of RIC Status.
In general, in order to qualify as a RIC, a Fund must, among other things, derive at least 90% of its gross income from certain specified sources (qualifying income). As discussed above, some Funds may gain indirect exposure to commodity-linked instruments through investments in wholly-owned foreign subsidiaries. Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund achieves indirect exposure to commodities through foreign subsidiaries, which, in turn, invest in various commodity-related derivatives. Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund should generally be entitled to treat all of the income that they recognize from their respective investments in wholly-owned foreign subsidiaries as qualifying income. There is a risk that the IRS could determine that some or all of the income that one or more of these funds derive from investments in one or more of these foreign subsidiaries is not qualifying income, which might adversely affect the ability of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, or Special Opportunities Fund, as the case may be, to qualify as a RIC. See Loss of RIC Status.
In addition, a Fund may invest in Underlying RICs that invest in commodity-linked instruments or other instruments the treatment of which as securities is unclear. An Underlying RICs pursuit of an investment strategy that involves investments in certain such instruments will potentially be limited by the Underlying RICs intention to qualify as a RIC and could adversely affect the Underlying RICs ability to so qualify. The tax treatment of certain such instruments in which
99
an Underlying RIC might invest is not certain, in particular with respect to whether income or gains from such instruments constitute qualifying income to a RIC. If an Underlying RIC were to treat income or gains from a particular instrument as qualifying income and the income or gains were later determined not to constitute qualifying income and, together with any other nonqualifying income, caused the Underlying RICs nonqualifying income to exceed 10% of its gross income in any taxable year, the Underlying RIC would fail to qualify as a RIC unless it were eligible to and did pay a tax at the Underlying RIC level. If an Underlying RIC were to fail to qualify as a RIC for a particular year, the value of a Funds investment in such Underlying RIC and, depending on the size of the Funds investment in such Underlying RIC, the Funds ability to qualify as a RIC, could be adversely affected. See Loss of RIC Status.
To the extent a Fund invests in commodities-related entities that are partnerships (other than qualified publicly traded partnerships (as defined above)), income or other trusts, or other pass-through structures for U.S. federal income tax purposes, including, for instance, certain royalty trusts and certain ETFs (e.g., ETFs investing in gold bullion), all or a portion of any income and gains from such entities could constitute non-qualifying income to the Fund for purposes of the 90% gross income requirement described above. Similarly, certain other income trusts in which a Fund may invest could be partnerships or other pass-through structures for U.S. federal income tax purposes, such that, depending on the specific assets held by the income trust, all or a portion of any income or gains from such investment could constitute non-qualifying income to the Fund. In any such cases, a Funds pursuit of an investment strategy that involves investments in such entities will potentially be limited by the Funds intention to qualify as a RIC and could adversely affect the Funds ability to so qualify. See Loss of RIC Status.
Certain of the commodities-related ETFs in which a Fund may invest may qualify as qualified publicly traded partnerships sometimes referred to as QPTPs. In such cases, the net income derived from such investments will constitute qualifying income for purposes of the 90% gross income requirement described above for RIC qualification. If, however, such a vehicle were to fail to qualify as a QPTP in a particular year, a portion of the gross income derived from it in such year could constitute non-qualifying income to a Fund for purposes of the 90% gross income requirement and thus could adversely affect the Funds ability to qualify as a RIC for a particular year. In addition, the diversification requirement described above for RIC qualification will limit a Funds investments, including through corporations in which the Fund owns a 20% or more voting stock interest, in one or more vehicles that are QPTPs to 25% of the Funds total assets as of the close of each quarter of the Funds taxable year.
MLPs, if any, in which a Fund invests also may qualify as QPTPs, subject to the special RIC-related rules described in the immediately preceding paragraph, or, instead, may be treated as regular partnerships. To the extent an MLP is a regular (non-QPTP) partnership, the MLPs income and gains allocated to a Fund will constitute qualifying income to the Fund for purposes of the 90% gross income requirement only to the extent such items of income and gain would be qualifying income if earned directly by the Fund. Thus, all or a portion of any income and gains from a Funds investment in an MLP that is a regular (non-QPTP) partnership could constitute non-qualifying income to the Fund for purposes of the 90% gross income requirement described above. In such cases, a Funds pursuit of an investment strategy that includes investments in such entities will potentially be limited by its intention to qualify as a RIC, and could adversely affect the Funds ability to so qualify.
100
To the extent an MLP is a partnership (whether or not a QPTP), some amounts received by a Fund with respect to an investment in MLPs will likely be treated as a return of capital for U.S. federal income tax purposes because of accelerated deductions available with respect to the activities of such MLPs. If the Fund distributes these amounts, these distributions could constitute a return of capital to Fund shareholders for U.S. federal income tax purposes. Further, because of these accelerated deductions, the Fund will likely realize taxable income in excess of economic gain with respect to interests in such an MLP on the disposition of such interests (or if the Fund does not dispose of the MLP, the Fund will likely realize taxable income in excess of cash flow with respect to the MLP in a later period), and the Fund must take such income into account in determining whether the Fund has satisfied its distribution requirements. The Fund may have to borrow or liquidate investments to satisfy its distribution requirements and to meet its redemption requests, even though investment considerations might otherwise make it undesirable for the Fund to sell investments or borrow money at such time. In addition, any gain recognized, either upon the sale of the a Funds MLP interest or sale by the MLP of property held by it, including in excess of economic gain thereon, treated as so-called recapture income, will be treated as ordinary income. Therefore, to the extent a Fund invests in MLPs, Fund shareholders might receive greater amounts of distributions from the Fund taxable as ordinary income than they otherwise would in the absence of such MLP investments.
Although MLPs are generally expected to be treated as partnerships for U.S. federal income tax purposes, some MLPs may be treated as passive foreign investment companies, controlled foreign corporations or regular corporations for U.S. federal income tax purposes. The treatment of particular MLPs for U.S. federal income tax purposes will affect the extent to which a Fund can invest in MLPs. The U.S. federal income tax consequences of a Funds investments in passive foreign investment companies and controlled foreign corporations are discussed in greater detail below.
A Funds investments in certain passive foreign investment companies (PFICs), as defined below, could subject the Fund to U.S. federal income tax (including interest charges) on distributions received from a PFIC or on proceeds received from the disposition of shares in a PFIC, which tax cannot be eliminated by making distributions to Fund shareholders. However, a Fund may elect to avoid the imposition of that tax. For example, a Fund may elect to treat a PFIC as a qualified electing fund (QEF) (i.e., make a QEF election), in which case the Fund will be required to include its share of the PFICs income and net capital gain annually, regardless of whether it receives any distribution from the PFIC. Alternatively, a Fund may elect to mark the gains (and to a limited extent the losses) in such holdings to the market as though it had sold (and, solely for purposes of this mark-to-market election, repurchased) its holdings in those PFICs on the last day of the Funds taxable year. Such gains and losses are treated as ordinary income and loss. The QEF and mark-to-market elections may have the effect of accelerating the recognition of income (without the receipt of cash) and increasing the amount required to be distributed for the Fund to avoid taxation. Making either of these elections therefore may require the Fund to liquidate other investments (including when it is not advantageous to do so) to meet its distribution requirement, which also may accelerate the
101
recognition of gain and affect the Funds total return. In general, a Fund that indirectly invests in PFICs by virtue of the Funds investment in Underlying RICs or other investment companies may not make such elections; rather, the Underlying RICs or other investment companies directly investing in PFICs would decide whether to make such elections. In addition, whether a foreign corporation is a PFIC is not always entirely clear. Therefore there is a risk, for example, that a Fund may not realize that a foreign corporation in which it invests is a PFIC for U.S. federal tax purposes and thus fail to timely make a QEF or mark-to-market election in respect of that corporation, in which event the Fund could be subject to the U.S. federal income taxes and interest charges described above.
A PFIC is any foreign corporation in which (i) 75% or more of the gross income for the taxable year is passive income, or (ii) the average percentage of the assets (generally by value, but by adjusted tax basis in certain cases) that produce, or are held for the production of, passive income is at least 50%. Generally, passive income for this purpose means dividends, interest (including income equivalent to interest), royalties, rents, annuities, the excess of gains over losses from certain property transactions and commodities transactions, income from certain notional principal contracts, and foreign currency gains. Passive income for this purpose does not include rents and royalties received by the foreign corporation from active business and certain income received from related persons.
Dividends paid by PFICs will not be eligible to be treated as qualified dividend income or for the dividends-received deduction.
Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund invests a portion of its assets in one or more foreign subsidiaries that are (or will be) classified as corporations for U.S. federal income tax purposes. It is expected that each subsidiary will neither be subject to taxation on its net income in the same manner as a corporation formed in the United States nor subject to branch profits tax on the income and gain derived from its activities in the United States. A foreign corporation will generally not be subject to such taxation unless it is deemed to be engaged in a U.S. trade or business.
Each subsidiary conducts (or intends to conduct) its activities in a manner so as to meet the requirements of a safe harbor under Section 864(b)(2) of the Code (the Safe Harbor), pursuant to which each subsidiary, provided it is not a dealer in securities or commodities, may engage in the following activities without being deemed to be engaged in a U.S. trade or business: (i) engage in the United States in trading securities (including contracts or options to buy or sell securities) for its own account; and (ii) engage in the United States in trading, for its own account, commodities that are of a kind customarily dealt in on an organized commodity exchange, if the transaction is of a kind customarily consummated at such place. If certain of a subsidiarys activities were determined to be not of the type described in the Safe Harbor, then the activities of such subsidiary may constitute a U.S. trade or business.
In addition, as described below, a foreign corporation is subject to U.S. federal income tax as if it earned income that is effectively connected with a U.S. trade or business (ECI) to the extent it realizes any gains from U.S. real property interests (USRPIs). It is not expected that a subsidiary will invest in any USRPI.
102
In general, a foreign corporation that does not conduct a U.S. trade or business is nonetheless subject to tax at a flat rate of 30% (or lower tax treaty rate), generally payable through withholding, on the gross amount of certain U.S.-source income that is not effectively connected with a U.S. trade or business. There is presently no tax treaty in force between the United States and the jurisdiction in which any subsidiary is (or would be) resident that would reduce this rate of withholding tax. Income subject to such a flat tax is of a fixed or determinable annual or periodic nature and includes dividends and interest income. Certain types of income are specifically exempted from the 30% tax and thus withholding is not required on payments of such income to a foreign corporation. The 30% tax generally does not apply to capital gains (whether long-term or short-term) or to interest paid to a foreign corporation on its deposits with U.S. banks. The 30% tax also does not apply to interest which qualifies as portfolio interest. Very generally, the term portfolio interest includes U.S.-source interest (including OID) on an obligation in registered form, and with respect to which the person, who would otherwise be required to deduct and withhold the 30% tax, received the required statement that the beneficial owner of the obligation is not a U.S. person within the meaning of the Code.
As discussed in more detail below, FATCA (as defined below) generally imposes a reporting and 30% withholding tax regime (which is different from the withholding regime described above) with respect to certain U.S.-source income (withholdable payments) paid to foreign financial institutions and certain other non-U.S. entities when those entities fail to satisfy the applicable account documentation, information reporting, withholding, registration, certification and/or other requirements applicable to their status under FATCA. A subsidiary will be subject to the 30% withholding tax in respect of any withholdable payment it receives if it fails to satisfy these requirements, as may be applicable to the subsidiary. Each subsidiary expects to satisfy these requirements, as may be applicable to it, so as to avoid this additional 30% withholding. See Other Reporting and Withholding Requirements for more discussion of these rules.
A U.S. person, including a Fund, who owns (directly or indirectly) 10% or more of the total combined voting power of all classes of stock of a foreign corporation is a U.S. Shareholder for purposes of the CFC provisions of the Code. A CFC is a foreign corporation that, on any day of its taxable year, is owned (directly, indirectly, or constructively) more than 50% (measured by voting power or value) by U.S. Shareholders. From time to time, a Fund may be a U.S. Shareholder in one or more CFCs. As a U.S. Shareholder, a Fund is required to include in gross income for U.S. federal income tax purposes for each taxable year of the Fund its pro rata share of its CFCs subpart F income for the CFCs taxable year ending within the Funds taxable year whether or not such income is actually distributed by the CFC, provided that the foreign corporation has been a CFC for at least 30 uninterrupted days in its taxable year. Subpart F income generally includes interest, OID, dividends, net gains from the disposition of stocks or securities, net gains from transactions (including futures, forward, and similar transactions) in commodities, receipts with respect to securities loans, and net payments received with respect to equity swaps and similar derivatives. Subpart F income is treated as ordinary income, regardless of the character of the CFCs underlying income. Net losses incurred by a CFC during a tax year do not flow through to an investing Fund and thus will not be available to offset income or capital gain generated from that Funds other investments. In addition, net losses incurred by a CFC during a tax year generally cannot be carried forward by the CFC to offset gains realized by it in subsequent taxable years. To the extent a Fund invests in any foreign subsidiary treated as a
103
CFC or other CFCs, if any, and recognizes subpart F income in excess of actual cash distributions from such CFCs, if any, it may be required to sell assets (including when it is not advantageous to do so) to generate the cash necessary to distribute as dividends to its shareholders all of its income and gains and therefore to eliminate any tax liability at the Fund level. Subpart F income also includes the excess of gains over losses from transactions (including futures, forward and other similar transactions) in commodities. A Funds recognition of any subpart F income from an investment in any foreign subsidiary treated as a CFC will increase the Funds tax basis in such subsidiary. Distributions by any foreign subsidiary treated as a CFC to a Fund, including in redemption of such subsidiarys shares, will be tax free, to the extent of any such subsidiarys previously undistributed subpart F income, and will correspondingly reduce the Funds tax basis in any such subsidiary, and any distributions in excess of the Funds tax basis in any such subsidiary will be treated as realized gain. Any losses with respect to the Funds shares of its subsidiary will not be currently recognized. Subpart F income is generally treated as ordinary income, regardless of the character of any foreign subsidiary treated as a CFCs underlying income.
Each of Benchmark-Free Fund, Implementation Fund, SGM Major Markets Fund, and Special Opportunities Fund intends to gain exposure to commodities, precious metals or other assets, in whole or in part, through investments in foreign subsidiaries. In the past, the IRS issued private letter rulings to RICs to the effect that income a fund was deemed to earn from its direct or indirect foreign subsidiary was qualifying income to the fund for purposes of the 90% gross income requirement for RIC qualification without regard to whether such income was currently paid to the parent RIC in the form of a cash dividend (repatriated). In 2011, the IRS suspended the issuance of such rulings. It is unclear whether or when the IRS will release published guidance on the issue, and whether such guidance would be favorable to RICs, and, for example, eliminate the need for funds to seek their own rulings, or be unfavorable. In the absence of a private letter ruling to the effect described above or guidance issued by the IRS to the same or similar effect, the Funds will employ other means of ensuring that this requirement is satisfied, including but not limited to receiving a distribution from a foreign subsidiary out of the subsidiarys earnings and profits at least once during every taxable year.
A Funds investment in any foreign subsidiary treated as a CFC will potentially have the effect of accelerating the Funds recognition of income and causing its income to be treated as ordinary income, regardless of the character of such subsidiarys income. If a net loss is realized by any foreign subsidiary treated as a CFC, such loss is generally not available to offset the income earned by a Fund. In addition, the net losses incurred during a taxable year by any foreign subsidiary treated as a CFC cannot be carried forward by such subsidiary to offset gains realized by it in subsequent taxable years. The Funds will not receive any credit in respect of any non-U.S. tax borne by any foreign subsidiary treated as a CFC.
Although the interest on municipal obligations is generally exempt from U.S. federal income tax, distributions from a Fund derived from interest on municipal obligations are taxable to shareholders of a Fund when received. In addition, gains realized by a Fund on the sale or exchange of municipal obligations are taxable to shareholders of the Fund.
104
Special Tax Considerations Pertaining to a Funds Investment in Underlying Funds
Tax Considerations Related to the Asset Allocation Funds and Other Funds Investments in Underlying RICs.
If an Asset Allocation Fund or any other Fund invests substantially or entirely in shares of one or more Underlying RICs (the Asset Allocation Funds and such other Funds are referred to in this section as Funds of Funds), their distributable income and gains will normally consist substantially or entirely, as the case may be, of distributions from Underlying RICs and gains and losses on the disposition of shares of Underlying RICs. To the extent that an Underlying RIC realizes net capital losses on its investments for a given taxable year, a Fund of Funds investing in that Underlying RIC will not be able to benefit from those losses until and only to the extent that (i) the Underlying RIC realizes capital gains that can be reduced by those losses, or (ii) the Fund of Funds recognizes a portion or all of its share of those losses when it disposes of shares of the Underlying RIC. Moreover, even when a Fund of Funds does make such a disposition of Underlying RIC shares at a net capital loss, a portion of its loss may be recognized as a long-term capital loss, which will not be treated as favorably for U.S. federal income tax purposes as a short-term capital loss or an ordinary deduction. A Fund of Funds also will not be able to offset any capital losses realized from its dispositions of Underlying RIC shares against its ordinary income (including distributions of any net short-term capital gains realized by an Underlying RIC).
In addition, in certain circumstances, the wash-sale rules under Section 1091 of the Code may apply to a Fund of Funds sales of Underlying RIC shares that have generated losses. A wash sale occurs if shares of an Underlying RIC are sold by the Fund of Funds at a loss and the Fund of Funds acquires additional shares of that same Underlying RIC 30 days before or after the date of the sale. The wash-sale rules could defer losses in the Fund of Funds hands on sales of Underlying RIC shares (to the extent such sales are wash sales) for extended periods of time.
As a result of the foregoing rules, and certain other special rules, the amounts of net investment income and net capital gains that a Fund of Funds will be required to distribute to shareholders may be greater than such amounts would have been had the Fund of Funds invested directly in the investments held by the Underlying RICs, rather than investing in shares of the Underlying RICs. For similar reasons, the amount or timing of distributions from a Fund of Funds qualifying for treatment as a particular character (e.g., long-term capital gain, eligibility for dividends-received deduction, etc.) will not necessarily be the same as it would have been had the Fund of Funds invested directly in the investments held by the Underlying RICs.
If a Fund were to own 20% or more of the voting interests of an Underlying RIC, subject to a safe harbor in respect of certain fund of funds arrangements, which is anticipated to be available to many Funds, the Fund would be required to look through the Underlying RIC to its holdings and combine the appropriate percentage of the Underlying RICs assets with the Funds assets for purposes of satisfying the 25% diversification test described above.
Depending on a Fund of Funds percentage ownership in an Underlying RIC both before and after a redemption of Underlying RIC shares, the Funds redemption of shares of such
105
Underlying RIC may cause it to be treated as receiving a dividend taxable as ordinary income on the full amount of the redemption instead of being treated as realizing capital gain (or loss) on the redemption of the shares of the Underlying RIC. This could be the case where the Fund of Funds holds a significant interest in an Underlying RIC that is not a publicly offered RIC within the meaning of the Code (e.g., certain underlying GMO Funds principally available only to other GMO Funds and certain other accredited investors, including GMO High Quality Short-Duration Bond Fund) and redeems only a small portion of such interest. Dividend treatment of a redemption by a Fund of Funds would affect the amount and character of income required to be distributed by both the Fund of Funds and the Underlying RIC for the year in which the redemption occurred. It is possible that any such dividend would qualify as qualified dividend income taxable at long-term capital gain rates; otherwise, it would be taxable as ordinary income and could cause shareholders of the Fund of Funds to recognize higher amounts of ordinary income than if the shareholders held shares of the Underlying RICs directly.
If a Fund of Funds were to own 20% of more of the voting interests of an Underlying RIC, subject to a safe harbor in respect of certain fund of fund arrangements, which is anticipated to be available to many Fund of Funds, the Fund of Funds would be required to look through the Underlying RIC to its holdings and combine the appropriate percentage of the Underlying RICs assets with the Fund of Funds assets for purposes of satisfying the 25% diversification test described above.
If a Fund of Funds receives dividends from an Underlying RIC, and the Underlying RIC reports such dividends as qualified dividend income, then the Fund of Funds is permitted, in turn, to report a portion of its distributions as qualified dividend income, provided that the Fund of Funds meets the holding period and other requirements with respect to shares of the Underlying RIC.
If a Fund of Funds receives dividends from an Underlying RIC, and the Underlying RIC reports such dividends as eligible for the dividends-received deduction, then the Fund of Funds is permitted, in turn, to report a portion of its distributions as eligible for the dividends-received deduction, provided that the Fund of Funds meets the holding period and other requirements with respect to shares of the Underlying RIC.
If, at the close of each quarter of a Funds, including a Fund of Funds, taxable year, at least 50% of its total assets consists of interests in Underlying RICs, that Fund of Funds will be a qualified fund of funds. In that case, the Fund of Funds is permitted to elect to pass through to its shareholders foreign income and other similar taxes paid by the Fund of Funds in respect of non-U.S. investments held directly by the Fund of Funds or by an Underlying RIC in which its invests that itself elected to pass such taxes through to shareholders, so that shareholders of the Fund of Funds will be eligible to claim a tax credit or deduction for such taxes. Each eligible Asset Allocation Fund expects to make this election for any taxable year in which it directly or indirectly (through one or more Underlying RICs making this election) pays qualifying non-U.S. taxes. However, even if a Fund of Funds qualifies to make such election for any year, it may determine not to do so in its sole discretion. See Non-U.S. Taxes for more information.
106
Tax Considerations Related to a Funds Investments in Partnerships.
Special tax considerations apply if a Fund invests in investment companies treated as partnerships for U.S. federal income tax purposes, including one or more GMO Trust Funds offered pursuant to separate private placement memoranda. For U.S. federal income tax purposes, a Fund investing in such a partnership generally will be allocated its share of the income, gains, losses, deductions, credits, and other tax items of the partnership so as to reflect the Funds interest in the partnership. A partnership in which a Fund invests may modify its partner allocations to comply with applicable tax regulations, including, without limitation, the income tax provisions under Sections 704, 706, 708, 734, 743, 754, and 755 of the Code and the regulations thereunder. It also may make special allocations of specific tax items, including gross income, gain, deduction, or loss. These modified or special allocations could result in the Fund, as a partner, receiving more or fewer items of income, gain, deduction, or loss (and/or income, gain, deduction, or loss of a different character) than it would in the absence of such modified or special allocations. A Fund will be required to include in its income its share of a partnerships tax items, including gross income, gain, deduction, or loss, for any partnership taxable year ending within or with the Funds taxable year, regardless of whether or not the partnership distributes any cash to the Fund in such year.
In general, a Fund will not recognize its share of these tax items until the close of the partnerships taxable year. However, absent the availability of an exception, a Fund will recognize its share of these tax items as they are recognized by the partnership for purposes of determining the Funds liability for the 4% excise tax (described above). If a Fund and a partnership have different taxable years, the Fund may be obligated to make distributions in excess of the net income and gains recognized from that partnership and yet be unable to avoid the 4% excise tax because it is without sufficient earnings and profits at the end of its taxable year. In some cases, however, a Fund can take advantage of certain safe harbors which would allow it to include its share of a partnerships income, gain, loss, and certain other tax items at the close of the partnerships taxable year for both excise tax purposes and general Subchapter M purposes, thus avoiding the potential complexities arising from different taxable years.
In general, cash distributions to a Fund by a partnership in which it invests (including in partial or complete redemption of its interest in the partnership) will represent a nontaxable return of capital to the Fund up to the amount of the Funds adjusted tax basis in its interest in the partnership, with any amounts exceeding such basis treated as capital gain. Any loss may be recognized by a Fund only if it redeems its entire interest in the partnership for money.
If a Fund receives allocations of income from a partnership in which it invests that are eligible for qualified dividend treatment or the dividends-received deduction, then the Fund, in turn, may report a portion of its distributions as qualified dividend income or as eligible for the dividend-received deduction, as applicable, provided certain conditions are met.
More generally, as a result of the foregoing and certain other special rules, a Funds investment in investment companies that are partnerships for U.S. federal income tax purposes can cause a Funds distributions to shareholders to vary in terms of their timing, character, and/or amount from what that Funds distributions would have been had the Fund invested directly in the investments held by those underlying partnerships.
107
If a partnership in which a Fund invests were not treated as a partnership for U.S. federal income tax purposes and were instead taxed as a corporation, a Funds return on its investment in such partnership could be adversely affected.
Loss of RIC Status
If a Fund were to fail to meet the income, diversification or distribution test described in Tax Status and Taxation of Each Fund above, the Fund could in some cases cure such failure, including by paying a Fund-level tax, paying interest charges, making additional distributions or disposing of certain assets. If the Fund were ineligible to or otherwise did not cure such failure for any year, or if the Fund were otherwise to not qualify for taxation as a RIC for such year, the Funds income would be taxed at the Fund level at regular corporate rates, and depending on when the Fund discovered its qualification failure for a particular taxable year, the Fund may be subject to penalties and interest on any late payments of its Fund-level taxes for such year. In addition, in the event of any such loss of RIC status, all distributions from earnings and profits, including distributions of net long-term capital gains and net tax-exempt income (if any), generally would be taxable to shareholders as ordinary income. Such distributions generally would be eligible (i) to be treated as qualified dividend income in the case of shareholders taxed as individuals and (ii) for the dividends-received deduction in the case of corporate shareholders, provided, in both cases, the shareholder meets certain holding period and other requirements in respect of the Funds shares. In addition, in order to re-qualify for taxation as a RIC that is accorded special tax treatment, a Fund may be required to recognize unrealized gains, pay substantial taxes and interest on such gains, and make certain substantial distributions. If an Underlying RIC were to fail to qualify as a RIC in a particular taxable year, a Funds return on its investment in such Underlying RIC and, depending on the size of the Funds investment in such Underlying RIC, the Funds ability to qualify as a RIC, could be adversely affected.
Certain of a Funds investments could affect the amount, timing and character of the Funds income, gains and distributions, and could cause the Fund to recognize taxable income in excess of the cash generated by such investment, which may require the Fund to liquidate investments, including when it is not advantageous to do so, in order to make required distributions. Further, the application of the requirements for treatment as a RIC under the Code can be unclear with respect to certain of these investments. As a result, certain of the Funds investments could cause the Fund to fail to qualify as a RIC.
Backup Withholding
Each Fund (or in the case of shares held through an intermediary, the intermediary) generally is required to withhold and remit to the U.S. Treasury a percentage of the taxable distributions and redemption proceeds paid to any individual shareholder who fails to properly furnish the Fund (or the intermediary) with a correct taxpayer identification number, who has under-reported dividend or interest income, or who fails to certify that he or she is not subject to such withholding. The backup withholding tax rate is 28%. Any tax withheld as a result of backup withholding does not constitute an additional tax imposed on the record owner of the account, and may be claimed as a credit on the record owners U.S. federal income tax return, provided the appropriate information is furnished to the IRS.
108
Distributions to Non-U.S. Investors
Distributions by a Fund to a shareholder that is not a U.S. Person within the meaning of the Code (a Non-U.S. Shareholder) properly reported by the Fund as (1) Capital Gain Dividends, (2) short-term capital gain dividends and (3) interest-related dividends, each as defined and subject to certain conditions described below, generally are not subject to withholding of U.S. federal income tax.
In general, the Code defines (1) short-term capital gain dividends as distributions of net short-term capital gains in excess of net long-term capital losses, and (2) interest-related dividends as distributions from U.S.-source interest income of types similar to those not subject to U.S. federal income tax if earned directly by an individual Non-U.S. Shareholder, in each case to the extent such distributions are properly reported as such by a Fund in a written notice to shareholders.
The exceptions to withholding for Capital Gain Dividends and short-term capital gain dividends do not apply to (A) distributions to an individual Non-U.S. Shareholder who is present in the United States for a period or periods aggregating 183 days or more during the year of the distribution and, as described below, (B) distributions attributable to gain that is treated as effectively connected with the conduct by the Non-U.S. Shareholder of a trade or business within the United States under special rules regarding the disposition of U.S. real property interests. The exception to withholding for interest-related dividends does not apply to distributions to a Non-U.S. Shareholder (A) that has not provided a satisfactory statement that the beneficial owner is not a U.S. person, (B) to the extent that the dividend is attributable to certain interest on an obligation if the Non-U.S. Shareholder is the issuer or is a 10% shareholder of the issuer, (C) that is within certain foreign countries that have inadequate information exchange with the United States, or (D) to the extent the dividend is attributable to interest paid by a person that is a related person of the Non-U.S. Shareholder and the Non-U.S. Shareholder is a controlled foreign corporation. A Fund is permitted to report such part of its dividends as interest-related and/or short-term capital gain dividends as are eligible, but is not required to do so. In the case of shares held through an intermediary, the intermediary may withhold even if a Fund reports all or a portion of a payment as an interest-related or short-term capital gain dividend to shareholders. Such Non-U.S. Shareholders should contact their intermediaries regarding the application of these rules to their accounts.
Additionally, if a Fund invests in an Underlying Fund or another investment company registered under the 1940 Act, including an Underlying RIC, that properly reports and pays such short-term capital gain or interest-related dividends to its shareholders, such distributions generally remain not subject to withholding if properly reported as such in respect of distributions paid by the Fund to its shareholders. Similarly, if a Fund has invested in an Underlying Fund that is treated as a partnership for U.S. federal income tax purposes, then to the extent that the Underlying Fund has allocated to the Fund income that would have given rise to interest-related or short-term capital gain dividends if it had been earned directly by the Fund, the Fund generally is permitted to report any dividends attributable to such income as interest-related or short-term capital gain dividends, as applicable.
109
In certain circumstances, a Non-U.S. Shareholder may be required to file appropriate U.S. federal tax forms in order to receive the benefit of these exemptions.
Distributions by a Fund to Non-U.S. Shareholders other than Capital Gain Dividends, short-term capital gain dividends, and interest-related dividends (e.g., dividends attributable to foreign-source dividend and interest income or to short-term capital gains or U.S. source interest income to which the exception from withholding described above does not apply) are generally subject to withholding of U.S. federal income tax at a rate of 30% (or lower applicable treaty rate).
Under U.S. federal tax law, a Non-U.S. Shareholder is not, in general, subject to U.S. federal income tax on gains (and is not allowed a deduction for losses) realized on the sale of shares of a Fund unless (i) such gain is effectively connected with the conduct by the Non-U.S. Shareholder of a trade or business within the United States; (ii) in the case of a Non-U.S. Shareholder that is an individual, the shareholder is present in the United States for a period or periods aggregating 183 days or more during the year of the sale and certain other conditions are met; or, as described below, (iii) the special rules relating to gain attributable to the sale or exchange of USRPIs apply to the Non-U.S. Shareholders sale of shares of a Fund.
Also, Non-U.S. Shareholders with respect to whom income from a Fund is effectively connected with a U.S. trade or business carried on by such shareholder will in general be subject to U.S. federal income tax on the income derived from the Fund at the graduated rates applicable to U.S. citizens, residents, or domestic corporations, whether such income is received in cash or reinvested in shares, and, in the case of a foreign corporation, may also be subject to a branch profits tax. If a Non-U.S. Shareholder is eligible for the benefits of a tax treaty, any effectively connected income or gain will generally be subject to U.S. federal income tax on a net basis only if it is also attributable to a permanent establishment maintained by the shareholder in the United States. Again, Non-U.S. Shareholders who are residents in a country with an income tax treaty with the United States may obtain different tax results, and are urged to consult their tax advisers.
Special rules would apply if a Fund were a qualified investment entity (QIE) because it is either a U.S. real property holding corporation (USRPHC) or would be a USRPHC but for the operation of the exceptions to the definition thereof described below. Very generally, a USRPHC is a domestic corporation that holds USRPIs USRPIs are defined as any interest in U.S. real property or any equity interest in a USRPHC or former USRPHC the fair market value of which equals or exceeds 50% of the sum of the fair market values of the corporations USRPIs, interests in real property located outside the United States, and other trade or business assets. A Fund that holds (directly or indirectly) significant interests in real estate investment trusts (as defined in Section 856 of the Code) qualifying for the special tax treatment under Subchapter M of the Code (U.S. REITs) may be a USRPHC. Interests in domestically controlled QIEs, including REITs and RICs that are QIEs, not-greater-than-10% interests in publicly traded classes of stock in REITs and not-greater-than-5% interests in publicly traded classes of stock in RICs generally are not USRPIs, but these exceptions do not apply for purposes of determining whether a Fund is a QIE. If an interest in a Fund were a USRPI, the Fund would be required to withhold U.S. tax on the proceeds of a share redemption by a greater-than-5% Non-U.S. Shareholder, in which case such Non-U.S. Shareholder generally would also be required to file U.S. tax returns and pay any additional taxes due in connection with the redemption.
110
If a Fund were a QIE, under a special look-through rule, any dividend distributions by the Fund and certain distributions made by the Fund in redemption of its shares that are attributable directly or indirectly to (i) distributions received by the Fund from a lower-tier RIC or REIT that the Fund is required to treat as USRPI gain in its hands and (ii) gains realized on the diposition of USRPIs by the Fund would retain their character as gains realized from USRPIs in the hands of the Funds Non-U.S. Shareholders. If a Non-U.S. Shareholder holds (or has held in the prior year) more than a 5% interest in any class of such a Fund, such distributions generally will be treated as gains effectively connected with the conduct of a U.S. trade or business, and subject to tax at graduated rates. Moreover, such shareholders generally will be required to file a U.S. income tax return for the year in which the gain was recognized and the Fund generally will be required to withhold 35% of the amount of such distribution. In the case of all other Non-U.S. Shareholders (i.e., those whose interest in the Fund did not exceed 5% in any class of the Fund at any time during the prior year), the USRPI distribution generally will be treated as ordinary income (regardless of any reporting by the Fund that such distribution is a short-term capital gain dividend or a Capital Gain Dividend), and the Fund generally must withhold 30% (or a lower applicable treaty rate) of the amount of the distribution paid to such Non-U.S. Shareholder.
In addition, if a Fund were a USRPHC or former USRPHC, it would potentially be required to withhold 15% of the amount realized in a redemption by a greater-than-5% Non-U.S. Shareholder, and that shareholder typically must file a U.S. income tax return for the year of the disposition of Fund shares and pay any additional tax due on the sale. A similar withholding obligation may apply to Return of Capital Distributions by a Fund that is a USRPHC or former USRPHC to a greater-than-5% Non-U.S. Shareholder, even if all or a portion of such distribution would be treated as a return of capital to the Non-U.S. Shareholder. Such withholding on these redemptions and distributions generally would not be required if the Fund were a domestically controlled QIE or, in certain limited cases, if the Fund (whether or not domestically controlled) were to hold substantial investments in Underlying RICs that were domestically controlled USRPHCs.
If a qualified foreign pension fund described in Section 897(l) of the Code, or any entity all of the interests of which are held by such a qualified foreign pension fund, were to hold, directly or indirectly through one more partnerships, shares of a Fund an interest in which were a USRPI, the special withholding and other rules regarding U.S. real property interests described above would not apply to distributions and redemptions with respect to such shares.
Non-U.S. Shareholders of a Fund also may be subject to certain wash sale rules to prevent the avoidance of the tax filing and payment obligations discussed above through the sale and repurchase of Fund shares.
Non-U.S. Shareholders should consult their tax advisers (and if holding shares through an intermediary, their intermediary) concerning the application of these rules to their investment in a Fund.
111
In order to qualify for any exemptions from withholding described above or for lower withholding tax rates under income tax treaties, or to establish an exemption from backup withholding, a Non-U.S. Shareholder must comply with special certification and filing requirements relating to its non-U.S. status (including, for example, furnishing an IRS Form W-8BEN or W-8BEN-E). Non-U.S. shareholders in a Fund should consult their tax advisers and, if holding shares through intermediaries, their intermediaries, in this regard.
Special rules (including withholding and reporting requirements) apply to foreign partnerships and those holding Fund shares through foreign partnerships. Also, additional considerations may apply to foreign trusts and estates. Investors holding Fund shares through foreign entities should consult their tax advisers about their particular situation.
A Non-U.S. Shareholder may be subject to state and local taxes and to the U.S. federal estate tax in addition to the U.S. federal income tax referred to above.
Non-U.S. shareholders described in section 892 of the Code should consult their tax advisers with respect to their investment in a Fund.
See also Other Reporting and Withholding Requirements below for information regarding the potential application of an additional withholding regime.
Non-U.S. Taxes
A Funds non-U.S. investments may be subject to non-U.S. withholding and other taxes on dividends, interest, capital gains, or the proceeds of dispositions that will decrease a Funds return on its investments. A Fund may otherwise be subject to non-U.S. taxation on repatriation proceeds generated from those investments or to other transaction-based non-U.S. taxes on those investments, including potentially on a retroactive basis, which can also decrease the Funds return on its investments. Such non-U.S. withholding taxes and other taxes may be reduced or eliminated under income tax treaties between the United States and certain non-U.S. jurisdictions. In some cases, a Fund may seek to collect a refund in respect of taxes paid to a non-U.S. jurisdiction. In particular, certain Funds have previously filed for and/or may file for additional tax refunds with respect to certain taxes withheld by member states of the European Union (such taxes, E.U. Taxes and such refunds, E.U. Refunds). Generally, E.U. Refunds that a Fund reasonably determines are collectible and free from significant contingencies are reflected in a Funds net asset value. In certain circumstances, a Funds receipt of an E.U. Refund may cause the Fund and/or its shareholders to be liable for U.S. federal income tax (including interest). Each Fund that has previously elected to permit its shareholders to claim foreign tax credits or deductions on their U.S. income tax returns with respect to E.U. Taxes withheld from the Fund expects that its receipt of E.U. Refunds will likely significantly reduce the amount of foreign tax credits or deductions otherwise available to the Funds shareholders for U.S. federal income tax purposes. See Descriptions and Risks of Fund Investments Risks of Non-U.S. Investments for more information. The non-U.S. withholding and other tax rates applicable to a Funds investments in certain non-U.S. jurisdictions may be higher, in certain circumstances, for instance, if a Fund has a significant number of Non-U.S. Shareholders or if a Fund or Underlying Fund invests through a subsidiary.
112
If, at the end of a Funds taxable year, more than 50% of the value of the total assets of the Fund is represented by direct investments in stock or other securities of non-U.S. corporations, the Fund may make an election that allows shareholders to claim a foreign tax credit or deduction (but not both) on their U.S. income tax return in respect of non-U.S. taxes paid by or withheld from the Fund on its non-U.S. portfolio investments. Only non-U.S. taxes that meet certain qualifications are eligible for this pass-through treatment. If a Fund is eligible for and makes such an election, its shareholders generally will include in gross income from non-U.S. sources their pro rata shares of such taxes paid by the Fund. A shareholders ability to claim an offsetting foreign tax credit or deduction in respect of these taxes is subject to limitations imposed by the Code, which may result in the shareholders not receiving a full credit or deduction (if any) for the amount of such taxes. Shareholders who do not itemize deductions on their U.S. federal income tax returns may claim a credit (but not a deduction) for such non-U.S. taxes. Certain of the Funds are eligible for and expect to make this election. However, even if a Fund is eligible to make this election, it may determine not to do so in its sole discretion, in which case any such qualified non-U.S. taxes paid by the Fund cannot be given this special pass-through treatment by the Fund or its shareholders. Investors should consult their tax advisers for further information relating to the foreign tax credit and deduction. Shareholders that are not subject to U.S. federal income tax, and those who invest in a Fund through tax-advantaged accounts (including those who invest through individual retirement accounts or other tax-advantaged retirement plans), generally will receive no benefit from any tax credit or deduction passed through by a Fund.
In some cases, a Fund also may be eligible to pass through to its shareholders the non-U.S. taxes paid by Underlying RICs in which it invests that themselves elected to pass through such taxes to their shareholders. Each eligible Asset Allocation Fund expects to make this election for any taxable year in which it directly or indirectly (through one or more Underlying RICs making this election) pays qualifying non-U.S. taxes as described above. However, even if a Fund is eligible to make such an election for a given year, it may determine not to do so. See Special Tax Considerations Pertaining to a Funds Investment in Underlying Funds for more information.
Withholding taxes that are accrued on dividends in respect of (i) securities on loan pursuant to a securities lending transaction during the period that any such security was not directly held by a Fund or (ii) securities the Fund temporarily purchased from a counterparty pursuant to a repurchase agreement that is treated as a loan for U.S. federal income tax purposes generally will not qualify as a non-U.S. tax paid by the Fund, in which case they could not be passed through to shareholders even if the Fund meets the other requirements described above.
Shareholder Reporting Obligations With Respect to Foreign Bank and Financial Accounts
Shareholders that are U.S. persons and own, directly or indirectly, more than 50% of a Fund could be required to report annually their financial interest in the Funds foreign financial accounts, if any, on FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR). Shareholders should consult their intermediaries through which a Fund investment is made (if applicable), as well as a tax adviser, regarding the applicability to them of this reporting requirement.
113
Other Reporting and Withholding Requirements
The Code generally requires a Fund to obtain information sufficient to identify the status of each of its shareholders under Sections 1471-1474 of the Code (including the U.S. Treasury Regulations and IRS guidance issued thereunder, FATCA) or under an applicable intergovernmental agreement (an IGA). If a shareholder fails to provide this information or otherwise fails to comply with FATCA or an IGA, a Fund or its agent may be required under FATCA to withhold 30% of the distributions, other than those properly reported as capital gain dividends, the Fund pays to that shareholder. On or after January 1, 2017 (which date, under Treasury guidance, is expected to be delayed until on or after January 1, 2019), the Fund or its agent may also be required under FATCA to withhold 30% of the gross proceeds of the sale, redemption or exchange of Fund shares and certain capital gain dividends the Fund pays to that shareholder. If a payment by a Fund is subject to FATCA withholding, the Fund or its agent is required to withhold even if such payment would otherwise be exempt from withholding under the rules applicable to Non-U.S. Shareholders described above (e.g., Capital Gain Dividends).
Payments to a shareholder will generally not be subject to FATCA withholding, provided the shareholder provides a Fund with such certifications, waivers or other documentation or information as the Fund requires, including, to the extent required, with regard to such shareholders direct and indirect owners, to establish the shareholders FATCA status and otherwise to comply with these rules. In order to avoid withholding, a shareholder that is a foreign financial institution (FFI) must either (i) become a participating FFI by entering into a valid U.S. tax compliance agreement with the IRS; (ii) qualify for an exception from the requirement to enter into such an agreement, for example by becoming a deemed compliant FFI; or (iii) be covered by and in compliance with an applicable intergovernmental agreement between the United States and a non-U.S. government to implement FATCA. In any of these cases, the investing FFI generally will be required to provide a Fund with appropriate identifiers, certifications or documentation concerning its status. The IRS has issued guidance on how FATCA interacts with other U.S. withholding tax rules and, accordingly, the above-described withholding tax may apply differently in the event that income is subject to multiple types of withholding.
A Fund will disclose the information that it receives from (or concerning) its shareholders to the IRS, non-U.S. taxing authorities or other parties as necessary to comply with FATCA, related intergovernmental agreements or other applicable law or regulation.
If an Underlying Fund were to fail to comply with FATCA or were to be a member of an expanded affiliated group in which a member of such group causes other members to not be in compliance with FATCA, such non-compliance could reduce a Funds return on its investments.
Each prospective investor is urged to consult its tax adviser regarding the applicability and consequences of FATCA and any other reporting requirements with respect to the prospective investors own situation, including investments through an intermediary.
The Funds and their shareholders may be subject to certain other tax reporting requirements as a result of the investment strategies and activities of the Funds. Certain U.S. federal, state, local and non-U.S. tax reporting requirements may require a Fund to provide certain information about its shareholders to the IRS or other similar authorities responsible for tax matters in other jurisdictions (e.g., non-U.S. countries).
114
Tax Shelter Reporting Regulations
Under Treasury regulations, if a shareholder recognizes a loss on disposition of a Funds shares of $2 million or more for an individual shareholder or $10 million or more for a corporate shareholder, the shareholder must file with the IRS a disclosure statement on Form 8886. Direct holders of portfolio securities are in many cases excepted from this reporting requirement, but under current guidance, shareholders of a RIC are not excepted. Future guidance may extend the current exception from this reporting requirement to shareholders of most or all RICs. The fact that a loss is reportable under these regulations does not affect the legal determination of whether the taxpayers treatment of the loss is proper. Shareholders should consult their tax advisers to determine the applicability of these regulations in light of their individual circumstances.
State and Local Tax Matters
Most states permit mutual funds, such as the Funds, to pass through to their shareholders the state tax exemption on income earned from investments in some direct U.S. Treasury obligations, as well as some limited types of U.S. government agency securities (such as Federal Farm Credit Bank and Federal Home Loan Bank securities), so long as a Fund meets all applicable state requirements. Therefore, shareholders in a Fund may be allowed to exclude from their state taxable income distributions made to them by the Fund to the extent attributable to interest the Fund directly or indirectly earned on such investments. The availability of these exemptions varies by state. Investments in securities of certain U.S. government agencies, including securities issued by Ginnie Mae, Fannie Mae, and Freddie Mac, and repurchase agreements collateralized by U.S. government securities generally do not qualify for these exemptions. Moreover, these exemptions may not be available to corporate shareholders. All shareholders should consult their tax advisers regarding the applicability of these exemptions to their situation.
115
The following tables present information as of [June 30, 2016] regarding each current Trustee and officer of the Trust. Each Trustees and officers year of birth (YOB) is set forth after his or her name. Unless otherwise noted, (i) each Trustee and officer has engaged in the principal occupation(s) noted in the table for at least the most recent five years, although not necessarily in the same capacity, and (ii) the address of each Trustee and officer is c/o GMO Trust, 40 Rowes Wharf, Boston, Massachusetts 02110. Each Trustee serves in office until the earlier of (a) the election and qualification of a successor at the next meeting of shareholders called to elect Trustees or (b) the Trustee dies, resigns, or is removed as provided in the Trusts governing documents. Each of the Trustees of the Trust, other than Mr. Kittredge, is not an interested person of the Trust, as such term is used in the 1940 Act (each, an Independent Trustee). Because the Funds do not hold annual meetings of shareholders, each Trustee will hold office for an indeterminate period. Each officer serves in office until his or her successor is elected and determined to be qualified to carry out the duties and responsibilities of the office, or until the officer resigns or is removed from office.
[To be updated by amendment.]
116
1 | The Fund Complex includes series of each of GMO Trust and GMO Series Trust. Mr. Kittredge also serves as a Trustee of GMO Series Trust. |
2 | As part of Mr. Glazers work as a consultant, he provides part-time consulting services to Goodwin Procter LLP (Goodwin). Goodwin has provided legal services to Renewable Resources, LLC, an affiliate of GMO; GMO, in connection with its relationship with Renewable Resources; and funds managed by Renewable Resources. Mr. Glazer has represented that he has no financial interest in, and is not involved in the provision of, such legal services. In the calendar years ended December 31, 2014 and December 31, 2015, these entities paid $1,194.25 and $0, respectively, in legal fees and disbursements to Goodwin. In correspondence with the staff of the SEC (the Staff) beginning in August 2006, the Independent Trustees legal counsel provided the Staff with information regarding Mr. Glazers relationship with Goodwin and his other business activities. On September 11, 2007, based on information that had been given to the Staff as of that date, the Staff provided oral no-action assurance consistent with the opinion of the Independent Trustees legal counsel that Mr. Glazer is not an interested person of the Trust. |
3 | Mr. Kittredge is an interested person of the Trust, as such term is used in the 1940 Act (an Interested Trustee), by virtue of his positions with the Trust and GMO indicated in the table above and his interest as a member of GMO. |
117
Information About Each Trustees Experience, Qualifications, Attributes, or Skills for Board Membership. As described in additional detail below under Committees, the Governance Committee, which is comprised solely of Independent Trustees, has responsibility for recommending to the Board of Trustees the nomination of candidates for election as Trustees, including identifying and evaluating the skill sets and qualifications of, potential candidates. In recommending the election of the current board members as Trustees, the Governance Committee generally considered the educational, business, and professional experience of each Trustee in determining his or her qualifications to serve as a Trustee of the Funds. The Governance Committee focuses on the complementary skills and experience of the Trustees as a group, as well as on those of any particular Trustee. With respect to Messrs. Glazer, Tufano, and Braverman, the Governance Committee noted that these Trustees all had considerable experience in overseeing investment management activities and/or related operations and in serving on the boards of other companies. In addition, the Committee also considered, among other factors, the particular attributes described below with respect to the various individual Trustees:
Donald W. Glazer Mr. Glazers experience serving as Chairman of the Board of Trustees and as a director of other companies, his professional training and his experience as a business lawyer, including as a partner at a leading law firm, and his business experience.
Peter Tufano Mr. Tufanos experience serving as Trustee of the Trust and as a director of other companies, and his professional training and his experience in business and finance, including as a dean of a leading business school.
Paul Braverman Mr. Bravermans experience as a director, his professional training and his experience as a certified public accountant and lawyer and his experience in the management of a leading investment management firm.
Joseph B. Kittredge, Jr. Mr. Kittredges experience serving as President of the Trust, President and Trustee of GMO Series Trust, and General Counsel and a member of GMO, his professional training and his experience as a lawyer representing mutual funds and investment management firms, including as a partner at a leading law firm, and his perspective on Board matters as a senior executive of GMO.
Information relating to the experience, qualifications, attributes, and skills of the Trustees is required by the registration form adopted by the SEC, does not constitute holding out the Board or any Trustee as having any special expertise or experience, and does not impose any greater responsibility or liability on any such person or on the Board as a whole than would otherwise be the case.
118
Officers
Name and Year of Birth |
Position(s) Held with the Trust |
Length of Time Served |
Principal Occupation(s) During Past 5 Years * |
|||
Joseph B. Kittredge, Jr. YOB: 1954 |
Trustee and President | Trustee since March 2010; President since March 2009; Chief Executive Officer, March 2009-June 2015. | General Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (October 2005-present); Partner, Ropes & Gray LLP (1988-2005). | |||
Sheppard N. Burnett YOB: 1968 |
Chief Executive Officer | Chief Executive Officer since June 2015; Chief Financial Officer, March 2007-June 2015; Treasurer, November 2006-June 2015; Assistant Treasurer, September 2004-November 2006. | Head of Fund Treasury and Tax, Grantham, Mayo, Van Otterloo & Co. LLC (December 2006-present). | |||
Carly Cushman YOB: 1984 |
Treasurer, Chief Accounting Officer and Chief Financial Officer | Treasurer and Chief Financial Officer since June 2015; Chief Accounting Officer since May 2014; Assistant Treasurer, September 2013-June 2015. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (December 2009-present); Senior Accountant, Renaissance HealthCare (February 2009-December 2009); Auditor/Senior Auditor, Deloitte & Touche (September 2006-February 2009). | |||
John L. Nasrah YOB: 1977 |
Assistant Treasurer and Chief Tax Officer | Since March 2007. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (September 2004-present). | |||
Betty Chang YOB: 1972 |
Assistant Treasurer | Since September 2013. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (July 2010-present); Assistant Treasurer (June 2009-July 2010), Manager, Fund Administration and Regulatory Affairs (2006-2009), Hambrecht & Quist Capital Management LLC. | |||
Craig Parker YOB: 1982 |
Assistant Treasurer | Since February 2015. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (October 2010-present); Senior Associate, PricewaterhouseCoopers LLP (September 2009-October 2010). | |||
Mahmoodur Rahman YOB: 1967 |
Assistant Treasurer | Since September 2007. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (April 2007-present). | |||
Brian Kadehjian YOB: 1974 |
Assistant Treasurer and Treasury Officer | Assistant Treasurer since February 2015; Treasury Officer since September 2013. | Fund Administrator, Grantham, Mayo, Van Otterloo & Co. LLC (April 2002-present). |
119
Name and Year of Birth |
Position(s) Held with the Trust |
Length of Time Served |
Principal Occupation(s) During Past 5 Years * |
|||
Douglas Y. Charton YOB: 1982 |
Chief Legal Officer, Vice President and Clerk | Since August 2015. | Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (July 2015-present); Associate, K&L Gates LLP (September 2007-July 2015). | |||
Megan Bunting YOB: 1978 |
Vice President and Assistant Clerk | Since September 2013. | Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (September 2006-present). | |||
Meta S. David YOB: 1982 |
Vice President and Assistant Clerk | Since September 2013. | Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (August 2012-present). | |||
Kevin OBrien YOB: 1985 |
Vice President and Assistant Clerk | Since March 2016. | Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (February 2015-present); Associate, Dechert LLP (October 2010-February 2015). | |||
Gregory L. Pottle YOB: 1971 |
Chief Compliance Officer | Chief Compliance Officer since May 2015; Vice President and Assistant Clerk, November 2006-November 2015. | Chief Compliance Officer, Grantham, Mayo, Van Otterloo & Co. LLC (May 2015-present); Legal Counsel, Grantham, Mayo, Van Otterloo & Co. LLC (March 2000-May 2015). | |||
Claire Wilkinson YOB: 1965 |
Anti-Money Laundering Officer | Since February 2016. | Compliance Associate, GMO UK Limited (April 2013-present); General Counsel, MVision Private Equity Advisers Limited (November 2009 -January 2013). |
* | Each officer of the Trust may also serve as an officer and/or director of certain pooled investment vehicles of which GMO or an affiliate of GMO serves as the investment adviser. With the exceptions of Messrs. Kittredge and Parker, each officer listed in the table above also serves as an officer of GMO Series Trust. |
Trustees Responsibilities. Under the provisions of the Declaration of Trust (as defined below under Description of the Trust and Ownership of Shares), the Trustees manage the business of the Trust, an open-end management investment company. The Trustees have all powers necessary or convenient to carry out that responsibility, including the power to engage in securities transactions on behalf of the Trust. Without limiting the foregoing, the Trustees may: amend the Declaration of Trust to the extent permitted by such document and applicable law; adopt by-laws not inconsistent with the Declaration of Trust providing for the regulation and management of the affairs of the Trust; amend and repeal by-laws to the extent that such by-laws do not reserve that right to the shareholders; fill vacancies in or remove members of the Board of Trustees (including any vacancies created by an increase in the number of Trustees); remove members of the Board of Trustees with or without cause; elect and remove such officers and appoint and terminate agents as they consider appropriate; appoint members of the Board of Trustees to one or more committees consisting of two or more Trustees, which may exercise the powers and authority of the Trustees, and terminate any such appointments; employ one or more custodians of the assets of the Trust and authorize such custodians to employ subcustodians and to deposit all or any part of such assets in a system or systems for the central handling of securities or with a Federal Reserve Bank; retain a transfer agent or a shareholder servicing
120
agent, or both; provide for the distribution of Shares by the Trust, through one or more principal underwriters or otherwise; set record dates for the determination of Shareholders with respect to various matters; and in general delegate such authority as they consider desirable to any officer of the Trust, to any committee of the Trustees, and to any agent or employee of the Trust or to any such custodian or underwriter.
Board Leadership Structure and Risk Oversight. The Board of Trustees is responsible for the general oversight of each GMO Funds affairs and for assuring that each GMO Fund is managed in the best interests of its shareholders. The Board regularly reviews each GMO Funds investment performance as well as the quality of services provided to each GMO Fund and its shareholders by GMO and its affiliates, including shareholder servicing. At least annually, the Board reviews and evaluates the fees and operating expenses paid by each GMO Fund for these services and negotiates changes that it deems appropriate. In carrying out these responsibilities, the Board is assisted by the GMO Funds auditors, independent counsel to the Independent Trustees and other persons as appropriate, who are selected by and responsible to the Board. In addition, the GMO Funds Chief Compliance Officer reports directly to the Board.
Currently, all but one of the Trustees are Independent Trustees. The Independent Trustees must vote separately to approve all financial arrangements and other agreements with the Funds investment adviser, GMO, and other affiliated parties. The role of the Independent Trustees has been characterized as that of a watchdog charged with oversight of protecting shareholders interests against overreaching and abuse by those who are in a position to control or influence a fund. The Independent Trustees meet regularly as a group in executive session without representatives of GMO present. An Independent Board Member currently serves as Chairman of the Board of Trustees.
Taking into account the number, diversity, and complexity of the GMO Funds overseen by the Board of Trustees and the aggregate amount of assets under management in the GMO Funds, the Board has determined that the efficient conduct of its affairs makes it desirable to delegate responsibility for certain specific matters to committees of the Board. These committees, which are described in more detail below, review and evaluate matters specified in their charters and make recommendations to the Board as they deem appropriate. Each committee may utilize the resources of the GMO Funds counsel and auditors as well as other persons. The committees meet from time to time, either in conjunction with regular meetings of the Board or otherwise. The membership and chair of each committee are appointed by the Board upon recommendation of the Governance Committee. The membership and chair of each committee other than the Risk Oversight Committee consists exclusively of Independent Trustees.
The Board of Trustees has determined that this committee structure also allows the Board to focus more effectively on the oversight of risk as part of its broader oversight of each GMO Funds affairs. While risk management is primarily the responsibility of the Funds investment adviser, GMO, the Board regularly receives reports, including reports from GMO and the GMO Funds Chief Compliance Officer, regarding investment risks, compliance risks, and certain other risks applicable to the GMO Funds. The Boards committee structure allows separate committees, such as the Audit Committee, Pricing Committee, and Governance Committee, which are discussed in more detail below under Committees, to focus on different aspects of these risks within the scope of the committees authority and their potential impact on some or
121
all of the GMO Funds, and to discuss with the GMO the ways in which GMO monitors and controls such risks. The Board has also established a separate Risk Oversight Committee to assist the Board in overseeing the management of operational and systems risks applicable to the Funds.
The Board recognizes that not all risks that may affect the GMO Funds can be identified, that it may not be practical or cost-effective to eliminate or mitigate certain risks, that it may be necessary to bear certain risks (such as investment-related risks) to achieve a GMO Funds goals, that reports received by the Trustees with respect to risk management matters are typically summaries of the relevant information, and that the processes, procedures and controls employed to address risks may be limited in their effectiveness. As a result of the foregoing and other factors, risk management oversight by the Board and by the Committees is subject to substantial limitations.
Committees
The Board of Trustees has the authority to establish committees, which may exercise the power and authority of the Trustees to the extent the Board determines. The committees assist the Board of Trustees in performing its functions and duties under the 1940 Act and Massachusetts law.
The Board of Trustees currently has established four standing committees: the Audit Committee, the Pricing Committee, the Risk Oversight Committee, and the Governance Committee. During the fiscal year ended February 29, 2016, the Audit Committee held [ ] meetings; the Governance Committee held [ ] meetings; the Pricing Committee held [ ] meetings; and the Risk Oversight Committee held [ ] meetings.
Audit Committee. The Audit Committee (i) oversees the Trusts accounting and financial reporting policies and practices and internal controls over financial reporting; (ii) oversees the quality and objectivity of the Trusts financial statements and the independent audit of those statements; (iii) appoints, determines the independence and compensation of, and oversees the work performed by the Trusts independent auditors in preparing or issuing an audit report or related work; (iv) approves all audit and permissible non-audit services provided to the Trust, and certain other persons by the Trusts independent auditors; and (v) acts as a liaison between the Trusts independent auditors and the Board of Trustees. Mr. Braverman and Mr. Tufano are members of the Audit Committee, and Mr. Glazer is an alternate member of the Audit Committee. Mr. Braverman is the Chairman of the Audit Committee.
Governance Committee. The Governance Committee oversees general GMO Fund governance-related matters, including making recommendations to the Board of Trustees relating to governance of the Trust, reviewing possible conflicts of interest and independence issues involving Trustees, considering the skill sets and qualifications of prospective Trustees and to propose to the Board candidates to serve as Trustees, overseeing the determination that any person serving as legal counsel for the Independent Trustees qualifies as independent legal counsel, as that term is defined in the 1940 Act, and performing any other functions delegated to it by the Board of Trustees. Mr. Glazer and Mr. Braverman are members of the Governance Committee, and Mr. Tufano is an alternate member of the Governance Committee. Mr. Glazer is the Chairman of the Governance Committee.
122
As described above under Information About Each Trustees Experience, Qualifications, Attributes or Skills for Board Membership, the Governance Committee has responsibility for recommending to the Board of Trustees the nomination of candidates for election as Trustees, including identifying and evaluating the skill sets and qualifications of potential candidates. Prospective nominees may be recommended by the current Trustees, the Trusts Officers, GMO, current shareholders, or other sources that the Governance Committee deems appropriate. Candidates properly submitted by shareholders will be considered on the same basis as candidates recommended by other sources. The Governance Committee has full discretion to reject nominees.
The Governance Committee considers a variety of qualifications, skills, and other attributes in evaluating potential candidates for nomination to the Board of Trustees. The attributes considered may include, but are not limited to: (i) relevant industry and related experience, including experience serving on other boards; (ii) skill sets, areas of expertise, abilities, and judgment; and (iii) availability and commitment to attend meetings and to perform the responsibilities of a Trustee. In evaluating potential candidates, the Governance Committee also considers the overall composition of the Board of Trustees and assesses the needs of the Board and its committees.
Shareholders may recommend nominees to the Board of Trustees by writing the Board of Trustees, c/o GMO Trust Chief Compliance Officer, GMO Trust, 40 Rowes Wharf, Boston, Massachusetts 02110. A recommendation must (i) be in writing and signed by the shareholder; (ii) identify the GMO Fund to which it relates; and (iii) identify the class and number of shares held by the shareholder.
Pricing Committee. The Pricing Committee oversees the valuation of the securities and other assets held by the GMO Funds, reviews and makes recommendations regarding the Trusts Pricing Policies, and, to the extent required by the Trusts Pricing Policies, determines the fair value of the securities or other assets held by the GMO Funds. Mr. Tufano and Mr. Glazer are members of the Pricing Committee, and Mr. Braverman is an alternate member of the Pricing Committee. Mr. Tufano is the Chairman of the Pricing Committee.
Risk Oversight Committee. The Risk Oversight Committee assists the Board in overseeing the management of operational and systems risks applicable to the GMO Funds. All of the Trustees are members of the Risk Oversight Committee, and Messrs. Braverman and Tufano are Co-Chairmen of the Risk Oversight Committee.
123
Trustee Fund Ownership
The following table sets forth ranges of the current Trustees direct beneficial share ownership in the Funds and the aggregate dollar ranges of their direct beneficial share ownership in all series of GMO Trust and GMO Series Trust (the Family of Investment Companies) overseen by the Trustee as of December 31, 2015.
Name/Funds |
Dollar Range of
Shares Directly Owned in the Funds |
Aggregate Dollar Range of Shares
Directly Owned in all Registered Investment Companies (whether or not offered in the Prospectus) Overseen by Trustee in Family of Investment Companies |
||
INDEPENDENT TRUSTEES |
||||
Donald W. Glazer Alpha Only Fund Benchmark-Free Allocation Fund Emerging Markets Fund Global Focused Equity Fund 1 Quality Fund |
Over $100,000
Over $100,000 Over $100,000 Over $100,000 $10,001-$50,000 |
Over $100,000 | ||
Peter Tufano Benchmark-Free Allocation Fund Emerging Country Debt Fund |
$50,001-$100,000
$50,001-$100,000 |
Over $100,000 | ||
Paul Braverman |
None | None | ||
INTERESTED TRUSTEE |
||||
Joseph B. Kittredge, Jr. |
None | None |
1 | [ ] |
The following table sets forth ranges of the current Trustees indirect beneficial share ownership in the Funds and the aggregate dollar range of their indirect beneficial share ownership in the Family of Investment Companies as of December 31, 2015.
Name/Funds |
Dollar Range of
Shares Indirectly Owned in the Funds |
Aggregate Dollar Range of Shares
Indirectly Owned in all Registered Investment Companies (whether or not offered in the Prospectus) Overseen by Trustee in Family of Investment Companies |
||
INDEPENDENT TRUSTEES |
||||
Donald W. Glazer Debt Opportunities Fund Emerging Country Debt Fund Implementation Fund SGM Major Markets Fund Special Opportunities Fund U.S. Treasury Fund |
$50,001-$100,000
$50,001-$100,000 Over $100,000 $50,001-$100,000 $10,001-$50,000 Over $100,000 |
Over $100,000 | ||
Peter Tufano Debt Opportunities Fund Emerging Country Debt Fund Implementation Fund SGM Major Markets Fund Special Opportunities Fund U.S. Treasury Fund |
$1-$10,000
$1-$10,000 $50,001-$100,000 $1-$10,000 $1-$10,000 $1-$10,000 |
$50,001-$100,000 | ||
Paul Braverman |
None | None | ||
INTERESTED TRUSTEE |
||||
Joseph B. Kittredge, Jr. |
None | None |
124
Independent Trustee Ownership of Securities Issued by GMO or Principal Underwriter
[None.]
Independent Trustee Ownership of Related Companies
The following table sets forth information about securities owned by the current Independent Trustees and their family members, as of December 31, 2015, in GMO, Funds Distributor, LLC (Funds Distributor), the GMO Funds principal underwriter, or entities directly or indirectly controlling, controlled by, or under common control with GMO or Funds Distributor.
Name of Independent Trustee |
Name of Owner(s) and
Relationship
|
Company |
Title of Class |
Value of
Securities² |
% of
Class |
|||||||||
Donald W. Glazer | Self | GMO Multi-Strategy Fund (Offshore), a private investment company managed by GMO. 1 | Limited partnership interest Class A | $620,552.94 | 0.027 | % | ||||||||
Peter Tufano | N/A | None | N/A | N/A | N/A | |||||||||
Paul Braverman | N/A | None | N/A | N/A | N/A |
1 | GMO may be deemed to control this fund by virtue of its serving as investment manager of the fund and by virtue of its ownership interest in the fund. |
2 | Securities valued as of December 31, 2015. |
Remuneration. The Trust has adopted a compensation policy for its Independent Trustees. Each Independent Trustee receives an annual retainer from the Trust for his services. In addition, each Chairman of the Trusts standing committees and the Chairman of the Board of Trustees receive an annual fee. The Trust reimburses the Independent Trustees for travel expenses incurred in connection with attending Board and committee meetings. The Trust pays no additional compensation for travel time to meetings, attendance at directors educational seminars or conferences, service on industry or association committees, participation as speakers at directors conferences, or service on special director task forces or subcommittees, although
125
the Trust does reimburse Independent Trustees for seminar or conference fees and for travel expenses incurred in connection with attendance at seminars or conferences. The Independent Trustees do not receive any employee benefits such as pension or retirement benefits or health insurance.
Other than as set forth in the following table, no Trustee of the Trust received any direct compensation from the Fund Complex or any Fund during the fiscal year ended February 29, 2016:
[To be updated by amendment.]
Donald W.
Glazer, Trustee |
Peter Tufano,
Trustee |
Paul Braverman,
Trustee |
||||||||||
Alpha Only Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Asset Allocation Bond Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Benchmark-Free Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Benchmark-Free Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Core Plus Bond Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Currency Hedged International Bond Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Debt Opportunities Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Developed World Stock Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Emerging Countries Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Emerging Country Debt Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Emerging Domestic Opportunities Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Emerging Markets Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Foreign Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Foreign Small Companies Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Global Asset Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Global Bond Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Global Developed Equity Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Global Equity Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Implementation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
International Developed Equity Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
International Equity Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
International Equity Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
International Large/Mid Cap Equity Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
International Small Companies Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Quality Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Resources Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Risk Premium Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
SGM Major Markets Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Special Opportunities Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Strategic Opportunities Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Taiwan Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Tax-Managed International Equities Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] |
126
Donald W.
Glazer, Trustee |
Peter Tufano,
Trustee |
Paul Braverman,
Trustee |
||||||||||
U.S. Equity Allocation Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
U.S. Treasury Fund |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Pension or Retirement Benefits Accrued as Part of Fund Expenses: |
[N/A | ] |
|
[N/A |
] |
|
[N/A |
] |
||||
Estimated Annual Benefits Upon Retirement: |
[N/A | ] |
|
[N/A |
] |
|
[N/A |
] |
||||
Total Compensation from the Fund Complex: 1 |
$ | [ | ] | $ | [ | ] | $ | [ | ] |
1 | Reflects actual direct compensation received during the fiscal year ended February 29, 2016 from series of the Fund Complex that had commenced operations on or before February 29, 2016, which consisted of 50 series of GMO Trust and GMO Series Trust. |
[No officer of the Trust received aggregate compensation exceeding $60,000 from any Fund offered in the Prospectus during the fiscal year ended February 29, 2016.]
Mr. Kittredge does not receive any compensation from the Fund Complex, but as a member of GMO will benefit from management, shareholder servicing, administration, and any other fees paid to GMO and its affiliates by the Funds and various other series of the Fund Complex not offered through the Prospectus. The officers of the Trust do not receive any employee benefits such as pension or retirement benefits or health insurance from the Trust.
[As of [ ], the Trustees and officers of the Trust as a group owned [less than 1%] of the outstanding shares of each class of shares of each Fund offered in the Prospectus, with the exception of [ ] of which the Trustees and officers of the Trust as a group owned [ ]% of the outstanding shares.] [ T o be upda t e d by am e ndm e n t . ]
Code of Ethics. The Trust and GMO have each adopted a Code of Ethics pursuant to the requirements of the 1940 Act. Under each Code of Ethics, personnel are permitted to engage in personal securities transactions only in accordance with specified conditions relating to their position, the identity of the security, the timing of the transaction, and similar factors. Transactions in securities that may be purchased or held by the Funds are permitted, subject to compliance with each Code. Personal securities transactions must be reported quarterly and broker confirmations must be provided for review.
The independent Trustees of the Trust are subject to a separate Code of Ethics for the Independent Trustees pursuant to the requirements of the 1940 Act. Transactions by the Independent Trustees in securities, including securities that may be purchased or held by the Funds, are permitted, subject to compliance with the Code of Ethics. Pursuant to the Code of Ethics, an Independent Trustee ordinarily is not required to report his or her personal securities transactions or to identify his or her brokerage accounts to a Fund or its representatives, subject to certain limited exceptions specified in the Code of Ethics.
Funds Distributor, which is not affiliated with the Funds or GMO, and GMO U.K. Limited (GMO U.K.), the Funds distributor for the limited purpose of offering shares of the Funds to qualified investors in Switzerland, also have each adopted a Code of Ethics pursuant to the requirements of the 1940 Act. Transactions in securities effected by Funds Distributors or
127
GMO U.K.s personnel who are designated as Access Persons under their respective Code of Ethics, including securities that may be purchased or held by the Funds, are permitted, subject to compliance with their respective Code of Ethics.
INVESTMENT ADVISORY AND OTHER SERVICES
Management Contracts
As disclosed in the Prospectus under the heading Management of the Trust, under separate Management Contracts (each, a Management Contract) between the Trust, on behalf of the Funds, and GMO, subject to such policies as the Trustees of the Trust may determine, GMO furnishes continuously an investment or asset allocation program, as applicable, for each Fund, and makes investment decisions on behalf of the Fund and places all orders for the purchase and sale of portfolio securities. Subject to the control of the Trustees, GMO also manages, supervises, and conducts the other affairs and business of the Trust, furnishes office space and equipment, provides bookkeeping and certain clerical services, and pays all salaries, fees, and expenses of officers and Trustees of the Trust who are affiliated with GMO. As indicated under Portfolio Transactions Brokerage and Research Services, the Trusts portfolio transactions may be placed with brokers who furnish GMO, at no cost, research, statistical and quotation services of value to GMO in advising the Trust or its other clients.
In addition, as disclosed in the Prospectus, GMO has contractually agreed to waive and/or reimburse each Fund for specified Fund expenses through at least [June 30, 2017].
Each Management Contract provides that GMO shall not be subject to any liability in connection with the performance of its services in the absence of willful misfeasance, bad faith, gross negligence, or reckless disregard of its obligations and duties.
Each Management Contract was approved by the Trustees of the Trust (including a majority of the Trustees who were not interested persons of GMO) and by the relevant Funds sole initial shareholder in connection with the organization of the Trust and the establishment of the Funds. Generally, each Management Contract continues in effect for a period of two years from the date of its execution and continuously thereafter so long as its continuance is approved at least annually by (i) the vote, cast in person at a meeting called for that purpose, of a majority of those Trustees who are not interested persons of GMO or the Trust, and by (ii) the majority vote of either the full Board of Trustees or the vote of a majority of the outstanding shares of the relevant Fund. Each Management Contract automatically terminates on assignment, and is terminable on not more than 60 days notice by the Trust to GMO. In addition, each Management Contract may be terminated on not more than 60 days written notice by GMO to the Trust.
128
For each Fund, the Management Fee is calculated based on a fixed percentage of the Funds average daily net assets. Pursuant to their Management Contracts, the Funds that commenced operations prior to the end of the most recent fiscal year have paid the following amounts as Management Fees to GMO during the last three fiscal years:
[To be updated by amendment.]
Gross | Reduction | Net | ||||||||||
ALPHA ONLY FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
19,583,444 | 1,506,024 | 18,077,420 | |||||||||
Year ended 2/28/14 |
16,993,837 | 10,429,113 | 6,564,724 | |||||||||
ASSET ALLOCATION BOND FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
11,266,713 | 969,199 | 10,297,514 | |||||||||
Year ended 2/28/14 |
4,052,593 | 273,483 | 3,779,110 | |||||||||
BENCHMARK-FREE ALLOCATION FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
120,035,547 | 32,024,649 | 88,010,898 | |||||||||
Year ended 2/28/14 |
60,739,219 | 21,890,854 | 38,848,365 | |||||||||
BENCHMARK-FREE FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
0 | 0 | 0 | |||||||||
Year ended 2/28/14 |
0 | 0 | 0 | |||||||||
CORE PLUS BOND FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
601,406 | 269,744 | 331,662 | |||||||||
Year ended 2/28/14 |
598,670 | 284,059 | 314,611 | |||||||||
CURRENCY HEDGED INTERNATIONAL BOND FUND |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
183,825 | 157,367 | 26,458 | |||||||||
Year ended 2/28/14 |
174,708 | 162,339 | 12,369 | |||||||||
DEBT OPPORTUNITIES FUND 1 |
||||||||||||
Year ended 2/29/16 |
$ | [ | ] | $ | [ | ] | $ | [ | ] | |||
Year ended 2/28/15 |
4,855,961 | 587,052 | 4,268,909 | |||||||||
Year ended 2/28/14 |
2,786,510 | 254,241 | 2,532,269 |
129
130
131
132
1 | GMO Debt Opportunities Fund, a former series of GMO Trust offered pursuant to a private placement memorandum (the Predecessor Fund) is the accounting and performance successor to the Fund. The Predecessor Fund had an investment objective and policies and restrictions substantially identical to those of the Fund. Effective February 12, 2014, the Predecessor Fund merged into the Fund (which was formerly known as GMO Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund. Management Fees paid to GMO by the Fund through February 11, 2014 are those of the Predecessor Fund. |
2 | Reflects Management Fees paid from the Funds commencement of operations on July 28, 2014 through February 28, 2015. |
133
In the event that GMO ceases to be the manager of a Fund, the right of the Trust to use the identifying initials GMO and the name Grantham, Mayo, Van Otterloo & Co. LLC may be withdrawn.
Portfolio Management
Management of each Fund is the responsibility of one or more investment teams comprising investment professionals associated with GMO. Each teams members work collaboratively to manage a Funds portfolio, and no one person is primarily responsible for management of any Fund.
The following table sets forth information about accounts overseen or managed by the senior members of the teams as of February 29, 2016 (except as otherwise noted below).
[To be updated by amendment.]
134
Senior Member |
Registered investment companies managed
(including non-GMO mutual fund subadvisory relationships) |
Other pooled investment vehicles
managed (world-wide) |
Separate accounts managed
(world-wide) |
|||||||||||||||||||||
Number
of accounts 1 |
Total assets 1 |
Number
of accounts |
Total assets |
Number
of accounts |
Total assets | |||||||||||||||||||
Joe Auth |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Amit Bhartia |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Warren Chiang |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Neil Constable |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Thomas Cooper 2 |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
David Cowan |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Arjun Divecha |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Michael Emanuel |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Chris Fortson |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Jason Halliwell |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Thomas Hancock |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Anthony Hene |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Chris Hudson |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Ben Inker |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Greg Jones |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Drew Spangler |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Tina Vandersteel 2 |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Lucas White |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Sam Wilderman |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] |
135
Senior Member |
Registered investment companies managed
for which GMO receives a performance- based fee (including non-GMO mutual fund subadvisory relationships) |
Other pooled investment vehicles
managed (world-wide) for which GMO receives a performance-based fee |
Separate accounts managed (world-wide)
for which GMO receives a performance- based fee |
|||||||||||||||||||||
Number of
accounts 1 |
Total assets 1 |
Number
of accounts |
Total assets |
Number of
accounts |
Total assets | |||||||||||||||||||
Joe Auth |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Amit Bhartia |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Warren Chiang |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Neil Constable |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Thomas Cooper 2 |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
David Cowan |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Arjun Divecha |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Michael Emanuel |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Chris Fortson |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Jason Halliwell |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Thomas Hancock |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Anthony Hene |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Chris Hudson |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Ben Inker |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Greg Jones |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Drew Spangler |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Tina Vandersteel 2 |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Lucas White |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] | |||||||||
Sam Wilderman |
[ | ] | $ | [ | ] | [ | ] | $ | [ | ] | [ | ] | $ | [ | ] |
1 | For some senior members, Total assets includes assets invested by other GMO Funds (including GMO Funds not offered through the Prospectus). |
2 | [Following Mr. Coopers retirement on September 30, 2016, Ms. Vandersteel will be the sole Senior Member and Head of the Emerging Country Debt Team.] |
136
Because each senior member manages other accounts, including accounts that pay higher fees or accounts that pay performance-based fees, potential conflicts of interest exist, including potential conflicts between the investment strategy of a Fund and the investment strategy of the other accounts managed by the senior member and potential conflicts in the allocation of investment opportunities between a Fund and the other accounts.
Senior members of each team are generally members (partners) of GMO. [As of February 29, 2016, the compensation of each senior member consisted of a fixed annual base salary and, possibly, an additional, discretionary, bonus related to the senior members contribution to GMOs success and, in the case of partners, a partnership interest in the firms profits. The compensation program does not disproportionately reward outperformance by higher-fee/performance-fee products. Base salary is determined by taking into account current industry norms and market data to ensure that GMO pays a competitive base salary. A discretionary bonus may be paid to recognize specific business contributions and to ensure that the total level of compensation is competitive with the market. The level of partnership interest is determined by taking into account the individuals contribution to GMO and its mission statement. Because each persons compensation is based on his or her individual performance, GMO does not have a typical percentage split among base salary, bonus, and other compensation. A GMO partnership interest is the primary incentive for persons to maintain employment with GMO. GMO believes this is the best incentive to maintain stability of portfolio management personnel.]
Senior Member Fund Ownership. The following table sets forth the dollar range of each senior members direct beneficial share ownership, as of February 29, 2016 (except as otherwise noted below), in the Funds offered in the Prospectus that are overseen or managed by the senior member as of the date of this SAI:
[To be updated by amendment.]
Name of Senior Member |
Dollar Range of Shares Directly Owned in the Fund |
|||||
Joe Auth |
[Debt Opportunities Fund] | [ | ] | |||
Amit Bhartia |
[Emerging Countries Fund] [Emerging Domestic Opportunities Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ [ |
]
] ] ] |
||
Warren Chiang |
[Emerging Countries Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ |
]
] ] |
||
Neil Constable |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Thomas Cooper 1 |
[Emerging Country Debt Fund] | [ | ] |
137
Name of Senior Member |
Dollar Range of Shares Directly Owned in the Fund |
|||||
David Cowan |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Arjun Divecha |
[Emerging Countries Fund] [Emerging Domestic Opportunities Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ [ |
]
] ] ] |
||
Michael Emanuel |
[Asset Allocation Bond Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Global Bond Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ |
]
] ] ] ] |
||
Chris Fortson |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Jason Halliwell |
[SGM Major Markets Fund] | [ | ] | |||
Thomas Hancock |
[Quality Fund] [Resources Fund] |
|
[
[ |
]
] |
||
Anthony Hene |
[Quality Fund] | [ | ] | |||
Chris Hudson |
[Special Opportunities Fund] | [ | ] |
138
Name of Senior Member |
Dollar Range of Shares Directly Owned in the Fund |
|||||
Ben Inker |
[Alpha Only Fund] [Asset Allocation Bond Fund] [Benchmark-Free Allocation Fund] [Benchmark-Free Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Debt Opportunities Fund] [Developed World Stock Fund] [Global Asset Allocation Fund] [Global Bond Fund] [Global Developed Equity Allocation Fund] [Global Equity Allocation Fund] [Implementation Fund] [International Developed Equity Allocation Fund] [International Equity Allocation Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Special Opportunities Fund] [Strategic Opportunities Allocation Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ |
]
] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] |
||
Greg Jones |
[Asset Allocation Bond Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Global Bond Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ |
]
] ] ] ] |
||
Drew Spangler |
[Foreign Fund] [Foreign Small Companies Fund] [International Small Companies Fund] |
|
[
[ [ |
]
] ] |
||
Tina Vandersteel 1 |
[Emerging Country Debt Fund] | [ | ] | |||
Lucas White |
[Resources Fund] | [ | ] |
139
Name of Senior Member |
Dollar Range of Shares Directly Owned in the Fund |
|||||
Sam Wilderman |
[Alpha Only Fund] [Asset Allocation Bond Fund] [Benchmark-Free Allocation Fund] [Benchmark-Free Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Debt Opportunities Fund] [Developed World Stock Fund] [Global Asset Allocation Fund] [Global Bond Fund] [Global Developed Equity Allocation Fund] [Global Equity Allocation Fund] [Implementation Fund] [International Developed Equity Allocation Fund] [International Equity Allocation Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Special Opportunities Fund] [Strategic Opportunities Allocation Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ |
]
] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] |
1 | [Following Mr. Coopers retirement on September 30, 2016, Ms. Vandersteel will be the sole Senior Member and Head of the Emerging Country Debt Team.] |
The following table sets forth the dollar range of each senior members indirect beneficial share ownership, as of February 29, 2016 (except as otherwise noted below), in the Funds offered in the Prospectus that are overseen or managed by the senior member as of the date of this SAI, by virtue of the senior members direct ownership of shares of certain other Funds of the Trust that invest in the Funds:
[To be updated by amendment.]
Name of Senior Member |
Dollar Range of Shares Indirectly Owned in the Fund |
|||||
Joe Auth |
[Debt Opportunities Fund] | [ | ] | |||
Amit Bhartia |
[Emerging Countries Fund] [Emerging Domestic Opportunities Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ [ |
]
] ] ] |
||
Warren Chiang |
[Emerging Countries Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ |
]
] ] |
140
Name of Senior Member |
Dollar Range of Shares Indirectly Owned in the Fund |
|||||
Neil Constable |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Thomas Cooper 1 |
[Emerging Country Debt Fund] | [ | ] | |||
David Cowan |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Arjun Divecha |
[Emerging Countries Fund] [Emerging Domestic Opportunities Fund] [Emerging Markets Fund] [Taiwan Fund] |
|
[
[ [ [ |
]
] ] ] |
||
Michael Emanuel |
[Asset Allocation Bond Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Global Bond Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ |
]
] ] ] ] |
||
Chris Fortson |
[Developed World Stock Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Risk Premium Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] |
|
[
[ [ [ [ [ |
]
] ] ] ] ] |
||
Jason Halliwell |
[SGM Major Markets Fund] | [ | ] | |||
Thomas Hancock |
[Quality Fund] [Resources Fund] |
|
[
[ |
]
] |
||
Anthony Hene |
[Quality Fund] | [ | ] | |||
Chris Hudson |
[Special Opportunities Fund] | [ | ] |
141
Name of Senior Member |
Dollar Range of Shares Indirectly Owned in the Fund |
|||||
Ben Inker |
[Alpha Only Fund] [Asset Allocation Bond Fund] [Benchmark-Free Allocation Fund] [Benchmark-Free Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Debt Opportunities Fund] [Developed World Stock Fund] [Global Asset Allocation Fund] [Global Bond Fund] [Global Developed Equity Allocation Fund] [Global Equity Allocation Fund] [Implementation Fund] [International Developed Equity Allocation Fund] [International Equity Allocation Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Special Opportunities Fund] [Strategic Opportunities Allocation Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ |
]
] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] |
||
Greg Jones |
[Asset Allocation Bond Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Global Bond Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ |
]
] ] ] ] |
||
Drew Spangler |
[Foreign Fund] [Foreign Small Companies Fund] [International Small Companies Fund] |
|
[
[ [ |
]
] ] |
||
Tina Vandersteel 1 |
[Emerging Country Debt Fund] | [ | ] | |||
Lucas White |
[Resources Fund] | [ | ] |
142
Name of Senior Member |
Dollar Range of Shares Indirectly Owned in the Fund |
|||||
Sam Wilderman |
[Alpha Only Fund] [Asset Allocation Bond Fund] [Benchmark-Free Allocation Fund] [Benchmark-Free Fund] [Core Plus Bond Fund] [Currency Hedged International Bond Fund] [Debt Opportunities Fund] [Developed World Stock Fund] [Global Asset Allocation Fund] [Global Bond Fund] [Global Developed Equity Allocation Fund] [Global Equity Allocation Fund] [Implementation Fund] [International Developed Equity Allocation Fund] [International Equity Allocation Fund] [International Equity Fund] [International Large/Mid Cap Equity Fund] [Special Opportunities Fund] [Strategic Opportunities Allocation Fund] [Tax-Managed International Equities Fund] [U.S. Equity Allocation Fund] [U.S. Treasury Fund] |
|
[
[ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ [ |
]
] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] ] |
1 | [Following Mr. Coopers retirement on September 30, 2016, Ms. Vandersteel will be the sole Senior Member and Head of the Emerging Country Debt Team.] |
Custodial Arrangements and Fund Accounting Agents . As described in the Prospectus, State Street Bank and Trust Company (State Street Bank), [One Lincoln Street, Boston, Massachusetts 02111], serves as the Trusts custodian and fund accounting agent on behalf of some of the Funds, and Brown Brothers Harriman & Co. (BBH), 50 Post Office Square, Boston, Massachusetts 02110, serves as the Trusts custodian and fund accounting agent on behalf of the other Funds. As such, State Street Bank or BBH holds in safekeeping certificated securities and cash belonging to a Fund and, in such capacity, is the registered owner of securities in book-entry form belonging to a Fund. Upon instruction, State Street Bank or BBH receives and delivers cash and securities of a Fund in connection with Fund transactions and collects all dividends and other distributions made with respect to Fund portfolio securities. Each of State Street Bank and BBH also maintains certain accounts and records of the Trust and calculates the total net asset value, total net income and net asset value per share of each Fund on a daily basis.
Shareholder Service Arrangements . As disclosed in the Prospectus, pursuant to the terms of an amended and restated servicing and supplemental support agreement (the Servicing Agreement) with the Funds of the Trust (except for Implementation Fund and U.S. Treasury Fund), GMO provides (i) direct client service, maintenance, and reporting to Fund shareholders (except for shareholders of Class MF shares of Benchmark-Free Allocation Fund) and/or their consultants/agents; and (ii) supplemental support to shareholders of Class MF shares of Benchmark-Free Allocation Fund and their investment advisers. The Servicing Agreement was
143
approved by the Trustees of the Trust (including a majority of the Trustees who are not interested persons of GMO or the Trust). The Servicing Agreement will continue in effect for a period of more than one year from the date of its execution only so long as its continuance is approved at least annually by (i) the vote, cast in person at a meeting called for the purpose, of a majority of those Trustees who are not interested persons of GMO or the Trust; and (ii) the majority vote of the full Board of Trustees. The Servicing Agreement automatically terminates on assignment (except as specifically provided in the Servicing Agreement) and is terminable by either party upon not more than 60 days written notice to the other party.
The Trust entered into the Servicing Agreement with GMO on May 30, 1996. Pursuant to the terms of the Servicing Agreement, each Fund that commenced operations prior to the end of the most recent fiscal year paid GMO the following amounts (after reimbursement by GMO) during the last three fiscal years:
[To be updated by amendment.]
March 1, 2013
Through February 28, 2014 |
March 1, 2014
Through February 28, 2015 |
March 1, 2015
Through February 29, 2016 |
||||||||||
Alpha Only Fund |
$ | 1,703,345 | $ | 3,933,930 | $ | [ | ] | |||||
Asset Allocation Bond Fund |
$ | 1,049,592 | $ | 2,753,557 | $ | [ | ] | |||||
Benchmark-Free Allocation Fund |
$ | 6,684,170 | $ | 4,041,643 | $ | [ | ] | |||||
Benchmark-Free Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Core Plus Bond Fund |
$ | 253,301 | $ | 246,309 | $ | [ | ] | |||||
Currency Hedged International Bond Fund |
$ | 101,773 | $ | 102,639 | $ | [ | ] | |||||
Debt Opportunities Fund (a) |
$ | 613,033 | $ | 1,068,311 | $ | [ | ] | |||||
Developed World Stock Fund |
$ | 481,553 | $ | 530,607 | $ | [ | ] | |||||
Emerging Countries Fund |
$ | 116,836 | $ | 74,425 | $ | [ | ] |
144
March 1, 2013
Through February 28, 2014 |
March 1, 2014
Through February 28, 2015 |
March 1, 2015
Through February 29, 2016 |
||||||||||
Emerging Country Debt Fund |
$ | 2,883,242 | $ | 3,786,209 | $ | [ | ] | |||||
Emerging Domestic Opportunities Fund |
$ | 2,812,176 | $ | 3,426,401 | $ | [ | ] | |||||
Emerging Markets Fund |
$ | 8,676,161 | $ | 6,940,715 | $ | [ | ] | |||||
Foreign Fund |
$ | 753,259 | $ | 628,486 | $ | [ | ] | |||||
Foreign Small Companies Fund |
$ | 1,093,502 | $ | 1,205,867 | $ | [ | ] | |||||
Global Asset Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Global Bond Fund |
$ | 211,682 | $ | 107,111 | $ | [ | ] | |||||
Global Developed Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Global Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Implementation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
International Developed Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
International Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
International Equity Fund |
$ | 12,298,995 | $ | 13,134,328 | $ | [ | ] |
145
March 1, 2013
Through February 28, 2014 |
March 1, 2014
Through February 28, 2015 |
March 1, 2015
Through February 29, 2016 |
||||||||||
International Large/Mid Cap Equity Fund |
$ | 2,601,278 | $ | 2,028,230 | $ | [ | ] | |||||
International Small Companies Fund |
$ | 523,094 | $ | 466,388 | $ | [ | ] | |||||
Quality Fund |
$ | 14,778,454 | $ | 12,641,163 | $ | [ | ] | |||||
Resources Fund |
$ | 230,342 | $ | 200,360 | $ | [ | ] | |||||
Risk Premium Fund |
$ | 414,506 | $ | 369,859 | $ | [ | ] | |||||
SGM Major Markets Fund |
$ | 2,419,008 | $ | 2,272,572 | $ | [ | ] | |||||
Special Opportunities Fund |
N/A | $ | 207,642 | (b) | $ | [ | ] | |||||
Strategic Opportunities Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Taiwan Fund |
$ | 165,135 | $ | 223,867 | $ | [ | ] | |||||
Tax-Managed International Equities Fund |
$ | 738,611 | $ | 684,529 | $ | [ | ] | |||||
U.S. Equity Allocation Fund |
$ | 1,362,456 | $ | 4,609,233 | $ | [ | ] | |||||
U.S. Treasury Fund |
$ | 0 | $ | 0 | $ | [ | ] |
(a) | GMO Debt Opportunities Fund, a former series of GMO Trust offered pursuant to a private placement memorandum (the Predecessor Fund) is the accounting and performance successor to the Fund. The Predecessor Fund had an investment objective and policies and restrictions substantially identical to those of the Fund. Effective February 12, 2014, the Predecessor Fund merged into the Fund (which was formerly known as GMO Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund. Amounts paid to GMO by the Fund pursuant to the Servicing Agreement through February 11, 2014 are those of the Predecessor Fund. |
(b) | Reflects fees paid from the Funds commencement of operations on July 28, 2014 through February 28, 2015. |
146
Independent Registered Public Accounting Firm . The Trusts independent registered public accounting firm is [ ], [ ]. [ ] conducts annual audits of the Trusts financial statements, assists in the preparation of each Funds federal and state income tax returns, consults with the Trust as to matters of accounting and federal and state income taxation, provides assistance in connection with the preparation of various SEC filings, and consults with the Trust as to certain non-U.S. tax matters.
Distributors . Funds Distributor, 3 Canal Plaza, Suite 100, Portland, Maine 04101, serves as the Trusts distributor on behalf of the Funds. GMO U.K., No. l London Bridge, London SE1 9BG, England, serves as the Trusts distributor for the limited purpose of offering shares of the Funds to qualified investors in Switzerland. GMO pays all distribution-related expenses of the Funds. Funds Distributor and GMO U.K. offer shares of each Fund for sale on a continuous basis and will use reasonable efforts in connection with distribution of shares of the Funds.
Counsel . Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, Massachusetts 02199, serves as counsel to the Trust. Morgan, Lewis & Bockius LLP, 225 Franklin Street, Boston, Massachusetts 02110, serves as independent counsel to the independent Trustees of the Trust.
Transfer Agent. State Street Bank serves as the Trusts transfer agent on behalf of the Funds.
Decisions to buy and sell investments for each Fund and for each of its other investment advisory clients are made by the relevant GMO investment team with a view to achieving each clients investment objectives taking into consideration other account-specific factors such as, without limitation, cash flows into or out of the account, current holdings, the accounts benchmark(s), if any, applicable regulatory limitations, liquidity, cash restrictions, applicable transaction documentation requirements, market registration requirements, and/or time constraints limiting GMOs ability to confirm adequate transaction documentation or seek interpretation of investment guideline ambiguities. Therefore, a particular investment may be bought or sold only for some clients of GMO even though it could have been bought or sold for other clients at the same time. Likewise, a particular investment may be bought for one or more clients when one or more other clients are selling the security or taking a short position in the security, including clients invested in the same investment strategy. Additionally, one of GMOs investment teams may share investment ideas with one or more other investment teams and/or may manage a portion of another investment teams client accounts.
To the extent permitted by applicable law, GMOs compliance policies and procedures and a clients investment guidelines, GMO may engage in cross trades where, as investment manager to a client account, GMO causes that client account to purchase a security directly from (or sell a security directly to) another client account.
In certain cases, GMO may identify investment opportunities that are suitable for the Funds and one or more private investment companies for which GMO or one of its affiliates serves as investment manager, general partner, and/or managing member (GMO Private Funds). In
147
most cases, GMO receives greater compensation in respect of a GMO Private Fund (including incentive-based compensation) than it receives in respect of a GMO Fund. In addition, senior members or other portfolio managers frequently have a personal investment in a GMO Private Fund that is greater than such persons investment in a similar GMO Fund (or, in some cases, may have no investment in the similar GMO Fund). GMO itself also makes investments in GMO Private Funds. To help manage these potential conflicts, GMO has developed and reviewed with the Trusts Board of Trustees trade allocation policies that establish a framework for allocating IPOs and other limited opportunities that take into account the needs and objectives of each GMO Fund and the other GMO clients.
Transactions involving the issuance of Fund shares for securities or assets other than cash will be limited to a bona fide reorganization or statutory merger and to other acquisitions of portfolio securities that meet all of the following conditions: (i) such securities meet the investment objectives and policies of the Fund; (ii) such securities are acquired for investment and not for resale; and (iii) such securities can be valued pursuant to the Trusts pricing policies.
Brokerage and Research Services . Orders for the purchase or sale of securities may be placed on a principal or agency basis with brokers, in GMOs discretion. In selecting brokers and dealers to effect portfolio transactions for each Fund, GMO seeks best execution and also takes into account the research services provided by the broker. Best execution is not based solely on the explicit commission charged by the broker and, consequently, a broker effecting a transaction may be paid a commission higher than that charged by another broker for the same transaction. Seeking best execution involves the weighing of qualitative as well as quantitative factors, and evaluations of best execution are, to a large extent, possible, if at all, only after multiple trades have been completed.
GMOs broker/dealer selection may, in addition to the factors listed below, also be based on research services provided by the broker/dealer and therefore GMO may select or recommend a broker/dealer based in part on GMOs interest in receiving the research. GMO does not participate in any formal soft dollar arrangements involving third party research (i.e., research provided by someone other than the executing broker/dealer) or the payment of GMOs out-of-pocket expenses for data or other research services. The research services received are limited to the types of research contemplated by Section 28(e) of the Securities Exchange Act of 1934. Research services provided by broker/dealers take various forms, including personal interviews with analysts, written reports, pricing services in respect of securities, and meetings arranged with various sources of information regarding particular issuers, industries, governmental policies, specific information about local markets and applicable regulations, economic trends, and other matters. To the extent that services of value are received, a benefit is obtained because no payment for services is required in order to receive such services. Such services may be used in furnishing investment or other advice to all or some subset of GMOs and/or its affiliates accounts, and services received from a broker/dealer that executed transactions for a particular account will not necessarily be used specifically in providing investment advice to that particular account. GMO does place trades with brokers that provide investment ideas and other research services, even if the relevant broker has not yet demonstrated an ability to effect best execution; however, trading with such a broker (as with any and all brokers) will typically be curtailed or suspended, in due course, if GMO is not reasonably satisfied with the quality of particular trade executions, unless or until the broker has altered its execution capabilities in such a way that GMO can reasonably conclude that the broker is capable of achieving best execution.
148
The determination of what may constitute best execution involves a number of considerations in varying degrees of emphasis, including, without limitation, the overall net economic result to a Fund; the efficiency with which the transaction is effected; access to order flow; the ability of the executing broker to effect the transaction where a large block is involved; reliability (i.e., lack of failed trades); availability of the broker to stand ready to execute possibly difficult transactions in the future; technological capabilities of the broker, including but not limited to execution technology; the brokers inventory of securities sought; reported broker flow; post-transaction reporting capabilities; the financial strength and stability of the broker; past bids and willingness to commit capital in the case of principal trades; and the relative weighting of opportunity costs (i.e., timeliness of execution) by different trading strategies. Due to the similarities among brokers in technological execution capabilities and commissions paid, GMO often allocates program or algorithmic developed market equity trades across multiple brokers. Additionally, regulations in certain markets, particularly emerging markets, require GMO to identify and trade with one or a limited number of brokers. Most of the foregoing are subjective considerations made in advance of the trade and are not always borne out by the actual execution.
For spot currency trades, GMO generally executes trades through an independent electronic trading platform that nets buy and sell orders in the same currency and selects the counterparty providing the most competitive price for the resulting net trade. All of the buy and sell orders receive the price provided by the selected counterparty and each account trades independently with the counterparty. While the purpose of trading spot currency trades in this manner is to achieve a more favorable execution price for all clients, there can be no assurance that all clients will benefit or that they will benefit equally over time.
For legal, regulatory and/or operational purposes, orders for some accounts may not be netted for price discovery (as described above). As a result, such accounts may receive inferior prices than accounts that are netted for price discovery even though the trades may be executed at or close to the same time and/or by the same counterparty.
Generally, GMO determines the overall reasonableness of brokerage commissions paid upon consideration of the relative merits of a number of factors, which may include: (i) the net economic effect to the particular Fund; (ii) historical and current commission rates; (iii) the kind and quality of the execution services rendered; (iv) the size and nature of the transactions effected; and (v) research services received. These factors are considered mostly over multiple transactions covering extended periods of time in varying degrees of emphasis. In some instances, GMO may evaluate best execution on principal bids based on the total commissions charged (the bid for handling a trade as a principal trade) because the trades were filled at the price set at an agreed upon time (e.g., previous nights close). In those cases, any additional impact or cost is represented by the cents per share or basis points paid in addition to a typical commission rate. GMO may also direct trades to brokers/dealers based in part on the broker/dealers history of providing, and capability to continue providing, pricing information for securities purchased.
149
The Trust paid, on behalf of the Funds that commenced operations prior to the end of the most recent fiscal year, the following amounts in brokerage commissions during the three most recent fiscal years:
[To be updated by amendment.]
March 1,
2013 Through February 28, 2014 |
March 1,
2014 Through February 28, 2015 |
March 1,
2015 Through February 29, 2016 |
||||||||||
Alpha Only Fund |
$ | 784,904 | $ | 2,333,262 | $ | [ | ] | |||||
Asset Allocation Bond Fund |
$ | 40,823 | $ | 338,272 | $ | [ | ] | |||||
Benchmark-Free Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Benchmark-Free Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Core Plus Bond Fund |
$ | 52,306 | $ | 15,604 | $ | [ | ] | |||||
Currency Hedged International Bond Fund |
$ | 12,926 | $ | 7,346 | $ | [ | ] | |||||
Debt Opportunities Fund (a) |
$ | 16,326 | $ | 17,242 | $ | [ | ] | |||||
Developed World Stock Fund |
$ | 125,899 | $ | 175,383 | $ | [ | ] | |||||
Emerging Countries Fund |
$ | 168,508 | $ | 77,476 | $ | [ | ] | |||||
Emerging Country Debt Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Emerging Domestic Opportunities Fund |
$ | 10,864,916 | $ | 10,391,063 | $ | [ | ] | |||||
Emerging Markets Fund |
$ | 15,081,968 | $ | 12,453,760 | $ | [ | ] | |||||
Foreign Fund |
$ | 607,966 | $ | 401,613 | $ | [ | ] | |||||
Foreign Small Companies Fund |
$ | 893,808 | $ | 765,146 | $ | [ | ] | |||||
Global Asset Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Global Bond Fund |
$ | 26,196 | $ | 9,965 | $ | [ | ] | |||||
Global Developed Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Global Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Implementation Fund |
$ | 4,286,745 | $ | 8,740,553 | $ | [ | ] |
150
March 1,
2013 Through February 28, 2014 |
March 1,
2014 Through February 28, 2015 |
March 1,
2015 Through February 29, 2016 |
||||||||||
International Developed Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
International Equity Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
International Equity Fund |
5,316,468 | $ | 4,729,008 | $ | [ | ] | ||||||
International Large/Mid Cap Equity Fund |
$ | 2,025,018 | $ | 960,347 | $ | [ | ] | |||||
International Small Companies Fund |
$ | 211,571 | $ | 211,008 | $ | [ | ] | |||||
Quality Fund |
$ | 2,443,697 | $ | 1,917,062 | $ | [ | ] | |||||
Resources Fund |
$ | 120,945 | $ | 186,524 | $ | [ | ] | |||||
Risk Premium Fund |
$ | 406,525 | $ | 336,267 | $ | [ | ] | |||||
SGM Major Markets Fund |
$ | 414,973 | $ | 517,175 | $ | [ | ] | |||||
Special Opportunities Fund |
N/A | $ | 1,187,419 | (b) | $ | [ | ] | |||||
Strategic Opportunities Allocation Fund |
$ | 0 | $ | 0 | $ | [ | ] | |||||
Taiwan Fund |
$ | 278,114 | $ | 256,369 | $ | [ | ] | |||||
Tax-Managed International Equities Fund |
$ | 202,745 | $ | 219,800 | $ | [ | ] | |||||
U.S. Equity Allocation Fund |
$ | 398,686 | $ | 998,288 | $ | [ | ] | |||||
U.S. Treasury Fund |
$ | 0 | $ | 0 | $ | [ | ] |
(a) | GMO Debt Opportunities Fund, a former series of GMO Trust offered pursuant to a private placement memorandum (the Predecessor Fund) is the accounting and performance successor to the Fund. The Predecessor Fund had an investment objective and policies and restrictions substantially identical to those of the Fund. Effective February 12, 2014, the Predecessor Fund merged into the Fund (which was formerly known as GMO Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund. Commissions generated through February 11, 2014 are those of the Predecessor Fund. |
(b) | Reflects commissions generated from the Funds commencement of operations on July 28, 2014 through February 28, 2015. |
Differences in the amount of brokerage commissions paid by a Fund during a Funds three most recent fiscal years (as disclosed in the table above) are generally the result of [(i) active trading strategies employed by GMO when responding to changes in market conditions; (ii) management of cash flows into and out of a Fund as a result of shareholder purchases and redemptions; (iii) rebalancing portfolios to reflect GMOs desired allocations (which in many cases are determined by GMOs portfolio management models); (iv) changes in commission rates in the relevant
151
markets; or (v) the use of principal trades. Changes in the amount of brokerage commissions paid by a Fund do not reflect material changes in the Funds investment objective or strategies.]
[To be updated by amendment.]
The following table lists each Fund that acquired securities of its regular brokers or dealers (as defined in the 1940 Act) or of their parents during the fiscal year ended February 29, 2016, the name of each such broker or dealer, and the value of each Funds aggregate holdings of the securities of each issuer as of February 29, 2016:
[To be updated by amendment.]
Name of Fund |
Name of Broker or Dealer |
Aggregate Value of
Holdings as of February 29, 2016 |
||||||
[ ] |
[ | ] | [ | ] |
Due to restrictions under the 1940 Act, it is possible that, as the result of certain affiliations between a broker or its affiliates and a Fund, GMO or the Funds distributor, all of the GMO Funds may refrain, or be required to refrain, from engaging in principal trades with such broker. Additionally, the GMO Funds may be restricted in their ability to purchase securities issued by affiliates of the Funds distributor.
PROXY VOTING POLICIES AND PROCEDURES
The Trust has adopted a proxy voting policy under which responsibility to vote proxies related to its portfolio securities has been delegated to GMO. The Board of Trustees of the Trust has reviewed and approved the proxy voting policies and procedures GMO follows when voting proxies on behalf of the Funds. The Trusts proxy voting policy and GMOs proxy voting policies and procedures are attached to this SAI as Appendix C .
GMOs proxy voting policies on a particular issue may or may not reflect the views of individual members of the Board of Trustees of the Trust, or a majority of the Board of Trustees.
Information regarding how the Funds voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 will be available without charge on GMOs website at www.gmo.com and on the SECs website at www.sec.gov no later than August 31 of each year.
DISCLOSURE OF PORTFOLIO HOLDINGS
The policy of the Trust is to protect the confidentiality of each Funds portfolio holdings and to prevent inappropriate selective disclosure of those holdings. The Board of Trustees has approved such a policy and material amendments require its approval.
Registered investment companies that are sub-advised by GMO may be subject to different portfolio holdings disclosure policies, and neither GMO nor the Board of Trustees exercises control over those policies. In addition, separate account clients of GMO have access to their
152
portfolio holdings and are not subject to the Funds portfolio holdings disclosure policies. Some of the funds that are sub-advised by GMO and some of the separate accounts managed by GMO have substantially similar investment objectives and strategies and, therefore, potentially similar portfolio holdings.
Information regarding the composition of a Funds portfolio is the property of that Fund. Neither GMO nor any Fund will receive any compensation or other consideration in connection with its disclosure of a Funds portfolio holdings.
GMO may disclose a Funds portfolio holdings (together with any other information from which the Funds portfolio holdings could reasonably be derived, as reasonably determined by GMO) (the Portfolio Holdings Information) to shareholders (including shareholders of record of indirect investments in a Fund through another fund managed by GMO), qualified potential shareholders as determined by GMO (including qualified potential shareholders of record who are considering an indirect investment in a Fund through another fund managed by GMO), and their consultants and agents (collectively, Permitted Recipients).
Except as otherwise noted, to receive Portfolio Holdings Information, Permitted Recipients must generally enter into a confidentiality agreement with GMO that requires that the Portfolio Holdings Information be used solely for purposes determined by GMOs General Counsel or persons designated by General Counsel to be lawful and in the best interest of the shareholders of the Fund to which the information relates. Any exception must be approved in advance as described below.
The Funds Prospectus describes the type of information disclosed on GMOs website, as well as the frequency with which it is disclosed and the lag between the date of the information and the date of its disclosure. Up to the largest fifteen holdings of some GMO Funds (on a look through basis in the case of Asset Allocation Funds) and all of the direct holdings of the Asset Allocation Funds (which includes GMO Funds in which the Fund invests) may be posted monthly on GMOs website and typically are available to shareholders without a confidentiality agreement. In addition, position attribution information regarding one or more Funds may be posted monthly to GMOs website (e.g., best/worst performing positions in the Fund over a specified time period). For Asset Allocation Funds, position attribution information may be provided on a look through basis. Such information is available without a confidentiality agreement to registered users of GMOs website.
GMO also may make Portfolio Holdings Information available to Permitted Recipients without a confidentiality agreement, by e-mail, or by any other means in such scope and form and with such frequency as GMO may reasonably determine, (i) on any day following the day on which the Portfolio Holdings Information is posted on the GMO website (provided that the Funds Prospectus describes the nature and scope of the Portfolio Holdings Information that will be available on the GMO website, when the information will be available and the period for which the information will remain available, and the location on the Funds website where the information will be made available) or (ii) on the same day or any day after the day such Portfolio Holdings Information is made available through a publicly available, routine filing with the SEC.
153
GMO also may from time to time disclose Portfolio Holdings Information to all shareholders of a Fund and, as applicable, their consultants and agents (including shareholders of record of indirect investments in a Fund through another fund managed by GMO). Such disclosure may be made by e-mail, written notice or any other means in such scope and form as GMO may reasonably determine, and generally will not be subject to a confidentiality agreement and will not be required to be posted to GMOs website in advance.
In some cases, GMO may disclose to a third party Portfolio Holdings Information that has not been made available to Permitted Recipients on the GMO website or in a publicly available, routine filing with the SEC. That disclosure may only be made if GMO determines that it is in the best interests of the shareholders of the Fund to which the information relates. That determination may be made by either GMOs General Counsel (or persons designated by GMOs General Counsel) or GMOs Chief Compliance Officer, in consultation with the relevant portfolio manager. The third party receiving the Portfolio Holdings Information must be, and shall be informed that it is, under a duty not to trade on such information or disclose it to others and shall agree in writing not to do so. In addition, the third party receiving the Portfolio Holdings Information must enter into a confidentiality agreement with GMO that requires that the Portfolio Holdings Information be used solely for purposes determined by GMO senior management to be in the best interest of the Funds shareholders.
The procedures pursuant to which GMO may disclose to a third party Portfolio Holdings Information that has not been made available to Permitted Recipients do not apply to Portfolio Holdings Information provided to entities who provide on-going services to the Funds in connection with their day-to-day operations and management, including GMO, GMOs affiliates, the Funds custodians and auditors, tax agents, the Funds pricing service vendors, brokers when requesting bids for or price quotations on securities, brokers in the normal course of trading on a Funds behalf, and persons assisting the Funds in the voting of proxies. In addition, (i) when an investor indicates that it wants to purchase shares of a Fund in exchange for securities acceptable to GMO, GMO may make available a list of securities that it would be willing to accept for the Fund, and, from time to time, the securities on the list may overlap with securities currently held by the Fund; and (ii) when the Fund determines to pay redemption proceeds wholly or partly in-kind with securities, GMO may make available a list of securities it intends to deliver from the Fund.
No provision of such a policy is intended to restrict or prevent the disclosure of Portfolio Holdings Information as may be required by applicable law, rules or regulations.
GMOs General Counsel or Chief Compliance Officer may authorize exceptions to these procedures. Exceptions must be disclosed to the Chief Compliance Officer of the Trust or his/her designee.
If GMO becomes aware that a recipient has or is likely to violate the terms of a confidentiality agreement regarding Portfolio Holdings Information, GMO shall cease providing such information to such recipient.
If GMOs General Counsel or persons designated by General Counsel identifies a potential conflict with respect to the disclosure of Portfolio Holdings Information between the interest of a Funds shareholders, on the one hand, and GMO or an affiliated person of GMO or the Fund, on
154
the other, GMO is required to inform the Trusts Chief Compliance Officer of the potential conflict, and the Trusts Chief Compliance Officer has the power to decide whether, in light of the potential conflict, disclosure should be permitted under the circumstances. The Trusts Chief Compliance Officer also is required to report his decision to the Board of Trustees.
GMO periodically reports the following information to the Board of Trustees:
| Determinations made by senior management of GMO relating to the use of Portfolio Holdings Information by Permitted Recipients and third parties; |
| The nature and scope of disclosure of Portfolio Holdings Information to third parties; |
| Exceptions to the disclosure policy authorized by GMOs General Counsel or Chief Compliance Officer; and |
| Any other information the Trustees may request relating to the disclosure of Portfolio Holdings Information. |
Ongoing Arrangements to Make Portfolio Holdings Available . Senior management of GMO has authorized disclosure of Portfolio Holdings Information on an on-going basis (generally, daily, except with respect to [ ], which receives holdings semi-annually and as necessary in connection with the services it provides to the Funds) to the following entities that provide on-going services to the Funds in connection with their day-to-day operations and management, provided that they agree to, or have a duty to, maintain this information in confidence:
Name of Recipient |
Funds |
Purpose of Disclosure |
||
State Street Bank and Trust Company | Multi-Asset Class Funds, Fixed Income Funds, Benchmark-Free Fund, Implementation Fund, Quality Fund, Risk Premium Fund, SGM Major Markets Fund and U.S. Equity Allocation Fund | Custodial and fund accounting services | ||
All Funds | Compliance testing | |||
Brown Brothers Harriman & Co. | Alpha Only Fund, Developed World Stock Fund, Emerging Countries Fund, Emerging Domestic Opportunities Fund, Emerging Markets Fund, Foreign Fund, Foreign Small Companies Fund, International Equity Fund, International Large/Mid Cap Equity Fund, International Small Companies Fund, Resources Fund, Tax-Managed International Equities Fund, and Taiwan Fund | Custodial and fund accounting services |
155
Name of Recipient |
Funds |
Purpose of Disclosure |
||
[ ] | All Funds | Independent registered public accounting firm | ||
Institutional Shareholder Services Inc. | All Funds | Corporate actions services | ||
Interactive Data Corporation | All Funds | Fair value pricing | ||
Super Derivatives, Inc. | All Funds | Derivative valuations | ||
Markit | All Funds | Derivative valuations | ||
TriOptima AB | All Funds | Portfolio derivative reconciliations | ||
FactSet | All Funds | Data service provider | ||
Goldman, Sachs & Co. and affiliates | Implementation Fund and Risk Premium Fund | Prime brokerage arrangement | ||
Morgan Stanley & Co. LLC and affiliates | Implementation Fund and Risk Premium Fund | Prime brokerage arrangement | ||
Ernst & Young | All Funds | Consulting and local tax services | ||
Fidessa (Sentinel Trading Compliance) | [ ] | [Compliance Testing] |
Senior management of GMO has authorized disclosure of Portfolio Holdings Information on an on-going basis (daily) to the following recipients, provided that they agree or have a duty to maintain this information in confidence and are limited to using the information for the specific purpose for which it was provided:
Name of Recipient |
Funds |
Purpose of Disclosure |
||
Epstein & Associates, Inc. | All Funds | Software provider for Code of Ethics monitoring system |
DESCRIPTION OF THE TRUST AND OWNERSHIP OF SHARES
The Trust, an open-end management investment company, is organized as a Massachusetts business trust under the laws of Massachusetts by an Agreement and Declaration of Trust (Declaration of Trust or Declaration) dated June 24, 1985, as amended and restated March 9, 2016, and as such Declaration of Trust may be amended from time to time. A copy of the Declaration of Trust is on file with the Secretary of The Commonwealth of Massachusetts. The Trust operates as a series investment company that consists of separate series of investment portfolios, each of which is represented by a separate series of shares of beneficial interest. Each Fund is a series of the Trust. The fiscal year for each Fund ends on the last day of February.
156
Pursuant to the Declaration of Trust, the Trustees have currently authorized the issuance of an unlimited number of full and fractional shares of [thirty-seven] series: Alpha Only Fund; Asset Allocation Bond Fund; Benchmark-Free Allocation Fund; Benchmark-Free Fund; Core Plus Bond Fund; Currency Hedged International Bond Fund; Debt Opportunities Fund; Developed World Stock Fund; Emerging Countries Fund; Emerging Country Debt Fund; Emerging Domestic Opportunities Fund; Emerging Markets Fund; Foreign Fund; Foreign Small Companies Fund; GAAR Implementation Fund; Global Asset Allocation Fund; Global Bond Fund; Global Developed Equity Allocation Fund; Global Equity Allocation Fund; High Quality Short-Duration Bond Fund; Implementation Fund; International Developed Equity Allocation Fund; International Equity Allocation Fund; International Equity Fund; International Large/Mid Cap Equity Fund; International Small Companies Fund; Quality Fund; Resources Fund; Risk Premium Fund; SGM Major Markets Fund; Special Opportunities Fund; Strategic Opportunities Allocation Fund; Taiwan Fund; Tax-Managed International Equities Fund; U.S. Equity Allocation Fund; U.S. Treasury Fund; and World Opportunity Overlay Fund.
Prior to December 1, 2015, SGM Major Markets Fund was known as GMO Systematic Global Macro Opportunity Fund. Prior to June 25, 2014, SGM Major Markets Fund was known as GMO Alternative Asset Opportunity Fund. Prior to June 30, 2014, U.S. Equity Allocation Fund was known as GMO U.S. Core Equity Fund. Prior to February 12, 2014, Global Developed Equity Allocation Fund was known as GMO World Opportunities Equity Allocation Fund, International Developed Equity Allocation Fund was known as GMO International Opportunities Equity Allocation Fund, International Equity Fund was known as GMO International Intrinsic Value Fund, and International Large/Mid Cap Equity Fund was known as GMO International Core Equity Fund. Prior to September 15, 2011, Global Asset Allocation Fund was known as GMO Global Balanced Asset Allocation Fund.
GMO Debt Opportunities Fund, a former series of GMO Trust offered pursuant to a private placement memorandum (the Predecessor Fund) is the accounting and performance successor to Debt Opportunities Fund. The Predecessor Fund had an investment objective and policies and restrictions substantially identical to those of Debt Opportunities Fund. Effective February 12, 2014, the Predecessor Fund merged into Debt Opportunities Fund (which was formerly known as GMO Short-Duration Collateral Fund), and the surviving entity was renamed GMO Debt Opportunities Fund.
Interests in each portfolio (GMO Fund) are represented by shares of the corresponding series. Each share of each series represents an equal proportionate interest, together with each other share, in the corresponding GMO Fund. The shares of such series do not have any preemptive rights. Upon liquidation of a GMO Fund, shareholders of the corresponding series are entitled to share pro rata in the net assets of the GMO Fund available for distribution to shareholders. The Declaration of Trust also permits the Trustees to charge shareholders directly for custodial, transfer agency, and servicing expenses, but the Trustees have no present intention to make such charges.
157
The Declaration of Trust also permits the Trustees, without shareholder approval, to subdivide any series of shares into various sub-series or classes of shares with such dividend preferences and other rights as the Trustees may designate. This power is intended to allow the Trustees to provide for an equitable allocation of the effect of any future regulatory requirements that might affect various classes of shareholders differently. The Trustees have currently authorized the establishment and designation of up to ten classes of shares for each series of the Trust: Class I Shares, Class II Shares, Class III Shares, Class IV Shares, Class V Shares, Class VI Shares, Class VII Shares, Class VIII Shares, Class M Shares, and Class MF Shares.
The Trustees also may, without shareholder approval, establish one or more additional separate portfolios for investments in the Trust or merge two or more existing portfolios (i.e., a new fund). Shareholders investments in such a portfolio would be evidenced by a separate series of shares.
The Declaration of Trust provides for the perpetual existence of the Trust. The Trust, however, may be terminated at any time by vote of at least two-thirds of the outstanding shares of the Trust. While the Declaration of Trust further provides that the Trustees also may terminate the Trust upon written notice to the shareholders, the 1940 Act requires that the Trust receive the authorization of a majority of its outstanding shares in order to change the nature of its business so as to cease to be an investment company.
The Declaration of Trust provides that, subject to the provisions of the Declaration of Trust, the business of the Trust shall be managed by the Trustees, and the Trustees shall have all powers necessary or convenient to carry out that responsibility including the exclusive power to bring, permit or maintain any action, proceeding or claim on behalf of the Trust or any Fund. The Declaration of Trust further provides that shares of the Funds give shareholders only the rights provided in the Declaration of Trust, and that among the rights shareholders shall not have unless expressly provided by the by-laws of the Trust or expressly provided by law and not permitted to be waived are rights to: (i) enforce contractual claims of the Trust or any Fund; (ii) assert claims against the Trust or any Fund or its Trustees, officers or service providers; (iii) assert derivative claims on behalf of the Trust or any Fund involving any alleged harm to the Trust or any Fund; or (iv) bring a claim on behalf of any other shareholder.
The Trusts Amended and Restated By-Laws (the By-Laws) provide that the laws of The Commonwealth of Massachusetts shall govern the validity, interpretation, construction and effect of the By-Laws and the operations of the Trust, including, absent a provision to the contrary therein, any contract between the Trust and any party relating to the provision of investment advisory, administrative or distribution services to the Trust. The By-Laws further provide that, absent the consent of all parties, the sole and exclusive forum for: (i) any action or proceeding brought by or on behalf of the Trust or any Fund or shareholders against the Trust, any Fund, the Trusts investment adviser, or the Trustees, officers or employees of the Trust; and (ii) any action arising under or to interpret, apply, enforce or determine the validity of the Declaration of Trust or the By-Laws or any investment advisory agreement, among other types of enumerated claims, shall be the federal courts sitting within the City of Boston or the Business Litigation Session of the Massachusetts Superior Court. The By-Laws also provide that no shareholder shall have the right to bring or maintain any court action or other proceeding (including but not limited to any putative class action) asserting a derivative claim without first making written demand on the
158
Trustees, and that any decision by the Trustees to bring, maintain or settle (or not to bring, maintain or settle) such court action, proceeding or claim shall be binding upon shareholders. The By-Laws define derivative and direct shareholder claims, and provide that a direct claim shall refer to: (i) a claim based upon alleged violations of a shareholders individual rights distinct from any harm to the Trust or a Fund or other individual shareholders, including a particular shareholders voting rights, rights to a dividend payment, rights to inspect books and records, or other similar rights personal to the shareholder and distinct from any harm to the Trust or a Fund or other individual shareholders; and (ii) a claim for which a direct shareholder action is expressly provided under the U.S. federal securities laws. Any other claim asserted by a shareholders is considered a derivative claim (and subject to the demand requirements) under the By-Laws.
Copies of the Trusts Declaration of Trust and By-Laws, as amended from time to time, have been filed with the SEC as exhibits to the Trusts registration statement, and are available on the EDGAR database on the SECs website at www.sec.gov.
On [ ], the following shareholders held beneficially (unless otherwise indicated) greater than 25% of the outstanding shares of a Fund offered in the Prospectus. For each shareholder listed that is not an individual, the jurisdiction under the laws of which the shareholder is organized (if applicable) and any parent company of the shareholder are listed, if known:
[To be updated by amendment.]
Fund |
Shareholders |
Jurisdiction
of Organization |
Parent
Company |
|||
[ ] |
[ ] | [ ] | [ ] |
The above shareholders may be deemed to control their respective series as such term is defined in the 1940 Act.
Shareholders should be aware that to the extent a shareholders investment in a Fund exceeds certain threshold amounts or percentages, the investment may constitute a reportable acquisition under the Hart-Scott-Rodino Act (HSR) and the shareholder may be required to make a corresponding filing under HSR. HSR regulations are complex and shareholders should consult their legal advisers about the precise HSR filing consequences of an investment in a Fund.
[As of [ ], greater than 10% of the following Funds shares were held by accounts for which GMO has investment discretion: [ ]. As of [ ], a significant portion of the following Funds shares were held by accounts for which GMO has investment discretion: [ ]. As of [ ], substantially all of the following Funds shares were held by accounts for which GMO has investment discretion: [ ]].
159
Shareholders are entitled to one vote for each full share held (with fractional votes for fractional shares held) and to vote by individual GMO Fund (to the extent described below) in the election of Trustees and the termination of the Trust and on other matters submitted to the vote of shareholders. Shareholders vote by individual GMO Fund on all matters except (i) when required by the 1940 Act, shares are voted in the aggregate and not by individual GMO Fund, and (ii) when the Trustees have determined that the matter affects the interests of more than one GMO Fund, then shareholders of the affected GMO Funds are entitled to vote. Shareholders of one GMO Fund are not entitled to vote on matters exclusively affecting another GMO Fund including, without limitation, such matters as the adoption of or change in the investment objectives, policies, or restrictions of the other GMO Fund and the approval of the investment advisory contract of the other GMO Fund. Shareholders of a particular class of shares do not have separate class voting rights except for matters that affect only that class of shares and as otherwise required by law.
Normally the Trust does not hold meetings of shareholders to elect Trustees except in accordance with the 1940 Act (i) the Trust will hold a shareholders meeting for the election of Trustees at such time as less than a majority of the Trustees holding office have been elected by shareholders, and (ii) if, as a result of a vacancy in the Board of Trustees, less than two-thirds of the Trustees holding office have been elected by the shareholders, that vacancy may only be filled by a vote of the shareholders. In addition, Trustees may be removed from office by a written consent signed by the holders of two-thirds of the outstanding shares and filed with the Trusts custodian or by a vote of the holders of two-thirds of the outstanding shares at a meeting duly called for that purpose, which meeting shall be held upon the written request of the holders of not less than 10% of the outstanding shares. Upon written request by the holders of at least 1% of the outstanding shares stating that such shareholders wish to communicate with the other shareholders for the purpose of obtaining the signatures necessary to demand a meeting to consider removal of a Trustee, the Trust has undertaken to provide a list of shareholders or to disseminate appropriate materials (at the expense of the requesting shareholders). Except as set forth above, the Trustees will continue to hold office and may appoint successor Trustees. Voting rights are not cumulative.
The Declaration of Trust may be amended at any time by an instrument in writing signed by a majority of the then Trustees when authorized so to do by vote of a majority of the outstanding shares of the Trust entitled to vote, except that the Trustees may amend the Declaration of Trust without a shareholder vote (1) as described in Article III, Section 5 of the Declaration of Trust (permitting the Trustees to add to, delete, replace or otherwise modify any provisions relating to shares contained in the Declaration of Trust for the purpose of (i) responding to or complying with any regulations, orders, rulings or interpretations of any governmental agency or any laws applicable to the Trust, or (ii) designating and establishing series and classes); (2) for the purpose of changing the name of the Trust; or (3) for the purpose of supplying any omission, curing any ambiguity or curing, correcting or supplementing any defective or inconsistent provision contained in the Declaration of Trust.
160
SHAREHOLDER AND TRUSTEE LIABILITY
Under Massachusetts law, shareholders could, under some circumstances, be held personally liable for the obligations of the Trust. However, the Declaration of Trust disclaims shareholder liability for acts or obligations of the Trust and requires that notice of that disclaimer be given in each agreement, obligation, or instrument entered into or executed by the Trust or the Trustees. The Declaration of Trust provides for indemnification out of all the property of a Fund for all loss and expense of any shareholder of the Fund held personally liable for the obligations of the Trust. Thus, the risk of a shareholder incurring financial loss on account of shareholder liability is limited to circumstances in which the disclaimer is inoperative and the Fund in which the shareholder holds shares is unable to meet its obligations.
The Declaration of Trust further provides that the Trustees will not be liable for errors of judgment or mistakes of fact or law. However, nothing in the Declaration of Trust protects a Trustee against any liability to which the Trustee would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence, or reckless disregard of the duties involved in the conduct of his office. The By-Laws of the Trust provide for indemnification by the Trust of the Trustees and the officers of the Trust except for any matter as to which any such person did not act in good faith in the reasonable belief that his action was in or not opposed to the best interests of the Trust. Trustees and officers may not be indemnified against any liability to the Trust or the Trust shareholders to which they would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence, or reckless disregard of the duties involved in the conduct of their office.
BENEFICIAL OWNERS OF 5% OR MORE OF THE FUNDS SHARES
The following chart sets forth the names, addresses and percentage ownership of those shareholders owning beneficially 5% or more of the outstanding Class [ ] Shares of [ ] as of [ ]:
[To be updated by amendment.]
Name and Address |
% Ownership | |
[ ] |
[ ] |
161
[To be updated by amendment.]
Indian regulators have alleged that in 2002, Emerging Markets Fund violated certain conditions under which it was granted permission to operate in India and have restricted Emerging Markets Funds locally held assets pending resolution of the dispute. Although these locally held assets remain the property of Emerging Markets Fund, a portion of the assets are not permitted to be withdrawn from the Funds local custodial account located in India. The amount of restricted assets is small relative to the size of the Fund, approximately [ ]% of the Funds net assets as of May 31, 2016. The effect of this claim on the value of the restricted assets, and all matters relating to the Funds response to these allegations are subject to the supervision and control of the Trusts Board of Trustees. Emerging Markets Funds costs in respect of this matter are being borne by the Fund.
[In addition, in December 2005, Emerging Country Debt Fund entered into litigation against the Government of Argentina (Argentina) relating to Argentinas failure to make payments on certain of its sovereign debt held by the Fund. On September 24, 2007, judgment was awarded in the Funds favor. Valuations of the Funds holdings of the applicable Argentine debt do not reflect any adjustment related to the judgment because of uncertainties associated with enforcement of the judgment. Costs in respect of this matter are being treated as extraordinary expenses and are being borne by the Fund. In 2010, Argentina commenced a public debt exchange in which certain defaulted debts, including legal judgments on those debts, were eligible to be exchanged for a combination of currently performing Argentina bonds, GDP-linked securities, and cash. The eligible portion of the Funds judgment and other defaulted Argentine debts were tendered in the debt exchange and the Fund subsequently received the proceeds of the exchange. The valuation of the remaining portion of the Funds judgment and all matters relating to the defaulted Argentine securities are subject to the supervision and control of the Trusts Board of Trustees. The Funds judgment represented approximately [ ]% of the net assets of Emerging Country Debt Fund as of May 31, 2016. Supplemental claims specifically seeking pari passu relief were filed by the Fund on October 30, 2014.]
[In December 2011, creditors of LyondellBasell Industries AF S.C.A. (LBI) filed an amended complaint in the United States Bankruptcy Court for the Southern District of New York naming numerous defendants, including U.S. Equity Allocation Fund (formerly, U.S. Core Equity Fund). The litigation seeks to recover pre-bankruptcy distributions by Lyondell Chemical Company (the predecessor to LBI) to its shareholders as part of a 2007 leveraged buyout transaction of Lyondell Chemical Company by which the Company converted to a privately held company, renamed LyondellBasell Industries AF S.C.A. The creditors allege that certain parties to the leveraged buyout damaged LBI and ultimately forced LBI and its subsidiaries to file for bankruptcy protection in 2009. The creditors seek recovery of funds that shareholders received in connection with the leveraged buyout based on allegations, under state law, of fraudulent conveyance. In January 2011, a motion to dismiss the Second Amended Complaint was filed and joined by many defendants. By order dated January 14, 2014, the motion to dismiss was granted with leave to replead with respect to the intentional fraudulent transfer claims but denied with respect to the constructive fraudulent transfer claims. [A motion to dismiss a further amended complaint was fully briefed and argued on January 14, 2015. On November 18, 2015,
162
the Court granted the motion to dismiss the claims for intentional fraudulent transfer (this time without leave to replead), but denied the motion to dismiss the claims for constructive fraudulent transfer. On December 8, 2015, judgment was entered dismissing the intentional fraudulent transfer claims, and on December 12, 2015, a notice of appeal to the United States District Court for the Southern District of New York was filed. Briefing of the appeal is scheduled to complete on April 29, 2016. Costs in respect of this matter are being treated as extraordinary expenses and are being borne by the Funds.] [ To be updated by amendment .]
The Trusts audited financial statements, financial highlights, and, for each Fund other than the Bond Funds, report of the independent registered public accounting firm of the Funds, included in the Annual Report for the fiscal year ended February 29, 2016 for each Fund and filed with the SEC pursuant to Section 30(d) of the 1940 Act and the rules promulgated thereunder, are hereby incorporated in this SAI by reference. The Funds Annual Reports for the fiscal year ended February 29, 2016 were filed electronically with the SEC on Form N-CSR on [ ] (Accession No. [ ]). [To be updated by amendment.]
163
GMO TRUST
SPECIMEN PRICE MAKE-UP SHEETS
Following are computations for each Fund of the total offering price per share of each class of shares of beneficial interest of the Fund that are offered through the Prospectus and that had shares of beneficial interest outstanding as of February 29, 2016, in each case based upon their respective net asset values and shares of beneficial interest outstanding as of the close of business on February 29, 2016.
[To be updated by amendment.]
Alpha Only Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Alpha Only Fund - Class IV |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Asset Allocation Bond Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Asset Allocation Bond Fund - Class VI |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Benchmark-Free Allocation Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Benchmark-Free Allocation Fund - Class IV |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Benchmark-Free Allocation Fund - Class MF |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-1
Offering Price ([ ])* |
$ | [ | ] | |
Benchmark-Free Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Core Plus Bond Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Core Plus Bond Fund - Class IV |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Currency Hedged International Bond Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Debt Opportunities Fund - Class VI |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Developed World Stock Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Developed World Stock Fund - Class IV |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Countries Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Emerging Country Debt Fund - Class III |
||||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-2
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Country Debt Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Domestic Opportunities Fund - Class II |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Domestic Opportunities Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Domestic Opportunities Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Domestic Opportunities Fund - Class V |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Domestic Opportunities Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Markets Fund - Class II |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Markets Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Markets Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-3
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Markets Fund - Class V |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Emerging Markets Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Foreign Fund - Class II |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Foreign Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Foreign Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Foreign Small Companies Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Foreign Small Companies Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Global Asset Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Global Bond Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-4
Offering Price |
$ | [ | ] | |
Global Developed Equity Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Global Equity Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Implementation Fund |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
International Developed Equity Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
International Equity Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
International Equity Fund - Class II |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
International Equity Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
International Equity Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
International Large/Mid Cap Equity Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-5
Offering Price |
$ | [ | ] | |
International Large/Mid Cap Equity Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
International Large/Mid Cap Equity Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
International Small Companies Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Quality Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Quality Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Quality Fund - Class V |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Quality Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Resources Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Resources Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-6
Offering Price ([ ])* |
$ | [ | ] | |
Risk Premium Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Risk Premium Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Risk Premium Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
SGM Major Markets Fund Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
Special Opportunities Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Strategic Opportunities Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Taiwan Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price ([ ])* |
$ | [ | ] | |
Tax-Managed International Equities Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
U.S. Equity Allocation Fund - Class III |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] |
A-7
Offering Price |
$ | [ | ] | |
U.S. Equity Allocation Fund - Class IV |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
U.S. Equity Allocation Fund - Class VI |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] | |
U.S. Treasury Fund |
|
|||
Net Assets at Value (Equivalent to $[ ] per share based on [ ] shares of beneficial interest outstanding) |
$ | [ | ] | |
Offering Price |
$ | [ | ] |
Footnotes to Specimen Price Make-Up Sheets
* | Represents maximum offering price charged on certain cash purchases. See How to Purchase Shares and Purchase Premiums and Redemption Fees in the Funds Prospectus. |
A-8
COMMERCIAL PAPER AND CORPORATE DEBT RATINGS
[To be updated by amendment]
Commercial Paper Ratings
Standard & Poors . Standard & Poors short-term ratings are generally assigned to those obligations considered short-term in the relevant market. In the U.S., for example, that means obligations with an original maturity of no more than 365 days including commercial paper. The following are excerpts from Standard & Poors short-term issue credit ratings definitions:
A-1 A short-term obligation rated A-1 is rated in the highest category by Standard & Poors. The obligors capacity to meet its financial commitment on the obligation is strong. Within this category, certain obligations are designated with a plus sign (+). This indicates that the obligors capacity to meet its financial commitment on these obligations is extremely strong.
A-2 A short-term obligation rated A-2 is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than obligations in higher rating categories. However, the obligors capacity to meet its financial commitment on the obligation is satisfactory.
A-3 A short-term obligation rated A-3 exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation.
B A short-term obligation rated B is regarded as vulnerable and has significant speculative characteristics. The obligor currently has the capacity to meet its financial commitments; however, it faces major ongoing uncertainties which could lead to the obligors inadequate capacity to meet its financial commitments.
C A short-term obligation rated C is currently vulnerable to nonpayment and is dependent upon favorable business, financial, and economic conditions for the obligor to meet its financial commitment on the obligation.
D A short-term obligation rated D is in default or in breach of an imputed promise. For non-hybrid capital instruments, the D rating category is used when payments on an obligation are not made on the date due, unless Standard & Poors believes that such payments will be made within any stated grace period. However, any stated grace period longer than five business days will be treated as five business days. The D rating also will be used upon the filing of a bankruptcy petition or the taking of a similar action and where default on an obligation is a virtual certainty, for example due to automatic stay provisions. An obligations rating is lowered to D if it is subject to a distressed exchange offer.
Moodys . Moodys short-term ratings are assigned to obligations with an original maturity of thirteen months or less and reflect the likelihood of a default on contractually promised payments and the expected financial loss suffered in the event of default. The following are excerpts from Moodys short-term ratings definitions:
P-1 Issuers (or supporting institutions) rated Prime-1 have a superior ability to repay short-term debt obligations.
B-1
P-2 Issuers (or supporting institutions) rated Prime-2 have a strong ability to repay short-term debt obligations.
P-3 Issuers (or supporting institutions) rated Prime-3 have an acceptable ability to repay short-term obligations.
NP Issuers (or supporting institutions) rated Not Prime do not fall within any of the Prime rating categories.
Corporate Debt Ratings
Standard & Poor s . A Standard & Poors issue credit rating is a forward-looking opinion about the creditworthiness of an obligor with respect to a specific financial obligation, a specific class of financial obligations, or a specific financial program. The following are excerpts from Standard & Poors long-term issue credit ratings definitions:
AAA An obligation rated AAA has the highest rating assigned by Standard & Poors. The obligors capacity to meet its financial commitment on the obligation is extremely strong.
AA An obligation rated AA differs from the highest-rated obligations only to a small degree. The obligors capacity to meet its financial commitment on the obligation is very strong.
A An obligation rated A is somewhat more susceptible to the adverse effects of changes in circumstances and economic conditions than obligations in higher-rated categories. However, the obligors capacity to meet its financial commitment on the obligation is still strong.
BBB An obligation rated BBB exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation.
BB, B, CCC, CC, and C Obligations rated BB, B, CCC, CC, and C are regarded as having significant speculative characteristics. BB indicates the least degree of speculation and C the highest. While such obligations will likely have some quality and protective characteristics, these may be outweighed by large uncertainties or major exposures to adverse conditions.
BB An obligation rated BB is less vulnerable to nonpayment than other speculative issues. However, it faces major ongoing uncertainties or exposure to adverse business, financial, or economic conditions, which could lead to the obligors inadequate capacity to meet its financial commitment on the obligation.
B An obligation rated B is more vulnerable to nonpayment than obligations rated BB, but the obligor currently has the capacity to meet its financial commitment on the obligation. Adverse business, financial, or economic conditions will likely impair the obligors capacity or willingness to meet its financial commitment on the obligation.
B-2
CCC An obligation rated CCC is currently vulnerable to nonpayment, and is dependent upon favorable business, financial, and economic conditions for the obligor to meet its financial commitment on the obligation. In the event of adverse business, financial, or economic conditions, the obligor is not likely to have the capacity to meet its financial commitment on the obligation.
CC An obligation rated CC is currently highly vulnerable to nonpayment. The CC rating is used when a default has not yet occurred, but Standard & Poors expects default to be a virtual certainty, regardless of the anticipated time to default.
C An obligation rated C is currently highly vulnerable to nonpayment, and the obligation is expected to have lower relative seniority or lower ultimate recovery compared to obligations that are rated higher.
D An obligation rated D is in default or in breach of an imputed promise. For non-hybrid capital instruments, the D rating category is used when payments on an obligation are not made on the date due, unless Standard & Poors believes that such payments will be made within five business days, in the absence of a stated grace period or within the earlier of the stated grace period or 30 calendar days. The D rating also will be used upon the filing of a bankruptcy petition or the taking of similar action and where default on an obligation is a virtual certainty, for example due to automatic stay provisions. An obligations rating is lowered to D if it is subject to a distressed exchange offer.
Plus (+) or Minus (-) The ratings from AA to CCC may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the major rating categories.
NR This indicates that no rating has been requested, or that there is insufficient information on which to base a rating, or that Standard & Poors does not rate a particular obligation as a matter of policy.
Moody s . Moodys long-term ratings are assigned to issuers or obligations with an original maturity of one year or more and reflect both on the likelihood of a default on contractually promised payments and expected financial loss suffered in the event of default. The following are excerpts from Moodys long-term obligation ratings definitions:
Aaa Obligations rated Aaa are judged to be of the highest quality, subject to the lowest level of credit risk.
Aa Obligations rated Aa are judged to be of high quality and are subject to very low credit risk.
A Obligations rated A are judged to be upper-medium grade and are subject to low credit risk.
Baa Obligations rated Baa are judged to be medium-grade and subject to moderate credit risk and as such may possess certain speculative characteristics.
Ba Obligations rated Ba are judged to be speculative and are subject to substantial credit risk.
B-3
B Obligations rated B are considered speculative and are subject to high credit risk.
Caa Obligations rated Caa are judged to be speculative of poor standing and are subject to very high credit risk.
Ca Obligations rated Ca are highly speculative and are likely in, or very near, default, with some prospect of recovery of principal and interest.
C Obligations rated C are the lowest rated and are typically in default, with little prospect for recovery of principal or interest.
Note: Moodys appends numerical modifiers 1, 2, and 3 to each generic rating classification from Aa through Caa. The modifier 1 indicates that the obligation ranks in the higher end of its generic rating category; the modifier 2 indicates a mid-range ranking; and the modifier 3 indicates a ranking in the lower end of that generic rating category. Additionally, a (hyb) indicator is appended to all ratings of hybrid securities issued by banks, insurers, finance companies, and securities firms.*
*By their terms, hybrid securities allow for the omission of scheduled dividends, interest, or principal payments, which can potentially result in impairment if such an omission occurs. Hybrid securities may also be subject to contractually allowable write-downs of principal that could result in impairment. Together with the hybrid indicator, the long-term obligation rating assigned to a hybrid security is an expression of the relative credit risk associated with that security.
B-4
GMO TRUST
PROXY VOTING POLICY
Adopted September 16, 2003, Revised March 11, 2010
I. Statement of Policy
GMO Trust (the Trust) delegates the authority and responsibility to vote proxies related to portfolio securities held by the series of the Trust (each, a Fund, and collectively, the Funds) to Grantham, Mayo, Van Otterloo & Co. LLC, its investment adviser (the Adviser).
The Board of Trustees (the Board) of the Trust has reviewed and approved the use of the proxy voting policies and procedures of the Adviser (Proxy Voting Procedures) on behalf of the Funds when exercising voting authority on behalf of the Funds.
II. Standard
The Adviser shall vote proxies related to portfolio securities in the best interests of the Funds and their shareholders. In the event of any conflicts of interest between the Adviser and the Funds, the Adviser shall follow procedures that enable it to cause the proxy to be voted in the best interests of the Funds and their shareholders, which may include (1) causing the proxy to be voted pursuant to the recommendation of an independent third party, pursuant to pre-established proxy voting guidelines, or (2) seeking instructions from the Board on the manner in which the proxy should be voted.
III. Review of Proxy Voting Procedures
The Board shall periodically review the Proxy Voting Procedures presented by the Adviser.
The Adviser shall provide periodic reports to the Board regarding any proxy votes where a material conflict of interest was identified except in circumstances where the Adviser caused the proxy to be voted consistent with the recommendation of the independent third party.
The Adviser shall notify the Board promptly of any material change to its Proxy Voting Procedures.
IV. Securities Lending
When a Fund lends its portfolio securities, the Adviser pursuant to the authority delegated to it by the Fund retains an obligation with respect to voting proxies relating to such securities. However, while such securities are on loan, a Fund will not have the right to vote the proxies relating to those securities. As a result, a Fund will only loan its portfolio securities pursuant to securities lending arrangements that permit the Fund to recall a loaned security or to exercise voting rights associated with the security. However, the Adviser generally will not arrange to have a security recalled or to exercise voting rights associated with a security unless the Adviser both (1) receives adequate notice of a proposal upon which shareholders are being asked to vote (which the Adviser often does not receive, particularly in the case of non-U.S. issuers) and (2) the Adviser believes that the benefits to the Fund of voting on such proposal outweigh the benefits to the Fund of having the security remain out on loan. The Adviser may use third party service providers to assist it in identifying and evaluating proposals, and to assist it in recalling loaned securities for proxy voting purposes.
C-1
V. Certain Non-U.S. Markets
In certain non-U.S. markets, shareholders who vote proxies of a non-U.S. issuer may not be able to trade in the issuers stock for a period of time around the shareholder meeting date. In addition, there may be other costs or impediments to voting proxies in certain non-U.S. markets (e.g., receiving adequate notice, arranging for a proxy, and re-registration requirements). In non-U.S. markets with the foregoing attributes, the Adviser generally will determine not to vote proxies unless it believes that the potential benefits to the Fund of voting outweigh the impairment of portfolio management flexibility and the expected costs/impediments associated with voting.
VI. Disclosure
The following disclosure shall be provided:
A. | Each Funds proxy voting record shall annually be included in the Funds Form N-PX. |
B. | The Adviser shall cause each Fund to include the Trusts proxy voting policies and procedures in the Trusts statement of additional information. |
C. | Each Funds shareholder report shall include a statement that a description of the Funds proxy voting policies and procedures is available (i) without charge, upon request, by calling a specified toll-free or collect telephone number; (ii) on the Funds website, if applicable; and (iii) on the Commissions website at http://www.sec.gov. |
D. | The Trusts statement of additional information and each Funds shareholder report shall include a statement that information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available (i) without charge, upon request, by calling a specified toll-free or collect telephone number, or on or through the Funds website, or both; and (ii) on the Commissions website at http://www.sec.gov. |
C-2
GRANTHAM, MAYO, VAN OTTERLOO & CO. LLC
GMO AUSTRALIA LTD.
GMO EUROPE LLC
GMO SINGAPORE PTE LTD.
(TOGETHER GMO)
PROXY VOTING POLICIES AND PROCEDURES
Amended and Restated as of May 12, 2011
Amended as of December 12, 2011, October 22, 2013, and June 25, 2014
I. | Introduction and General Principles |
GMO provides investment advisory services primarily to institutional, including both ERISA and non-ERISA clients, and commercial clients. GMO understands that proxy voting is an integral aspect of security ownership. Accordingly, in cases where GMO has been delegated authority to vote proxies, that function must be conducted with the same degree of prudence and loyalty accorded any fiduciary or other obligation of an investment manager.
This policy permits clients of GMO to: (1) delegate to GMO the responsibility and authority to vote proxies on their behalf according to GMOs proxy voting polices and guidelines; (2) delegate to GMO the responsibility and authority to vote proxies on their behalf according to the particular clients own proxy voting policies and guidelines; or (3) elect to vote proxies themselves. In instances where clients elect to vote their own proxies, GMO shall not be responsible for voting proxies on behalf of such clients.
GMO believes that the following policies and procedures are reasonably designed to ensure that proxy matters are conducted in the best interest of its clients, in accordance with GMOs fiduciary duties, applicable rules under the Investment Advisers Act of 1940 and fiduciary standards and responsibilities for ERISA clients set out in the Department of Labor interpretations.
II. | Proxy Voting Guidelines |
GMO has engaged Institutional Shareholder Services Group, Inc. (ISS) as its proxy voting agent to:
(1) | research and make voting recommendations or, for matters for which GMO has so delegated, to make the voting determinations; |
(2) | ensure that proxies are voted and submitted in a timely manner; |
(3) | handle other administrative functions of proxy voting; |
(4) | maintain records of proxy statements received in connection with proxy votes and provide copies of such proxy statements promptly upon request; |
(5) | maintain records of votes cast; and |
(6) | provide recommendations with respect to proxy voting matters in general. |
C-3
Proxies generally will be voted in accordance with the voting recommendations contained in the applicable ISS Regional Proxy Voting Policy, as in effect from time to time, subject to such modifications as may be determined by GMO (as described below). Copies of concise summaries of the current ISS regional proxy voting guidelines are available through ISS Policy Gateway at http://www.issgovernance.com. To the extent GMO determines to adopt proxy voting guidelines that differ from the ISS proxy voting recommendations, such guidelines will be set forth on Exhibit A and proxies with respect to such matters will be voted in accordance with the guidelines set forth on Exhibit A. GMO reserves the right to modify any of the recommendations set forth in the ISS Proxy Voting Manual in the future. If any such changes are made, an amended Exhibit A to these Proxy Voting Policies and Procedures will be made available for clients.
Except in instances where a GMO client retains voting authority, GMO will instruct custodians of client accounts to forward all proxy statements and materials received in respect of client accounts to ISS.
In certain non-U.S. markets, shareholders who vote proxies of a non-U.S. issuer may not be able to trade in the issuers stock for a period of time around the shareholder meeting date. In addition, there may be other costs or impediments to voting proxies in certain non-U.S. markets (e.g., receiving adequate notice, arranging for a proxy, and re-registration requirements). In non-U.S. markets with the foregoing attributes, GMO generally will determine to not vote proxies unless it believes that the potential benefits to the client of voting outweigh the impairment of portfolio management flexibility and the expected costs/impediments associated with voting. In addition, if a portfolio security is out on loan, GMO generally will not arrange to have the security recalled or to exercise voting rights associated with the security unless GMO both (1) receives adequate notice of a proposal upon which shareholders are being asked to vote (which GMO often does not receive, particularly in the case of non-U.S. issuers) and (2) GMO believes that the benefits to the client of voting on such proposal outweigh the benefits to the client of having the security remain out on loan. GMO may use third-party service providers to assist it in identifying and evaluating proposals, and to assist it in recalling loaned securities for proxy voting purposes.
III. | Proxy Voting Procedures |
GMO has a Corporate Actions Group with responsibility for administering the proxy voting process, including:
1. | Implementing and updating the applicable ISS regional proxy voting guidelines set forth in the ISS Proxy Voting Manual, as modified from time to time by Exhibit A hereto; |
2. | Overseeing the proxy voting process; and |
3. | Providing periodic reports to GMOs Compliance Department and clients as requested. |
There may be circumstances under which a portfolio manager or other GMO investment professional (GMO Investment Professional) believes that it is in the best interest of a client or clients to vote proxies in a manner inconsistent with the proxy voting guidelines described in Section II. In such an event, the GMO Investment Professional will inform GMOs Corporate Actions Group of its decision to vote such proxy in a manner inconsistent with the proxy voting guidelines described in Section II.
C-4
IV. | Conflicts of Interest |
As ISS will vote proxies in accordance with the proxy voting guidelines described in Section II, GMO believes that this process is reasonably designed to address conflicts of interest that may arise between GMO and a client as to how proxies are voted.
In addition, if GMO is aware that one of the following conditions exists with respect to a proxy, GMO shall consider such event a potential material conflict of interest:
1. | GMO has a business relationship or potential relationship with the issuer; |
2. | GMO has a business relationship with the proponent of the proxy proposal; or |
3. | GMO members, employees or consultants have a personal or other business relationship with the participants in the proxy contest, such as corporate directors or director candidates. |
In the event of a potential material conflict of interest, GMO will (i) vote such proxy according to Exhibit A (if applicable) or the specific recommendation of ISS; (ii) seek instructions from the client or request that the client votes such proxy; or (iii) abstain. All such instances shall be reported to GMOs Compliance Department at least quarterly.
V. | Special Procedures for Voting Shares of GMO Trust |
GMOs responsibility and authority to vote proxies on behalf of its clients for shares of GMO Trust, a family of registered mutual funds for which GMO serves as the investment adviser, may give rise to conflicts of interest. Accordingly, GMO will (i) vote such proxies in the best interests of its clients with respect to routine matters, including proxies relating to the election of Trustees; and (ii) with respect to matters where a conflict of interest exists between GMO and GMO Trust, such as proxies relating to a new or amended investment management contract between GMO Trust and GMO, or a re-organization of a series of GMO Trust, GMO will either (a) vote such proxies in the same proportion as the votes cast with respect to that proxy, (b) seek instructions from its clients and vote on accordance with those instructions, or (c) take such other action as GMO deems appropriate in consultation with the Trusts Chief Compliance Officer.
VI. | Special Procedures for Voting Shares of GMO Series Trust |
GMO also serves as investment adviser for the GMO Series Trust family of registered mutual funds. Each series of GMO Series Trust is a Feeder Fund investing substantially of its assets in shares of a corresponding series of GMO Trust (each a Master Fund) in reliance on Section 12(d)(1)(E) of the Investment Company Act of 1940 (the 1940 Act). In accordance with Section 12(d)(1)(E) of the 1940 Act, GMO will either (i) seek instructions from a Feeder Funds holders with regard to the voting of all proxies with respect to the Feeder Funds shares in the corresponding Master Fund and vote such proxies only in accordance with such instructions, or (ii) vote the shares of the corresponding Master Fund held by a Feeder Fund in the same proportion as the vote of all other holders of the Master Fund.
C-5
VII. | Recordkeeping |
GMO will maintain records relating to the implementation of these proxy voting policies and procedures, including:
(1) | a copy of these policies and procedures which shall be made available to clients, upon request; |
(2) | a record of each vote cast (which ISS maintains on GMOs behalf); and |
(3) | each written client request for proxy records and GMOs written response to any client request for such records. |
Such proxy voting records shall be maintained for a period of five years.
VIII. | Disclosure |
Except as otherwise required by law, GMO has a general policy of not disclosing to any issuer or third party how GMO or its voting delegate voted a clients proxy.
C-6
Exhibit A (as amended February 2, 2009)
Modifications to recommendations set forth in the ISS Proxy Voting Manual
Shareholder Ability to Act by Written Consent
Vote FOR proposals to restrict or prohibit shareholder activity to take action by written consent.
Vote AGAINST proposals to allow or make easier shareholder action by written consent.
Cumulative Voting
Vote FOR proposals to eliminate cumulative voting.
Vote AGAINST proposals to restore or provide for cumulative voting.
Incumbent Director Nominees
Vote WITH managements recommendations regarding incumbent director nominees.
C-7
GMO Trust
Multiple Classes - Supplemental Information
Class Designations
In addition to the classes of shares identified in the GMO Trust Prospectus dated June 30, 2016 (the Multi-Class Prospectus) as being currently offered by each Fund of GMO Trust (the Trust), each Fund of the Trust may also from time to time issue one or more of the following classes of shares: Class I Shares, Class II Shares, Class III Shares, Class IV Shares, Class V Shares, Class VI Shares, Class VII Shares, Class VIII Shares, and Class MF Shares. Exhibit A to this Supplement identifies the classes (except Class MF) each Fund may offer, and Exhibit B to this Supplement identifies the Funds that may offer Class MF Shares. Each class of shares of a Fund will represent interests in the same portfolio of investments and, except as described herein, shall have the same rights and obligations as each other class of shares of such Fund. The sole economic difference among Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII, and Class VIII Shares is the level of shareholder service fee (Shareholder Service Fee) that the classes bear for client and shareholder service, reporting and other support. The existence of multiple classes reflects the fact that, as the size of a client relationship increases, the cost to service that client decreases as a percentage of the assets in that account. Thus, the Shareholder Service Fee generally is lower for classes that require greater total assets under management of Grantham, Mayo, Van Otterloo & Co. LLC (GMO). Class MF Shares are subject to a supplemental support fee (Supplemental Support Fee), but not a Shareholder Service Fee.
Each class of shares that is not presently being offered shall be subject to such investment minimums and other eligibility requirements as shall be set forth in the Trusts prospectuses or statements of additional information prior to the commencement of sale of such shares (the Registration Statement). Each such class will bear the same purchase premium and redemption fee, if any, assessed by the class(es) of shares of the relevant Fund currently being offered.
Class Eligibility
Class eligibility is generally dependent on the size of the clients total assets under the management of GMO, the Trusts investment adviser, and its affiliates, the size of the clients total investment in the particular Fund of the Trust, or a combination of both, as described from time to time in the Registration Statement. Mutual funds that wish to invest in a Fund and that wish to receive supplemental support services will be eligible to purchase its Class MF shares (to the extent available).
Eligibility requirements for classes of shares currently offered by the Trust are set forth in the Multi-Class Prospectus. Eligibility requirements for classes of shares not currently being offered will be established and disclosed in the relevant Funds prospectus prior to the offering of such shares. GMO will make all determinations as to aggregation of client accounts for purposes of determining eligibility.
Class Characteristics
Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII, and Class VIII Shares
The sole difference among the various classes of shares is the level of Shareholder Service Fee borne by the class for client and shareholder service, reporting and other support provided to such class by GMO. The Shareholder Service Fee borne by each class of shares of each Fund is set forth in Exhibit A hereto. The expenses associated with an investment in any of the classes currently being offered by a Fund are described in detail under Fees and Expenses for that Fund in the Multi-Class Prospectus.
Investors should be aware that, because of the different Shareholder Service Fee borne by each class of shares of a particular Fund, the net annual fund operating expenses associated with an investment in Class I Shares or Class II Shares of a Fund (other than an asset allocation fund) will typically be 0.13% higher and 0.07% higher, respectively, than an investment in Class III Shares of the same Fund. As a result, the total return earned by an investment in Class I or Class II Shares of a Fund will always be lower than the total return earned by Class III Shares of the same Fund. Similarly, an investor in Class IV, Class V, Class VI, Class VII, and Class VIII Shares can expect to pay lower net annual fund operating expenses and earn correspondingly higher returns than an investor in Class III Shares of the same Fund over the same period.
The multiple class structure reflects the fact that, as the size of the client relationship increases, the cost to service that client decreases as a percentage of the assets in that account. Thus, the Shareholder Service Fee is generally lower for classes that require greater total assets under GMOs management.
All classes of shares of a Fund bear the same level of purchase premium and/or redemption fee, if any.
Class MF Shares
Class MF Shares of each Fund pay GMO the Supplemental Support Fee, which is used by GMO to defray its expenses (or the expenses of a third party) in providing supplemental support with respect to Class MF shareholders and their investment advisers. The Supplemental Support Fee borne by the Class MF Shares of each Fund is set forth in Exhibit B hereto. The expenses associated with an investment in Class MF Shares currently being offered by a Fund are described in detail in the Multi-Class Prospectus under Fees and Expenses.
The Class MF Shares of a Fund bear the same level of purchase premium and/or redemption fee, if any, as all other classes of the same Fund.
Conversion and Exchange Features
Conversion and exchange features for classes of shares currently offered by the Trust are set forth in the Multi-Class Prospectus. Conversion and exchange features for classes of shares not currently being offered will be established and disclosed in the relevant Funds prospectus prior to the offering of such shares.
-2-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
Class I Shares | ||||
Fund |
Service Fee | |||
GMO International Equity Fund |
0.28 | % | ||
GMO Foreign Fund |
0.28 | % | ||
GMO Core Plus Bond Fund |
0.28 | % | ||
GMO International Small Companies Fund |
0.28 | % | ||
GMO Emerging Markets Fund |
0.28 | % | ||
GMO Alpha Only Fund |
0.28 | % | ||
GMO Currency Hedged International Bond Fund |
0.28 | % | ||
GMO Global Bond Fund |
0.28 | % | ||
GMO Emerging Country Debt Fund |
0.28 | % | ||
GMO Emerging Countries Fund |
0.28 | % | ||
GMO Tax-Managed International Equities Fund |
0.28 | % | ||
GMO International Equity Allocation Fund |
0.13 | % | ||
GMO Global Equity Allocation Fund |
0.13 | % | ||
GMO Global Asset Allocation Fund |
0.13 | % | ||
GMO Benchmark-Free Allocation Fund |
0.13 | % |
Class II Shares | ||||
Fund |
Service Fee | |||
GMO Quality Fund |
0.22 | % | ||
GMO International Equity Fund |
0.22 | % | ||
GMO Foreign Fund |
0.22 | % | ||
GMO Core Plus Bond Fund |
0.22 | % | ||
GMO International Small Companies Fund |
0.22 | % | ||
GMO Emerging Markets Fund |
0.22 | % | ||
GMO Emerging Domestic Opportunities Fund |
0.22 | % | ||
GMO Alpha Only Fund |
0.22 | % | ||
GMO Currency Hedged International Bond Fund |
0.22 | % | ||
GMO Global Bond Fund |
0.22 | % |
-3-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
GMO Emerging Country Debt Fund |
0.22 | % | ||
GMO Emerging Countries Fund |
0.22 | % | ||
GMO Tax-Managed International Equities Fund |
0.22 | % | ||
GMO International Equity Allocation Fund |
0.07 | % | ||
GMO Global Equity Allocation Fund |
0.07 | % | ||
GMO Global Asset Allocation Fund |
0.07 | % | ||
GMO Benchmark-Free Allocation Fund |
0.07 | % |
Class III Shares | ||||
Fund |
Service Fee | |||
GMO U.S. Equity Allocation Fund |
0.15 | % | ||
GMO Quality Fund |
0.15 | % | ||
GMO International Large/Mid Cap Equity Fund |
0.15 | % | ||
GMO International Equity Fund |
0.15 | % | ||
GMO Core Plus Bond Fund |
0.15 | % | ||
GMO International Small Companies Fund |
0.15 | % | ||
GMO Emerging Markets Fund |
0.15 | % | ||
GMO Emerging Domestic Opportunities Fund |
0.15 | % | ||
GMO Alpha Only Fund |
0.15 | % | ||
GMO Currency Hedged International Bond Fund |
0.15 | % | ||
GMO Global Bond Fund |
0.15 | % | ||
GMO Emerging Country Debt Fund |
0.15 | % | ||
GMO Emerging Countries Fund |
0.15 | % | ||
GMO Tax-Managed International Equities Fund |
0.15 | % | ||
GMO Foreign Fund |
0.15 | % | ||
GMO Foreign Small Companies Fund |
0.15 | % | ||
GMO Developed World Stock Fund |
0.15 | % | ||
GMO Asset Allocation Bond Fund |
0.15 | % | ||
GMO Taiwan Fund |
0.15 | % | ||
GMO International Equity Allocation Fund |
0.00 | % |
-4-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
GMO International Developed Equity Allocation Fund |
0.00 | % | ||
GMO Global Equity Allocation Fund |
0.00 | % | ||
GMO Global Asset Allocation Fund |
0.00 | % | ||
GMO Benchmark-Free Allocation Fund |
0.15 | % | ||
GMO Benchmark-Free Fund |
0.00 | % | ||
GMO Strategic Opportunities Allocation Fund |
0.00 | % | ||
GMO Global Developed Equity Allocation Fund |
0.00 | % | ||
GMO Resources Fund |
0.15 | % | ||
GMO Risk Premium Fund |
0.15 | % | ||
GMO Debt Opportunities Fund |
0.15 | % | ||
GMO Special Opportunities Fund |
0.15 | % | ||
GMO SGM Major Markets Fund |
0.15 | % |
Class IV Shares | ||||
Fund |
Service Fee | |||
GMO U.S. Equity Allocation Fund |
0.10 | % | ||
GMO Quality Fund |
0.105 | % | ||
GMO International Large/Mid Cap Equity Fund |
0.09 | % | ||
GMO International Equity Fund |
0.09 | % | ||
GMO Tax-Managed International Equities Fund |
0.09 | % | ||
GMO Foreign Fund |
0.09 | % | ||
GMO International Small Companies Fund |
0.11 | % | ||
GMO Foreign Small Companies Fund |
0.10 | % | ||
GMO Emerging Markets Fund |
0.105 | % | ||
GMO Emerging Domestic Opportunities Fund |
0.105 | % | ||
GMO Core Plus Bond Fund |
0.10 | % | ||
GMO Global Bond Fund |
0.13 | % | ||
GMO Currency Hedged International Bond Fund |
0.13 | % | ||
GMO Emerging Country Debt Fund |
0.10 | % | ||
GMO Alpha Only Fund |
0.10 | % |
-5-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
GMO Emerging Countries Fund |
0.10 | % | ||
GMO Developed World Stock Fund |
0.10 | % | ||
GMO Resources Fund |
0.10 | % | ||
GMO Benchmark-Free Allocation Fund |
0.10 | % | ||
GMO Risk Premium Fund |
0.10 | % | ||
GMO Special Opportunities Fund |
0.10 | % | ||
GMO SGM Major Markets Fund |
0.10 | % |
Class V Shares | ||||
Fund |
Service Fee | |||
GMO U.S. Equity Allocation Fund |
0.085 | % | ||
GMO Quality Fund |
0.085 | % | ||
GMO International Equity Fund |
0.085 | % | ||
GMO Foreign Fund |
0.10 | % | ||
GMO International Small Companies Fund |
0.07 | % | ||
GMO Emerging Markets Fund |
0.085 | % | ||
GMO International Large/Mid Cap Equity Fund |
0.085 | % | ||
GMO Emerging Domestic Opportunities Fund |
0.085 | % | ||
GMO Core Plus Bond Fund |
0.12 | % | ||
GMO Currency Hedged International Bond Fund |
0.12 | % | ||
GMO Global Bond Fund |
0.12 | % | ||
GMO Emerging Country Debt Fund |
0.12 | % | ||
GMO Alpha Only Fund |
0.12 | % | ||
GMO Emerging Countries Fund |
0.05 | % | ||
GMO Developed World Stock Fund |
0.085 | % | ||
GMO Resources Fund |
0.085 | % | ||
GMO Risk Premium Fund |
0.085 | % | ||
GMO Benchmark-Free Allocation Fund |
0.085 | % | ||
GMO Special Opportunities Fund |
0.085 | % | ||
GMO SGM Major Markets Fund |
0.085 | % |
-6-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
Class VI Shares | ||||
Fund |
Service Fee | |||
GMO U.S. Equity Allocation Fund |
0.055 | % | ||
GMO Quality Fund |
0.055 | % | ||
GMO International Large/Mid Cap Equity Fund |
0.055 | % | ||
GMO International Equity Fund |
0.055 | % | ||
GMO Foreign Fund |
0.08 | % | ||
GMO International Small Companies Fund |
0.04 | % | ||
GMO Emerging Markets Fund |
0.055 | % | ||
GMO Emerging Domestic Opportunities Fund |
0.055 | % | ||
GMO Core Plus Bond Fund |
0.10 | % | ||
GMO Currency Hedged International Bond Fund |
0.10 | % | ||
GMO Global Bond Fund |
0.10 | % | ||
GMO Emerging Country Debt Fund |
0.10 | % | ||
GMO Alpha Only Fund |
0.10 | % | ||
GMO Emerging Countries Fund |
0.02 | % | ||
GMO Developed World Stock Fund |
0.055 | % | ||
GMO Asset Allocation Bond Fund |
0.055 | % | ||
GMO Taiwan Fund |
0.055 | % | ||
GMO Resources Fund |
0.055 | % | ||
GMO Risk Premium Fund |
0.055 | % | ||
GMO Benchmark-Free Allocation Fund |
0.055 | % | ||
GMO Debt Opportunities Fund |
0.055 | % | ||
GMO Special Opportunities Fund |
0.055 | % | ||
GMO SGM Major Markets Fund |
0.055 | % |
-7-
EXHIBIT A: SHAREHOLDER SERVICE FEE SCHEDULE
Class VII Shares | ||||
Fund |
Service Fee | |||
GMO Core Plus Bond Fund |
0.06 | % | ||
GMO Currency Hedged International Bond Fund |
0.06 | % | ||
GMO Global Bond Fund |
0.06 | % | ||
GMO Special Opportunities Fund |
0.04 | % |
Class VIII Shares | ||||
Fund |
Service Fee | |||
GMO Core Plus Bond Fund |
0.01 | % | ||
GMO Currency Hedged International Bond Fund |
0.01 | % | ||
GMO Global Bond Fund |
0.01 | % |
-8-
EXHIBIT B: SUPPLEMENTAL SUPPORT FEE SCHEDULE
Fund |
Supplemental
Support Fee |
|||
GMO Benchmark-Free Allocation Fund |
0.10 | % |
-9-
GMO TRUST
PART C. OTHER INFORMATION
Item 28. | Exhibits |
(a) | Amended and Restated Agreement and Declaration of Trust of GMO Trust (the Trust or Registrant), dated March 9, 2016 (the Declaration of Trust)Exhibit (a); |
(b) | Amended and Restated By-laws of the Trust, effective as of March 1, 2007, as amended November 17, 2015 (the By-laws). 37 |
(c) | 1. | Please refer to Article III (Shares) and Article V (Shareholders Voting Powers and Meetings) of the Amended and Restated Declaration of Trust, which is filed herewith as Exhibit (a); and |
2. | Please refer to Article 11 (Meetings of Shareholders), Article 12 (Choice of Law), Article 13 (Forum) and Article 14 (Claims) of the By-laws, which are hereby incorporated by reference. 37 |
(d) | 1. | Amended and Restated Management Contract, dated as of June 30, 2008, between the Trust, on behalf of GMO International Equity Fund (formerly GMO International Intrinsic Value Fund and GMO International Core Fund), and GMO; 15 |
2. | Management Contract, dated October 15, 1991, between the Trust, on behalf of GMO International Small Companies Fund, and GMO; 30 |
3. | Form of Management Contract between the Trust, on behalf of GMO Emerging Countries Fund (formerly GMO Evolving Countries Fund), and GMO; 13 |
4. | Management Contract, dated June 24, 1994, between the Trust, on behalf of GMO Currency Hedged International Bond Fund, and GMO; 30 |
5. | Form of Management Contract between the Trust, on behalf of GMO Emerging Country Debt Fund, and GMO; 13 |
6. | Management Contract, dated June 25, 1994, between the Trust, on behalf of GMO Alpha Only Fund (formerly GMO Global Hedged Equity Fund), and GMO; 30 |
7. | Amended and Restated Management Contract, dated as of January 1, 2012, between the Trust, on behalf of GMO Benchmark-Free Allocation Fund, and GMO; 25 |
8. | Form of Management Contract between the Trust, on behalf of GMO Taiwan Fund, and GMO; 13 |
9. | Management Contract, dated December 20, 1995, between the Trust, on behalf of GMO Global Bond Fund, and GMO; 30 |
10. | Management Contract, dated June 27, 1995, between the Trust, on behalf of GMO Foreign Fund, and GMO; 30 |
11. | Form of Management Contract between the Trust, on behalf of GMO International Equity Allocation Fund, and GMO; 1 |
1
12. | Form of Management Contract between the Trust, on behalf of GMO Global Asset Allocation Fund (formerly GMO Global Balanced Asset Allocation Fund, GMO World Balanced Allocation Fund, and GMO World Equity Allocation Fund), and GMO; 2 |
13. | Form of Management Contract between the Trust, on behalf of GMO Global Equity Allocation Fund (formerly GMO Global (U.S.+) Equity Allocation Fund), and GMO; 2 |
14. | Form of Management Contract between the Trust, on behalf of GMO Core Plus Bond Fund (formerly GMO U.S. Bond/Global Alpha A Fund and GMO Global Fund), and GMO; 13 |
15. | Amended and Restated Management Contract, dated as of June 30, 2008, between the Trust, on behalf of GMO Tax-Managed International Equities Fund, and GMO; 15 |
16. | Form of Management Contract between the Trust, on behalf of GMO Foreign Small Companies Fund, and GMO; 3 |
17. | Amended and Restated Management Contract, dated February 12, 2014, between the Trust, on behalf of GMO Debt Opportunities Fund (formerly GMO Short-Duration Collateral Fund), and GMO; 29 |
18. | Form of Management Contract between the Trust, on behalf of GMO Quality Fund (formerly GMO U.S. Quality Equity Fund), and GMO; 7 |
19. | Form of Management Contract between the Trust, on behalf of GMO World Opportunity Overlay Fund, and GMO; 8 |
20. | Form of Management Contract between the Trust, on behalf of GMO Strategic Opportunities Allocation Fund (formerly GMO Strategic Balanced Allocation Fund), and GMO; 9 |
21. | Form of Management Contract between the Trust, on behalf of GMO Global Developed Equity Allocation Fund (formerly GMO World Opportunities Equity Allocation Fund), and GMO; 9 |
22. | Amended and Restated Management Contract, dated as of June 30, 2008, between the Trust, on behalf of GMO Developed World Stock Fund, and GMO; 15 |
23. | Form of Management Contract between the Trust, on behalf of GMO U.S. Equity Allocation Fund (formerly GMO U.S. Core Equity Fund), and GMO; 11 |
24. | Form of Management Contract between the Trust, on behalf of GMO International Large/Mid Cap Equity Fund (formerly GMO International Core Equity Fund), and GMO; 11 |
25. | Management Contract between the Trust, on behalf of GMO International Developed Equity Allocation Fund (formerly GMO International Opportunities Equity Allocation Fund), and GMO; 12 |
26. | Management Contract between the Trust, on behalf of GMO U.S. Treasury Fund, and GMO; 16 |
27. | Management Contract between the Trust, on behalf of GMO Asset Allocation Bond Fund, and GMO; 16 |
2
28. | Amended and Restated Management Contract, dated as of August 12, 2009, between the Trust, on behalf of GMO Emerging Markets Fund, and GMO; 18 |
29. | Amended and Restated Management Contract, dated as of December 1, 2015, between the Trust, on behalf of GMO SGM Major Markets Fund (formerly GMO Systematic Global Macro Opportunity Fund and GMO Alternative Asset Opportunity Fund), and GMO; 37 |
30. | Management Contract, dated as of December 2, 2009, between the Trust, on behalf of GMO High Quality Short-Duration Bond Fund, and GMO; 19 |
31. | Management Contract, dated as of August 2, 2010, between the Trust, on behalf of GMO Emerging Domestic Opportunities Fund, and GMO; 21 |
32. | Management Contract, dated as of May 20, 2011, between the Trust, on behalf of GMO Benchmark-Free Fund, and GMO; 22 |
(i) | Management Contract, dated as of November 24, 2015, between GMO Benchmark-Free SPC Ltd. and GMO; 37 |
33. | Management Contract, dated as of December 6, 2011, between the Trust, on behalf of GMO Resources Fund, and GMO; 23 |
34. | Management Contract, dated as of December 5, 2011, between the Trust, on behalf of GMO Implementation Fund, and GMO; 24 |
(i) | Management Contract, dated as of February 23, 2015, between GMO Implementation SPC Ltd. and GMO. 33 |
35. | Management Contract, dated as of June 27, 2014, between the Trust, on behalf of GMO Special Opportunities Fund, and GMO; 31 |
(i) | Management Contract, dated as of July 9, 2014, between GMO Special Opportunities SPC Ltd. and GMO. 31 |
36. | Management Contract, dated as of April 13, 2015, between the Trust, on behalf of GMO GAAR Implementation Fund, and GMO; 33 |
(i) | Management Contract, dated as of April 13, 2015, between GMO GAAR Implementation SPC Ltd. and GMO. 33 and |
37. | Sub-Advisory Agreement, dated as of December 30, 2013, among GMO, GMO Singapore Pte. Limited, and the Trust, on behalf of GMO Emerging Domestic Opportunities Fund. 37 |
(e) | 1. | Amended and Restated Distribution Agreement (the Distribution Agreement), effective June 30, 2012, between the Trust, on behalf of the Funds listed on Schedule A thereto, as Schedule A may be amended from time to time, and Funds Distributor, LLC; 27 and |
(i) Schedule A to the Distribution Agreement amended as of December 1, 2015. 37
2. | Master Placement Agency Agreement between the Trust, on behalf of the Funds listed on Schedule A thereto, as Schedule A may be amended from time to time, and Funds Distributor, LLC, dated September 8, 2014. 32 |
(i) Schedule A to the Master Placement Agency Agreement amended as of December 1, 2015. 37
3
(f) | None. |
(g) | 1. | Form of Custodian Agreement (the IBT Custodian Agreement), dated August 1, 1991, among the Trust, on behalf of certain Funds listed therein, GMO and Investors Bank & Trust Company (IBT), as amended from time to time to include GMO Currency Hedged International Bond Fund, GMO Emerging Country Debt Fund, GMO Benchmark-Free Allocation Fund, GMO Global Bond Fund, GMO International Equity Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO Core Plus Bond Fund, GMO Debt Opportunities Fund, GMO Quality Fund, GMO World Opportunity Overlay Fund, GMO Strategic Opportunities Allocation Fund, GMO SGM Major Markets Fund, GMO Global Developed Equity Allocation Fund, GMO U.S. Equity Allocation Fund, GMO International Developed Equity Allocation Fund, GMO U.S. Treasury Fund, GMO Asset Allocation Bond Fund, GMO High Quality Short-Duration Bond Fund, GMO Benchmark-Free Fund, GMO Implementation Fund, GMO Risk Premium Fund, GMO Special Opportunities Fund, and GMO GAAR Implementation Fund; 13 |
(i) | Letter Amendment to the IBT Custodian Agreement, dated May 30, 2003, among the Trust, GMO and IBT; 6 |
(ii) | Form of Letter Amendment to the IBT Custodian Agreement, dated January 2005, among the Trust, on behalf of GMO SGM Major Markets Fund, GMO and IBT; 10 |
(iii) | Letter Amendment to the IBT Custodian Agreement, dated March 10, 2009, among the Trust, on behalf of GMO U.S. Treasury Fund and GMO Asset Allocation Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 16 |
(iv) | Form of Letter Amendment to the IBT Custodian Agreement, dated November 25, 2009, among the Trust, on behalf of GMO Debt Opportunities Fund and GMO High Quality Short-Duration Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 19 |
(v) | Form of Letter Amendment to the IBT Custodian Agreement, dated May 20, 2011, among the Trust, on behalf of GMO Benchmark-Free Fund, GMO and State Street Bank (as successor by merger to IBT); 22 |
(vi) | Form of Letter Amendment to the IBT Custodian Agreement, dated December 2011, among the Trust, on behalf of GMO Implementation Fund, GMO and State Street Bank (as successor by merger to IBT); 24 |
(vii) | Form of Letter Amendment to the IBT Custodian Agreement, dated September 2012, among the Trust, on behalf of GMO Risk Premium Fund, GMO and State Street Bank (as successor by merger to IBT); 26 |
(viii) | Letter Amendment to the IBT Custodian Agreement, dated July 1, 2014, among the Trust, on behalf of GMO Special Opportunities Fund, GMO and State Street Bank (as successor by merger to IBT); 31 |
4
(ix) | Amendment to the IBT Custodian Agreement, dated February 17, 2015, among the Trust, GMO and State Street Bank (as successor by merger to IBT); 33 and |
(x) | Letter Amendment to the IBT Custodian Agreement, dated April 13, 2015, among the Trust, on behalf of GMO GAAR Implementation Fund, GMO and State Street Bank (as successor by merger to IBT). 34 |
2. | Form of Custodian Agreement (the BBH Custodian Agreement), dated June 29, 2001, between the Trust, on behalf of certain Funds listed on Schedule I thereto, and Brown Brothers Harriman & Co. (BBH), as amended from time to time to include GMO Taiwan Fund, GMO Developed World Stock Fund, GMO International Large/Mid Cap Equity Fund, GMO Emerging Domestic Opportunities Fund, and GMO Resources Fund; 5 |
(i) | Letter Amendment to the BBH Custodian Agreement, dated June 4, 2003, among the Trust and BBH; 6 |
(ii) | Amendment to the BBH Custodian Agreement, dated June 30, 2009, among the Trust and BBH; 17 |
(iii) | Letter Amendment to the BBH Custodian Agreement, dated May 21, 2010, between the Trust, on behalf of GMO Emerging Domestic Opportunities Fund, and BBH; 21 and |
(iv) | Form of Letter Amendment to the BBH Custodian Agreement, dated December 2011 among the Trust, on behalf of GMO Resources Fund, and BBH. 23 |
3. | Form of Accounting Agency Agreement (the Accounting Agency Agreement), dated June 29, 2001, between the Trust, on behalf of certain Funds listed on Schedule I thereto, and BBH, as amended to include GMO Taiwan Fund, GMO Emerging Domestic Opportunities Fund, and GMO Resources Fund; 5 |
(i) | Form of Second Amendment to the Accounting Agency Agreement, dated November 22, 2005, between the Trust, on behalf of the Funds listed on Schedule I thereto, and BBH; 13 |
(ii) | Letter Amendment to the Accounting Agency Agreement, dated May 21, 2010, between the Trust, on behalf of GMO Emerging Domestic Opportunities Fund, and BBH; 21 and |
(iii) | Form of Letter Amendment to the Accounting Agency Agreement, dated December 2011 among the Trust, on behalf of GMO Resources Fund, and BBH. 23 |
4. | Form of 17f-5 Delegation Schedule (the Delegation Schedule), dated June 29, 2001, between the Trust, on behalf of certain Funds listed on Schedule 1 thereto, and BBH, as amended from time to time to include GMO Taiwan Fund, GMO Developed World Stock Fund, GMO International Large/Mid Cap Equity Fund, GMO Emerging Domestic Opportunities Fund, and GMO Resources Fund; 5 |
(i) | Letter Amendment to the Delegation Schedule, dated May 21, 2010, between the Trust, on behalf of GMO Emerging Domestic Opportunities Fund, and BBH; 21 |
(ii) | Form of Letter Amendment to the Delegation Schedule, dated December 2011, among the Trust, on behalf of GMO Resources Fund, and BBH. 23 |
5
5. | Form of Amended and Restated Delegation Agreement (the Delegation Agreement), dated June 29, 2001, between the Trust, on behalf of GMO Core Plus Bond Fund, GMO Currency Hedged International Bond Fund, GMO Global Bond Fund, and GMO Emerging Country Debt Fund, and IBT, as amended from time to time to include GMO Strategic Opportunities Allocation Fund, GMO SGM Major Markets Fund, GMO Global Developed Equity Allocation Fund, GMO U.S. Equity Allocation Fund, GMO International Developed Equity Allocation Fund, GMO U.S. Treasury Fund, GMO Asset Allocation Bond Fund, GMO Debt Opportunities Fund, GMO High Quality Short-Duration Bond Fund, GMO Benchmark-Free Fund, GMO Implementation Fund, GMO Risk Premium Fund, GMO Special Opportunities Fund, and GMO GAAR Implementation Fund; 5 |
(i) | Form of Letter Amendment to the Delegation Agreement, dated January 2005, among the Trust, on behalf of GMO SGM Major Markets Fund, GMO and State Street Bank (as successor by merger to IBT); 10 |
(ii) | Letter Amendment to the Delegation Agreement, dated March 10, 2009, among the Trust, on behalf of GMO U.S. Treasury Fund and GMO Asset Allocation Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 16 |
(iii) | Form of Letter Amendment to the Delegation Agreement, dated November 25, 2009, among the Trust, on behalf of GMO Debt Opportunities Fund and GMO High Quality Short-Duration Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 19 |
(iv) | Form of Letter Amendment to the Delegation Agreement, dated May 20, 2011, among the Trust, on behalf of GMO Benchmark-Free Fund, GMO and State Street Bank (as successor by merger to IBT); 22 |
(v) | Form of Letter Amendment to the Delegation Agreement, dated December 2011, among the Trust, on behalf of GMO Implementation Fund, GMO and State Street Bank (as successor by merger to IBT); 24 |
(vi) | Form of Letter Amendment to the Delegation Agreement, dated September 2012, among the Trust, on behalf of GMO Risk Premium Fund, GMO and State Street Bank (as successor by merger to IBT); 26 |
(vii) | Letter Amendment to the Delegation Agreement, dated July 1, 2014, among the Trust, on behalf of GMO Special Opportunities Fund, GMO and State Street Bank (as successor by merger to IBT); 31 and |
(viii) | Letter Amendment to the Delegation Agreement, dated April 13, 2015, among the Trust, on behalf of GMO GAAR Implementation Fund, GMO and State Street Bank (as successor by merger to IBT). 34 |
6
(h) | 1. | Form of Transfer Agency and Service Agreement (the Transfer Agency and Service Agreement), dated August 1, 1991, among the Trust, on behalf of certain Funds listed therein, GMO and IBT, as amended from time to time to include GMO Global Bond Fund, GMO Foreign Fund, GMO International Equity Allocation Fund, GMO Global Asset Allocation Fund, GMO Global Equity Allocation Fund, GMO Core Plus Bond Fund, GMO Tax-Managed International Equities Fund, GMO Foreign Small Companies Fund, GMO Debt Opportunities Fund, GMO Quality Fund, GMO World Opportunity Overlay Fund, GMO Strategic Opportunities Allocation Fund, GMO SGM Major Markets Fund, GMO Global Developed Equity Allocation Fund, GMO Developed World Stock Fund, GMO International Large/Mid Cap Equity Fund, GMO U.S. Equity Allocation Fund, GMO International Developed Equity Allocation Fund, GMO U.S. Treasury Fund, GMO Asset Allocation Bond Fund, GMO High Quality Short-Duration Bond Fund, GMO Emerging Domestic Opportunities Fund, GMO Benchmark-Free Fund, GMO Resources Fund, GMO Implementation Fund, GMO Risk Premium Fund, GMO Special Opportunities Fund, and GMO GAAR Implementation Fund; 13 |
(i) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated January 2005, among the Trust, on behalf of GMO SGM Major Markets Fund, GMO and State Street Bank (as successor by merger to IBT); 10 |
(ii) | Letter Amendment to the Transfer Agency and Service Agreement, dated March 10, 2009, among the Trust, on behalf of GMO U.S. Treasury Fund and GMO Asset Allocation Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 16 |
(iii) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated November 25, 2009, among the Trust, on behalf of GMO Debt Opportunities Fund and GMO High Quality Short-Duration Bond Fund, GMO and State Street Bank (as successor by merger to IBT); 19 |
(iv) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated July 30, 2010, among the Trust, on behalf of GMO Emerging Domestic Opportunities Fund, GMO and State Street Bank (as successor by merger to IBT); 21 |
(v) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated May 20, 2011 among the Trust, on behalf of GMO Benchmark-Free Fund, GMO and State Street Bank (as successor by merger to IBT); 22 |
7
(vi) | Letter Amendment Regarding Fund of Fund Procedures to the Transfer Agency and Service Agreement, dated June 1, 2010, among the Trust, GMO, and State Street Bank (as successor by merger to IBT); 23 |
(vii) | Letter Amendment to the Transfer Agency and Service Agreement, dated November 17, 2011 among the Trust, on behalf of GMO Resources Fund, GMO and State Street Bank (as successor by merger to IBT); 23 |
(viii) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated December 2011, among the Trust, on behalf of GMO Implementation Fund, GMO and State Street Bank (as successor by merger to IBT); 24 |
(ix) | Form of Letter Amendment to the Transfer Agency and Service Agreement, dated September 2012, among the Trust, on behalf of GMO Risk Premium Fund, GMO and State Street Bank (as successor by merger to IBT); 26 |
(x) | Letter Amendment to the Transfer Agency and Service Agreement, dated July 1, 2014, among the Trust, on behalf of GMO Special Opportunities Fund, GMO and State Street Bank (as successor by merger to IBT); 32 |
(xi) | Letter Amendment to the Transfer Agency and Service Agreement, dated April 13, 2015, among the Trust, on behalf of GMO GAAR Implementation Fund, GMO and State Street Bank (as successor by merger to IBT); 34 and |
(xii) | FATCA Support Services Amendment to the Transfer Agency and Service Agreement, dated May 22, 2015, among the Trust, GMO and State Street Bank (as successor by merger to IBT). 35 |
2. | Notification of Undertaking to Reimburse Selected Fund Expenses and Waive Selected Fees by GMO to the Trust, dated as of [June 30, 2016] to be filed by amendment. |
(i) | Notification of Undertaking to Reimburse Selected Fund Expenses and Waive Selected Fees by GMO to the Trust, on behalf of its GMO SGM Major Markets Fund, dated as of December 1, 2015. 37 |
3. | Amended and Restated Servicing and Supplemental Support Agreement, dated May 30, 1996, as amended and restated effective December 1, 2015, between the Trust, on behalf of certain Funds listed on Exhibit I thereto, and GMO. 37 |
(i) | Notification of Undertaking to Reduce Supplemental Support Fees by GMO to the Trust, dated as of [June 30, 2016] to be filed by amendment. |
4. | Distribution Agreement, dated as of February 27, 2015, between the Trust and GMO U.K. Limited. 33 |
5. | Letters Regarding Services Provided by GMO Under Management Contracts with the Trust. 37 |
8
(i) | Opinion and Consent of Ropes & Gray LLP previously filed with the Securities and Exchange Commission (the SEC). |
(j) | Consent of Independent Registered Public Accounting Firm to be filed by amendment. |
(k) | Financial Statements Not applicable. |
(l) | None. |
(m) | 1. | GMO Trust Amended and Restated Distribution and Service Plan (Class M), dated as of November 15, 2001, as amended and restated as of June 30, 2013, on behalf of GMO Emerging Countries Fund; 27 |
2. | Amended and Restated Administration Agreement, dated as of June 30, 2013, on behalf of GMO Emerging Countries Fund; 27 |
3. | Form of Service Agreement (Service Agreement), dated October 1, 2001, between American Express Financial Advisors Inc. and the Trust, on behalf of certain Funds listed on Schedule A thereto, as Schedule A may be amended from time to time; 4 |
(i) | Second Amendment to Service Agreement, dated September 9, 2005, between American Express Financial Advisors Inc. and the Trust, on behalf of certain Funds listed on Schedule A thereto; 13 and |
(ii) | Assignment Agreement, effective as of April 2, 2007, between Wachovia Bank, Ameriprise Financial Services, Inc. (f/k/a American Express Financial Advisors Inc.) and the Trust, on behalf of certain Funds listed on Schedule A thereto. 14 |
4. | Form of Services Agreement, dated as of March 2002, between Fidelity Brokerage Services LLC and National Financial Services LLC, and the Trust, on behalf of certain Funds listed on Exhibit B thereto; 5 |
5. | Funds Trading Agreement (Funds Trading Agreement), dated July 1, 2001, between Fidelity Investments Institutional Operations Company, Inc. (FIIOC), IBT, GMO, and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 |
(i) | Second Amendment to Funds Trading Agreement, dated as of April 1, 2003, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 |
9
(ii) | Third Amendment to Funds Trading Agreement, dated as of November 28, 2003, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 |
(iii) | Fourth Amendment to Funds Trading Agreement, dated as of April 1, 2004, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 |
(iv) | Fifth Amendment to Funds Trading Agreement, dated as of February 1, 2005, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 |
(v) | Sixth Amendment to Funds Trading Agreement, dated as of July 2005, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 13 and |
(vi) | Seventh Amendment to Funds Trading Agreement, dated as of September, 2005, between FIIOC, IBT, GMO and the Trust, on behalf of certain Funds listed on Exhibit A thereto. 13 |
6. | Form of Funds Trading Agreement (BBH Funds Trading Agreement), dated July 1, 2001, between FIIOC, IBT, BBH, GMO and the Trust on behalf of certain Funds listed on Exhibit A thereto; 5 |
(i) | Form of First Amendment to the BBH Funds Trading Agreement, dated January 1, 2002, between FIIOC, IBT, BBH, GMO, and the Trust, on behalf of certain Funds listed on Exhibit A thereto; 5 and |
(ii) | Second Amendment to the BBH Funds Trading Agreement, dated July 1, 2002, between FIIOC, IBT, BBH, GMO, and the Trust, on behalf of certain Funds listed on Exhibit A thereto. 13 |
7. | Form of Shareholder Services Agreement (Shareholder Services Agreement), dated as of October 31, 2001, between Citistreet LLC (Citistreet) and the Trust, on behalf of certain Funds listed on Attachment A thereto; 6 and |
(i) | First Amendment to Shareholder Services Agreement, dated as of May 6, 2002, between Citistreet and the Trust, on behalf of certain Funds listed on Attachment A thereto; 13 |
(ii) | Second Amendment to Shareholder Services Agreement, dated as of October 15, 2002, between Citistreet and the Trust, on behalf of certain Funds listed on Attachment A thereto; 13 |
(iii) | Third Amendment to Shareholder Services Agreement, dated as of April 30, 2003, between Citistreet and the Trust, on behalf of certain Funds listed on Attachment A thereto; 13 |
(iv) | Fourth Amendment to Shareholder Services Agreement, dated as of July 1, 2005, between Citistreet and the Trust, on behalf of certain Funds listed on Attachment A thereto; 13 and |
(v) | Fifth Amendment to Shareholder Services Agreement, dated as of September 1, 2005, between Citistreet and the Trust, on behalf of certain Funds listed on Attachment A thereto. 13 |
8. | Operating Agreement (Operating Agreement), dated as of April 19, 2000, between Charles Schwab & Co., Inc. (Schwab) and the Trust, on behalf of certain Funds listed on Schedule I thereto. 20 |
(i) | First Amendment to Operating Agreement, dated as of March 10, 2010, between Schwab and the Trust, on behalf of certain Funds listed on Schedule I thereto. 20 |
10
(n) | Plan pursuant to Rule 18f-3 under the Investment Company Act of 1940, effective June 1, 1996, as amended and restated June 20, 2014. 32 |
(o) | Reserved. |
(p) | 1. | GMO Code of Ethics, dated June 19, 2015, adopted by GMO, GMO Australia Ltd., GMO Europe LLC, GMO Netherlands, a branch office of GMO U.K. Ltd., GMO Singapore PTE Ltd., GMO U.K. Ltd., GMO Renewable Resources LLC, GMO Renewable Resources (in New Zealand), and GMO Renewable Resources Uruguay, SRL; 36 |
2. | GMO Trust Code of Ethics, dated August 27, 2015, adopted by the Trust; 36 and |
3. | Code of Ethics for the Independent Trustees of GMO Trust, dated as of June 1, 2006, as revised August 27, 2015, adopted by the Board of Trustees of the Trust. 36 |
1. | Previously filed with the SEC as part of Post-Effective Amendment No. 27 to the Registration Statement under the Securities Act of 1933 (the 1933 Act) and Amendment No. 28 to the Registration Statement under the Investment Company Act of 1940 Act (the 1940 Act) on March 13, 1996, and hereby incorporated by reference. |
2. | Previously filed with the SEC as part of Post-Effective Amendment No. 29 to the Registration Statement under the 1933 Act and Amendment No. 30 to the Registration Statement under the 1940 Act on June 28, 1996, and hereby incorporated by reference. |
3. | Previously filed with the SEC as part of Amendment No. 63 to the Registration Statement under the 1940 Act on July 3, 2000, and hereby incorporated by reference. |
4. | Previously filed with the SEC as part of Post-Effective Amendment No. 63 to the Registration Statement under the 1933 Act and Amendment No. 76 to the Registration Statement under the 1940 Act on March 1, 2002, and hereby incorporated by reference. |
5. | Previously filed with the SEC as part of Post-Effective Amendment No. 64 to the Registration Statement under the 1933 Act and Amendment No. 77 to the Registration Statement under the 1940 Act on May 1, 2002, and hereby incorporated by reference. |
6. | Previously filed with the SEC as part of Post-Effective Amendment No. 71 to the Registration Statement under the 1933 Act and Amendment No. 89 to the Registration Statement under the 1940 Act on June 30, 2003, and hereby incorporated by reference. |
7. | Previously filed with the SEC as part of Post-Effective Amendment No. 72 to the Registration Statement under the 1933 Act and Amendment No. 90 to the Registration Statement under the 1940 Act on October 31, 2003, and hereby incorporated by reference. |
8. | Previously filed with the SEC as part of Amendment No. 126 to the Registration Statement under the 1940 Act on November 18, 2004, and hereby incorporated by reference. |
9. | Previously filed with the SEC as part of Post-Effective Amendment No. 105 to the Registration Statement under the 1933 Act and Amendment No. 131 to the Registration Statement under the 1940 Act on March 15, 2005, and hereby incorporated by reference. |
10. | Previously filed with the SEC as part of Amendment No. 132 to the Registration Statement under the 1940 Act on March 29, 2005, and hereby incorporated by reference. |
11. | Previously filed with the SEC as part of Post-Effective Amendment No. 114 to the Registration Statement under the 1933 Act and Amendment No. 142 to the Registration Statement under the 1940 Act on August 17, 2005, and hereby incorporated by reference. |
11
12. | Previously filed with the SEC as part of Post-Effective Amendment No. 123 to the Registration Statement under the 1933 Act and Amendment No. 151 to the Registration Statement under the 1940 Act on May 17, 2006, and hereby incorporated by reference. |
13. | Previously filed with the SEC as part of Amendment No. 154 to the Registration Statement under the 1940 Act on June 28, 2006, and hereby incorporated by reference. |
14. | Previously filed with the SEC as part of Post-Effective Amendment No. 128 to the Registration Statement under the 1933 Act and Amendment No. 158 to the Registration Statement under the 1940 Act on June 29, 2007, and hereby incorporated by reference. |
15. | Previously filed with the SEC as part of Amendment No. 161 to the Registration Statement under the 1940 Act on June 27, 2008, and hereby incorporated by reference. |
16. | Previously filed with the SEC as part of Post-Effective Amendment No. 133 to the Registration Statement under the 1933 Act and Amendment No. 167 to the Registration Statement under the 1940 Act on March 13, 2009, and hereby incorporated by reference. |
17. | Previously filed with the SEC as part of Post-Effective Amendment No. 137 to the Registration Statement under the 1933 Act and Amendment No. 172 to the Registration Statement under the 1940 Act on July 17, 2009, and hereby incorporated by reference. |
18. | Previously filed with the SEC as part of Post-Effective Amendment No. 139 to the Registration Statement under the 1933 Act and Amendment No. 174 to the Registration Statement under the 1940 Act on October 30, 2009, and hereby incorporated by reference. |
19. | Previously filed with the SEC as part of Amendment No. 175 to the Registration Statement under the 1940 Act on December 3, 2009, and hereby incorporated by reference. |
20. | Previously filed with the SEC as part of Amendment No. 178 to the Registration Statement under the 1940 Act on June 25, 2010, and hereby incorporated by reference. |
21. | Previously filed with the SEC as part of Post-Effective Amendment No. 143 to the Registration Statement under the 1933 Act and Amendment No. 180 to the Registration Statement under the 1940 Act on August 2, 2010, and hereby incorporated by reference. |
22. | Previously filed with the SEC as part of Amendment No. 183 to the Registration Statement under the 1940 Act on May 20, 2011, and hereby incorporated by reference. |
23. | Previously filed with the SEC as part of Post-Effective Amendment No. 153 to the Registration Statement under the 1933 Act and Amendment No. 192 to the Registration Statement under the 1940 Act on December 6, 2011, and hereby incorporated by reference. |
24. | Previously filed with the SEC as part of Amendment No. 193 to the Registration Statement under the 1940 Act on December 8, 2011, and hereby incorporated by reference. |
25. | Previously filed with the SEC as part of Amendment No. 156 to the Registration Statement under the 1933 Act and Amendment No. 196 to the Registration Statement under the 1940 Act on December 29, 2011, and hereby incorporated by reference. |
26. | Previously filed with the SEC as part of Post-Effective Amendment No. 164 to the Registration Statement under the 1933 Act and Amendment No. 206 to the Registration Statement under the 1940 Act on September 25, 2012, and hereby incorporated by reference. |
27. | Previously filed with the SEC as part of Amendment No. 209 to the Registration Statement under the 1940 Act on June 26, 2013, and hereby incorporated by reference. |
28. | Previously filed with the SEC as part of Post-Effective Amendment No. 170 to the Registration Statement under the 1933 Act and Amendment No. 213 to the Registration Statement under the 1940 Act on February 7, 2014, and hereby incorporated by reference. |
29. | Previously filed with the SEC as part of Post-Effective Amendment No. 172 to the Registration Statement under the 1933 Act and Amendment No. 215 to the Registration Statement under the 1940 Act on April 30, 2014, and hereby incorporated by reference. |
30. | Previously filed with the SEC as part of Amendment No. 217 to the Registration Statement under the 1940 Act on June 25, 2014, and hereby incorporated by reference. |
31. | Previously filed with the SEC as part of Post-Effective Amendment No. 176 to the Registration Statement under the 1933 Act and Amendment No. 220 to the Registration Statement under the 1940 Act on July 18, 2014, and hereby incorporated by reference. |
32. | Previously filed with the SEC as part of Post-Effective Amendment No. 179 to the Registration Statement under the 1933 Act and Amendment No. 223 to the Registration Statement under the 1940 Act on September 15, 2014, and hereby incorporated by reference. |
33. | Previously filed with the SEC as part of Amendment No. 225 to the Registration Statement under the 1940 Act on April 13, 2015, and hereby incorporated by reference. |
34. | Previously filed with the SEC as part of Post-Effective Amendment No. 181 to the Registration Statement under the 1933 Act and Amendment No. 226 to the Registration Statement under the 1940 Act on April 16, 2015, and hereby incorporated by reference. |
35. | Previously filed with the SEC as part of Amendment No. 228 to the Registration Statement under the 1940 Act on June 26, 2015, and hereby incorporated by reference. |
12
36. | Previously filed with the SEC as part of Post-Effective Amendment No. 185 to the Registration Statement under the 1933 Act and Amendment No. 231 to the Registration Statement under the 1940 Act on September 17, 2015, and hereby incorporated by reference. |
37. | Previously filed with the SEC as part of Post-Effective Amendment No. 186 to the Registration Statement under the 1933 Act and Amendment No. 232 to the Registration Statement under the 1940 Act on December 1, 2015, and hereby incorporated by reference. |
Item 29. | Persons Controlled by or Under Common Control with a Fund |
Controlling Fund |
Person Controlled |
Nature of Control |
||
GMO SGM Major Markets Fund | GMO Alternative Asset SPC Ltd. (a) (b) | 100% Ownership (c) | ||
GMO Special Opportunities Fund | GMO Special Opportunities SPC Ltd. (a) (b) | 100% Ownership (c) | ||
GMO Implementation Fund | GMO Implementation SPC Ltd. (a) (b) | 100% Ownership (c) | ||
GMO Benchmark-Free Fund | GMO Benchmark-Free SPC Ltd. (a) (b) | 100% Ownership (c) |
(a) | Included (or, in the case of GMO Benchmark-Free SPC Ltd., will be included, when available) in the controlling Funds consolidated financial statements. |
(b) | Organized under the laws of Bermuda. |
(c) | As of the most recent fiscal year ended February 29, 2016. |
Item 30. | Indemnification |
Please refer to Article 4 (Indemnification) of the By-laws.
In addition, the Trust will maintain a trustees and officers liability insurance policy under which the Trust and its trustees and officers will be named insureds. The Trust also has entered into agreements with each of its trustees pursuant to which each of the Funds has agreed to indemnify each Trustee to the maximum extent permitted by applicable law against any liability and expense incurred by the Trustee by reason of the Trustee being or having been a Trustee.
Insofar as indemnification for liability arising under the Securities Act of 1933 (the Securities Act) may be permitted to trustees, officers and controlling persons of the Registrant pursuant to the Trusts By-laws, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission (SEC) such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a trustee, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such trustee, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
13
Item 31. | Business and Other Connections of Investment Adviser |
A description of the business of Grantham, Mayo, Van Otterloo & Co. LLC, the investment adviser of the Funds of the Registrant (the Investment Adviser), is set forth under the captions Management of the Trust in the Prospectus and Investment Advisory and Other Services in the Statement of Additional Information, all forming part of this Registration Statement.
Except as set forth below, the directors, officers, and members of the Investment Adviser, have been engaged during the past two fiscal years in no business, profession, vocation or employment of a substantial nature other than as directors, officers, or members of the Investment Adviser or certain of its affiliates. Certain directors, officers, and members of the Investment Adviser serve as officers or trustees of the Registrant as set forth under the caption Management of the Trust in the Registrants Statement of Additional Information, forming part of this Registration Statement, and/or as officers and/or directors of certain private investment companies managed by the Investment Adviser or certain of its affiliates. The address of the Investment Adviser and the Registrant is 40 Rowes Wharf, Boston, Massachusetts 02110.
Name |
Position with Investment Adviser |
Other Connections |
||
Stephen P. Casper | Member of the Board of Directors | Director, KLS Diversified Fund, KS Rates Fund and KLS Credit Opportunities Fund, 452 Fifth Avenue, New York, NY 10018; Co-Chair Alzheimers Disease and Related Disorders, New York City, Inc., 600 3 rd Avenue, 2 nd Floor, New York, NY 10016; Lead Independent Director, MarketAxess, 299 Park Avenue, 10 th Floor, New York, NY 10171; Investment Committee Member, Brooklyn Museum, 200 Eastern Parkway, Brooklyn, NY 11238 |
14
Name |
Position with Investment Adviser |
Other Connections |
||
Arjun Divecha | Member, Chairman of the Board of Directors, and Investment Director | Board Member, Divecha Centre for Climate Change, Indian Institute of Science, Bengaluru, India; Director, Spiers New Technologies, 50 NE 42nd Street, Oklahoma City, OK 73105 | ||
Myra Drucker | Member of the Board of Directors |
Chair of the Board, TrustedPeer Inc., 800 Noe Street, San Francisco, CA 94114; Investment Committee Advisor, The Boeing Company, 100 North Riverside Plaza, Chicago, IL 60606; Investment Committee Member, The Kresge Foundation, 3215 West Big Beaver Road, Troy, MI 48084; Investment Committee Chair, The Nathan Cummings Foundation, 475 Tenth Avenue, 14 th Floor, New York, NY 10018; Advisory Committee Member, Disciplina Group, LLC, 3100 West End Avenue, Nashville, TN 37203; Trustee, Financial Accounting Foundation, 401 Merritt 7, PO Box 5116, Norwalk, CT 06856 |
15
Name |
Position with Investment Adviser |
Other Connections |
||
R. Jeremy Grantham | Founding Member, Member of the Board of Directors, and Chief Investment Strategist | Advisor, Divecha Centre for Climate Change, Indian Institute of Science, Bengaluru, India; Advisory Board Member, Imperial College of London Grantham Institute for Climate Change, London SW7 2AZ; Board Member, London School of Economics Grantham Institute for Climate Change, Houghton Street, London, WC2A 2AE; Member, Systemic Risk Council, systemicriskcouncil.org; Trustee, The Grantham Foundation for the Protection of the Environment, 40 Rowes Wharf, Boston, MA 02110; Trustee, The Jeremy and Hannelore Grantham Environmental Trust, 40 Rowes Wharf, Boston, MA 02110 | ||
Margaret McGetrick | Member of the Board of Directors | Investment Committee Member, Partners Healthcare, Prudential Center, 800 Boylston Street, 11 th Floor, Boston, MA, 02199; Finance and Investment Committee Member, Our Sisters School, 145 Brownell Avenue, New Bedford, MA 02740 |
16
Name |
Position with Investment Adviser |
Other Connections |
||
John Rosenblum | Member and Vice Chairman of the Board of Directors | Vice Chair of the Board, Maine Media Workshops, 70 Camden Street, Rockport, ME 04856; Director Emeritus, The Apprenticeshop, 643 Main Street, Rockland, ME 04841; Board Member, Maine Chapter, The Nature Conservancy, 14 Maine Street, Brunswick, ME 04011; Partner 15Rocks (real estate development for the arts and entertainment in Maine) | ||
Eyk Van Otterloo | Founding Member | Board Member, Chemonics International, 1133 20 th Street, NW, Suite 600, Washington, D.C. 20036; Board Member, CliniLabs, 423 W. 55 th Street, 4 th Floor, New York, NY 10019 | ||
Ben Inker | Member of the Board of Directors | Board Member, Jewish Vocational Services, 75 Federal Street, Boston, MA 02110; Member of Investment Committee, Yale University, New Haven, CT 06520 |
Item 32. | Principal Underwriters |
Item 32(a). | Funds Distributor, LLC (FD) acts as principal underwriter for the following investment companies registered under the Investment Company Act of 1940, as amended: |
GMO Series Trust
GMO Trust
17
Mirae Asset Discovery Funds
GMO U.K. Limited, a distributor of the Funds for the limited purpose of offering shares of the Funds to qualified investors in Switzerland, acts as distributor for the following investment companies registered under the Investment Company Act of 1940, as amended:
GMO Trust
Item 32(b). | (1) FD is registered with the SEC as a broker-dealer and is a member of the Financial Industry Regulatory Authority. FDs principal business address is Three Canal Plaza, Suite 100, Portland, Maine 04101. |
Information about the Manager and Officers of FD is as follows:
Manager or Officer |
Positions and Offices with FD |
|
Richard J. Berthy | President, Treasurer, and Manager | |
Mark Fairbanks | Vice President | |
Jennifer K. DiValerio | Vice President | |
Nanette K. Chern | Vice President and Chief Compliance Officer | |
Jennifer E. Hoopes | Secretary |
The above FD manager and officers do not have positions or offices with the Trust.
(2) GMO U.K. Limiteds principal business address is No. l London Bridge, London SE1 9BG, England.
Information about the Manager(s) and Officers of GMO U.K. Limited is as follows:
Manager or Officer |
Positions and Offices with GMO U.K. Limited |
|
[ ] | [ ] | |
[ ] | [ ] | |
[ ] | [ ] | |
[ ] | [ ] | |
[ ] | [ ] |
[The above GMO U.K. Limited manager(s) and officers do not have positions or offices with the Trust.]
Item 32(c). | None. |
Item 33. | Location of Accounts and Records |
The accounts, books, and other documents required to be maintained by Section 31(a) and the rules thereunder will be maintained at the offices of the Registrant, 40 Rowes Wharf, Boston, MA 02110; the Registrants investment adviser, Grantham, Mayo, Van Otterloo & Co. LLC, 40 Rowes Wharf, Boston, MA 02110; the Registrants
18
distributor, Funds Distributor, LLC, 3 Canal Plaza, Suite 100, Portland, Maine 04101; the Registrants custodian for certain of the Funds, Brown Brothers Harriman & Co., 50 Post Office Square, Boston, MA 02110; and the Registrants custodian for certain of the Funds and transfer agent, State Street Bank and Trust Company, One Lincoln Street, Boston, MA 02111.
Item 34. | Management Services |
Not applicable.
Item 35. | Undertakings |
None.
19
Notice
A copy of the Declaration of Trust, together with all amendments thereto, is on file with the Secretary of the Commonwealth of Massachusetts and notice is hereby given that this instrument is executed on behalf of the Trust by an officer of the Trust as an officer and not individually and that the obligations of this instrument are not binding upon any of the Trustees or officers of the Trust or shareholders of any series of the Trust individually but are binding only upon the assets and property of the Trust or the respective series.
20
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933 (the 1933 Act) and the Investment Company Act of 1940 (the 1940 Act), each as amended, the Registrant, GMO Trust, has duly caused this Post-Effective Amendment No. 188 under the 1933 Act and Amendment No. 234 under the 1940 Act to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston and The Commonwealth of Massachusetts, on the 29 th day of April, 2016.
GMO Trust | ||||
By: |
SHEPPARD N. BURNETT* |
|||
Sheppard N. Burnett | ||||
Title: | Chief Executive Officer; | |||
Principal Executive Officer |
Pursuant to the requirements of the 1933 Act, this Post-Effective Amendment No. 188 to GMO Trusts Registration Statement under the 1933 Act has been signed below by the following persons in the capacities and on the date indicated.
Signatures |
Title |
Date |
||
SHEPPARD N. BURNETT* Sheppard N. Burnett |
Chief Executive Officer; Principal Executive Officer |
April 29, 2016 | ||
CARLY CUSHMAN* Carly Cushman |
Treasurer; Chief Financial Officer; Chief Accounting Officer; Principal Financial and Accounting Officer | April 29, 2016 | ||
PAUL BRAVERMAN* Paul Braverman |
Trustee |
April 29, 2016 | ||
DONALD W. GLAZER* Donald W. Glazer |
Trustee |
April 29, 2016 | ||
J.B. KITTREDGE* J.B. Kittredge |
Trustee |
April 29, 2016 | ||
PETER TUFANO* Peter Tufano |
Trustee |
April 29, 2016 |
* By: |
/s/ Douglas Y. Charton |
|
Douglas Y. Charton | ||
Attorney-in-Fact** |
** | Pursuant to Power of Attorney for each of Paul Braverman, Donald W. Glazer, J.B. Kittredge and Peter Tufano filed with the SEC as part of Post-Effective Amendment No. 186 to the Registration Statement under the 1933 Act and Amendment No. 232 to the Registration Statement under the 1940 Act on December 1, 2015 and pursuant to Power of Attorney for each of Sheppard N. Burnett and Carly Cushman filed with the SEC as part of Post-Effective Amendment No. 186 to the Registration Statement under the 1933 Act and Amendment No. 232 to the Registration Statement under the 1940 Act on December 1, 2015. |
GMO TRUST 485(a) FILING
EXHIBIT INDEX
GMO TRUST
Exhibit
|
Title of Exhibit |
|
(a) | Amended and Restated Agreement and Declaration of Trust, dated March 9, 2016. | |
Other | ||
1 | Certificate of Clerk. |
Exhibit (a)
AMENDED AND RESTATED
AGREEMENT AND DECLARATION OF TRUST
GMO TRUST
THIS AMENDED AND RESTATED AGREEMENT AND DECLARATION OF TRUST made at Boston, Massachusetts this 9th day of March, 2016 hereby amends and restates in its entirety the Amended and Restated Agreement and Declaration of Trust of GMO Trust dated September 10, 2009, as heretofore amended from time to time. This Amended and Restated Agreement and Declaration of Trust shall be effective upon filing with the Secretary of The Commonwealth of Massachusetts:
WITNESSETH that
WHEREAS the Trustees have agreed to manage all property coming into their hands as trustees of a Massachusetts business trust in accordance with the provisions hereinafter set forth.
NOW, THEREFORE, the Trustees hereby direct that this Amended and Restated Agreement and Declaration of Trust be filed with the Secretary of The Commonwealth of Massachusetts and with the City Clerk of the City of Boston and do hereby declare that they will hold all cash, securities and other assets, which they may from time to time acquire in any manner as Trustees hereunder IN TRUST to manage and dispose of the same upon the following terms and conditions for the pro rata benefit of the holders from time to time of Shares in this Trust as hereinafter set forth.
ARTICLE I.
Name and Definitions
Section 1. This Trust shall be known as GMO Trust with its principal place of business at 40 Rowes Wharf, Boston, Massachusetts 02110, and the Trustees shall conduct the business of the Trust under that name or any other name as they may from time to time determine. The address of each Trustee is c/o GMO Trust, 40 Rowes Wharf, Boston, Massachusetts 02110.
Section 2. Definitions . Whenever used herein, unless otherwise required by the context or specifically provided:
(a) Trust refers to the Massachusetts business trust established by this Amended and Restated Agreement and Declaration of Trust, as amended from time to time;
(b) Trustees refers to the Trustees of the Trust named in Article IV hereof or elected in accordance with such Article;
(c) Shares means the equal proportionate units of interest into which the beneficial interest in the Trust or in the Trust property belonging to any Series of the Trust (or in the property belonging to any Series allocable to any Class of that Series) (as the context may require) shall be divided from time to time;
(d) Shareholder means a record owner of Shares;
(e) 1940 Act refers to the Investment Company Act of 1940 and the Rules and Regulations thereunder, all as amended from time to time;
(f) The terms Commission and principal underwriter shall have the meanings given to them in the 1940 Act;
(g) Declaration of Trust shall mean this Agreement and Declaration of Trust, as amended or restated from time to time;
(h) By-Laws shall mean the By-Laws of the Trust as amended from time to time;
(i) Series Company refers to the form of registered open-end investment company described in Section 18(f)(2) of the 1940 Act or in any successor statutory provision;
(j) Series refers to Series of Shares established and designated under or in accordance with the provisions of Article III; and
(k) Class refers to any Class of Shares established and designated under or in accordance with the provisions of Article III. The Shares of any Class shall represent a subset of Shares of a Series, and together with all other Classes of the same Series, shall constitute all Shares of that Series.
-2-
ARTICLE II.
Purpose of Trust
The purpose of the Trust is to provide investors a managed investment primarily in securities (including options), debt instruments, commodities, commodity contracts and options thereon.
ARTICLE III.
Shares
Section 1. Division of Beneficial Interest . The beneficial interest in the Trust shall at all times be divided into an unlimited number of transferable Shares, without par value. Subject to the provisions of Section 6 of this Article III, each Share shall have voting rights as provided in Article V hereof, and holders of the Shares of any Series or Class shall be entitled to receive dividends, when and as declared with respect thereto in the manner provided in Article VI, Section 1 hereof. No Share shall have any priority or preference over any other Share of the same Series and Class with respect to dividends or distributions upon termination of the Trust or of such Series or Class made pursuant to Article VIII, Section 4 hereof. All dividends and distributions shall be made ratably among all Shareholders of a particular Series or Class from the assets belonging to such Series (or, in the case of a Class, allocable to such Class) according to the number of Shares of such Series or Class held of record by such Shareholders on the record date for any dividend or on the date of termination, as the case may be. Shareholders shall have no preemptive or other right to subscribe to any additional Shares or other securities issued by the Trust. The Trust may from time to time divide or combine the Shares of any particular Series or Class into a greater or lesser number of Shares of that Series or Class without thereby changing the proportionate beneficial interest of the Shares of that Series or Class in the assets belonging to that Series (or, in the case of a Class, allocable to such Class) in any way affecting the rights of Shares of any other Series or Class.
Section 2. Ownership of Shares . The ownership of Shares shall be recorded on the books of the Trust or a transfer or similar agent for the Trust, which books shall be maintained separately for the Shares of each Series and Class. No certificates certifying the ownership of Shares shall be issued except as the Trustees may otherwise determine from time to time. The Trustees may make such rules as they consider appropriate for the transfer of Shares of each Series and Class and similar matters. The record books of the Trust as kept by the Trust or any transfer or similar agent, as the case may be, shall be conclusive as to who are the Shareholders of each Series and Class and as to the number of Shares of each Series and Class held from time to time by each.
Section 3. Investments in the Trust . The Trustees shall accept investments in the Trust from such persons and on such terms and for such consideration as they from time to time authorize.
-3-
Section 4. Status of Shares and Limitation of Personal Liability . Shares shall be deemed to be personal property giving Shareholders only the rights provided in this Declaration of Trust. Among the rights Shareholders shall not have unless expressly provided by the By-Laws or expressly provided by law and not permitted to be waived are rights to: (i) enforce contractual claims of the Trust or any Series, (ii) assert claims against the Trust or any Series or its Trustees, Officers or service providers, (iii) assert derivative claims on behalf of the Trust or any Series or involving any alleged harm to the Trust or any Series, or (iv) bring a claim on behalf of any other shareholder. Every Shareholder by virtue of having become a Shareholder shall be held to have expressly assented and agreed to the terms hereof and to have become a party hereto.
The death of a Shareholder during the continuance of the Trust shall not operate to terminate the same nor entitle the representative of any deceased Shareholder to an accounting or to take any action in court or elsewhere against the Trust or the Trustees, but entitles such representative only to the rights of said deceased Shareholder under this Trust.
Ownership of Shares shall not entitle the Shareholder to any title in or to the whole or any part of the Trust property or right to call for a partition or division of the same or for an accounting, nor shall the ownership of Shares constitute the Shareholders partners.
Neither the Trust nor the Trustees, nor any officer, employee or agent of the Trust shall have any power to bind personally any Shareholders, nor except as specifically provided herein to call upon any Shareholder for the payment of any sum of money or assessment whatsoever other than such as the Shareholder may at any time personally agree to pay.
Section 5. Power of Trustees to Change Provisions Relating to Shares . Notwithstanding any other provisions of this Declaration of Trust and without limiting the power of the Trustees to amend the Declaration of Trust as provided elsewhere herein, the Trustees shall have the power to amend this Declaration of Trust, at any time and from time to time, in such manner as the Trustees may determine in their sole discretion, without the need for Shareholder action, so as to add to, delete, replace or otherwise modify any provisions relating to the Shares contained in this Declaration of Trust for the purpose of (i) responding to or complying with any regulations, orders, rulings or interpretations of any governmental agency or any laws, now or hereafter applicable to the Trust, or (ii) designating and establishing Series and Classes in addition to the Series and Classes established in Section 6 of this Article III; provided that before adopting any such amendment without Shareholder approval the Trustees shall determine that it is consistent with the fair and equitable treatment of all Shareholders. The establishment and designation of any Series or Class of Shares in addition to the Series and Classes established and designated in Section 6 of this Article III shall be effective upon the execution by a majority of the then Trustees of an amendment to this Declaration of Trust, taking the form of a complete restatement or otherwise, setting forth such establishment and designation and the relative rights and preferences of such Series or Class, as the case may be, or as otherwise provided in such instrument.
Without limiting the generality of the foregoing, the Trustees may, for the above-stated purposes, amend the Declaration of Trust to:
-4-
(a) create one or more Series or Classes of Shares (in addition to any Series or Classes already existing or otherwise) with such rights and preferences and such eligibility requirements for investment therein as the Trustees shall determine and reclassify any or all outstanding Shares as shares of particular Series or Classes in accordance with such eligibility requirements;
(b) amend any of the provisions set forth in paragraphs (a) through (j) of Section 6 of this Article III;
(c) combine one or more Series or Classes of Shares into a single Series or Class on such terms and conditions as the Trustees shall determine;
(d) change or eliminate any eligibility requirements for investment in Shares of any Series or Class, including without limitation the power to provide for the issue of Shares of any Series or Class in connection with any merger or consolidation of the Trust with another trust or company or any acquisition by the Trust of part or all of the assets of another trust or company;
(e) change the designation of any Series or Class of Shares;
(f) change the method of allocating dividends among the various Series and Classes of Shares;
(g) allocate any specific assets or liabilities of the Trust or any specific items of income or expense of the Trust to one or more Series or Classes of Shares; and
(h) specifically allocate assets to any or all Series or Classes of Shares or create one or more additional Series or Classes of Shares which are preferred over all other Series or Classes of Shares in respect of assets specifically allocated thereto or any dividends paid by the Trust with respect to any net income, however determined, earned from the investment and reinvestment of any assets so allocated or otherwise and provide for any special voting or other rights with respect to such Series or Classes.
Section 6. Establishment and Designation of Series . Without limiting the authority of the Trustees set forth in Section 5, inter alia , to establish and designate any further Series or Classes or to modify the rights and preferences of any Series, each Series set forth on Schedule 3.6 hereto (as may be amended from time to time by the Trustees) shall be, and are hereby, established and designated. In addition, with respect to each such Series, the Class I Shares, Class II Shares, Class III Shares, Class IV Shares, Class V Shares, Class VI Shares, Class VII Shares, Class VIII Shares and Class M Shares which each such Series may issue from time to time, shall be, and are hereby, established and designated, which Classes shall have the
-5-
respective rights and preferences as are set forth in Exhibit 3.6 attached hereto as it may be amended from time to time by the Board of Trustees.
Shares of each Series (or Class, as the case may be) established in this Section 6 shall have the following relative rights and preferences:
(a) Assets belonging to Series . All consideration received by the Trust for the issue or sale of Shares of a particular Series, together with all assets in which such consideration is invested or reinvested, all income, earnings, profits, and proceeds thereof from whatever source derived, including, without limitation, any proceeds derived from the sale, exchange or liquidation of such assets, and any funds or payments derived from any reinvestment of such proceeds in whatever form the same may be, shall irrevocably belong to that Series for all purposes, subject only to the rights of creditors, and shall be so recorded upon the books of account of the Trust. Such consideration, assets, income, earnings, profits and proceeds thereof, from whatever source derived, including, without limitation, any proceeds derived from the sale, exchange or liquidation of such assets, and any funds or payments derived from any reinvestment of such proceeds, in whatever form the same may be, are herein referred to as assets belonging to that Series. The right to bring, permit or maintain any action, proceeding or claim on behalf of the Trust or any Series is not an asset belonging to any Series, and the exclusive power to exercise this right is vested in the Trustees; provided, however, that nothing in this sentence shall restrict the treatment of the proceeds of an action, proceeding or claim on behalf of a Series as an asset belonging to that Series. In the event that there are any assets, income, earnings, profits and proceeds thereof, funds or payments which are not readily identifiable as belonging to any particular Series (collectively General Assets), the Trustees shall allocate such General Assets to, between or among any one or more of the Series established and designated from time to time in such manner and on such basis as they, in their sole discretion, deem fair and equitable, and any General Asset so allocated to a particular Series shall belong to that Series. Each such allocation by the Trustees shall be conclusive and binding upon the Shareholders of all Series for all purposes.
(b) Liabilities Belonging to Series . The assets belonging to each particular Series shall be charged solely with the liabilities of the Trust in respect to that Series, expenses, costs, charges and reserves attributable to that Series, and any general liabilities of the Trust which are not readily identifiable as belonging to any particular Series but which are allocated and charged by the Trustees to and among any one or more of the Series established and designated from time to time in a manner and on such basis as the Trustees in their sole discretion deem fair and equitable. The liabilities, expenses, costs, charges, and reserves so charged to a Series are herein referred to as liabilities belonging to that Series. Each allocation of liabilities, expenses, costs, charges and reserves by the Trustees shall be conclusive and binding upon the holders of all Series for all purposes.
-6-
(c) Dividends, Distributions, Redemptions, and Repurchases . Notwithstanding any other provisions of this Declaration, including, without limitation, Article VI, no dividend or distribution (including, without limitation, any distribution paid upon termination of the Trust or of any Series or Class) with respect to, nor any redemption or repurchase of, the Shares of any Series shall be effected by the Trust other than from the assets belonging to such Series, nor shall any Shareholder of any particular Series otherwise have any right or claim against the assets belonging to any other Series except to the extent that such Shareholder has such a right or claim hereunder as a Shareholder of such other Series.
(d) Voting . Notwithstanding any of the other provisions of this Declaration, including, without limitation, Section 1 of Article V, the Shareholders of any particular Series or Class shall not be entitled to vote on any matters as to which such Series or Class is not affected except as otherwise required by the 1940 Act or other applicable law. On any matter submitted to a vote of Shareholders, all Shares of the Trust then entitled to vote shall be voted by individual Series, unless otherwise required by the 1940 Act or other applicable law.
(e) Equality . All the Shares of each particular Class of a Series shall represent an equal proportionate interest in the assets allocable to that Class, and each Share of any particular Series shall be equal to each other Share of that Series (subject to the liabilities allocated to each Class of that Series).
(f) Fractions . Any fractional Share of a Series or Class shall carry proportionately all the rights and obligations of a whole share of that Series or Class, including rights with respect to voting, receipt of dividends and distributions, redemption of Shares and termination of the Trust.
(g) Exchange Privilege . The Trustees shall have the authority to provide that the holders of Shares of any Series or Class shall have the right to exchange said Shares for Shares of one or more other Series or Class of Shares in accordance with such requirements and procedures as may be established by the Trustees.
(h) Combination of Series or Classes . The Trustees shall have the authority, without the approval of the Shareholders of any Series or Class unless otherwise required by applicable law, to combine the assets and liabilities belonging to any two or more Series (or the assets allocable to any two or more Classes) into assets and liabilities belonging (or allocable) to a single Series (or Class).
-7-
(i) Elimination of Series or Classes . At any time that there are no Shares outstanding of any particular Series or Class previously established and designated, the Trustees may amend this Declaration of Trust to abolish that Series or Class and to rescind the establishment and designation thereof, such amendment to be effected in the manner provided in Section 5 of this Article III.
(j) Assets and Liabilities Allocable to a Class . The assets and liabilities belonging to a Series shall be proportionately allocated among all the Classes of that Series according to the percentage of net assets allocated to each particular Class. For purposes of determining the assets and liabilities belonging to a Series that are allocable to a Class of that Series, subject to the provisions of paragraph (g) of Section 5 of this Article III, expenses shall be accrued as set forth in Exhibit 3.6 attached hereto.
Section 7. Indemnification of Shareholders . In case any Shareholder or former Shareholder shall be held to be personally liable solely by reason of his or her being or having been a Shareholder of the Trust or of a particular Series and not because of his or her acts or omissions or for some other reason, the Shareholder or former Shareholder (or his or her heirs, executors, administrators or other legal representatives or in the case of a corporation or other entity, its corporate or other general successor) shall be entitled out of the assets of the Series of which he is a Shareholder or former Shareholder to be held harmless from and indemnified against all loss and expense arising from such liability.
Section 8. No Preemptive Rights . Shareholders shall have no preemptive or other right to subscribe to any additional Shares or other securities issued by the Trust.
ARTICLE IV.
The Trustees
Section 1. Election and Tenure . The Trustees may fix the number of vacancies arising from an increase in the number of Trustees, or remove Trustees with or without cause. Each Trustee shall serve during the continued lifetime of the Trust until he dies, resigns or is removed, or if sooner, until the next meeting of Shareholders called for the purpose of electing Trustees and until the election and qualification of his successor. Any Trustee may resign at any time by written instrument signed by him and delivered to any officer of the Trust or to a meeting of the Trustees. Such resignation shall be effective upon receipt unless specified to be effective at some other time. Except to the extent expressly provided in a written agreement with the Trust, no Trustee resigning and no Trustee removed shall have any right to any compensation for any period following his resignation or removal, or any right to damages on account of such removal. The Shareholders may fix the number of Trustees and elect Trustees at any meeting of Shareholders called by the Trustees for that purpose.
-8-
Section 2. Effect of Death, Resignation, etc. of a Trustee . The death, declination, resignation, retirement, removal, or incapacity of the Trustees, or any of them, shall not operate to annul the Trust or to revoke any existing agency created pursuant to the terms of this Declaration of Trust.
Section 3. Powers . Subject to the provisions of this Declaration of Trust, the business of the Trust shall be managed by the Trustees, and they shall have all powers necessary or convenient to carry out that responsibility including the power to engage in securities transactions of all kinds on behalf of the Trust and the exclusive power to bring, permit or maintain any action, proceeding or claim on behalf of the Trust or a Series. Without limiting the foregoing, the Trustees may adopt By-Laws not inconsistent with this Declaration of Trust providing for the regulation and management of the affairs of the Trust and may amend and repeal them to the extent that such By-Laws do not reserve that right to the Shareholders; they may fill vacancies in or remove from their number (including any vacancies created by an increase in the number of Trustees); they may remove from their number with or without cause; they may elect and remove such officers and appoint and terminate such agents as they consider appropriate; they may appoint from their own number and terminate one or more committees consisting of two or more Trustees which may exercise the powers and authority of the Trustees to the extent that the Trustees determine; they may employ one or more custodians of the assets of the Trust and may authorize such custodians to employ subcustodians and to deposit all or any part of such assets in a system or systems for the central handling of securities or with a Federal Reserve Bank, retain a transfer agent or a shareholder servicing agent, or both, provide for the distribution of Shares by the Trust, through one or more principal underwriters or otherwise, set record dates for the determination of Shareholders with respect to various matters, and in general delegate such authority as they consider desirable to any officer of the Trust, to any committee of the Trustees and to any agent or employee of the Trust or to any such custodian or underwriter.
Without limiting the foregoing, the Trustees shall have power and authority:
(a) To invest and reinvest cash, and to hold cash uninvested;
(b) To sell, exchange, lend, pledge, mortgage, hypothecate, lease, or write options with respect to or otherwise deal in any property rights relating to any or all of the assets of the Trust;
(c) To vote or give assent, or exercise any rights of ownership, with respect to stock or other securities or property; and to execute and deliver proxies or powers of attorney to such person or persons as the Trustees shall deem proper, granting to such person or persons such power and discretion with relation to securities or property as the Trustees shall deem proper;
-9-
(d) To exercise power and rights of subscription or otherwise which in any manner arise out of ownership of securities;
(e) To hold any security or property in a form not indicating any trust, whether in bearer, unregistered or other negotiable form, or in its own name or in the name of a custodian or subcustodian or a nominee or nominees or otherwise;
(f) To consent to or participate in any plan for the reorganization, consolidation or merger of any corporation or issuer of any security which is held in the Trust; to consent to any contract, lease, mortgage, purchase or sale of property by such corporation or issuer; and to pay calls or subscriptions with respect to any security held in the Trust;
(g) To join with other security holders in acting through a committee, depositary, voting trustee or otherwise, and in that connection to deposit any security with, or transfer any security to, any such committee, depositary or trustee, and to delegate to them such power and authority with relation to any security (whether or not so deposited or transferred) as the Trustees shall deem proper and to agree to pay, and to pay, such portion of the expenses and compensation of such committee, depositary or trustee as the Trustees shall deem proper;
(h) To compromise, arbitrate or otherwise adjust claims in favor of or against the Trust or any matter in controversy, including but not limited to claims for taxes;
(i) To enter into joint ventures, general or limited partnerships and any other combinations or associations;
(j) To borrow funds or other property;
(k) To endorse or guarantee the payment of any notes or other obligations of any person; to make contracts of guaranty or suretyship, or otherwise assume liability for payment thereof;
-10-
(l) To purchase and pay for entirely out of Trust property such insurance as they may deem necessary or appropriate for the conduct of the business, including without limitation, insurance policies insuring the assets of the Trust and payment of distributions and principal on its portfolio investments, and insurance policies insuring the Shareholders, Trustees, officers, employees, agents, investment advisers, principal underwriters, or independent contractors of the Trust individually against all claims and liabilities of every nature arising by reason of holding being or having held any such office or position, or by reason of any action alleged to have been taken or omitted by any such person as Trustee, officer, employee, agent, investment adviser, principal underwriter, or independent contractor, including any action taken or omitted that may be determined to constitute negligence, whether or not the Trust would have the power to indemnify such person against liability; and
(m) To pay pensions as deemed appropriate by the Trustees and to adopt, establish and carry out pension, profit-sharing, share bonus, share purchase, savings, thrift and other retirement, incentive and benefit plans, trusts and provisions, including the purchasing of life insurance and annuity contracts as a means of providing such retirement and other benefits, for any or all of the Trustees, officers, employees and agents of the Trust.
The Trustees shall not in any way be bound or limited by any present or future law or custom in regard to investments by Trustees. The Trustees shall not be required to obtain any court order to deal with any assets of the Trust or take any other action hereunder.
Section 4. Payment of Expenses by the Trust . The Trustees are authorized to pay or cause to be paid out of the principal or income of the Trust, or partly out of principal and partly out of income, as they deem fair, all expenses, fees, charges, taxes and liabilities incurred or arising in connection with the Trust, or in connection with the management thereof, including but not limited to, the Trustees compensation and such expenses and charges for the services of the Trusts officers, employees, investment adviser or manager, principal underwriter, auditor, counsel, custodian, transfer agent, shareholder servicing agent, and such other agents or independent contractors and such other expenses and charges as the Trustees may deem necessary or proper to incur.
Section 5. Payment of Expenses by Shareholders . The Trustees shall have the power, as frequently as they may determine, to cause each Shareholder, or each Shareholder of any particular Series or Class, to pay directly, in advance or arrears, for charges of the Trusts custodian or transfer, shareholder servicing or similar agent, an amount fixed from time to time by the Trustees, by setting off such charges due from such Shareholder from declared but unpaid dividends owed such Shareholder and/or by reducing the number of Shares in the account of such Shareholder by that number of full and/or fractional Shares which represents the outstanding amount of such charges due from such Shareholder.
Section 6. Ownership of Assets of the Trust . Title to all of the assets of the Trust shall at all times be considered as vested in the Trustees.
-11-
Section 7. Advisory, Management and Distribution Contracts . Subject to such requirements and restrictions as may be set forth in the By-Laws, the Trustees may, at any time and from time to time, contract for exclusive or nonexclusive advisory and/or management services for the Trust or for any Series with Grantham, Mayo, Van Otterloo & Co. LLC (including any limited liability company, provided that a majority of the beneficial owners of Grantham, Mayo, Van Otterloo & Co. LLC hold a majority of the equity interest in such entity and substantially all business of Grantham, Mayo, Van Otterloo & Co. LLC is assigned thereto) or any other partnership, corporation, trust, association or other organization (the Manager); and any such contract may contain such other terms as the Trustees may determine, including, without limitation, authority for a Manager to determine from time to time without prior consultation with the Trustees what investments shall be purchased, held, sold or exchanged and what portion, if any, of the assets of the Trust shall be held uninvested and to make changes in the Trusts investments. The Trustees may also, at any time and from time to time, contract with the Manager or any other partnership, corporation, trust, association or other organization, appointing it exclusive or nonexclusive distributor or principal underwriter for the Shares, every such contract to comply with such requirements and restrictions as may be set forth in the By-Laws; and any such contract may contain such other terms as the Trustees may determine. The Trustees may clarify or interpret on behalf of the Trust provisions of the contracts that it enters into pursuant to this Article IV, Section 7 that are ambiguous, implicit or missing.
The fact that:
(i) any of the Shareholders, Trustees or officers of the Trust is a shareholder, director, officer, partner, trustee, employee, manager, adviser, principal underwriter, distributor or affiliate or agent of or for any partnership, corporation, trust, association, or other organization, or of or for any parent or affiliate of any organization, with which an advisory or management contract, or principal underwriters or distributors contract, or transfer, shareholder servicing or other agency contract may have been or may hereafter be made, or that any such organization, or any parent or affiliate thereof, is a Shareholder or has an interest in the Trust, or that
(ii) any corporation, trust, association or other organization with which an advisory or management contract or principal underwriters or distributors contract, or transfer, shareholder servicing or other agency contract may have been or may hereafter be made also has an advisory or management contract, or principal underwriters or distributors contract, or transfer, shareholder servicing or other agency contract with one or more other corporations, trusts, associations, or other organizations, or has other business or interests,
shall not affect the validity of any such contract or disqualify any Shareholder, Trustee or officer of the Trust from voting upon or executing the same or create any liability or accountability to the Trust or its Shareholders.
-12-
ARTICLE V.
Shareholders Voting Powers and Meetings
Section 1. Voting Powers . The Shareholders shall have power to vote only (i) for the election of Trustees as provided in Article IV, Section 1, (ii) with respect to any amendment of this Declaration of Trust to the extent and as provided in Article VIII, Section 8, (iii) to the same extent as the stockholders of a Massachusetts business corporation as to whether or not a court action, proceeding or claim should or should not be brought or maintained derivatively or as a class action on behalf of the Trust or the Shareholders, (iv) with respect to the termination of the Trust or any Series or Class to the extent and as provided in Article VIII, Section 4, and (v) with respect to such additional matters relating to the Trust as may be required by this Declaration of Trust, the By-Laws or any registration of the Trust with the Commission (or any successor agency) or any state, or as the Trustees may consider necessary or desirable. Each whole Share shall be entitled to one vote as to any matter on which it is entitled to vote and each fractional Share shall be entitled to a proportionate fractional vote. There shall be no cumulative voting in the election of Trustees. Shares may be voted in person or by proxy. A proxy with respect to Shares held in the name of two or more persons shall be valid if executed by any one of them unless at or prior to exercise of the proxy the Trust receives a specific written notice to the contrary from any one of them. A proxy purporting to be executed by or on behalf of a Shareholder shall be deemed valid unless challenged at or prior to its exercise and the burden of proving invalidity shall rest on the challenger. At any time when no Shares of a Series or Class are outstanding the Trustees may exercise all rights of Shareholders of that Series or Class with respect to matters affecting that Series or Class and may with respect to that Series or Class take any action required by law, this Declaration of Trust or the By-Laws to be taken by the Shareholders.
Section 2. Voting Power and Meetings . Meetings of the Shareholders may be called by the Trustees for the purpose of electing Trustees as provided in Article IV, Section 1 and for such other purposes as may be prescribed by law, by this Declaration of Trust or by the By-Laws. Meetings of the Shareholders may also be called by the Trustees from time to time for the purpose of taking action upon any other matter deemed by the Trustees to be necessary or desirable. A meeting of Shareholders may be held at any place designated by the Trustees. Written notice of any meeting of Shareholders shall be given or caused to be given by the Trustees by mailing such notice at least seven days before such meeting, postage prepaid, stating the time and place of the meeting, to each Shareholder at the Shareholders address as it appears on the records of the Trust. Whenever notice of a meeting is required to be given to a Shareholder under this Declaration of Trust or the By-Laws, a written waiver thereof, executed before or after the meeting by such Shareholder or his attorney thereunto authorized and filed with the records of the meeting, shall be deemed equivalent to such notice.
Section 3. Quorum and Required Vote . Except when a larger quorum is required by law, by the By-Laws or by this Declaration of Trust, 40% of the Shares entitled to vote shall constitute a quorum at a Shareholders meeting. When any one Series or Class is to vote separately from any
-13-
other Shares which are to vote on the same matters as a separate Series or Class, 40% of the Shares of each such Series or Class entitled to vote shall constitute a quorum at a Shareholders meeting of that Series or Class. Any meeting of Shareholders may be adjourned from time to time by a majority of the votes property cast upon the question, whether or not a quorum is present, and the meeting may be held as adjourned within a reasonable time after the date set for the original meeting without further notice. When a quorum is present at any meeting, a majority of the Shares voted shall decide any questions and a plurality shall elect a Trustee, except when a larger vote is required by any provision of this Declaration of Trust or the By-Laws or by law. If any question on which the Shareholders are entitled to vote would adversely affect the rights of any Series or Class of Shares, the vote of a majority (or such larger vote as is required as aforesaid) of the Shares of such Series or Class which are entitled to vote, voting separately, shall also be required to decide such question.
Section 4. Action by Written Consent . Any action taken by Shareholders may be taken without a meeting if Shareholders holding a majority of the Shares entitled to vote on the matter (or such larger proportion thereof as shall be required by any express provision of this Declaration of Trust or by the By-Laws) and holding a majority (or such larger proportion as aforesaid) of the Shares of any Series or Class entitled to vote separately on the matter consent to the action in writing and such written consents are filed with the records of the meetings of Shareholders. Such consent shall be treated for all purposes as a vote taken at a meeting of Shareholders.
Section 5. Record Dates . For the purpose of determining the Shareholders of any Series or Class who are entitled to vote or act at any meeting or any adjournment thereof, the Trustees may from time to time fix a time, which shall be not more than 60 days before the date of any meeting of Shareholders, as the record date for determining the Shareholders of such Series or Class having the right to notice of and to vote at such meeting and any adjournment thereof, and in such case only Shareholders of record on such record date shall have such right, notwithstanding any transfer of shares on the books of the Trust after the record date. For the purpose of determining the Shareholders of any Series or Class who are entitled to receive payment of any dividend or of any other distribution, the Trustees may from time to time fix a date, which shall be before the date for the payment of such dividend or such other payment, as the record date for determining the Shareholders of such Series or Class having the right to receive such dividend or distribution. Without fixing a record date the Trustees may for voting and/or distribution purposes close the register or transfer books for one or more Series or Class for all or any part of the period between a record date and a meeting of shareholders or the payment of a distribution. Nothing in this section shall be construed as precluding the Trustees from setting different record dates for different Series or Classes.
Section 6. Additional Provisions . The By-Laws may include further provisions for Shareholders votes and meetings and related matters.
-14-
ARTICLE VI.
Net Income, Distributions, Allocations, and Redemptions and Repurchases
Section 1. Distributions of Net Income . The Trustees shall each year, or more frequently if they so determine in their sole discretion, distribute to the Shareholders of each Series or Class, in shares of that Series or Class, cash or otherwise, an amount approximately equal to the net income attributable to the assets belonging to such Series (or the assets allocable to such Class) and may from time to time distribute to the Shareholders of each Series or Class, in shares of that Series, cash or otherwise, such additional amounts, but only from the assets belonging to such Series (or allocable to that Class), as they may authorize; provided, however, that with respect to GMO World Opportunity Overlay Fund and any other Series for which it is determined, prior to the time that any Shares of such Series are outstanding, that the Series will elect to be treated as a partnership for tax purposes, the Trustees shall determine in their sole discretion the timing and amount of any distributions to Shareholders of such Series. All dividends and distributions on Shares of a particular Series or Class shall be distributed pro rata to the holders of that Series or Class in proportion to the number of Shares of that Series or Class held by such holders and recorded on the books of the Trust at the date and time of record established for that payment or such dividend or distributions.
The manner of determining net income, income, asset values, capital gains, expenses, liabilities and reserves of any Series or Class may from time to time be altered as necessary or desirable in the judgment of the Trustees to conform such manner of determination to any other method prescribed or permitted by applicable law. Net income shall be determined by the Trustees or by such person as they may authorize at the times and in the manner provided in the By-Laws. Determinations of net income of any Series or Class and determination of income, asset value, capital gains, expenses, and liabilities made by the Trustees, or by such person as they may authorize, in good faith, shall be binding on all parties concerned. The foregoing sentence shall not be construed to protect any Trustee, officer or agent of the Trust against any liability to the Trust or its security holders to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office.
If, for any reason, the net income of any Series or Class determined at any time is a negative amount, the pro rata share of such negative amount allocable to each Shareholder of such Series or Class shall constitute a liability of such Shareholder to that Series or Class which shall be paid out of such Shareholders account at such times and in such manner as the Trustees may from time to time determine (x) out of the accrued dividend account of such Shareholder, (y) by reducing the number of Shares of that Series or Class in the account of such Shareholder, or (z) otherwise.
Section 2 . Allocations . In respect of any Series that is treated as a partnership for federal income tax purposes, the Trustees (or such other person designated by the Trustees as having responsibility for making tax determinations on behalf of the Series) shall have authority to make special allocations of income, gain, loss or deduction among Shareholders upon withdrawals or
-15-
transfers of shares as necessary to avoid mandatory basis adjustments in the assets of the Series as required by Internal Revenue Code of 1986, as amended (the Code), section 743 or 734 that would otherwise apply as a result of amendments to such Code sections under The American Jobs Creation Act of 2004, enacted on October 22, 2004.
Section 3 . Redemptions and Repurchases . The Trust shall purchase such Shares as are offered by any Shareholder for redemption, upon the presentation of a proper instrument of transfer together with a request directed to the Trust or a person designated by the Trust that the Trust purchase such Shares or in accordance with such other procedures for redemption as the Trustees may from time to time authorize; and the Trust will pay therefor the net asset value thereof, as determined in accordance with the By-Laws, next determined. Payment for said Shares shall be made by the Trust to the Shareholder within seven days after the date on which the request is made. The obligation set forth in this Section 2 is subject to the provision that in the event that any time the New York Stock Exchange is closed for other than weekends or holidays, or if permitted by the rules of the Commission during periods when trading on the Exchange is restricted or during any emergency which makes it impracticable for the Trust to dispose of the investments of the applicable Series or to determine fairly the value of the net assets belonging to such Series (or net assets allocable to such Class) or during any other period permitted by order of the Commission for the protection of investors, such obligations may be suspended or postponed by the Trustees. The Trust may also purchase or repurchase Shares at a price not exceeding the net asset value of such Shares in effect when the purchase or repurchase or any contract to purchase or repurchase is made.
The redemption price may in any case or cases be paid wholly or partly in kind if the Trustees determine that such payment is advisable in the interest of the remaining Shareholders of the Series or Class the Shares of which are being redeemed. In making any such payment wholly or partly in kind, the Trust shall, so far as may be practicable, deliver assets which approximate the diversification of all of the assets belonging at the time to the Series (or allocable to the Class) the Shares of which are being redeemed. Subject to the foregoing, the fair value, selection and quantity of securities or other property so paid or delivered as all or part of the redemption price may be determined by or under authority of the Trustees. In no case shall the Trust be liable for any delay of any corporation or other person in transferring securities selected for delivery as all or part of any payment in kind.
For avoidance of doubt, nothing in this Section 3 shall preclude the Trust from purchasing Shares of any Series or Class offered for redemption at net asset value less any applicable redemption fee as the Board may approve from time to time.
Section 4 . Redemptions at the Option of the Trust . The Trust shall have the right at its option and at any time to redeem Shares of any Shareholder at the net asset value thereof as described in Section 1 of this Article VI: (i) if at such time such Shareholder owns Shares of any Series or Class having an aggregate net asset value of less than an amount determined from time to time by the Trustees; or (ii) to the extent that such Shareholder owns Shares equal to or in excess of a percentage determined from time to time by the Trustees of the outstanding Shares of the Trust or of any Series or Class.
-16-
ARTICLE VII.
Compensation and Limitation of Liability of Trustees
Section 1. Compensation . The Trustees as such shall be entitled to reasonable compensation from the Trust; they may fix the amount of their compensation. Nothing herein shall in any way prevent the employment of any Trustee for advisory, management, legal, accounting, investment banking or other services and payment for the same by the Trust.
Section 2. Limitation of Liability . The Trustees shall not be responsible or liable in any event for any neglect or wrong-doing of any officer, agent, employee, Manager or principal underwriter of the Trust, nor shall any Trustee be responsible for the act or omission of any other Trustee, but nothing herein contained shall protect any Trustee against any liability to which he would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his office.
Every note, bond, contract, instrument, certificate or undertaking and every other act or thing whatsoever issued, executed or done by or on behalf of the Trust or the Trustees or any of them in connection with the Trust shall be conclusively deemed to have been issued, executed or done only in or with respect to their or his capacity as Trustees or Trustee, and such Trustees or Trustee shall not be personally liable thereon.
ARTICLE VIII.
Miscellaneous
Section 1. Trustees, Shareholders, etc. Not Personally Liable; Notice . All persons extending credit to, contracting with or having any claim against the Trust or any Series or Class shall look only to the assets of the Trust, or, to the extent that the liability of the Trust may have been expressly limited by contract to the assets of a particular Series (or the assets allocable to a particular Class), only to the assets belonging to the relevant Series (or allocable to the relevant Class), for payment under such credit, contract or claim; and neither the Shareholders nor the Trustees, nor any of the Trusts officers, employees or agents, whether past, present or future, shall be personally liable therefor. Nothing in this Declaration of Trust shall protect any Trustee against any liability to which such Trustee would otherwise be subject by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of the office of Trustee.
Every note, bond, contract, instrument, certificate or undertaking made or issued on behalf of the Trust by the Trustees, by any officers or officer or otherwise shall give notice that this Declaration of Trust is on file with the Secretary of The Commonwealth of Massachusetts and shall recite that the same was executed or made by or on behalf of the Trust or by them as
-17-
Trustee or Trustees or as officers or officer or otherwise and not individually and that the obligations of such instrument are not binding upon any of them or the shareholders individually but are binding only upon the assets and property of the Trust or upon the assets belonging to the Series (or allocable to the Class) for the benefit of which the Trustees have caused the note, bond, contract, instrument, certificate or undertaking to be made, or issued, and may contain such further recital as he or they may deem appropriate, but the omission of any such recital shall not operate to bind any Trustee or Trustees or officers or officer or Shareholders or any other person individually.
Section 2. Trustees Good Faith Action, Expert Advice, No Bond or Surety . The exercise by the Trustees of their powers and discretions hereunder shall be binding upon everyone interested. A Trustee shall be liable for his own willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of the office of Trustee, and for nothing else, and shall not be liable for errors of judgment or mistakes of fact or law. The Trustees may take advice of counsel or other experts with respect to the meaning and operation of this Declaration of Trust, and shall be under no liability for any act or omission in accordance with such advice or for failing to follow such advice. The Trustees shall not be required to give any bond as such, nor any surety if a bond is required.
Section 3. Liability of Third Persons Dealing with Trustees . No person dealing with the Trustees shall be bound to make any inquiry concerning the validity of any transaction made or to be made by the Trustees or to see to the application of any payments made or property transferred to the Trust or upon its order.
Section 4. Termination of Trust or Series or Class . Unless terminated as provided herein, the Trust shall continue without limitation of time. The Trust may be terminated at any time by vote of at least 66-2/3% of the Shares of each Series entitled to vote and voting separately by Series or by the Trustees by written notice to the Shareholders. Any Series may be terminated at any time by vote of at least 66-2/3% of the Shares of that Series or by the Trustees by written notice to the Shareholders of that Series. Any Class may be separately terminated at any time by vote of at least a majority of the Shares of that Class present and voting on the question (a quorum being present) or by the Trustees by written notice to the Shareholders of that Class.
Upon termination of the Trust (or any Series or Class, as the case may be), after paying or otherwise providing for all charges, taxes, expenses and liabilities belonging, severally, to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), whether due or accrued or anticipated as may be determined by the Trustees, the Trust shall in accordance with such procedures as the Trustees consider appropriate reduce the remaining assets belonging, severally, to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), to distributable form in cash or shares or other securities, or any combination thereof, and distribute the proceeds belonging to each Series or allocable to each Class (or the applicable Series or Classes, as the case may be), to the Shareholders of that Series or Class, as a Series or Class, ratably according to the number of Shares of that Series or Class held by the several Shareholders on the date of termination.
-18-
Section 5. Merger and Consolidation . The Trustees may cause the Trust to be merged into or consolidated with another trust or company or its shares exchanged under or pursuant to any state or federal statute, if any, or otherwise to the extent permitted by law, if such merger or consolidation or share exchange has been authorized by vote of a majority of the outstanding Shares; provided that in all respects not governed by statute or applicable law, the Trustees shall have power to prescribe the procedure necessary or appropriate to accomplish a sale of assets, merger or consolidation.
Section 6. Filing of Copies, References, Headings . The original or a copy of this instrument and of each amendment hereto shall be kept at the office of the Trust where it may be inspected by any Shareholder. A copy of this instrument and of each amendment hereto shall be filed by the Trust with the Secretary of The Commonwealth of Massachusetts and with any other governmental office where such filing may from time to time be required. Anyone dealing with the Trust may rely on a certificate by an officer of the Trust as to whether or not any such amendments have been made and as to any matters in connection with the Trust hereunder; and, with the same effect as if it were the original, may rely on a copy certified by an officer of the Trust to be a copy of this instrument or of any such amendments. In this instrument and in any such amendment, references to this instrument, and all expressions like herein, hereof and hereunder, shall be deemed to refer to this instrument as amended or affected by any such amendments. Headings are placed herein for convenience of reference only and shall not be taken as a part hereof or control or affect the meaning, construction or effect of this instrument. This instrument may be executed in any number of counterparts each of which shall be deemed an original.
Section 7. Applicable Law . This Declaration of Trust is made in The Commonwealth of Massachusetts, and it is created under and is to be governed by and construed and administered according to the laws of said Commonwealth. The Trust shall be of the type commonly called a Massachusetts business trust, and without limiting the provisions hereof, the Trust may exercise all powers which are ordinarily exercised by such a trust.
Section 8. Amendments . This Declaration of Trust may be amended at any time by an instrument in writing signed by a majority of the then Trustees when authorized so to do by vote of a majority of the Shares entitled to vote, except that amendments described in Article III, Section 5 hereof or having the purpose of changing the name of the Trust or of supplying any omission, curing any ambiguity or curing, correcting or supplementing any defective or inconsistent provision contained herein shall not require authorization by Shareholder vote.
-19-
IN WITNESS WHEREOF, the Trustees as aforesaid do hereto set their hands this 9th day of March 2016.
/s/ Donald W. Glazer |
Donald W. Glazer |
Trustee |
/s/ Paul Braverman |
Paul Braverman |
Trustee |
/s/ Peter Tufano |
Peter Tufano |
Trustee |
/s/ Joseph B. Kittredge, Jr. |
Joseph B. Kittredge, Jr. |
Trustee |
-20-
Exhibit 3.6 to Declaration of Trust
GMO TRUST
Plan pursuant to Rule 18f-3 under the
Investment Company Act of 1940
Effective June 1, 1996
As Amended and Restated June 20, 2014
This Plan (the Plan) is adopted by GMO Trust (the Trust) pursuant to Rule 18f-3 under the Investment Company Act of 1940 (the Act) and sets forth the general characteristics of, and the general conditions under which the Trust may offer, multiple classes of shares of its now existing and hereafter created portfolios (Funds). This Plan may be revised or amended from time to time as provided below.
Class Designations
Each Fund of the Trust may from time to time issue one or more of the following classes of shares: Class I Shares, Class II Shares, Class III Shares, Class IV Shares, Class V Shares, Class VI Shares, Class VII Shares, Class VIII Shares, and Class MF Shares. Each of the classes of shares of any Fund will represent interests in the same portfolio of investments and, except as described herein, shall have the same rights and obligations as each other class. Each class shall be subject to such investment minimums and other conditions of eligibility as are set forth in the Trusts prospectus or statement of additional information as from time to time in effect (the Prospectus). The Trust may determine to modify such investment minimums from time to time as set forth in the Prospectus from time to time.
Class Eligibility
Eligibility Information for Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII and Class VIII Shares:
With certain exceptions described below, eligibility for Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII and Class VIII Shares is dependent upon the client meeting either (i) a minimum Total Fund Investment requirement, which includes only a clients total investment in a particular Fund, or (ii) a minimum Total GMO Investment requirement, which includes the clients total investment with Grantham, Mayo, Van Otterloo & Co. LLC (GMO or the Manager), provided that clients who qualify for investment in Class IV, Class V, Class VI, Class VII or Class VIII shares of a particular Fund as a result of satisfying the minimum Total GMO Investment requirement may also be required to make a minimum investment in such Fund, in such amount as is set forth in the Prospectus from time to time.
Determination of Total GMO Investments: A clients Total GMO Investment will be determined by GMO (i) at the time of the clients initial investment, (ii) at the close of business
-21-
on the last business day of each calendar quarter, or (iii) on such other dates as may be determined by GMO (each a Determination Date).
A clients Total GMO Investment as of any Determination Date will be determined as of such Determination Date by reference to the criteria set forth in the Prospectus (as amended from time to time) and this Plan, provided that any changes to the definition of Total GMO Investment must be approved by the Trusts Board of Trustees and provided further that, in the event that the terms of this Plan and the Prospectus conflict, the provisions of this Plan shall apply. For the avoidance of doubt, a determination as to aggregation of client accounts does not constitute a change in the definition of Total GMO Investment.
Aggregation of Accounts. GMO will make all determinations as to aggregation of client accounts for purposes of determining eligibility. GMO may, in its sole discretion, determine that an account is part of a larger client relationship with GMO that includes other accounts managed by GMO and its affiliates (including accounts managed for affiliates of the client) and, accordingly, that the account should be aggregated with those other accounts for purposes of determining its eligibility for a particular class of shares of a Fund. When making decisions regarding whether an account should be aggregated with other accounts because they are part of a larger client relationship, GMO considers several factors, including, but not limited to, whether: the multiple accounts are for one or more subsidiaries of the same parent company; the multiple accounts have the same beneficial owner regardless of the legal form of ownership; the investment mandate is the same or substantially similar across the relationship; the asset allocation strategies are substantially similar across the relationship; GMO reports to the same investment board; the consultant is the same for the entire relationship; GMO services the relationship through a single GMO relationship manager; the relationships have substantially similar reporting requirements; and/or the relationship can be serviced from a single geographic location.
Commitments to Invest. For purposes of calculating a clients Total Fund Investment or Total GMO Investment on a Determination Date, GMO may determine to include assets which the client has committed to deliver to GMO or its affiliates for management over an agreed upon period of time, but which have not been delivered as of the Determination Date.
Waiver of Eligibility Requirements. The Trust may waive eligibility requirements for certain persons, accounts, or special situations (e.g., GMO employees and their family members, the Trustees of the Trust, and other Funds of the Trust and other accounts over which GMO has investment discretion that invest in the Funds).
Eligibility Information for Class MF Shares :
Investors that are retail mutual funds seeking supplemental support services will be eligible to purchase Class MF Shares.
Class Characteristics
Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII and Class VIII Shares :
-22-
Shareholder Service Fees. The sole economic difference among the Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII and Class VIII Shares is the level of shareholder service fee (Shareholder Service Fee) borne by the class for client and shareholder service, reporting, and other support provided to such class by GMO. The multiple class structure reflects the fact that, as the size of the client relationship increases, the cost to service that client decreases as a percentage of the clients assets. Thus, the Shareholder Service Fee generally is lower for classes requiring greater minimum investments.
Conversion Features. For Class I, Class II, Class III, Class IV, Class V, Class VI, Class VII and Class VIII Shares, GMO considers the value of each clients Total Fund Investment and Total GMO Investment on each Determination Date. Based on that determination, and subject to the following, each clients shares of a Fund eligible for conversion will be converted to the class of shares of that Fund with the lowest Shareholder Service Fee for which the client satisfies all minimum investment requirements (or, to the extent the client already holds shares of that class, the client will remain in that class). With respect to any Fund:
(i) | To the extent a client satisfies all minimum investment requirements for a class of shares then being offered that bears a lower Shareholder Service Fee than the class held by the client on the Determination Date (generally at the close of business on the last business day of each calendar quarter), the clients shares eligible for conversion will be automatically converted to that class within the period of time following the Determination Date specified in the Prospectus in effect from time to time. |
(ii) |
If a client no longer satisfies all minimum investment requirements for the class of shares of a Fund held by the client on the last Determination Date of a calendar year (generally at the close of business on the last business day of the calendar year), except as noted below, the Fund will convert the clients shares to the class it is then offering bearing the lowest Shareholder Service Fee for which the client satisfies all minimum investment requirements (and which class will typically bear a higher Shareholder Service Fee than the class then held by the client). If a client no longer satisfies all minimum investment requirements for any class of shares of a Fund as of the last Determination Date of a calendar year, the Fund will convert the clients shares to the class of that Fund then being offered bearing the highest Shareholder Service Fee. Notwithstanding the foregoing, a clients shares will not be converted to a class of shares bearing a higher Shareholder Service Fee without prior notification by the Fund. In addition, as described in the Prospectus in effect from time to time, if the client makes an additional investment and/or the value of the clients shares otherwise increases prior to the end of the notice period so as to satisfy all minimum investment requirements for the clients current class of shares, the client will remain in the class of shares then held by the client. Solely for the purpose of determining whether a client has satisfied the minimum investment requirements for a clients current class of shares, the value of the clients shares is considered to be the greater of |
-23-
(A) the value of the clients shares on the relevant Determination Date or (B) the value of the clients shares on the date that GMO reassesses the value of the clients account for the purpose of sending notice of a proposed conversion. In addition, if the client is not able to make an additional investment in a Fund solely because the Fund is closed to new investment or is capacity constrained, the class of shares then held by the client will not be converted unless the Manager approves reopening the Fund to permit the client to make an additional investment. Any conversion of a clients shares to a class of shares bearing a higher Shareholder Service Fee generally will occur within the period of time following the last Determination Date of a calendar year specified in the Prospectus in effect from time to time. |
Notwithstanding anything to the contrary in clause (ii) above, if a client no longer satisfies all minimum investment requirements for the class of shares of a Fund held by the client as of any date , the Fund at any time without notice may convert the clients shares to the class it is then offering bearing the lowest Shareholder Service Fee for which the client satisfies all minimum investment requirements (or, if the Fund has no such class, the class of that Fund bearing the highest Shareholder Service Fee) if:
| The Manager believes the client has engaged in an abusive pattern of investments and/or redemptions (e.g., a large investment just before a Determination Date and a redemption right after the Determination Date); or |
| The client fails to meet the applicable Total Fund Investment or Total GMO Investment minimums by the time specified in the clients commitment letter; or |
| The total expense ratio borne by client immediately following the conversion is equal to or less than the total expense ratio borne by client immediately prior to such conversion (after giving effect to any applicable fee and expense waivers or reimbursements). |
Shares of one class will always convert into shares of another class on the basis of the relative net asset value of the two classes, without the imposition of any sales load, fee or other charge. The conversion of a clients investment from one class of shares to another is not a taxable event, and will not result in the realization of gain or loss that may exist in Fund shares held by the client. The clients tax basis in the new class of shares will equal its basis in the old class before conversion. The conversion of shares from one class to another class of shares may be suspended if the opinion of counsel obtained by the Fund that the conversion does not constitute a taxable event under current federal income tax law is no longer available.
Special Rules for Shareholders of Accounts Since May 31, 1996. Certain special rules will be applied by the Manager with respect to clients for whom GMO managed assets prior to the creation of multiple classes on May 31, 1996. Any client that has been a continuous shareholder of GMO Foreign Fund or GMO International Intrinsic Value Fund since May 31,
-24-
1996 (prior to the issuance of multiple classes of shares) will be eligible indefinitely to remain invested in Class III shares of that Fund.
Notwithstanding the foregoing special rules applicable to clients owning shares of the Funds on May 31, 1996, such clients shall always be eligible to remain in and/or be converted to any class of shares of the relevant Fund with a lower Shareholder Service Fee which the client would be eligible to purchase pursuant to the eligibility requirements set forth elsewhere in this Plan or in the Prospectus.
Class MF :
Supplemental Support Fees. Class MF Shares are subject to a supplemental support fee (Supplement Support Fee) for support (other than personal services or services in connection with the maintenance of shareholder accounts described in the Shareholder Service Fees section above) provided to the shareholders of Class MF Shares.
Conversion Features. Clients holding Class MF Shares are not currently eligible to convert their Class MF Shares to any other class of shares offered by the Trust.
Allocations to Each Class
Expense Allocations:
Shareholder Service Fees payable by the Trust to the shareholder servicer of the Trusts shares (the Shareholder Servicer) shall be allocated, to the extent practicable, on a class-by-class basis, excluding Class MF Shares, which pay no Shareholder Service Fees. In addition, all Supplemental Support Fees payable by the Trust to the supplemental support provider (the Support Provider) in respect of its Class MF Shares shall be allocated exclusively to Class MF Shares. Subject to the approval of the Trusts Board of Trustees, including a majority of the independent Trustees, the following Class Expenses may (if such expense is properly assessable at the class level) in the future be allocated on a class-by-class basis: (a) transfer agency costs attributable to each class, (b) printing and postage expenses related to preparing and distributing materials such as shareholder reports, prospectuses and proxy statements to current shareholders of a specific Class, (c) SEC registration fees incurred with respect to a specific class, (d) blue sky and foreign registration fees and expenses incurred with respect to a specific class, (e) the expenses of personnel and services required to support shareholders of a specific class (including, but not limited to, maintaining telephone lines and personnel to answer shareholder inquiries about their accounts or about the Trust), (f) litigation and other legal expenses relating to a specific class of shares, (g) Trustees fees or expenses incurred as a result of issues relating to a specific class of shares, (h) accounting and consulting expenses relating to a specific class of shares, (i) any fees imposed pursuant to a non-Rule 12b-1 shareholder service or support plan that relate to a specific class of shares, and (j) any additional expenses, not including advisory or custodial fees or other expenses related to the management of the Trusts assets, if these expenses are actually incurred in a different amount with respect to a class, or if services are provided with respect to a class, or if services are provided with respect to a class that are of a different kind or to a different degree than with respect to one or more other classes.
-25-
All expenses not now or hereafter designated as Class Expenses (Fund Expenses) will be allocated to each class on the basis of the net asset value of that class in relation to the net asset value of the relevant Fund.
However, notwithstanding the above, a Fund may allocate all expenses other than Class Expenses on the basis of any methodology permitted by Rule 18f-3(c) under the Act, provided, however, that until such time as this Plan is amended with respect to the Funds allocation methodology, the Fund will allocate all expenses other than Class Expenses on the basis of relative net assets.
Waivers and Reimbursements:
The Manager, the Shareholder Servicer, the Funds distributor, and the Support Provider may choose to waive or reimburse Shareholder Service Fees, Supplemental Support Fees, or any other Class Expenses on a voluntary or temporary basis.
Income, Gain and Loss Allocations:
Income and realized and unrealized capital gains and losses shall be allocated to each class on the basis of the net asset value of that class in relation to the net asset value of the relevant Fund.
Each Fund may allocate income and realized and unrealized capital gains and losses to each share based on any methodology permitted by Rule 18f-3(c) under the Act, consistent with the provisions set forth in Expense Allocations above.
Redemptions at the Option of the Trust
Notwithstanding anything to the contrary in this Plan, pursuant to Article VI, Section 4 of the Trusts Amended and Restated Agreement and Declaration of Trust, the Trust has the right to redeem unilaterally any shareholder of the Trust (i) if at such time such shareholder owns shares of any Fund or class thereof having an aggregate net asset value of less than an amount determined from time to time by the Trustees or (ii) to the extent that such shareholder owns shares equal to or in excess of a percentage, determined from time to time by the Trustees, of the outstanding shares of the Trust or of any Fund or class thereof.
Dividends
Dividends paid by the Trust with respect to any class of shares, to the extent any dividends are paid, will be calculated in the same manner, at the same time and will be in the same amount, except that any Shareholder Service Fee or Supplemental Support Fee payments relating to a class of shares will be borne exclusively by that class and, if applicable, Class Expenses relating to a class shall be borne exclusively by that class.
-26-
Voting Rights
Each share of the Trust entitles the shareholder of record to one vote. Each class of shares of the Trust will vote separately as a class on matters for which class voting is required under applicable law.
Amendments
The Plan may be amended from time to time in accordance with the provisions and requirements of Rule 18f-3 under the Act.
Adopted this 20th day of June, 2014
By: |
/s/ Jason Harrison |
|||
Name: | Jason Harrison | |||
Title: | Clerk |
-27-
Schedule 3.6 to Declaration of Trust
Series
GMO U.S. Equity Allocation Fund
GMO Quality Fund
GMO International Large/Mid Cap Equity Fund
GMO International Equity Fund
GMO Developed World Stock Fund
GMO Foreign Fund
GMO Foreign Small Companies Fund
GMO International Small Companies Fund
GMO Emerging Markets Fund
GMO Emerging Countries Fund
GMO Tax-Managed International Equities Fund
GMO Core Plus Bond Fund
GMO Currency Hedged International Bond Fund
GMO Global Bond Fund
GMO Emerging Country Debt Fund
GMO International Equity Allocation Fund
GMO International Developed Equity Allocation Fund
GMO Global Equity Allocation Fund
GMO Global Developed Equity Allocation Fund
GMO Global Asset Allocation Fund
GMO Strategic Opportunities Allocation Fund
GMO Benchmark-Free Allocation Fund
GMO Alpha Only Fund
GMO SGM Major Markets Fund
GMO Debt Opportunities Fund
GMO Taiwan Fund
GMO World Opportunity Overlay Fund
GMO U.S. Treasury Fund
GMO Asset Allocation Bond Fund
GMO High Quality Short-Duration Bond Fund
GMO Emerging Domestic Opportunities Fund
GMO Benchmark-Free Fund
GMO Global Focused Equity Fund
GMO Resources Fund
GMO Implementation Fund
GMO Risk Premium Fund
GMO Special Opportunities Fund
GMO GAAR Implementation Fund
-28-
Exhibit 1
GMO TRUST
CERTIFICATE OF CLERK
I, Douglas Y. Charton, hereby certify that I am the duly elected and acting Clerk of GMO Trust, a Massachusetts business trust (the Trust), and do hereby further certify as follows:
1. Attached hereto as Exhibit A are true and correct copies of resolutions from the meeting of the Board of Trustees of the Trust (the Board) held November 17, 2015 (the Meeting). The resolutions were duly adopted by the Board at the Meeting. Such resolutions have not been modified or rescinded since their adoption and are in full force and effect as of the date hereof.
IN WITNESS WHEREOF, I have hereunto set my hand this 29 th day of April, 2016.
By: |
/s/ Douglas Y. Charton |
|||
Name: | Douglas Y. Charton | |||
Title: | Clerk |
Exhibit A
Resolutions of the Board November 17, 2015
Power of Attorney Authorizations
VOTED : | That each of Megan Bunting, Douglas Y. Charton and Meta S. David is authorized to sign for Sheppard N. Burnett, in his name and in the capacity of Chief Executive Officer and Principal Executive Officer, on behalf of the Trust, the Trusts Registration Statement on Form N-1A filed with the Securities and Exchange Commission (the SEC) and any and all amendments, pursuant to a power of attorney executed by Mr. Burnett. | |
VOTED : | That each of Megan Bunting, Douglas Y. Charton and Meta S. David is authorized to sign for Carly Cushman, in her name and in the capacity of Treasurer, Chief Financial Officer, Chief Accounting Officer and Principal Financial and Accounting Officer, on behalf of the Trust, the Trusts Registration Statement on Form N-1A filed with the SEC and any and all amendments, pursuant to a power of attorney executed by Ms. Cushman. |